Clustering O 0 0.0007926301914267242
of O 0 3.347628444316797e-05
missense O 0 0.19695964455604553
mutations O 0 0.0013816488208249211
in O 0 1.6536941984668374e-05
the O 0 0.00011839410581160337
ataxia B-Disease 1 1.0
- I-Disease 1 0.9984606504440308
telangiectasia I-Disease 1 0.9999865293502808
gene O 0 4.918510967399925e-05
in O 0 1.36471669520688e-06
a O 0 3.7304901070456253e-06
sporadic B-Disease 0 0.0016971721779555082
T I-Disease 1 0.9903526902198792
- I-Disease 0 0.2446877360343933
cell I-Disease 0 0.21040114760398865
leukaemia I-Disease 1 0.9930551648139954
. O 0 6.485798803623766e-05

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999978542327881
telangiectasia I-Disease 1 0.9999997615814209
( O 0 0.0043910788372159
A B-Disease 1 0.9974719882011414
- I-Disease 1 0.9999401569366455
T I-Disease 1 0.9999676942825317
) O 0 1.2061491361237131e-06
is O 0 2.414989239696297e-07
a O 0 2.1965890937281074e-06
recessive B-Disease 0 0.4509858191013336
multi I-Disease 1 0.5504160523414612
- I-Disease 1 0.9988874793052673
system I-Disease 1 0.8893219232559204
disorder I-Disease 1 0.9972516894340515
caused O 0 4.754624387715012e-05
by O 0 1.7053308738468331e-06
mutations O 0 2.006330578296911e-05
in O 0 6.159871190902777e-07
the O 0 8.726597116037738e-07
ATM O 0 2.783360287139658e-05
gene O 0 8.106374480121303e-06
at O 0 1.7529384876979748e-06
11q22 O 0 4.1937644709832966e-05
- O 0 3.708167059812695e-05
q23 O 0 5.086910823592916e-05
( O 0 5.323838649928803e-06
ref O 0 6.891424709465355e-05
. O 0 6.820500857429579e-07
3 O 0 2.309578576387139e-06
) O 0 4.4216812966624275e-06
. O 0 1.2897467058792245e-05

The O 0 4.163344783592038e-05
risk O 0 5.45536786376033e-05
of O 0 3.2692801141820382e-06
cancer B-Disease 0 0.313973069190979
, O 0 1.2223703151903464e-06
especially O 0 2.6423238068673527e-06
lymphoid B-Disease 0 0.0030516176484525204
neoplasias I-Disease 0 0.013271625153720379
, O 0 6.839226784904895e-07
is O 0 4.0265649658977054e-07
substantially O 0 2.4351091269636527e-05
elevated O 0 0.0006163858924992383
in O 0 5.314291684044292e-06
A B-Disease 1 0.9999181032180786
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.012346294708549976
and O 0 7.21221567800967e-07
has O 0 5.94476716742065e-07
long O 0 1.178312231786549e-06
been O 0 1.144038833444938e-06
associated O 0 8.987790351966396e-06
with O 0 1.4167266272124834e-05
chromosomal O 1 0.9999629259109497
instability O 1 0.9484473466873169
. O 0 8.238678856287152e-05

By O 0 0.00017402501543983817
analysing O 0 0.008437125943601131
tumour B-Disease 1 0.9999997615814209
DNA O 0 0.0011636295821517706
from O 0 1.9231660189689137e-05
patients O 0 5.1367798732826486e-05
with O 0 1.4486408872471657e-06
sporadic B-Disease 0 0.003348570317029953
T I-Disease 1 0.9297013878822327
- I-Disease 0 0.004532722290605307
cell I-Disease 0 0.00444761523976922
prolymphocytic I-Disease 1 0.8089049458503723
leukaemia I-Disease 1 0.999981164932251
( O 0 4.5184158807387576e-05
T B-Disease 0 0.3167426288127899
- I-Disease 0 0.00017948553431779146
PLL I-Disease 0 0.0006450858199968934
) O 0 7.983711611814215e-07
, O 0 1.7622366499381314e-07
a O 0 4.637708741483948e-07
rare O 0 3.6292094591772184e-06
clonal B-Disease 0 0.00013833146658726037
malignancy I-Disease 0 0.0007372415857389569
with O 0 4.770750479110575e-07
similarities O 0 1.4443781992667937e-06
to O 0 4.5752662458653504e-07
a O 0 2.100582378261606e-06
mature B-Disease 0 3.778601603698917e-05
T I-Disease 1 0.9248520731925964
- I-Disease 0 0.04409200698137283
cell I-Disease 0 0.049379270523786545
leukaemia I-Disease 1 0.8529036641120911
seen O 0 2.558579808464856e-06
in O 0 1.0389568387836334e-06
A B-Disease 1 0.8129622340202332
- I-Disease 1 0.9998189806938171
T I-Disease 1 0.9999874830245972
, O 0 3.9847279253990564e-07
we O 0 9.596475791795456e-08
demonstrate O 0 5.606432864624367e-07
a O 0 3.979851612712082e-07
high O 0 8.99993381153763e-07
frequency O 0 2.186025312767015e-06
of O 0 4.555955683827051e-07
ATM O 0 0.0003949090314563364
mutations O 0 0.00010013808059738949
in O 0 9.404327101947274e-06
T B-Disease 0 0.24794407188892365
- I-Disease 0 0.000989120570011437
PLL I-Disease 0 0.008684437721967697
. O 0 6.33547460893169e-05

In O 0 3.335130895720795e-05
marked O 0 2.526577009120956e-05
contrast O 0 9.713181498227641e-06
to O 0 7.554632475148537e-07
the O 0 7.68187476296589e-07
ATM O 0 9.281210077460855e-05
mutation O 0 1.4693750017613638e-05
pattern O 0 4.101867034478346e-06
in O 0 1.3509876453099423e-06
A B-Disease 1 0.9394748210906982
- I-Disease 1 0.9997507929801941
T I-Disease 1 0.9998766183853149
, O 0 1.1089849039080946e-07
the O 0 8.646888716157264e-08
most O 0 1.2398302828842134e-07
frequent O 0 1.3815937336403294e-06
nucleotide O 0 1.649034288675466e-06
changes O 0 1.00919135093136e-06
in O 0 6.300218728938489e-07
this O 0 3.067288162128534e-06
leukaemia B-Disease 1 0.9898011088371277
were O 0 1.8671125872060657e-05
missense O 0 0.011903378181159496
mutations O 0 0.0010860624024644494
. O 0 5.337087350198999e-05

These O 0 1.842989877332002e-05
clustered O 0 4.512086161412299e-05
in O 0 1.4327197277452797e-06
the O 0 4.813641112377809e-07
region O 0 6.637428100475518e-07
corresponding O 0 4.4384731268110045e-07
to O 0 1.4068693587887537e-07
the O 0 2.2089466256147716e-07
kinase O 0 1.4908111552358605e-05
domain O 0 7.376407324954926e-07
, O 0 1.0722543919428063e-07
which O 0 8.445825727676493e-08
is O 0 4.457230318166694e-08
highly O 0 1.6218265841416724e-07
conserved O 0 6.13055647136207e-07
in O 0 3.233227516830084e-07
ATM O 0 2.703125028347131e-05
- O 0 1.1710881153703667e-05
related O 0 1.0495208471184014e-06
proteins O 0 6.676726229670749e-07
in O 0 4.818220418201236e-07
mouse O 0 1.009373227134347e-05
, O 0 9.916057024383917e-07
yeast O 0 1.4892337276251055e-05
and O 0 2.344566610190668e-06
Drosophila O 0 5.8916401030728593e-05
. O 0 1.586344478710089e-05

The O 0 5.160661748959683e-05
resulting O 0 5.7323926739627495e-05
amino O 0 3.2768919481895864e-05
- O 0 4.737105336971581e-05
acid O 0 6.611333446926437e-06
substitutions O 0 4.883288966084365e-06
are O 0 3.115987396995479e-07
predicted O 0 2.932124516519252e-06
to O 0 4.731511467070959e-07
interfere O 0 2.3168233838077867e-06
with O 0 5.638680704578292e-07
ATP O 0 1.806085856514983e-05
binding O 0 6.444345217460068e-06
or O 0 3.4823872283595847e-06
substrate O 0 4.1036033508135006e-05
recognition O 0 2.374813993810676e-05
. O 0 3.502181789372116e-05

Two O 0 1.4032801118446514e-05
of O 0 5.870882432645885e-06
seventeen O 0 4.9719037633622065e-05
mutated O 0 0.001756437704898417
T B-Disease 0 0.4043881297111511
- I-Disease 0 0.0002550577337387949
PLL I-Disease 0 0.001328685786575079
samples O 0 3.6025364806846483e-06
had O 0 1.2916023024445167e-06
a O 0 1.1392613714633626e-06
previously O 0 1.0341000233893283e-05
reported O 0 0.0004539014189504087
A B-Disease 0 0.15379631519317627
- I-Disease 1 0.9707129597663879
T I-Disease 1 0.9997203946113586
allele O 0 0.0008932616910897195
. O 0 4.345549314166419e-05

In O 0 3.826795727945864e-05
contrast O 0 4.147553045186214e-05
, O 0 2.7717019293049816e-06
no O 0 1.5738229421913275e-06
mutations O 0 1.2599854017025791e-05
were O 0 5.730569228035165e-07
detected O 0 3.76360867448966e-06
in O 0 2.4976347390293085e-07
the O 0 3.6314384033175884e-07
p53 O 0 7.069643288559746e-06
gene O 0 2.969161187138525e-06
, O 0 1.6872630226316687e-07
suggesting O 0 1.1595154774113325e-06
that O 0 2.0136371858825441e-07
this O 0 7.884966066740162e-07
tumour B-Disease 1 0.9999579191207886
suppressor O 0 0.000995317124761641
is O 0 2.7919494982597826e-07
not O 0 1.8763327602755453e-07
frequently O 0 1.1636185490715434e-06
altered O 0 1.1686169273161795e-05
in O 0 1.52878885728569e-06
this O 0 8.145578249241225e-06
leukaemia B-Disease 1 0.9921680092811584
. O 0 4.0248880395665765e-05

Occasional O 0 0.0021649564150720835
missense O 1 0.6720242500305176
mutations O 0 0.0024125874042510986
in O 0 8.514862201991491e-06
ATM O 0 8.80995430634357e-05
were O 0 1.7331838080281159e-06
also O 0 6.594397632397886e-07
found O 0 5.872942665519076e-07
in O 0 3.4334300380578497e-06
tumour B-Disease 1 0.9999997615814209
DNA O 0 7.922010991023853e-05
from O 0 7.780221494613215e-06
patients O 0 5.280095501802862e-05
with O 0 1.3892092738387873e-06
B B-Disease 0 4.5656888687517494e-05
- I-Disease 0 4.952266681357287e-05
cell I-Disease 0 5.8538989833323285e-05
non I-Disease 0 1.6893682186491787e-05
- I-Disease 1 0.5940085649490356
Hodgkins I-Disease 1 0.9999901056289673
lymphomas I-Disease 1 0.9964991807937622
( O 0 5.462286480906187e-06
B B-Disease 0 7.777447535772808e-06
- I-Disease 0 5.052513643022394e-06
NHL I-Disease 0 3.0221258384699468e-06
) O 0 3.614756565184507e-07
and O 0 2.1676537187431677e-07
a O 0 1.6436049463663949e-06
B B-Disease 0 1.7575084712007083e-05
- I-Disease 0 1.6581696399953216e-05
NHL I-Disease 0 1.8488537534722127e-05
cell O 0 6.247991404961795e-05
line O 0 4.439713666215539e-05
. O 0 2.0936602595611475e-05

The O 0 1.0835370630957186e-05
evidence O 0 2.7144269552081823e-06
of O 0 4.422560664352204e-07
a O 0 9.486227554589277e-07
significant O 0 7.210799140011659e-07
proportion O 0 7.096189733601932e-07
of O 0 1.8803669377120968e-07
loss O 0 0.0002462014090269804
- O 0 2.2117945263744332e-05
of O 0 2.694672787129093e-07
- O 0 0.000124254627735354
function O 0 1.8518496744945878e-06
mutations O 0 3.654057991298032e-06
and O 0 9.865454586588385e-08
a O 0 1.9794545380591444e-07
complete O 0 5.340684765542392e-07
absence O 0 6.004406145621033e-07
of O 0 3.643002699504905e-08
the O 0 1.2877400479283097e-07
normal O 0 4.6999051050988783e-07
copy O 0 7.661316203666502e-07
of O 0 7.648323219200392e-08
ATM O 0 2.4743585527176037e-06
in O 0 1.497663220106915e-07
the O 0 1.8352463371229533e-07
majority O 0 9.112068823924346e-07
of O 0 1.2480828672778443e-06
mutated O 0 0.019386958330869675
tumours B-Disease 1 0.9999551773071289
establishes O 0 0.00018095820269081742
somatic O 0 0.00013679781113751233
inactivation O 0 0.0001772284449543804
of O 0 2.9593499561997305e-07
this O 0 2.3857452902120713e-07
gene O 0 1.487768145125301e-06
in O 0 2.118696613706561e-07
the O 0 3.273973732120794e-07
pathogenesis O 0 1.624261676624883e-05
of O 0 5.568217602558434e-07
sporadic B-Disease 0 0.0016055530868470669
T I-Disease 1 0.8530954718589783
- I-Disease 0 8.959573460742831e-05
PLL I-Disease 0 0.0003047869831789285
and O 0 4.856501050198858e-07
suggests O 0 9.068073723028647e-07
that O 0 2.1425734075819491e-07
ATM O 0 6.9597472247551195e-06
acts O 0 1.0346715271225548e-06
as O 0 1.027540292852791e-06
a O 0 2.06479035114171e-05
tumour B-Disease 1 0.9999945163726807
suppressor O 0 0.01572233811020851
. O 0 6.308410956989974e-05

As O 0 2.128431515302509e-05
constitutional O 0 2.7642192435450852e-05
DNA O 0 2.3680044250795618e-05
was O 0 5.287448857416166e-06
not O 0 3.53358132088033e-07
available O 0 3.769887939597538e-07
, O 0 1.7204904168011126e-07
a O 0 1.242852022187435e-06
putative O 0 0.0002479235699865967
hereditary O 1 0.9725583791732788
predisposition O 0 0.123328298330307
to O 0 3.635428220150061e-05
T B-Disease 1 0.9756929278373718
- I-Disease 0 0.0007466250099241734
PLL I-Disease 0 0.0007799092563800514
will O 0 7.467758109669376e-07
require O 0 1.1603428902162705e-06
further O 0 1.2541248679553973e-06
investigation O 0 9.30462556425482e-06
. O 0 3.347038045831141e-06
. O 0 1.3987987586006057e-05

Myotonic B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 0.9999998807907104
protein O 0 0.001843254896812141
kinase O 0 0.018254971131682396
is O 0 3.85112980438862e-06
involved O 0 1.739117919896671e-06
in O 0 3.5780715279543074e-07
the O 0 3.7563549426522513e-07
modulation O 0 4.069604983669706e-06
of O 0 2.487494441538729e-07
the O 0 1.3370359965847456e-06
Ca2 O 0 0.00017128139734268188
+ O 0 4.4813230488216504e-05
homeostasis O 0 0.0014483283739537
in O 0 9.038140888151247e-06
skeletal O 0 0.37353408336639404
muscle O 0 0.4095365107059479
cells O 0 0.0004860587068833411
. O 0 6.739723175996915e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.978721559047699
DM B-Disease 1 1.0
) O 0 1.1825296496681403e-05
, O 0 5.789102601738705e-07
the O 0 4.025137059215922e-07
most O 0 8.245889375757542e-07
prevalent O 0 0.016218293458223343
muscular B-Disease 1 0.9999995231628418
disorder I-Disease 1 0.9999966621398926
in O 0 4.9497830332256854e-05
adults O 0 5.265106665319763e-05
, O 0 6.567811396962497e-07
is O 0 3.437672262407432e-07
caused O 0 7.293262569874059e-06
by O 0 9.902835245156894e-07
( O 0 3.1193310405797092e-06
CTG O 0 0.0002621448365971446
) O 0 1.1298869821985136e-06
n O 0 4.273776085028658e-06
- O 0 2.571036702647689e-06
repeat O 0 1.904234295579954e-06
expansion O 0 1.226649146701675e-06
in O 0 2.4705337864361354e-07
a O 0 4.814664862351492e-07
gene O 0 2.8132105853728717e-06
encoding O 0 2.2579888536711223e-06
a O 0 1.551802370158839e-06
protein O 0 5.337366474122973e-06
kinase O 0 0.0001225101004820317
( O 0 5.969718586129602e-06
DM B-Disease 1 0.9994925260543823
protein O 0 9.139133908320218e-06
kinase O 0 5.6638782552909106e-05
; O 0 1.063392119249329e-06
DMPK O 0 3.932713298127055e-05
) O 0 4.218870230943139e-07
and O 0 1.8184115901931364e-07
involves O 0 8.237911970354617e-07
changes O 0 1.5655132301617414e-06
in O 0 1.3791477613267489e-06
cytoarchitecture O 0 0.00017782600480131805
and O 0 6.729151209583506e-06
ion O 0 0.0008415302145294845
homeostasis O 0 0.022297793999314308
. O 0 5.061072442913428e-05

To O 0 1.7950893379747868e-05
obtain O 0 1.0443636710988358e-05
clues O 0 7.620475571457064e-06
to O 0 5.525801611838688e-07
the O 0 3.9034253518366313e-07
normal O 0 1.1971258118137484e-06
biological O 0 1.2055351135131787e-06
role O 0 3.5194156566831225e-07
of O 0 1.9022942865376535e-07
DMPK O 0 9.827271424001083e-05
in O 0 1.0749855618996662e-06
cellular O 0 3.181996726198122e-05
ion O 0 0.0006002059089951217
homeostasis O 0 0.09032968431711197
, O 0 4.266793780516309e-07
we O 0 1.0284741591704005e-07
have O 0 1.3222819461589097e-07
compared O 0 4.407298206388077e-07
the O 0 4.2239025788148865e-07
resting O 0 2.238702836621087e-05
[ O 0 9.573415809427388e-06
Ca2 O 0 0.00011288314271951094
+ O 0 2.0449742805794813e-05
] O 0 3.913110958819743e-06
i O 0 2.758722246198886e-07
, O 0 4.525858798842819e-08
the O 0 9.290851465948435e-08
amplitude O 0 1.1570940614546998e-06
and O 0 2.247883372774595e-07
shape O 0 1.3851307585355244e-06
of O 0 3.897034730471205e-07
depolarization O 0 9.100870374822989e-05
- O 0 0.0004443977086339146
induced O 0 0.0003691735619213432
Ca2 O 0 0.00010176064097322524
+ O 0 1.1730777259799652e-05
transients O 0 1.2340515240794048e-05
, O 0 1.186752882631481e-07
and O 0 6.20258475692026e-08
the O 0 7.247988520475701e-08
content O 0 1.5216077997592947e-07
of O 0 7.995478057409855e-08
ATP O 0 6.5415601966378745e-06
- O 0 8.868976692610886e-06
driven O 0 4.8226979743049014e-06
ion O 0 9.929003681463655e-06
pumps O 0 8.606724804849364e-06
in O 0 8.879063670974574e-07
cultured O 0 2.5841147362370975e-05
skeletal O 0 0.02407054230570793
muscle O 0 0.004325784742832184
cells O 0 5.737646915804362e-06
of O 0 2.5587110030755866e-07
wild O 0 1.3123601547704311e-06
- O 0 1.5029262613097671e-05
type O 0 3.050427039852366e-06
and O 0 7.090000622156367e-07
DMPK O 0 0.0009193237056024373
[ O 0 2.471161678840872e-05
- O 0 0.0008089892799034715
/ O 0 0.0011721819173544645
- O 0 9.929144289344549e-05
] O 0 3.535200085025281e-05
knockout O 0 0.00022464263020083308
mice O 0 0.0008215036359615624
. O 0 4.782792166224681e-05

In O 0 0.00016185600543394685
vitro O 0 0.0010654600337147713
- O 0 0.0005432503530755639
differentiated O 0 0.0001821849582483992
DMPK O 0 0.04534044489264488
[ O 0 0.00011303857172606513
- O 0 0.0026056277565658092
/ O 0 0.0011041798861697316
- O 0 4.47140664618928e-05
] O 0 7.002635811659275e-06
myotubes O 0 2.519195550121367e-05
exhibit O 0 4.56489897260326e-06
a O 0 1.2235529993631644e-06
higher O 0 3.769761860894505e-06
resting O 0 3.5901099181501195e-05
[ O 0 1.5369270840892568e-05
Ca2 O 0 0.0001984315167646855
+ O 0 2.4951141313067637e-05
] O 0 3.728921683432418e-06
i O 0 3.7682309539377457e-07
than O 0 8.106067639346293e-08
do O 0 1.21292544008611e-07
wild O 0 6.161321834952105e-07
- O 0 3.292092515039258e-05
type O 0 6.900859261804726e-06
myotubes O 0 0.00010623530397424474
because O 0 1.6956607851170702e-07
of O 0 4.51534774015272e-08
an O 0 1.1658306675599306e-07
altered O 0 3.7004535897722235e-06
open O 0 4.14036463780576e-07
probability O 0 3.234056862311263e-07
of O 0 2.0542221079722367e-07
voltage O 0 2.413087713648565e-05
- O 0 5.591306762653403e-05
dependent O 0 7.493393695767736e-06
l O 0 0.0002600101288408041
- O 0 2.2953910956857726e-05
type O 0 1.3530296200769953e-05
Ca2 O 0 6.711413152515888e-05
+ O 0 1.4927288248145487e-05
and O 0 2.394133616689942e-06
Na O 0 6.90982342348434e-05
+ O 0 4.573558908305131e-05
channels O 0 3.436811675783247e-05
. O 0 2.487333222234156e-05

The O 0 6.369221955537796e-05
mutant O 0 0.00023980160767678171
myotubes O 0 0.0002565750328358263
exhibit O 0 2.510154627088923e-05
smaller O 0 4.606808488460956e-06
and O 0 1.585304403306509e-06
slower O 0 2.1216668756096624e-05
Ca2 O 0 0.00011516771337483078
+ O 0 9.76423416432226e-06
responses O 0 3.4213101116620237e-06
upon O 0 1.1207316674699541e-06
triggering O 0 1.0765525985334534e-05
by O 0 2.1075293261674233e-06
acetylcholine O 0 0.0001301596057601273
or O 0 2.639754939082195e-06
high O 0 6.034104899299564e-06
external O 0 5.4925974836805835e-05
K O 0 0.00013719964772462845
+ O 0 8.121857536025345e-05
. O 0 2.343347114219796e-05

In O 0 4.4654701923718676e-05
addition O 0 9.976060937333386e-06
, O 0 1.1573268920983537e-06
we O 0 1.955093154037968e-07
observed O 0 6.404213195310149e-07
that O 0 1.3050484426457842e-07
these O 0 3.908074006631068e-07
Ca2 O 0 4.6097178710624576e-05
+ O 0 1.9308161427034065e-05
transients O 0 8.269800309790298e-05
partially O 0 2.479539398336783e-05
result O 0 8.309223744618066e-07
from O 0 2.0452185367503262e-07
an O 0 1.6491681265051739e-07
influx O 0 1.149471927419654e-06
of O 0 3.817488618551579e-07
extracellular O 0 9.51453603192931e-06
Ca2 O 0 3.294435373391025e-05
+ O 0 4.010869361081859e-06
through O 0 6.185548500070581e-07
the O 0 1.212644860970613e-06
l O 0 0.00024760205997154117
- O 0 3.2823245419422165e-05
type O 0 2.2876463845022954e-05
Ca2 O 0 0.00014133626245893538
+ O 0 4.565828203340061e-05
channel O 0 6.323806155705824e-05
. O 0 2.163735007343348e-05

Neither O 0 8.71434313012287e-05
the O 0 7.166278010117821e-06
content O 0 5.5304171837633476e-06
nor O 0 3.1847878290136578e-06
the O 0 5.34427101683832e-07
activity O 0 1.3724680911764153e-06
of O 0 8.403370657106279e-07
Na O 0 4.9378078983863816e-05
+ O 0 3.57062672264874e-05
/ O 0 5.947405952611007e-05
K O 0 3.220234430045821e-05
+ O 0 3.5565546568250284e-05
ATPase O 0 8.55534672155045e-05
and O 0 5.33823686055257e-06
sarcoplasmic O 0 0.0011665624333545566
reticulum O 0 0.0014831072185188532
Ca2 O 0 0.0007320817676372826
+ O 0 7.719577115494758e-05
- O 0 5.70615848118905e-05
ATPase O 0 7.958188507473096e-05
are O 0 9.200875865644775e-07
affected O 0 3.339984914418892e-06
by O 0 3.37459528054751e-06
DMPK O 0 0.002082086866721511
absence O 0 0.0001771951501723379
. O 0 4.7949401050573215e-05

In O 0 2.2769074348616414e-05
conclusion O 0 1.1119942428194918e-05
, O 0 1.1232709766773041e-06
our O 0 5.837000003339199e-07
data O 0 1.2116692005292862e-06
suggest O 0 8.472688364236092e-07
that O 0 1.8042175042864983e-07
DMPK O 0 6.70707449899055e-05
is O 0 2.5127917524514487e-07
involved O 0 3.923144902273634e-07
in O 0 3.969261115344125e-07
modulating O 0 2.1873411242268048e-05
the O 0 4.076943866948568e-07
initial O 0 1.268324808734178e-06
events O 0 4.95345830131555e-07
of O 0 2.3098245094388403e-07
excitation O 0 2.7778341973316856e-05
- O 0 5.558982593356632e-05
contraction O 0 5.475982106872834e-05
coupling O 0 2.5238603484467603e-05
in O 0 5.805616638099309e-06
skeletal O 0 0.04387130215764046
muscle O 0 0.0019304455490782857
. O 0 5.818720637762453e-06
. O 0 1.8935330444946885e-05

Constitutional O 0 0.0027751903980970383
RB1 O 1 0.9846817255020142
- O 0 0.34797942638397217
gene O 0 0.0011357994517311454
mutations O 0 0.0007016640156507492
in O 0 8.66604023030959e-06
patients O 0 0.00010288311023032293
with O 0 5.1631736823765095e-06
isolated O 0 0.00046073057455942035
unilateral B-Disease 0 0.013089478015899658
retinoblastoma I-Disease 1 0.9388787150382996
. O 0 0.00011030424502678216

In O 0 5.846985732205212e-05
most O 0 6.640469109697733e-06
patients O 0 5.798329220851883e-05
with O 0 1.508987679699203e-06
isolated O 0 4.177363734925166e-05
unilateral B-Disease 0 0.0003022455202881247
retinoblastoma I-Disease 1 0.7219237089157104
, O 0 4.2350693547632545e-06
tumor B-Disease 0 0.000250355718890205
development O 0 9.015809041557077e-07
is O 0 2.4819684085741756e-07
initiated O 0 2.101804739140789e-06
by O 0 6.453457785937644e-07
somatic O 0 2.170377229049336e-05
inactivation O 0 4.42340096924454e-05
of O 0 2.9419877023428853e-07
both O 0 4.546485286027746e-07
alleles O 0 3.692634436447406e-06
of O 0 4.131738364776538e-07
the O 0 6.746571216353914e-06
RB1 O 0 0.008757193572819233
gene O 0 0.00011234834528295323
. O 0 2.51187157118693e-05

However O 0 4.204640936222859e-05
, O 0 1.7427074681108934e-06
some O 0 2.5215368282260897e-07
of O 0 3.305113125406933e-07
these O 0 1.5061956446515978e-06
patients O 0 0.0010161380050703883
can O 0 2.641865421537659e-06
transmit O 0 0.008051199838519096
retinoblastoma B-Disease 1 0.9599945545196533
predisposition O 0 0.0005221549072302878
to O 0 2.3165714537753956e-06
their O 0 3.91895218854188e-06
offspring O 0 9.592259448254481e-05
. O 0 3.6593799450201914e-05

To O 0 1.4002483112562913e-05
determine O 0 4.94366031489335e-06
the O 0 1.0902118674493977e-06
frequency O 0 5.8813275245483965e-06
and O 0 4.0353839381168655e-07
nature O 0 6.605601470255351e-07
of O 0 2.976505015794828e-07
constitutional O 0 1.6595176930422895e-05
RB1 O 1 0.891427218914032
- O 0 0.03241638466715813
gene O 0 7.834863208699971e-05
mutations O 0 5.790951763628982e-05
in O 0 1.5283442280633608e-06
patients O 0 1.271493783860933e-05
with O 0 4.04832775302566e-07
isolated O 0 1.1980272574874107e-05
unilateral B-Disease 0 0.00010493909940123558
retinoblastoma I-Disease 0 0.25056445598602295
, O 0 4.3517124481695646e-07
we O 0 1.5353096216585982e-07
analyzed O 0 1.2581450619109091e-06
DNA O 0 1.366991000395501e-06
from O 0 1.1522685099407681e-06
peripheral O 0 0.0001325991761405021
blood O 0 2.013374432863202e-05
and O 0 2.0086536096641794e-06
from O 0 1.6774272808106616e-05
tumor B-Disease 1 0.9339861869812012
tissue O 0 0.015006343834102154
. O 0 5.248869274510071e-05

The O 0 2.6893996619037353e-05
analysis O 0 1.674796294537373e-05
of O 0 3.2839475352375302e-06
tumors B-Disease 1 0.9785017967224121
from O 0 1.775625605660025e-06
54 O 0 4.637377969629597e-06
( O 0 1.3673065950570162e-06
71 O 0 2.182215439461288e-06
% O 0 3.0387442961909983e-07
) O 0 2.0624314345241146e-07
of O 0 1.721453770642256e-07
76 O 0 3.880756048602052e-05
informative O 0 0.00013133275206200778
patients O 0 0.01822422258555889
showed O 0 7.58562091505155e-05
loss O 0 3.09076567646116e-05
of O 0 1.4253740800995729e-06
constitutional O 0 6.831633800175041e-05
heterozygosity O 0 0.2763925790786743
( O 0 0.00010188765736529604
LOH O 1 0.9359822273254395
) O 0 4.671654551202664e-06
at O 0 8.56788938108366e-06
intragenic O 0 0.000523354159668088
loci O 0 0.00029604375595226884
. O 0 4.6740544348722324e-05

Three O 0 1.4096392078499775e-05
of O 0 4.354777956905309e-06
13 O 0 2.8472231861087494e-05
uninformative O 1 0.8070542812347412
patients O 0 0.18893128633499146
had O 0 2.4432600184809417e-05
constitutional O 0 6.403063161997125e-05
deletions O 0 0.0006922248867340386
. O 0 4.9946953367907554e-05

For O 0 3.964380084653385e-05
39 O 0 5.50965778529644e-05
randomly O 0 2.5523297153995372e-05
selected O 0 2.3533220883109607e-05
tumors B-Disease 1 0.9998188614845276
, O 0 3.011136186614749e-06
SSCP O 0 0.008907441981136799
, O 0 3.471444870228879e-06
hetero O 0 0.002237058011814952
- O 0 7.822112092981115e-05
duplex O 0 0.00013656191003974527
analysis O 0 7.914634352346184e-07
, O 0 1.3777659546576615e-07
sequencing O 0 4.5176051344242296e-07
, O 0 8.20158803094273e-08
and O 0 9.580546844745186e-08
Southern O 0 6.954452373975073e-07
blot O 0 7.68371537560597e-05
analysis O 0 1.2889838671981124e-06
were O 0 2.7949491254730674e-07
used O 0 6.087955171096837e-07
to O 0 1.6044244830482057e-06
identify O 0 3.0400762625504285e-05
mutations O 0 0.0003176534955855459
. O 0 2.977776966872625e-05

Mutations O 0 0.09054222702980042
were O 0 2.4523731553927064e-05
detected O 0 3.984134309575893e-05
in O 0 2.3928669179440476e-06
21 O 0 3.1714880606159568e-06
( O 0 1.0246584452033858e-06
91 O 0 2.4139721972460393e-06
% O 0 3.5955477528659685e-07
) O 0 3.115247295681911e-07
of O 0 4.545093474916939e-07
23 O 0 0.00015388634346891195
tumors B-Disease 1 0.9999808073043823
with O 0 6.76115887472406e-05
LOH O 1 0.9998558759689331
. O 0 0.00010168266453547403

In O 0 4.4346819777274504e-05
6 O 0 1.6312611478497274e-05
( O 0 2.800792344714864e-06
38 O 0 1.9651290585898096e-06
% O 0 3.9170063814708556e-07
) O 0 2.2718116099440522e-07
of O 0 2.2156450540933292e-07
16 O 0 3.4079112083418295e-05
tumors B-Disease 1 0.9999829530715942
without O 0 9.880339348455891e-06
LOH O 1 0.9955304265022278
, O 0 4.561425157589838e-07
one O 0 1.6325667218097806e-07
mutation O 0 3.4935503663291456e-06
was O 0 1.1276199529675068e-06
detected O 0 2.742495098573272e-06
, O 0 7.036550186967361e-08
and O 0 5.956191273526201e-08
in O 0 1.3915625629579154e-07
9 O 0 5.643452709591656e-07
( O 0 3.006454107890022e-07
56 O 0 5.382868266678997e-07
% O 0 1.0070496614389413e-07
) O 0 1.028772373956599e-07
of O 0 1.1443276548561698e-07
the O 0 9.976118235499598e-06
tumors B-Disease 1 0.9999984502792358
without O 0 1.844282087404281e-05
LOH O 1 0.9979596138000488
, O 0 8.833354741000221e-07
both O 0 1.074981582860346e-06
mutations O 0 2.7817626687465236e-05
were O 0 1.3337604514163104e-06
found O 0 4.603756224241806e-06
. O 0 1.3934384696767665e-05

Thus O 0 3.474279219517484e-05
, O 0 1.4538281902787276e-06
a O 0 9.593893537385156e-07
total O 0 2.1407558392638748e-07
of O 0 1.8279310154412087e-07
45 O 0 1.5078355772857321e-06
mutations O 0 2.3739061361993663e-05
were O 0 7.15211854185327e-07
identified O 0 5.019212949264329e-06
in O 0 6.786632638977608e-06
tumors B-Disease 1 0.9992319345474243
of O 0 2.4603250494692475e-06
36 O 0 0.00017967866733670235
patients O 0 0.012097997590899467
. O 0 6.491428939625621e-05

Thirty O 0 0.0001900387869682163
- O 0 6.179151387186721e-05
nine O 0 2.063060037471587e-06
of O 0 2.919296093750745e-07
the O 0 6.072507403587224e-07
mutations O 0 1.0280587957822718e-05
- O 0 2.6562297534837853e-06
including O 0 3.3733073223629617e-07
34 O 0 1.0475030194356805e-06
small O 0 9.665653806223418e-07
mutations O 0 6.140050118119689e-06
, O 0 1.4176129070619936e-07
2 O 0 3.0535133532794134e-07
large O 0 4.0073840068544087e-07
structural O 0 1.2084625268471427e-05
alterations O 0 1.8605396689963527e-05
, O 0 2.766333579984348e-07
and O 0 4.5592287278850563e-07
hypermethylation O 0 0.0002579597057774663
in O 0 2.8640051823458634e-06
3 O 0 8.319252083310857e-05
tumors O 1 0.9999982118606567
- O 0 0.0015718865906819701
were O 0 3.433642348227295e-07
not O 0 1.7939163399205427e-07
detected O 0 3.3800097298808396e-06
in O 0 2.459180166169972e-07
the O 0 6.62000559259468e-07
corresponding O 0 7.014145467110211e-06
peripheral O 0 0.0008150447392836213
blood O 0 0.00017557773389853537
DNA O 0 0.00010825447679962963
. O 0 5.104141746414825e-05

In O 0 3.551785630406812e-05
6 O 0 1.5410645573865622e-05
( O 0 2.787482117128093e-06
17 O 0 1.0466302455824916e-06
% O 0 1.7769423266145168e-07
) O 0 8.921829675045956e-08
of O 0 3.044650043193542e-08
the O 0 2.2491590812023787e-07
36 O 0 4.489744242164306e-06
patients O 0 1.9094579329248518e-05
, O 0 2.557805771630228e-07
a O 0 1.4244961903386866e-06
mutation O 0 2.795655200316105e-05
was O 0 6.855199444544269e-06
detected O 0 7.772242497594561e-06
in O 0 2.6652810447558295e-07
constitutional O 0 1.1914743254237692e-06
DNA O 0 1.0695536047933274e-06
, O 0 1.0209551959405871e-07
and O 0 4.7233783107003546e-08
1 O 0 8.644975224569862e-08
of O 0 4.667334252417277e-08
these O 0 1.685546919816261e-07
mutations O 0 5.159221473149955e-06
is O 0 9.321060900902012e-08
known O 0 3.3119980002993543e-07
to O 0 1.956661748181432e-07
be O 0 1.6776823485997738e-07
associated O 0 1.0039980224973988e-06
with O 0 1.1815282050520182e-06
reduced O 0 5.889263411518186e-05
expressivity O 0 0.005917960312217474
. O 0 6.15455792285502e-05

The O 0 1.1249710951233283e-05
presence O 0 5.128888915351126e-06
of O 0 3.867526743306371e-07
a O 0 1.4430675037147012e-06
constitutional O 0 1.0187208317802288e-05
mutation O 0 3.660150832729414e-05
was O 0 3.7952363527438138e-06
not O 0 1.4085098598570767e-07
associated O 0 3.0562637221009936e-07
with O 0 8.40173797200805e-08
an O 0 2.19571674620056e-07
early O 0 5.287257408781443e-06
age O 0 4.63232163383509e-06
at O 0 1.0970874427584931e-05
treatment O 0 0.00477259885519743
. O 0 4.054373857798055e-05

In O 0 6.184149242471904e-05
1 O 0 2.5799241484492086e-05
patient O 0 0.00010426362132420763
, O 0 2.0018226223328384e-06
somatic O 0 0.00015816075028851628
mosaicism O 0 0.023139722645282745
was O 0 1.1790792086685542e-05
demonstrated O 0 3.7785082440677797e-06
by O 0 6.29030694199173e-07
molecular O 0 2.5932931748684496e-06
analysis O 0 5.445997999231622e-07
of O 0 1.9101494785900286e-07
DNA O 0 2.2955468921281863e-06
and O 0 5.850972684129374e-07
RNA O 0 5.804587544844253e-06
from O 0 3.98553311242722e-06
peripheral O 0 0.0006057058344595134
blood O 0 0.00026748180971480906
. O 0 3.6726294638356194e-05

In O 0 0.00011027647997252643
2 O 0 5.559204873861745e-05
patients O 0 0.00014257208385970443
without O 0 1.6524157899766578e-06
a O 0 4.673125204135431e-06
detectable O 0 9.037384734256193e-05
mutation O 0 1.2378079190966673e-05
in O 0 1.2505371387305786e-06
peripheral O 0 0.0004171841137576848
blood O 0 4.129092121729627e-05
, O 0 1.3562417962020845e-06
mosaicism O 0 0.0007254608208313584
was O 0 4.6356535676750354e-06
suggested O 0 1.4485068504654919e-06
because O 0 1.0044502829487101e-07
1 O 0 9.110490140074035e-08
of O 0 4.739116477026073e-08
the O 0 1.4724038237545756e-06
patients O 0 0.016159897670149803
showed O 0 0.4494437575340271
multifocal O 1 0.9999998807907104
tumors B-Disease 1 0.9999997615814209
and O 0 6.994353611844417e-07
the O 0 3.2503581337550713e-07
other O 0 2.2383210307452828e-07
later O 0 2.517891971365316e-06
developed O 0 1.3286380635690875e-05
bilateral B-Disease 0 3.7552264984697104e-05
retinoblastoma I-Disease 0 0.20242713391780853
. O 0 6.068212678655982e-05

In O 0 2.6193212761427276e-05
conclusion O 0 9.731993486639112e-06
, O 0 1.1060292308684438e-06
our O 0 6.167959440972481e-07
results O 0 1.0437813671160256e-06
emphasize O 0 1.4402681927094818e-06
that O 0 1.475710149634324e-07
the O 0 1.7256354567507515e-07
manifestation O 0 2.3530383259640075e-06
and O 0 2.2131553123472258e-07
transmissibility O 0 1.078808509191731e-05
of O 0 2.208152523053286e-07
retinoblastoma B-Disease 0 0.00016132691234815866
depend O 0 5.869857204743312e-07
on O 0 1.640279236880815e-07
the O 0 1.0872179956322725e-07
nature O 0 1.4059290265322488e-07
of O 0 2.439278645738341e-08
the O 0 6.732147994625848e-08
first O 0 1.894874372965205e-07
mutation O 0 1.394441596858087e-06
, O 0 5.568355732066266e-08
its O 0 9.446092974485509e-08
time O 0 5.903924815697792e-08
in O 0 5.693484084190459e-08
development O 0 1.0092166746744624e-07
, O 0 2.5920661173017834e-08
and O 0 1.659191184444353e-08
the O 0 2.713173863355678e-08
number O 0 3.987395658100468e-08
and O 0 6.158014542734236e-08
types O 0 1.5226471816731646e-07
of O 0 8.883640134627058e-08
cells O 0 5.4062124945630785e-06
that O 0 3.0575958476219967e-07
are O 0 2.744211542449193e-07
affected O 0 3.268681439294596e-06
. O 0 2.1701184778066818e-06
. O 0 1.3128836144460365e-05

Hereditary B-Disease 1 0.9999992847442627
deficiency I-Disease 1 0.9988491535186768
of I-Disease 0 3.6794872357859276e-06
the I-Disease 0 2.237088438050705e-06
fifth I-Disease 0 6.023198693583254e-06
component I-Disease 0 3.2195000585488742e-06
of I-Disease 0 5.358892849471886e-07
complement I-Disease 0 5.572931058850372e-06
in O 0 3.232248673157301e-06
man O 0 2.8853264666395262e-05
. O 0 2.4106080672936514e-05

I O 0 0.002656554337590933
. O 0 0.0006385554443113506

Clinical O 0 0.0015650608111172915
, O 0 1.1936594091821462e-05
immunochemical O 0 0.0003772276977542788
, O 0 2.1850539724255214e-06
and O 0 1.4515865132125327e-06
family O 0 1.3744074749411084e-05
studies O 0 2.3950651666382328e-05
. O 0 2.9092318072798662e-05

The O 0 1.5160389011725783e-05
first O 0 6.683047558908584e-06
recognized O 0 3.7452018659678288e-06
human O 0 3.7275276554282755e-06
kindred O 0 0.003196938196197152
with O 0 0.00011351654393365607
hereditary B-Disease 1 0.9999992847442627
deficiency I-Disease 0 0.4961106777191162
of I-Disease 0 1.7700401144793432e-07
the I-Disease 0 3.160457140438666e-07
fifth I-Disease 0 1.5012195717645227e-06
component I-Disease 0 1.4361575040311436e-06
of I-Disease 0 2.853721809970011e-07
complement I-Disease 0 3.793911901084357e-06
( O 0 3.1091499295143876e-06
C5 O 0 9.874135139398277e-05
) O 0 1.179904529635678e-06
is O 0 8.469182262160757e-07
described O 0 1.3878182471671607e-05
. O 0 1.29916807054542e-05

The O 0 4.234813241055235e-05
proband O 0 0.0008392183226533234
, O 0 2.2861265733808978e-06
a O 0 9.858105158855324e-07
20 O 0 1.0478506737854332e-06
- O 0 7.516267942264676e-06
year O 0 7.262296435328608e-07
- O 0 5.910813797527226e-06
old O 0 1.369404913020844e-06
black O 0 2.075556039926596e-06
female O 0 8.015211278689094e-06
with O 0 0.23518580198287964
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 0.017221523448824883
age O 0 1.0282294169883244e-05
11 O 0 2.662489123395062e-06
, O 0 9.002664000945515e-07
lacked O 0 0.00010071496217278764
serum O 0 0.02359304390847683
hemolytic O 0 0.3624792695045471
complement O 0 8.243466254498344e-06
activity O 0 5.417598458734574e-06
, O 0 1.049490833793243e-06
even O 0 2.3218951810122235e-06
during O 0 2.1346029825508595e-05
remission O 0 0.001683680573478341
. O 0 3.9689388358965516e-05

C5 O 0 0.10254943370819092
was O 0 0.0001721652806736529
undetectable O 0 0.0002752867294475436
in O 0 4.708052529167617e-06
her O 0 9.725424206408206e-06
serum O 0 5.311011409503408e-05
by O 0 2.2105932657723315e-06
both O 0 3.0864111977280118e-06
immunodiffusion O 0 0.0019003284396603703
and O 0 5.5405645980499685e-05
hemolytic O 1 0.9997745156288147
assays O 0 0.002438549418002367
. O 0 0.00011997482215519994

Other O 0 7.189291409304133e-06
complement O 0 1.7592185031389818e-05
components O 0 8.490957043250091e-06
were O 0 9.505516231911315e-07
normal O 0 2.3571710698888637e-06
during O 0 6.539538844663184e-06
remission O 0 0.0006978208548389375
of O 0 3.7428881114465185e-06
lupus O 1 0.9997500777244568
, O 0 1.4871709481667494e-06
but O 0 1.3351426559893298e-06
C1 O 0 0.00020719920576084405
, O 0 7.503409733544686e-07
C4 O 0 8.748882100917399e-05
, O 0 8.668270083944662e-07
C2 O 0 0.00011156326218042523
, O 0 5.06541596223542e-07
and O 0 7.514057642765692e-07
C3 O 0 0.00025665407883934677
levels O 0 7.258817731781164e-06
fell O 0 6.763351120753214e-05
during O 0 5.4571944929193705e-05
exacerbations O 0 0.497696191072464
. O 0 8.624859037809074e-05

A O 0 0.0001385260547976941
younger O 0 4.825812720810063e-05
half O 0 7.164378075685818e-06
- O 0 0.0002228597877547145
sister O 0 8.640129817649722e-05
, O 0 5.591023750639579e-07
who O 0 7.114634286153887e-07
had O 0 1.9749600141949486e-06
no O 0 2.4993316856125602e-06
underlying O 0 0.10341791808605194
disease O 0 0.080109603703022
, O 0 2.7092676191387e-07
was O 0 8.750698157200532e-07
also O 0 2.606101077162748e-07
found O 0 3.7737510183433187e-07
to O 0 7.578344138892135e-07
lack O 0 1.4172833289194386e-05
immunochemically O 0 0.06678376346826553
detectable O 0 0.0008250357932411134
C5 O 0 0.0009278225479647517
. O 0 4.744832040159963e-05

By O 0 0.00046341432607732713
hemolytic O 1 0.9999276399612427
assay O 0 0.03179381415247917
, O 0 1.0872509847104084e-05
she O 0 3.3886012715811376e-06
exhibited O 0 6.58602903058636e-06
1 O 0 8.967975873019896e-07
- O 0 1.8159174715037807e-06
2 O 0 2.1416154538655974e-07
% O 0 7.063039930699233e-08
of O 0 4.7659934665489345e-08
the O 0 3.938259567348723e-07
normal O 0 6.428300366678741e-06
serum O 0 4.866554809268564e-05
C5 O 0 1.8206519598606974e-05
level O 0 5.132613978275913e-07
and O 0 3.1933168997966277e-07
normal O 0 9.750459639690234e-07
concentrations O 0 1.186844997391745e-06
of O 0 1.1455320247932832e-07
other O 0 2.3979603724910703e-07
complement O 0 5.179013442102587e-06
components O 0 1.992603574763052e-05
. O 0 2.006209979299456e-05

C5 O 0 0.002423736732453108
levels O 0 1.8942066162708215e-05
of O 0 7.752615829303977e-07
other O 0 3.340744854085642e-07
family O 0 8.208362487494014e-07
members O 0 1.9915350435439905e-07
were O 0 1.1404121380564902e-07
either O 0 1.7396475016084878e-07
normal O 0 3.775461152599746e-07
or O 0 1.2949988104082877e-07
approximately O 0 1.5904304007108294e-07
half O 0 4.2571284097903117e-07
- O 0 6.796269190090243e-06
normal O 0 6.380790864568553e-07
, O 0 8.731311140763864e-08
consistent O 0 3.868279350172088e-07
with O 0 5.92803189647384e-07
autosomal O 0 0.0057033053599298
codominant O 0 0.0008127227774821222
inheritance O 0 8.175680704880506e-06
of O 0 3.7678464082091523e-07
the O 0 3.163625024171779e-06
gene O 0 0.00015262173837982118
determining O 0 0.00043046430801041424
C5 B-Disease 1 0.9999991655349731
deficiency I-Disease 1 0.9999990463256836
. O 0 0.00010613101039780304

Normal O 0 0.04814745485782623
hemolytic O 1 0.999984860420227
titers O 0 0.4056967496871948
were O 0 3.0950657674111426e-05
restored O 0 7.125350384740159e-05
to O 0 2.557669859015732e-06
both O 0 3.56595865014242e-06
homozygous O 0 0.11658505350351334
C5 B-Disease 1 0.9999978542327881
- I-Disease 1 0.9999061822891235
deficient I-Disease 1 0.9999977350234985
( O 0 2.188960206694901e-05
C5D B-Disease 1 0.9990577101707458
) O 0 2.096005800922285e-06
sera O 0 1.8516540876589715e-05
by O 0 4.0335061157747987e-07
addition O 0 3.844565128474642e-07
of O 0 2.630687276905519e-07
highly O 0 2.852627403626684e-06
purified O 0 3.1958821637090296e-05
human O 0 1.4032371836947277e-05
C5 O 0 0.0006744497804902494
. O 0 3.2431762519991025e-05

In O 0 5.2975159633206204e-05
specific O 0 3.107161683146842e-05
C5 O 0 0.0017382509540766478
titrations O 0 0.0024861404672265053
, O 0 2.8298288725636667e-06
however O 0 8.74468355505087e-07
, O 0 1.944471961223826e-07
it O 0 1.0283054763249311e-07
was O 0 4.1557450458640233e-07
noted O 0 1.7040908062426752e-07
that O 0 5.7292695032629126e-08
when O 0 1.0689503682215218e-07
limited O 0 2.204730975563507e-07
amounts O 0 1.479958058325792e-07
of O 0 7.777470045766677e-08
C5 O 0 1.8603586795507e-05
were O 0 2.2076555694638955e-07
assayed O 0 3.110490524704801e-06
in O 0 1.2474600907808053e-07
the O 0 9.610636197976419e-08
presence O 0 2.670433048024279e-07
of O 0 1.274329690659215e-07
low O 0 1.8293922039447352e-06
dilutions O 0 2.2459049432654865e-05
of O 0 5.90893193930242e-07
either O 0 3.721550001500873e-06
C5D B-Disease 1 0.9999523162841797
serum O 0 0.00027999948360957205
, O 0 6.274501629377482e-07
curving O 0 4.931831881549442e-06
rather O 0 5.85244038120436e-07
than O 0 2.2395529697405436e-07
linear O 0 2.0656432297982974e-06
dose O 0 1.4324494259199128e-05
- O 0 7.26968073649914e-06
response O 0 1.5937783928166027e-06
plots O 0 1.6009992123144912e-06
were O 0 3.923698841390433e-07
consistently O 0 1.4757580402147141e-06
obtained O 0 1.0055695156552247e-06
, O 0 2.0806619716040586e-07
suggesting O 0 2.507621047698194e-06
some O 0 8.784361398284091e-07
inhibitory O 0 4.990705565433018e-05
effect O 0 3.5072553146164864e-05
. O 0 2.2762042135582305e-05

Further O 0 9.89199397736229e-05
studies O 0 3.8579892134293914e-05
suggested O 0 1.8002599972533062e-05
that O 0 9.745216402734513e-07
low O 0 4.400907073431881e-06
dilutions O 0 6.718994700349867e-05
of O 0 1.962780288522481e-06
C5D B-Disease 1 0.999984622001648
serum O 0 0.0004896412719972432
contain O 0 2.462869815644808e-06
a O 0 1.4484364783129422e-06
factor O 0 1.984941491173231e-06
( O 0 5.547259434024454e-07
or O 0 2.8792709372282843e-07
factors O 0 3.157890091642912e-07
) O 0 1.478034050705901e-07
interfering O 0 5.917328849136538e-07
at O 0 1.6365275712360017e-07
some O 0 9.076390483642172e-08
step O 0 4.6694270849911845e-07
in O 0 3.040515252905607e-07
the O 0 2.2505073502543382e-06
hemolytic O 1 0.9244186878204346
assay O 0 2.197087451349944e-05
of O 0 4.4957286604585533e-07
C5 O 0 0.00011796845501521602
, O 0 2.731894710450433e-07
rather O 0 2.991296241816599e-07
than O 0 1.7291607434799516e-07
a O 0 1.4985461120886612e-06
true O 0 1.686515679466538e-05
C5 O 0 0.006972310598939657
inhibitor O 0 0.00027202567434869707
or O 0 2.4409006073256023e-05
inactivator O 0 0.0011885835556313396
. O 0 7.648122846148908e-05

Of O 0 2.019048588408623e-05
clinical O 0 0.0003241322410758585
interest O 0 7.414630090352148e-06
are O 0 4.3425916373962536e-07
( O 0 4.818983256882348e-07
a O 0 3.4664253689697944e-07
) O 0 1.9611397306107392e-07
the O 0 1.8054912231946219e-07
documentation O 0 1.2270376146261697e-06
of O 0 8.472511012769246e-07
membranous O 1 0.9952319264411926
glomerulonephritis B-Disease 1 1.0
, O 0 0.001598929869942367
vasculitis B-Disease 1 1.0
, O 0 6.53933166177012e-05
and O 0 0.06371941417455673
arthritis B-Disease 1 1.0
in O 0 2.29379179472744e-06
an O 0 4.572374336930807e-07
individual O 0 5.805173941553221e-07
lacking O 0 1.2948290532222018e-05
C5 O 0 0.0008173208334483206
( O 0 7.92490652656852e-07
and O 0 1.9308254195493646e-07
its O 0 6.633124485233566e-07
biologic O 0 8.97626068763202e-06
functions O 0 3.9252410033441265e-07
) O 0 1.5889280291503383e-07
, O 0 9.150858204520773e-08
and O 0 1.230765178661386e-07
( O 0 5.570022949541453e-07
b O 0 7.877720236137975e-07
) O 0 1.1789984455390368e-07
a O 0 1.5203646341888089e-07
remarkable O 0 1.0403687156212982e-06
propensity O 0 9.714875341160223e-05
to O 0 1.7751055565895513e-05
bacterial B-Disease 1 0.9999725818634033
infections I-Disease 1 0.9997454285621643
in O 0 5.141770316186012e-07
the O 0 4.1917351722986496e-07
proband O 0 0.00031903869239613414
, O 0 1.8508137600292685e-07
even O 0 1.353256919855994e-07
during O 0 4.2922280840684834e-07
periods O 0 7.41019505312579e-07
of O 0 1.5642089579159801e-07
low O 0 6.598854724870762e-06
- O 0 1.751986019371543e-05
dose O 0 6.146248324512271e-06
or O 0 5.709208039661462e-07
alternate O 0 3.062617224713904e-06
- O 0 3.22974992741365e-05
day O 0 1.5579573300783522e-05
corticosteroid O 1 0.5173797607421875
therapy O 0 0.006605660077184439
. O 0 5.186336420592852e-05

Other O 0 1.5607321984134614e-05
observations O 0 2.5392972020199522e-05
indicate O 0 8.16290412331e-06
that O 0 3.979100142714742e-07
the O 0 6.648730277447612e-07
C5D B-Disease 1 0.9558414816856384
state O 0 6.132585781415401e-07
is O 0 1.599215266878673e-07
compatible O 0 8.019347319532244e-07
with O 0 2.4903235384954314e-07
normal O 0 3.084466015934595e-06
coagulation O 0 1.030009843816515e-05
function O 0 4.2172447933808144e-07
and O 0 7.516645439409331e-08
the O 0 1.21839875077967e-07
capacity O 0 4.97503719998349e-07
to O 0 3.304873530396435e-07
mount O 0 2.066116030619014e-05
a O 0 1.5037821867736056e-05
neutrophilic O 1 0.856099545955658
leukocytosis O 1 0.932743489742279
during O 0 0.0020094201900064945
pyogenic B-Disease 1 0.9992685914039612
infection I-Disease 1 0.7948901057243347
. O 0 1.7086233128793538e-05
. O 0 3.3248990803258494e-05

Susceptibility O 1 0.9923958778381348
to O 1 0.7539832592010498
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.3546721637248993
twins O 0 0.26405662298202515
: O 0 7.339245939874672e-07
the O 0 2.138684607189134e-07
role O 0 3.2526682502975746e-07
of O 0 1.1840204905411156e-07
genes O 0 1.6290454141199007e-06
, O 0 7.359985261246038e-07
HLA O 0 0.000529525219462812
, O 0 2.720616123497166e-07
and O 0 2.280809781041171e-07
the O 0 1.2586370985445683e-06
environment O 0 4.364804408396594e-05
. O 0 2.4000748453545384e-05

OBJECTIVE O 0 6.390868657035753e-05
To O 0 3.6321698644314893e-06
determine O 0 2.044572511294973e-06
the O 0 8.078568498604e-07
relative O 0 3.320452833577292e-06
effects O 0 5.4744791668781545e-06
of O 0 2.8055808343196986e-07
genetic O 0 3.133559175694245e-06
and O 0 4.826613348996034e-07
environmental O 0 4.132185495109297e-06
factors O 0 1.8401182160232565e-06
in O 0 3.2172440569411265e-06
susceptibility O 0 0.1010318323969841
to O 0 0.21909578144550323
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.00047439889749512076
AS B-Disease 0 0.00033586734207347035
) O 0 1.4413301869353745e-05
. O 0 1.8940929294331e-05

METHODS O 0 0.00026798335602506995
Twins O 0 0.0003683744871523231
with O 0 2.5700906007841695e-06
AS B-Disease 0 1.2781146324414294e-05
were O 0 3.7481888170987077e-07
identified O 0 5.830335680911958e-07
from O 0 2.5314230356343614e-07
the O 0 5.954759103588003e-07
Royal O 0 0.00011247696966165677
National O 0 1.6436253645224497e-05
Hospital O 1 0.9737583994865417
for O 0 0.0015966303180903196
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 0.9998831748962402
database O 0 0.0002314106677658856
. O 0 6.82185564073734e-05

Clinical O 0 0.011267815716564655
and O 0 4.495957909966819e-05
radiographic O 0 0.14874744415283203
examinations O 0 0.00023887194402050227
were O 0 2.727088940446265e-06
performed O 0 2.527519882278284e-06
to O 0 1.3501337434718153e-06
establish O 0 3.8961901736911386e-05
diagnoses O 1 0.8964440822601318
, O 0 5.342229542293353e-06
and O 0 0.000991896027699113
disease O 1 0.9945724606513977
severity O 1 0.9087849855422974
was O 0 6.886616029078141e-05
assessed O 0 3.3536871342221275e-06
using O 0 6.45722479930555e-07
a O 0 1.1290640031802468e-06
combination O 0 3.09490292238479e-06
of O 0 7.392930001515197e-07
validated O 0 2.551799116190523e-05
scoring O 0 9.518284059595317e-06
systems O 0 0.00018792817718349397
. O 0 2.4162376575986855e-05

HLA O 1 0.9076764583587646
typing O 0 0.0006521841278299689
for O 0 3.134231883450411e-05
HLA O 0 0.11073195189237595
- O 0 7.654506771359593e-05
B27 O 0 7.899500633357093e-05
, O 0 2.731295353441965e-06
HLA O 0 0.0005573714151978493
- O 0 1.0516767360968515e-05
B60 O 0 1.2432595212885644e-05
, O 0 5.142702548255329e-07
and O 0 8.357926049029629e-07
HLA O 0 0.11805421859025955
- O 0 0.000596697791479528
DR1 O 1 0.7876920104026794
was O 0 3.889953404723201e-06
performed O 0 1.113454345613718e-06
by O 0 5.873021109437104e-07
polymerase O 0 8.40274242364103e-06
chain O 0 1.2366338523861486e-05
reaction O 0 2.1485434444912244e-06
with O 0 2.3113560132514976e-07
sequence O 0 8.335431402883842e-07
- O 0 1.9678459466376808e-06
specific O 0 3.1247330412043084e-07
primers O 0 7.573859420517692e-06
, O 0 3.0171216280905355e-07
and O 0 4.53934518418464e-07
zygosity O 0 0.00016726728063076735
was O 0 5.880721801077016e-06
assessed O 0 1.1284975698799826e-05
using O 0 1.0308666787750553e-05
microsatellite O 0 0.0009292808827012777
markers O 0 0.00022527990222442895
. O 0 5.833993054693565e-05

Genetic O 0 0.0005786730907857418
and O 0 1.104313378164079e-05
environmental O 0 8.900513421394862e-06
variance O 0 3.809534518950386e-06
components O 0 6.126714652054943e-06
were O 0 5.287461704028829e-07
assessed O 0 1.1494238378872979e-06
with O 0 1.4328357167414651e-07
the O 0 2.880929912407737e-07
program O 0 1.1545025699888356e-06
Mx O 0 1.2577883353515062e-05
, O 0 7.695221171388766e-08
using O 0 1.004641845270271e-07
data O 0 1.7940584484676947e-07
from O 0 8.96037022357632e-08
this O 0 3.8370629340533924e-08
and O 0 6.936357266340565e-08
previous O 0 4.5465762354979233e-07
studies O 0 5.590575824498956e-07
of O 0 2.604873543532449e-07
twins O 0 8.72745004016906e-05
with O 0 2.265369630549685e-06
AS B-Disease 0 0.00025252695195376873
. O 0 2.434979069221299e-05

RESULTS O 0 0.00020831622532568872
Six O 0 1.2902978596684989e-05
of O 0 3.3678825275273994e-06
8 O 0 2.5652798285591416e-05
monozygotic O 0 0.0034648061264306307
( O 0 2.7397338271839544e-05
MZ O 1 0.993710994720459
) O 0 3.26210420098505e-06
twin O 0 0.00031308646430261433
pairs O 0 3.8109010347398e-06
were O 0 2.8561878480104497e-06
disease O 0 0.00014077164814807475
concordant O 0 8.413760951953009e-05
, O 0 5.321577987160708e-07
compared O 0 5.740557185163198e-07
with O 0 2.1212782996826718e-07
4 O 0 3.6686427051790815e-07
of O 0 2.0671672018579557e-07
15 O 0 1.4357700592881883e-06
B27 O 0 6.597849278477952e-05
- O 0 8.688752859598026e-05
positive O 0 6.435035174945369e-06
dizygotic O 0 0.00019015115685760975
( O 0 5.566089839703636e-06
DZ O 0 0.001353660598397255
) O 0 1.2498624073487008e-06
twin O 0 1.7549660697113723e-05
pairs O 0 6.509341119453893e-07
( O 0 2.2874080229939864e-07
27 O 0 3.4889515632130497e-07
% O 0 7.701623161437965e-08
) O 0 7.468742069249856e-08
and O 0 4.650548035556312e-08
4 O 0 1.523544881365524e-07
of O 0 1.2903461765745305e-07
32 O 0 3.02225839732273e-06
DZ O 0 0.42144039273262024
twin O 0 0.0036554846446961164
pairs O 0 1.947060127349687e-06
overall O 0 1.951691046997439e-06
( O 0 5.724156721953477e-07
12 O 0 4.837465326090751e-07
. O 0 2.455481933338888e-07
5 O 0 1.4199104043655097e-06
% O 0 1.7182667306769872e-06
) O 0 4.529417765297694e-06
. O 0 9.022148333315272e-06

Nonsignificant O 0 0.04326682165265083
increases O 0 0.00015369028551504016
in O 0 3.1360048069473123e-06
similarity O 0 2.5834340249275556e-06
with O 0 4.115830449791247e-07
regard O 0 1.0185749488300644e-06
to O 0 1.4402010037883883e-06
age O 0 6.6460947891755495e-06
at O 0 3.878780989907682e-05
disease O 0 0.2289636880159378
onset O 0 0.07795001566410065
and O 0 2.5297143224634056e-07
all O 0 4.525668728661003e-08
of O 0 1.3508547169749363e-07
the O 0 5.514682561624795e-05
disease O 1 0.8664483428001404
severity O 0 0.014628523029386997
scores O 0 4.250671736372169e-06
assessed O 0 1.226675885845907e-05
were O 0 8.534223070455482e-07
noted O 0 2.1566727355093462e-06
in O 0 7.885290870035533e-06
disease O 0 0.24468781054019928
- O 0 0.008046676404774189
concordant O 0 0.43154388666152954
MZ O 1 0.9999957084655762
twins O 0 0.01128213107585907
compared O 0 1.2009143574687187e-05
with O 0 5.887713541596895e-06
concordant O 0 0.017946060746908188
DZ O 1 0.9996032118797302
twins O 0 0.12947289645671844
. O 0 0.00010361760359955952

HLA O 1 0.9860721230506897
- O 0 0.0006825874443165958
B27 O 0 0.000175395020050928
and O 0 3.228012928957469e-06
B60 O 0 6.732348265359178e-05
were O 0 1.1423206842664513e-06
associated O 0 1.262054183825967e-06
with O 0 2.1865142230126366e-07
the O 0 5.287660769681679e-06
disease O 0 0.007501210551708937
in O 0 6.877364171486988e-07
probands O 0 0.0006138961762189865
, O 0 1.533673525955237e-07
and O 0 9.269504630537995e-08
the O 0 1.6475787845138257e-07
rate O 0 6.641847676291945e-07
of O 0 2.4499755113538413e-07
disease O 0 0.00012687694106716663
concordance O 0 3.9453796489397064e-05
was O 0 4.636621724785073e-06
significantly O 0 4.384339263197035e-06
increased O 0 1.6322832152582123e-06
among O 0 6.343391873997462e-07
DZ O 0 0.27075642347335815
twin O 0 0.02171511948108673
pairs O 0 9.396439963893499e-07
in O 0 2.888803862788336e-07
which O 0 1.7569942656336934e-07
the O 0 3.893594850978843e-07
co O 0 3.390629717614502e-05
- O 0 6.158719770610332e-05
twin O 0 0.0017111875349655747
was O 0 7.780301416460134e-07
positive O 0 4.4554707301358576e-07
for O 0 1.721453770642256e-07
both O 0 7.470763989658735e-07
B27 O 0 5.610181324300356e-05
and O 0 1.23886602523271e-05
DR1 O 1 0.8679694533348083
. O 0 6.537749140989035e-05

Additive O 0 0.0016867081867530942
genetic O 0 0.00023389974376186728
effects O 0 6.224519165698439e-05
were O 0 6.116820827628544e-07
estimated O 0 5.35419871994236e-07
to O 0 2.4265784759336384e-07
contribute O 0 4.5122226310922997e-07
97 O 0 1.2308771601965418e-06
% O 0 2.663789473444922e-07
of O 0 9.244609344705168e-08
the O 0 7.168151796577149e-07
population O 0 3.501776291159331e-06
variance O 0 2.3834241801523603e-05
. O 0 2.4957424102467485e-05

CONCLUSION O 0 0.00038216746179386973
Susceptibility O 0 0.0024673903826624155
to O 0 7.125457159418147e-06
AS B-Disease 0 1.9927956600440666e-05
is O 0 4.896551786259806e-07
largely O 0 1.1330873803672148e-06
genetically O 0 1.9295566744403914e-06
determined O 0 9.347122613689862e-07
, O 0 1.0132246330840644e-07
and O 0 8.258854222731316e-08
the O 0 1.7644127581206703e-07
environmental O 0 1.7158072296297178e-06
trigger O 0 1.952864113263786e-05
for O 0 3.5508230666891905e-07
the O 0 6.265469892241526e-06
disease O 0 0.08653581887483597
is O 0 1.6208044826271362e-06
probably O 0 9.70705059444299e-06
ubiquitous O 0 6.470835069194436e-05
. O 0 2.0326589947217144e-05

HLA O 1 0.9925239682197571
- O 0 0.0005868092994205654
B27 O 0 0.00010645262227626517
accounts O 0 3.7917920963081997e-06
for O 0 2.6815828846338263e-07
a O 0 4.930383283863193e-07
minority O 0 1.0305649311703746e-06
of O 0 1.5023051957996358e-07
the O 0 6.929506639608007e-07
overall O 0 3.2347252272302285e-05
genetic O 0 8.389357390115038e-05
susceptibility O 0 0.0003501820901874453
to O 0 7.574913979624398e-06
AS B-Disease 0 0.0003776247613132
. O 0 4.9532627599546686e-05

Cell O 0 0.0025613822508603334
cycle O 0 0.00045053777284920216
- O 0 7.338019349845126e-05
dependent O 0 8.807893209450413e-06
colocalization O 0 2.4288423446705565e-05
of O 0 7.906124892542721e-07
BARD1 O 0 0.000787844997830689
and O 0 3.7523877836065367e-06
BRCA1 O 0 0.00017438313807360828
proteins O 0 3.587704668461811e-06
in O 0 1.5360360521299299e-06
discrete O 0 1.937098022608552e-05
nuclear O 0 5.586509723798372e-05
domains O 0 6.0375514294719324e-05
. O 0 3.194711825926788e-05

Germ O 1 0.7236106395721436
- O 0 0.003600390860810876
line O 0 4.583504778565839e-05
mutations O 0 2.0328412574599497e-05
of O 0 5.089103183308907e-07
the O 0 1.8065210269924137e-06
BRCA1 O 0 0.000220125395571813
gene O 0 1.390344368701335e-05
predispose O 0 1.6204448911594227e-05
women O 0 1.0416017630632268e-06
to O 0 5.315907287695154e-07
early O 0 1.4333813851408195e-05
- O 1 0.7642521262168884
onset O 1 0.9999825954437256
breast B-Disease 1 0.9999969005584717
and I-Disease 1 0.994295060634613
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
by O 0 2.517610937502468e-06
compromising O 0 4.8544854507781565e-05
the O 0 1.8716659724304918e-06
genes O 0 1.3801629393128678e-05
presumptive O 0 0.0026383481454104185
function O 0 2.9044995244476013e-06
as O 0 1.309880531152885e-06
a O 0 1.2305823474889621e-05
tumor B-Disease 0 0.01308765634894371
suppressor O 0 0.0015087000792846084
. O 0 4.6762208512518555e-05

Although O 0 3.643980744527653e-05
the O 0 6.4350106185884215e-06
biochemical O 0 4.0688020817469805e-05
properties O 0 7.323735644604312e-06
of O 0 1.5596820048813242e-06
BRCA1 O 0 0.0024177939631044865
polypeptides O 0 0.00012134883581893519
are O 0 4.647622233733273e-07
not O 0 2.2857855697111518e-07
understood O 0 5.481001608131919e-07
, O 0 1.0387651627752348e-07
their O 0 1.605388746384051e-07
expression O 0 7.988677452885895e-07
pattern O 0 1.6776469919932424e-06
and O 0 3.9389956896229705e-07
subcellular O 0 8.680565770191606e-06
localization O 0 8.443346814601682e-06
suggest O 0 1.2791346080121002e-06
a O 0 5.189298803998099e-07
role O 0 1.055038296726707e-06
in O 0 8.725931479602878e-07
cell O 0 7.606075814692304e-05
- O 0 6.376088276738301e-05
cycle O 0 6.303071859292686e-05
regulation O 0 5.3650819609174505e-05
. O 0 2.2520496713696048e-05

When O 0 9.232176671503112e-05
resting O 0 0.0002533444785512984
cells O 0 8.29096170491539e-05
are O 0 7.985188972270407e-07
induced O 0 4.172685294179246e-05
to O 0 9.668788152339403e-07
proliferate O 0 1.84542041097302e-05
, O 0 1.2636557755740796e-07
the O 0 9.686881696779892e-08
steady O 0 1.8692204548642621e-06
- O 0 1.1955057743762154e-06
state O 0 1.3524311270884937e-07
levels O 0 1.4642581902535312e-07
of O 0 1.0495393354403859e-07
BRCA1 O 0 1.5210349374683574e-05
increase O 0 7.102080417098477e-07
in O 0 5.333304216037504e-07
late O 0 1.3352558198675979e-05
G1 O 0 9.415576641913503e-05
and O 0 3.2483654877069057e-07
reach O 0 5.227665269558202e-07
a O 0 6.194823072291911e-07
maximum O 0 2.759019480436109e-06
during O 0 1.1372269909770694e-05
S O 0 0.0012033425737172365
phase O 0 6.94717382430099e-05
. O 0 2.416638562863227e-05

Moreover O 0 0.00021230679703876376
, O 0 7.120233021851163e-06
in O 0 4.345609795564087e-06
S O 0 0.00023956166114658117
phase O 0 2.3396472897729836e-05
cells O 0 2.9591275961138308e-05
, O 0 1.906900251924526e-06
BRCA1 O 0 7.358018046943471e-05
polypeptides O 0 2.2484464352601208e-05
are O 0 4.696410371707316e-07
hyperphosphorylated O 0 4.443542638910003e-05
and O 0 1.0113399184774607e-06
accumulate O 0 9.589873116055969e-06
into O 0 1.4997199286881369e-06
discrete O 0 2.1302063032635488e-05
subnuclear O 0 0.0005693001439794898
foci O 0 0.0005684732459485531
termed O 0 0.00018579885363578796
" O 0 1.844987491494976e-05
BRCA1 O 0 0.0005759389023296535
nuclear O 0 0.00013987354759592563
dots O 0 0.0004326821945142001
. O 0 5.5513322877231985e-05

" O 0 0.0004727741761598736
BRCA1 O 0 0.19889318943023682
associates O 0 0.015994949266314507
in O 0 1.463790158595657e-05
vivo O 0 0.00011766063835239038
with O 0 1.4651915307695162e-06
a O 0 5.7422066674917005e-06
structurally O 0 0.00024392051273025572
related O 0 8.499788236804307e-06
protein O 0 1.0493894478713628e-05
termed O 0 0.00010572071187198162
BARD1 O 0 0.003991341684013605
. O 0 3.892275344696827e-05

Here O 0 2.4868850232451223e-05
we O 0 1.1531656127772294e-06
show O 0 1.1137284445794648e-06
that O 0 1.1221751350376508e-07
the O 0 1.7475258573540486e-07
steady O 0 2.075261136269546e-06
- O 0 1.6795327155705309e-06
state O 0 1.8202750595719408e-07
levels O 0 2.423252851713187e-07
of O 0 8.592043343469413e-08
BARD1 O 0 6.228882557479665e-05
, O 0 1.5778127249177487e-07
unlike O 0 3.7873942915211956e-07
those O 0 1.0847240616840281e-07
of O 0 2.2344201511259598e-07
BRCA1 O 0 0.00012051845260430127
, O 0 4.6122238472889876e-07
remain O 0 9.194699828185549e-07
relatively O 0 1.1693588248817832e-06
constant O 0 1.921608827615273e-06
during O 0 7.457363608409651e-06
cell O 0 0.000409168831538409
cycle O 0 0.00014075015496928245
progression O 0 0.00020740952459163964
. O 0 3.504286360112019e-05

However O 0 6.383948493748903e-05
, O 0 8.744752449274529e-06
immunostaining O 0 0.00045245018554851413
revealed O 0 3.097120861639269e-05
that O 0 1.211974336001731e-06
BARD1 O 0 0.000206977259949781
resides O 0 1.3437250345305074e-05
within O 0 2.5963418011087924e-06
BRCA1 O 0 5.306561433826573e-05
nuclear O 0 8.84699693415314e-06
dots O 0 1.0725324500526767e-05
during O 0 3.6310336781752994e-06
S O 0 2.687597407202702e-05
phase O 0 9.424961717741098e-07
of O 0 9.916012544408659e-08
the O 0 3.3974828284044634e-07
cell O 0 2.0691069948952645e-05
cycle O 0 5.297089046507608e-06
, O 0 1.9881268542576436e-07
but O 0 1.434224685681329e-07
not O 0 1.7834071286415565e-07
during O 0 1.0272326562699163e-06
the O 0 1.952975935637369e-06
G1 O 0 0.00043100243783555925
phase O 0 5.473074270412326e-05
. O 0 1.7699347154120915e-05

Nevertheless O 0 0.0001995235652429983
, O 0 1.3033402865403332e-05
BARD1 O 0 0.000497576198540628
polypeptides O 0 6.259847577894107e-05
are O 0 3.330425499825651e-07
found O 0 2.396131719706318e-07
exclusively O 0 3.022452119694208e-07
in O 0 1.2361289236650919e-07
the O 0 2.2301070146113489e-07
nuclear O 0 8.8061364067471e-07
fractions O 0 7.439793421326613e-07
of O 0 1.2476670008254587e-07
both O 0 6.548386295435193e-07
G1 O 0 0.00044415233423933387
- O 0 1.859549774962943e-05
and O 0 1.1088787914559362e-06
S O 0 0.0002493028878234327
- O 0 4.776078276336193e-05
phase O 0 3.035206646018196e-05
cells O 0 7.503117376472801e-05
. O 0 2.2750473362975754e-05

Therefore O 0 7.943980017444119e-05
, O 0 7.183178240666166e-06
progression O 0 3.2588512112852186e-05
to O 0 2.1140192529855995e-06
S O 0 7.797164289513603e-05
phase O 0 3.0212900128390174e-06
is O 0 1.5709437661826087e-07
accompanied O 0 8.075001574070484e-07
by O 0 1.5121902663395304e-07
the O 0 2.003574763875804e-07
aggregation O 0 1.813688413676573e-06
of O 0 3.381814224212576e-07
nuclear O 0 1.074799456546316e-05
BARD1 O 0 0.00019532907754182816
polypeptides O 0 3.5006356483791023e-05
into O 0 6.2858844103175215e-06
BRCA1 O 0 0.0002961021673399955
nuclear O 0 9.441776637686417e-05
dots O 0 0.00026076333597302437
. O 0 4.959185389452614e-05

This O 0 6.430599023588002e-05
cell O 0 0.00045458145905286074
cycle O 0 0.0001611986808711663
- O 0 4.377251025289297e-05
dependent O 0 7.684009688091464e-06
colocalization O 0 1.950226942426525e-05
of O 0 6.157368943604524e-07
BARD1 O 0 0.0006712013273499906
and O 0 2.6351719952799613e-06
BRCA1 O 0 6.336035585263744e-05
indicates O 0 1.5509457398366067e-06
a O 0 4.189668914023059e-07
role O 0 6.648932640018757e-07
for O 0 4.5222688527246646e-07
BARD1 O 0 0.00020509897149167955
in O 0 4.980400262866169e-06
BRCA1 O 0 0.0007530126022174954
- O 0 0.00034752185456454754
mediated O 0 0.001791811198927462
tumor B-Disease 0 0.016925889998674393
suppression O 0 0.00030040377168916166
. O 0 4.558353975880891e-05

Ethnic O 0 6.549504905706272e-05
differences O 0 6.0039281379431486e-05
in O 0 9.208422852680087e-06
the O 0 8.322544999828096e-06
HFE O 0 0.0025789306964725256
codon O 0 0.0002922823478002101
282 O 0 0.0002214182895841077
( O 0 9.897561540128663e-05
Cys O 1 0.9741601347923279
/ O 0 0.021444398909807205
Tyr O 0 0.004093085415661335
) O 0 2.2569451175513677e-05
polymorphism O 0 0.0002536008832976222
. O 0 4.2620224121492356e-05

Recent O 0 0.00014156960241962224
studies O 0 3.498843580018729e-05
have O 0 2.0313873392296955e-06
shown O 0 1.118834097724175e-05
that O 0 3.452249802649021e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.15458865463733673
HH B-Disease 1 0.9999779462814331
) O 0 8.565353368794604e-07
is O 0 1.6499798505265062e-07
likely O 0 4.788234946317971e-07
to O 0 2.412597268630634e-07
be O 0 1.6699037530543137e-07
caused O 0 1.3682326880370965e-06
by O 0 5.071743771623005e-07
homozygosity O 0 2.1128375010448508e-05
for O 0 1.9835324849282188e-07
a O 0 1.3604362720798235e-06
Cys282Tyr O 0 0.0011967653408646584
mutation O 0 1.7861584638012573e-05
in O 0 9.631662578613032e-07
the O 0 3.1024533200252336e-06
HFE O 0 0.002167488681152463
gene O 0 5.458354644360952e-05
located O 0 1.7981907149078324e-05
4 O 0 1.790024180081673e-05
. O 0 2.0189118004054762e-05

5 O 0 0.00033856151276268065
Mb O 0 0.04300342872738838
telomeric O 0 0.0036183265037834644
to O 0 6.776856753276661e-05
HLA O 1 0.5261300206184387
- O 0 0.00014778561308048666
A O 0 2.8091597414459102e-05
. O 0 4.390055619296618e-05

Population O 0 3.75993549823761e-05
studies O 0 6.459395990532357e-06
of O 0 4.3286490836180747e-07
this O 0 4.922546850139042e-07
polymorphism O 0 1.0940062566078268e-05
are O 0 1.2847800689996802e-07
facilitated O 0 1.2761797734128777e-06
by O 0 1.5626343952135358e-07
the O 0 1.4453107155532052e-07
fact O 0 1.5923137652862351e-07
that O 0 8.695114672718773e-08
the O 0 4.6090886485217197e-07
Cys282Tyr O 0 0.00017324485816061497
mutation O 0 1.5732101019239053e-05
creates O 0 4.683266070060199e-06
a O 0 3.6246403851691866e-06
Rsal O 0 0.00016557886556256562
restriction O 0 3.876746632158756e-05
site O 0 3.343410571687855e-05
. O 0 1.8453518350725062e-05

We O 0 1.6418302038800903e-05
have O 0 2.7991236493107863e-06
studied O 0 4.031824119010707e-06
the O 0 2.145885446225293e-06
codon O 0 4.4602991692954674e-05
282 O 0 4.7959460061974823e-05
( O 0 1.89575512195006e-05
Cys O 1 0.9410858750343323
/ O 0 0.01650518923997879
Tyr O 0 0.0005128741613589227
) O 0 1.8483843859939952e-06
polymorphism O 0 7.08889774614363e-06
in O 0 4.051433108998026e-07
different O 0 3.52684111248891e-07
ethnic O 0 1.386630856359261e-06
groups O 0 4.6062946239544544e-06
. O 0 1.7369950001011603e-05

In O 0 2.1458901755977422e-05
agreement O 0 7.071693289617542e-06
with O 0 1.1076685950683895e-06
previous O 0 3.6557448765961453e-06
observations O 0 4.415650892042322e-06
the O 0 1.5555405070699635e-06
Tyr O 0 0.000988774816505611
allele O 0 4.077529956703074e-05
appeared O 0 4.6596851461799815e-06
to O 0 3.3364085538778454e-07
be O 0 1.6221360965573695e-07
rare O 0 7.804915185261052e-07
or O 0 6.940975367797364e-07
absent O 0 5.064071956439875e-06
in O 0 7.678915494579996e-07
Asiatic O 0 6.94951304467395e-05
( O 0 9.811856216401793e-07
Indian O 0 6.298038215390989e-07
, O 0 3.6132882996753324e-07
Chinese O 0 7.95859421032219e-07
) O 0 3.855738214042503e-06
populations O 0 1.7857122657005675e-05
. O 0 2.082765058730729e-05

The O 0 2.9038706998107955e-05
highest O 0 2.788024903566111e-05
allele O 0 8.162573067238554e-05
frequency O 0 2.4834676878526807e-05
( O 0 1.7003551420202712e-06
7 O 0 7.311706440304988e-07
. O 0 1.3073417903797235e-07
5 O 0 2.9067504669910704e-07
% O 0 2.419193378955242e-07
) O 0 3.162428754421853e-07
was O 0 9.437320045435627e-07
found O 0 1.4134700450085802e-06
in O 0 3.23223025588959e-06
Swedes O 0 0.00019621259707491845
. O 0 4.6367400500457734e-05

Saamis O 0 0.0032824601512402296
( O 0 2.598199716885574e-05
2 O 0 4.25361167799565e-06
% O 0 9.303687420469942e-07
) O 0 4.752658355755557e-07
and O 0 3.43234574984308e-07
Mordvinians O 0 3.017374183400534e-05
( O 0 6.251529498513264e-07
1 O 0 2.705513395540038e-07
. O 0 8.716268951047823e-08
8 O 0 3.2256636472993705e-07
% O 0 1.9360379610589007e-07
) O 0 2.7441410566098057e-07
had O 0 7.350032547037699e-07
significantly O 0 3.831048616120825e-06
lower O 0 2.8978481623198604e-06
frequencies O 0 3.377158236617106e-06
of O 0 7.195877742560697e-07
the O 0 7.557568096672185e-06
Tyr O 0 0.004425706807523966
allele O 0 0.0003944154304917902
. O 0 3.940679380320944e-05

Comparisons O 0 0.00011710490070981905
with O 0 1.5160475413722452e-05
allele O 0 0.00013864367792848498
frequencies O 0 2.8222175387782045e-05
based O 0 4.218208687234437e-06
on O 0 2.666798764039413e-06
prevalence O 0 3.7811285437783226e-05
estimates O 0 2.754928345893859e-06
of O 0 8.52485982250073e-07
HH B-Disease 1 0.999459445476532
showed O 0 5.04162608194747e-06
some O 0 1.485721980998278e-07
disagreements O 0 1.2015522088404396e-06
with O 0 1.8353880193444638e-07
the O 0 5.863166165909206e-07
RFLP O 0 9.099308954318985e-05
data O 0 2.0159998257440748e-06
, O 0 3.4463775477888703e-07
particularly O 0 1.13470082396816e-06
in O 0 2.127464540535584e-06
Finns O 0 0.00013161334209144115
. O 0 3.6856323276879266e-05

The O 0 6.521645991597325e-05
newly O 0 0.00019105694082099944
described O 0 0.0001251027570106089
HFE O 0 0.09149634838104248
marker O 0 3.2792333513498306e-05
provides O 0 2.422662191747804e-06
a O 0 8.59244266848691e-07
new O 0 8.953090286922816e-07
approach O 0 5.259183808448142e-07
to O 0 2.0445301629479218e-07
the O 0 2.917025199167256e-07
screening O 0 2.3279326342162676e-06
of O 0 3.5965797451353865e-07
HH B-Disease 1 0.9633628129959106
as O 0 1.8970258963690867e-07
well O 0 8.759601399788153e-08
as O 0 6.482349590442027e-08
studies O 0 1.0175317299854214e-07
of O 0 3.158250905244131e-08
the O 0 1.8125525969026057e-07
relationship O 0 8.972014029495767e-07
between O 0 3.551259908363136e-07
the O 0 1.719224087537441e-06
HFE O 0 0.06461295485496521
Tyr O 0 0.0024177294690161943
allele O 0 6.9375142629724e-05
and O 0 1.999655069084838e-06
different O 0 1.0155343261430971e-05
disorders O 1 0.999278724193573
including O 0 0.00025530322454869747
cancer B-Disease 1 0.9987229704856873

Autosomal B-Disease 1 0.9997701048851013
dominant I-Disease 1 0.9844606518745422
neurohypophyseal I-Disease 1 0.9999995231628418
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.999977707862854
associated O 0 0.0001799977762857452
with O 0 4.037480266561033e-06
a O 0 1.3564535038312897e-05
missense O 0 0.0006128097884356976
mutation O 0 9.518072329228744e-05
encoding O 0 4.627856469596736e-05
Gly23 O 0 0.0009617387549951673
- O 0 0.0012007469777017832
- O 0 0.00016322763985954225
> O 0 5.8649733546189964e-05
Val O 0 0.00030666470411233604
in O 0 9.462389243708458e-06
neurophysin O 0 0.0025464268401265144
II O 0 0.00465294299647212
. O 0 8.267253724625334e-05

Autosomal B-Disease 1 0.9997681975364685
dominant I-Disease 1 0.9866853952407837
neurohypophyseal I-Disease 1 0.9999984502792358
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999711513519287
( O 0 0.0001056926921592094
ADNDI B-Disease 0 0.12453319132328033
) O 0 4.901316515315557e-06
is O 0 1.1230545169382822e-06
an O 0 4.426346640684642e-05
inherited B-Disease 1 1.0
disease I-Disease 1 0.9999991655349731
caused O 0 0.0007532336749136448
by O 0 4.4886101022711955e-06
progressive O 0 0.14751146733760834
degeneration O 0 0.15406371653079987
of O 0 2.7926176926484914e-07
the O 0 7.385910407720075e-07
magnocellular O 0 0.0001143659683293663
neurons O 0 6.73880276735872e-06
of O 0 1.1710501723882771e-07
the O 0 4.1927586380552384e-07
hypothalamus O 0 1.7805445168050937e-05
leading O 0 1.1746881227736594e-06
to O 0 4.785696887665836e-07
decreased O 0 2.1987186755723087e-06
ability O 0 7.099384902176098e-07
to O 0 2.189439527455761e-07
produce O 0 7.379391036010929e-07
the O 0 2.0870877506240504e-06
hormone O 0 5.6874167057685554e-05
arginine O 0 6.48803252261132e-05
vasopressin O 0 0.00014488711894955486
( O 0 1.2354739737929776e-05
AVP O 0 0.00031683535780757666
) O 0 1.3542973647417966e-05
. O 0 2.2094272935646586e-05

Affected O 0 0.00039137937710620463
individuals O 0 1.012568191072205e-05
are O 0 9.21568187095545e-07
not O 0 8.317620086017996e-07
symptomatic O 0 0.0003818368131760508
at O 0 4.109525889361976e-06
birth O 0 0.00011223345791222528
, O 0 5.198219241719926e-07
but O 0 7.457388733200787e-07
usually O 0 1.1887200344062876e-05
develop O 0 0.2115103304386139
diabetes B-Disease 1 0.999996542930603
insipidus I-Disease 1 0.9465174078941345
at O 0 9.694727850728668e-06
1 O 0 6.052761364117032e-06
- O 0 3.998144165962003e-05
6 O 0 1.1575770258787088e-05
yr O 0 0.00028623503749258816
of O 0 3.078647296206327e-06
age O 0 2.2959691705182195e-05
. O 0 3.12200681946706e-05

The O 0 2.659528581716586e-05
genetic O 0 4.451694985618815e-05
locus O 0 4.187354716123082e-05
of O 0 8.175534844667709e-07
the O 0 6.402048256859416e-06
disease O 0 0.003638836555182934
is O 0 4.308493259941315e-07
the O 0 1.4671043118141824e-06
AVP O 0 0.015790371224284172
- O 0 0.0002925661683548242
neurophysin O 0 0.0013640739489346743
II O 0 0.0007425259100273252
( O 0 1.2938485269842204e-06
NPII O 0 5.0649447075556964e-05
) O 0 5.403575755735801e-07
gene O 0 1.5528667063335888e-06
, O 0 1.3706537060897972e-07
and O 0 2.774439167296805e-07
mutations O 0 8.125391104840674e-06
that O 0 3.283858518443594e-07
cause O 0 1.2760709068970755e-05
ADNDI B-Disease 0 0.00876526813954115
have O 0 3.236466739053867e-07
been O 0 1.6895107535219722e-07
found O 0 9.435217407371965e-08
in O 0 5.805733849229e-08
both O 0 6.973034771817765e-08
the O 0 1.2948086691721983e-07
signal O 0 1.0884240282393876e-06
peptide O 0 6.351345973598654e-07
of O 0 9.129136913088587e-08
the O 0 4.952258336743398e-07
prepro O 0 0.00022678957611788064
- O 0 9.974504791898653e-05
AVP O 0 0.0003407387703191489
- O 0 2.3635329853277653e-05
NPII O 0 4.91787759528961e-05
precursor O 0 7.008955890341895e-06
and O 0 8.454906037513865e-07
within O 0 2.177313717766083e-06
NPII O 0 0.00039430338074453175
itself O 0 6.636530451942235e-05
. O 0 2.2798909412813373e-05

An O 0 4.719002390629612e-05
affected O 0 7.16849826858379e-05
girl O 0 9.685257100500166e-05
who O 0 1.6392750694649294e-06
presented O 0 1.365009552500851e-06
at O 0 5.639336677631945e-07
9 O 0 7.852203225411358e-07
months O 0 4.915050908493868e-07
of O 0 7.356681663850395e-08
age O 0 4.397734016947652e-07
and O 0 2.3301929275021394e-07
her O 0 4.682658527599415e-06
similarly O 0 2.9254151741042733e-05
affected O 0 2.733802375587402e-06
younger O 0 2.2946057924855268e-06
brother O 0 7.693628504057415e-06
and O 0 3.2557099416408164e-07
father O 0 6.6945549406227656e-06
were O 0 1.4434994000112056e-07
all O 0 4.607752401852849e-08
found O 0 1.6702287553016504e-07
to O 0 1.1642453046079027e-07
have O 0 1.138521312782359e-07
a O 0 6.749710905751272e-07
novel O 0 8.234996130340733e-06
missense O 0 0.00027682006475515664
mutation O 0 3.2203912269324064e-05
( O 0 2.401297706455807e-06
G1758 O 0 6.547244265675545e-05
- O 0 0.0008277541492134333
- O 0 0.00011412000458221883
> O 0 2.2487980459118262e-05
T O 0 3.596393798943609e-05
) O 0 4.324564315538737e-07
encoding O 0 8.164003588717605e-07
the O 0 3.4063364751091285e-07
amino O 0 2.394044486209168e-06
acid O 0 6.3140983002085704e-06
substitution O 0 1.0258492693537846e-05
Gly23 O 0 0.00018643842486198992
- O 0 0.00021050799114163965
- O 0 0.00013224837312009186
> O 0 9.52017871895805e-05
Val O 0 0.0003260637749917805
within O 0 1.7277119695791043e-05
NPII O 0 0.0016827782383188605
. O 0 9.407581092091277e-05

The O 0 8.620387234259397e-05
mutation O 0 0.0005222519394010305
was O 0 2.5014182028826326e-05
confirmed O 0 2.503393989172764e-05
by O 0 8.355770660273265e-06
restriction O 0 6.854093953734264e-05
endonuclease O 0 0.00166756147518754
analysis O 0 8.20710847619921e-05
. O 0 5.2905183110851794e-05

A O 0 0.000643406470771879
T1 O 1 0.9492745399475098
- O 0 0.00024263965315185487
weighted O 0 1.9953135051764548e-05
magnetic O 0 3.278461372246966e-05
resonance O 0 4.6583903895225376e-05
imaging O 0 7.860801269998774e-05
of O 0 5.390337491917307e-07
the O 0 1.7414614603694645e-06
fathers O 0 3.510598253342323e-05
pituitary O 0 0.0003408989286981523
gland O 0 5.959282862022519e-05
demonstrates O 0 6.954227046662709e-06
an O 0 2.050271859843633e-06
attenuated O 0 0.0002431319880997762
posterior O 0 0.000500858819577843
pituitary O 0 0.002812909660860896
bright O 0 0.00037806257023476064
spot O 0 0.00012176333257229999
. O 0 3.862974335788749e-05

This O 0 6.987896631471813e-05
mutation O 0 0.0010584450792521238
may O 0 1.0603626833471935e-05
be O 0 2.698705259263079e-07
valuable O 0 2.8851144406871754e-07
for O 0 1.1357602858197424e-07
developing O 0 8.9801807234835e-07
models O 0 1.3083399608149193e-06
of O 0 6.70391955281957e-07
dominantly B-Disease 1 0.9966088533401489
inherited I-Disease 1 0.9999911785125732
neurodegeneration I-Disease 1 1.0
, O 0 9.561504157318268e-07
as O 0 1.899422983342447e-07
the O 0 2.0803899758448097e-07
early O 0 1.7264335383515572e-06
age O 0 4.819782475351531e-07
of O 0 2.6257970375809236e-07
onset O 0 0.26002901792526245
of O 0 9.321021025243681e-06
symptoms O 1 0.9994712471961975
suggests O 0 8.056793376454152e-06
that O 0 3.411267925912398e-07
this O 0 5.198511985327059e-07
mutation O 0 3.417169864405878e-05
may O 0 3.276687039033277e-06
be O 0 2.836619614754454e-07
particularly O 0 1.2013207424388384e-06
deleterious O 0 3.847048355964944e-05
to O 0 8.898696819414909e-07
the O 0 2.60636943494319e-06
magnocellular O 0 0.0021402244456112385
neuron O 0 0.03283088654279709
. O 0 8.622654604550917e-06
. O 0 2.7348733055987395e-05

Frequent O 0 0.0016179910162463784
inactivation O 0 0.006418595090508461
of O 0 6.280475645326078e-05
PTEN O 1 0.9383153915405273
/ O 0 0.022754140198230743
MMAC1 O 0 0.030391989275813103
in O 0 0.00017248469521291554
primary O 1 0.9418357610702515
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 0.00024584276252426207

Sporadic B-Disease 1 0.9999792575836182
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 5.926788162469165e-06
the O 0 6.917159680597251e-07
most O 0 2.4509432705599465e-07
common O 0 2.192186002503149e-06
male B-Disease 0 2.7727734050131403e-05
cancer I-Disease 0 0.04348904639482498
in O 0 1.693387048362638e-07
the O 0 1.9454196831247828e-07
Western O 0 7.950689564495406e-07
world O 0 4.993651714357839e-07
, O 0 1.1857935078296578e-07
yet O 0 1.496460981798009e-07
many O 0 2.4652704766481293e-08
of O 0 2.945262700393414e-08
the O 0 1.5615097481713747e-07
major O 0 4.7344772724500217e-07
genetic O 0 9.445739124203101e-07
events O 0 3.126700391931081e-07
involved O 0 1.7412557440366072e-07
in O 0 1.4859374175557605e-07
the O 0 1.8818181501956133e-07
progression O 0 1.9967640128015773e-06
of O 0 8.28656183671228e-08
this O 0 5.768259825345012e-07
often O 0 9.581362246535718e-05
fatal O 1 0.9999970197677612
cancer B-Disease 1 0.9996978044509888
remain O 0 1.2678950952249579e-05
to O 0 2.153556806661072e-06
be O 0 3.85771681976621e-06
elucidated O 0 0.000305214460240677
. O 0 2.2185759007697925e-05

Numerous O 0 0.00014576678222510964
cytogenetic O 0 0.0065817199647426605
and O 0 1.7870785086415708e-05
allelotype O 0 0.015763750299811363
studies O 0 1.1611904483288527e-05
have O 0 9.117736112784769e-07
reported O 0 1.9225955838919617e-05
frequent O 0 8.973229341791011e-06
loss O 0 1.1022848411812447e-05
of O 0 5.690888542631001e-07
heterozygosity O 0 0.00027358336956240237
on O 0 8.730111403565388e-06
chromosomal O 0 0.0009404683951288462
arm O 0 0.0014866039855405688
10q O 0 0.0002582788874860853
in O 0 4.3189436837565154e-05
sporadic B-Disease 1 0.999754011631012
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 0.0001820856414269656

Deletion O 0 0.004028195980936289
mapping O 0 0.0005361636867746711
studies O 0 5.694048013538122e-05
have O 0 3.7431375403684797e-06
unambiguously O 0 3.625851240940392e-05
identified O 0 3.3784465358621674e-06
a O 0 7.338462069128582e-07
region O 0 7.688059895372135e-07
of O 0 3.4670071613618347e-07
chromosome O 0 1.4205906154529657e-05
10q23 O 0 2.026855872827582e-05
to O 0 4.6615249971182493e-07
be O 0 1.25858761634845e-07
the O 0 1.392364339380947e-07
minimal O 0 1.0725668744271388e-06
area O 0 8.492800134263234e-07
of O 0 6.997442483225313e-07
loss O 0 0.00018096579879056662
. O 0 2.7212277927901596e-05

A O 0 0.00020168109040241688
new O 0 0.00010252113861497492
tumor B-Disease 0 0.0024431846104562283
suppressor O 0 0.0009343682322651148
gene O 0 5.3843945352127776e-05
, O 0 3.72440081264358e-06
PTEN O 0 0.012630782090127468
/ O 0 0.000704582838807255
MMAC1 O 0 0.000940340687520802
, O 0 7.264554255925759e-07
was O 0 1.6453301441288204e-06
isolated O 0 3.076202347074286e-06
recently O 0 1.4157957366478513e-06
at O 0 1.7071585034500458e-07
this O 0 8.800479633919167e-08
region O 0 3.777690551487467e-07
of O 0 1.2923278802645655e-07
chromosome O 0 5.246386535873171e-06
10q23 O 0 1.2099479135940783e-05
and O 0 2.91314989908642e-07
found O 0 2.1878219058635295e-07
to O 0 1.9712729226739611e-07
be O 0 2.1853070109045802e-07
inactivated O 0 8.308309588755947e-06
by O 0 5.942550842519267e-07
mutation O 0 5.588077328866348e-06
in O 0 1.8109507209373987e-06
three O 0 0.0005882540135644376
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.12751248478889465
lines O 0 0.00015596006414853036
. O 0 2.8851476599811576e-05

We O 0 6.0569851484615356e-05
screened O 0 0.00037509226240217686
80 O 0 0.00037315156077966094
prostate B-Disease 1 0.9999994039535522
tumors I-Disease 1 0.9999966621398926
by O 0 6.068436505302088e-06
microsatellite O 0 0.00028595191542990506
analysis O 0 3.0198209515219787e-06
and O 0 6.7148357629776e-07
found O 0 1.29021248085337e-06
chromosome O 0 1.0516938345972449e-05
10q23 O 0 1.8603657736093737e-05
to O 0 6.217840677891218e-07
be O 0 2.732986388309655e-07
deleted O 0 3.3051016998797422e-06
in O 0 6.090301098993223e-07
23 O 0 4.072500814800151e-06
cases O 0 6.5193944465136155e-06
. O 0 1.4450545677391347e-05

We O 0 1.2538865121314302e-05
then O 0 2.8194847345730523e-06
proceeded O 0 3.3366866318829125e-06
with O 0 3.8471543462037516e-07
sequence O 0 4.792941012965457e-07
analysis O 0 2.877289091429702e-07
of O 0 8.203997481359693e-08
the O 0 3.549076268427598e-07
entire O 0 7.554700459877495e-06
PTEN O 0 0.08685187250375748
/ O 0 0.0003057168214581907
MMAC1 O 0 0.0002368892019148916
coding O 0 1.9898423488484696e-05
region O 0 2.7347773539077025e-06
and O 0 6.716128950756683e-07
tested O 0 6.4733694671303965e-06
for O 0 5.153258371137781e-07
homozygous O 0 3.653908061096445e-05
deletion O 0 9.191147910314612e-06
with O 0 3.7269836639097775e-07
new O 0 2.9537461614381755e-06
intragenic O 0 0.003599126823246479
markers O 0 5.031280579714803e-06
in O 0 3.825853127636947e-07
these O 0 1.4617063470723224e-07
23 O 0 6.714233791171864e-07
cases O 0 4.187064348570857e-07
with O 0 7.118869689293206e-07
10q23 O 0 0.00026952335610985756
loss O 0 5.2856274123769253e-05
of O 0 5.057700946053956e-06
heterozygosity O 0 0.004360157996416092
. O 0 0.00010281052527716383

The O 0 1.1280306353000924e-05
identification O 0 4.677619926951593e-06
of O 0 5.146520152266021e-07
the O 0 8.670270972288563e-07
second O 0 2.352831870666705e-06
mutational O 0 0.00016418263840023428
event O 0 1.8379398625256727e-06
in O 0 6.044473934707639e-07
10 O 0 7.1696013037581e-07
( O 0 8.254001500063168e-07
43 O 0 2.4450230284855934e-06
% O 0 1.6780485339040752e-06
) O 0 9.505502930551302e-06
tumors B-Disease 1 0.9984410405158997
establishes O 0 0.0003464828769210726
PTEN O 1 0.7078132629394531
/ O 0 0.00026780253392644227
MMAC1 O 0 6.340254185488448e-05
as O 0 3.514981301577791e-07
a O 0 4.285512034130079e-07
main O 0 1.1757012998714345e-06
inactivation O 0 1.4675361853733193e-05
target O 0 1.2802501032638247e-06
of O 0 4.7370198785756656e-07
10q O 0 7.833362178644165e-05
loss O 0 7.13796544005163e-05
in O 0 2.812593629641924e-05
sporadic B-Disease 1 0.9999685287475586
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.954131196020171e-05
. O 0 4.974369949195534e-05

Risk O 0 0.004202581010758877
reversals O 0 0.0019815885461866856
in O 0 5.235986100160517e-05
predictive O 0 0.0009545675129629672
testing O 0 0.0012548263184726238
for O 0 0.00229898770339787
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999996423721313
. O 0 0.0002538420376367867

The O 0 3.922109681298025e-05
first O 0 2.5838486180873588e-05
predictive O 0 0.00019020700710825622
testing O 0 7.712300430284813e-05
for O 0 0.00010578244109638035
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999985694885254
( O 0 7.287992502824636e-06
HD B-Disease 0 0.0002864250564016402
) O 0 4.674644458191324e-07
was O 0 3.1470909789277357e-07
based O 0 1.983634518865074e-07
on O 0 1.724500151567554e-07
analysis O 0 2.6600628189044073e-07
of O 0 1.708650501086595e-07
linked O 0 2.6532308766036294e-05
polymorphic O 0 6.675947952317074e-05
DNA O 0 7.228201866382733e-06
markers O 0 4.8817523747857194e-06
to O 0 4.2883002038252016e-07
estimate O 0 9.103920888264838e-07
the O 0 2.906511724631855e-07
likelihood O 0 1.2057512321916874e-06
of O 0 3.453398562669463e-07
inheriting O 0 1.7842585293692537e-05
the O 0 2.1282803572830744e-06
mutation O 0 2.4065378966042772e-05
for O 0 4.124193765164819e-06
HD B-Disease 0 0.0007375343702733517
. O 0 3.2161093258764595e-05

Limits O 0 7.150398596422747e-05
to O 0 5.295967639540322e-06
accuracy O 0 5.227922429185128e-06
included O 0 1.1786695495175081e-06
recombination O 0 4.439385065779788e-06
between O 0 3.727495538896619e-07
the O 0 3.807421080637141e-07
DNA O 0 1.5042404584164615e-06
markers O 0 1.3042177897659712e-06
and O 0 1.1677223454853447e-07
the O 0 3.6950225990040053e-07
mutation O 0 5.214935299591161e-06
, O 0 2.3321514674989885e-07
pedigree O 0 2.6793206870934227e-06
structure O 0 8.406697133978014e-07
, O 0 1.0741231193378553e-07
and O 0 9.071977302710366e-08
whether O 0 2.921788961884886e-07
DNA O 0 7.838571036700159e-07
samples O 0 6.086875146138482e-07
were O 0 1.3650443975166127e-07
available O 0 2.341078442213984e-07
from O 0 4.3783373371297785e-07
family O 0 3.1644065074942773e-06
members O 0 5.428241365734721e-06
. O 0 1.5821260603843257e-05

With O 0 1.61436455528019e-05
direct O 0 9.748203410708811e-06
tests O 0 4.041502052132273e-06
for O 0 3.6402838077265187e-07
the O 0 9.423865208191273e-07
HD B-Disease 0 0.028700020164251328
mutation O 0 2.198118636442814e-05
, O 0 2.8855714617748163e-07
we O 0 7.642766775006749e-08
have O 0 7.768455390078088e-08
assessed O 0 4.1295754726888845e-07
the O 0 1.0322671073481615e-07
accuracy O 0 4.2891917928500334e-07
of O 0 8.788520489133589e-08
results O 0 9.633381523599382e-07
obtained O 0 6.318341547739692e-07
by O 0 2.429574976758886e-07
linkage O 0 3.0918938591639744e-06
approaches O 0 7.038644298518193e-07
when O 0 2.2350936035309132e-07
requested O 0 6.179422484819952e-07
to O 0 1.947884982200776e-07
do O 0 1.2731464948956273e-07
so O 0 1.071784012651733e-07
by O 0 2.195113779634994e-07
the O 0 6.471940992014424e-07
test O 0 1.09869151856401e-05
individuals O 0 5.844637144036824e-06
. O 0 1.8929877114715055e-05

For O 0 4.989951321476838e-06
six O 0 2.222248667749227e-06
such O 0 2.625271235956461e-07
individuals O 0 2.5957672278309474e-07
, O 0 1.1063567484370651e-07
there O 0 1.1127012555789406e-07
was O 0 5.900924406887498e-07
significant O 0 5.746099986936315e-07
disparity O 0 2.5124470539594768e-06
between O 0 9.50127514443011e-07
the O 0 4.199279828753788e-06
tests O 0 0.00012046581832692027
. O 0 2.9698816433665343e-05

Three O 0 1.2452280316210818e-05
went O 0 5.50173217561678e-06
from O 0 1.2752066140819807e-06
a O 0 1.5284914525182103e-06
decreased O 0 3.560575714800507e-05
risk O 0 2.2317633465718245e-06
to O 0 1.8529860312810342e-07
an O 0 2.0576945303218963e-07
increased O 0 4.602290118782548e-06
risk O 0 2.6627833449310856e-06
, O 0 8.665247719363833e-08
while O 0 6.738095947866896e-08
in O 0 6.650036254995939e-08
another O 0 1.3454034331061848e-07
three O 0 1.3495348127889883e-07
the O 0 1.5607653267579735e-06
risk O 0 2.7494335881783627e-05
was O 0 1.5563236956950277e-05
decreased O 0 0.00012964777124579996
. O 0 2.583257264632266e-05

Knowledge O 0 2.0440074877114967e-05
of O 0 1.4272620774136158e-06
the O 0 1.0456146810611244e-06
potential O 0 1.0033567150458111e-06
reasons O 0 5.728509222535649e-07
for O 0 1.654268544371007e-07
these O 0 1.1665525789794629e-07
changes O 0 1.0462031241331715e-06
in O 0 4.968654820913798e-07
results O 0 1.0145981832465623e-06
and O 0 1.1746058703465678e-07
impact O 0 2.7862145657309156e-07
of O 0 6.553171516543443e-08
these O 0 1.5447871248852607e-07
risk O 0 1.4107872630120255e-06
reversals O 0 7.142404683690984e-06
on O 0 1.7311650708506932e-06
both O 0 1.8983015479534515e-06
patients O 0 2.0237463104422204e-05
and O 0 1.694700557663964e-07
the O 0 4.938472670801275e-07
counseling O 0 1.3102118828101084e-05
team O 0 5.779602929578687e-07
can O 0 1.555580695367098e-07
assist O 0 2.4423775357718114e-07
in O 0 7.942734470134383e-08
the O 0 7.129224854907079e-08
development O 0 1.0706276043492835e-07
of O 0 5.74277052578509e-08
strategies O 0 7.732709264018922e-07
for O 0 6.891060877478594e-08
the O 0 4.6447064505628077e-07
prevention O 0 2.939893602160737e-05
and O 0 1.8773798160509614e-07
, O 0 6.2029869241087e-08
where O 0 8.89747724386325e-08
necessary O 0 1.9126669315028266e-07
, O 0 1.1032695823587346e-07
management O 0 6.562671615029103e-07
of O 0 9.297498593241471e-08
a O 0 5.383035386330448e-06
risk O 0 2.0770943592651747e-05
reversal O 0 2.328835216758307e-05
in O 0 6.732764177286299e-07
any O 0 1.0412302344775526e-06
predictive O 0 3.05732901324518e-05
testing O 0 1.3801813111058436e-05
program O 0 7.004980034253094e-06
. O 0 3.02483613268123e-06
. O 0 1.2393068573146593e-05

A O 0 0.00024770430172793567
novel O 0 0.00013617560034617782
common O 0 3.338790702400729e-05
missense O 0 0.0007214241777546704
mutation O 0 8.931892807595432e-05
G301C O 0 5.642868927679956e-05
in O 0 1.7058936236935551e-06
the O 0 1.596005176907056e-06
N O 0 3.773635398829356e-05
- O 0 3.1228169973473996e-05
acetylgalactosamine O 0 0.0001307380007347092
- O 0 2.7046155082643963e-05
6 O 0 1.028914084599819e-05
- O 0 0.00018074952822644264
sulfate O 0 0.0003019767755176872
sulfatase O 0 0.0009127950179390609
gene O 0 9.199765918310732e-05
in O 0 2.1921126972301863e-05
mucopolysaccharidosis B-Disease 0 0.0024966325145214796
IVA I-Disease 0 0.010459177196025848
. O 0 0.0001427852694178

Mucopolysaccharidosis B-Disease 0 0.3700004816055298
IVA I-Disease 1 0.9852762818336487
( O 0 0.0008491327171213925
MPS B-Disease 1 0.9995344877243042
IVA I-Disease 1 0.999895453453064
) O 0 7.24219489711686e-06
is O 0 1.0498512210688205e-06
an O 0 5.805395630886778e-06
autosomal B-Disease 1 0.9945117235183716
recessive I-Disease 1 0.9999510049819946
lysosomal I-Disease 1 0.9999971389770508
storage I-Disease 1 0.9999644756317139
disorder I-Disease 1 0.9999802112579346
caused O 0 0.00010281847062287852
by O 0 2.3058548777044052e-06
a O 0 7.265313615789637e-05
genetic B-Disease 1 0.9812209606170654
defect I-Disease 1 0.9954758286476135
in O 0 5.69065605304786e-06
N O 0 9.139937174040824e-05
- O 0 5.6408029195154086e-05
acetylgalactosamine O 0 0.00030456503736786544
- O 0 5.794288153992966e-05
6 O 0 1.0164015293412376e-05
- O 0 0.0004924000822938979
sulfate O 0 0.0006255162879824638
sulfatase O 0 0.00160889676772058
( O 0 2.2648322556051426e-05
GALNS O 0 0.000568305840715766
) O 0 1.592612170497887e-05
. O 0 2.092530303343665e-05

In O 0 2.4337115974049084e-05
previous O 0 1.9815877749351785e-05
studies O 0 5.116884949529776e-06
, O 0 4.833209459320642e-07
we O 0 9.31939041493024e-08
have O 0 7.326841000576678e-08
found O 0 1.2293304507693392e-07
two O 0 9.027804992456367e-08
common O 0 1.2640983868550393e-06
mutations O 0 9.886804036796093e-06
in O 0 5.285747306515987e-07
Caucasians O 0 3.854014266835293e-06
and O 0 5.858890403942496e-07
Japanese O 0 3.06074275613355e-06
, O 0 1.8764289961836766e-06
respectively O 0 1.0596389074635226e-05
. O 0 1.4214688235369977e-05

To O 0 2.8857997676823288e-05
characterize O 0 0.00012328602315392345
the O 0 6.155434675747529e-06
mutational O 0 0.0009282096871174872
spectrum O 0 2.8606573323486373e-05
in O 0 5.256119948171545e-07
various O 0 1.7884893566133542e-07
ethnic O 0 3.007572217939014e-07
groups O 0 2.978839006573253e-07
, O 0 2.925589228652825e-07
mutations O 0 2.9189945962571073e-06
in O 0 1.8812781377164356e-07
the O 0 4.71543927460516e-07
GALNS O 0 0.00010875454609049484
gene O 0 3.168404646203271e-06
in O 0 5.927246320425184e-07
Colombian O 0 1.322807111137081e-05
MPS B-Disease 1 0.9999830722808838
IVA I-Disease 1 0.9999998807907104
patients O 0 0.1430739462375641
were O 0 1.6698669469406013e-06
investigated O 0 2.04567641048925e-05
, O 0 2.967757950500527e-07
and O 0 2.4972729306682595e-07
genetic O 0 1.4928248219803208e-06
backgrounds O 0 1.0208748335571727e-06
were O 0 4.5033240780867345e-07
extensively O 0 1.8619224647409283e-05
analyzed O 0 7.512183401559014e-06
to O 0 4.6727680569347285e-07
identify O 0 1.007812215902959e-06
racial O 0 1.0662192835297901e-06
origin O 0 6.325257118078298e-07
, O 0 2.9028055337221303e-07
based O 0 5.266898028821743e-07
on O 0 8.895183896129311e-07
mitochondrial O 0 2.3097099983715452e-05
DNA O 0 1.1265621651546098e-05
( O 0 5.35090794073767e-06
mtDNA O 0 1.9566148694138974e-05
) O 0 6.1622245084436145e-06
lineages O 0 4.259731213096529e-05
. O 0 2.332965232199058e-05

Three O 0 7.8578494139947e-05
novel O 0 0.00017853343160822988
missense O 0 0.11003314703702927
mutations O 0 0.001408127835020423
never O 0 1.2313349543546792e-05
identified O 0 4.17139972341829e-06
previously O 0 1.7091180097850156e-06
in O 0 2.518945905194414e-07
other O 0 1.1002498467860278e-07
populations O 0 4.478509083583049e-07
and O 0 1.4226699818209454e-07
found O 0 2.348390495399144e-07
in O 0 1.609960804671573e-07
16 O 0 2.6379427708889125e-07
out O 0 9.747041218588492e-08
of O 0 9.014745216973097e-08
19 O 0 1.4729923805134604e-06
Colombian O 0 1.1125776836706791e-05
MPS B-Disease 1 0.9949695467948914
IVA I-Disease 1 0.999922513961792
unrelated O 0 0.00035649174242280424
alleles O 0 6.951780233066529e-05
account O 0 1.00465013019857e-05
for O 0 3.071368382734363e-06
84 O 0 6.486058555310592e-05
. O 0 3.025525620614644e-05

2 O 0 2.592695273051504e-05
% O 0 2.6015816274593817e-06
of O 0 4.2633567431948904e-07
the O 0 1.2983725810045144e-06
alleles O 0 2.9924434784334153e-05
in O 0 1.6685395394233637e-06
this O 0 3.543458888088935e-06
study O 0 2.658727316884324e-05
. O 0 3.5985485737910494e-05

The O 0 5.6551409215899184e-05
G301C O 0 0.00034296599915251136
and O 0 9.102739568334073e-06
S162F O 0 0.0003081018221564591
mutations O 0 8.281195914605632e-05
account O 0 8.189384061552119e-06
for O 0 5.384632459026761e-06
68 O 0 0.00010636323713697493
. O 0 4.712688678409904e-05

4 O 0 0.00013795804989058524
% O 0 2.1348780137486756e-05
and O 0 6.600283541047247e-06
10 O 0 1.6418709492427297e-05
. O 0 3.139813998132013e-05

5 O 0 8.199130388675258e-05
% O 0 5.50647200725507e-06
of O 0 1.3447175888359197e-06
mutations O 0 2.938307443400845e-05
, O 0 5.332205432750925e-07
respectively O 0 9.804430192161817e-07
, O 0 2.0589530436154746e-07
whereas O 0 5.268515792522521e-07
the O 0 2.1035643271716253e-07
remaining O 0 5.405812544267974e-07
F69V O 0 9.12034884095192e-05
is O 0 2.944971413398889e-07
limited O 0 6.415204438781075e-07
to O 0 4.3118475900882913e-07
a O 0 2.2275808078120463e-06
single O 0 1.3301973922352772e-05
allele O 0 0.00019528386474121362
. O 0 2.6139414330828004e-05

The O 0 6.586828385479748e-05
skewed O 0 0.00031045119976624846
prevalence O 0 0.00010511114669498056
of O 0 1.6663577753206482e-06
G301C O 0 4.0864910261007026e-05
in O 0 9.944363910108223e-07
only O 0 3.894541862337064e-07
Colombian O 0 3.470345973255462e-06
patients O 0 2.7147347282152623e-05
and O 0 8.947115475166356e-07
haplotype O 0 0.00020548714383039623
analysis O 0 1.2832363154302584e-06
by O 0 3.9454019429285836e-07
restriction O 0 1.706751277197327e-06
fragment O 0 3.374897914909525e-06
length O 0 1.3638033351526246e-06
polymorphisms O 0 4.8228816922346596e-06
in O 0 3.023510259936302e-07
the O 0 3.761161622151121e-07
GALNS O 0 0.00012318193330429494
gene O 0 4.521140454016859e-06
suggest O 0 8.296269697893877e-07
that O 0 1.3000735066270863e-07
G301C O 0 5.7640759223431814e-06
originated O 0 1.693092940513452e-06
from O 0 4.7356829213640594e-07
a O 0 1.394566538692743e-06
common O 0 5.060499461251311e-06
ancestor O 0 6.0629256040556356e-05
. O 0 3.1239906093105674e-05

Investigation O 0 9.408235200680792e-05
of O 0 3.4023212265310576e-06
the O 0 2.2237284156290116e-06
genetic O 0 5.552072707359912e-06
background O 0 1.899786639114609e-06
by O 0 3.479142947071523e-07
means O 0 2.6345361447965843e-07
of O 0 1.2776955315985106e-07
mtDNA O 0 5.669108759320807e-06
lineages O 0 3.811297119682422e-06
indicate O 0 8.336901942129771e-07
that O 0 8.508902737958124e-08
all O 0 4.760151739446883e-08
our O 0 4.561738364827761e-07
patients O 0 9.109183338296134e-06
are O 0 9.58906625214695e-08
probably O 0 3.5632726280709903e-07
of O 0 2.575682458427764e-07
native O 0 3.906899110006634e-06
American O 0 1.4714966710016597e-05
descent O 0 0.0008161009172908962

Low O 0 0.0003097145236097276
frequency O 0 0.00012444102321751416
of O 0 1.9007229639100842e-05
BRCA1 O 0 0.00761039461940527
germline O 0 0.009933575987815857
mutations O 0 0.0001966698036994785
in O 0 8.202561730286106e-06
45 O 0 2.6956033252645284e-05
German O 1 0.9988064765930176
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 0.00022367658675648272
. O 0 6.733555346727371e-05

In O 0 3.813618604908697e-05
this O 0 6.478934210463194e-06
study O 0 5.0830194595619105e-06
we O 0 6.774706662326935e-07
investigated O 0 9.495853191765491e-06
45 O 0 5.125182724441402e-06
German O 1 0.996195912361145
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.122369763441384e-06
for O 0 3.4954698548972374e-06
germline O 0 0.08489250391721725
mutations O 0 8.339776104548946e-05
in O 0 2.84379416370939e-06
the O 0 1.2986020010430366e-05
BRCA1 O 0 0.003064587712287903
gene O 0 0.00023344058718066663
. O 0 5.950446575297974e-05

We O 0 2.2943408112041652e-05
identified O 0 2.0991723431507125e-05
four O 0 8.46884631755529e-06
germline O 0 0.006010451819747686
mutations O 0 0.00016079000488389283
in O 0 3.2220525554294e-06
three O 0 4.075959441252053e-05
breast B-Disease 1 0.9999873638153076
cancer I-Disease 1 0.962914764881134
families O 0 1.350755837847828e-06
and O 0 4.3074496147710306e-07
in O 0 1.3615499483421445e-06
one O 0 3.8542828406207263e-05
breast B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 2.6384805096313357e-05
. O 0 1.9774996928845212e-07
among O 0 1.1152296508498694e-07
these O 0 8.137980245237486e-08
were O 0 1.9383325877697644e-07
one O 0 3.7785770246046013e-07
frameshift O 0 0.031180715188384056
mutation O 0 1.5523513866355643e-05
, O 0 2.8413631980583887e-07
one O 0 3.3984775882345275e-07
nonsense O 0 8.753505426284391e-06
mutation O 0 6.1528639889729675e-06
, O 0 2.0395097521941352e-07
one O 0 2.5412143145331356e-07
novel O 0 1.9662970771605615e-06
splice O 0 3.8595713704125956e-05
site O 0 8.555919521313626e-06
mutation O 0 1.064454045263119e-05
, O 0 4.005011078334064e-07
and O 0 6.645028634011396e-07
one O 0 2.5351773729198612e-06
missense O 0 0.0006671612500213087
mutation O 0 0.0003118053136859089
. O 0 3.702997128129937e-05

The O 0 8.251257531810552e-05
missense O 0 0.007685941178351641
mutation O 0 0.000736688612960279
was O 0 1.1975886081927456e-05
also O 0 1.5223697573674144e-06
found O 0 1.0905092722168774e-06
in O 0 2.101520067299134e-06
2 O 0 1.4320464288175572e-05
. O 0 1.9436300135566853e-05

8 O 0 3.178272527293302e-05
% O 0 1.7363304323225748e-06
of O 0 2.1027379659699363e-07
the O 0 2.3280871630504407e-07
general O 0 5.008579933019064e-07
population O 0 2.2193586346475058e-07
, O 0 1.5597579761106317e-07
suggesting O 0 1.4532001841871534e-06
that O 0 1.534191369501059e-07
it O 0 2.131671692495729e-07
is O 0 4.888731268692936e-07
not O 0 3.946883680328028e-06
disease O 0 0.010754553601145744
associated O 0 3.494279008009471e-05
. O 0 3.231660230085254e-05

The O 0 1.636899287404958e-05
average O 0 1.5243371308315545e-05
age O 0 4.138302301726071e-06
of O 0 2.1859939351998037e-06
disease O 1 0.7629190683364868
onset O 1 0.8331190347671509
in O 0 2.9470886602211976e-06
those O 0 6.306440241132805e-07
families O 0 3.980143446824513e-06
harbouring O 0 0.0686202198266983
causative O 0 0.00315056461840868
mutations O 0 0.00018136117432732135
was O 0 4.453586370800622e-06
between O 0 5.5390369197994005e-06
32 O 0 3.155169906676747e-05
. O 0 2.7301357476972044e-05

3 O 0 0.00016678871179465204
and O 0 2.768585727608297e-05
37 O 0 0.00013405687059275806
. O 0 3.8658195990137756e-05

4 O 0 7.942707452457398e-05
years O 0 7.459369498974411e-06
, O 0 8.543261742488539e-07
whereas O 0 1.1161910151713528e-06
the O 0 3.7052382140245754e-07
family O 0 1.7939298686542315e-06
harbouring O 0 3.95376373489853e-05
the O 0 1.1803816732935957e-06
missense O 0 0.000332189112668857
mutation O 0 1.478518606745638e-05
had O 0 8.063735208452272e-07
an O 0 2.712512241487275e-07
average O 0 1.1659302572297747e-06
age O 0 5.077905029793328e-07
of O 0 3.800339811732556e-07
onset O 0 0.0003665570402517915
of O 0 2.908640681198449e-06
51 O 0 7.351538079092279e-05
. O 0 3.46624365192838e-05

2 O 0 0.0006981394835747778
years O 0 0.00021971861133351922
. O 0 0.0001334518165094778

These O 0 2.303377550560981e-05
findings O 0 2.188607322750613e-05
show O 0 4.978130164090544e-06
that O 0 1.3271410352899693e-06
BRCA1 O 0 9.983896597987041e-05
is O 0 5.165588845557068e-07
implicated O 0 4.224968506605364e-06
in O 0 2.8199048074384336e-07
a O 0 3.96382148437624e-07
small O 0 4.522234462456254e-07
fraction O 0 2.474198026902741e-06
of O 0 1.672226790105924e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.9853736123186536e-06
suggesting O 0 2.7040916847909102e-06
the O 0 3.1069160399965767e-07
involvement O 0 1.6870454828676884e-06
of O 0 4.457162390281155e-07
another O 0 9.816884812607896e-06
susceptibility O 0 0.0017040774691849947
gene O 0 0.0001305927144130692
( O 0 2.180201954615768e-05
s O 0 0.0004971546586602926
) O 0 6.200779171194881e-05

Paternal O 1 0.8434212803840637
transmission O 1 0.9951883554458618
of O 0 0.004548362456262112
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.006405951455235481

We O 0 3.756064688786864e-05
report O 0 3.065696728299372e-05
a O 0 3.5686427963810274e-06
rare O 0 8.173450623871759e-06
case O 0 9.241844963980839e-06
of O 0 1.6671823686920106e-05
paternally O 1 0.9999935626983643
transmitted O 1 0.9999998807907104
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.788784921169281
DM B-Disease 1 1.0
) O 0 0.0001362271432299167
. O 0 6.239322101464495e-05

The O 0 4.641637860913761e-05
proband O 0 0.00047091080341488123
is O 0 2.8082920380256837e-06
a O 0 1.865978788373468e-06
23 O 0 2.431717348372331e-06
year O 0 1.4792033198318677e-06
old O 0 4.137436189921573e-05
, O 0 1.4051040125195868e-05
mentally B-Disease 1 0.9999412298202515
retarded I-Disease 1 0.9980023503303528
male O 0 0.00010746857151389122
who O 0 0.003873384790495038
suffers O 1 0.9999995231628418
severe O 1 0.9999997615814209
muscular B-Disease 1 0.9999990463256836
weakness I-Disease 1 0.9999141693115234
. O 0 0.00017883414693642408

He O 0 4.7214332880685106e-05
presented O 0 3.0623272323282436e-05
with O 0 1.005518606689293e-05
respiratory O 1 0.9988161325454712
and O 0 6.729119832016295e-06
feeding O 0 7.076764450175688e-05
difficulties O 0 5.85099114687182e-05
at O 0 1.9237071683164686e-05
birth O 0 0.00034188819699920714
. O 0 5.174287434783764e-05

His O 0 0.000201298767933622
two O 0 0.0001141495886258781
sibs O 1 0.991209864616394
suffer O 0 0.2925991714000702
from O 0 0.00016316633264068514
childhood O 1 0.9855107069015503
onset O 1 0.999997615814209
DM B-Disease 1 1.0
. O 0 0.000654534378554672

Their O 0 2.571478944446426e-05
late O 0 9.325845167040825e-05
father O 0 2.412333014945034e-05
had O 0 1.252998686140927e-06
the O 0 3.385247566711769e-07
adult O 0 1.938698005687911e-06
type O 0 2.6872071430261713e-06
of O 0 8.283146257781482e-07
DM B-Disease 1 1.0
, O 0 9.849479738477385e-07
with O 0 1.0076449825646705e-06
onset O 0 0.0015688264975324273
around O 0 2.5728372747835238e-06
30 O 0 2.890715904868557e-06
years O 0 5.438220796349924e-06
. O 0 1.4359960005094763e-05

Only O 0 6.496555215562694e-06
six O 0 2.1407588519650744e-06
other O 0 3.041817535631708e-07
cases O 0 4.018861829990783e-07
of O 0 3.3120608122771955e-07
paternal O 0 0.013102253898978233
transmission O 1 0.9683283567428589
of O 0 0.00023171756765805185
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 3.97807452827692e-05
been O 0 1.1433340660005342e-05
reported O 0 0.0002475293294992298
recently O 0 0.00011445871496107429
. O 0 2.680611942196265e-05

We O 0 2.6642857847036794e-05
review O 0 1.495903870818438e-05
the O 0 2.646032953634858e-06
sex O 0 8.544177035219036e-06
related O 0 1.0476365787326358e-05
effects O 0 2.5564855604898185e-05
on O 0 1.0787180144689046e-05
transmission O 0 0.12198849022388458
of O 0 5.6257184041896835e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0005764084635302424

Decreased O 0 0.002093630377203226
fertility O 0 0.00032432758598588407
of O 0 4.2903070607280824e-06
males O 0 9.954620509233791e-06
with O 0 2.1733430912718177e-06
adult O 0 9.402172145200893e-05
onset O 1 0.9999878406524658
DM B-Disease 1 1.0
and O 0 4.2383580876048654e-06
contraction O 0 1.8158923921873793e-05
of O 0 1.3366455675623e-07
the O 0 2.555543403559568e-07
repeat O 0 1.9405331386224134e-06
upon O 0 5.088909347250592e-07
male O 0 1.6173981975953211e-06
transmission O 0 3.109070530626923e-05
contribute O 0 5.30843976775941e-07
to O 0 1.7428291698706744e-07
the O 0 2.0051383842201176e-07
almost O 0 3.3771698326745536e-07
absent O 0 2.881149157474283e-06
occurrence O 0 2.879220801332849e-06
of O 0 7.287800372068887e-07
paternal O 0 0.003338143927976489
transmission O 1 0.5496069192886353
of O 0 0.00012812727072741836
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0006134663708508015

Also O 0 2.3184182282420807e-05
the O 0 2.833198777807411e-06
fathers O 0 4.466704467631644e-06
of O 0 2.9304953841347015e-07
the O 0 1.3992746517033083e-06
reported O 0 0.03746800869703293
congenitally O 1 0.9543259143829346
affected O 0 2.8240590836503543e-05
children O 0 2.193518184867571e-06
showed O 0 3.6552567053149687e-06
, O 0 1.732265531018129e-07
on O 0 3.71957668221512e-07
average O 0 1.236932575920946e-06
, O 0 5.671422513842117e-07
shorter O 0 2.0374975065351464e-05
CTG O 0 0.0003155058075208217
repeat O 0 7.522535725001944e-06
lengths O 0 4.851260200666729e-06
and O 0 5.821634658786934e-07
hence O 0 5.050480922363931e-06
less O 0 1.981262903427705e-05
severe O 1 0.9999855756759644
clinical O 1 0.9994744658470154
symptoms O 1 0.9973418116569519
than O 0 4.4639091356657445e-07
the O 0 1.0941198524960782e-06
mothers O 0 5.227313977229642e-06
of O 0 4.845480816584313e-07
children O 0 1.7141754142357968e-05
with O 0 0.0031317095272243023
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.00048613816034048796

We O 0 2.2793323296355084e-05
conclude O 0 5.434333797893487e-05
that O 0 4.3857612581632566e-06
paternal O 0 0.0013988773571327329
transmission O 0 0.2428431659936905
of O 0 3.961670881835744e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 6.099936854297994e-06
rare O 0 7.116546839824878e-06
and O 0 9.756078043210437e-07
preferentially O 0 1.013072414934868e-05
occurs O 0 1.301476800108503e-06
with O 0 3.835040445210325e-07
onset O 0 0.0004451000422704965
of O 0 1.5161916735451086e-06
DM B-Disease 1 0.9999997615814209
past O 0 2.4337148261110997e-06
30 O 0 9.328510373052268e-07
years O 0 3.3518890063533036e-07
in O 0 3.7232322824820585e-07
the O 0 8.787025649326097e-07
father O 0 2.179811053792946e-05
. O 0 2.8439728794182884e-06
. O 0 1.345420241705142e-05

The O 0 0.00024365926219616085
RB1 O 0 0.3577789068222046
gene O 0 0.0007220036932267249
mutation O 0 0.00011460560926934704
in O 0 4.778910351888044e-06
a O 0 7.179575732152443e-06
child O 0 4.101459853700362e-05
with O 0 3.525033753248863e-05
ectopic B-Disease 1 0.9999711513519287
intracranial I-Disease 1 0.9999955892562866
retinoblastoma I-Disease 1 0.9982689619064331
. O 0 0.00027467901236377656

The O 0 0.00013851971016265452
RB1 O 0 0.37357401847839355
gene O 0 0.0007077731424942613
mutation O 0 0.00030476812389679253
was O 0 2.1339679733500816e-05
investigated O 0 2.9014074243605137e-05
in O 0 7.45657075640338e-07
a O 0 1.8896893152486882e-06
child O 0 1.1560920938791241e-05
with O 0 4.4695889300783165e-06
ectopic B-Disease 1 0.9995442032814026
intracranial I-Disease 1 0.9993425011634827
retinoblastoma I-Disease 0 0.022897403687238693
using O 0 2.9591708425869e-06
DNA O 0 3.013983359778649e-06
obtained O 0 7.756224249533261e-07
from O 0 2.574606696725823e-07
both O 0 2.438874560084514e-07
the O 0 6.026963887961756e-07
pineal B-Disease 0 0.002371769631281495
and I-Disease 0 2.2731021090294234e-05
retinal I-Disease 1 0.9990748167037964
tumours I-Disease 1 0.9999642372131348
of O 0 3.5160317111149197e-06
the O 0 2.00414469873067e-05
patient O 0 0.011832205578684807
. O 0 4.854263170273043e-05

A O 0 0.00034687406150624156
nonsense O 0 0.0007487026159651577
mutation O 0 0.0002797961060423404
in O 0 9.374633918923791e-06
exon O 0 0.00011917290976271033
17 O 0 9.082501492230222e-06
( O 0 3.1132178719417425e-06
codon O 0 1.0950888281513471e-05
556 O 0 8.666776921018027e-06
) O 0 3.872346781008673e-07
of O 0 1.6968158433883218e-07
the O 0 1.1721377859430504e-06
RB1 O 0 0.005441116634756327
gene O 0 8.795545909379143e-06
was O 0 1.6709294641259476e-06
found O 0 2.432136341212754e-07
to O 0 1.426355566991333e-07
be O 0 8.066460566169553e-08
present O 0 2.792308748666983e-07
homozygously O 0 2.2129634089651518e-05
in O 0 2.5236587930521637e-07
both O 0 2.172206592376824e-07
the O 0 9.085298984246037e-07
retinal B-Disease 0 0.0008353775483556092
and I-Disease 0 2.8778867999790236e-06
the I-Disease 0 1.911682920763269e-05
pineal I-Disease 1 0.9969722032546997
tumours I-Disease 1 0.9999982118606567
. O 0 7.16812937753275e-05

The O 0 2.28591488848906e-05
same O 0 9.260310434910934e-06
mutation O 0 2.962640064652078e-05
was O 0 1.8813385622706846e-06
present O 0 7.495285103686911e-07
heterozygously O 0 2.9916045605205e-05
in O 0 2.0717024540317652e-07
the O 0 1.433870409073279e-07
DNA O 0 4.6141110487951664e-07
from O 0 1.2182941588889662e-07
the O 0 1.634733877153849e-07
constitutional O 0 1.2585650210894528e-06
cells O 0 1.284869995288318e-06
of O 0 5.747361342400836e-08
the O 0 5.012689143768512e-07
patient O 0 7.260176062118262e-05
, O 0 3.402670643026795e-07
proving O 0 2.4022688194236252e-06
it O 0 9.118747357206303e-08
to O 0 1.3431343859338085e-07
be O 0 1.1330815397059268e-07
of O 0 4.658027421555744e-07
germline O 0 0.00014949047181289643
origin O 0 1.6462923667859286e-05
. O 0 2.089491499646101e-05

The O 0 2.6409370548208244e-05
initial O 0 6.946596840862185e-05
mutation O 0 0.00011465795250842348
was O 0 4.015423655800987e-06
shown O 0 1.5795968693055329e-06
to O 0 3.493763074402523e-07
have O 0 2.962611063139775e-07
occurred O 0 1.809000195862609e-06
in O 0 6.545239443767059e-07
the O 0 4.2382935134810396e-06
paternally O 0 0.0011260954197496176
derived O 0 9.526772191748023e-05
RB1 O 0 0.00649384455755353
allele O 0 0.0007810277165845037
. O 0 8.781612996244803e-05

The O 0 3.754961653612554e-05
mutation O 0 9.301456884713843e-05
is O 0 7.973637252689514e-07
in O 0 3.008516102909198e-07
an O 0 8.851453969782597e-08
area O 0 1.821813810920503e-07
of O 0 4.210926718428709e-08
the O 0 1.551568402646808e-07
gene O 0 7.449854138030787e-07
that O 0 4.896084604411044e-08
encodes O 0 5.084165195512469e-07
the O 0 1.352415637256854e-07
protein O 0 5.371586553337693e-07
- O 0 7.799989134582574e-07
binding O 0 3.685351543936122e-07
region O 0 2.205591158599418e-07
known O 0 1.1460105753258176e-07
as O 0 3.5091527905706243e-08
the O 0 7.879601326976626e-08
pocket O 0 5.784560926258564e-06
region O 0 3.5898773376175086e-07
and O 0 1.41405635645242e-07
has O 0 2.643218408593384e-07
been O 0 2.971779622384929e-07
detected O 0 2.39824930758914e-06
in O 0 1.424607347644269e-07
other O 0 8.746378910018393e-08
cases O 0 4.540258657925733e-07
of O 0 8.601404033470317e-07
retinoblastoma B-Disease 0 0.2772536873817444
. O 0 8.663991138746496e-06
. O 0 2.5420884412596934e-05

Low O 0 0.00017307349480688572
levels O 0 2.0078523448319174e-05
of O 0 1.4425445442611817e-06
beta O 0 1.6507337932125665e-05
hexosaminidase O 0 9.741778194438666e-05
A O 0 3.587475475796964e-06
in O 0 1.1716628023350495e-06
healthy O 0 7.4095269155805e-06
individuals O 0 3.3528161225149233e-07
with O 0 2.677813654372585e-06
apparent O 1 0.9843655824661255
deficiency O 1 0.9296551942825317
of O 0 5.181476012694475e-07
this O 0 2.4042490167630604e-06
enzyme O 0 5.8897298004012555e-05
. O 0 1.975156192202121e-05

Appreciable O 0 0.0016768929781392217
beta O 0 0.000339392339810729
hexosaminidase O 0 0.0016050533158704638
A O 0 4.3519772589206696e-05
( O 0 5.630616669805022e-06
hex O 0 2.19249941437738e-05
A O 0 2.016157395701157e-06
) O 0 4.872403565059358e-07
activity O 0 5.492597097145335e-07
has O 0 2.3977867158464505e-07
been O 0 2.866989916583407e-07
detected O 0 3.444742105784826e-06
in O 0 9.666372307037818e-07
cultured O 0 6.454196409322321e-05
skin O 1 0.9866440892219543
fibroblasts O 0 0.03669378161430359
and O 0 0.00014666689094156027
melanoma B-Disease 1 0.9999465942382812
tissue O 0 0.016780972480773926
from O 0 1.9872882148774806e-06
healthy O 0 7.588420885440428e-06
individuals O 0 1.969609826346641e-07
previously O 0 5.932199655944714e-06
reported O 0 0.0004647263849619776
as O 0 1.3284732176543912e-06
having O 0 2.226197102572769e-05
deficiency B-Disease 0 0.0005149654462002218
of I-Disease 0 1.3211348459662986e-07
hex I-Disease 0 1.1299019206489902e-05
A I-Disease 0 1.1893695273101912e-06
activity O 0 1.8008756796916714e-06
indistinguishable O 0 2.090984708047472e-06
from O 0 2.435481292195618e-07
that O 0 1.0466487054827667e-07
of O 0 3.1232374908540805e-07
patients O 0 0.00012461617006920278
with O 0 0.0003679392393678427
Tay B-Disease 1 1.0
- I-Disease 1 0.9999992847442627
Sachs I-Disease 1 0.9999997615814209
disease I-Disease 1 0.9980816841125488
( O 0 6.342872802633792e-05
TSD B-Disease 0 0.22352184355258942
) O 0 3.7460060411831364e-05
. O 0 2.6468320356798358e-05

Identification O 0 6.907110218890011e-05
and O 0 6.429140285035828e-06
quantitation O 0 0.00010426839435240254
of O 0 1.4814507949267863e-06
hex O 0 3.2733842090237886e-05
A O 0 2.0738189050462097e-06
, O 0 5.949502792645944e-07
amounting O 0 2.8297963581280783e-06
to O 0 2.229448909929488e-06
3 O 0 1.4643207578046713e-05
. O 0 1.6014671928132884e-05

5 O 0 0.00023503496777266264
% O 0 5.203923137742095e-05
- O 0 0.00017705179925542325
6 O 0 6.201807991601527e-05
. O 0 3.6882694985251874e-05

9 O 0 6.86554194544442e-05
% O 0 4.333343440521276e-06
of O 0 5.236087758930807e-07
total O 0 8.410731311414565e-07
beta O 0 5.839778623339953e-06
hexosaminidase O 0 3.246468986617401e-05
activity O 0 2.7595485789788654e-06
, O 0 2.4871977188922756e-07
has O 0 1.3826229405822232e-07
been O 0 1.0879813316932996e-07
obtained O 0 4.1492981495139247e-07
by O 0 6.741065021742543e-07
cellulose O 0 0.00012200344644952565
acetate O 0 0.000258661835687235
gel O 0 0.0001543800171930343
electrophoresis O 0 2.7495436370372772e-05
, O 0 1.0239961056868196e-06
DEAE O 0 7.277871191035956e-05
- O 0 1.5583467757096514e-05
cellulose O 0 3.074638152611442e-05
ion O 0 2.1356434444896877e-05
- O 0 9.4799552243785e-06
exchange O 0 3.3220237583009293e-06
chromatography O 0 1.6396379578509368e-05
, O 0 8.049805728660431e-07
radial O 0 2.45003066083882e-05
immunodiffusion O 0 7.608499436173588e-05
, O 0 1.1929932952625677e-06
and O 0 2.213453853983083e-06
radioimmunoassay O 0 0.0005153373931534588
. O 0 2.780131580948364e-05

Previous O 0 0.0001254707167390734
family O 0 4.253317092661746e-05
studies O 0 9.585675798007287e-06
suggested O 0 5.56629174752743e-06
that O 0 3.324079216326936e-07
these O 0 2.1373959668835596e-07
individuals O 0 3.252786200391711e-07
may O 0 1.1938582247239538e-06
be O 0 1.3093506368022645e-07
compound O 0 4.294744030630682e-06
heterozygotes O 0 1.6017251255107112e-05
for O 0 1.7704486765524052e-07
the O 0 3.299211641660804e-07
common O 0 2.0234581370459637e-06
mutant O 0 6.776411464670673e-05
TSD B-Disease 0 0.007064928766340017
gene O 0 1.232318209076766e-05
and O 0 5.129604687681422e-07
a O 0 1.5165661579885636e-06
rare O 0 7.71651048125932e-06
( O 0 4.751910637423862e-06
allelic O 0 9.99282201519236e-05
) O 0 9.960906936612446e-06
mutant O 0 0.00013062710058875382
gene O 0 9.462597517995164e-05
. O 0 4.139622251386754e-05

Thus O 0 4.619557876139879e-05
, O 0 3.1429149203177076e-06
the O 0 1.5697786466262187e-06
postulated O 0 3.215514880139381e-05
rate O 0 6.43247039988637e-06
mutant O 0 1.9787930796155706e-05
gene O 0 4.966578671883326e-06
appears O 0 1.4682071878269198e-06
to O 0 1.8308183769022435e-07
code O 0 2.697765921766404e-07
for O 0 5.684629655888784e-08
the O 0 1.0216642465366021e-07
expression O 0 2.8800945983675774e-07
of O 0 9.216720542326584e-08
low O 0 1.3047974789515138e-06
amounts O 0 5.532097588911711e-07
of O 0 5.529059876607789e-07
hex O 0 7.737125270068645e-05
A O 0 2.9275917768245563e-05
. O 0 3.66312924597878e-05

Heterozygotes O 0 0.002539540408179164
for O 0 8.65606216393644e-06
the O 0 3.6769652069779113e-06
rare O 0 1.6724086890462786e-05
mutant O 0 0.0007610563770867884
may O 0 1.0822263902809937e-05
be O 0 3.6570941119862255e-07
indistinguishable O 0 2.9517157145164674e-06
from O 0 8.317612127939356e-07
heterozygotes O 0 1.811371294024866e-05
for O 0 6.819355462539534e-07
the O 0 2.152195747839869e-06
common O 0 2.2274967705016024e-05
TSD B-Disease 0 0.3644918203353882
mutant O 0 0.00124717119615525
. O 0 7.826156070223078e-05

However O 0 3.455945989117026e-05
, O 0 3.2318077956006164e-06
direct O 0 2.9249381441331934e-06
visualization O 0 1.4213604117685463e-05
and O 0 7.266945090123045e-07
quantitation O 0 2.0246379790478386e-05
of O 0 2.7638390065476415e-07
hex O 0 1.5365651051979512e-05
A O 0 8.471517389807559e-07
by O 0 2.271646906137903e-07
the O 0 1.8884880148561933e-07
methods O 0 1.560027158120647e-06
described O 0 5.238358426140621e-05
may O 0 4.106716460228199e-06
prevent O 0 3.5912989915232174e-06
false O 0 1.574326779518742e-05
- O 0 0.0022279233671724796
positive O 0 1.6801266610855237e-05
prenatal O 0 0.28453537821769714
diagnosis O 0 0.027322756126523018
of O 0 1.3199427257859497e-06
TSD B-Disease 1 0.9787449836730957
in O 0 2.0133706129854545e-05
fetuses O 0 0.00019387529755476862
having O 0 6.877030500618275e-07
the O 0 3.040631497697177e-07
incomplete O 0 3.070665570703568e-06
hex B-Disease 0 0.00024116678105201572
A I-Disease 0 0.0011743115028366446
deficiency I-Disease 0 0.013736319728195667
of O 0 7.967786075369077e-08
the O 0 4.249093308317242e-07
type O 0 9.478699212195352e-06
described O 0 2.830463017744478e-06
in O 0 2.8127496420893294e-07
the O 0 5.164573622096214e-07
four O 0 3.808452220255276e-06
healthy O 0 4.804121272172779e-05
individuals O 0 2.8012065740767866e-05

The O 0 0.00019423999765422195
tumor B-Disease 0 0.01320391334593296
suppressor O 0 0.005564022343605757
gene O 0 0.00038316851714625955
Smad4 O 0 0.004717950243502855
/ O 0 0.0008721551275812089
Dpc4 O 0 9.553034760756418e-05
is O 0 4.888037210548646e-07
required O 0 3.4885522381955525e-07
for O 0 1.6798806257156684e-07
gastrulation O 0 2.1663570805685595e-05
and O 0 3.813620423898101e-07
later O 0 6.896641480125254e-07
for O 0 1.9075972090831783e-07
anterior O 0 7.5169273259234615e-06
development O 0 7.312369234568905e-07
of O 0 2.757412573828333e-07
the O 0 2.5946685582312057e-06
mouse O 0 0.00019668084860313684
embryo O 0 0.0001792985713109374
. O 0 3.926058343495242e-05

Mutations O 0 0.006531425751745701
in O 0 2.993802263517864e-05
the O 0 1.9947521650465205e-05
SMAD4 O 0 0.2778715193271637
/ O 0 0.04280922934412956
DPC4 O 0 0.10597003251314163
tumor B-Disease 0 0.024666374549269676
suppressor O 0 0.0006910879164934158
gene O 0 1.1298651770630386e-05
, O 0 3.4962792483383964e-07
a O 0 4.2599998550940654e-07
key O 0 8.218498237511085e-07
signal O 0 3.0742169201403158e-06
transducer O 0 1.4827137420070358e-05
in O 0 3.228463754112454e-07
most O 0 2.475552491887356e-07
TGFbeta O 0 0.00018928358622360975
- O 0 4.8680401960154995e-05
related O 0 1.3592976984000416e-06
pathways O 0 1.4277644595495076e-06
, O 0 9.555655111626038e-08
are O 0 4.507173301249168e-08
involved O 0 1.5623781735030207e-07
in O 0 1.9950860519202251e-07
50 O 0 6.277877560023626e-07
% O 0 6.914765435794834e-07
of O 0 3.2564503271714784e-06
pancreatic B-Disease 1 0.9999896287918091
cancers I-Disease 1 0.9349473118782043
. O 0 6.501502502942458e-05

Homozygous O 0 0.02163580246269703
Smad4 O 0 0.1569061279296875
mutant O 0 0.4501214325428009
mice O 1 0.686858594417572
die O 0 0.0009263172396458685
before O 0 1.1242418622714467e-05
day O 0 1.17330591820064e-05
7 O 0 3.6436260415939614e-05
. O 0 2.902129926951602e-05

5 O 0 0.00016308359045069665
of O 0 3.4520555345807225e-05
embryogenesis O 0 0.002939456608146429
. O 0 0.00023900819360278547

Mutant O 0 0.0011368585983291268
embryos O 0 0.00014600979920942336
have O 0 5.106423031975282e-06
reduced O 0 5.364059688872658e-06
size O 0 3.2352679681935115e-06
, O 0 9.82925826065184e-07
fail O 0 5.71039072383428e-06
to O 0 9.620821401767898e-07
gastrulate O 0 0.00015406691818498075
or O 0 1.2249610108483466e-06
express O 0 5.0881262723123655e-06
a O 0 1.6795341934994212e-06
mesodermal O 0 0.00010980816296068951
marker O 0 1.4060168723517563e-05
, O 0 5.050328013567196e-07
and O 0 5.742347752857313e-07
show O 0 7.224053206300596e-06
abnormal O 0 0.00012517579307314008
visceral O 0 0.00011866998102050275
endoderm O 0 0.0009232360171154141
development O 0 5.087221506983042e-05
. O 0 4.514866668614559e-05

Growth B-Disease 1 0.9996328353881836
retardation I-Disease 1 0.9999393224716187
of O 0 4.663544132199604e-06
the O 0 8.139118108374532e-06
Smad4 O 1 0.5245425701141357
- O 0 0.3783165514469147
deficient O 0 0.009257694706320763
embryos O 0 6.700048288621474e-06
results O 0 1.5317440329454257e-06
from O 0 6.514880510621879e-07
reduced O 0 6.9854936555202585e-06
cell O 0 7.260771235451102e-05
proliferation O 0 1.3993645552545786e-05
rather O 0 1.7600175397092244e-06
than O 0 1.098548864320037e-06
increased O 0 1.7050322639988735e-05
apoptosis O 0 0.0005557010299526155
. O 0 3.337705129524693e-05

Aggregation O 0 0.00075083679985255
of O 0 2.326833055121824e-05
mutant O 0 0.00033430533949285746
Smad4 O 0 0.002119804499670863
ES O 0 0.0009865494212135673
cells O 0 2.3829152269172482e-05
with O 0 1.3324878409548546e-06
wild O 0 8.276851076516323e-06
- O 0 8.36264734971337e-05
type O 0 2.770025093923323e-05
tetraploid O 0 0.00016875665460247546
morulae O 0 0.000582830049097538
rescues O 0 0.000325595960021019
the O 0 3.440831642365083e-05
gastrulation B-Disease 0 0.0833941400051117
defect I-Disease 0 0.03927535563707352
. O 0 0.00010946139809675515

These O 0 3.6035758967045695e-05
results O 0 2.244106690341141e-05
indicate O 0 7.192185421445174e-06
that O 0 6.413234245883359e-07
Smad4 O 0 4.4954867917113006e-05
is O 0 3.692201175908849e-07
initially O 0 9.387608201905095e-07
required O 0 1.5737492731204838e-07
for O 0 7.980866456591684e-08
the O 0 1.3849825108991354e-07
differentiation O 0 4.5362205014498613e-07
of O 0 6.165923593925982e-08
the O 0 3.946722983982909e-07
visceral O 0 9.65742947300896e-06
endoderm O 0 5.174519174033776e-05
and O 0 2.7239650535193505e-07
that O 0 1.3787057184799778e-07
the O 0 4.240369548824674e-07
gastrulation B-Disease 0 0.000500128255225718
defect I-Disease 0 0.0001587077567819506
in O 0 6.990092629166611e-07
the O 0 6.529123766085831e-07
epiblast O 0 0.0002050250768661499
is O 0 3.9547893493363517e-07
secondary O 0 1.3070741715637268e-06
and O 0 3.8867167972966854e-07
non O 0 2.92177378469205e-06
- O 0 5.079814218333922e-05
cell O 0 4.339172301115468e-05
autonomous O 0 3.94644848711323e-05
. O 0 2.890035648306366e-05

Rescued O 0 0.00573714030906558
embryos O 0 0.001106823212467134
show O 0 0.0002502884017303586
severe O 1 0.654137909412384
anterior O 0 0.012200688011944294
truncations O 0 0.005532333627343178
, O 0 2.595319301690324e-06
indicating O 0 4.605275535141118e-06
a O 0 5.083176120024291e-07
second O 0 3.1386923637910513e-07
important O 0 1.5811386333552946e-07
role O 0 4.081791473709018e-07
for O 0 4.1198515532414604e-07
Smad4 O 0 7.575457129860297e-05
in O 0 3.659637741293409e-06
anterior O 0 0.0003613980661612004
patterning O 0 0.002074324991554022
during O 0 7.819524762453511e-05
embryogenesis O 0 0.0012962209293618798
. O 0 6.582779315067455e-05

Prevalence O 0 0.0008495293441228569
of O 0 1.3964450772618875e-05
p16 O 0 0.0003143246576655656
and O 0 1.6806714484118856e-05
CDK4 O 0 0.11044611036777496
germline O 0 0.43422335386276245
mutations O 0 0.0004836756852455437
in O 0 9.59992848947877e-06
48 O 0 0.00036203430499881506
melanoma B-Disease 1 0.9999953508377075
- O 0 0.3180021643638611
prone O 0 0.00014721656043548137
families O 0 4.154293037572643e-06
in O 0 6.782458967791172e-06
France O 0 0.0002260590117657557
. O 0 4.030757918371819e-05

The O 0 0.00016989119467325509
French O 0 0.003231827402487397
Familial B-Disease 1 0.9997774958610535
Melanoma I-Disease 1 0.9999967813491821
Study O 0 0.0002962224534712732
Group O 0 0.00013350069639272988
. O 0 6.085202767280862e-05

Germline O 1 0.9909226298332214
mutations O 0 0.013808941468596458
in O 0 1.3889461115468293e-05
the O 0 4.733696187031455e-06
p16 O 0 6.004260649206117e-05
and O 0 1.7316853018201073e-06
CDK4 O 0 0.0010503247613087296
genes O 0 3.933075277018361e-06
have O 0 2.8635579951696855e-07
been O 0 3.487447770567087e-07
reported O 0 2.7867431526829023e-06
in O 0 1.8267128609750216e-07
a O 0 3.59240459602006e-07
subset O 0 1.7549723452248145e-06
of O 0 9.236630944542412e-07
melanoma B-Disease 1 0.9956581592559814
pedigrees O 0 0.00011901451216544956
, O 0 3.18207526106562e-07
but O 0 1.6131451729961555e-07
their O 0 4.2093972751899855e-07
prevalence O 0 4.0256636566482484e-05
is O 0 1.8991964623182866e-07
not O 0 2.0735090799917089e-07
well O 0 6.035194246578612e-07
known O 0 4.9286345529253595e-06
. O 0 1.3480800589604769e-05

We O 0 2.2667467419523746e-05
searched O 0 4.850190816796385e-05
for O 0 2.0897127797070425e-06
such O 0 2.0411550849530613e-06
germline O 0 0.0019188100704923272
mutations O 0 4.94745145260822e-05
in O 0 2.407927468084381e-06
48 O 0 1.0020648005593102e-05
French O 0 0.01891375333070755
melanoma B-Disease 1 0.9999995231628418
- O 1 0.9417535662651062
prone O 0 8.626537601230666e-05
families O 0 5.106809908284049e-07
selected O 0 2.0277452961181552e-07
according O 0 1.4382159463366406e-07
to O 0 8.440238019602475e-08
two O 0 7.509795807436603e-08
major O 0 2.5548098392391694e-07
criteria O 0 3.9111534988478525e-07
families O 0 1.9152588492943323e-07
with O 0 9.639348519385749e-08
at O 0 2.9219643238320714e-07
least O 0 1.3845995283645607e-07
three O 0 1.3858043246273155e-07
affected O 0 7.019097552074527e-07
members O 0 3.4432366646797163e-07
( O 0 6.141792141534097e-07
n O 0 2.616131268950994e-06
= O 0 1.2802537412426318e-06
20 O 0 1.5214017423659243e-07
) O 0 7.348253205918809e-08
or O 0 7.713575200796186e-08
families O 0 8.587980460106337e-08
with O 0 4.043773671469353e-08
two O 0 7.143653135699424e-08
affected O 0 2.1987048626215255e-07
members O 0 5.102710787241449e-08
, O 0 3.637517309584837e-08
one O 0 2.342000016142265e-08
of O 0 2.624516959315315e-08
them O 0 5.8179942641345406e-08
affected O 0 4.962016078025044e-07
before O 0 1.5565333910672052e-07
the O 0 1.5629265703864803e-07
age O 0 1.8740382756732288e-07
of O 0 5.886484899519928e-08
50 O 0 3.8183736705832416e-07
( O 0 5.668463813890412e-07
n O 0 3.3241312848986126e-06
= O 0 2.0880593183392193e-06
28 O 0 3.389363030237291e-07
) O 0 1.0271664763195076e-07
, O 0 5.258797131091342e-08
and O 0 5.7277947718148425e-08
one O 0 1.2476670008254587e-07
additional O 0 9.629624173612683e-07
minor O 0 2.1907519112573937e-05
criterion O 0 5.3365940402727574e-05
. O 0 1.885744495666586e-05

Sixteen O 0 0.00018543248006608337
different O 0 1.9867193259415217e-05
p16 O 0 0.0008909174939617515
germline O 1 0.5188770890235901
mutations O 0 0.0017243579495698214
were O 0 2.2944898319110507e-06
found O 0 7.968300792526861e-07
in O 0 3.3649629926912894e-07
21 O 0 9.411686505700345e-07
families O 0 3.5781670248979935e-07
, O 0 1.693921802825571e-07
while O 0 2.096038826948643e-07
one O 0 4.5578809704238665e-07
germline O 0 0.00021063769236207008
mutation O 0 1.0264168849971611e-05
, O 0 5.866829724254785e-07
Arg24His O 0 4.228590478305705e-05
, O 0 5.595114771494991e-07
was O 0 1.4461368209595094e-06
detected O 0 5.210739800531883e-06
in O 0 5.610262974187208e-07
the O 0 2.7275625598122133e-06
CDK4 O 0 0.0017827528063207865
gene O 0 0.00013867461530026048
. O 0 2.6826959583559074e-05

The O 0 3.0031640562810935e-05
frequency O 0 5.335581226972863e-05
of O 0 3.4423414945194963e-06
p16 O 0 0.00012318156950641423
gene O 0 2.751552892732434e-05
mutation O 0 1.4876296518195886e-05
in O 0 5.505644935510645e-07
our O 0 3.2630950386192126e-07
sample O 0 5.333624244485691e-07
( O 0 2.5103844336626935e-07
44 O 0 3.769632712646853e-07
% O 0 1.0382303372580282e-07
) O 0 7.370501009518193e-08
is O 0 3.951576843519433e-08
among O 0 4.7484359555483024e-08
the O 0 1.0769151970180246e-07
highest O 0 5.435444450085924e-07
rates O 0 3.0049970973777818e-06
yet O 0 6.106807290962024e-07
reported O 0 5.219384092924884e-06
and O 0 1.569253100797141e-07
the O 0 5.81553081246966e-07
CDK4 O 0 0.039154499769210815
mutation O 0 1.0987062523781788e-05
is O 0 2.3916271629786934e-07
the O 0 2.6989161483470525e-07
second O 0 2.0493062038440257e-06
mutation O 0 1.8769711459754035e-05
detected O 0 1.1606523003138136e-05
in O 0 6.658559073002834e-07
this O 0 1.1554818684089696e-06
gene O 0 2.8036492949468084e-05
worldwide O 0 2.521238275221549e-05
. O 0 2.5429662855458446e-05

In O 0 5.192898242967203e-05
summary O 0 7.193561759777367e-05
, O 0 2.0799427602469223e-06
our O 0 8.34559671147872e-07
results O 0 1.141996108344756e-06
show O 0 8.363930419363896e-07
frequent O 0 1.5056268694024766e-06
involvement O 0 1.1284331549177296e-06
of O 0 1.5341358050591225e-07
the O 0 7.181275805123732e-07
p16 O 0 5.3559830121230334e-05
gene O 0 1.92577008419903e-05
in O 0 4.820858521270566e-06
familial B-Disease 1 0.862767219543457
melanoma I-Disease 1 0.9993632435798645
and O 0 9.594652965461137e-07
confirm O 0 3.398766921236529e-06
the O 0 2.1533546146201843e-07
role O 0 3.113180184755038e-07
of O 0 6.860661017071834e-08
the O 0 2.9176428029131785e-07
CDK4 O 0 0.00015661216457374394
gene O 0 4.776869445777265e-06
as O 0 6.326342827378539e-07
a O 0 7.630197615071665e-06
melanoma B-Disease 1 0.9924347400665283
- O 0 0.0010420518228784204
predisposing O 0 0.0001499903592048213
gene O 0 4.9981550546362996e-05
. O 0 7.191856639110483e-06
. O 0 2.212739855167456e-05

Progression O 0 0.0009784894064068794
of O 0 3.3410266041755676e-05
somatic O 0 0.0011098021641373634
CTG O 0 0.007339494302868843
repeat O 0 8.540397539036348e-05
length O 0 1.2279340808163397e-05
heterogeneity O 0 2.990007124026306e-05
in O 0 1.065721107806894e-06
the O 0 1.7553038560436107e-06
blood O 0 5.132637306815013e-05
cells O 0 0.00011879498924827203
of O 0 0.00011007602734025568
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9997065663337708
. O 0 0.00021572303376160562

The O 0 4.4361542677506804e-05
genetic O 0 7.678032125113532e-05
basis O 0 1.1645872291410342e-05
of O 0 2.6707879442255944e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.4057512879371643
DM B-Disease 1 1.0
) O 0 9.951327228918672e-07
is O 0 1.0814064665964906e-07
the O 0 9.537336609355407e-08
expansion O 0 4.2972126834683877e-07
of O 0 9.783641274907495e-08
an O 0 5.861405156792898e-07
unstable O 0 0.00022672147315461189
CTG O 0 0.000317669240757823
repeat O 0 5.057016096543521e-06
in O 0 2.950087605313456e-07
the O 0 3.2443037412122067e-07
34 O 0 1.2690532003034605e-06
UTR O 0 7.427723630826222e-06
of O 0 3.1591673632647144e-07
the O 0 2.9699001515837153e-06
DM B-Disease 1 0.9999971389770508
protein O 0 2.0171395590296015e-05
kinase O 0 0.00016493391012772918
gene O 0 1.6784259059932083e-05
on O 0 5.253972176433308e-06
chromosome O 0 9.371023770654574e-05
19 O 0 3.310411557322368e-05
. O 0 3.695127452374436e-05

One O 0 1.1148930752824526e-05
of O 0 8.290923005915829e-07
the O 0 9.353595942229731e-07
principal O 0 1.135419552156236e-06
features O 0 6.575946827069856e-07
of O 0 2.862465748876275e-07
the O 0 1.6779104043962434e-05
DM B-Disease 1 1.0
mutation O 0 0.00022537444601766765
is O 0 4.732459331080463e-07
an O 0 3.0970059583523835e-07
extraordinarily O 0 4.96103029945516e-06
high O 0 9.348682965537591e-07
level O 0 3.4445079677425383e-07
of O 0 1.9113176108476182e-07
somatic O 0 3.863290839944966e-05
mosaicism O 0 0.0014202636666595936
, O 0 5.05227433222899e-07
due O 0 1.1135350632685004e-06
to O 0 1.7511109717815998e-07
an O 0 1.9816020824237057e-07
extremely O 0 1.230989823852724e-06
high O 0 6.453432774833345e-07
degree O 0 4.549434606815339e-07
of O 0 1.8392148604107206e-07
somatic O 0 6.547800148837268e-05
instability O 0 1.5671754226787016e-05
both O 0 2.873260882552131e-07
within O 0 5.155184794602974e-07
and O 0 4.136765312523494e-07
between O 0 9.796129916139762e-07
different O 0 2.95730865218502e-06
tissues O 0 0.0004367817018646747
. O 0 4.050428105983883e-05

This O 0 3.934851338271983e-05
instability O 0 0.00023064522247295827
appears O 0 2.1248013581498526e-05
to O 0 1.1792700433943537e-06
be O 0 2.0516829124517244e-07
biased O 0 1.0435346666781697e-06
towards O 0 2.976249504627049e-07
further O 0 3.239468355786812e-07
expansion O 0 6.944153483345872e-07
and O 0 9.369311726459273e-08
continuous O 0 4.508643769440823e-07
throughout O 0 2.1753180590167176e-07
the O 0 6.767449178823881e-08
life O 0 9.761553343423657e-08
of O 0 2.236129326149694e-08
an O 0 3.721676833379206e-08
individual O 0 4.153002919338178e-08
, O 0 4.8425061294210536e-08
features O 0 3.4498037848607055e-07
that O 0 7.168535631763007e-08
could O 0 1.155181763579094e-07
be O 0 3.280430149743552e-08
associated O 0 1.0262794347681847e-07
with O 0 3.469672549272218e-08
the O 0 1.518175452019932e-07
progressive O 0 1.210958907904569e-05
nature O 0 4.943953513247834e-07
of O 0 2.2629201623658446e-07
the O 0 1.6870400941115804e-05
disease O 1 0.6046318411827087
. O 0 2.260339715576265e-05

Although O 0 7.213152275653556e-05
increasing O 0 2.544526068959385e-05
measured O 0 1.5929022993077524e-05
allele O 0 7.143196125980467e-05
size O 0 6.111670245445566e-06
between O 0 3.5024640965275466e-06
patients O 0 5.2364106522873044e-05
clearly O 0 1.357831024506595e-06
correlates O 0 3.854694114124868e-06
with O 0 2.200924456019493e-07
an O 0 3.281119234088692e-07
increased O 0 6.129444045654964e-06
severity O 0 0.004091861192137003
of O 0 1.378355023007316e-06
symptoms O 1 0.949234664440155
and O 0 2.4102953943838656e-07
an O 0 1.796083495264611e-07
earlier O 0 7.61591309128562e-06
age O 0 4.161396702784259e-07
of O 0 1.8389482647762634e-07
onset O 0 0.14192120730876923
, O 0 2.6055863600049634e-07
this O 0 1.1757400386613881e-07
correlation O 0 4.934042863169452e-07
is O 0 8.080657920572776e-08
not O 0 4.165362099683989e-08
precise O 0 2.625681645440636e-07
and O 0 1.55973111759522e-07
measured O 0 1.0023992444985197e-06
allele O 0 7.075740995787783e-06
length O 0 1.1099558605565107e-06
cannot O 0 5.354647782951361e-07
be O 0 4.842884848699214e-08
used O 0 9.412730861413365e-08
as O 0 4.281378096493427e-08
an O 0 8.393057271405269e-08
accurate O 0 1.1482887884994852e-06
predictor O 0 9.79296601144597e-06
of O 0 2.143566888435089e-07
age O 0 1.9253436676081037e-06
of O 0 2.016547796301893e-06
onset O 1 0.895778477191925
. O 0 4.999918746761978e-05

In O 0 2.0893818145850673e-05
order O 0 3.979668690590188e-06
to O 0 1.1738056855392642e-06
further O 0 1.7767893041309435e-06
characterize O 0 9.301574209530372e-06
the O 0 1.3241398164609564e-06
dynamics O 0 6.728780135745183e-05
of O 0 3.4234901704621734e-06
DM B-Disease 1 0.9999998807907104
CTG O 0 0.22329199314117432
repeat O 0 7.73612191551365e-05
somatic O 0 0.00012545780919026583
instability O 0 3.1440085876965895e-05
, O 0 4.6571258849326114e-07
we O 0 1.1371312780283915e-07
have O 0 1.4252024982397415e-07
studied O 0 9.08655579223705e-07
repeat O 0 3.591251015677699e-06
length O 0 9.274037324757956e-07
changes O 0 9.064692676474806e-07
over O 0 4.3372483560233377e-07
time O 0 5.855723088643572e-07
in O 0 2.695708190003643e-06
111 O 1 0.9630805850028992
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.36827313899993896
with O 0 2.707611656660447e-06
varying O 0 3.7247929867589846e-05
clinical O 0 0.020604625344276428
severity O 1 0.5445446372032166
and O 0 8.854956831783056e-06
CTG O 0 0.032850783318281174
repeat O 0 1.216308373841457e-05
size O 0 1.174468593490019e-06
over O 0 3.953797715894325e-07
time O 0 2.0874232120604574e-07
intervals O 0 5.972612484583806e-07
of O 0 1.1249910869537416e-07
1 O 0 6.490701025541057e-07
- O 0 6.8010285758646205e-06
7 O 0 3.8700204640917946e-06
years O 0 4.495738266996341e-06
. O 0 1.118406180466991e-05

We O 0 2.2596219423576258e-05
have O 0 1.9285998860141262e-06
found O 0 9.050474432115152e-07
a O 0 5.141113774698169e-07
direct O 0 1.2494166412579943e-06
progression O 0 3.285482307546772e-06
of O 0 1.0106440839763309e-07
the O 0 3.5388893593335524e-07
size O 0 1.558682811264589e-06
heterogeneity O 0 7.819353413651697e-06
over O 0 5.042628004048311e-07
time O 0 3.2530590488022426e-07
related O 0 5.572009627030639e-07
to O 0 2.941070249562472e-07
initial O 0 4.203563094051788e-06
CTG O 0 0.0002571502991486341
repeat O 0 6.79584218232776e-06
size O 0 6.647905479439942e-07
and O 0 1.2197985199691175e-07
the O 0 1.6323626539360703e-07
time O 0 1.9991200872482295e-07
interval O 0 1.3101891909172991e-06
and O 0 2.814426522945723e-07
always O 0 4.951875780534465e-07
biased O 0 2.4185349047911586e-06
towards O 0 9.40929965054238e-07
further O 0 2.901083462347742e-06
expansion O 0 3.773315256694332e-05
. O 0 2.6763051209854893e-05

Attempts O 0 0.00024654719163663685
to O 0 1.90556856978219e-05
mathematically O 0 3.4056043659802526e-05
model O 0 8.130476089718286e-06
the O 0 1.3786021781925228e-06
dynamics O 0 0.0003150398551952094
have O 0 3.6755554333467444e-07
proved O 0 1.0128650274054962e-06
only O 0 1.2952396843957104e-07
partially O 0 4.135378731007222e-06
successful O 0 8.22859931304265e-07
suggesting O 0 1.1619241604421404e-06
that O 0 8.467100798270621e-08
individual O 0 8.55848156788852e-08
specific O 0 2.607838780477323e-07
genetic O 0 2.429714641039027e-06
and O 0 1.1844026630569715e-06
/ O 0 0.006845900788903236
or O 0 9.036692745212349e-07
environmental O 0 2.0381849026307464e-06
factors O 0 3.4315340258217475e-07
also O 0 2.0397119726567325e-07
play O 0 1.554379451818022e-07
a O 0 5.995147489556985e-07
role O 0 2.035197667282773e-06
in O 0 3.769639761230792e-06
somatic O 0 0.0006232715677469969
mosaicism O 0 0.005468662362545729
. O 0 1.7404005120624788e-05
. O 0 3.545822619344108e-05

Aspartylglucosaminuria B-Disease 1 0.8653351068496704
among O 0 0.00013646273873746395
Palestinian O 0 0.00045918289106339216
Arabs O 0 0.0004759960575029254
. O 0 0.00019013884593732655

Aspartylglucosaminuria B-Disease 1 0.9999971389770508
( O 0 0.028772281482815742
AGU B-Disease 1 0.9999958276748657
) O 0 1.7893842596095055e-05
is O 0 1.4579184153262759e-06
a O 0 2.9860339054721408e-06
rare O 0 5.0645343435462564e-05
disorder B-Disease 0 0.32376405596733093
of I-Disease 0 9.925263384502614e-07
glycoprotein I-Disease 0 0.0005308504914864898
metabolism I-Disease 0 0.0023263830225914717
caused O 0 3.318633753224276e-05
by O 0 1.1981788929915638e-06
the O 0 1.171435542346444e-05
deficiency B-Disease 0 0.0244677122682333
of I-Disease 0 5.619103262688441e-07
the I-Disease 0 4.08813639296568e-06
lysosomal I-Disease 0 0.01751144416630268
enzyme I-Disease 0 6.996858428465202e-05
aspartylglucosaminidase I-Disease 0 0.0005445147398859262
( O 0 1.569248161104042e-05
AGA O 0 0.0006634275778196752
) O 0 1.3255991689220537e-05
. O 0 1.823284401325509e-05

AGU B-Disease 1 0.9999994039535522
is O 0 0.0007225301815196872
inherited O 1 0.7307065725326538
as O 0 8.544845513824839e-06
an O 0 2.7679650884238072e-05
autosomal O 1 0.9996874332427979
recessive O 1 0.9997418522834778
trait O 0 0.00029456085758283734
and O 0 1.0923432682830025e-06
occurs O 0 5.521535513253184e-07
with O 0 1.4804322745476384e-07
a O 0 5.150845936441328e-07
high O 0 1.5392283785331529e-06
frequency O 0 5.3811108955414966e-06
in O 0 6.826682579230692e-07
Finland O 0 6.782413493056083e-06
because O 0 2.2458947057657497e-07
of O 0 1.4090942102029658e-07
a O 0 2.878905206671334e-06
founder O 0 0.00016269994375761598
effect O 0 3.9970116631593555e-05
. O 0 2.2767013433622196e-05

While O 0 5.3552066674456e-05
very O 0 7.968430509208702e-06
few O 0 5.537352080864366e-06
patients O 0 8.912833436625078e-05
with O 0 1.0799777555803303e-05
AGU B-Disease 1 0.9999998807907104
have O 0 3.0764579150854843e-06
been O 0 8.995883717943798e-07
reported O 0 4.437399638845818e-06
from O 0 3.161029837883689e-07
non O 0 1.0830057135535753e-06
- O 0 4.059929324284894e-06
Finnish O 0 4.526490101852687e-06
origin O 0 9.769931921255193e-07
, O 0 8.489884635309863e-07
we O 0 2.651259137564921e-06
diagnosed O 1 0.9475427269935608
the O 0 4.085812906851061e-05
disorder O 1 0.9946126937866211
in O 0 2.393966951785842e-06
8 O 0 1.1545385859790258e-05
patients O 0 1.9525885363691486e-05
originating O 0 1.513273673481308e-06
from O 0 4.054161593103345e-07
3 O 0 7.510468549298821e-07
unrelated O 0 4.064205768372631e-06
families O 0 3.183580474797054e-07
, O 0 8.313411115068448e-08
all O 0 4.141564602377912e-08
Palestinian O 0 1.4317458862933563e-06
Arabs O 0 9.129882982961135e-07
from O 0 2.0505366649103962e-07
the O 0 3.4412801142025273e-07
region O 0 1.7013916249197791e-06
of O 0 1.2788552794518182e-06
Jerusalem O 0 0.0001850615517469123
. O 0 3.370500053279102e-05

The O 0 0.0002377100317971781
clinical O 1 0.7959707379341125
diagnosis O 1 0.9907904863357544
of O 0 3.1506748200627044e-05
AGU B-Disease 1 1.0
is O 0 6.0256229517108295e-06
often O 0 7.819905363248836e-07
difficult O 0 7.699580351072655e-07
, O 0 1.2586835396177776e-07
in O 0 1.0661912597242917e-07
particular O 0 1.427072646720262e-07
early O 0 3.6566754602063156e-07
in O 0 8.259861772330623e-08
the O 0 8.683695540412373e-08
course O 0 2.40010649577016e-07
of O 0 5.660858093392562e-08
the O 0 4.016327693534549e-06
disease O 0 0.010500261560082436
, O 0 1.0160713515006137e-07
and O 0 4.6594088587426086e-08
most O 0 3.5175428791944796e-08
of O 0 6.30745091712015e-08
the O 0 4.5985079850652255e-06
patients O 0 0.10873953253030777
are O 0 3.19449736707611e-06
diagnosed O 1 0.9166324734687805
after O 0 2.0586892333085416e-06
the O 0 5.28472924088419e-07
age O 0 5.799861924060679e-07
of O 0 3.181228578341688e-07
5 O 0 4.868381438427605e-06
years O 0 6.721461431880016e-06
. O 0 1.767452158674132e-05

However O 0 3.797592216869816e-05
, O 0 4.015867943962803e-06
since O 0 3.613636863519787e-06
these O 0 9.304645232077746e-07
patients O 0 2.128508458554279e-05
excrete O 0 1.4425196241063531e-05
early O 0 1.059462647390319e-06
large O 0 2.316632361498705e-07
amounts O 0 2.8880600666525424e-07
of O 0 1.302765468835787e-07
aspartylglucosamine O 0 8.133964001899585e-05
in O 0 1.0320677574782167e-06
urine O 0 8.28263091534609e-06
, O 0 5.056458007857145e-07
biochemical O 0 6.201287305884762e-06
screening O 0 3.645759761639056e-06
is O 0 2.7146057846039184e-07
easy O 0 1.0083178949571447e-06
by O 0 2.038694219663739e-06
urine O 0 6.617268809350207e-05
chromatography O 0 0.00012256280751898885
. O 0 6.145814950286876e-06
. O 0 1.639354923099745e-05

Detection O 0 0.0006192700820975006
of O 0 2.142229823220987e-05
heterozygous O 0 0.00030080010765232146
carriers O 0 2.531704740249552e-05
of O 0 2.216605707872077e-06
the O 0 6.359516555676237e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9998544454574585
telangiectasia I-Disease 1 0.9999963045120239
( O 0 1.380065532430308e-05
ATM O 0 5.621835225610994e-05
) O 0 3.19799073622562e-06
gene O 0 7.5945822572975885e-06
by O 0 2.4440719244012143e-06
G2 O 0 0.0009138431632891297
phase O 0 4.3831274524563923e-05
chromosomal O 0 0.00023916500504128635
radiosensitivity O 0 0.00013366680650506169
of O 0 5.784052973467624e-06
peripheral O 0 0.03337957337498665
blood O 0 0.021617326885461807
lymphocytes O 0 0.027692891657352448
. O 0 0.00010040369670605287

In O 0 0.004677775781601667
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999852180480957
telangiectasia I-Disease 1 0.9999998807907104
( O 0 0.0013356150593608618
A B-Disease 1 0.9991781115531921
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
) O 0 2.0454503101063892e-05
patients O 0 0.00017338765610475093
, O 0 8.190924063455896e-07
mutations O 0 5.769212293671444e-06
in O 0 1.3055775127668312e-07
a O 0 2.598442279122537e-07
single O 0 4.997977498533146e-07
gene O 0 1.5263094610418193e-06
, O 0 1.5120461682727182e-07
ATM O 0 4.772416104970034e-06
, O 0 1.5780686624111695e-07
result O 0 5.273894316815131e-07
in O 0 2.765357521639089e-06
an O 0 0.08189448714256287
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.4382807194124325e-06
embraces O 0 3.5922578263125615e-06
a O 0 5.870512040928588e-07
variety O 0 2.255908526649364e-07
of O 0 1.5843914979996043e-07
clinical O 0 2.2703334252582863e-05
features O 0 8.248530320997816e-06
and O 0 1.9700128177646548e-06
manifests O 0 0.0020741818007081747
extreme O 0 8.951350901043043e-05
radiosensitivity O 0 0.0022065190132707357
and O 0 6.363951570165227e-07
a O 0 1.0361862905483576e-06
strong O 0 4.706400432041846e-06
pre O 0 0.0002663607883732766
- O 0 0.0003097375447396189
disposition O 0 8.123229054035619e-05
to O 0 1.2630400306079537e-05
malignancy B-Disease 0 0.012133033946156502
. O 0 4.322956738178618e-05

Heterozygotes O 0 0.0016417601145803928
for O 0 6.516851954074809e-06
the O 0 3.7942445487715304e-06
ATM O 0 0.0001750681985868141
gene O 0 1.6152729585883208e-05
have O 0 4.4490849404610344e-07
no O 0 3.143959474982694e-07
clinical O 0 2.0179618331894744e-06
expression O 0 6.084402457418037e-07
of O 0 2.483369883066189e-07
A B-Disease 1 0.9966931343078613
- I-Disease 1 0.999998927116394
T I-Disease 1 0.9999998807907104
but O 0 1.3243721696198918e-05
may O 0 0.0004948217538185418
be O 0 5.3790486163052265e-06
cancer B-Disease 0 0.1416669338941574
prone O 0 3.788546109717572e-06
with O 0 1.2612261457434215e-07
a O 0 6.01935823851818e-07
moderate O 0 2.144368045264855e-05
increase O 0 1.3076302138870233e-06
in O 0 6.968633101678279e-07
in O 0 2.860374934243737e-06
vitro O 0 0.00019958709890488535
radiosensitivity O 0 0.0020791918504983187
. O 0 4.070870272698812e-05

We O 0 2.3257769498741254e-05
performed O 0 1.546455496281851e-05
a O 0 9.554053576721344e-06
blind O 0 9.3764130724594e-05
chromosomal O 0 0.00028004671912640333
analysis O 0 5.6746689551800955e-06
on O 0 5.961571787338471e-06
G2 O 1 0.6832777261734009
- O 0 9.060069714905694e-05
phase O 0 9.51747551880544e-06
lymphocytes O 0 5.1078040996799245e-05
from O 0 6.998203048169671e-07
7 O 0 1.9652884475362953e-06
unrelated O 0 6.59010183881037e-05
A B-Disease 1 0.9996576309204102
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 0.003206480061635375
, O 0 4.964264235240989e-07
13 O 0 1.4607576304115355e-06
obligate O 0 2.1249230485409498e-05
A B-Disease 1 0.9805041551589966
- I-Disease 1 0.99997878074646
T I-Disease 1 0.9999977350234985
heterozygotes O 0 0.004326636902987957
( O 0 1.3742559303864255e-06
parents O 0 5.082972620584769e-07
of O 0 1.2406641758389014e-07
the O 0 1.404526187798183e-06
patients O 0 3.750123505597003e-05
) O 0 2.419835141154181e-07
, O 0 7.006698155009872e-08
and O 0 1.0925479188017562e-07
14 O 0 3.575070479655551e-07
normal O 0 1.1891268059116555e-06
controls O 0 1.0431353985040914e-05
following O 0 3.049938186450163e-06
X O 0 0.0002456705260556191
- O 0 1.2798283933079801e-05
irradiation O 0 5.2545233302225824e-06
with O 0 3.073787127050309e-07
1 O 0 7.353144724220328e-07
Gy O 0 4.106876440346241e-05
in O 0 2.1773688274606684e-07
order O 0 2.903331619563687e-07
to O 0 2.3673531757140154e-07
evaluate O 0 2.075955762848025e-06
this O 0 2.626771333780198e-07
cytogenetic O 0 2.3055927158566192e-05
method O 0 5.338138180377427e-07
as O 0 1.8343662588904408e-07
a O 0 4.103547155409615e-07
tool O 0 1.6854952491485165e-06
for O 0 3.064152167553402e-07
detection O 0 6.0834559008071665e-06
of O 0 1.8166900872529368e-06
ATM O 0 0.0007974640466272831
carriers O 0 0.00021623395150527358
. O 0 3.736401777132414e-05

Both O 0 8.76663689268753e-05
A B-Disease 1 0.7134066820144653
- I-Disease 1 0.9979540109634399
T I-Disease 1 0.9995778203010559
homozygotes O 0 0.0006852163933217525
and O 0 3.37603432853939e-06
heterozygotes O 0 6.214038876350969e-05
showed O 0 5.884087840968277e-06
significantly O 0 4.0414483919448685e-06
increased O 0 1.3327648957783822e-06
levels O 0 1.0109195045515662e-06
of O 0 7.445401024597231e-07
radiation O 1 0.6082412004470825
- O 0 0.11389302462339401
induced O 0 0.05239798501133919
chromatid O 0 0.0480831079185009
damage O 0 4.2702122300397605e-05
relative O 0 1.6219486269619665e-06
to O 0 2.657250774973363e-07
that O 0 9.261923139547434e-08
of O 0 2.1704671837596834e-07
normal O 0 9.884352948574815e-06
controls O 0 0.0002059040853055194
. O 0 2.2712190911988728e-05

These O 0 2.7998605219181627e-05
results O 0 1.1721226655936334e-05
show O 0 3.846637355309213e-06
that O 0 5.658909003614099e-07
the O 0 1.3744904663326452e-06
G2 O 0 0.10387366265058517
- O 0 9.621318167774007e-05
phase O 0 2.0025056073791347e-05
chromosomal O 0 0.0002543525188229978
radiosensitivity O 0 0.00046075895079411566
assay O 0 0.00012508868530858308
can O 0 4.1282211782345257e-07
be O 0 7.781921596006214e-08
used O 0 1.1453932557969893e-07
for O 0 6.23381239961418e-08
the O 0 1.4062764819300355e-07
detection O 0 1.958089569598087e-06
of O 0 5.960242219771317e-07
A B-Disease 1 0.8244653940200806
- I-Disease 1 0.9987806677818298
T I-Disease 1 0.9999649524688721
heterozygotes O 0 0.010074852034449577
. O 0 4.7453206207137555e-05

In O 0 2.953370494651608e-05
combination O 0 2.7351263270247728e-05
with O 0 2.1323355667846045e-06
molecular O 0 4.40313269791659e-05
genetic O 0 1.0428946552565321e-05
analyses O 0 6.9831221480853856e-06
, O 0 4.71723808459501e-07
this O 0 2.8611367497433093e-07
test O 0 1.8535993149271235e-05
may O 0 1.7346587810607161e-06
be O 0 4.11276879219713e-08
of O 0 3.1169346215165206e-08
value O 0 6.088117032732043e-08
in O 0 1.3282017619076214e-07
studies O 0 3.3374331565028115e-07
of O 0 1.9581048604777607e-07
familial B-Disease 0 0.0002070540504064411
and I-Disease 0 2.225663138233358e-06
sporadic I-Disease 0 0.002515037776902318
cancers I-Disease 0 0.003513330826535821
aimed O 0 1.8302193893759977e-06
at O 0 3.625341378210578e-07
determination O 0 5.40576081675681e-07
of O 0 7.33046050527264e-08
the O 0 1.2368388979666634e-07
potential O 0 2.9910623311479867e-07
involvement O 0 7.087870699251653e-07
of O 0 3.3011880873345945e-07
ATM O 0 0.0056183370761573315
mutations O 0 0.00014799684868194163
in O 0 9.051415872818325e-06
tumor B-Disease 0 0.3920929431915283
risk O 0 1.1857514436997008e-05
or O 0 1.672602024882508e-06
development O 0 3.075208041991573e-06
. O 0 3.4078482258337317e-06
. O 0 1.8793673007166944e-05

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999817609786987
telangiectasia I-Disease 1 0.9999982118606567
: O 0 1.3040066733083222e-05
identification O 0 5.4982228903099895e-06
and O 0 8.03941702542943e-07
detection O 0 5.851904916198691e-06
of O 0 6.602288635804143e-07
founder O 0 0.0005561986472457647
- O 0 0.0019428613595664501
effect O 0 1.0040544111689087e-05
mutations O 0 6.3845313889032695e-06
in O 0 2.3319090303175471e-07
the O 0 4.5762394051962474e-07
ATM O 0 2.3124981453293003e-05
gene O 0 8.26892937766388e-06
in O 0 1.3931083913121256e-06
ethnic O 0 3.949674010073068e-06
populations O 0 1.9364497347851284e-05
. O 0 2.5123315936070867e-05

To O 0 1.926813456520904e-05
facilitate O 0 8.922133019950707e-06
the O 0 1.496419713475916e-06
evaluation O 0 3.218339543309412e-06
of O 0 4.0197969042310433e-07
ATM O 0 6.745509017491713e-05
heterozygotes O 0 7.63674543122761e-05
for O 0 5.871167445548053e-07
susceptibility O 0 3.902076423401013e-05
to O 0 6.498901825580106e-07
other O 0 5.218917635829712e-07
diseases O 0 0.004809341859072447
, O 0 1.79865978111593e-07
such O 0 2.3586342479120503e-07
as O 0 0.00026018894277513027
breast B-Disease 1 0.9999991655349731
cancer I-Disease 1 0.9973752498626709
, O 0 4.5388691205516807e-07
we O 0 9.458172200993431e-08
have O 0 6.735564284099382e-08
attempted O 0 1.3792083564112545e-06
to O 0 1.6492482757257676e-07
define O 0 4.5422811467688007e-07
the O 0 1.5486887150473194e-07
most O 0 1.0490710167232464e-07
common O 0 6.679553621324885e-07
mutations O 0 2.6634997993824072e-06
and O 0 1.202811716893848e-07
their O 0 2.830226151218085e-07
frequencies O 0 1.2925997907586861e-05
in O 0 3.73842594854068e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9982876181602478
telangiectasia I-Disease 1 0.9999980926513672
( O 0 2.3307637093239464e-05
A B-Disease 0 0.45970895886421204
- I-Disease 1 0.9882490634918213
T I-Disease 1 0.9978213310241699
) O 0 2.4561898044339614e-06
homozygotes O 0 2.6644380341167562e-05
from O 0 6.933545364518068e-07
10 O 0 1.1566063449208741e-06
ethnic O 0 3.2797127005324e-06
populations O 0 2.6923633413389325e-05
. O 0 2.2752125005354173e-05

Both O 0 6.550329271703959e-05
genomic O 0 0.0011221820022910833
mutations O 0 0.0008729973924346268
and O 0 3.06547508444055e-06
their O 0 2.335822728127823e-06
effects O 0 1.7495114661869593e-05
on O 0 3.843212198262336e-06
cDNA O 0 4.0274149796459824e-05
were O 0 5.174145826458698e-06
characterized O 0 9.627686813473701e-05
. O 0 3.100280082435347e-05

Protein O 0 0.00031811566441319883
- O 0 9.933538240147755e-05
truncation O 0 8.909843018045649e-05
testing O 0 8.876744686858729e-06
of O 0 5.110093752591638e-07
the O 0 8.520089522789931e-07
entire O 0 3.548606173353619e-06
ATM O 0 2.5326176910311915e-05
cDNA O 0 2.349379974475596e-05
detected O 0 1.5882988009252585e-05
92 O 0 6.080909315642202e-06
( O 0 1.6235735529335216e-06
66 O 0 4.203298431093572e-06
% O 0 1.3929475244367495e-06
) O 0 1.197986875922652e-06
truncating O 0 0.00012545875506475568
mutations O 0 4.091099981451407e-05
in O 0 1.673961492087983e-06
140 O 0 1.5312172763515264e-05
mutant O 0 0.00018889557395596057
alleles O 0 0.0002315062447451055
screened O 0 0.00022725388407707214
. O 0 4.8706959205446765e-05

The O 0 4.841706686420366e-05
haplotyping O 0 0.002016622805967927
of O 0 8.923664609028492e-06
patients O 0 0.0006732206675224006
with O 0 4.640368388209026e-06
identical O 0 0.02243085578083992
mutations O 0 0.0005667238729074597
indicates O 0 2.504750682419399e-06
that O 0 1.4871423559270625e-07
almost O 0 8.736942191944763e-08
all O 0 1.737285693081958e-08
of O 0 2.1348977696789007e-08
these O 0 4.439683820578466e-08
represent O 0 1.9095649861355923e-07
common O 0 8.109236091513594e-07
ancestry O 0 3.3982289551204303e-06
and O 0 6.378296575348941e-07
that O 0 4.4635089579969645e-07
very O 0 8.619452955827001e-07
few O 0 2.1848059077456128e-06
spontaneously O 0 5.189611329114996e-05
recurring O 0 0.0003111469268333167
ATM O 0 0.00316877500154078
mutations O 0 0.0004852855345234275
exist O 0 4.275884202797897e-05
. O 0 3.805194501182996e-05

Assays O 0 0.0008625912596471608
requiring O 0 6.227991980267689e-05
minimal O 0 2.6685831471695565e-05
amounts O 0 3.3740097933332436e-06
of O 0 5.344398346096568e-07
genomic O 0 1.3217982996138744e-05
DNA O 0 5.64491801924305e-06
were O 0 6.083474772822228e-07
designed O 0 3.35301888299e-06
to O 0 3.0764235248170735e-07
allow O 0 7.266772286129708e-07
rapid O 0 1.5044391147966962e-05
screening O 0 7.375588211289141e-06
for O 0 5.067576580586319e-07
common O 0 2.709171667447663e-06
ethnic O 0 7.012967671471415e-06
mutations O 0 0.00030606152722612023
. O 0 4.266666655894369e-05

These O 0 6.224204116733745e-05
rapid O 0 0.00043640428339131176
assays O 0 0.0011995580280199647
detected O 0 0.0007944112876430154
mutations O 0 7.873479626141489e-05
in O 0 1.8432375554766622e-06
76 O 0 2.9751302008662606e-06
% O 0 2.8072238933418703e-07
of O 0 1.4496343681003054e-07
Costa O 0 3.0521730423060944e-06
Rican O 0 2.4681374270585366e-05
patients O 0 0.0005701666814275086
( O 0 6.384759672073415e-07
3 O 0 4.255103078776301e-07
) O 0 1.5086655480445188e-07
, O 0 5.203303032885742e-08
50 O 0 9.702598902094905e-08
% O 0 7.221935049983585e-08
of O 0 7.292111092738196e-08
Norwegian O 0 0.000557310355361551
patients O 0 0.00024334627960342914
( O 0 5.817438477606629e-07
1 O 0 2.934279166311171e-07
) O 0 1.8017311731455266e-07
, O 0 5.990300877556365e-08
25 O 0 1.3312389057773544e-07
% O 0 9.142431878217394e-08
of O 0 1.1824113954617133e-07
Polish O 0 0.017899364233016968
patients O 0 0.005191938951611519
( O 0 8.131787012644054e-07
4 O 0 5.389504735830997e-07
) O 0 1.7778356209419144e-07
, O 0 4.038855649923789e-08
and O 0 4.9206786201239083e-08
14 O 0 2.50855833883179e-07
% O 0 8.875104384742372e-08
of O 0 8.767140258214567e-08
Italian O 0 3.581540295272134e-05
patients O 0 0.005836149211972952
( O 0 7.738625527053955e-07
1 O 0 3.3697091339490726e-07
) O 0 1.8042329941181379e-07
, O 0 4.803290920563086e-08
as O 0 5.40814397709255e-08
well O 0 7.889225628332497e-08
as O 0 1.22265305435576e-07
in O 0 4.590296498463431e-07
patients O 0 3.6091043966735015e-06
of O 0 3.429240678087808e-07
Amish O 0 0.0005660860915668309
/ O 0 0.0004942499799653888
Mennonite O 0 0.00012341317778918892
and O 0 1.6717790458642412e-06
Irish O 0 1.2065232112945523e-05
English O 0 9.571371265337802e-06
backgrounds O 0 5.469421739690006e-05
. O 0 3.6889585317112505e-05

Additional O 0 0.00012502835306804627
mutations O 0 0.0004889642004854977
were O 0 2.5396154796908377e-06
observed O 0 2.9144161999283824e-06
in O 0 5.753129812546831e-07
Japanese O 0 1.3790215689368779e-06
, O 0 2.832818495335232e-07
Utah O 0 1.553933316245093e-06
Mormon O 0 1.4338980918182642e-06
, O 0 2.480274190475029e-07
and O 0 3.723594375060202e-07
African O 0 2.5758079118531896e-06
American O 0 1.0498139090486802e-05
patients O 0 0.0018159298924729228
. O 0 4.404299761517905e-05

These O 0 4.603436536854133e-05
assays O 0 0.00012024809984723106
should O 0 3.936129814974265e-06
facilitate O 0 4.945207365381066e-06
screening O 0 1.0524342542339582e-05
for O 0 1.1573478104764945e-06
A B-Disease 1 0.7749961614608765
- I-Disease 1 0.9996483325958252
T I-Disease 1 0.9999655485153198
heterozygotes O 0 0.0002389712753938511
in O 0 9.60854436016234e-07
the O 0 1.0838156185855041e-06
populations O 0 5.3792127800988965e-06
studied O 0 8.068234819802456e-06
. O 0 3.855278464470757e-06
. O 0 1.49131874422892e-05

The O 0 0.00029409953276626766
von B-Disease 1 0.9142009019851685
Hippel I-Disease 1 0.9962202906608582
- I-Disease 1 0.8832145929336548
Lindau I-Disease 1 0.9923713207244873
tumor I-Disease 0 0.4797424077987671
suppressor O 0 0.0028980784118175507
gene O 0 3.846417530439794e-05
is O 0 7.098071819200413e-07
required O 0 8.691182529219077e-07
for O 0 5.251790753391106e-07
cell O 0 3.578091855160892e-05
cycle O 0 2.455897629261017e-05
exit O 0 1.724663161439821e-05
upon O 0 1.1025603271264117e-05
serum O 0 0.0003857080591842532
withdrawal O 0 0.00017124286387115717
. O 0 4.6961878979345784e-05

The O 0 5.138381675351411e-05
inactivation O 0 0.0005672629922628403
of O 0 5.295220034895465e-06
the O 0 1.0549725629971363e-05
von B-Disease 1 0.8461118936538696
Hippel I-Disease 1 0.987251877784729
- I-Disease 0 0.22541141510009766
Lindau I-Disease 0 0.14224015176296234
( I-Disease 0 2.1274940081639215e-05
VHL I-Disease 0 0.0011323192156851292
) I-Disease 0 1.3229635442257859e-05
tumor I-Disease 0 0.0003833208465948701
suppressor O 0 0.0006954348646104336
gene O 0 4.402074409881607e-05
predisposes O 0 0.00014798485790379345
affected O 0 3.997195108240703e-06
individuals O 0 2.8409593255673826e-07
to O 0 2.9789583777528605e-07
the O 0 2.4381263301620493e-06
human O 0 0.0027053270023316145
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 2.111468347720802e-06
is O 0 6.757130108780984e-07
associated O 0 2.692625230338308e-06
with O 0 1.925982587636099e-06
sporadic B-Disease 1 0.9476473927497864
renal I-Disease 1 1.0
cell I-Disease 1 0.9999837875366211
carcinomas I-Disease 1 1.0
( O 0 0.00016242743004113436
RCC B-Disease 1 0.9705389738082886
) O 0 3.889218533004168e-06
and O 0 4.3502786866156384e-06
brain B-Disease 0 0.0031913663260638714
hemangioblastomas I-Disease 0 0.0027564684860408306
. O 0 5.319344563758932e-05

VHL O 1 0.9720686078071594
- O 0 0.041513387113809586
negative O 0 0.00035750752431340516
786 O 0 0.0014041922986507416
- O 0 0.0006082621985115111
0 O 0 2.5746125174919143e-05
RCC B-Disease 1 0.8526502847671509
cells O 0 2.014997517107986e-05
are O 0 4.544161527064716e-07
tumorigenic O 0 4.1725899791345e-05
in O 0 1.7202194158016937e-06
nude O 0 0.0003576499002519995
mice O 0 5.9764071920653805e-05
which O 0 4.3553825435083127e-07
is O 0 2.3629254997104e-07
suppressed O 0 2.342988636883092e-06
by O 0 2.2149248479763628e-07
the O 0 6.143256428003951e-07
reintroduction O 0 3.149824988213368e-05
of O 0 5.779874300060328e-06
VHL B-Disease 0 0.010567148216068745
. O 0 6.139164179330692e-05

Remarkably O 0 0.0038333118427544832
, O 0 7.602582172694383e-06
this O 0 9.735612138683791e-07
occurs O 0 1.3175971389500774e-06
without O 0 2.814230697367748e-07
affecting O 0 8.261727089120541e-07
the O 0 2.1621494283863285e-07
growth O 0 1.1636374210866052e-06
rate O 0 5.202911665946885e-07
and O 0 1.6708087002825778e-07
cell O 0 4.965536845702445e-06
cycle O 0 2.892629709094763e-06
profile O 0 1.0118994850927265e-06
of O 0 1.380304297526891e-07
these O 0 3.3390503517694015e-07
cells O 0 5.835959655087208e-06
in O 0 1.7790835045161657e-06
culture O 0 1.8899210772360675e-05
. O 0 2.146491897292435e-05

The O 0 5.4036845540395007e-05
786 O 0 0.0008422192186117172
- O 0 0.00018254489987157285
0 O 0 6.812538231315557e-06
cell O 0 3.650589133030735e-05
line O 0 4.633505341189448e-06
, O 0 2.422647469302319e-07
like O 0 2.0899391017792368e-07
many O 0 4.368294241885451e-07
cancer B-Disease 0 0.12713268399238586
cells O 0 9.226567271980457e-06
, O 0 3.4908751445072994e-07
fails O 0 3.3173321298818337e-06
to O 0 2.1322001941825874e-07
exit O 0 1.5043810890347231e-06
the O 0 8.905836921258015e-07
cell O 0 2.353842864977196e-05
cycle O 0 1.534353941679001e-05
upon O 0 7.220499355753418e-06
serum O 0 0.00023361938656307757
withdrawal O 0 0.0001358706649625674
. O 0 3.604603625717573e-05

Here O 0 2.780030990834348e-05
, O 0 2.5610895590943983e-06
it O 0 4.010790632946737e-07
is O 0 1.9440250298430328e-07
shown O 0 2.928810545199667e-07
that O 0 9.680545787205119e-08
reintroduction O 0 1.970127414097078e-06
of O 0 7.765537191062322e-08
the O 0 3.05627537500186e-07
wild O 0 2.1587839000858366e-06
- O 0 0.000136862276121974
type O 0 2.374716495978646e-05
VHL B-Disease 0 0.00030595011776313186
gene O 0 6.774514531571185e-06
restores O 0 1.3968392522656359e-05
the O 0 4.926660608361999e-07
ability O 0 1.6404887901444454e-06
of O 0 7.289906989171868e-07
VHL O 0 0.11600986123085022
- O 0 0.418314665555954
negative O 0 0.0033113760873675346
RCC B-Disease 1 0.9999957084655762
cancer I-Disease 1 0.6587935090065002
cells O 0 5.186050657357555e-06
to O 0 3.1602641570316337e-07
exit O 0 1.6505699704794097e-06
the O 0 4.7223332444445987e-07
cell O 0 8.680209248268511e-06
cycle O 0 5.688973942596931e-06
and O 0 5.72244857721671e-07
enter O 0 5.692653303412953e-06
G0 O 0 0.014017023146152496
/ O 0 0.00021428558102343231
quiescence O 0 0.0003395046223886311
in O 0 7.550278041890124e-06
low O 0 6.42540690023452e-05
serum O 0 0.00044183729914948344
. O 0 3.467883652774617e-05

Both O 0 0.00010680065315682441
VHL O 0 0.097401924431324
- O 0 0.0006084893248043954
positive O 0 1.2883722774859052e-05
and O 0 3.4809461340046255e-06
VHL O 0 0.03040447272360325
- O 0 0.0029369296971708536
negative O 0 3.379480040166527e-05
RCC B-Disease 1 0.5111939311027527
cells O 0 9.660819159762468e-06
exit O 0 4.221456492814468e-06
the O 0 8.400342039749376e-07
cell O 0 1.9904080545529723e-05
cycle O 0 7.867218300816603e-06
by O 0 3.6286385238781804e-06
contact O 0 4.95076019433327e-05
inhibition O 0 0.00016596012574154884
. O 0 3.867179839289747e-05

The O 0 0.0001362883485853672
cyclin O 0 0.050635676831007004
- O 0 0.00027212061104364693
dependent O 0 3.746099173440598e-05
kinase O 0 0.0002594037214294076
inhibitor O 0 4.1829167457763106e-05
, O 0 1.1780997510868474e-06
p27 O 0 2.7851283448399045e-05
, O 0 6.317456495708029e-07
accumulates O 0 4.111340786039364e-06
upon O 0 1.3404130640992662e-06
serum O 0 2.0104733266634867e-05
withdrawal O 0 4.7179228204186074e-06
, O 0 1.186764109206706e-07
only O 0 4.1258587657466705e-08
in O 0 5.781896916801088e-08
the O 0 7.43105843525882e-08
presence O 0 2.6214434001303744e-07
of O 0 1.4608939125082543e-07
VHL B-Disease 0 0.0008345342939719558
, O 0 1.4888281896219269e-07
as O 0 6.562564891510192e-08
a O 0 9.265457379115105e-08
result O 0 1.3915121144236764e-07
of O 0 4.494451033565383e-08
the O 0 1.8776700017042458e-07
stabilization O 0 4.245875061315019e-06
of O 0 2.399795278051897e-07
the O 0 2.441174274281366e-06
protein O 0 2.682831654965412e-05
. O 0 1.9393824914004654e-05

We O 0 1.8547323634265922e-05
propose O 0 5.846985732205212e-05
that O 0 1.3288507716424647e-06
the O 0 1.1118373777208035e-06
loss O 0 3.141650040561217e-06
of O 0 2.6894224447460147e-07
wild O 0 4.797633209818741e-06
- O 0 0.0014713548589497805
type O 0 4.742416422232054e-05
VHL B-Disease 0 0.0033170036040246487
gene O 0 9.719575245981105e-06
results O 0 9.343531246486236e-07
in O 0 1.5667110631056858e-07
a O 0 3.46899184933136e-07
specific O 0 6.948790769456537e-07
cellular O 0 0.00010266104072798043
defect O 0 0.0001734200632199645
in O 0 1.7730264971760334e-06
serum O 0 9.81808261713013e-05
- O 0 1.651774437050335e-05
dependent O 0 2.055804998235544e-06
growth O 0 1.0818660030054161e-06
control O 0 3.1085066893865587e-06
, O 0 3.1722760240882053e-07
which O 0 5.839116283823387e-07
may O 0 4.7247931433958e-06
initiate O 0 0.00012966457870788872
tumor B-Disease 0 0.007501909974962473
formation O 0 8.549589256290346e-05
. O 0 4.2488907638471574e-05

This O 0 2.9049455406493507e-05
is O 0 6.788794053136371e-06
corrected O 0 3.4579898056108505e-05
by O 0 5.375706564336724e-07
the O 0 3.746030472484563e-07
reintroduction O 0 6.727117579430342e-06
of O 0 2.6871254021898494e-07
wild O 0 3.524736712279264e-06
- O 0 0.00042573516839183867
type O 0 2.5706893211463466e-05
VHL B-Disease 0 0.0004882344219367951
, O 0 8.693968425177445e-07
implicating O 0 5.099286499898881e-05
VHL B-Disease 0 0.000144207471748814
as O 0 2.9089633812873217e-07
the O 0 1.8155074599235377e-07
first O 0 7.977166092132393e-07
tumor B-Disease 0 0.00013147509889677167
suppressor O 0 3.358013418619521e-05
involved O 0 2.2856546877392248e-07
in O 0 1.0640723502319815e-07
the O 0 1.1997472881830618e-07
regulation O 0 6.504208727164951e-07
of O 0 1.6193042995382712e-07
cell O 0 2.8731134079862386e-05
cycle O 0 1.1064216778322589e-05
exit O 0 4.526550583250355e-06
, O 0 1.667634421664843e-07
which O 0 1.277041548064517e-07
is O 0 5.710341355324999e-08
consistent O 0 1.5992428359368205e-07
with O 0 8.099977577558093e-08
its O 0 4.741033308164333e-07
gatekeeper O 0 1.718952444207389e-05
function O 0 9.039347332873149e-07
in O 0 5.336061690286442e-07
the O 0 3.260312951169908e-06
kidney O 0 0.009089301340281963
. O 0 5.32969579580822e-06
. O 0 1.8832337445928715e-05

Piebaldism B-Disease 1 0.9999624490737915
with O 0 0.006724571343511343
deafness B-Disease 1 1.0
: O 0 1.5776364307384938e-05
molecular O 0 1.5891318980720825e-05
evidence O 0 1.5776787449794938e-06
for O 0 9.727259566716384e-07
an O 0 6.640051196882268e-06
expanded O 0 0.09520938992500305
syndrome O 1 0.9999969005584717
. O 0 6.312900222837925e-05

In O 0 2.393487375229597e-05
a O 0 5.4378988352254964e-06
South O 0 3.31072033077362e-06
African O 0 1.7705038999338285e-06
girl O 0 3.8046148347348208e-06
of O 0 4.27722341100889e-07
Xhosa O 0 0.004064188804477453
stock O 0 1.8928307326859795e-05
with O 0 2.5399303922313266e-06
severe O 1 0.8811914920806885
piebaldism B-Disease 1 0.9638462066650391
and O 0 0.007242192048579454
profound O 1 0.9999836683273315
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 1.5151109437283594e-05
identified O 0 8.577929293096531e-06
a O 0 1.9003772422365728e-06
novel O 0 5.5591353884665295e-06
missense O 0 2.641647370182909e-05
substitution O 0 2.9448074201354757e-06
at O 0 4.5441356633091345e-07
a O 0 3.8436814975284506e-07
highly O 0 5.223175207902386e-07
conserved O 0 1.3206024505052483e-06
residue O 0 1.8625225948198931e-06
in O 0 1.9459912437014282e-07
the O 0 2.930067921624868e-07
intracellular O 0 6.628004939557286e-06
kinase O 0 1.2949254596605897e-05
domain O 0 1.0090662954098661e-06
of O 0 1.9967764330885984e-07
the O 0 1.429827420906804e-06
KIT O 0 0.011266009882092476
proto O 0 0.08580899238586426
- O 0 0.0002926827874034643
oncogene O 0 0.0003488008806016296
, O 0 6.356051471811952e-06
R796G O 0 0.00017490037134848535
. O 0 3.1005285563878715e-05

Though O 0 0.00024184190260712057
auditory B-Disease 0 0.11426028609275818
anomalies I-Disease 1 0.9280025959014893
have O 0 3.1847271202423144e-06
been O 0 1.0791455906655756e-06
observed O 0 2.3276350020751124e-06
in O 0 7.921385076770093e-07
mice O 0 1.4918236956873443e-05
with O 0 4.5278184757080453e-07
dominant O 0 9.855890311882831e-06
white O 0 2.860755739675369e-05
spotting O 0 0.0010231249034404755
( O 0 1.3662265700986609e-05
W O 0 0.19214500486850739
) O 0 3.3782427522055514e-07
due O 0 1.1315800065858639e-06
to O 0 1.1417064342822414e-06
KIT O 1 0.9761919975280762
mutations O 0 0.007454375270754099
, O 0 1.2230862921569496e-05
deafness B-Disease 1 0.9999996423721313
is O 0 8.462674827569572e-07
not O 0 3.2577068509453966e-07
typical O 0 2.24747896027111e-06
in O 0 1.4738579920958728e-06
human O 0 1.1081800039391965e-05
piebaldism B-Disease 0 0.0015641667414456606
. O 0 3.4852768294513226e-05

Thus O 0 5.222541585681029e-05
, O 0 3.772128366108518e-06
the O 0 1.726545519886713e-06
occurrence O 0 1.4909176570654381e-05
of O 0 6.205120826052735e-06
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 7.939905481180176e-05
this O 0 5.10683730681194e-06
patient O 0 0.0001876359892776236
extends O 0 1.0207453669863753e-05
considerably O 0 6.826058779552113e-06
the O 0 4.811571443497087e-07
phenotypic O 0 3.1931149351294152e-06
range O 0 5.944330609963799e-07
of O 0 2.3161109652392042e-07
piebaldism B-Disease 0 0.0003330796316731721
due O 0 8.011359568627086e-06
to O 0 2.3885665996203898e-06
KIT O 0 0.12066936492919922
gene O 0 2.8273952921153978e-05
mutation O 0 8.143154445861e-06
in O 0 3.648754329788062e-07
humans O 0 7.494298301935487e-07
and O 0 3.537995212354872e-07
tightens O 0 0.008153286762535572
the O 0 8.505355140187021e-07
clinical O 0 9.174832484859508e-06
similarity O 0 1.660085899857222e-06
between O 0 8.181649491234566e-07
piebaldism B-Disease 0 6.637878686888143e-05
and O 0 2.1840611452716985e-07
the O 0 1.6681289594089321e-07
various O 0 2.792854729705141e-07
forms O 0 2.7306571155349957e-06
of O 0 4.42211858171504e-05
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 2.561717883509118e-05
. O 0 3.832123911706731e-05

Cycloheximide O 0 0.003779276739805937
facilitates O 0 0.00024393956118728966
the O 0 7.054193702060729e-06
identification O 0 4.571607860270888e-06
of O 0 9.795027153813862e-07
aberrant O 0 5.419982335297391e-05
transcripts O 0 2.3836197215132415e-05
resulting O 0 5.909686478844378e-06
from O 0 8.033830454223789e-07
a O 0 1.431001919627306e-06
novel O 0 4.194872872176347e-06
splice O 0 0.00011186004121555015
- O 0 9.852219955064356e-05
site O 0 6.406097327271709e-06
mutation O 0 9.48640354181407e-06
in O 0 1.1323745638947003e-06
COL17A1 O 0 0.00022399910085368901
in O 0 2.236830368929077e-06
a O 0 8.959804290498141e-06
patient O 0 0.0004603567940648645
with O 0 4.977121716365218e-05
generalized O 1 0.9891505837440491
atrophic B-Disease 1 0.9999991655349731
benign I-Disease 1 0.999988317489624
epidermolysis I-Disease 1 0.9999822378158569
bullosa I-Disease 1 0.9998433589935303
. O 0 0.0005896445363759995

Patients O 1 0.5694276094436646
with O 0 0.00038493392639793456
generalized O 1 0.9979118704795837
atrophic B-Disease 1 0.9999997615814209
benign I-Disease 1 0.9999984502792358
epidermolysis I-Disease 1 0.9999945163726807
bullosa I-Disease 1 0.9998741149902344
often O 0 4.966463893651962e-05
show O 0 1.1106335477961693e-05
decreased O 0 1.0540835319261532e-05
expression O 0 1.4003852584210108e-06
of O 0 6.488831445494725e-07
type O 0 0.005629674531519413
XVII O 1 0.9998899698257446
collagen O 0 0.008452869951725006
, O 0 1.014061240312003e-06
a O 0 1.6893349084057263e-06
transmembrane O 0 2.563670750532765e-05
hemidesmosomal O 0 5.2257651987019926e-05
protein O 0 4.033154709759401e-06
encoded O 0 4.5005858737567905e-06
by O 0 4.322999302530661e-06
COL17A1 O 0 0.0006211118306964636
. O 0 3.413418016862124e-05

This O 0 3.324436329421587e-05
report O 0 2.4397089873673394e-05
documents O 0 6.180263426358579e-06
a O 0 1.908957983687287e-06
novel O 0 5.846527074027108e-06
splice O 0 0.00013243465218693018
- O 0 0.0001267563784494996
site O 0 7.098110472725239e-06
mutation O 0 1.0319406101189088e-05
in O 0 9.444468673791562e-07
COL17A1 O 0 0.0001332994579570368
in O 0 1.167816435554414e-06
a O 0 4.696482847066363e-06
patient O 0 0.00025965317036025226
with O 0 1.630912629480008e-05
generalized O 1 0.9278571605682373
atrophic B-Disease 1 0.999998927116394
benign I-Disease 1 0.9999916553497314
epidermolysis I-Disease 1 0.9999947547912598
bullosa I-Disease 1 0.999679684638977
, O 0 3.978731456300011e-06
and O 0 4.237951998220524e-07
applies O 0 9.326286658506433e-07
a O 0 5.831113867316162e-07
new O 0 1.8816400597643224e-06
methodology O 0 2.645884023877443e-06
to O 0 6.290642886597198e-07
define O 0 1.7461144352637348e-06
and O 0 5.397209861257579e-07
characterize O 0 5.9056637837784365e-06
the O 0 7.681925922042865e-07
resulting O 0 7.168355296016671e-06
mRNA O 0 2.3072643671184778e-05
splice O 0 0.0001989187439903617
variants O 0 0.00011488012387417257
. O 0 3.412363366805948e-05

Mutational O 0 0.007573738694190979
analysis O 0 5.6730837968643755e-05
of O 0 6.13306383456802e-06
COL17A1 O 0 0.006010939367115498
identified O 0 1.828654967539478e-05
a O 0 1.4022927643964067e-05
maternally O 1 0.6143490076065063
inherited O 1 0.9349055290222168
G O 0 0.05338571220636368
- O 0 0.0003171245916746557
to O 0 3.023249973921338e-06
- O 0 0.0014101475244387984
T O 0 0.00046900243614800274
transversion O 0 2.199154369009193e-05
at O 0 4.811731741938274e-07
the O 0 3.3686779943309375e-07
- O 0 2.67671066467301e-06
1 O 0 4.84140230128105e-07
position O 0 1.10520261387137e-06
of O 0 9.61387854658824e-07
exon O 0 0.00011344187805661932
32 O 0 3.883040335495025e-05
. O 0 2.4140494133462198e-05

This O 0 4.5482800487661734e-05
acceptor O 0 0.00032451999140903354
splice O 0 0.0008761465433053672
- O 0 0.0002992175577674061
site O 0 1.2445358152035624e-05
mutation O 0 1.2203658116050065e-05
led O 0 1.3530919886761694e-06
to O 0 2.7660169621412933e-07
the O 0 1.6566146143759397e-07
formation O 0 9.478395668338635e-07
of O 0 2.730105279624695e-07
aberrant O 0 1.65630153787788e-05
transcripts O 0 6.7103683250024915e-06
present O 0 1.8379995481154765e-06
at O 0 1.8886838688558782e-06
extremely O 0 1.2448148481780663e-05
low O 0 2.9019885914749466e-05
levels O 0 2.6721714675659314e-05
. O 0 2.534028135414701e-05

Based O 0 4.437431925907731e-05
on O 0 4.784629254572792e-06
our O 0 8.736772656448011e-07
recent O 0 2.0372754079289734e-06
finding O 0 1.6039487036323408e-06
that O 0 8.877523214323446e-07
cycloheximide O 0 0.00021016625396441668
stabilized O 0 0.0006760885589756072
mutant O 0 3.8907615817151964e-05
COL17A1 O 0 9.166349627776071e-05
transcripts O 0 1.3011867849854752e-05
in O 0 2.1947464574623154e-06
keratinocytes O 0 0.00012641801731660962
homozygous O 0 3.05409703287296e-05
for O 0 6.719383236486465e-07
a O 0 4.207228812447283e-06
frameshift O 0 0.36716148257255554
mutation O 0 2.876908183679916e-05
, O 0 2.3556557948722912e-07
the O 0 2.454447098898527e-07
effects O 0 1.6981382486846996e-06
of O 0 8.109176263815243e-08
the O 0 3.341101830756088e-07
splice O 0 8.033376070670784e-05
- O 0 5.563150261878036e-05
site O 0 2.2985173018241767e-06
mutation O 0 2.365922910030349e-06
on O 0 3.547039284512721e-07
splicing O 0 2.994686610691133e-06
of O 0 2.409385331247904e-07
COL17A1 O 0 8.33888552733697e-05
transcripts O 0 5.603276349575026e-06
were O 0 4.674894000800123e-07
determined O 0 1.093894525183714e-06
using O 0 1.1251235036979779e-06
reverse O 0 2.3145059458329342e-05
transcriptase O 0 6.508797378046438e-05
polymerase O 0 1.9066646927967668e-05
chain O 0 9.074207810044754e-06
reaction O 0 1.2964646884938702e-06
of O 0 1.2806943061605125e-07
total O 0 4.965111770616204e-07
RNA O 0 3.8005389342288254e-06
from O 0 1.950809064510395e-06
keratinocytes O 0 0.00010027471580542624
incubated O 0 2.499715265003033e-05
for O 0 2.3608583887835266e-06
2 O 0 1.0987323548761196e-05
. O 0 1.3958218914922327e-05

5 O 0 0.00014024482516106218
h O 0 0.0001967487478395924
in O 0 2.2105300558905583e-06
the O 0 1.0711806908147992e-06
presence O 0 2.2419260403694352e-06
or O 0 8.116825824799889e-07
absence O 0 1.1669769719446776e-06
of O 0 3.605931908623461e-07
10 O 0 1.916378323585377e-06
microg O 0 0.00021221369388513267
cycloheximide O 0 0.0006866211188025773
per O 0 2.1782234398415312e-05
ml O 0 0.0014017286011949182
. O 0 4.457671821000986e-05

Using O 0 2.6159566914429888e-05
this O 0 2.4311657398357056e-06
approach O 0 3.2589045986242127e-06
, O 0 4.95276822221058e-07
an O 0 6.043447910997202e-07
abnormally O 0 0.00014611105143558234
spliced O 0 0.00010454866423970088
transcript O 0 0.0005061995470896363
was O 0 6.078862952563213e-06
identified O 0 1.0513903134778957e-06
that O 0 8.767541714860272e-08
contains O 0 1.3295387191192276e-07
an O 0 6.526067153345139e-08
extra O 0 2.6222809879072884e-07
264 O 0 1.2742315220748424e-06
bases O 0 4.987949751011911e-07
upstream O 0 8.084896307991585e-07
from O 0 3.5993110714116483e-07
exon O 0 7.599964646942681e-06
32 O 0 1.2476247093218262e-06
, O 0 3.0267125339378254e-07
resulting O 0 1.9747567421291023e-06
in O 0 7.875662504375214e-07
a O 0 6.9628677010769024e-06
premature O 0 0.005675195716321468
termination O 0 8.989228081190959e-05
codon O 0 4.0401628211839125e-05
27 O 0 1.0114091310242657e-05
bp O 0 2.6778268875204958e-05
downstream O 0 9.21869468584191e-06
from O 0 2.210346792708151e-06
the O 0 3.2943742098723305e-06
cryptic O 0 9.004292951431125e-05
splice O 0 0.0004647647147066891
site O 0 9.179540938930586e-05
. O 0 3.385059972060844e-05

Three O 0 1.0961064617731608e-05
other O 0 1.8371864598520915e-06
splice O 0 5.830705413245596e-05
variants O 0 1.0656973245204426e-05
, O 0 4.6971493361525063e-07
including O 0 1.2824627049212722e-07
one O 0 1.0159416063970639e-07
derived O 0 3.307989118184196e-07
from O 0 1.0441682718465017e-07
the O 0 1.041447319494182e-07
skipping O 0 1.0823964657902252e-06
of O 0 1.9649607452265627e-07
exon O 0 9.412061444891151e-06
32 O 0 1.1989023960268241e-06
, O 0 2.796548983496905e-07
were O 0 3.5503489925758913e-07
also O 0 1.5413818346132757e-06
identified O 0 1.558051008032635e-05
. O 0 2.1637886675307527e-05

These O 0 2.24513205466792e-05
results O 0 1.3212109479354694e-05
indicate O 0 5.071330633654725e-06
the O 0 1.003299189505924e-06
usefulness O 0 6.1087571339157876e-06
of O 0 7.321447128560976e-07
cycloheximide O 0 0.3305349051952362
treatment O 0 0.0006643662345595658
in O 0 7.478983548026008e-07
evaluating O 0 2.0952124941686634e-06
the O 0 4.703066167621728e-07
abnormal O 0 8.054980753513519e-06
processing O 0 4.054254532093182e-07
of O 0 6.785026585021114e-08
mRNA O 0 7.935252028801187e-07
due O 0 8.881316375664028e-07
to O 0 4.3320065401530883e-07
splice O 0 4.924452878185548e-05
- O 0 8.741542842471972e-05
site O 0 5.5841569519543555e-06
mutations O 0 1.1661709322652314e-05
, O 0 2.3877029775576375e-07
because O 0 4.388370200558711e-07
( O 0 7.709072633588221e-07
i O 0 4.919074285680836e-07
) O 0 4.4732843207384576e-07
aberrant O 0 6.969683454371989e-06
splicing O 0 7.590896075271303e-06
often O 0 7.835820952095673e-07
generates O 0 3.238095359847648e-06
a O 0 2.6949421680910746e-06
premature O 0 0.00014150403148960322
termination O 0 3.9470694900956005e-05
codon O 0 1.7106889572460204e-05
, O 0 6.945895165699767e-07
( O 0 8.864274150255369e-07
ii O 0 1.6123749446705915e-05
) O 0 4.7468512320847367e-07
transcripts O 0 3.3949577300518285e-06
with O 0 1.8782155848384718e-06
premature O 0 0.0013014698633924127
termination O 0 5.8620935305953026e-05
codons O 0 1.737059574224986e-05
can O 0 8.877997288436745e-07
occur O 0 7.837539328647836e-07
at O 0 6.265872798394412e-07
low O 0 2.357562152610626e-06
or O 0 7.973272317940427e-07
undetectable O 0 1.5544224879704416e-05
levels O 0 7.336894327636401e-07
due O 0 9.352026495434984e-07
to O 0 3.754066426608915e-07
nonsense O 0 1.8552507299318677e-06
- O 0 2.487210167601006e-06
mediated O 0 4.064260338054737e-06
mRNA O 0 1.4718325473950244e-06
decay O 0 1.96053542822483e-06
, O 0 1.4667152470337896e-07
and O 0 1.4377346246874367e-07
( O 0 6.18779097294464e-07
iii O 0 1.3691979802388232e-05
) O 0 1.2093829582227045e-07
the O 0 8.862789258046178e-08
levels O 0 1.3388130071234627e-07
of O 0 4.225739047569732e-08
these O 0 9.244132570529473e-08
transcripts O 0 1.6928959212236805e-06
can O 0 2.2064853055780986e-07
be O 0 2.3639240964712371e-07
increased O 0 2.311892558282125e-06
by O 0 3.9377064240397885e-06
cycloheximide O 0 0.0009125236538238823
. O 0 3.29590002365876e-05

A O 0 0.000337436591507867
deletion O 0 0.0031980706844478846
mutation O 0 0.0002976015966851264
in O 0 7.642585842404515e-06
COL17A1 O 0 0.0005905446596443653
in O 0 2.0689160464826273e-06
five O 0 1.4010211089043878e-06
Austrian O 0 6.348337046802044e-05
families O 0 5.665065600624075e-06
with O 0 1.4955758160795085e-05
generalized O 1 0.9903292655944824
atrophic B-Disease 1 0.9999995231628418
benign I-Disease 1 0.9999769926071167
epidermolysis I-Disease 1 0.9999581575393677
bullosa I-Disease 1 0.9547044634819031
represents O 0 2.0486950234044343e-05
propagation O 0 1.7869591829366982e-05
of O 0 9.356031682727917e-07
an O 0 2.536299689381849e-06
ancestral O 0 0.00017289831885136664
allele O 0 0.0006674454780295491
. O 0 4.8178389988606796e-05

Patients O 1 0.7253106236457825
with O 0 0.0006497121066786349
generalized O 1 0.9995337724685669
atrophic B-Disease 1 0.9999997615814209
benign I-Disease 1 0.999998927116394
epidermolysis I-Disease 1 0.9999970197677612
bullosa I-Disease 1 0.9999725818634033
, O 0 3.944657510146499e-05
a O 0 1.1219734005862847e-05
usually O 0 4.407379492477048e-06
nonlethal O 0 3.392010694369674e-05
form O 0 4.817517037736252e-06
of O 0 5.805882665299578e-06
junctional B-Disease 1 0.9849928617477417
epidermolysis I-Disease 1 0.9999728202819824
bullosa I-Disease 1 0.9997140765190125
, O 0 1.1702362826326862e-05
have O 0 2.825282308549504e-06
generalized O 0 5.234213676885702e-05
blistering B-Disease 0 0.21039746701717377
, O 0 1.8318714865017682e-05
nail B-Disease 1 0.9999548196792603
dystrophy I-Disease 1 0.9999651908874512
, O 0 2.8711961931549013e-05
patchy B-Disease 1 0.9999611377716064
alopecia I-Disease 1 1.0
, O 0 1.881164098449517e-05
and O 0 0.00014034289051778615
dental B-Disease 1 0.9999992847442627
abnormalities I-Disease 1 0.9999958276748657
. O 0 8.382512896787375e-05

Skin B-Disease 1 0.9999959468841553
fragility I-Disease 1 0.9985602498054504
in O 0 2.800939546432346e-05
most O 0 1.965944420589949e-06
cases O 0 1.6411959222750738e-06
is O 0 2.7811813652078854e-07
due O 0 3.5419386676949216e-06
to O 0 1.3089602362015285e-06
mutations O 0 8.172984053089749e-06
in O 0 2.511742138722184e-07
the O 0 7.091941256476275e-07
gene O 0 1.0327498785045464e-05
encoding O 0 2.4476958060404286e-05
type O 0 0.0002480581169947982
XVII O 1 0.9918748736381531
collagen O 0 0.011025615967810154
( O 0 1.3766243682766799e-05
COL17A1 O 0 0.0007064550882205367
) O 0 1.2977391634194646e-05
. O 0 1.765017987054307e-05

Recently O 0 0.0006182747893035412
, O 0 6.450555702031124e-06
we O 0 9.505008620180888e-07
reported O 0 3.7672032249247422e-06
five O 0 6.530313498842588e-07
Austrian O 0 2.9341967092477717e-05
families O 0 4.8995316319633275e-06
with O 0 9.915717782860156e-06
generalized O 1 0.9651565551757812
atrophic B-Disease 1 0.9999995231628418
benign I-Disease 1 0.9999924898147583
epidermolysis I-Disease 1 0.9999918937683105
bullosa I-Disease 1 0.9998993873596191
who O 0 2.4598546588094905e-05
share O 0 7.731522600806784e-06
the O 0 3.5471712180878967e-06
same O 0 1.0232864042336587e-05
COL17A1 O 0 0.05544852092862129
mutation O 0 0.0005508047761395574
. O 0 6.025850962032564e-05

Affected O 0 0.0002283657668158412
individuals O 0 5.586116913036676e-06
in O 0 1.3334234836293035e-06
three O 0 6.696653827020782e-07
families O 0 8.13568874491466e-07
are O 0 2.609401121844712e-07
homozygous O 0 7.512118827435188e-06
for O 0 2.6310158318665344e-07
4003delTC O 0 3.572421701392159e-05
, O 0 3.896514897405723e-07
whereas O 0 9.361770594296104e-07
those O 0 1.5753033721921383e-07
in O 0 1.773153854855991e-07
two O 0 1.9724558342204546e-07
others O 0 8.146294021571521e-07
are O 0 7.936357064863842e-07
compound O 0 9.114088607020676e-05
heterozygotes O 0 0.0023179517593234777
. O 0 4.584475755109452e-05

To O 0 2.6036765120807104e-05
determine O 0 7.950789040478412e-06
if O 0 6.404451369235176e-07
the O 0 2.753528463017574e-07
occurrence O 0 2.5423828446946573e-06
of O 0 3.1414117529493524e-07
4003delTC O 0 9.306105494033545e-05
in O 0 1.1657612049020827e-06
these O 0 3.646023571945989e-07
unrelated O 0 4.844094746658811e-06
families O 0 7.032256803540804e-07
signifies O 0 1.4045394891581964e-06
propagation O 0 1.783667016752588e-06
of O 0 1.230660586770682e-07
an O 0 3.6763967159458844e-07
ancestral O 0 1.698744745226577e-05
allele O 0 1.895234890980646e-05
or O 0 7.50373885693989e-07
a O 0 1.7312361251242692e-06
mutational O 0 0.00011542431457201019
hot O 0 1.2726413842756301e-05
spot O 0 3.17352123602177e-06
, O 0 5.436999117591768e-07
haplotypes O 0 1.1007617104041856e-05
were O 0 3.9197604451146617e-07
determined O 0 9.125704423240677e-07
for O 0 2.4598040226919693e-07
polymorphisms O 0 5.556829819397535e-06
both O 0 3.2446811815134424e-07
within O 0 9.70394694377319e-07
and O 0 1.7926814734892105e-06
flanking O 0 0.0004715549002867192
COL17A1 O 0 0.07083358615636826
. O 0 5.045142097515054e-05

Five O 0 6.409746129065752e-05
intragenic O 0 0.001346216886304319
polymorphisms O 0 0.00018656716565601528
were O 0 2.7060473257733975e-06
chosen O 0 2.0948027668055147e-06
based O 0 1.3236904123914428e-06
on O 0 1.1444732308518724e-06
their O 0 3.3181672733917367e-06
informativeness O 0 0.0026342107448726892
. O 0 3.9227568777278066e-05

One O 0 6.689028396067442e-06
of O 0 8.657530088385101e-07
these O 0 3.2401570138063107e-07
, O 0 1.8402798218630778e-07
not O 0 1.0627174873434342e-07
previously O 0 8.48300487632514e-07
reported O 0 6.274206043599406e-06
, O 0 1.4810549942012585e-07
was O 0 5.146671924194379e-07
2988 O 0 1.638195499253925e-05
A O 0 4.312326382205356e-06
or O 0 1.5104016028999467e-06
C O 0 7.636116606590804e-06
that O 0 9.918471732817125e-08
introduces O 0 1.2704360869975062e-06
a O 0 3.554699219421309e-07
new O 0 7.238054422487039e-07
restriction O 0 2.1442447177832946e-06
site O 0 1.4715629959027865e-06
for O 0 9.103538900490094e-07
Eco0109 O 0 0.00015252016601152718
I O 0 1.6996407794067636e-05
. O 0 2.0593903172994033e-05

All O 0 7.824374733900186e-06
the O 0 6.3196653172781225e-06
4003delTC O 0 0.00017028285947162658
alleles O 0 4.443347643245943e-05
showed O 0 5.156884981261101e-06
the O 0 6.946723374312569e-07
same O 0 1.4880433809594251e-06
haplotype O 0 9.437221160624176e-05
for O 0 6.310375511020538e-07
these O 0 7.686285812269489e-07
five O 0 3.910499799530953e-06
polymorphic O 0 0.000607802125159651
markers O 0 0.0002415980852674693
. O 0 5.874881389900111e-05

Fourteen O 0 0.0005606880877166986
microsatellite O 0 0.0036657110322266817
polymorphisms O 0 0.0005101353162899613
were O 0 2.9036741580057424e-06
selected O 0 1.080008360077045e-06
based O 0 4.506408686211216e-07
on O 0 2.4666985609655967e-07
their O 0 2.7025890858567436e-07
high O 0 2.021357659032219e-06
heterozygosity O 0 2.918863538070582e-05
and O 0 2.7478728270580177e-07
their O 0 3.226801936762058e-07
location O 0 1.6695294107194059e-06
within O 0 1.3326455245987745e-06
10q23 O 0 6.160147313494235e-05
- O 0 5.0838756578741595e-05
q25 O 0 6.720225064782426e-05
near O 0 4.088981950189918e-05
COL17A1 O 0 0.0011552348732948303
. O 0 3.301505421404727e-05

Three O 0 4.9135043809656054e-05
families O 0 2.655250864336267e-05
shared O 0 2.166285048588179e-05
microsatellite O 0 0.0007460645283572376
polymorphisms O 0 0.00013531908916775137
covering O 0 1.0724158528319094e-05
at O 0 7.82703807544749e-07
most O 0 3.6484479437604023e-07
19 O 0 1.2924846259920741e-06
cM O 0 5.753750883741304e-06
, O 0 1.9670476092414901e-07
whereas O 0 4.5527505676545843e-07
the O 0 1.681281389664946e-07
others O 0 2.2601962257340347e-07
shared O 0 2.1528329341435892e-07
smaller O 0 4.750746143145079e-07
regions O 0 3.9332860524154967e-07
consistent O 0 3.364093288382719e-07
with O 0 9.634936759539414e-08
cross O 0 4.628836336451059e-07
- O 0 2.499622496543452e-06
over O 0 1.538457894412204e-07
events O 0 1.7892263315388846e-07
during O 0 2.7412011149863247e-07
passage O 0 5.270093765830097e-07
of O 0 8.251232941347553e-08
this O 0 1.7781458439003472e-07
mutation O 0 2.7727674023481086e-06
through O 0 5.894815444662527e-07
several O 0 9.205369337905722e-07
generations O 0 1.3273386684886646e-05
. O 0 1.7368623957736418e-05

These O 0 2.2535083189723082e-05
results O 0 1.81684172275709e-05
indicate O 0 7.961267328937538e-06
that O 0 7.265053341143357e-07
4003delTC O 0 2.7375293939257972e-05
occurs O 0 1.45880289892375e-06
on O 0 3.8346635733432777e-07
a O 0 6.340730465126398e-07
single O 0 2.3122474885894917e-06
ancestral O 0 3.5536897485144436e-05
allele O 0 6.40548751107417e-05
. O 0 5.784886070614448e-06
. O 0 1.3618040611618198e-05

The O 0 0.00014125854067970067
haptoglobin O 0 0.004804408177733421
- O 0 0.0008117278339341283
gene O 0 0.00013064280210528523
deletion O 0 0.00019898607570212334
responsible O 0 3.224665852030739e-05
for O 0 1.423490175511688e-05
anhaptoglobinemia B-Disease 0 0.004128541797399521
. O 0 7.631738117197528e-05

We O 0 1.6796268027974293e-05
have O 0 2.187412064813543e-06
found O 0 8.893182439351222e-07
an O 0 4.939711288898252e-07
allelic O 0 3.640757131506689e-05
deletion O 0 1.549996159155853e-05
of O 0 3.2229021940111124e-07
the O 0 1.1053375601477455e-06
haptoglobin O 0 0.00020175569807179272
( O 0 2.742694050539285e-06
Hp O 0 2.198072434111964e-05
) O 0 6.868345394650532e-07
gene O 0 8.816169270176033e-07
from O 0 1.2434122709237272e-07
an O 0 1.3879405003081047e-07
individual O 0 3.8208216324164823e-07
with O 0 3.0977316782809794e-06
anhaptoglobinemia B-Disease 0 0.0066550783812999725
. O 0 3.5871766158379614e-05

The O 0 7.904082303866744e-05
Hp O 0 0.0005178205319680274
gene O 0 4.440306656761095e-05
cluster O 0 8.692478331795428e-06
consists O 0 1.1200723974980065e-06
of O 0 1.8117057720701268e-07
coding O 0 3.5327357181813568e-06
regions O 0 3.7576518252535607e-07
of O 0 7.784741740124446e-08
the O 0 3.19665048209572e-07
alpha O 0 3.634616177805583e-06
chain O 0 6.163470516185043e-06
and O 0 3.1238272413247614e-07
beta O 0 1.426832000106515e-06
chain O 0 1.252915012628364e-06
of O 0 8.698664544226631e-08
the O 0 4.495900327583513e-07
haptoglobin O 0 7.567053398815915e-05
gene O 0 6.422993919841247e-06
( O 0 8.33511364817241e-07
Hp O 0 5.409920959209558e-06
) O 0 1.4604133014017862e-07
and O 0 3.1458242233384226e-08
of O 0 3.2760535617626374e-08
the O 0 1.6677807934684097e-07
alpha O 0 1.5522892908848007e-06
chain O 0 3.0362436973518925e-06
and O 0 2.2632697493918386e-07
beta O 0 1.257401436305372e-06
chain O 0 1.241512109118048e-06
of O 0 9.003525036632709e-08
the O 0 5.603215527116845e-07
haptoglobin O 0 0.00018921085575129837
- O 0 5.498792233993299e-05
related O 0 5.74268869968364e-06
gene O 0 6.605043381568976e-06
( O 0 1.4229890439310111e-06
Hpr O 0 2.550660246924963e-05
) O 0 2.580540865437797e-07
, O 0 9.034833681198506e-08
in O 0 1.4428374583985715e-07
tandem O 0 2.827460093612899e-06
from O 0 2.8914993777107156e-07
the O 0 4.83142571283679e-07
5 O 0 2.7763660455093486e-06
side O 0 1.5708863429608755e-05
. O 0 1.8828224710887298e-05

Southern O 0 0.0002259717439301312
blot O 0 0.0036465309094637632
and O 0 1.2557125955936499e-05
PCR O 0 0.0004127025022171438
analyses O 0 2.119824603141751e-05
have O 0 1.0280206197421649e-06
indicated O 0 4.740725671581458e-06
that O 0 1.6972673222426238e-07
the O 0 1.169446406379393e-07
individual O 0 1.121584531915687e-07
with O 0 2.400493315235508e-07
anhaptoglobinemia B-Disease 0 0.00201966380700469
was O 0 3.203112555638654e-06
homozygous O 0 3.6939200072083622e-06
for O 0 8.361180192650863e-08
the O 0 2.037233315377307e-07
gene O 0 2.2580059066967806e-06
deletion O 0 4.6079685489530675e-06
and O 0 1.494941983537501e-07
that O 0 7.430349313608531e-08
the O 0 2.3299240581309277e-07
gene O 0 2.6257143872499e-06
deletion O 0 5.5131663430074695e-06
was O 0 3.930732646040269e-07
included O 0 1.6246796974428435e-07
at O 0 1.60960468065241e-07
least O 0 9.677998491497419e-08
from O 0 8.956867247889022e-08
the O 0 1.1239358599368643e-07
promoter O 0 1.8511009329813533e-06
region O 0 3.4530231118878874e-07
of O 0 1.504157296494668e-07
Hp O 0 2.6094681743416004e-05
to O 0 7.680922635699972e-07
Hpr O 0 5.558770499192178e-05
alpha O 0 3.658611831269809e-06
but O 0 3.2726129006732663e-07
not O 0 2.575080770839122e-07
to O 0 7.376520443358459e-07
Hpr O 0 9.66241568676196e-05
beta O 0 1.448097827960737e-05
( O 0 5.1561764848884195e-06
Hpdel O 0 0.00010498193296371028
) O 0 1.0328740245313384e-05
. O 0 1.7018937796819955e-05

In O 0 2.153438254026696e-05
addition O 0 6.21251047050464e-06
, O 0 7.119637643882015e-07
we O 0 1.66747540220058e-07
found O 0 1.3630318562718458e-07
seven O 0 1.2724692055599007e-07
individuals O 0 6.39344861497193e-08
with O 0 1.1159126955817555e-07
hypohaptoglobinemia B-Disease 0 0.0002827621065080166
in O 0 2.031016066439406e-07
three O 0 1.0118804283365535e-07
families O 0 1.9756825508920883e-07
, O 0 5.183818174714361e-08
and O 0 4.78482071741837e-08
the O 0 1.557771867055635e-07
genotypes O 0 4.113430350116687e-06
of O 0 4.872152814527908e-08
six O 0 9.172982373684135e-08
of O 0 2.864851822437231e-08
the O 0 9.264237377237805e-08
seven O 0 1.9560667396945064e-07
individuals O 0 1.0560353302935255e-07
were O 0 2.04056036068323e-07
found O 0 4.974467628926504e-07
to O 0 7.370078947133152e-07
be O 0 2.6351669930591015e-06
Hp2 O 0 0.0023927188012748957
/ O 0 0.0034864761400967836
Hpdel O 0 0.0011856298660859466
. O 0 4.2051942727994174e-05

The O 0 6.041974120307714e-05
phenotypes O 0 0.0024157497100532055
and O 0 7.553144769190112e-06
genotypes O 0 0.00011565016757231206
in O 0 4.2645075382097275e-07
one O 0 7.105806787421898e-08
of O 0 3.290751848794571e-08
these O 0 3.6046625240260255e-08
three O 0 6.350474279770424e-08
families O 0 2.196127155684735e-07
showed O 0 9.639915106163244e-07
the O 0 2.5079987153731054e-07
father O 0 4.727696250483859e-06
to O 0 3.383624118669104e-07
be O 0 2.398980711859622e-07
hypohaptoglobinemic B-Disease 0 3.451505835982971e-05
( O 0 1.1575774578886922e-06
Hp2 O 0 1.600140421942342e-05
) O 0 4.756050202558981e-07
and O 0 4.359721117452864e-07
Hp2 O 0 0.00012199380580568686
/ O 0 0.00012678236817009747
Hpdel O 0 3.481927706161514e-05
, O 0 2.579979820893641e-07
the O 0 3.103309040852764e-07
mother O 0 3.057137064388371e-06
to O 0 2.495487194664747e-07
be O 0 2.1955052886823978e-07
Hp2 O 0 2.3787577447365038e-05
- O 0 4.729094143840484e-06
1 O 0 3.3352057471347507e-07
and O 0 2.377269225917189e-07
Hp1 O 0 0.00013822046457789838
/ O 0 8.289823745144531e-05
Hp2 O 0 1.6341960872523487e-05
, O 0 8.484867919378303e-08
one O 0 2.217682570915258e-08
of O 0 1.6311359374299172e-08
the O 0 3.7080514658782704e-08
two O 0 8.463096179411878e-08
children O 0 1.6098071853321017e-07
to O 0 1.2901949730803608e-07
be O 0 1.7904638127674843e-07
hypohaptoglobinemic B-Disease 0 3.671424929052591e-05
( O 0 8.498471402162977e-07
Hp2 O 0 1.3931859939475544e-05
) O 0 4.452981841041037e-07
and O 0 3.0725357191840885e-07
Hp2 O 0 6.655391916865483e-05
/ O 0 5.4305364756146446e-05
Hpdel O 0 1.9341945517226122e-05
, O 0 9.432050518398682e-08
and O 0 4.063753067384823e-08
the O 0 6.60793375573121e-08
other O 0 7.119413680811704e-08
child O 0 6.705268447149138e-07
to O 0 1.4488257704670104e-07
be O 0 1.1152339141062839e-07
Hp1 O 0 1.1503007954161149e-05
and O 0 6.061259796297236e-07
Hp1 O 0 0.00109397794585675
/ O 0 0.00030123430769890547
Hpdel O 0 3.553364149411209e-05
, O 0 2.498373419257405e-07
showing O 0 7.049862915664562e-07
an O 0 2.394733371602342e-07
anomalous O 0 2.1120658857398666e-05
inheritance O 0 4.3384584387240466e-06
of O 0 3.18435809276707e-07
Hp O 0 0.0007461064960807562
phenotypes O 0 8.415815682383254e-05
in O 0 4.7664116209489293e-07
the O 0 6.580312970072555e-07
child O 0 5.7061547522607725e-06
with O 0 3.1206013773044106e-06
Hp1 O 0 0.0010831262916326523
. O 0 3.6015080695506185e-05

The O 0 0.00010476791794644669
Hp2 O 0 0.0349809005856514
/ O 0 0.04658418148756027
Hpdel O 0 0.001013987697660923
individuals O 0 2.7172009140485898e-06
had O 0 1.716206497803796e-06
an O 0 6.737639068887802e-07
extremely O 0 2.979932105517946e-06
low O 0 2.76858736469876e-06
level O 0 6.169865400806884e-07
of O 0 3.4059792142215883e-07
Hp O 0 8.330182754434645e-05
( O 0 1.3682822554983431e-06
mean O 0 2.0646525626943912e-06
+ O 0 1.4214308066584636e-05
/ O 0 4.1613599023548886e-05
- O 0 2.077217141049914e-05
SD O 0 0.00027841347036883235
= O 0 1.7826496332418174e-05
0 O 0 4.5647511797142215e-06
. O 0 2.1664397991116857e-06
049 O 0 0.0002937775570899248
+ O 0 5.1744897064054385e-05
/ O 0 6.171565473778173e-05
- O 0 9.634524758439511e-06
0 O 0 3.2098339488584315e-06
. O 0 1.2644890148294508e-06
043 O 0 0.00019737669208552688
mg O 0 0.195624440908432
/ O 0 0.004193515051156282
ml O 0 0.00041755932033993304
; O 0 1.5077966963872313e-06
n O 0 4.1137363950838335e-06
= O 0 3.007147597600124e-06
6 O 0 3.3832142776191176e-07
) O 0 1.7331593937797152e-07
, O 0 6.767035642951669e-08
compared O 0 1.508415294892984e-07
with O 0 5.2271065698050734e-08
the O 0 9.979727622067003e-08
level O 0 2.57073025977661e-07
( O 0 2.1116122184139385e-07
1 O 0 1.5686457288666134e-07
. O 0 1.1867573590507163e-07
64 O 0 1.4215676173989777e-06
+ O 0 1.1710300896083936e-05
/ O 0 3.446710616117343e-05
- O 0 3.744866035049199e-06
1 O 0 6.912662229296984e-07
. O 0 5.538263394555543e-07
07 O 0 2.206679346272722e-05
mg O 0 0.03603618964552879
/ O 0 0.0004203187127131969
ml O 0 8.936697122408077e-05
) O 0 4.1198947542397946e-07
obtained O 0 7.910755925877311e-07
from O 0 4.762295304772124e-07
52 O 0 2.2928034013602883e-06
healthy O 0 3.159503194183344e-06
volunteers O 0 1.90961350199359e-06
having O 0 3.030616881005699e-06
phenotype O 0 0.0010470848064869642
Hp2 O 0 0.00010523812670726329
, O 0 3.852812255900062e-07
whereas O 0 7.774812615934934e-07
the O 0 4.7402599534507317e-07
serum O 0 1.8845614249585196e-05
Hp O 0 6.073913482396165e-06
level O 0 1.6727824458939722e-07
of O 0 3.1671969935587185e-08
an O 0 7.65208767461445e-08
individual O 0 1.964569236179159e-07
with O 0 8.366929478142993e-07
Hp1 O 0 0.010352340526878834
/ O 0 0.007645804900676012
Hpdel O 0 0.0005217050784267485
was O 0 1.8334183550905436e-05
0 O 0 2.2323411030811258e-05
. O 0 2.1243960873107426e-05

50 O 0 0.0002833682228811085
mg O 1 0.9786293506622314
/ O 0 0.09933335334062576
ml O 0 0.007589414715766907
, O 0 5.973056431685109e-07
which O 0 1.801356717123781e-07
was O 0 1.0506509795504826e-07
approximately O 0 7.601333606999106e-08
half O 0 9.80938992256597e-08
the O 0 8.085361002940772e-08
level O 0 1.518531576039095e-07
of O 0 7.670806922988049e-08
Hp O 0 1.64197881531436e-05
in O 0 4.4968180645810207e-07
control O 0 1.0464353181305341e-05
sera O 0 1.781725040927995e-05
from O 0 2.261640759115835e-07
the O 0 6.377907766363933e-07
Hp1 O 0 0.000421761826146394
phenotype O 0 0.0004151863104198128
( O 0 1.071327801582811e-06
1 O 0 5.761871193499246e-07
. O 0 2.3145521765854937e-07
26 O 0 1.4945769635232864e-06
+ O 0 9.593247341399547e-06
/ O 0 2.072308234346565e-05
- O 0 3.7964853163430234e-06
0 O 0 9.272525289816258e-07
. O 0 3.466557529918646e-07
33 O 0 3.628714694059454e-06
mg O 0 0.043244246393442154
/ O 0 0.002536000916734338
ml O 0 0.0004330275405663997
; O 0 1.1985114269918995e-06
n O 0 4.98634108225815e-06
= O 0 2.722162662394112e-06
9 O 0 5.680055323864508e-07
) O 0 1.8753810593352682e-07
, O 0 1.1305277780593315e-07
showing O 0 1.0037892934633419e-06
a O 0 1.9203778265364235e-06
gene O 0 2.788024903566111e-05
- O 0 0.00011835447367047891
dosage O 0 0.00019189732847735286
effect O 0 4.631679621525109e-05
. O 0 2.3008789867162704e-05

The O 0 3.635400571511127e-05
other O 0 6.964780368434731e-06
allele O 0 7.177425140980631e-05
( O 0 2.448093482598779e-06
Hp2 O 0 1.4681619177281391e-05
) O 0 2.761333348644257e-07
of O 0 6.605513647173211e-08
individuals O 0 1.0588550480861159e-07
with O 0 2.3046624164635432e-07
Hp2 O 0 0.005013354122638702
/ O 0 0.027599908411502838
Hpdel O 0 0.0009044682374224067
was O 0 2.7470316581457155e-06
found O 0 3.711809313244885e-07
to O 0 1.0255319438101651e-07
have O 0 6.172513167257421e-08
, O 0 4.943802167645117e-08
in O 0 7.533754597943698e-08
all O 0 6.618591896767612e-08
exons O 0 2.1839871351403417e-06
, O 0 2.2296093504792225e-07
no O 0 3.565454846921057e-07
mutation O 0 5.113357929076301e-06
, O 0 4.4964363610233704e-07
by O 0 2.010393473028671e-06
DNA O 0 2.614898949104827e-05
sequencing O 0 7.046623068163171e-05
. O 0 2.7525293262442574e-05

On O 0 8.064473149715923e-06
the O 0 8.768216162025055e-07
basis O 0 2.3688527051035635e-07
of O 0 6.526913409743429e-08
the O 0 9.229457020865084e-08
present O 0 1.764681769600429e-07
study O 0 2.1295139163157728e-07
, O 0 5.460747942720445e-08
the O 0 5.515009959822237e-08
mechanism O 0 3.013584546351922e-07
of O 0 6.675580266346515e-08
anhaptoglobinemia B-Disease 0 2.073436917271465e-05
and O 0 1.1583422576677549e-07
the O 0 9.573953008157332e-08
mechanism O 0 5.469534585245128e-07
of O 0 1.658623745015575e-07
anomalous O 0 4.065865869051777e-05
inheritance O 0 1.1615049515967257e-05
of O 0 1.2455026308089145e-06
Hp O 0 0.04378058388829231
phenotypes O 0 0.0008852269384078681
were O 0 1.8302716853213497e-06
well O 0 3.022321834578179e-06
explained O 0 2.5376824851264246e-05
. O 0 1.6059573681559414e-05

However O 0 3.311665204819292e-05
, O 0 2.0343281903478783e-06
the O 0 9.734349077916704e-07
mechanism O 0 5.48256684851367e-06
of O 0 1.3367798601393588e-06
hypohaptoglobinemia B-Disease 0 0.0003961467300541699
remains O 0 4.616097066900693e-05
unknown O 0 0.00014804965758230537

ATM O 0 0.22589409351348877
mutations O 0 0.06421114504337311
and O 0 7.016997551545501e-05
phenotypes O 0 0.12405417859554291
in O 0 0.0004457313916645944
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999185800552368
telangiectasia I-Disease 1 0.9999979734420776
families O 0 4.637297934095841e-06
in O 0 5.472644488691003e-07
the O 0 4.5765798972752236e-07
British O 0 1.1367206752765924e-05
Isles O 0 3.305210339021869e-05
: O 0 3.4735535336949397e-07
expression O 0 2.476201927947841e-07
of O 0 9.312549309470342e-08
mutant O 0 3.5944030969403684e-06
ATM O 0 5.504156433744356e-06
and O 0 1.9364534864507732e-07
the O 0 3.324294937101513e-07
risk O 0 2.9605596409965074e-06
of O 0 2.44412103711511e-06
leukemia B-Disease 1 0.9999982118606567
, O 0 0.007861041463911533
lymphoma B-Disease 1 1.0
, O 0 3.875268157571554e-05
and O 0 0.0057966262102127075
breast B-Disease 1 0.9999963045120239
cancer I-Disease 1 0.9994889497756958
. O 0 0.0001034965316648595

We O 0 2.02841438294854e-05
report O 0 1.0909483535215259e-05
the O 0 1.62565288519545e-06
spectrum O 0 7.90150534157874e-06
of O 0 6.743611038473318e-07
59 O 0 1.1409225407987833e-05
ATM O 0 0.01038876548409462
mutations O 0 0.0003295344940852374
observed O 0 1.815830182749778e-05
in O 0 3.77980868506711e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999196529388428
telangiectasia I-Disease 1 0.9999997615814209
( O 0 9.249307186109945e-05
A B-Disease 1 0.9973088502883911
- I-Disease 1 0.9999954700469971
T I-Disease 1 0.9999995231628418
) O 0 8.255598004325293e-06
patients O 0 7.167740477598272e-06
in O 0 4.145643401898269e-07
the O 0 1.1747173402909539e-06
British O 0 9.639187919674441e-05
Isles O 0 0.004086010158061981
. O 0 4.262798756826669e-05

Of O 0 3.9077662222553045e-05
51 O 0 8.356078615179285e-05
ATM O 0 0.001794740790501237
mutations O 0 0.00018631367129273713
identified O 0 2.9385821562755154e-06
in O 0 3.170588342982228e-07
families O 0 3.544164997038024e-07
native O 0 2.8970697485419805e-07
to O 0 1.4914004964339256e-07
the O 0 2.3686899908170744e-07
British O 0 5.504539785761153e-06
Isles O 0 3.86856627301313e-05
, O 0 2.2336104166242876e-07
11 O 0 3.986978356351756e-07
were O 0 2.3959395889505686e-07
founder O 0 1.6730944480514154e-05
mutations O 0 4.493758297030581e-06
, O 0 7.978994176482956e-08
and O 0 5.0772555937328434e-08
2 O 0 1.2474100685722078e-07
of O 0 4.989595581150752e-08
these O 0 9.117929522517443e-08
11 O 0 6.590009320461832e-07
conferred O 0 5.990602858219063e-06
a O 0 1.356999473500764e-05
milder O 1 0.9969158172607422
clinical O 1 0.5674048066139221
phenotype O 0 0.04937855899333954
with O 0 4.1566727304598317e-07
respect O 0 3.573256890376797e-07
to O 0 5.23781011452229e-07
both O 0 2.290012616867898e-06
cerebellar B-Disease 1 0.9704416394233704
degeneration I-Disease 1 0.9927310347557068
and O 0 5.740596861869562e-06
cellular O 0 0.00013474174193106592
features O 0 5.0622162234503776e-05
. O 0 3.975177605752833e-05

We O 0 2.244532515760511e-05
report O 0 1.4233883121050894e-05
, O 0 4.656326382246334e-07
in O 0 2.895821182846703e-07
two O 0 3.170763989146508e-07
A B-Disease 0 0.4867655634880066
- I-Disease 1 0.9995546936988831
T I-Disease 1 0.9999617338180542
families O 0 9.134516290032479e-07
, O 0 2.206068785426396e-07
an O 0 4.206825110486534e-07
ATM O 0 6.458246934926137e-05
mutation O 0 1.2561305993585847e-05
( O 0 1.2991578159926576e-06
7271T O 0 3.804464722634293e-05
- O 0 0.0003311702748760581
- O 0 0.00011378552881069481
> O 0 1.918676025525201e-05
G O 0 7.062539953039959e-05
) O 0 3.1649634024688567e-07
that O 0 1.342716871022276e-07
may O 0 5.503125066752546e-07
be O 0 3.990477281945459e-08
associated O 0 9.824294266991274e-08
with O 0 3.3347156147556234e-08
an O 0 1.03255459293905e-07
increased O 0 4.127100964979036e-06
risk O 0 5.519441856449703e-06
of O 0 4.636223820853047e-06
breast B-Disease 1 0.9999935626983643
cancer I-Disease 1 0.9330774545669556
in O 0 1.3113530030750553e-06
both O 0 1.1301801805529976e-06
homozygotes O 0 0.00018524410552345216
and O 0 1.8334093283556285e-06
heterozygotes O 0 0.00015815878577996045
( O 0 1.1421747103668167e-06
relative O 0 4.269140390533721e-06
risk O 0 2.421475073788315e-06
12 O 0 5.528817155209254e-07
. O 0 3.4653675129447947e-07
7 O 0 1.932403620230616e-06
; O 0 2.032226348092081e-06
P O 0 0.0005046475562267005
= O 0 5.802141004096484e-06
. O 0 4.07590988515949e-07
0025 O 0 6.718443182762712e-05
) O 0 2.408213788385183e-07
, O 0 7.448966954370917e-08
although O 0 1.036002998944241e-07
there O 0 4.115593910114512e-08
is O 0 4.824979527029427e-08
a O 0 4.27327250918097e-07
less O 0 3.259231107222149e-06
severe O 1 0.9967464208602905
A B-Disease 1 0.9999940395355225
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
phenotype O 0 0.09044961631298065
in O 0 4.0093451048051065e-07
terms O 0 2.461315204982384e-07
of O 0 6.771981020392559e-08
the O 0 2.722084957440529e-07
degree O 0 4.369000180304283e-06
of O 0 1.1684809578582644e-05
cerebellar B-Disease 1 0.9999589920043945
degeneration I-Disease 1 0.999975323677063
. O 0 0.00016790789959486574

This O 0 8.321821951540187e-05
mutation O 0 0.00030723592499271035
( O 0 1.9816161511698738e-05
7271T O 0 0.0002570135402493179
- O 0 0.0008335594902746379
- O 0 0.00015251013974193484
> O 0 3.984939758083783e-05
G O 0 4.8943027650238946e-05
) O 0 5.200713530939538e-07
also O 0 1.595889358441127e-07
allows O 0 1.7007494079734897e-07
expression O 0 1.933211422056047e-07
of O 0 6.716398814887725e-08
full O 0 5.315881708156667e-07
- O 0 3.070709681196604e-06
length O 0 9.210181701746478e-07
ATM O 0 6.374547865561908e-06
protein O 0 9.427029681319254e-07
at O 0 2.9316666427803284e-07
a O 0 2.89141382836533e-07
level O 0 2.688837810183031e-07
comparable O 0 6.96883262207848e-07
with O 0 2.3600563281434006e-07
that O 0 3.237902319597197e-07
in O 0 2.2157560124469455e-06
unaffected O 0 0.00015588868700433522
individuals O 0 7.062277745717438e-06
. O 0 1.799847996153403e-05

In O 0 2.973401569761336e-05
addition O 0 9.108679478231352e-06
, O 0 1.2614947308975388e-06
we O 0 2.8657709094659367e-07
have O 0 1.5880812043178594e-07
studied O 0 1.1018181567123975e-06
18 O 0 2.843587935785763e-06
A B-Disease 1 0.9987866282463074
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.005206522066146135
, O 0 1.5247076134983217e-07
in O 0 1.1325921889238089e-07
15 O 0 1.79795321741949e-07
families O 0 2.7290249704492453e-07
, O 0 3.327104991512897e-07
who O 0 5.092907940706937e-06
developed O 1 0.6378081440925598
leukemia B-Disease 1 0.9999997615814209
, O 0 0.03186216577887535
lymphoma B-Disease 1 1.0
, O 0 9.481402230449021e-06
preleukemic O 1 0.6451844573020935
T O 1 0.6742612719535828
- O 0 9.683004464022815e-05
cell O 0 7.681708666495979e-05
proliferation O 0 2.5472134439041838e-05
, O 0 2.365548425586894e-06
or O 0 0.0040153320878744125
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 3.7156278267502785e-06
mostly O 0 3.225969749109936e-06
in O 0 1.4518782336381264e-05
childhood O 0 0.0012841485440731049
. O 0 4.071142029715702e-05

A O 0 9.122732444666326e-05
wide O 0 2.4764931367826648e-05
variety O 0 4.180579253443284e-06
of O 0 9.669746532381396e-07
ATM O 0 0.0004270985955372453
mutation O 0 4.2644616769393906e-05
types O 0 2.2480965071736136e-06
, O 0 3.82146993160859e-07
including O 0 8.705318350621383e-07
missense O 0 0.0018413836369290948
mutations O 0 4.367297879070975e-05
and O 0 4.7553876925121585e-07
in O 0 7.03594594142487e-07
- O 0 1.1442765753599815e-05
frame O 0 1.0365942216594703e-05
deletions O 0 6.449055035773199e-06
, O 0 1.7237258020941226e-07
were O 0 1.9357408120868058e-07
seen O 0 7.807013844285393e-07
in O 0 8.54499717206636e-07
these O 0 3.5709545045392588e-06
patients O 0 0.0005691660917364061
. O 0 3.693337566801347e-05

We O 0 1.1382285265426617e-05
also O 0 1.6826380715428968e-06
show O 0 1.1339998309267685e-06
that O 0 1.6613435604995175e-07
25 O 0 1.6740224850764207e-07
% O 0 8.102527715436736e-08
of O 0 4.8300254462674275e-08
all O 0 2.2650058895123948e-07
A B-Disease 1 0.9991687536239624
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.019573327153921127
carried O 0 5.308228992362274e-06
in O 0 5.43743510661443e-07
- O 0 1.2837533176934812e-05
frame O 0 1.2339479326328728e-05
deletions O 0 9.994038919103332e-06
or O 0 1.439441575712408e-06
missense O 0 0.00010373039549449459
mutations O 0 1.159729617938865e-05
, O 0 8.324978040263886e-08
many O 0 2.6248272888551583e-08
of O 0 2.8171891486294953e-08
which O 0 1.1902358920679035e-07
were O 0 1.2006893257421325e-07
also O 0 1.6994037821405072e-07
associated O 0 3.6056428598385537e-07
with O 0 1.607824913207878e-07
expression O 0 9.046332252182765e-07
of O 0 5.059829959463968e-07
mutant O 0 5.2295832574600354e-05
ATM O 0 0.00014074532373342663
protein O 0 3.0465105737675913e-05
. O 0 2.3941354811540805e-05

The O 0 6.634176679654047e-05
DMPK O 0 0.003601952688768506
gene O 0 0.00015625805826857686
of O 0 1.4775599993299693e-05
severely O 1 0.9998465776443481
affected O 1 0.9973148703575134
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9991412162780762
is O 0 5.705970124836313e-06
hypermethylated O 0 0.0034438446164131165
proximal O 0 0.00045600454905070364
to O 0 1.6668186617607716e-06
the O 0 1.7498250599601306e-06
largely O 0 8.758098374528345e-06
expanded O 0 4.2140578443650156e-05
CTG O 0 0.0011687914375215769
repeat O 0 0.0001973697217181325
. O 0 3.989749529864639e-05

Using O 0 0.00010149357694899663
methylation O 0 0.00025363132590427995
- O 0 0.00017291118274442852
sensitive O 0 1.7695465430733748e-05
restriction O 0 1.0938070772681385e-05
enzymes O 0 6.638550530624343e-06
, O 0 3.4145196536883304e-07
we O 0 7.575874150234085e-08
characterized O 0 6.348506076392368e-07
the O 0 1.4489363309166947e-07
methylation O 0 1.420784201400238e-06
pattern O 0 1.2886040394732845e-06
on O 0 1.7884039493765158e-07
the O 0 1.6746595576933032e-07
5 O 0 2.326861903156896e-07
side O 0 1.744109425771967e-07
of O 0 5.438784356215365e-08
the O 0 4.5414236637952854e-07
CTG O 0 0.0002790988946799189
repeat O 0 4.813765372091439e-06
in O 0 3.7022925880592084e-07
the O 0 4.008606993011199e-07
DMPK O 0 8.176783740054816e-05
gene O 0 2.534901796025224e-06
of O 0 1.614217808310059e-07
normal O 0 8.52769801440445e-07
individuals O 0 1.5191862701158243e-07
and O 0 1.322073757137332e-07
of O 0 3.430882884458697e-07
patients O 0 0.0005796228069812059
affected O 0 1.5687483028159477e-05
with O 0 0.0006188782281242311
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 2.404152837698348e-06
showing O 0 4.256086867826525e-06
expansions O 0 8.346620234078728e-06
of O 0 4.168772989032732e-07
the O 0 2.45152341449284e-06
repetitive O 0 0.00010800742893479764
sequence O 0 4.053349402965978e-05
. O 0 2.4976039640023373e-05

The O 0 6.521857721963897e-05
gene O 0 0.00017574353842064738
segment O 0 5.7307639508508146e-05
analyzed O 0 2.4758297513471916e-05
corresponds O 0 5.270533620205242e-06
to O 0 9.11095639821724e-07
the O 0 1.0424743095427402e-06
genomic O 0 2.3124055587686598e-05
SacI O 0 0.0003045006305910647
- O 0 3.097445733146742e-05
HindIII O 0 3.631283834693022e-05
fragment O 0 1.0024107723438647e-05
carrying O 0 4.735664788313443e-06
exons O 0 2.0586598111549392e-05
11 O 0 6.584157745237462e-06
- O 0 3.570654007489793e-05
15 O 0 1.557421092002187e-05
. O 0 2.170729021599982e-05

There O 0 1.589826206327416e-05
is O 0 3.1117722301132744e-06
constitutive O 0 3.658936475403607e-05
methylation O 0 2.366830267419573e-05
in O 0 2.264311206090497e-06
intron O 0 5.867865911568515e-05
12 O 0 1.5485367157452856e-06
at O 0 4.45695008011171e-07
restriction O 0 7.797831926836807e-07
sites O 0 2.8712366884064977e-07
of O 0 1.3555896316574945e-07
SacII O 0 1.669118501013145e-05
and O 0 6.628078494941292e-07
HhaI O 0 4.4718286517309025e-05
, O 0 4.4069028604099003e-07
localized O 0 3.7604836506943684e-06
1 O 0 5.016984232497634e-07
, O 0 2.379825900789001e-07
159 O 0 3.7663839975721203e-06
- O 0 4.828348664887017e-06
1 O 0 4.354767781933333e-07
, O 0 1.9309985077597958e-07
232 O 0 2.679729732335545e-06
bp O 0 4.643188276531873e-06
upstream O 0 6.409969159903994e-07
of O 0 8.114591310004471e-08
the O 0 3.878940901813621e-07
CTG O 0 0.0002708130923565477
repeat O 0 8.262954906967934e-06
, O 0 1.6366196575745562e-07
whereas O 0 2.656528863553831e-07
most O 0 4.2171482306230246e-08
, O 0 4.2968068214577215e-08
if O 0 3.168901230310439e-08
not O 0 1.5205163350628936e-08
all O 0 9.35689747905144e-09
, O 0 1.4431643435841579e-08
of O 0 1.1125417032076257e-08
the O 0 2.8535685814290446e-08
other O 0 3.1389674859383376e-08
sites O 0 1.2350402300853602e-07
of O 0 6.042328948296927e-08
SacII O 0 1.2642246474570129e-05
, O 0 2.609712339562975e-07
HhaI O 0 1.2022860573779326e-05
, O 0 1.8612604435475077e-07
and O 0 2.1779295877877303e-07
HpaII O 0 1.0694928278098814e-05
in O 0 1.703401721897535e-07
this O 0 1.1237107599981755e-07
region O 0 4.790134653376299e-07
are O 0 1.1011336908950398e-07
unmethylated O 0 9.391501407662872e-06
, O 0 1.576838002392833e-07
in O 0 1.9016340502275852e-07
normal O 0 8.95211655915773e-07
individuals O 0 1.5436752676123433e-07
and O 0 8.512831328744142e-08
most O 0 8.960028452520419e-08
of O 0 2.474787663686584e-07
the O 0 1.832768066378776e-05
patients O 0 0.015078100375831127
. O 0 3.4463326301192865e-05

In O 0 2.1270114302751608e-05
a O 0 3.750641781152808e-06
number O 0 3.7199032476564753e-07
of O 0 2.65376854713395e-07
young O 0 1.6208246051974129e-06
and O 0 9.945455531124026e-06
severely O 1 0.9991490840911865
affected O 0 0.008426094427704811
patients O 0 0.004345748107880354
, O 0 2.3500012957811123e-07
however O 0 2.0489278540480882e-07
, O 0 6.760392068372312e-08
complete O 0 3.092077349720057e-07
methylation O 0 1.1689796792779816e-06
of O 0 7.016527803216377e-08
these O 0 9.0052594714507e-08
restriction O 0 5.875413080502767e-07
sites O 0 5.251695824881608e-07
was O 0 6.988092309256899e-07
found O 0 3.659822596091544e-07
in O 0 5.408401193562895e-07
the O 0 3.777931851800531e-06
mutated O 0 0.0003918097645509988
allele O 0 0.0003514696145430207
. O 0 4.872819408774376e-05

In O 0 2.4095692424452864e-05
most O 0 1.441213498765137e-06
of O 0 3.5061029279859213e-07
these O 0 7.800123285051086e-07
patients O 0 3.654332977021113e-05
, O 0 2.3308041363634402e-07
the O 0 4.5454143560164084e-07
onset O 0 0.002198822796344757
of O 0 7.870796707720729e-07
the O 0 0.0005066472804173827
disease O 1 0.9997615218162537
was O 0 0.47836339473724365
congenital O 1 0.9999991655349731
. O 0 9.254741598851979e-05

Preliminary O 0 0.00040302061825059354
in O 0 0.0001044463278958574
vivo O 0 0.0037717369850724936
footprinting O 0 0.03656303510069847
data O 0 9.693766514828894e-06
gave O 0 2.2414469640352763e-06
evidence O 0 8.094802410596458e-07
for O 0 2.1051356213774852e-07
protein O 0 1.1183902870470774e-06
- O 0 4.931036528432742e-06
DNA O 0 1.3972343140267185e-06
contact O 0 1.1909858130820794e-06
in O 0 2.532813709876791e-07
normal O 0 9.365699611407763e-07
genes O 0 7.890201345617243e-07
at O 0 1.9491933755944046e-07
an O 0 2.5594849262233765e-07
Sp1 O 0 1.0544274118728936e-05
consensus O 0 8.41719838717836e-07
binding O 0 9.827308531384915e-07
site O 0 9.164322705146333e-07
upstream O 0 4.101246702248318e-07
of O 0 6.278907704881931e-08
the O 0 2.883937213482568e-07
CTG O 0 0.00011128806363558397
repeat O 0 2.6960526611219393e-06
and O 0 1.2733784160445794e-07
for O 0 5.3139199707175067e-08
a O 0 1.7705312416183006e-07
significant O 0 2.829478660260065e-07
reduction O 0 4.959858870279277e-07
of O 0 5.220909216063774e-08
this O 0 7.106714861038199e-08
interaction O 0 3.9626797843084205e-07
in O 0 3.1427421731677896e-07
cells O 0 1.9412955225561745e-06
with O 0 3.958494971811888e-07
a O 0 3.1628014767193235e-06
hypermethylated O 0 0.003138591768220067
DMPK O 0 0.01833948865532875
gene O 0 6.779106479370967e-05
. O 0 4.872682438872289e-06
. O 0 1.2995956240047235e-05

The O 0 0.00042849796591326594
hemochromatosis B-Disease 1 0.9999927282333374
gene O 0 0.0003362348070368171
product O 0 1.816103576857131e-05
complexes O 0 1.3208909876993857e-05
with O 0 6.036127047082118e-07
the O 0 1.0985822882503271e-06
transferrin O 0 4.188372986391187e-05
receptor O 0 1.1558066034922376e-05
and O 0 5.782248990726657e-07
lowers O 0 1.551171953906305e-05
its O 0 8.296981945932203e-07
affinity O 0 2.5697572709759697e-06
for O 0 8.541339298062667e-07
ligand O 0 3.325926809338853e-05
binding O 0 4.019763946416788e-05
. O 0 2.8746619136654772e-05

We O 0 3.3518259442644194e-05
recently O 0 4.8816888011060655e-05
reported O 0 1.2934763617522549e-05
the O 0 1.0675724979591905e-06
positional O 0 1.919404348882381e-05
cloning O 0 6.364604359987425e-06
of O 0 2.724399053022353e-07
a O 0 1.5697860362706706e-06
candidate O 0 7.019404165475862e-06
gene O 0 2.5878684027702548e-05
for O 0 2.3578393665957265e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 0 0.27526167035102844
HFE O 1 0.9952713847160339
. O 0 0.00012144166976213455

The O 0 3.1915940780891106e-05
gene O 0 3.876000118907541e-05
product O 0 3.551585223249276e-06
, O 0 2.4144085841726337e-07
a O 0 1.7376096650423278e-07
member O 0 1.934646434165188e-07
of O 0 5.3568026459061e-08
the O 0 2.7064916707786324e-07
major O 0 1.3551892834584578e-06
histocompatibility O 0 0.0008551730425097048
complex O 0 7.450006705767009e-06
class O 0 9.5460281954729e-06
I O 0 3.6332021409180015e-06
- O 0 7.479371106455801e-06
like O 0 2.0276138457120396e-07
family O 0 7.347572363869403e-07
, O 0 9.258090472030744e-08
was O 0 4.0728050976213126e-07
found O 0 1.6227269838964276e-07
to O 0 1.1136460642546808e-07
have O 0 1.3317468017248757e-07
a O 0 9.578507160767913e-07
mutation O 0 8.606395567767322e-06
, O 0 9.362244099975214e-07
Cys O 0 0.006540652830153704
- O 0 1.77571018866729e-05
282 O 0 1.7882719475892372e-05
- O 0 0.0001011465210467577
- O 0 4.697178155765869e-05
> O 0 1.7221651432919316e-05
Tyr O 0 7.696379907429218e-05
( O 0 1.201730924549338e-06
C282Y O 0 6.4748392105684616e-06
) O 0 2.895572492889187e-07
, O 0 7.530738344030397e-08
in O 0 1.1824767653934032e-07
85 O 0 1.1785391507146414e-06
% O 0 5.502905082721554e-07
of O 0 8.123973884721636e-07
patient O 0 0.0006932890973985195
chromosomes O 0 0.0001740193838486448
. O 0 4.299070860724896e-05

This O 0 3.7630881706718355e-05
mutation O 0 0.00012939162843395025
eliminates O 0 3.455787737038918e-05
the O 0 1.46608601880871e-06
ability O 0 2.5143931452475954e-06
of O 0 6.443679581025208e-07
HFE O 0 0.001529481029137969
to O 0 1.2609390296347556e-06
associate O 0 2.6967418307322077e-06
with O 0 7.878065844124649e-07
beta2 O 0 0.002360563026741147
- O 0 0.00015468870697077364
microglobulin O 0 0.00017411132284905761
( O 0 2.124755837940029e-06
beta2m O 0 3.0336876079672948e-05
) O 0 7.505320240852598e-07
and O 0 4.1964466390709276e-07
prevents O 0 4.148991592956008e-06
cell O 0 2.5755749447853304e-05
- O 0 2.920311271736864e-05
surface O 0 9.603297257854138e-06
expression O 0 1.4744238796993159e-05
. O 0 2.0423472960828803e-05

A O 0 8.436384086962789e-05
second O 0 1.8092960090143606e-05
mutation O 0 2.9924662158009596e-05
that O 0 4.335019241352711e-07
has O 0 2.8007420382891723e-07
no O 0 1.2498129819960013e-07
effect O 0 4.27163485028359e-07
on O 0 3.314541459076281e-07
beta2m O 0 6.551203841809183e-05
association O 0 1.7395857412338955e-06
, O 0 3.073526215757738e-07
H63D O 0 0.00031542545184493065
, O 0 3.6542178349918686e-07
was O 0 7.95214589288662e-07
found O 0 2.0078364570963458e-07
in O 0 1.0065253519542239e-07
eight O 0 1.04240122311694e-07
out O 0 7.790356448822422e-08
of O 0 1.0599178068559922e-07
nine O 0 2.7142896215082146e-06
patients O 0 3.836804535239935e-05
heterozygous O 0 1.2115757272113115e-05
for O 0 5.946939154455322e-07
the O 0 2.9315315259736963e-06
C282Y O 0 0.00025426087086088955
mutant O 0 0.00021562680194620043
. O 0 3.7233472539810464e-05

In O 0 5.4355001338990405e-05
this O 0 5.6091462283802684e-06
report O 0 8.154765055223834e-06
, O 0 5.300062753121892e-07
we O 0 1.5192472346825525e-07
demonstrate O 0 9.154138069789042e-07
in O 0 6.010616289131576e-07
cultured O 0 1.0464333172421902e-05
293 O 0 4.51184569101315e-05
cells O 0 4.203406206215732e-05
overexpressing O 0 0.0002596912672743201
wild O 0 5.512850748345954e-06
- O 0 3.173589720972814e-05
type O 0 4.086822627868969e-06
or O 0 8.01080147994071e-07
mutant O 0 1.5420819181599654e-05
HFE O 0 0.0003727577568497509
proteins O 0 1.1428535344748525e-06
that O 0 8.392208883378771e-08
both O 0 7.327483331209805e-08
the O 0 1.7270133412239375e-07
wild O 0 1.780470256562694e-06
- O 0 3.549387838575058e-05
type O 0 6.469605068559758e-06
and O 0 1.105447267946147e-06
H63D O 0 0.0023960014805197716
HFE O 0 0.0066618118435144424
proteins O 0 4.307878953113686e-06
form O 0 1.8831498209692654e-06
stable O 0 7.095998626027722e-06
complexes O 0 2.365007048865664e-06
with O 0 3.278079248048016e-07
the O 0 1.4626730262534693e-06
transferrin O 0 0.00020507023145910352
receptor O 0 0.00010842689516721293
( O 0 1.066577806341229e-05
TfR O 0 0.0002404770493740216
) O 0 9.318621778220404e-06
. O 0 1.2777320080203936e-05

The O 0 4.0190814615925774e-05
C282Y O 0 0.0006580922054126859
mutation O 0 0.00013505636889021844
nearly O 0 5.646931640512776e-06
completely O 0 7.897633622633293e-06
prevents O 0 3.1840529572946252e-06
the O 0 3.7127867358321964e-07
association O 0 5.941757876826159e-07
of O 0 8.802008011343787e-08
the O 0 7.271625008797855e-07
mutant O 0 4.13382331316825e-05
HFE O 0 0.0004351090465206653
protein O 0 4.300321961636655e-06
with O 0 1.106618015001004e-06
the O 0 8.176460141839925e-06
TfR O 0 0.0012208778643980622
. O 0 3.879654104821384e-05

Studies O 0 9.535633580526337e-05
on O 0 1.3676971320819575e-05
cell O 0 0.00018226350948680192
- O 0 7.215560617623851e-05
associated O 0 5.428873009805102e-06
transferrin O 0 2.8040209144819528e-05
at O 0 1.0868203617064864e-06
37 O 0 1.3444046089716721e-06
degrees O 0 2.3737470655760262e-06
C O 0 4.9923146434593946e-05
suggest O 0 1.0583810308162356e-06
that O 0 1.5044743406633643e-07
the O 0 6.099043048379826e-07
overexpressed O 0 3.705911512952298e-05
wild O 0 2.8377580747473985e-06
- O 0 2.6526260626269504e-05
type O 0 7.286449545063078e-06
HFE O 0 0.00018837791867554188
protein O 0 2.2356573481374653e-06
decreases O 0 1.0994585863954853e-06
the O 0 1.5055709923217364e-07
affinity O 0 7.727150546088524e-07
of O 0 2.8782000072169467e-07
the O 0 1.829873781389324e-06
TfR O 0 0.00014184362953528762
for O 0 3.5450273117021425e-06
transferrin O 0 0.0005636049318127334
. O 0 3.2559528335696086e-05

The O 0 0.00010112570453202352
overexpressed O 0 0.00847465917468071
H63D O 0 0.05071242153644562
protein O 0 3.1767573091201484e-05
does O 0 2.733207793426118e-06
not O 0 2.4740467097217334e-07
have O 0 9.770550235543851e-08
this O 0 6.930709872676744e-08
effect O 0 3.536527515279886e-07
, O 0 4.154175314852182e-08
providing O 0 5.880806597247101e-08
the O 0 5.662737478928648e-08
first O 0 1.2651992165046977e-07
direct O 0 1.9101533155208017e-07
evidence O 0 1.2347375388799264e-07
for O 0 6.520978246271625e-08
a O 0 3.931489800379495e-07
functional O 0 1.4394429399544606e-06
consequence O 0 1.830331143537478e-06
of O 0 4.1457380461906723e-07
the O 0 6.095767730585067e-06
H63D O 1 0.5392805337905884
mutation O 0 0.000620821607299149
. O 0 4.757005808642134e-05

Addition O 0 8.177235577022657e-05
of O 0 7.721692782070022e-06
soluble O 0 7.817034929757938e-05
wild O 0 2.596413833089173e-05
- O 0 0.00044903199886903167
type O 0 0.00010656484664650634
HFE O 0 0.24980764091014862
/ O 0 0.0006666454719379544
beta2m O 0 0.00023495385539717972
heterodimers O 0 8.559525304008275e-05
to O 0 1.4574651459042798e-06
cultured O 0 1.1199379514437169e-05
cells O 0 4.571895715343999e-06
also O 0 4.24022005063307e-07
decreased O 0 1.2564880762511166e-06
the O 0 1.4340250231725804e-07
apparent O 0 1.5968606703609112e-06
affinity O 0 7.195534976744966e-07
of O 0 7.865951801022675e-08
the O 0 3.457247146343434e-07
TfR O 0 2.1653346266248263e-05
for O 0 1.0100061587081655e-07
its O 0 2.6978636924468447e-07
ligand O 0 2.3242191673489287e-06
under O 0 5.435853722701722e-07
steady O 0 7.799180821166374e-06
- O 0 1.4554521840182133e-05
state O 0 2.943115475773084e-07
conditions O 0 1.6285763422274613e-06
, O 0 7.223518849741595e-08
both O 0 6.81480543107682e-08
in O 0 2.134751753146702e-07
293 O 0 8.712878297956195e-06
cells O 0 7.398921297863126e-06
and O 0 6.702935024804901e-07
in O 0 5.085725206299685e-06
HeLa O 0 0.004972290247678757
cells O 0 0.00011282996274530888
. O 0 2.589055657153949e-05

Furthermore O 0 0.00016553733439650387
, O 0 4.8643851187080145e-06
at O 0 2.1970374746160815e-06
4 O 0 1.6974613572529051e-06
degrees O 0 5.362616775528295e-06
C O 0 3.0435399821726605e-05
, O 0 2.54046312875289e-07
the O 0 4.1597499489398615e-07
added O 0 1.549301828163152e-06
soluble O 0 6.274624865909573e-06
complex O 0 1.2741927548631793e-06
of O 0 1.1931218750760308e-06
HFE O 1 0.8083774447441101
/ O 0 0.0036746873520314693
beta2m O 0 0.00027905788738280535
inhibited O 0 2.3913904442451894e-05
binding O 0 2.4606067654531216e-06
of O 0 3.5050194924224343e-07
transferrin O 0 2.4235489036072977e-05
to O 0 1.7444018567402964e-06
HeLa O 0 0.00022017894661985338
cell O 0 5.967192191747017e-05
TfR O 0 7.442730566253886e-05
in O 0 7.430023174492817e-07
a O 0 1.4490913144982187e-06
concentration O 0 2.532347025407944e-05
- O 0 4.717292540590279e-05
dependent O 0 9.239474820788018e-06
manner O 0 1.8712409655563533e-05
. O 0 1.641182097955607e-05

Scatchard O 0 0.001890314044430852
plots O 0 8.068069291766733e-05
of O 0 2.5317224299215013e-06
these O 0 8.255512966570677e-07
data O 0 1.7293170913035283e-06
indicate O 0 1.3326759926712839e-06
that O 0 1.7321251277735428e-07
the O 0 2.443642870275653e-07
added O 0 8.698670512785611e-07
heterodimer O 0 3.4188353311037645e-05
substantially O 0 1.1704651114996523e-05
reduced O 0 1.942725475601037e-06
the O 0 4.109836879706563e-07
affinity O 0 3.2722432479204144e-06
of O 0 1.1036312344003818e-06
TfR O 0 0.000203233867068775
for O 0 8.5875062723062e-06
transferrin O 0 0.000861721346154809
. O 0 4.605561844073236e-05

These O 0 1.9630084352684207e-05
results O 0 1.2898081877210643e-05
establish O 0 5.308385425450979e-06
a O 0 1.759069391482626e-06
molecular O 0 6.0884822232765146e-06
link O 0 8.27285839477554e-06
between O 0 1.5007558431534562e-06
HFE O 0 0.003167086746543646
and O 0 2.8963404474779963e-07
a O 0 2.2661681953195512e-07
key O 0 3.0061730171837553e-07
protein O 0 3.0468549994111527e-07
involved O 0 1.0053415877564476e-07
in O 0 1.53287800230828e-07
iron O 0 7.925398676889017e-06
transport O 0 2.169027993659256e-06
, O 0 7.645959954061254e-08
the O 0 1.7102595961659972e-07
TfR O 0 3.09454626403749e-05
, O 0 1.1248430098476092e-07
and O 0 5.625479104764963e-08
raise O 0 2.261008944515197e-07
the O 0 9.713060222793501e-08
possibility O 0 4.350135611730366e-07
that O 0 1.2923709391543525e-07
alterations O 0 3.8068724279582966e-06
in O 0 1.75519062395324e-07
this O 0 1.4491408251160465e-07
regulatory O 0 1.27080993479467e-05
mechanism O 0 5.7542506510799285e-06
may O 0 6.183861955832981e-07
play O 0 7.772916887915926e-08
a O 0 1.3735650838953006e-07
role O 0 2.7048167794418987e-07
in O 0 1.885637459508871e-07
the O 0 8.615919000476424e-07
pathogenesis O 0 0.0001494219177402556
of O 0 2.1821988411829807e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 9.591509297024459e-05
. O 0 5.621138188871555e-05

Genomic O 0 0.0007573416805826128
organization O 0 3.0756880732951686e-05
of O 0 3.249014753237134e-06
the O 0 5.350713763618842e-06
UBE3A O 0 0.029051605612039566
/ O 0 0.004125429783016443
E6 O 0 0.0008595911785960197
- O 0 0.0010306588374078274
AP O 0 0.00016591376333963126
gene O 0 2.6300591343897395e-05
and O 0 2.7815708563139196e-06
related O 0 2.305500311194919e-05
pseudogenes O 0 0.00021903942979406565
. O 0 4.74634362035431e-05

The O 0 0.0001796668511815369
UBE3A O 0 0.00413406640291214
gene O 0 0.00020961668633390218
encodes O 0 6.646689143963158e-05
the O 0 6.413848041120218e-06
E6 O 0 0.00016642014088574797
- O 0 9.376529487781227e-05
AP O 0 6.088464942877181e-05
ubiquitin O 0 2.6436229745741002e-05
- O 0 8.891987818060443e-06
protein O 0 2.0585282527463278e-06
ligase O 0 2.861327175196493e-06
and O 0 2.123849185409199e-07
has O 0 1.6537481428713363e-07
recently O 0 1.0111451729244436e-06
been O 0 1.708846042447476e-07
shown O 0 2.906755867115862e-07
to O 0 2.3268219706551463e-07
be O 0 8.273466960417863e-07
mutated O 0 0.0030908510088920593
in O 1 0.885425865650177
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.8320267796516418
who O 0 4.363070729596075e-06
lack O 0 6.101822236814769e-06
15q11 O 0 0.00019997532945126295
- O 0 0.00013224610302131623
q13 O 0 0.00010746077896328643
deletions O 0 7.346941129071638e-05
or O 0 8.882282600097824e-06
chromosome O 0 8.886660361895338e-05
15 O 0 2.2280810298980214e-05
paternal O 0 0.000909023976419121
uniparental B-Disease 1 0.7655890583992004
disomy I-Disease 0 0.2141391783952713
. O 0 0.00014900376845616847

Previous O 0 0.0004166070430073887
UBE3A O 0 0.002768877660855651
cDNA O 0 0.0002828483993653208
analysis O 0 2.5839572117547505e-05
has O 0 2.868780939024873e-06
shown O 0 2.382042566750897e-06
a O 0 1.919621354318224e-06
coding O 0 8.563412848161533e-06
region O 0 1.4246496675696108e-06
of O 0 4.2713821812867536e-07
approximately O 0 4.221850758767687e-06
2 O 0 1.2231726032041479e-05
. O 0 1.8543309124652296e-05

6 O 0 0.0002647896471899003
kb O 0 0.0027296736370772123
and O 0 3.885896603605943e-06
a O 0 3.4366601084911963e-06
3 O 0 4.811145117855631e-06
- O 0 1.937301021825988e-05
untranslated O 0 3.086265132878907e-05
region O 0 2.9194845865276875e-06
( O 0 1.1551975376278278e-06
UTR O 0 1.2101968422939535e-05
) O 0 3.610150542954216e-07
of O 0 2.326351591364073e-07
< O 0 4.262069978722138e-06
50 O 0 6.945650170564477e-07
bp O 0 8.373791388294194e-06
, O 0 2.811044339523505e-07
whereas O 0 7.85424049354333e-07
Northern O 0 8.388349783672311e-07
analysis O 0 5.612296263279859e-07
has O 0 4.15828253608197e-07
indicated O 0 1.8603764146973845e-06
mRNA O 0 2.177976057282649e-06
sizes O 0 1.8196517430624226e-06
of O 0 4.3018911810577265e-07
5 O 0 3.1031427170091774e-06
- O 0 5.236260767560452e-05
8 O 0 1.7029213267960586e-05
kb O 0 0.001160480547696352
. O 0 2.4126529751811177e-05

We O 0 1.4771824680792633e-05
have O 0 1.930313146658591e-06
analyzed O 0 3.855951490550069e-06
additional O 0 7.604508596159576e-07
cDNA O 0 8.238553164119367e-06
clones O 0 6.082249001337914e-06
and O 0 2.0049299109814456e-07
provide O 0 1.5812170772733225e-07
evidence O 0 1.7810413055485697e-07
for O 0 1.0483670109806553e-07
an O 0 2.9766016496068914e-07
additional O 0 3.2148057016456733e-06
0 O 0 1.3981054507894441e-05
. O 0 1.1583335435716435e-05

5 O 0 9.609728294890374e-05
kb O 0 0.0003974422870669514
of O 0 2.915428012784105e-06
5 O 0 6.493811270047445e-06
- O 0 1.8208551409770735e-05
UTR O 0 3.763831045944244e-05
and O 0 1.2643117770494428e-06
> O 0 1.154436085926136e-05
2 O 0 2.635078999446705e-06
kb O 0 6.49528083158657e-05
of O 0 1.1150015097882715e-06
3 O 0 1.1907248335774057e-05
- O 0 0.0001770755770849064
UTR O 0 0.0007970883743837476
. O 0 5.6008215324254707e-05

We O 0 1.6341042282874696e-05
have O 0 1.9578876617742935e-06
established O 0 1.8806747448252281e-06
the O 0 5.012569772588904e-07
genomic O 0 5.90929766985937e-06
organization O 0 8.717148034520505e-07
of O 0 3.8164330362633336e-07
UBE3A O 0 7.570849265903234e-05
and O 0 3.5904147921428375e-07
the O 0 3.891300650593621e-07
sequence O 0 1.462865498069732e-06
of O 0 1.4340266716317274e-06
intron O 0 0.0006767334998585284
- O 0 0.00014511441986542195
exon O 0 0.00017851468874141574
borders O 0 6.638150807702914e-05
. O 0 3.65093037544284e-05

We O 0 2.077561839541886e-05
have O 0 2.7907005915039917e-06
also O 0 9.280017820856301e-07
mapped O 0 4.9245090849581175e-06
two O 0 3.9930171169544337e-07
highly O 0 1.06605762084655e-06
homologous O 0 4.151794200879522e-06
processed O 0 1.5444101109096664e-06
pseudogenes O 0 6.698750894429395e-06
, O 0 3.535977839419502e-07
UBE3AP1 O 0 1.7637459677644074e-05
and O 0 3.4319202768529067e-07
UBE3AP2 O 0 4.841406553168781e-05
, O 0 1.1041201020134395e-07
to O 0 1.4134603532056644e-07
chromosomes O 0 5.515756242857606e-07
2 O 0 1.8793073763845314e-07
and O 0 9.665859579399694e-08
21 O 0 3.9284165609387856e-07
, O 0 1.3593334813322144e-07
respectively O 0 4.029284923490195e-07
, O 0 1.0044196585567988e-07
and O 0 1.4955051597098645e-07
determined O 0 1.3324510064194328e-06
their O 0 1.4654220876764157e-06
genomic O 0 5.133748345542699e-05
organization O 0 2.0863972167717293e-05
. O 0 2.067844798148144e-05

These O 0 1.2972900549357291e-05
results O 0 7.543872015958186e-06
will O 0 5.342089934856631e-07
form O 0 2.6729631485977734e-07
the O 0 1.0979878339867355e-07
basis O 0 1.1408602773599341e-07
for O 0 7.689850889391892e-08
studies O 0 2.9933394785075507e-07
of O 0 1.657660817500073e-07
mutation O 0 7.560509402537718e-06
and O 0 1.0335432989450055e-06
imprinting O 0 9.584469080436975e-05
of O 0 8.661462743475568e-06
UBE3A O 0 0.00839725136756897
. O 0 7.105910481186584e-05

Mutation O 0 0.004928376991301775
spectrum O 0 0.000619146681856364
and O 0 1.5604942745994776e-05
genotype O 0 0.009875979274511337
- O 0 0.05118287727236748
phenotype O 0 0.05486949905753136
analyses O 0 4.702793376054615e-05
in O 0 3.516572542139329e-05
Cowden B-Disease 1 0.9999599456787109
disease I-Disease 1 0.8908197283744812
and O 0 1.3169817066227552e-05
Bannayan B-Disease 1 0.9975979924201965
- I-Disease 1 0.999982476234436
Zonana I-Disease 1 0.9999994039535522
syndrome I-Disease 1 0.999998927116394
, O 0 3.466561565801385e-06
two O 0 9.183463589579333e-06
hamartoma B-Disease 1 0.9987094402313232
syndromes I-Disease 1 0.9928284287452698
with O 0 7.000369078014046e-05
germline O 1 0.9560844898223877
PTEN O 1 0.9945542812347412
mutation O 0 0.00394419627264142
. O 0 0.00014419329818338156

The O 0 0.00039029400795698166
tumour B-Disease 1 0.9999425411224365
suppressor O 0 0.1596003770828247
gene O 0 0.0011057319352403283
PTEN O 0 0.05987320467829704
, O 0 4.333719061833108e-06
which O 0 2.018720351770753e-06
maps O 0 9.074813533516135e-06
to O 0 5.896468337596161e-06
10q23 O 0 0.0003299950622022152
. O 0 4.596277358359657e-05

3 O 0 4.1785624489421025e-05
and O 0 3.835808456642553e-06
encodes O 0 1.4979208572185598e-05
a O 0 3.825995008810423e-06
403 O 0 1.0179400305787567e-05
amino O 0 4.957265900884522e-06
acid O 0 4.384815838420764e-06
dual O 0 7.164596354414243e-06
specificity O 0 1.3713542102777865e-05
phosphatase O 0 0.00063177733682096
( O 0 2.9964578516228357e-06
protein O 0 3.221677616238594e-06
tyrosine O 0 2.4547129214624874e-05
phosphatase O 0 0.00010306121839676052
; O 0 8.100632840069011e-07
PTPase O 0 8.717466698726639e-06
) O 0 2.6913210149359656e-07
, O 0 8.098263037936704e-08
was O 0 2.690422888917965e-07
shown O 0 3.527349008436431e-07
recently O 0 9.371935902890982e-07
to O 0 8.343020141410307e-08
play O 0 9.540757872628092e-08
a O 0 2.5310461637673143e-07
broad O 0 1.6333343637597864e-06
role O 0 1.439153265891946e-06
in O 0 2.8561662475112826e-06
human O 0 2.6454288672539406e-05
malignancy B-Disease 0 0.19935071468353271
. O 0 5.974013765808195e-05

Somatic O 0 0.009847293607890606
PTEN O 1 0.8724773526191711
deletions O 0 0.00502022635191679
and O 0 3.659665890154429e-05
mutations O 0 0.00017111259512603283
were O 0 1.2746496622639825e-06
observed O 0 2.124595766872517e-06
in O 0 8.402249136452156e-07
sporadic B-Disease 0 0.0005892323679290712
breast I-Disease 1 0.7035641074180603
, I-Disease 0 6.8216922954889014e-06
brain I-Disease 0 0.33787572383880615
, I-Disease 0 2.0457058781175874e-05
prostate I-Disease 1 0.9999610185623169
and I-Disease 0 0.10779682546854019
kidney I-Disease 1 0.9999986886978149
cancer I-Disease 1 0.9997544884681702
cell O 0 0.005122273229062557
lines O 0 4.782813448400702e-06
and O 0 1.8717199168349907e-07
in O 0 2.036485540202193e-07
several O 0 6.731313533236971e-07
primary O 0 3.128104071947746e-05
tumours B-Disease 1 0.9995644688606262
such O 0 1.2548210861496045e-06
as O 0 2.70082127826754e-05
endometrial B-Disease 1 0.9999502897262573
carcinomas I-Disease 1 1.0
, O 1 0.9935168027877808
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9978060126304626
thyroid B-Disease 1 1.0
tumours I-Disease 1 0.9999996423721313
. O 0 0.00024253697483800352

In O 0 2.331646282982547e-05
addition O 0 8.546231583750341e-06
, O 0 4.385313332022633e-06
PTEN O 0 0.012698336504399776
was O 0 4.714072474598652e-06
identified O 0 1.3248725281300722e-06
as O 0 2.440163484607183e-07
the O 0 4.25285122673813e-07
susceptibility O 0 3.2328687666449696e-05
gene O 0 5.266730113362428e-06
for O 0 1.0908983085755608e-06
two O 0 2.9703063773922622e-05
hamartoma B-Disease 1 0.9999996423721313
syndromes I-Disease 1 1.0
Cowden B-Disease 1 0.9999997615814209
disease I-Disease 1 0.9995369911193848
( O 0 1.244776740350062e-05
CD B-Disease 0 7.789153460180387e-05
; O 0 5.275909188640071e-06
MIM O 0 0.0005772903678007424
158350 O 0 4.236792665324174e-05
) O 0 1.4678375919174869e-06
and O 0 1.1530622714417404e-06
Bannayan B-Disease 0 0.00020034595218021423
- I-Disease 0 0.0002571512886788696
Zonana I-Disease 0 0.0008127274340949953
( I-Disease 0 4.661552338802721e-06
BZS I-Disease 0 8.16542305983603e-05
) I-Disease 0 1.7357161823383649e-06
or I-Disease 0 1.886070322143496e-06
Ruvalcaba I-Disease 0 0.0002828160359058529
- I-Disease 0 0.0004150444583501667
Riley I-Disease 0 0.009538236074149609
- I-Disease 1 0.9591566920280457
Smith I-Disease 1 0.794945478439331
syndrome I-Disease 1 0.9999886751174927
( O 0 5.294450602377765e-05
MIM O 0 0.09064950048923492
153480 O 0 0.0007710393983870745
) O 0 3.14037679345347e-05
. O 0 2.4873284928617068e-05

Constitutive O 0 0.0016269858460873365
DNA O 0 0.00011159880523337051
from O 0 8.737041753192898e-06
37 O 0 9.829082046053372e-06
CD B-Disease 0 2.6151707061217166e-05
families O 0 1.7720917639962863e-06
and O 0 6.747992529199109e-07
seven O 0 1.568291168041469e-06
BZS B-Disease 0 0.00016310956561937928
families O 0 2.5134006591542857e-06
was O 0 3.93044319935143e-06
screened O 0 2.3265269192052074e-05
for O 0 9.827995199884754e-06
germline O 0 0.20248422026634216
PTEN O 1 0.9752668738365173
mutations O 0 0.003205768531188369
. O 0 9.208648407366127e-05

PTEN O 1 0.9991796612739563
mutations O 0 0.0703553557395935
were O 0 8.668834198033437e-06
identified O 0 3.383050852789893e-06
in O 0 5.970579195491155e-07
30 O 0 4.393818358039425e-07
of O 0 1.2823208805912145e-07
37 O 0 1.4036196489541908e-06
( O 0 5.330506951395364e-07
81 O 0 1.9650335616461234e-06
% O 0 3.654813838238624e-07
) O 0 3.140015962799225e-07
CD B-Disease 0 6.54868836136302e-06
families O 0 7.029306630101928e-07
, O 0 1.4666760250747757e-07
including O 0 4.4451832081904286e-07
missense O 0 2.7386180590838194e-05
and O 0 9.294570304518857e-07
nonsense O 0 7.2107286541722715e-06
point O 0 1.7973241028812481e-06
mutations O 0 1.4178674064169172e-05
, O 0 4.859707019022608e-07
deletions O 0 1.0620062312227674e-05
, O 0 5.139451673130679e-07
insertions O 0 7.772560820740182e-06
, O 0 4.011379814983229e-07
a O 0 2.038534603343578e-06
deletion O 0 0.00011600294237723574
/ O 0 7.97088723629713e-05
insertion O 0 1.819490898924414e-05
and O 0 1.9517619875841774e-06
splice O 0 0.0002296697930432856
site O 0 8.058534149313346e-05
mutations O 0 0.00019143987447023392
. O 0 3.163853398291394e-05

These O 0 3.133603968308307e-05
mutations O 0 0.0002005118440138176
were O 0 1.3128508271620376e-06
scattered O 0 1.8319219634577166e-06
over O 0 4.198604415250884e-07
the O 0 2.5956484250855283e-07
entire O 0 4.431972229212988e-07
length O 0 4.28528295515207e-07
of O 0 1.8221872721824184e-07
PTEN O 0 0.0009129089303314686
, O 0 1.0762621371895875e-07
with O 0 4.6480206350452136e-08
the O 0 5.635369859646744e-08
exception O 0 1.1580683434431194e-07
of O 0 3.436143813928538e-08
the O 0 6.999351853664848e-08
first O 0 2.0057331084899488e-07
, O 0 2.0009625245620555e-07
fourth O 0 1.2982042107978486e-06
and O 0 1.0051380741060711e-06
last O 0 1.019029787130421e-05
exons O 0 0.00012702244566753507
. O 0 2.347015106352046e-05

A O 0 0.00016646234143991023
hot O 0 0.00015749527665320784
spot O 0 3.728698720806278e-05
for O 0 5.4118559091875795e-06
PTEN O 0 0.021364251151680946
mutation O 0 3.000673314090818e-05
in O 0 1.1636518593149958e-06
CD B-Disease 0 2.1881294742343016e-05
was O 0 2.205716100434074e-06
identified O 0 9.72922521214059e-07
in O 0 3.314516163754888e-07
exon O 0 6.345985184452729e-06
5 O 0 3.3050815773094655e-07
that O 0 7.60287122147929e-08
contains O 0 1.7803009200179076e-07
the O 0 2.0867803129931417e-07
PTPase O 0 1.1410878869355656e-05
core O 0 1.3295607459440362e-06
motif O 0 1.588234113114595e-06
, O 0 7.836241877612338e-08
with O 0 7.744621655092487e-08
13 O 0 1.845047421511481e-07
of O 0 7.409884972275904e-08
30 O 0 3.6376567891238665e-07
( O 0 3.2713586506361025e-07
43 O 0 6.413454798348539e-07
% O 0 2.21071459804989e-07
) O 0 5.594922640739242e-07
CD B-Disease 0 4.095065378351137e-05
mutations O 0 4.2010498873423785e-05
identified O 0 3.534154302542447e-06
in O 0 1.5960658856783994e-06
this O 0 4.426883151609218e-06
exon O 0 0.0003379620029591024
. O 0 3.4920569305540994e-05

Seven O 0 1.9513710867613554e-05
of O 0 1.7603598507776042e-06
30 O 0 2.712610239541391e-06
( O 0 9.850823516899254e-07
23 O 0 6.64947833683982e-07
% O 0 2.1870813782243204e-07
) O 0 1.3219440120337822e-07
were O 0 6.476355451923155e-08
within O 0 6.469010571663603e-08
the O 0 9.576144321954416e-08
core O 0 4.592205584685871e-07
motif O 0 1.131330805037578e-06
, O 0 7.904407794967483e-08
the O 0 8.71926246759358e-08
majority O 0 2.598476953608042e-07
( O 0 1.344518381074522e-07
five O 0 4.0663117317762953e-08
of O 0 2.981020585934857e-08
seven O 0 1.108790428361317e-07
) O 0 6.507993788318345e-08
of O 0 4.090223271191462e-08
which O 0 1.9618899216311547e-07
were O 0 6.314648999250494e-07
missense O 0 0.00013336226402316242
mutations O 0 2.9520975658670068e-05
, O 0 3.054690012049832e-07
possibly O 0 6.795854119445721e-07
pointing O 0 1.2110592706449097e-06
to O 0 2.1045394760221825e-07
the O 0 2.1201741162713006e-07
functional O 0 9.097047382056189e-07
significance O 0 3.6744722820003517e-07
of O 0 1.4508181322980818e-07
this O 0 6.222194315341767e-07
region O 0 1.3571469935413916e-05
. O 0 1.817127485992387e-05

Germline O 1 0.9977396726608276
PTEN O 1 0.9998724460601807
mutations O 0 0.43632519245147705
were O 0 1.2496057024691254e-05
identified O 0 5.578312084253412e-06
in O 0 3.787654350162484e-07
four O 0 2.2303495939013374e-07
of O 0 1.4850023433155002e-07
seven O 0 6.574153417204798e-07
( O 0 1.2739521935145603e-06
57 O 0 4.3989471123495605e-06
% O 0 1.637433001633326e-06
) O 0 3.035748477486777e-06
BZS B-Disease 0 0.00022568879649043083
families O 0 1.0868466233660001e-05
studied O 0 4.215087028569542e-05
. O 0 4.230062768328935e-05

Interestingly O 0 0.0010174675844609737
, O 0 9.83045083557954e-06
none O 0 2.2897352209838573e-06
of O 0 3.188092705386225e-07
these O 0 6.913163588251336e-07
mutations O 0 2.7640875487122685e-05
was O 0 1.9932767827413045e-06
observed O 0 1.356787606709986e-06
in O 0 5.129027726979984e-07
the O 0 1.0224182460660813e-06
PTPase O 0 0.00010670903429854661
core O 0 2.204988049925305e-05
motif O 0 8.677177538629621e-05
. O 0 2.588344614196103e-05

It O 0 1.4367025869432837e-05
is O 0 1.4236718470783671e-06
also O 0 6.49571063604526e-07
worthy O 0 7.0969747412164e-07
of O 0 1.3707176549360156e-07
note O 0 9.127958833232697e-07
that O 0 8.619027624945375e-08
a O 0 2.451738225772715e-07
single O 0 4.31714681781159e-07
nonsense O 0 2.024878767770133e-06
point O 0 4.172272838331992e-07
mutation O 0 2.2476976937468862e-06
, O 0 1.490777492563211e-07
R233X O 0 4.730253294837894e-06
, O 0 1.871673447340072e-07
was O 0 3.4872883247771824e-07
observed O 0 4.321150584019051e-07
in O 0 1.354161867084258e-07
the O 0 2.7936565061281726e-07
germline O 0 5.4486197768710554e-05
DNA O 0 1.4436427591135725e-06
from O 0 2.865227202164533e-07
two O 0 2.1476674305631605e-07
unrelated O 0 2.838537511706818e-06
CD B-Disease 0 1.0705020940804388e-05
families O 0 8.613289992354112e-07
and O 0 4.788326464222337e-07
one O 0 1.6496539956278866e-06
BZS B-Disease 0 0.0005025101127102971
family O 0 2.973322079924401e-05
. O 0 2.0987619791412726e-05

Genotype O 1 0.9845496416091919
- O 1 0.9854018688201904
phenotype O 1 0.9042672514915466
studies O 0 1.886320205812808e-05
were O 0 1.1382122693248675e-06
not O 0 1.769069655210842e-07
performed O 0 4.007242466741445e-07
on O 0 2.1843361253104376e-07
this O 0 8.253169170302499e-08
small O 0 2.4551704314035305e-07
group O 0 8.477343840240792e-07
of O 0 8.140842169268581e-07
BZS B-Disease 0 0.000505699950736016
families O 0 1.9726434402400628e-05
. O 0 2.7925301765208133e-05

However O 0 0.00011596400145208463
, O 0 2.1038478735135868e-05
genotype O 0 0.0014890889870002866
- O 0 0.001989471958950162
phenotype O 0 0.0010185878491029143
analysis O 0 7.837458724679891e-06
inthe O 0 0.00010660814587026834
group O 0 2.4368107460759347e-06
of O 0 2.713867957027105e-07
CD B-Disease 0 2.8436495995265432e-05
families O 0 1.0948829185508657e-06
revealed O 0 2.2287324554781662e-06
two O 0 1.3860065450899128e-07
possible O 0 3.1121888355301053e-07
associations O 0 4.795592758455314e-07
worthy O 0 4.79281709431234e-07
of O 0 1.6153650506112172e-07
follow O 0 2.15226555155823e-06
- O 0 1.2300707567192148e-05
up O 0 5.397354243541486e-07
in O 0 7.965124382280919e-07
independent O 0 3.82626512873685e-06
analyses O 0 1.9777156921918504e-05
. O 0 1.3270424460642971e-05

The O 0 7.777640348649584e-06
first O 0 2.2837903088657185e-06
was O 0 1.134296098825871e-06
an O 0 2.8163438514638983e-07
association O 0 1.2696801832134952e-06
noted O 0 4.418716343934648e-07
in O 0 1.1290440937727908e-07
the O 0 1.0480590617589769e-07
group O 0 2.942994967725099e-07
of O 0 1.3813959753861127e-07
CD B-Disease 0 1.3470943486026954e-05
families O 0 2.647211658768356e-06
with O 0 6.761042459402233e-05
breast B-Disease 1 0.9999947547912598
disease I-Disease 1 0.9923837780952454
. O 0 4.54113760497421e-05

A O 0 0.0001036931062117219
correlation O 0 7.332927634706721e-05
was O 0 9.361250704387203e-06
observed O 0 1.917903318826575e-06
between O 0 2.3795512049673562e-07
the O 0 2.5759945287973096e-07
presence O 0 1.5877433270361507e-06
/ O 0 1.9182954929419793e-05
absence O 0 8.974838578978961e-07
of O 0 1.291307683004561e-07
a O 0 2.3398758912662743e-06
PTEN O 0 0.2408994436264038
mutation O 0 7.627396826137556e-06
and O 0 1.6258685775483173e-07
the O 0 2.973324626509566e-07
type O 0 3.0225407954276307e-06
of O 0 7.420789529533067e-07
breast O 0 0.015349184162914753
involvement O 0 5.2353170758578926e-05
( O 0 1.6940208297455683e-05
unaffected O 0 0.001352670369669795
versus O 0 0.0016829402884468436
benign O 1 0.9948786497116089
versus O 0 0.09089354425668716
malignant O 1 0.9999105930328369
) O 0 3.2278654543915763e-05
. O 0 3.38938225468155e-05

Specifically O 0 3.48052017216105e-05
and O 0 1.377287958348461e-06
more O 0 1.7829820819770248e-07
directly O 0 2.691649569896981e-07
, O 0 7.635394183580502e-08
an O 0 8.685302077537926e-08
association O 0 1.581716333021177e-06
was O 0 2.8032959562551696e-06
also O 0 1.957193802581969e-07
observed O 0 3.082099908624514e-07
between O 0 7.863057049917188e-08
the O 0 8.099144110929046e-08
presence O 0 2.556001561515586e-07
of O 0 1.955042705503729e-07
a O 0 4.540489953797078e-06
PTEN O 1 0.8037061095237732
mutation O 0 0.001122665242291987
and O 0 0.00723837036639452
malignant B-Disease 1 1.0
breast I-Disease 1 0.9999995231628418
disease I-Disease 1 0.9989873766899109
. O 0 0.00010520701471250504

Secondly O 0 0.003180410247296095
, O 0 8.072899618127849e-06
there O 0 7.95310143075767e-07
appeared O 0 3.4227002743136836e-06
to O 0 2.7912810196539795e-07
be O 0 1.0124750815521111e-07
an O 0 1.2338747978901665e-07
interdependent O 0 7.919180461612996e-06
association O 0 1.2122320640628459e-06
between O 0 3.942761566122499e-07
mutations O 0 2.4587677671661368e-06
upstream O 0 4.437508209775842e-07
and O 0 8.122317751713126e-08
within O 0 1.1336393157534985e-07
the O 0 2.1594438237571012e-07
PTPase O 0 9.565622349327896e-06
core O 0 9.598386441211915e-07
motif O 0 1.3376163678913144e-06
, O 0 6.341831237932638e-08
the O 0 6.878585168124118e-08
core O 0 3.188104642504186e-07
motif O 0 5.800409326184308e-07
containing O 0 1.6414105630246922e-07
the O 0 6.678280328742403e-08
majority O 0 1.9879675505762862e-07
of O 0 1.5186620316853805e-07
missense O 0 0.00012700114166364074
mutations O 0 1.1074668691435363e-05
, O 0 1.01569355592801e-07
and O 0 5.4520370440513943e-08
the O 0 7.86779779105018e-08
involvement O 0 3.9925029682308377e-07
of O 0 7.473958163473071e-08
all O 0 7.135210466913122e-08
major O 0 6.530599989673647e-07
organ O 0 0.00020457555365283042
systems O 0 0.00011413858737796545
( O 0 7.70507483593974e-07
central O 0 1.4219581316865515e-06
nervous O 0 6.60725636407733e-05
system O 0 1.377743228658801e-05
, O 0 3.5233417747804197e-06
thyroid O 1 0.5421013236045837
, O 0 5.597828021564055e-06
breast O 1 0.6908963918685913
, O 0 1.7740325347403996e-05
skin O 1 0.9999587535858154
and O 0 0.026647793129086494
gastrointestinal O 1 0.9999996423721313
tract O 1 0.9907286167144775
) O 0 2.979077908094041e-05
. O 0 3.5067536373389885e-05

However O 0 4.0447659557685256e-05
, O 0 2.2357041871146066e-06
these O 0 3.6757518273589085e-07
observations O 0 1.9201249870093307e-06
would O 0 3.762051221656293e-07
need O 0 2.1526872728827584e-07
to O 0 1.4557716099261597e-07
be O 0 8.049784838704e-08
confirmed O 0 5.135131004863069e-07
by O 0 8.699129239175818e-08
studying O 0 1.7973069077470427e-07
a O 0 3.1818990464671515e-07
larger O 0 6.020896989866742e-07
number O 0 2.1588198251265567e-07
of O 0 4.0479338281329547e-07
CD B-Disease 0 7.736387487966567e-05
families O 0 1.2237583177920897e-05
. O 0 2.2452626581070945e-05

Molecular O 1 0.7578168511390686
defects O 1 0.9981536269187927
leading O 0 2.6319612516090274e-05
to O 0 3.812271415881696e-06
human O 0 4.537563654594123e-06
complement B-Disease 0 5.406477794167586e-05
component I-Disease 1 0.6691060066223145
C6 I-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
in O 0 1.709362436486117e-06
an O 0 6.881813305881224e-07
African O 0 2.1846810795977945e-06
- O 0 1.5585012079100125e-05
American O 0 2.865349415515084e-06
family O 0 2.554601633164566e-05
. O 0 2.2131827790872194e-05

Complement B-Disease 0 0.005056012887507677
component I-Disease 1 0.9673983454704285
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 9.463265450904146e-05
C6D B-Disease 0 0.41286394000053406
) O 0 2.067872446787078e-05
was O 0 0.0007072920561768115
diagnosed O 0 0.4429854154586792
in O 0 3.8350074760273856e-07
a O 0 7.397422336907766e-07
16 O 0 2.121564648405183e-06
- O 0 2.2339385395753197e-05
year O 0 6.330821520350582e-07
- O 0 4.295300641388167e-06
old O 0 1.3088879313727375e-06
African O 0 5.611525466520106e-07
- O 0 2.5934859877452254e-06
American O 0 6.619411578867584e-07
male O 0 3.2074469800136285e-06
with O 0 2.519335066608619e-05
meningococcal B-Disease 1 0.9999996423721313
meningitis I-Disease 1 0.9999980926513672
. O 0 0.00014209408254828304

The O 0 0.00014155151438899338
patients O 0 0.01129509974271059
father O 0 3.1273826607503e-05
and O 0 9.060855177267513e-07
two O 0 3.9214430103129416e-07
brothers O 0 1.6363623217330314e-05
also O 0 6.246190196179668e-07
had O 0 1.370571681036381e-06
C6D B-Disease 0 0.000590865034610033
, O 0 2.2628641715982667e-07
but O 0 1.111189078528696e-07
gave O 0 3.9570531384924834e-07
no O 0 1.8569451754046895e-07
history O 0 4.407386597904406e-07
of O 0 5.736704906667001e-07
meningitis B-Disease 1 0.9975524544715881
or O 0 2.609217062854441e-06
other O 0 3.576274366423604e-06
neisserial B-Disease 1 0.9473860263824463
infection I-Disease 1 0.7734003663063049
. O 0 5.677928129443899e-05

By O 0 5.522555875359103e-05
using O 0 4.126560452277772e-05
exon O 0 0.0003663889947347343
- O 0 3.742556873476133e-05
specific O 0 5.974377472739434e-06
polymerase O 0 4.4255866669118404e-05
chain O 0 5.962244176771492e-05
reaction O 0 1.9847708244924434e-05
( O 0 2.939585783678922e-06
PCR O 0 4.6189947170205414e-05
) O 0 1.3648103731611627e-06
/ O 0 6.097686309658457e-06
single O 0 9.654165751271648e-07
- O 0 4.038905444758711e-06
strand O 0 4.280530902178725e-06
conformation O 0 6.67299127599108e-06
polymorphism O 0 4.371588602225529e-06
as O 0 2.2846741387638758e-07
a O 0 3.559376864359365e-07
screening O 0 1.7471987803219236e-06
step O 0 3.378361839168065e-07
and O 0 1.221613530333343e-07
nucleotide O 0 5.636944138132094e-07
sequencing O 0 4.2230564645251434e-07
of O 0 6.020104592607822e-08
target O 0 5.675257739312656e-07
exons O 0 2.510181275283685e-06
, O 0 1.845121317956e-07
we O 0 5.707096661922151e-08
determined O 0 1.7533452023599239e-07
that O 0 6.02099987645488e-08
the O 0 1.9783749394264305e-07
proband O 0 4.089781214133836e-05
was O 0 7.940036539366702e-07
a O 0 7.29945838884305e-07
compound O 0 5.0443240979802795e-06
heterozygote O 0 2.2582669771509245e-05
for O 0 6.567523769263062e-07
two O 0 2.770959326880984e-06
C6 O 0 0.06890907883644104
gene O 0 0.0005936603411100805
mutations O 0 0.0006385128363035619
. O 0 6.553778075613081e-05

The O 0 1.1032734619220719e-05
first O 0 3.998747160949279e-06
, O 0 1.2166761962362216e-06
1195delC O 0 1.5107953004189767e-05
located O 0 1.7560957985551795e-06
in O 0 5.033028855905286e-07
exon O 0 1.3261239473649766e-05
7 O 0 1.1692561656673206e-06
, O 0 1.337369894827134e-07
is O 0 8.09063678275379e-08
a O 0 2.5410105308765196e-07
novel O 0 1.4921388356015086e-06
mutation O 0 3.535802989063086e-06
, O 0 9.495516195556775e-08
while O 0 6.179109846016217e-08
the O 0 1.0213798162794774e-07
second O 0 2.733974326929456e-07
, O 0 1.7119549511335208e-07
1936delG O 0 4.054442797496449e-06
in O 0 2.770785272332432e-07
exon O 0 3.832396942016203e-06
12 O 0 3.591650852285966e-07
, O 0 1.0861484867064064e-07
has O 0 1.1339798788867483e-07
been O 0 9.939852674278882e-08
described O 0 3.8062231055846496e-07
before O 0 1.5507622208588145e-07
to O 0 2.500342191069649e-07
cause O 0 4.4413714022084605e-06
C6D B-Disease 0 7.937088957987726e-05
in O 0 2.850297278200742e-07
an O 0 2.0080605622752046e-07
unrelated O 0 2.7608830350800417e-06
African O 0 1.2287659956200514e-06
- O 0 7.439577530021779e-06
American O 0 1.597893515281612e-06
individual O 0 3.509626139930333e-06
. O 0 1.742290442052763e-05

Both O 0 0.0001526703272247687
mutations O 0 0.001951880636624992
result O 0 3.450403528404422e-05
in O 0 2.2969063138589263e-05
premature O 0 0.011158094741404057
termination O 0 0.0003975883300881833
codons O 0 0.00015497839194722474
and O 0 2.0358776964712888e-05
C6 O 0 0.07196745276451111
null O 0 0.0019705661106854677
alleles O 0 0.0008949464536271989
. O 0 6.623064837185666e-05

Allele O 0 0.003470510710030794
- O 0 0.0002859453670680523
specific O 0 1.4306403500086162e-05
PCR O 0 0.00010967714479193091
indicated O 0 1.168593553302344e-05
that O 0 2.2123492726677796e-07
the O 0 2.953533169147704e-07
probands O 0 1.1083840036008041e-05
two O 0 2.545393158470688e-07
brothers O 0 1.5443774827872403e-05
also O 0 5.588198632722197e-07
inherited O 0 1.0930479220405687e-05
the O 0 3.5079756344202906e-07
1195delC O 0 3.0194813007256016e-05
mutation O 0 4.661596449295757e-06
from O 0 3.2112865255840006e-07
their O 0 4.6074711690380354e-07
heterozygous O 0 2.2135100152809173e-05
mother O 0 3.763188487937441e-06
and O 0 1.413473853517644e-07
the O 0 3.181252736794704e-07
1936delG O 0 3.016862137883436e-05
mutation O 0 6.372165444190614e-06
from O 0 4.5165279516368173e-07
their O 0 9.093508310797915e-07
homozygous O 0 0.0001641469425521791
father O 0 2.9535789508372545e-05
. O 0 5.247842636890709e-06
. O 0 1.912322659336496e-05

PAX6 O 1 0.9984727501869202
mutations O 1 0.9844686388969421
reviewed O 0 0.012649599462747574
. O 0 0.0010932799195870757

Mutations O 0 0.020906485617160797
in O 0 4.148110747337341e-05
PAX6 O 0 0.0029259291477501392
are O 0 1.8812560256264987e-06
responsible O 0 1.9186165900464403e-06
for O 0 3.9954662156560516e-07
human O 0 1.3730676755585591e-06
aniridia B-Disease 1 0.9996260404586792
and O 0 1.7296567875746405e-06
have O 0 2.7763081789089483e-07
also O 0 3.10060528363465e-07
been O 0 3.2786107340143644e-07
found O 0 1.007093487714883e-06
in O 0 1.5581329080305295e-06
patients O 0 0.0001244689046870917
with O 0 1.4971254131523892e-05
Peters B-Disease 1 1.0
anomaly I-Disease 1 0.9999912977218628
, O 0 1.2901452464575414e-05
with O 0 0.024369828402996063
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.9999986886978149
, O 0 5.1219431043136865e-06
with O 0 8.37668267195113e-06
autosomal B-Disease 1 0.532845139503479
dominant I-Disease 0 0.0008989336201921105
keratitis I-Disease 1 0.79156094789505
, O 0 1.2748465678669163e-06
and O 0 9.092971140489681e-07
with O 0 5.456080089061288e-06
isolated B-Disease 0 0.016549551859498024
foveal I-Disease 1 0.9999972581863403
hypoplasia I-Disease 1 0.9999980926513672
. O 0 0.0001581207907292992

No O 0 3.696177736856043e-05
locus O 0 8.705157961230725e-05
other O 0 1.494405978519353e-06
than O 0 8.598254908065428e-07
chromosome O 0 1.1379636816855054e-05
11p13 O 0 2.5856874344754033e-05
has O 0 8.738923042983515e-07
been O 0 5.995891001475684e-07
implicated O 0 6.942365416762186e-06
in O 0 1.0760296618173015e-06
aniridia B-Disease 1 0.9970699548721313
, O 0 5.741235895584396e-07
and O 0 4.164783433679986e-07
PAX6 O 0 0.0007012796122580767
is O 0 1.978639119215586e-07
clearly O 0 2.187842937928508e-07
the O 0 7.855891226427048e-08
major O 0 2.042509237298873e-07
, O 0 8.571632292841969e-08
if O 0 6.945055019969004e-08
not O 0 6.655238848907175e-08
only O 0 1.0682919793225665e-07
, O 0 4.1555668417458946e-07
gene O 0 9.121074981521815e-06
responsible O 0 1.5154433640418574e-05
. O 0 2.3702594262431376e-05

Twenty O 0 0.00020532771304715425
- O 0 7.698361878283322e-05
eight O 0 6.455196398746921e-06
percent O 0 4.183486908004852e-06
of O 0 6.659009841314401e-07
identified O 0 3.0529354262398556e-05
PAX6 O 1 0.7912492156028748
mutations O 0 0.000501100963447243
are O 0 1.1025402955056052e-06
C O 0 0.0005863405531272292
- O 0 0.003021534066647291
T O 0 0.000247411138843745
changes O 0 1.4408150263989228e-06
at O 0 6.226183586477418e-07
CpG O 0 1.634238287806511e-05
dinucleotides O 0 1.4664785339846276e-05
, O 0 1.2254056969140947e-07
20 O 0 1.3671706255991012e-07
% O 0 1.1563158608396407e-07
are O 0 5.6432106987358566e-08
splicing O 0 3.1606273296347354e-06
errors O 0 1.2386985872581135e-06
, O 0 1.0534060379541188e-07
and O 0 6.401892704843704e-08
more O 0 4.788335417060807e-08
than O 0 8.625984548871202e-08
30 O 0 2.937807153102767e-07
% O 0 2.514992445412645e-07
are O 0 1.7703085575249133e-07
deletion O 0 1.3506551113096066e-05
or O 0 2.1840394310856936e-06
insertion O 0 3.223814201191999e-05
events O 0 1.885548590507824e-05
. O 0 2.2081361748860218e-05

There O 0 2.1422338249976747e-05
is O 0 2.7727649012376787e-06
a O 0 4.188436832919251e-06
noticeably O 0 8.27025796752423e-05
elevated O 0 3.330805338919163e-05
level O 0 5.980301125418919e-07
of O 0 1.8309789595605253e-07
mutation O 0 3.64667766916682e-06
in O 0 2.49712769573307e-07
the O 0 3.007193640769401e-07
paired O 0 2.2586887098441366e-06
domain O 0 7.91481568285235e-07
compared O 0 4.935878337164468e-07
with O 0 1.0546484219275953e-07
the O 0 2.011284152558801e-07
rest O 0 2.914352990046609e-07
of O 0 2.2678501920836425e-07
the O 0 3.232467406633077e-06
gene O 0 5.9981717640766874e-05
. O 0 2.3955286451382563e-05

Increased O 0 0.0001904816017486155
mutation O 0 0.00021701033983845264
in O 0 2.947150505860918e-06
the O 0 2.4396103981416672e-06
homeodomain O 0 7.37923983251676e-05
is O 0 1.1192566944373539e-06
accounted O 0 1.3501801277016057e-06
for O 0 2.3364256662716798e-07
by O 0 6.110372510192974e-07
the O 0 3.1798711006558733e-06
hypermutable O 0 0.000633628515060991
CpG O 0 0.00036688882391899824
dinucleotide O 0 0.00015771423932164907
in O 0 7.934018867672421e-06
codon O 0 0.000110444008896593
240 O 0 7.174584607128054e-05
. O 0 3.7141053326195106e-05

Very O 0 2.9201582947280258e-05
nearly O 0 6.601825589314103e-06
all O 0 1.1428949164837832e-06
mutations O 0 4.256620377418585e-05
appear O 0 4.916016223432962e-06
to O 0 1.007981268230651e-06
cause O 0 2.4121813112287782e-05
loss O 0 1.700788061498315e-06
of O 0 4.099619133057786e-08
function O 0 8.195333123239834e-08
of O 0 3.317004271252699e-08
the O 0 1.5653817797556258e-07
mutant O 0 7.082329375407426e-06
allele O 0 3.999822183686774e-06
, O 0 7.131237111934752e-08
and O 0 4.3200131472076464e-08
more O 0 2.075763738673686e-08
than O 0 3.076628374287793e-08
80 O 0 1.7649495021032635e-07
% O 0 1.1611183481363696e-07
of O 0 1.4849486262846767e-07
exonic O 0 0.00016103121743071824
substitutions O 0 9.160922672890592e-06
result O 0 3.695072109621833e-06
in O 0 6.360744919220451e-06
nonsense O 0 0.00010092472803080454
codons O 0 0.0001919743517646566
. O 0 5.504930959432386e-05

In O 0 2.670245521585457e-05
a O 0 8.630774573248345e-06
gene O 0 9.344286809209734e-06
with O 0 4.48991471557747e-07
such O 0 2.9709238447139796e-07
extraordinarily O 0 4.4448543121689e-06
high O 0 8.031057632251759e-07
sequence O 0 4.932988986183773e-07
conservation O 0 5.282234951664577e-07
throughout O 0 3.428838510899368e-07
evolution O 0 5.62920263291744e-07
, O 0 1.067499724172194e-07
there O 0 6.427709564604811e-08
are O 0 9.6711708863495e-08
presumed O 0 9.941320968209766e-06
undiscovered O 0 4.864225775236264e-05
missense O 0 0.0037347956094890833
mutations O 0 6.255520565900952e-05
, O 0 3.0120961014290515e-07
these O 0 1.0988760834607092e-07
are O 0 7.954575664825825e-08
hypothesized O 0 2.582104116299888e-06
to O 0 2.499355105101131e-07
exist O 0 3.026989645604772e-07
in O 0 1.8865961237679585e-07
as O 0 2.2768828955577192e-07
- O 0 8.060651452979073e-06
yet O 0 1.2414493539836258e-06
unidentified O 0 1.7975768059841357e-05
phenotypes O 0 0.00014252342225518078
. O 0 4.452855591807747e-06
. O 0 2.0659957954194397e-05

Genetic O 0 0.0020246675703674555
heterogeneity O 0 0.0014894449850544333
and O 0 1.9614888515206985e-05
penetrance O 0 0.00029486461426131427
analysis O 0 6.4098612710949965e-06
of O 0 5.979650836707151e-07
the O 0 2.525103582229349e-06
BRCA1 O 0 0.000431832333561033
and O 0 7.1911704253579956e-06
BRCA2 O 0 0.0020235541742295027
genes O 0 8.5792678873986e-05
in O 0 0.00026842934312298894
breast B-Disease 1 0.999994158744812
cancer I-Disease 1 0.9982448816299438
families O 0 8.367482223547995e-05
. O 0 9.073090041056275e-05

The O 0 0.07569154351949692
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999992847442627
Linkage O 0 0.011439312249422073
Consortium O 0 0.0012964148772880435
. O 0 0.00016547452833037823

The O 0 1.5971705579431728e-05
contribution O 0 1.2633170626941137e-05
of O 0 2.611701575006009e-06
BRCA1 O 0 0.000908189860638231
and O 0 2.807410783134401e-05
BRCA2 O 1 0.9338949918746948
to O 0 0.25775232911109924
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.0009168329415842891
assessed O 0 1.0821036084962543e-05
by O 0 1.2235867643539677e-06
linkage O 0 2.2849382730782963e-05
and O 0 9.92068294181081e-07
mutation O 0 5.159846296010073e-06
analysis O 0 5.749421916334541e-07
in O 0 2.5701049821691413e-07
237 O 0 1.9757515019591665e-06
families O 0 3.1803398314877995e-07
, O 0 4.331085179387628e-08
each O 0 2.3871626453342287e-08
with O 0 4.983118628842931e-08
at O 0 1.1769516561344062e-07
least O 0 1.1271882982555326e-07
four O 0 1.38219448331256e-07
cases O 0 4.876708317169687e-07
of O 0 3.017618837475311e-06
breast B-Disease 1 0.999985933303833
cancer I-Disease 1 0.8665300607681274
, O 0 3.644525179424818e-07
collected O 0 3.3389991926924267e-07
by O 0 1.0765614888441633e-06
the O 0 0.0035159040708094835
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999990463256836
Linkage O 0 0.0007692545186728239
Consortium O 0 0.0001869785482995212
. O 0 4.325241388869472e-05

Families O 0 5.376518674893305e-05
were O 0 4.063741016580025e-06
included O 0 2.012499862757977e-06
without O 0 7.292500754374487e-07
regard O 0 6.322965759864019e-07
to O 0 2.3481844380057737e-07
the O 0 2.800667004976276e-07
occurrence O 0 3.5271712022222346e-06
of O 0 1.3080331200399087e-06
ovarian B-Disease 1 0.8915122747421265
or I-Disease 0 8.333958248840645e-06
other I-Disease 0 1.133755358750932e-05
cancers I-Disease 0 0.2558462917804718
. O 0 5.466408038046211e-05

Overall O 0 0.006678455043584108
, O 0 0.0005411745514720678
disease O 0 0.4235963225364685
was O 0 1.6192245311685838e-05
linked O 0 5.835004776599817e-05
to O 0 1.5192022146948148e-06
BRCA1 O 0 4.800054375664331e-05
in O 0 2.9730128403571143e-07
an O 0 1.1881457595563916e-07
estimated O 0 1.880937219311818e-07
52 O 0 3.8490406950586475e-07
% O 0 1.0531368133115393e-07
of O 0 5.586227658227472e-08
families O 0 3.0988110211183084e-07
, O 0 1.528036790432452e-07
to O 0 3.314136733933992e-07
BRCA2 O 0 1.8886961697717197e-05
in O 0 2.3496203027661977e-07
32 O 0 3.55533984475187e-07
% O 0 9.370027242994183e-08
of O 0 3.9607073176739505e-08
families O 0 1.8523624589761312e-07
, O 0 9.309547266411755e-08
and O 0 1.0449372922494149e-07
to O 0 1.3637001927691017e-07
neither O 0 5.138780352353933e-07
gene O 0 9.815179282668396e-07
in O 0 1.6195298258026014e-07
16 O 0 4.620901279395184e-07
% O 0 2.1067303634936252e-07
( O 0 3.2411244887953217e-07
95 O 0 8.438513532382785e-07
% O 0 4.839791358790535e-07
confidence O 0 6.452721663663397e-06
interval O 0 8.867826181813143e-06
[ O 0 6.958433004911058e-06
CI O 0 0.00017165155441034585
] O 0 2.6274076390109258e-06
6 O 0 8.139996339195932e-07
% O 0 4.956619932272588e-07
- O 0 3.1635436243959703e-06
28 O 0 9.784010899238638e-07
% O 0 1.8323082429105852e-07
) O 0 2.371343583718044e-07
, O 0 2.089580419806225e-07
suggesting O 0 2.8223792014614446e-06
other O 0 1.7775419109966606e-06
predisposition O 0 0.0003078093577641994
genes O 0 5.945244993199594e-05
. O 0 3.23261265293695e-05

The O 0 2.9156781238270923e-05
majority O 0 1.710850301606115e-05
( O 0 4.204910055705113e-06
81 O 0 5.683561994374031e-06
% O 0 4.937587618769612e-07
) O 0 1.8154763381517114e-07
of O 0 1.1241373698567259e-07
the O 0 1.6002381016733125e-05
breast B-Disease 1 0.9999995231628418
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.032316953976988e-06
were O 0 5.442950055112306e-07
due O 0 4.597507995640626e-06
to O 0 2.211934543083771e-06
BRCA1 O 0 0.0001558449730509892
, O 0 2.0811481249438657e-07
with O 0 1.0097442526557643e-07
most O 0 1.1330470073289689e-07
others O 0 2.2715408931617276e-07
( O 0 2.5670286163403944e-07
14 O 0 3.533318420068099e-07
% O 0 2.8486533665272873e-07
) O 0 3.5398278441789444e-07
due O 0 2.6936063477478456e-06
to O 0 4.602333774528233e-06
BRCA2 O 0 0.001629856415092945
. O 0 3.3962704037548974e-05

Conversely O 0 0.0003905538178514689
, O 0 3.499599642964313e-06
the O 0 9.4644309456271e-07
majority O 0 5.248866727924906e-07
of O 0 9.575249748650094e-08
families O 0 2.451625960020465e-07
with O 0 2.39307837546221e-07
male B-Disease 0 9.193543064611731e-07
and I-Disease 0 1.8909366872321698e-06
female I-Disease 0 0.0006820512935519218
breast I-Disease 1 0.999995231628418
cancer I-Disease 1 0.9909877181053162
were O 0 1.5361898704213672e-06
due O 0 8.01175701781176e-06
to O 0 4.1365146898897365e-06
BRCA2 O 0 0.0005233831470832229
( O 0 6.381025286827935e-06
76 O 0 2.540260902605951e-05
% O 0 6.014107384544332e-06
) O 0 8.540446287952363e-06
. O 0 1.9386909116292372e-05

The O 0 1.851911838457454e-05
largest O 0 1.6538881027372554e-05
proportion O 0 6.971664788579801e-06
( O 0 1.6452454474347178e-06
67 O 0 2.088929704768816e-06
% O 0 2.646363839176047e-07
) O 0 1.0308622933052902e-07
of O 0 6.17310149664263e-08
families O 0 2.3895231038295606e-07
due O 0 7.523644853790756e-07
to O 0 1.3966572964818624e-07
other O 0 9.982544924014292e-08
genes O 0 8.228238925767073e-07
was O 0 1.2117732239858015e-06
found O 0 2.685083586584369e-07
in O 0 1.0453718601866058e-07
families O 0 1.0437859288003892e-07
with O 0 4.765029970599244e-08
four O 0 1.1730520554920076e-07
or O 0 1.781299516778745e-07
five O 0 1.641913200955969e-07
cases O 0 3.5883985560758447e-07
of O 0 6.007882120684371e-07
female O 0 0.0010220658732578158
breast B-Disease 1 0.99998939037323
cancer I-Disease 1 0.9865561723709106
only O 0 7.614242349518463e-06
. O 0 2.4417968234047294e-05

These O 0 3.24658649333287e-05
estimates O 0 3.18092861562036e-05
were O 0 1.7167728856293252e-06
not O 0 8.330250125254679e-07
substantially O 0 1.9630253518698737e-05
affected O 0 1.368096945952857e-06
either O 0 3.911854946636595e-07
by O 0 2.6238095074404555e-07
changing O 0 1.1768185004257248e-06
the O 0 4.558746127258928e-07
assumed O 0 8.413519026362337e-06
penetrance O 0 3.5262139135738835e-05
model O 0 3.1604074592905818e-06
for O 0 3.2152797757589724e-07
BRCA1 O 0 2.42423757299548e-05
or O 0 2.1513018566565734e-07
by O 0 1.7223339909833157e-07
including O 0 3.2223243806583923e-07
or O 0 1.3564797427534359e-06
excluding O 0 7.389350503217429e-05
BRCA1 O 0 0.0335545539855957
mutation O 0 0.00011620554141700268
data O 0 2.3207783669931814e-05
. O 0 2.1666259272024035e-05

Among O 0 2.0247287466190755e-05
those O 0 3.677768290799577e-06
families O 0 3.7350218917708844e-06
with O 0 6.4432574617967475e-06
disease O 1 0.6815078258514404
due O 0 4.749608342535794e-05
to O 0 6.792796739318874e-06
BRCA1 O 0 0.0062538678757846355
that O 0 4.112181386517477e-07
were O 0 4.616171054294682e-07
tested O 0 1.628571567380277e-06
by O 0 8.501391590698404e-08
one O 0 3.9128764228735236e-08
of O 0 3.0378689785948154e-08
the O 0 2.2841119573513424e-07
standard O 0 3.1563597531203413e-06
screening O 0 4.297398845665157e-06
methods O 0 1.413879772371729e-06
, O 0 7.634410508217115e-07
mutations O 0 7.16223985364195e-06
were O 0 2.9958641789562535e-07
detected O 0 2.7473251975607127e-06
in O 0 1.8738096230208612e-07
the O 0 3.889853701366519e-07
coding O 0 4.726145107269986e-06
sequence O 0 6.352364039230451e-07
or O 0 2.551232967107353e-07
splice O 0 6.073044914955972e-06
sites O 0 5.315339421940735e-07
in O 0 1.205896751343971e-07
an O 0 1.0036842468252871e-07
estimated O 0 4.5506411083806597e-07
63 O 0 1.2793761925422587e-06
% O 0 3.709813540808682e-07
( O 0 3.788210563016037e-07
95 O 0 1.7161606820081943e-06
% O 0 6.842867037448741e-07
CI O 0 5.1731425628531724e-05
51 O 0 2.795959289869643e-06
% O 0 8.321372888531187e-07
- O 0 1.300040639762301e-05
77 O 0 7.296985131688416e-06
% O 0 2.927804416685831e-06
) O 0 5.8365717450215016e-06
. O 0 2.1218367692199536e-05

The O 0 2.2067213649279438e-05
estimated O 0 1.364314175589243e-05
sensitivity O 0 1.5475590771529824e-05
was O 0 2.750019575614715e-06
identical O 0 2.965838575619273e-06
for O 0 2.8353349534882e-07
direct O 0 8.36009405702498e-07
sequencing O 0 2.3082618554326473e-06
and O 0 4.632134675830457e-07
other O 0 1.0442036000313237e-06
techniques O 0 2.0620667783077806e-05
. O 0 2.2922980861039832e-05

The O 0 4.031588105135597e-05
penetrance O 0 0.0005962287541478872
of O 0 8.082443855528254e-06
BRCA2 O 0 0.0034210807643830776
was O 0 5.554265499085886e-06
estimated O 0 1.0860816246349714e-06
by O 0 6.462017836383893e-07
maximizing O 0 5.6532794587838e-06
the O 0 1.6306184988934547e-06
LOD O 0 0.007123741786926985
score O 0 1.6992980818031356e-06
in O 0 3.515307525958633e-06
BRCA2 O 0 0.023231128230690956
- O 0 0.002198287285864353
mutation O 0 1.1363077646819875e-05
families O 0 3.9325547618318524e-07
, O 0 1.0849930731637869e-07
over O 0 2.415852975445887e-07
all O 0 2.3689227646173094e-07
possible O 0 2.9592245027743047e-06
penetrance O 0 0.00016567439888603985
functions O 0 2.0126102754147723e-05
. O 0 2.6471348974155262e-05

The O 0 3.445093898335472e-05
estimated O 0 1.660581438045483e-05
cumulative O 0 3.908164944732562e-05
risk O 0 2.7124575353809632e-05
of O 0 6.2022572819842026e-06
breast B-Disease 1 0.9999465942382812
cancer I-Disease 1 0.9399691224098206
reached O 0 4.590489879774395e-06
28 O 0 3.5996654332848266e-06
% O 0 5.861522254235751e-07
( O 0 5.497460051628877e-07
95 O 0 1.2017470680802944e-06
% O 0 6.576473765562696e-07
CI O 0 3.307294537080452e-05
9 O 0 1.2473260539991315e-06
% O 0 3.2217374723586545e-07
- O 0 1.3006281278649112e-06
44 O 0 3.542515969456872e-07
% O 0 1.1190203252908759e-07
) O 0 9.162297942566511e-08
by O 0 1.5116236795620352e-07
age O 0 2.3318291653140477e-07
50 O 0 2.0380281284815283e-07
years O 0 2.032000168128434e-07
and O 0 1.6955168291588052e-07
84 O 0 1.5360228644567542e-06
% O 0 2.808996839576139e-07
( O 0 3.772391323764168e-07
95 O 0 1.1272909432591405e-06
% O 0 5.565084961745015e-07
CI O 0 3.8940575905144215e-05
43 O 0 1.830949031500495e-06
% O 0 5.8558015325616e-07
- O 0 2.4554612991778413e-06
95 O 0 1.3094372661726084e-06
% O 0 3.113702859991463e-07
) O 0 2.228992883601677e-07
by O 0 3.099677030604653e-07
age O 0 9.87393150353455e-07
70 O 0 3.226434046155191e-06
years O 0 7.023314537946135e-06
. O 0 2.148449857486412e-05

The O 0 0.0005012887413613498
corresponding O 1 0.9996204376220703
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.10775867104530334
were O 0 2.5102215658989735e-05
0 O 0 8.998112025437877e-05
. O 0 4.850810728385113e-05

4 O 0 8.214171975851059e-05
% O 0 9.88746432994958e-06
( O 0 2.8277918318053707e-06
95 O 0 3.556784804459312e-06
% O 0 1.7509084955236176e-06
CI O 0 5.133802187629044e-05
0 O 0 1.8774206864691223e-06
% O 0 4.835698632632557e-07
- O 0 1.6071795698735514e-06
1 O 0 2.8289443321227736e-07
% O 0 1.2923524650432228e-07
) O 0 8.944267904098524e-08
by O 0 1.1676667099891347e-07
age O 0 1.555807784825447e-07
50 O 0 1.1007640665638974e-07
years O 0 1.2005278904325678e-07
and O 0 1.1304900482400626e-07
27 O 0 7.847105507607921e-07
% O 0 1.9424980735038844e-07
( O 0 2.3477589650156006e-07
95 O 0 1.066619915945921e-06
% O 0 6.490564601335791e-07
CI O 0 4.269247074262239e-05
0 O 0 1.3103291394145344e-06
% O 0 2.6469291469766176e-07
- O 0 1.4903611145200557e-06
47 O 0 7.340029810620763e-07
% O 0 1.5384696894216177e-07
) O 0 1.397943236725041e-07
by O 0 2.1439653608013032e-07
age O 0 8.05564980055351e-07
70 O 0 2.328407845197944e-06
years O 0 6.413004484784324e-06
. O 0 1.3636182302434463e-05

The O 0 5.454119309433736e-05
lifetime O 0 0.00022477311722468585
risk O 0 8.230746607296169e-05
of O 0 1.5940633602440357e-05
breast B-Disease 1 0.999998927116394
cancer I-Disease 1 0.9997679591178894
appears O 0 2.5258421374019235e-05
similar O 0 2.3310115011554444e-06
to O 0 4.921068352814473e-07
the O 0 5.728384167014156e-07
risk O 0 3.6474843909672927e-06
in O 0 1.3925172197559732e-06
BRCA1 O 0 0.0006090268143452704
carriers O 0 1.0767949788714759e-05
, O 0 2.369349658692954e-07
but O 0 8.941231754988621e-08
there O 0 5.086473464643859e-08
was O 0 1.0002747785620159e-07
some O 0 3.308373308641421e-08
suggestion O 0 4.1902563907569856e-07
of O 0 4.965509248222588e-08
a O 0 7.117770337572438e-07
lower O 0 0.00013686594320461154
risk O 0 1.2977985534234904e-05
in O 0 3.034694827874773e-06
BRCA2 O 0 0.0004999261000193655
carriers O 0 1.4017285138834268e-05
< O 0 8.884629096428398e-06
50 O 0 5.781946583738318e-07
years O 0 4.360485945653636e-07
of O 0 4.810176505998243e-07
age O 0 7.138393812056165e-06
. O 0 1.6636689906590618e-05

Eye B-Disease 1 0.98082435131073
movement I-Disease 0 0.41149958968162537
abnormalities I-Disease 1 0.9992547631263733
correlate O 0 0.00017207172641064972
with O 0 1.085653366317274e-05
genotype O 0 0.08076602220535278
in O 0 5.077499008621089e-05
autosomal O 1 0.9818150401115417
dominant O 1 0.5635311007499695
cerebellar B-Disease 1 0.9999963045120239
ataxia I-Disease 1 0.9999998807907104
type I-Disease 1 0.6732956171035767
I I-Disease 0 0.0001583111734362319
. O 0 5.393357059801929e-05

We O 0 6.51187656330876e-05
compared O 0 4.393711424199864e-05
horizontal O 0 0.00018573224951978773
eye O 0 0.0026415796019136906
movements O 0 5.827992572449148e-05
( O 0 5.79537254452589e-06
visually O 0 1.0265734999848064e-05
guided O 0 1.544047518109437e-05
saccades O 0 0.000746370293200016
, O 0 1.1717187362592085e-06
antisaccades O 0 4.374350464786403e-05
, O 0 2.8860446832368325e-07
and O 0 1.0797060667755431e-07
smooth O 0 1.3082027408017893e-06
pursuit O 0 2.7515386591403512e-06
) O 0 3.751654276129557e-07
in O 0 3.179417831233877e-07
control O 0 3.543405000527855e-06
subjects O 0 1.1638760497589828e-06
( O 0 8.046405355344177e-07
n O 0 5.097427219880046e-06
= O 0 2.270735876663821e-06
14 O 0 4.1233383285543823e-07
) O 0 2.3307130447847157e-07
and O 0 3.40536189469276e-07
patients O 0 2.601072992547415e-06
with O 0 1.1947348355079157e-07
three O 0 1.5468509673155495e-07
forms O 0 5.668626386068354e-07
of O 0 1.0178952152273268e-06
autosomal O 0 0.17233939468860626
dominant O 0 0.0009669979335740209
cerebellar B-Disease 1 0.8910071849822998
ataxias I-Disease 1 0.9430365562438965
type I-Disease 0 0.008138272911310196
I I-Disease 0 2.853083424270153e-05
spinocerebellar B-Disease 0 0.110865518450737
ataxias I-Disease 0 0.00011507463204907253
1 I-Disease 0 1.0858393579837866e-06
and I-Disease 0 2.0254356059012935e-07
2 I-Disease 0 8.044747801250196e-07
( O 0 8.606967298874224e-07
SCA1 B-Disease 0 5.031621549278498e-05
, O 0 4.1460626221123675e-07
n O 0 3.7538338801823556e-06
= O 0 3.240628529965761e-06
11 O 0 1.0018210332418676e-06
; O 0 7.156389756346471e-07
SCA2 B-Disease 0 4.448592517292127e-05
, O 0 6.410293167391501e-07
n O 0 5.9582011999737006e-06
= O 0 3.4610386592248688e-06
10 O 0 4.007200402611488e-07
) O 0 4.0464286144015205e-07
and O 0 1.011895619740244e-06
SCA3 B-Disease 1 0.9981335997581482
/ O 0 0.010350484400987625
Machado B-Disease 0 0.000133860157802701
- I-Disease 0 0.025213131681084633
Joseph I-Disease 0 0.001094003557227552
disease I-Disease 0 0.05831386148929596
( O 0 1.3776959349343088e-05
MJD B-Disease 1 0.9980413913726807
) O 0 4.650486971513601e-06
( O 0 4.320591870055068e-06
n O 0 1.3538506209442858e-05
= O 0 1.3699816008738708e-05
16 O 0 4.4897915358887985e-06
) O 0 6.3137254073808435e-06
. O 0 1.191679166367976e-05

In O 0 0.000106530096672941
SCA1 B-Disease 0 0.0008184493635781109
, O 0 9.156389751296956e-06
saccade O 0 0.00014429357543122023
amplitude O 0 3.5076904168818146e-05
was O 0 7.778516192047391e-06
significantly O 0 1.2653101293835789e-05
increased O 0 3.901708623743616e-06
, O 0 9.953073458746076e-07
resulting O 0 6.8813269535894506e-06
in O 0 7.171172455855412e-06
hypermetria B-Disease 0 0.002377112628892064
. O 0 4.5941829739604145e-05

The O 0 3.799258411163464e-05
smooth O 0 7.687102333875373e-05
pursuit O 0 6.509554805234075e-05
gain O 0 6.133160059107468e-05
was O 0 4.1171821067109704e-05
decreased O 0 0.00016603719268459827
. O 0 3.783473221119493e-05

In O 0 0.00015315719065256417
SCA2 B-Disease 0 0.0017737426096573472
, O 0 1.8390641344012693e-05
saccade O 0 0.0004512200830504298
velocity O 0 0.00011878729128511623
was O 0 6.256970664253458e-05
markedly O 0 0.0007142927497625351
decreased O 0 0.0002996628754772246
. O 0 5.2317282097646967e-05

The O 0 1.7244854461750947e-05
percentage O 0 1.1570594324439298e-05
of O 0 9.639069276090595e-07
errors O 0 3.919244136341149e-06
in O 0 2.0324512206570944e-06
antisaccades O 0 0.008469595573842525
was O 0 1.2199258890177589e-05
greatly O 0 3.080147735090577e-06
increased O 0 1.5521205796176218e-06
and O 0 5.229480279922427e-07
was O 0 3.0772264381084824e-06
significantly O 0 8.495136171404738e-06
correlated O 0 7.09773166818195e-06
with O 0 1.2322935845077154e-06
age O 0 1.7172515072161332e-05
at O 0 0.00013912678696215153
disease O 1 0.9762946963310242
onset O 1 0.9231953620910645
. O 0 9.518835577182472e-05

In O 0 2.1762964024674147e-05
addition O 0 5.471420536196092e-06
, O 0 7.948066809149168e-07
a O 0 6.45024556433782e-07
correlation O 0 1.7160493825940648e-06
between O 0 4.1247423610002443e-07
smooth O 0 2.5607475890865317e-06
pursuit O 0 2.8493916488514515e-06
gain O 0 1.8055100099445553e-06
and O 0 1.3675774823695974e-07
the O 0 1.4619880062127777e-07
number O 0 2.039336521875157e-07
of O 0 4.496080521221302e-07
trinucleotide O 0 0.00479076337069273
repeats O 0 0.0001574987400090322
was O 0 1.362924012937583e-05
found O 0 1.1148207704536617e-05
. O 0 1.7158929040306248e-05

In O 0 0.00016875311848707497
SCA3 B-Disease 1 0.9978207349777222
, O 0 1.888289079943206e-05
gaze B-Disease 0 0.0003399517445359379
- I-Disease 0 0.0012570532271638513
evoked I-Disease 0 0.0011047907173633575
nystagmus I-Disease 0 0.45007118582725525
was O 0 9.403501280758064e-06
often O 0 5.851686637470266e-07
present O 0 4.7564580540893076e-07
as O 0 3.3704773727549764e-07
was O 0 1.4437433719649562e-06
saccade O 0 4.1791641706367955e-05
hypometria O 0 4.124318002141081e-05
and O 0 5.709033530365559e-07
smooth O 0 3.607941152949934e-06
pursuit O 0 8.026134310057387e-06
gain O 0 1.4466899301623926e-05
was O 0 2.0312601918703876e-05
markedly O 0 0.00036374799674376845
decreased O 0 0.00025397035642527044
. O 0 4.597618317347951e-05

Three O 0 3.113479760941118e-05
major O 0 1.50756004586583e-05
criteria O 0 7.556639047834324e-06
, O 0 1.4512597772409208e-06
saccade O 0 5.283016798784956e-05
amplitude O 0 9.783351742953528e-06
, O 0 8.229659442804405e-07
saccade O 0 2.182514981541317e-05
velocity O 0 3.670724936455372e-06
, O 0 1.8225713915853703e-07
and O 0 1.1425392187902617e-07
presence O 0 3.207167083019158e-07
of O 0 2.3529682380285522e-07
gaze B-Disease 0 0.00010103546810569242
- I-Disease 0 0.0002625365159474313
evoked I-Disease 0 0.00017207892960868776
nystagmus I-Disease 0 0.0008153427042998374
, O 0 4.5234941126182093e-07
permitted O 0 5.165938432583062e-07
the O 0 3.129185301986581e-07
correct O 0 1.7056854630936868e-06
assignment O 0 6.261816452024505e-07
of O 0 6.589708334558964e-08
90 O 0 1.8678022684071038e-07
% O 0 8.029451237234753e-08
of O 0 3.1482972673302356e-08
the O 0 1.462722991618648e-07
SCA1 B-Disease 0 3.494828342809342e-05
, O 0 1.021865045913728e-07
90 O 0 1.4263991943153087e-07
% O 0 5.745191700157193e-08
of O 0 3.0244901694231885e-08
the O 0 2.142624566658924e-07
SCA2 B-Disease 0 0.00010735897376434878
, O 0 1.2273308414023631e-07
and O 0 8.601110579320448e-08
93 O 0 5.302459271661064e-07
% O 0 7.99721675548426e-08
of O 0 5.3983534087365115e-08
the O 0 8.468859959975816e-07
patients O 0 1.807295484468341e-05
with O 0 5.744095119553094e-07
SCA3 B-Disease 1 0.9998515844345093
to O 0 4.2500334984652e-07
their O 0 3.4720699204626726e-07
genetically O 0 4.85177861264674e-06
confirmed O 0 2.3277387299458496e-05
patient O 0 4.1950766899390146e-05
group O 0 8.140663680933358e-07
and O 0 1.2181385500298347e-07
, O 0 1.3045458047145075e-07
therefore O 0 2.678825126167794e-07
, O 0 2.3615601207893633e-07
may O 0 1.9082774542766856e-06
help O 0 8.740055932321411e-07
orient O 0 0.0002937092212960124
diagnoses O 0 0.00010891580313909799
of O 0 3.670066917038639e-07
SCA1 B-Disease 0 0.0008237136644311249
, O 0 7.560903441117262e-07
SCA2 B-Disease 0 8.670122770126909e-05
, O 0 3.073672871778399e-07
and O 0 4.2593782723088225e-07
SCA3 B-Disease 1 0.976045548915863
at O 0 1.3262440461403457e-06
early O 0 3.325082616356667e-06
clinical O 0 6.8377735260582995e-06
stages O 0 1.935081400006311e-06
of O 0 4.2200650796075934e-07
the O 0 2.7341431632521562e-05
diseases O 1 0.7729898691177368
. O 0 7.0753967520431615e-06
. O 0 2.038329330389388e-05

Genetic O 0 0.0005362633964978158
basis O 0 2.2882224584463984e-05
and O 0 7.892483154137153e-06
molecular O 0 7.595464558107778e-05
mechanism O 0 0.00018359944806434214
for O 0 0.0005224553169682622
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 0.0007815210265107453

Ventricular B-Disease 1 0.9999958276748657
fibrillation I-Disease 1 0.9999972581863403
causes O 0 0.002470944309607148
more O 0 2.359937752771657e-06
than O 0 4.20951380419865e-07
300 O 0 8.610563213551359e-07
, O 0 3.1214688078762265e-07
000 O 0 1.4332828186525148e-06
sudden O 0 0.0001346294884569943
deaths O 0 1.936747139552608e-05
each O 0 2.407853116892511e-07
year O 0 5.115759336149495e-07
in O 0 4.4418777633836726e-07
the O 0 1.6902131392271258e-06
USA O 0 0.00015548548253718764
alone O 0 2.3410400899592787e-05
. O 0 1.6771296941442415e-05

In O 0 1.585715108376462e-05
approximately O 0 5.159673946764087e-06
5 O 0 2.6326702027290594e-06
- O 0 4.302582055970561e-06
12 O 0 3.6877108300359396e-07
% O 0 7.858498207724551e-08
of O 0 3.929195457885726e-08
these O 0 6.076609082583673e-08
cases O 0 2.0444346660042356e-07
, O 0 1.0595297794679936e-07
there O 0 8.231238979305999e-08
are O 0 6.491244874951008e-08
no O 0 6.411289632524131e-07
demonstrable O 0 0.12148059904575348
cardiac O 1 0.9986749291419983
or O 0 5.398253051680513e-06
non O 0 2.955103263957426e-05
- O 1 0.9914727210998535
cardiac O 1 0.9999134540557861
causes O 0 2.3272725229617208e-05
to O 0 3.1903218200568517e-07
account O 0 2.98949686339256e-07
for O 0 5.7714849788226275e-08
the O 0 1.0874482114786588e-07
episode O 0 1.242785515387368e-06
, O 0 1.5351909610217263e-07
which O 0 2.5101329015342344e-07
is O 0 3.475959147181129e-07
therefore O 0 1.3592029972642194e-06
classified O 0 1.5846690075704828e-05
as O 0 9.774028876563534e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 0.032458219677209854
IVF B-Disease 1 0.999993085861206
) O 0 5.803922249469906e-05
. O 0 3.791006747633219e-05

A O 0 6.940161983948201e-05
distinct O 0 3.671683953143656e-05
group O 0 2.5982393708545715e-05
of O 0 9.75951388682006e-06
IVF B-Disease 1 1.0
patients O 1 0.9483019709587097
has O 0 6.9136781348788645e-06
been O 0 7.836964641683153e-07
found O 0 4.37554945165175e-07
to O 0 2.461096642036864e-07
present O 0 3.180958287885005e-07
with O 0 2.7861295848197187e-07
a O 0 2.4140226742019877e-06
characteristic O 0 3.3757693017832935e-05
electrocardiographic O 0 0.021196473389863968
pattern O 0 0.00027219823095947504
. O 0 3.493455733405426e-05

Because O 0 1.4311930499388836e-05
of O 0 1.0086987458635122e-06
the O 0 5.6802502967912e-07
small O 0 4.16770376432396e-07
size O 0 4.480038455767499e-07
of O 0 9.040349624456212e-08
most O 0 1.503240980582632e-07
pedigrees O 0 8.083299690042622e-06
and O 0 1.7163294785405014e-07
the O 0 3.2153377560462104e-07
high O 0 3.8838147702335846e-06
incidence O 0 3.845852552331053e-05
of O 0 2.5867672093227156e-07
sudden B-Disease 0 0.04528769478201866
death I-Disease 0 0.0004914014134556055
, O 0 2.2460253035205824e-07
however O 0 2.4284096866722393e-07
, O 0 1.3743172644353763e-07
molecular O 0 2.4373173346248223e-06
genetic O 0 2.8067202038073447e-06
studies O 0 1.2619976814676193e-06
of O 0 9.687413466963335e-07
IVF B-Disease 1 0.9999990463256836
have O 0 2.019351768467459e-06
not O 0 4.167624183537555e-07
yet O 0 9.004398293654958e-07
been O 0 1.4085583188716555e-06
done O 0 4.865308710577665e-06
. O 0 1.0707235560403205e-05

Because O 0 0.01878235675394535
IVF B-Disease 1 0.9999998807907104
causes O 1 0.993179440498352
cardiac O 1 0.9999868869781494
rhythm O 0 0.35717999935150146
disturbance O 0 0.2806951701641083
, O 0 2.4406435841228813e-06
we O 0 3.6013162230119633e-07
investigated O 0 8.252794941654429e-06
whether O 0 1.0496220284039737e-06
malfunction O 0 0.00013383642362896353
of O 0 4.288054640255723e-07
ion O 0 2.2641541363555007e-05
channels O 0 3.017054496012861e-06
could O 0 1.4699430721520912e-06
cause O 0 5.558101747737965e-06
the O 0 1.4470501810137648e-06
disorder O 0 0.04792093113064766
by O 0 6.31004411388858e-07
studying O 0 2.7887024316441966e-06
mutations O 0 1.6632373444736004e-05
in O 0 6.948220629965363e-07
the O 0 3.1835122626944212e-06
cardiac O 1 0.8384577631950378
sodium O 0 7.441268098773435e-05
channel O 0 7.330802327487618e-05
gene O 0 8.866497955750674e-05
SCN5A O 0 0.0007320145377889276
. O 0 3.658653804450296e-05

We O 0 2.2015945432940498e-05
have O 0 2.842828735083458e-06
now O 0 1.5752314084238606e-06
identified O 0 2.758288019322208e-06
a O 0 3.823558472504374e-06
missense O 0 0.0004855930746998638
mutation O 0 3.5092831240035594e-05
, O 0 4.824584038942703e-07
a O 0 1.2370446711429395e-06
splice O 0 0.00029944186098873615
- O 0 0.00035207963082939386
donor O 0 7.983826435520314e-06
mutation O 0 7.877722055127379e-06
, O 0 2.402634891041089e-07
and O 0 2.478916769632633e-07
a O 0 2.547533085817122e-06
frameshift O 0 0.08067093789577484
mutation O 0 1.799592428142205e-05
in O 0 6.203424618433928e-07
the O 0 5.335216997082171e-07
coding O 0 6.047741408110596e-06
region O 0 1.084431914932793e-06
of O 0 4.252332246323931e-07
SCN5A O 0 0.00030403415439650416
in O 0 2.9036687010375317e-06
three O 0 8.70347776071867e-06
IVF B-Disease 1 0.9998409748077393
families O 0 6.792553176637739e-05
. O 0 4.689967317972332e-05

We O 0 1.6587217032792978e-05
show O 0 6.135579042165773e-06
that O 0 6.802143275308481e-07
sodium O 0 4.587443982018158e-06
channels O 0 1.1354650268913247e-06
with O 0 2.8614013558581064e-07
the O 0 8.825591066852212e-07
missense O 0 0.0001480767532484606
mutation O 0 3.0515000617015176e-05
recover O 0 4.4016629544785246e-05
from O 0 8.588763762418239e-07
inactivation O 0 7.901008211774752e-05
more O 0 1.931543636146671e-07
rapidly O 0 1.3507416269931127e-06
than O 0 9.012768487082212e-08
normal O 0 3.9626198145015223e-07
and O 0 1.1128265242632551e-07
that O 0 7.402214663443374e-08
the O 0 6.215155394784233e-07
frameshift O 0 0.2318505346775055
mutation O 0 2.6538633392192423e-05
causes O 0 2.3121569938666653e-06
the O 0 3.7561073895631125e-07
sodium O 0 3.7954896470182575e-06
channel O 0 2.210176035077893e-06
to O 0 3.064780287331814e-07
be O 0 2.1366459179716912e-07
non O 0 2.128300593540189e-06
- O 0 2.3266045900527388e-05
functional O 0 2.0585439415299334e-05
. O 0 1.4487054613709915e-05

Our O 0 4.263978189555928e-05
results O 0 3.118507083854638e-05
indicate O 0 1.3221070730651263e-05
that O 0 1.433698457731225e-06
mutations O 0 3.330199251649901e-05
in O 0 2.2513358999276534e-06
cardiac O 1 0.5701084733009338
ion O 0 0.00022136424377094954
- O 0 4.233004437992349e-05
channel O 0 4.976307536708191e-06
genes O 0 1.1842062122013886e-06
contribute O 0 3.209186161257094e-07
to O 0 1.4359463307300757e-07
the O 0 3.0651543170279183e-07
risk O 0 2.1617920538119506e-06
of O 0 7.078359658407862e-07
developing O 0 6.354018114507198e-05
IVF B-Disease 1 0.9999724626541138
. O 0 1.6061396308941767e-05
. O 0 2.189319275203161e-05

Molecular O 0 0.001313841319642961
heterogeneity O 0 0.0009850063361227512
in O 0 3.9677881431998685e-05
mucopolysaccharidosis B-Disease 0 0.010451081208884716
IVA I-Disease 0 0.031226972118020058
in O 0 6.286064490268473e-06
Australia O 0 2.2560086563316872e-06
and O 0 3.667981332000636e-07
Northern O 0 1.3103941682857112e-06
Ireland O 0 2.9730426831520163e-06
: O 0 2.9918783184257336e-07
nine O 0 3.6422110838429944e-07
novel O 0 2.1496623503480805e-06
mutations O 0 3.773157459363574e-06
including O 0 2.741347486789891e-07
T312S O 0 1.585660720593296e-05
, O 0 3.0034277642698726e-07
a O 0 9.452686526856269e-07
common O 0 2.3875281840446405e-06
allele O 0 2.5947032554540783e-05
that O 0 1.2363263977022143e-06
confers O 0 5.740411870647222e-05
a O 0 6.23527739662677e-05
mild O 1 0.9986145496368408
phenotype O 1 0.9723837971687317
. O 0 0.00010535238106967881

Mucopolysaccharidosis B-Disease 1 0.7023256421089172
IVA I-Disease 1 0.9897803068161011
( O 0 0.0008321329369209707
MPS B-Disease 1 0.9994986057281494
IVA I-Disease 1 0.9999479055404663
) O 0 9.353219866170548e-06
is O 0 1.5984758192644222e-06
an O 0 5.347714250092395e-06
autosomal B-Disease 1 0.9904863238334656
recessive I-Disease 1 0.9999881982803345
lysosomal I-Disease 1 0.9999985694885254
storage I-Disease 1 0.9999924898147583
disorder I-Disease 1 0.9999885559082031
caused O 0 0.000209717036341317
by O 0 1.994524154724786e-06
a O 0 0.00014410891162697226
genetic B-Disease 1 0.9981482028961182
defect I-Disease 1 0.9995381832122803
in O 0 7.580508281535003e-06
N O 0 0.00012222878285683692
- O 0 7.62495692470111e-05
acetylgalactosamine O 0 0.0003524881321936846
- O 0 6.887253402965143e-05
6 O 0 1.6778159988461994e-05
- O 0 0.0003791383351199329
sulfate O 0 0.0008917527156881988
sulfatase O 0 0.0014678540173918009
( O 0 2.1796282453578897e-05
GALNS O 0 0.0005670265527442098
) O 0 2.904017674154602e-05
. O 0 2.8225837013451383e-05

Previous O 0 0.0001337040012003854
studies O 0 2.443798257445451e-05
of O 0 1.9721708213182865e-06
patients O 0 4.3681226088665426e-05
from O 0 7.069872367537755e-07
a O 0 1.3385939610088826e-06
British O 0 4.1726056224433705e-05
- O 0 3.8974088965915143e-05
Irish O 0 1.472993744755513e-06
population O 0 2.745392180258932e-07
showed O 0 7.716686241110438e-07
that O 0 6.366725102679993e-08
the O 0 1.5055121593832155e-07
I113F O 0 2.9612789148814045e-05
mutation O 0 3.4043787309201434e-06
is O 0 6.922333994907603e-08
the O 0 6.274908770365073e-08
most O 0 8.959840158695442e-08
common O 0 4.5991214392415714e-07
single O 0 1.4504020100503112e-06
mutation O 0 1.351157516182866e-05
among O 0 3.1479903555009514e-06
MPS B-Disease 1 0.9999141693115234
IVA I-Disease 1 0.9999998807907104
patients O 0 0.32130879163742065
and O 0 2.962417966045905e-06
produces O 0 2.8567477784235962e-05
a O 0 0.00010061033390229568
severe O 1 0.9999456405639648
clinical O 1 0.9897466897964478
phenotype O 1 0.9965859651565552
. O 0 0.00011428463767515495

We O 0 3.5931068850914016e-05
studied O 0 4.936028199153952e-05
mutations O 0 7.988252036739141e-05
in O 0 1.6891641507754684e-06
the O 0 1.5105255215530633e-06
GALNS O 0 0.0001865831873146817
gene O 0 5.1720935516641475e-06
from O 0 5.085920520286891e-07
23 O 0 1.3921720665166504e-06
additional O 0 3.5322102576174075e-06
MPS B-Disease 1 0.9999771118164062
IVA I-Disease 1 0.9999998807907104
patients O 0 0.10305069386959076
( O 0 8.986708621705475e-07
15 O 0 2.6610624104250746e-07
from O 0 2.093352122756187e-07
Australia O 0 3.450034284924186e-07
, O 0 6.55573444419133e-08
8 O 0 1.1491636087157531e-07
from O 0 1.2976629193417466e-07
Northern O 0 6.986027187849686e-07
Ireland O 0 1.3745049045610358e-06
) O 0 2.299349830536812e-07
, O 0 6.155723752954145e-08
with O 0 1.2685350725405442e-07
various O 0 6.554121796398249e-07
clinical O 0 0.002505731303244829
phenotypes O 1 0.637129008769989
( O 0 2.717892493819818e-05
severe O 1 0.5062010884284973
, O 0 9.443982094126113e-07
16 O 0 1.3688407989320694e-06
cases O 0 5.41596250513976e-07
; O 0 3.426556816066295e-07
intermediate O 0 8.829834428070171e-07
, O 0 2.5659687707957346e-07
4 O 0 1.2551646477731992e-06
cases O 0 2.8206950446474366e-06
; O 0 5.11845655637444e-06
mild O 0 0.06918177008628845
, O 0 1.3389130799623672e-06
3 O 0 2.7465391667647054e-06
cases O 0 4.012820681964513e-06
) O 0 7.6083047133579385e-06
. O 0 1.1825217370642349e-05

We O 0 1.3043002581980545e-05
found O 0 2.9656207516381983e-06
two O 0 6.727000823048002e-07
common O 0 2.8709075650112936e-06
mutations O 0 1.289225292566698e-05
that O 0 2.382275994250449e-07
together O 0 3.5212823945585114e-07
accounted O 0 5.931815394433215e-07
for O 0 7.78195072825838e-08
32 O 0 2.809248655921692e-07
% O 0 7.522497469381051e-08
of O 0 5.21410257192656e-08
the O 0 2.7241546263212513e-07
44 O 0 1.6806766325316858e-06
unrelated O 0 1.3888163266528863e-05
alleles O 0 2.362379018450156e-05
in O 0 2.623216687425156e-06
these O 0 4.7374442146974616e-06
patients O 0 0.0007900819764472544
. O 0 4.099700163351372e-05

One O 0 1.4144477972877212e-05
is O 0 1.9825918116112007e-06
the O 0 1.2847253856307361e-06
T312S O 0 7.554334297310561e-05
mutation O 0 2.4875540475477464e-05
, O 0 6.383274353538582e-07
a O 0 1.0017159866038128e-06
novel O 0 4.340366103861015e-06
mutation O 0 1.4806026229052804e-05
found O 0 1.4878334013701533e-06
exclusively O 0 3.2823693345562788e-06
in O 0 1.4409810319193639e-05
milder O 1 0.9972986578941345
patients O 1 0.5718542337417603
. O 0 8.924544090405107e-05

The O 0 1.1648059626168106e-05
other O 0 9.423865208191273e-07
is O 0 3.417581808662362e-07
the O 0 3.596202589051245e-07
previously O 0 1.6533711004740326e-06
described O 0 3.4647043776203645e-06
I113F O 0 2.1481751900864765e-05
that O 0 1.0162899570786976e-06
produces O 0 9.089501872949768e-06
a O 0 2.5319364794995636e-05
severe O 1 0.9991458654403687
phenotype O 1 0.9766602516174316
. O 0 0.00011934373469557613

The O 0 4.0955575968837366e-05
I113F O 0 0.0002628500806167722
and O 0 8.621231245342642e-06
T312S O 0 0.0001762365864124149
mutations O 0 5.180009247851558e-05
accounted O 0 2.4108846901071956e-06
for O 0 2.7332811214364483e-07
8 O 0 8.168458407453727e-07
( O 0 4.101946728951589e-07
18 O 0 2.9486304242709593e-07
% O 0 1.3011774058213632e-07
) O 0 1.0979417197631847e-07
and O 0 7.42798320629845e-08
6 O 0 4.1390936189600325e-07
( O 0 2.7900435384253797e-07
14 O 0 2.5184630203511915e-07
% O 0 1.0258116844852339e-07
) O 0 1.0275957151861803e-07
of O 0 1.4967379513564083e-07
44 O 0 1.7062125152733643e-06
unrelated O 0 2.029261850111652e-05
alleles O 0 4.143721525906585e-05
, O 0 2.3200582290883176e-06
respectively O 0 2.2651409381069243e-05
. O 0 2.7477139155962504e-05

The O 0 3.092750193900429e-05
relatively O 0 2.442901131871622e-05
high O 0 1.0537800335441716e-05
residual O 0 4.52111016784329e-05
GALNS O 0 0.00036818484659306705
activity O 0 6.380209470080445e-06
seen O 0 1.9889359919034177e-06
when O 0 2.997398667048401e-07
the O 0 3.075819279274583e-07
T312S O 0 6.8415956775425e-06
mutant O 0 8.219868504966144e-06
cDNA O 0 7.705266398261301e-06
is O 0 4.4887198669130157e-07
overexpressed O 0 1.2150470865890384e-05
in O 0 5.569661993831687e-07
mutant O 0 1.148847059084801e-05
cells O 0 3.098700972259394e-06
provides O 0 3.067850968818675e-07
an O 0 1.3326895498266822e-07
explanation O 0 6.01741817263246e-07
for O 0 1.8313579630557797e-07
the O 0 2.7540561404748587e-06
mild O 1 0.9997367262840271
phenotype O 1 0.9986605644226074
in O 0 5.705521834897809e-05
patients O 0 0.00019955971220042557
with O 0 1.5744053598609753e-06
this O 0 8.901599358068779e-06
mutation O 0 0.0003647974517662078
. O 0 3.580293559934944e-05

The O 0 2.0849493012065068e-05
distribution O 0 6.113162726251176e-06
and O 0 6.061647468413867e-07
relative O 0 1.211512085319555e-06
frequencies O 0 1.4797140011069132e-06
of O 0 9.75743859044087e-08
the O 0 3.069551155476802e-07
I113F O 0 7.655614354007412e-06
and O 0 4.937512017022527e-07
T312S O 0 0.00014168034249451011
mutations O 0 1.956417145265732e-05
in O 0 4.246545017849712e-07
Australia O 0 5.550975288315385e-07
corresponded O 0 8.023952773328347e-07
to O 0 1.216041169982418e-07
those O 0 5.340694286815051e-08
observed O 0 2.210484808529145e-07
in O 0 7.405504476309943e-08
Northern O 0 2.8408348384800775e-07
Ireland O 0 7.495727913919836e-07
and O 0 6.619715264832848e-08
are O 0 1.8019832737081742e-08
unique O 0 5.3133728528109714e-08
to O 0 3.914018620321258e-08
these O 0 2.7069193109241496e-08
two O 0 5.3144063372201344e-08
populations O 0 2.4377072804782074e-07
, O 0 7.233570187281657e-08
suggesting O 0 5.708957360184286e-07
that O 0 8.290197683891165e-08
both O 0 1.6628399635010283e-07
mutations O 0 3.6789679143112153e-06
were O 0 1.5070219205881585e-07
probably O 0 3.2998408983075933e-07
introduced O 0 7.900110290393059e-07
to O 0 1.1534291388670681e-07
Australia O 0 2.3814217797735182e-07
by O 0 1.2129451931741642e-07
Irish O 0 5.101484816805169e-07
migrants O 0 6.237100933503825e-07
during O 0 5.542733561014757e-07
the O 0 6.677248052255891e-07
19th O 0 9.39832807489438e-06
century O 0 2.551740726630669e-05
. O 0 2.2124359020381235e-05

Haplotype O 0 0.009975401684641838
analysis O 0 0.00010050159471575171
using O 0 1.4721451407240238e-05
6 O 0 1.1402003110561054e-05
RFLPs O 0 6.96705756126903e-05
provides O 0 2.1885430214751977e-06
additional O 0 7.992273935997218e-07
data O 0 1.1493766578496434e-06
that O 0 1.2516642300397507e-07
the O 0 3.7578882938760216e-07
I113F O 0 3.2287734939018264e-05
mutation O 0 9.101064279093407e-06
originated O 0 3.073607103942777e-06
from O 0 8.974170100373158e-07
a O 0 1.7564425434102304e-06
common O 0 8.697851626493502e-06
ancestor O 0 6.813987420173362e-05
. O 0 3.1351522920886055e-05

The O 0 1.8374566934653558e-05
other O 0 2.707916337385541e-06
9 O 0 8.741125384403858e-06
novel O 0 9.32455986912828e-06
mutations O 0 4.365303539088927e-05
identified O 0 2.7115343073091935e-06
in O 0 3.175296967583563e-07
these O 0 1.9771754011799203e-07
23 O 0 8.344613888766617e-06
patients O 0 2.5080491468543187e-05
were O 0 1.9281884533484117e-07
each O 0 7.464554840908022e-08
limited O 0 8.659197874294478e-07
to O 0 3.3108923958025116e-07
a O 0 1.1818956409115344e-06
single O 0 4.501629064179724e-06
family O 0 2.2105885363998823e-05
. O 0 1.607390004210174e-05

These O 0 1.094132585421903e-05
data O 0 5.986537416902138e-06
provide O 0 1.2025369642287842e-06
further O 0 4.693159496582666e-07
evidence O 0 2.3732914655738568e-07
for O 0 1.0226722224615514e-07
extensive O 0 1.476660600019386e-06
allelic O 0 3.9843125705374405e-05
heterogeneity O 0 5.2869680075673386e-05
in O 0 6.255619155126624e-06
MPS B-Disease 1 0.9950056672096252
IVA I-Disease 1 0.9957830905914307
in O 0 2.631307097544777e-06
British O 0 0.00023462520039174706
- O 0 0.04976693168282509
Irish O 0 5.8871017245110124e-05
patients O 0 3.2571115298196673e-05
and O 0 1.1545792233391694e-07
provide O 0 1.1334122973494232e-07
evidence O 0 1.5790892859968153e-07
for O 0 7.458093875811755e-08
their O 0 2.939331693596614e-07
transmission O 0 0.0002967204782180488
to O 0 2.770956939457392e-07
Australia O 0 4.105347954919125e-07
by O 0 2.4708776891202433e-07
British O 0 5.870154382137116e-06
- O 0 1.753500328049995e-05
Irish O 0 4.024548161396524e-06
migrants O 0 5.481427251652349e-06
. O 0 3.6281815027905395e-06
. O 0 1.4626765732828062e-05

Identification O 0 7.214686775114387e-05
of O 0 1.4398272469406947e-05
constitutional O 0 0.000234849241678603
WT1 O 1 0.997603714466095
mutations O 0 0.006002579815685749
, O 0 3.5149082577845547e-06
in O 0 3.833058599411743e-06
patients O 0 5.075010994914919e-05
with O 0 3.6384931263455655e-06
isolated O 0 0.486006498336792
diffuse B-Disease 1 0.9999996423721313
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 1.5569074776067282e-06
and O 0 3.0813856710665277e-07
analysis O 0 9.170145744974434e-07
of O 0 6.607567115679558e-07
genotype O 0 0.37995368242263794
/ O 1 0.6689738035202026
phenotype O 0 0.009393712505698204
correlations O 0 6.494071385532152e-06
by O 0 3.791419942444918e-07
use O 0 4.4065879478694114e-07
of O 0 2.534783334340318e-07
a O 0 4.127750344196102e-06
computerized O 0 0.004061117302626371
mutation O 0 0.00018157904560212046
database O 0 5.0614584324648604e-05
. O 0 3.261400343035348e-05

Constitutional O 0 0.0005122090224176645
mutations O 0 0.00034531307755969465
of O 0 3.397095042600995e-06
the O 0 3.4695319754973752e-06
WT1 O 0 0.0016586406854912639
gene O 0 1.6118721759994514e-05
, O 0 8.913245892472332e-07
encoding O 0 4.960027581546456e-06
a O 0 2.125037553923903e-06
zinc O 0 9.55563155002892e-05
- O 0 1.2101715583412442e-05
finger O 0 8.303010872623418e-06
transcription O 0 5.2675486585940234e-06
factor O 0 1.4066132507650764e-06
involved O 0 6.157861776046047e-07
in O 0 1.07119910808251e-06
renal O 0 0.3060902953147888
and O 0 1.0870184041777975e-06
gonadal O 0 0.0017546243034303188
development O 0 1.9394765331526287e-06
, O 0 1.757743461894279e-07
are O 0 5.570725036818658e-08
found O 0 1.761112571330159e-07
in O 0 2.2584056580399192e-07
most O 0 5.571637871071289e-07
patients O 0 3.5355507861822844e-05
with O 0 7.680405360588338e-06
Denys B-Disease 1 0.9993687272071838
- I-Disease 1 0.9998741149902344
Drash I-Disease 1 0.9999966621398926
syndrome I-Disease 1 1.0
( O 0 2.5509960323688574e-05
DDS B-Disease 1 0.9999984502792358
) O 0 3.8081143429735675e-06
, O 0 1.243471956513531e-06
or O 0 1.4162984371068887e-05
diffuse B-Disease 1 0.9997846484184265
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 0.000686164537910372
DMS B-Disease 1 0.9928808212280273
) O 0 1.4415021496461122e-06
associated O 0 1.8865903257392347e-06
with O 0 9.886124416880193e-07
pseudohermaphroditism B-Disease 1 0.9972901344299316
and O 0 1.039023027260555e-05
/ O 0 0.01097451988607645
or O 0 5.255169890006073e-05
Wilms B-Disease 1 0.9996373653411865
tumor I-Disease 1 0.9857924580574036
( O 0 8.711385453352705e-05
WT B-Disease 1 0.884678840637207
) O 0 2.191834573750384e-05
. O 0 2.8353280868032016e-05

Most O 0 0.000148302991874516
mutations O 0 0.2738654315471649
in O 0 0.001994021702557802
DDS B-Disease 1 1.0
patients O 1 0.9985474944114685
lie O 0 4.725162943941541e-05
in O 0 3.1777155982126715e-06
exon O 0 6.17855039308779e-05
8 O 0 3.3154155971715227e-06
or O 0 1.1574527434277115e-06
exon O 0 1.2194768714834936e-05
9 O 0 1.9013018572877627e-06
, O 0 5.172046257939655e-07
encoding O 0 6.292812486208277e-06
zinc O 0 3.205597749911249e-05
finger O 0 1.1101422387582716e-05
2 O 0 1.3055368981440552e-06
or O 0 7.716811296631931e-07
zinc O 0 8.15451676317025e-06
finger O 0 2.501019707779051e-06
3 O 0 3.768823830796464e-07
, O 0 1.0005820172409585e-07
respectively O 0 2.3444319197096775e-07
, O 0 5.53159189564667e-08
with O 0 7.161743553751876e-08
a O 0 4.954096084475168e-07
hot O 0 1.10893588498584e-05
spot O 0 5.49265723748249e-06
( O 0 2.3342772692558356e-06
R394W O 0 1.4996331628935877e-05
) O 0 1.0677537147785188e-06
in O 0 2.1773387288703816e-06
exon O 0 7.482246292056516e-05
9 O 0 1.8907649064203724e-05
. O 0 1.4992042451922316e-05

We O 0 2.4289674911415204e-05
analyzed O 0 3.3477241231594235e-05
a O 0 2.812813590935548e-06
series O 0 2.7681253413902596e-06
of O 0 4.599117175985157e-07
24 O 0 1.8030332284979522e-05
patients O 0 3.40228398272302e-05
, O 0 2.4562783096371277e-07
10 O 0 3.994113910721353e-07
with O 0 1.0287051281920867e-06
isolated B-Disease 0 0.0009466687915846705
DMS I-Disease 1 0.9982269406318665
( O 0 7.65403819968924e-06
IDMS B-Disease 0 0.0017902725376188755
) O 0 5.911654170631664e-07
, O 0 1.147826296232779e-07
10 O 0 2.264604006541049e-07
with O 0 4.3464697796480323e-07
DDS B-Disease 1 0.9999997615814209
, O 0 4.3804257643387245e-07
and O 0 2.3809721483303292e-07
4 O 0 1.1869695981658879e-06
with O 0 6.173212113935733e-06
urogenital B-Disease 1 0.9999657869338989
abnormalities I-Disease 1 0.9999594688415527
and O 0 2.0204410247970372e-05
/ O 0 0.12569260597229004
or O 0 6.124930951045826e-05
WT B-Disease 1 0.994239091873169
. O 0 5.42569650860969e-05

We O 0 0.00010011812264565378
report O 0 0.00012640765635296702
WT1 O 0 0.027440322563052177
heterozygous O 0 0.00206297030672431
mutations O 0 0.00028688745805993676
in O 0 3.107952352365828e-06
16 O 0 1.2622200301848352e-05
patients O 0 4.9538106395630166e-05
, O 0 2.7345637931830424e-07
4 O 0 7.017517873464385e-07
of O 0 2.990685743498034e-07
whom O 0 3.4430306641297648e-06
presented O 0 1.07859250420006e-05
with O 0 2.5291325073339976e-05
IDMS B-Disease 1 0.9755867719650269
. O 0 0.00010201471741311252

One O 0 1.4170509530231357e-05
male O 0 8.519785296812188e-06
and O 0 1.4066655467104283e-06
two O 0 2.6359107323514763e-06
female O 0 3.75770905520767e-05
IDMS B-Disease 1 0.9995666146278381
patients O 0 0.01809358224272728
with O 0 6.930968083906919e-05
WT1 O 1 0.9997894167900085
mutations O 0 0.27050644159317017
underwent O 1 0.9799126386642456
normal O 0 0.0005383154493756592
puberty O 0 0.0023623136803507805
. O 0 8.589073695475236e-05

Two O 0 8.337566396221519e-05
mutations O 0 0.001575573580339551
associated O 0 2.8914331778651103e-05
with O 0 3.948438461520709e-06
IDMS B-Disease 0 0.3494003117084503
are O 0 3.023481554009777e-07
different O 0 1.6691873838681204e-07
from O 0 3.512602120281372e-07
those O 0 6.583451863662049e-07
described O 0 9.712957398733124e-05
in O 0 0.0011832785094156861
DDS B-Disease 1 1.0
patients O 1 0.9984915256500244
. O 0 0.00010177908552577719

No O 0 0.00016837636940181255
WT1 O 1 0.9573202729225159
mutations O 0 0.006532446946948767
were O 0 4.5219944695418235e-06
detected O 0 9.747682270244695e-06
in O 0 4.341274859598343e-07
the O 0 2.9956211733406235e-07
six O 0 1.0732380815170472e-06
other O 0 2.109228262270335e-06
IDMS B-Disease 1 0.9999662637710571
patients O 0 0.07634279876947403
, O 0 1.8207140328740934e-06
suggesting O 0 2.0513851268333383e-05
genetic O 0 1.0811639185703825e-05
heterogeneity O 0 2.1637100871885195e-05
of O 0 1.2328048342169495e-06
this O 0 3.507857763906941e-05
disease O 1 0.8224645853042603
. O 0 5.08176235598512e-05

We O 0 8.148659981088713e-05
analyzed O 0 0.00040133108268491924
genotype O 1 0.6364743709564209
/ O 1 0.9104923009872437
phenotype O 0 0.2992064952850342
correlations O 0 3.637602276285179e-05
, O 0 3.1062316452334926e-07
on O 0 1.3128767761827476e-07
the O 0 7.280757330363485e-08
basis O 0 5.7048108459412106e-08
of O 0 4.0794557065737536e-08
the O 0 1.7538069130296208e-07
constitution O 0 5.159089937478711e-07
of O 0 1.0406272821228413e-07
a O 0 1.8649257071956526e-06
WT1 O 0 0.005961644928902388
mutation O 0 8.649122719361912e-06
database O 0 9.193279879582406e-07
of O 0 1.8876254159749806e-07
84 O 0 4.3100567381770816e-06
germ O 0 0.020732231438159943
- O 0 0.004421771503984928
line O 0 3.3981366868829355e-05
mutations O 0 1.4341674614115618e-05
, O 0 1.112919889578734e-07
to O 0 1.2436730401077511e-07
compare O 0 5.176906938686443e-07
the O 0 1.126941029383488e-07
distribution O 0 2.3244378155595768e-07
and O 0 1.2323341991304915e-07
type O 0 9.651799928178662e-07
of O 0 1.6590176699082804e-07
mutations O 0 1.200110637000762e-05
, O 0 1.0675852024633059e-07
according O 0 2.0678494649928325e-07
to O 0 2.2602047522468638e-07
the O 0 8.301857974402083e-07
different O 0 4.528890713118017e-06
symptoms O 1 0.8503602147102356
. O 0 2.8683634809567593e-05

This O 0 1.8780596292344853e-05
demonstrated O 0 1.5484065443160944e-05
( O 0 1.6357597587557393e-06
1 O 0 4.999312182007998e-07
) O 0 1.7053197609584458e-07
the O 0 1.9610668289260502e-07
association O 0 1.4309391644928837e-06
between O 0 5.534039360099996e-07
mutations O 0 4.953192274115281e-06
in O 0 2.7970048677161685e-07
exons O 0 4.2922051761706825e-06
8 O 0 6.801630547670356e-07
and O 0 1.7983305156121787e-07
9 O 0 9.51587480813032e-07
and O 0 1.0739588560682023e-06
DMS B-Disease 1 0.8818631172180176
; O 0 9.849094340097508e-07
( O 0 4.471134786854236e-07
2 O 0 4.122359200664505e-07
) O 0 3.696640362704784e-07
among O 0 4.208309576370084e-07
patients O 0 9.253794814867433e-06
with O 0 1.4639679193351185e-06
DMS B-Disease 1 0.9596045613288879
, O 0 2.917242341027304e-07
a O 0 3.4343298693784163e-07
higher O 0 4.2446421844033466e-07
frequency O 0 1.210740606438776e-06
of O 0 2.3193027232082386e-07
exon O 0 1.3033490176894702e-05
8 O 0 1.8948323941003764e-06
mutations O 0 6.735154784109909e-06
among O 0 5.079260745333158e-07
46 O 0 2.905225301219616e-06
, O 0 9.017426236823667e-06
XY O 1 0.9923074245452881
patients O 0 5.085164593765512e-05
with O 0 6.180029572533385e-07
female O 0 2.3361480998573825e-06
phenotype O 0 0.00011186057236045599
than O 0 2.3365126367025368e-07
among O 0 2.074195322165906e-07
46 O 0 2.231940015917644e-06
, O 0 7.68776226323098e-06
XY O 1 0.9986251592636108
patients O 0 9.208805568050593e-05
with O 0 5.831481075802003e-07
sexual O 0 1.6939779925451148e-06
ambiguity O 0 1.8796886251948308e-06
or O 0 8.02011243195011e-07
male O 0 3.1989820854505524e-06
phenotype O 0 0.003615659661591053
; O 0 7.245029678415449e-07
and O 0 2.538905903293198e-07
( O 0 3.968893906858284e-07
3 O 0 4.4399294552022184e-07
) O 0 2.793020144054026e-07
statistically O 0 5.301397436596744e-07
significant O 0 2.657575066677964e-07
evidence O 0 3.932790946237219e-07
that O 0 2.4217672489612596e-07
mutations O 0 3.0842836622468894e-06
in O 0 2.67918011331858e-07
exons O 0 2.253729235235369e-06
8 O 0 4.1589609622860735e-07
and O 0 2.0111900767005864e-07
9 O 0 1.4565620176654193e-06
preferentially O 0 5.411401616584044e-06
affect O 0 1.1980829413005267e-06
amino O 0 7.781756039548782e-07
acids O 0 3.9977683741199144e-07
with O 0 1.0591944032967149e-07
different O 0 1.6965279314717918e-07
functions O 0 1.2286909623071551e-06
. O 0 1.9822855392703786e-06
. O 0 1.1622762031038292e-05

The O 0 9.266469714930281e-05
185delAG O 0 0.0069717830047011375
BRCA1 O 0 0.0671396255493164
mutation O 0 9.857989789452404e-05
originated O 0 6.686534561595181e-06
before O 0 7.669372052987455e-07
the O 0 3.3774307439671247e-07
dispersion O 0 1.934370857270551e-06
of O 0 8.596437339747354e-08
Jews O 0 3.4614075161698565e-07
in O 0 1.2618998823654692e-07
the O 0 1.5048389911953564e-07
diaspora O 0 1.0636214256010135e-06
and O 0 2.173172077846175e-07
is O 0 1.8668121981590957e-07
not O 0 3.113554214451142e-07
limited O 0 2.2597034785576398e-06
to O 0 4.066314886586042e-06
Ashkenazim O 0 0.000591944670304656
. O 0 4.189327955828048e-05

The O 0 9.57661250140518e-05
185delAG O 0 0.0015222018118947744
mutation O 0 0.0003816995886154473
in O 0 1.5223294212773908e-05
BRCA1 O 0 0.000395255716284737
is O 0 1.3010748034503195e-06
detected O 0 1.2140914805058856e-05
in O 0 8.559131856600288e-07
Ashkenazi O 0 1.8992586774402298e-05
Jews O 0 7.195479838628671e-07
both O 0 2.627382684750046e-07
in O 0 2.6287561922799796e-06
familial B-Disease 1 0.996426522731781
breast I-Disease 1 0.9999979734420776
and I-Disease 1 0.9993857145309448
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
and O 0 5.267596634439542e-07
in O 0 2.1710798137064558e-07
the O 0 2.5845824325188005e-07
general O 0 2.0377106011437718e-06
population O 0 4.023489054816309e-06
. O 0 1.5032558621896897e-05

All O 0 3.778432437684387e-05
tested O 0 0.00035066099371761084
Ashkenazi O 0 0.0014467851724475622
mutation O 0 0.00012940372107550502
carriers O 0 2.2115920728538185e-05
share O 0 2.0121583474974614e-06
the O 0 6.670775292150211e-07
same O 0 8.708573204785353e-07
allelic O 0 4.212732528685592e-05
pattern O 0 1.2413164768076967e-05
at O 0 2.034582394117024e-06
the O 0 4.452066150406608e-06
BRCA1 O 0 0.0005547354812733829
locus O 0 0.0003077759174630046
. O 0 4.299054489820264e-05

Our O 0 1.8545944840298034e-05
previous O 0 1.4260606803873088e-05
study O 0 4.174894002062501e-06
showed O 0 3.050118721148465e-06
that O 0 2.1773355740606348e-07
this O 0 4.1936783645724063e-07
Ashkenazi O 0 0.0003580400953069329
mutation O 0 1.1877274118887726e-05
also O 0 4.7453394813601335e-07
occurs O 0 4.644237208140112e-07
in O 0 1.9773337101014477e-07
Iraqi O 0 6.827581273682881e-07
Jews O 0 5.324796461536607e-07
with O 0 3.0707428777532186e-07
a O 0 2.7195883376407437e-06
similar O 0 2.0008696083095856e-05
allelic O 0 0.0007834500283934176
pattern O 0 0.0004656629462260753
. O 0 4.821507536689751e-05

We O 0 1.1898791854036972e-05
extended O 0 1.1678181181196123e-05
our O 0 1.054712356562959e-06
analysis O 0 7.230700020954828e-07
to O 0 1.5126879304716567e-07
other O 0 1.0522814619662313e-07
non O 0 8.712394219401176e-07
- O 0 4.8847000471141655e-06
Ashkenazi O 0 7.798451406415552e-06
subsets O 0 2.167884531445452e-06
354 O 0 2.9268048820085824e-06
of O 0 1.864815715180157e-07
Moroccan O 0 3.3702281143632717e-06
origin O 0 8.604029062553309e-07
, O 0 3.1649994980398333e-07
200 O 0 6.702794621560315e-07
Yemenites O 0 1.6658155800541863e-05
and O 0 3.995771464815334e-07
150 O 0 1.7953898350242525e-06
Iranian O 0 7.724874194536824e-06
Jews O 0 1.4711935364175588e-05
. O 0 2.1023737645009533e-05

Heteroduplex O 0 0.006252717692404985
analysis O 0 0.00010655121877789497
complemented O 0 5.7433582696830854e-05
by O 0 3.0138999136397615e-06
direct O 0 3.041935542569263e-06
DNA O 0 5.544929081224836e-06
sequencing O 0 2.6359512048657052e-06
of O 0 5.715080533263972e-07
abnormally O 0 5.844177212566137e-05
migrating O 0 7.162751899159048e-06
bands O 0 5.5611344578210264e-06
were O 0 1.914814674819354e-06
employed O 0 2.7443256840342656e-05
. O 0 2.12490267585963e-05

Four O 0 9.348154890176374e-06
of O 0 1.4921558886271669e-06
Moroccan O 0 1.4247883882489987e-05
origin O 0 3.0898331715434324e-06
( O 0 8.03395266757434e-07
1 O 0 2.570090487097332e-07
. O 0 6.546987663114123e-08
1 O 0 1.3675226284703967e-07
% O 0 1.0629160840380791e-07
) O 0 7.286925551852619e-08
and O 0 5.363274269143403e-08
none O 0 7.636181464931724e-08
of O 0 3.849429575097929e-08
the O 0 2.2865332027777185e-07
Yemenites O 0 3.753794590011239e-05
or O 0 2.519464885608613e-07
Iranians O 0 3.518831874771422e-07
was O 0 3.967800239479402e-07
a O 0 5.10665415731637e-07
carrier O 0 8.53622805152554e-06
of O 0 2.7660328782985744e-07
the O 0 2.5612287117837695e-06
185delAG O 0 0.0009152099373750389
mutation O 0 0.00027839673566631973
. O 0 4.140404053032398e-05

BRCA1 O 1 0.919190526008606
allelic O 0 0.08000838756561279
patterns O 0 0.0009683439275249839
were O 0 5.380695256462786e-06
determined O 0 2.2963877199799754e-06
for O 0 1.5543706410880986e-07
four O 0 1.3043008095792175e-07
of O 0 7.598202955705347e-08
these O 0 7.191295736674874e-08
individuals O 0 7.82218947392721e-08
and O 0 6.425918996910696e-08
for O 0 7.436956650508364e-08
12 O 0 2.737723718837515e-07
additional O 0 4.27972082661654e-07
non O 0 1.9039728158531943e-06
- O 0 3.5475204640533775e-05
Ashkenazi O 0 5.590896398643963e-05
185delAG O 0 9.159727051155642e-05
mutation O 0 3.539423778420314e-05
carriers O 0 1.673506267252378e-05
who O 0 1.6460882761748508e-05
had O 1 0.5938135385513306
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0002856208593584597

Six O 0 7.369619561359286e-05
non O 0 5.1212988182669505e-05
- O 0 0.00017931209004018456
Ashkenazi O 0 0.00015791089390404522
individuals O 0 9.282753694606072e-07
shared O 0 7.47772105569311e-07
the O 0 5.202857096264779e-07
common O 0 2.68855046670069e-06
Ashkenazi O 0 0.0035415273159742355
haplotype O 0 0.005538464989513159
, O 0 4.309684982217732e-07
four O 0 2.2618499428972427e-07
had O 0 4.4478548488768865e-07
a O 0 3.5084309502053657e-07
closely O 0 1.8484918200556422e-06
related O 0 1.784303321983316e-06
pattern O 0 3.2257171369565185e-06
, O 0 9.051598937048766e-08
and O 0 7.834523074734534e-08
the O 0 2.3021144102131075e-07
rest O 0 1.2823212500734371e-06
( O 0 1.0680307696020463e-06
n O 0 5.157573014002992e-06
= O 0 4.051763880852377e-06
6 O 0 6.569077299900528e-07
) O 0 3.648597441952006e-07
displayed O 0 8.898171017790446e-07
a O 0 1.8685253735384322e-06
distinct O 0 1.8660019122762606e-05
BRCA1 O 0 0.0014850724255666137
allelic O 0 0.0014299747999757528
pattern O 0 0.0005552938091568649
. O 0 0.00010475773160578683

We O 0 1.1810892829089426e-05
conclude O 0 1.5685956896049902e-05
that O 0 8.672031981404871e-07
the O 0 1.7295874386036303e-06
185delAG O 0 0.0011236420832574368
BRCA1 O 0 0.03820651024580002
mutation O 0 5.727240568376146e-05
occurs O 0 1.8076515289067174e-06
in O 0 2.814059030242788e-07
some O 0 1.443646624466055e-07
non O 0 1.1138940863020252e-06
- O 0 2.2124570023152046e-05
Ashkenazi O 0 5.2467778004938737e-05
populations O 0 1.6567740885875537e-06
at O 0 9.119032142734795e-07
rates O 0 3.055685283470666e-06
comparable O 0 1.3050165534878033e-06
with O 0 2.7336719199411164e-07
that O 0 5.408447236732172e-07
of O 0 1.6990924223136972e-06
Ashkenazim O 0 0.0005292324349284172
. O 0 4.9633388698566705e-05

The O 0 1.3205949471739586e-05
majority O 0 9.206754839397036e-06
of O 0 9.529769045002467e-07
Jewish O 0 1.075769523595227e-05
185delAG O 0 0.0015180787304416299
mutation O 0 9.023752500070259e-05
carriers O 0 1.3142014722689055e-05
have O 0 3.033329676327412e-07
a O 0 5.185776785765484e-07
common O 0 9.431849434804462e-07
allelic O 0 2.2607620849157684e-05
pattern O 0 6.049956937204115e-06
, O 0 1.9409813489801309e-07
supporting O 0 2.6926997520604345e-07
the O 0 2.0951316059836245e-07
founder O 0 7.311076387850335e-06
effect O 0 8.259576702585036e-07
notion O 0 4.6726700020371936e-07
, O 0 8.085144287406365e-08
but O 0 8.227910797131699e-08
dating O 0 4.858020474785008e-07
the O 0 1.8718806416018197e-07
mutations O 0 2.0108768694626633e-06
origin O 0 1.3196363113365805e-07
to O 0 1.0235894620791441e-07
an O 0 1.085419398805243e-07
earlier O 0 1.2613359103852417e-06
date O 0 7.759627465020458e-07
than O 0 2.5631391054048436e-07
currently O 0 1.4060299236007268e-06
estimated O 0 5.575982868322171e-06
. O 0 1.2371529919619206e-05

However O 0 3.0999282898847014e-05
, O 0 1.7119890571848373e-06
the O 0 5.305990384840698e-07
different O 0 3.127517516077205e-07
allelic O 0 1.9474411601549946e-05
pattern O 0 6.930478775757365e-06
at O 0 9.7903398454946e-07
the O 0 1.6148150052686105e-06
BRCA1 O 0 0.00013865517394151539
locus O 0 1.1665558304230217e-05
even O 0 4.549399932329834e-07
in O 0 1.9983937704637356e-07
some O 0 1.2568627028031187e-07
Jewish O 0 2.05464857572224e-06
mutation O 0 1.734335091896355e-05
carriers O 0 7.384371656371513e-06
, O 0 3.534214840783534e-07
might O 0 5.672774250342627e-07
suggest O 0 6.219370902726951e-07
that O 0 2.0260770838831377e-07
the O 0 1.2955684951521107e-06
mutation O 0 3.381094575161114e-05
arose O 0 1.4202491911419202e-05
independently O 0 1.822971535148099e-05
. O 0 6.095727258070838e-06
. O 0 2.9470686058630235e-05

Crystal O 0 0.0008664852939546108
structure O 0 3.867231498588808e-05
of O 0 1.93206460608053e-06
the O 0 8.905751201382373e-06
hemochromatosis B-Disease 1 0.9999905824661255
protein O 0 2.9003947929595597e-05
HFE O 0 0.0063137938268482685
and O 0 9.396843552167411e-07
characterization O 0 2.5781523618206847e-06
of O 0 2.1470653166488773e-07
its O 0 1.135690354203689e-06
interaction O 0 2.5465760700171813e-06
with O 0 3.1914739793137414e-06
transferrin O 0 0.0005007301806472242
receptor O 0 0.0002674614079296589
. O 0 2.9648785130120814e-05

HFE O 1 0.8549182415008545
is O 0 4.25869548053015e-05
an O 0 1.6207724911510013e-05
MHC O 0 0.034838270395994186
- O 0 0.00015618746692780405
related O 0 2.8316806037764763e-06
protein O 0 9.945682677425793e-07
that O 0 1.1657495946337804e-07
is O 0 1.416510144736094e-07
mutated O 0 3.005705139003112e-06
in O 0 3.5682103316503344e-07
the O 0 1.2399608522173367e-06
iron B-Disease 1 0.5568850636482239
- I-Disease 1 0.9996969699859619
overload I-Disease 1 0.9999904632568359
disease I-Disease 1 0.9999966621398926
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.0007478875922970474

HFE O 0 0.03304315358400345
binds O 0 0.0005054703215137124
to O 0 4.398675446282141e-05
transferrin O 0 0.0005370004219003022
receptor O 0 0.00017041928367689252
( O 0 8.685037755640224e-06
TfR O 0 6.257841596379876e-05
) O 0 7.532316885772161e-07
and O 0 2.2185440684552304e-07
reduces O 0 1.764023522810021e-06
its O 0 3.513915771691245e-07
affinity O 0 1.2413191825544345e-06
for O 0 3.568393935893255e-07
iron O 0 1.630653059692122e-05
- O 0 5.23664948559599e-06
loaded O 0 3.422729605517816e-06
transferrin O 0 2.4056751499301754e-05
, O 0 1.3514038528228411e-06
implicating O 0 7.703142910031602e-05
HFE O 0 0.0036772103048861027
in O 0 7.5732100413006265e-06
iron O 0 0.0008157790289260447
metabolism O 0 0.000852263648994267
. O 0 4.2338360799476504e-05

The O 0 0.0002267080853926018
2 O 0 0.0002657550503499806
. O 0 0.00013285709428600967

6 O 0 0.00010471319546923041
A O 0 3.399987326702103e-05
crystal O 0 7.076095789670944e-05
structure O 0 5.808247806271538e-06
of O 0 8.517603760083148e-07
HFE O 0 0.0012382209533825517
reveals O 0 1.2308206351008266e-05
the O 0 4.7595344199180545e-07
locations O 0 1.3476637832354754e-06
of O 0 1.667195419940981e-06
hemochromatosis B-Disease 1 1.0
mutations O 0 0.00019293188233859837
and O 0 5.165859988665034e-07
a O 0 2.2919375624042004e-06
patch O 0 0.0089502464979887
of O 0 3.655023306237126e-07
histidines O 0 0.005799762438982725
that O 0 3.513218587158917e-07
could O 0 2.333840143364796e-07
be O 0 7.9035636701974e-08
involved O 0 3.315739718345867e-07
in O 0 1.872835468930134e-06
pH O 0 0.00025266926968470216
- O 0 0.0001225693558808416
dependent O 0 2.287419374624733e-05
interactions O 0 3.1318711990024894e-05
. O 0 2.617842983454466e-05

We O 0 1.717266241030302e-05
also O 0 5.139053428138141e-06
demonstrate O 0 6.947896054043667e-06
that O 0 1.7435386325814761e-06
soluble O 0 3.832387301372364e-05
TfR O 0 0.0001850880216807127
and O 0 2.1953369468974415e-06
HFE O 0 0.011893387883901596
bind O 0 1.4944722352083772e-05
tightly O 0 6.470406788139371e-06
at O 0 4.3245722736173775e-07
the O 0 1.7969058774269797e-07
basic O 0 7.000426194281317e-07
pH O 0 1.4055069641472073e-06
of O 0 6.573451827307508e-08
the O 0 2.31203500788979e-07
cell O 0 3.756999649340287e-05
surface O 0 3.5599136936070863e-06
, O 0 1.7469210433773696e-07
but O 0 1.0137794248521459e-07
not O 0 8.049646993413262e-08
at O 0 2.90058608243271e-07
the O 0 1.124649315897841e-06
acidic O 0 0.00011259867460466921
pH O 0 3.324626595713198e-05
of O 0 2.275034375998075e-06
intracellular O 0 0.00017095280054491013
vesicles O 0 0.0009540697210468352
. O 0 7.251997158164158e-05

TfR O 1 0.5578758716583252
HFE O 1 0.7621098160743713
stoichiometry O 0 0.0032014651224017143
( O 0 6.541615584865212e-05
2 O 0 8.773797162575647e-06
1 O 0 2.4124142328219023e-06
) O 0 1.0580348543953733e-06
differs O 0 3.5170237424608786e-06
from O 0 1.869471702775627e-06
TfR O 0 9.902564488584176e-05
transferrin O 0 6.484017649199814e-05
stoichiometry O 0 3.0576553399441764e-05
( O 0 1.1616293704719283e-06
2 O 0 4.4839410406893876e-07
2 O 0 3.647849382559798e-07
) O 0 1.8602561624447844e-07
, O 0 6.016684039877873e-08
implying O 0 4.649049571980868e-07
a O 0 1.1608072014723803e-07
different O 0 6.670183694268417e-08
mode O 0 5.27625900303974e-07
of O 0 5.696982086078606e-08
binding O 0 7.256377330122632e-07
for O 0 3.9205193047564535e-07
HFE O 0 0.00022904806246515363
and O 0 5.313843871590507e-07
transferrin O 0 3.114234277745709e-05
to O 0 9.234103686139861e-07
TfR O 0 0.00012140728358644992
, O 0 2.3034517937503551e-07
consistent O 0 3.9093708892323775e-07
with O 0 1.1376508979310529e-07
our O 0 2.899861328842235e-07
demonstration O 0 2.095070612995187e-06
that O 0 4.136520601605298e-07
HFE O 0 0.0001042383664753288
, O 0 5.744544182562095e-07
transferrin O 0 1.7774398656911217e-05
, O 0 5.34898788373539e-07
and O 0 9.243442491424503e-07
TfR O 0 9.484088514000177e-05
form O 0 2.6699287900555646e-06
a O 0 5.144300303072669e-06
ternary O 0 0.00011691644613165408
complex O 0 5.764406159869395e-05
. O 0 4.1231502109440044e-05

Identification O 0 5.711918856832199e-05
of O 0 3.748389190150192e-06
three O 0 1.9044558712266735e-06
novel O 0 1.2449037967598997e-05
mutations O 0 2.7573452825890854e-05
and O 0 2.7241989641879627e-07
a O 0 4.517234231116163e-07
high O 0 6.893051249790005e-07
frequency O 0 1.1306242413411383e-06
of O 0 1.006974628126045e-07
the O 0 7.86549946951709e-07
Arg778Leu O 0 0.0005666042561642826
mutation O 0 1.700963912298903e-05
in O 0 1.5712179219917743e-06
Korean O 0 1.2097586477466393e-05
patients O 0 8.276633161585778e-05
with O 0 1.3990134902996942e-05
Wilson B-Disease 0 0.33914732933044434
disease I-Disease 1 0.8990141153335571
. O 0 6.317272345768288e-05

Four O 0 0.00010567122808424756
mutations O 0 0.0006401933496817946
- O 0 9.847260662354529e-05
- O 0 2.2862592231831513e-05
R778L O 0 2.3185089958133176e-05
, O 0 5.37571224867861e-07
A874V O 0 6.2270423768495675e-06
, O 0 2.663946645498072e-07
L1083F O 0 6.181118351378245e-06
, O 0 2.6694809207583603e-07
and O 0 2.23331440452057e-07
2304delC O 0 3.11992916977033e-05
- O 0 1.7574748198967427e-05
- O 0 2.290967358931084e-06
in O 0 1.6734541929963598e-07
the O 0 2.7421032200436457e-07
copper O 0 2.861670964193763e-06
- O 0 2.3155334929469973e-06
transporting O 0 1.806486579880584e-06
enzyme O 0 3.6171777537674643e-06
, O 0 6.00402756845142e-07
P O 0 0.00014921504771336913
- O 0 1.9103141312371008e-05
type O 0 7.378831469395664e-06
ATPase O 0 4.071779039804824e-05
( O 0 8.013200272216636e-07
ATP7B O 0 1.2951823009643704e-05
) O 0 2.457262269217608e-07
, O 0 8.605196910593804e-08
were O 0 8.088337466460871e-08
identified O 0 3.92518842318168e-07
in O 0 3.3908534646798216e-07
Korean O 0 7.65700860938523e-06
Patients O 0 6.270577432587743e-05
with O 0 1.4268606719269883e-05
Wilson B-Disease 0 0.43325865268707275
disease I-Disease 1 0.7232126593589783
. O 0 4.381075996207073e-05

Arg778Leu O 0 0.0043064747005701065
, O 0 5.482943379320204e-06
the O 0 1.2181924375909148e-06
most O 0 7.308311182896432e-07
frequently O 0 6.030095391906798e-06
reported O 0 3.908262078766711e-05
mutation O 0 2.2961446575209266e-06
of O 0 8.129339335027908e-08
this O 0 1.3781931329504005e-07
enzyme O 0 9.764380592969246e-07
, O 0 1.1457494508704258e-07
was O 0 3.283874150383781e-07
found O 0 8.746529545078374e-08
in O 0 7.1967981796206e-08
six O 0 1.0446144216302855e-07
of O 0 8.432224518628573e-08
eight O 0 1.1869424270116724e-06
unrelated O 0 0.0009525710484012961
patients O 0 7.506344263674691e-05
studied O 0 2.2976057607593248e-06
, O 0 2.9120332101228996e-07
an O 0 4.792620984517271e-07
allele O 0 1.4227544852474239e-05
frequency O 0 7.360185918514617e-06
of O 0 1.1881542150149471e-06
37 O 0 2.3738130039419048e-05
. O 0 2.243944072688464e-05

5 O 0 4.2971616494469345e-05
% O 0 3.7063057334307814e-06
, O 0 5.066909238848893e-07
which O 0 2.509711691800476e-07
is O 0 1.5465353442323249e-07
considerably O 0 1.4256813756219344e-06
higher O 0 4.7117799795159954e-07
than O 0 8.973625398311924e-08
those O 0 1.019917874600651e-07
in O 0 2.0026330105338275e-07
other O 0 3.427504680075799e-07
Asian O 0 4.950500624545384e-06
populations O 0 2.7786447390099056e-05
. O 0 2.8897049560328014e-05

The O 0 2.7420130209065974e-05
novel O 0 2.0623205273295753e-05
single O 0 4.970871941623045e-06
nucleotide O 0 1.5779611203470267e-05
deletion O 0 2.1503066818695515e-05
, O 0 6.639491516580165e-07
2304delC O 0 1.9322531443322077e-05
, O 0 4.3219418444095936e-07
was O 0 1.4148321270113229e-06
found O 0 6.57884470456338e-07
in O 0 1.4256703479986754e-06
one O 0 4.8889737627177965e-06
patient O 0 0.0006876699044369161
. O 0 4.583705958793871e-05

Since O 0 0.00010006296361098066
a O 0 2.5318882762803696e-05
mutation O 0 6.31555012660101e-05
at O 0 6.021085482643684e-06
cDNA O 0 4.9370923079550266e-05
nucleotide O 0 3.223934254492633e-05
2302 O 0 0.00036932193324901164
( O 0 3.6639994505094364e-06
2302insC O 0 2.080295598716475e-05
) O 0 6.54802420285705e-07
had O 0 3.7467913216460147e-07
been O 0 1.0375236314530412e-07
previously O 0 4.246909668381704e-07
described O 0 8.364017958228942e-07
, O 0 6.412940933842037e-08
this O 0 3.9496629966606633e-08
region O 0 1.4668381709270761e-07
of O 0 8.470622248069049e-08
the O 0 6.836696115897212e-07
ATP7B O 0 0.11985239386558533
gene O 0 7.95882660895586e-05
may O 0 1.0296365871909074e-05
be O 0 6.112027790550201e-07
susceptible O 0 1.0254619155602995e-05
to O 0 2.397265916442848e-06
gene O 0 6.566383672179654e-05
rearrangements O 0 0.0008978747064247727
causing O 0 0.040174562484025955
Wilson B-Disease 0 0.1664149910211563
disease I-Disease 0 0.4998875856399536
. O 0 7.339279545703903e-05

Disruption O 0 0.0008319966145791113
of O 0 1.120702836487908e-05
splicing O 0 9.444227180210873e-05
regulated O 0 2.7410978873376735e-05
by O 0 1.7530587683722842e-06
a O 0 3.131366611341946e-06
CUG O 0 0.0006022955640219152
- O 0 4.9171932914759964e-05
binding O 0 2.197902722400613e-05
protein O 0 3.4508084354456514e-05
in O 0 7.794681005179882e-05
myotonic B-Disease 1 0.9999997615814209
dystrophy I-Disease 1 0.9999998807907104
. O 0 0.00024189401301555336

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.998012900352478
DM B-Disease 1 1.0
) O 0 4.8786918341647834e-05
is O 0 2.168035280192271e-06
caused O 0 6.068240054446505e-06
by O 0 7.510296882173861e-07
a O 0 1.7208512872457504e-06
CTG O 0 0.00014063800335861742
expansion O 0 3.6729870771523565e-06
in O 0 3.6383437418407993e-07
the O 0 3.304772633327957e-07
3 O 0 9.439237373953802e-07
untranslated O 0 1.630153928999789e-05
region O 0 2.280121179865091e-06
of O 0 9.379125458508497e-07
the O 0 2.0135434169787914e-05
DM B-Disease 1 0.9999997615814209
gene O 0 0.0008013761835172772
. O 0 6.501285679405555e-05

One O 0 4.022149005322717e-05
model O 0 4.9957434384850785e-05
of O 0 1.1040269782824907e-05
DM B-Disease 1 1.0
pathogenesis O 0 0.1963125318288803
suggests O 0 9.825557754084002e-06
that O 0 6.085772383812582e-07
RNAs O 0 1.1867491593875457e-05
from O 0 2.397763694261812e-07
the O 0 1.870791948022088e-07
expanded O 0 1.4013204463481088e-06
allele O 0 3.3216499559785007e-06
create O 0 4.297880593640002e-07
a O 0 2.797090417061554e-07
gain O 0 1.6901987009987351e-06
- O 0 2.8701219889626373e-06
of O 0 1.9626384073490044e-07
- O 0 9.002191291074269e-06
function O 0 8.11904726560897e-07
mutation O 0 1.7391278106515529e-06
by O 0 1.1361860430270099e-07
the O 0 2.0465023453652975e-07
inappropriate O 0 1.2290519180169213e-06
binding O 0 5.88199497997266e-07
of O 0 1.264040321302673e-07
proteins O 0 8.95380708243465e-07
to O 0 6.50373124244652e-07
the O 0 2.4809417027427116e-06
CUG O 0 0.0031195415649563074
repeats O 0 0.0003900451702065766
. O 0 3.7782378058182076e-05

Data O 0 9.785611473489553e-05
presented O 0 1.7011505406117067e-05
here O 0 1.984123855436337e-06
indicate O 0 1.9048118247155799e-06
that O 0 1.9617233704138926e-07
the O 0 3.891697986091458e-07
conserved O 0 3.906191068381304e-06
heterogeneous O 0 1.0789328371174634e-05
nuclear O 0 1.7266775103053078e-05
ribonucleoprotein O 0 0.00011462187831057236
, O 0 1.13998851247743e-06
CUG O 0 0.00013369560474529862
- O 0 1.1556533536349889e-05
binding O 0 2.96978964797745e-06
protein O 0 2.4221540115831885e-06
( O 0 1.0417587645861204e-06
CUG O 0 0.00010629215103108436
- O 0 4.7757501306477934e-05
BP O 0 4.2213221604470164e-05
) O 0 4.849910055781947e-07
, O 0 2.1077372025501973e-07
may O 0 5.688934834324755e-07
mediate O 0 2.8602876227523666e-06
the O 0 5.760794010711834e-07
trans O 0 2.4817158191581257e-05
- O 0 1.6286403479170986e-05
dominant O 0 3.3295661978627322e-06
effect O 0 1.4473097280642833e-06
of O 0 3.2660497595315974e-07
the O 0 2.249164253953495e-06
RNA O 0 4.618333696271293e-05
. O 0 2.761974246823229e-05

CUG O 0 0.49409815669059753
- O 0 0.09037557244300842
BP O 0 0.003511307993903756
was O 0 6.807205863879062e-06
found O 0 6.648032240264001e-07
to O 0 3.788427420658991e-07
bind O 0 1.6671747289365157e-06
to O 0 3.082587909375434e-07
the O 0 8.186754030248267e-07
human O 0 3.324398130644113e-05
cardiac O 1 0.9999927282333374
troponin O 1 0.9999547004699707
T O 0 0.2815414369106293
( O 0 3.3782855552999536e-06
cTNT O 0 2.222790317318868e-05
) O 0 1.085829012481554e-06
pre O 0 8.793901542958338e-06
- O 0 8.068050192377996e-06
messenger O 0 7.917768925835844e-06
RNA O 0 2.6217660433758283e-06
and O 0 4.40000349044567e-07
regulate O 0 4.087855813850183e-06
its O 0 3.0081168915785383e-06
alternative O 0 1.7275207937927917e-05
splicing O 0 0.00013088957348372787
. O 0 3.434180689509958e-05

Splicing O 0 0.0006567736272700131
of O 0 1.727079325064551e-05
cTNT O 0 0.0005121934227645397
was O 0 2.7109164875582792e-05
disrupted O 0 0.00026268299552612007
in O 0 4.826479562325403e-05
DM B-Disease 1 1.0
striated O 1 0.9901278614997864
muscle O 0 0.09271466732025146
and O 0 1.5472553513973253e-06
in O 0 8.535818665222905e-07
normal O 0 4.529633770289365e-06
cells O 0 9.083108125196304e-06
expressing O 0 5.141112069395604e-06
transcripts O 0 5.016906470700633e-06
that O 0 8.168598810698313e-07
contain O 0 6.597287665499607e-06
CUG O 0 0.0010197787778452039
repeats O 0 0.00037620437797158957
. O 0 4.116828858968802e-05

Altered O 0 0.0009322224650532007
expression O 0 6.123296043369919e-05
of O 0 6.032350029272493e-06
genes O 0 2.6314241040381603e-05
regulated O 0 2.0352214050944895e-05
posttranscriptionally O 0 7.615242066094652e-05
by O 0 4.8808587962412275e-06
CUG O 0 0.013182243332266808
- O 0 0.0012885462492704391
BP O 0 0.00013431532715912908
therefore O 0 1.8720908201430575e-06
may O 0 1.6417001234003692e-06
contribute O 0 2.990257371493499e-06
to O 0 2.0697878426290117e-05
DM B-Disease 1 1.0
pathogenesis O 0 0.1053851991891861
. O 0 1.1321519195917062e-05
. O 0 1.9961336874985136e-05

Identification O 0 8.279513713205233e-05
of O 0 3.510874648782192e-06
a O 0 5.628469352814136e-06
novel O 0 1.2757619515468832e-05
nonsense O 0 3.620906500145793e-05
mutation O 0 1.0067104085464962e-05
and O 0 4.014785872641369e-07
a O 0 1.1448072427810985e-06
missense O 0 1.6875468645594083e-05
substitution O 0 1.949492343555903e-06
in O 0 4.1718433863024984e-07
the O 0 7.230589744722238e-07
vasopressin O 0 6.538596062455326e-05
- O 0 4.8579717258689925e-05
neurophysin O 0 0.00011782522778958082
II O 0 0.00010969754657708108
gene O 0 3.545578465491417e-06
in O 0 3.3071435723286413e-07
two O 0 2.961532175049797e-07
Spanish O 0 3.699246690302971e-06
kindreds O 0 6.614600715693086e-05
with O 0 1.2554707609524485e-05
familial B-Disease 1 0.9950464963912964
neurohypophyseal I-Disease 1 0.9999912977218628
diabetes I-Disease 1 0.9999994039535522
insipidus I-Disease 1 0.9993910789489746
. O 0 0.00019477581372484565

Familial B-Disease 1 0.9999634027481079
neurohypophyseal I-Disease 1 0.999998927116394
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.999994158744812
( O 0 0.004179317504167557
FNDI B-Disease 1 0.9999939203262329
) O 0 1.055445409292588e-05
is O 0 1.1680825764415204e-06
an O 0 2.494133923391928e-06
autosomal B-Disease 1 0.9617735147476196
dominant I-Disease 1 0.9601075053215027
disease I-Disease 1 0.9996412992477417
caused O 0 0.03258490189909935
by O 0 0.00016346875054296106
deficiency O 1 0.8485375046730042
in O 0 1.5511025139858248e-06
the O 0 3.5475095501169562e-06
antidiuretic O 0 0.0005464473506435752
hormone O 0 9.483174653723836e-05
arginine O 0 5.3272433433448896e-05
vasopressin O 0 8.471646287944168e-05
( O 0 4.042115051561268e-06
AVP O 0 2.8560722057591192e-05
) O 0 4.447175854238594e-07
encoded O 0 6.199680342433567e-07
by O 0 1.966814835441255e-07
the O 0 4.41534211859107e-07
AVP O 0 0.00020463662804104388
- O 0 7.982829993125051e-05
neurophysin O 0 0.0004582320398185402
II O 0 0.0008433748735114932
( O 0 4.4336052269500215e-06
AVP O 0 0.00014836012269370258
- O 0 2.779440001177136e-05
NPII O 0 9.224890527548268e-05
) O 0 2.4985736217786325e-06
gene O 0 8.05729996500304e-06
on O 0 4.506151981331641e-06
chromosome O 0 0.00016549347492400557
20p13 O 0 0.0004954596515744925
. O 0 6.768034654669464e-05

In O 0 2.7711823349818587e-05
this O 0 3.987726813647896e-06
study O 0 4.768780399899697e-06
, O 0 5.171700649952982e-07
we O 0 1.7501861293567345e-07
analyzed O 0 7.535248300882813e-07
two O 0 1.3512888585864857e-07
families O 0 3.5849095070261683e-07
with O 0 3.580358622912172e-07
FNDI B-Disease 1 0.6671999096870422
using O 0 7.148041163418384e-07
direct O 0 1.0131780072697438e-06
automated O 0 4.135019935347373e-06
fluorescent O 0 2.093576404149644e-05
, O 0 1.7507855432086217e-07
solid O 0 6.01413091771974e-07
phase O 0 1.1825619594674208e-06
, O 0 1.682511623357641e-07
single O 0 5.249306695986888e-07
- O 0 3.379777581358212e-06
stranded O 0 1.743585244184942e-06
DNA O 0 1.2498218211476342e-06
sequencing O 0 1.5631457017661887e-06
of O 0 6.112412620495888e-07
PCR O 0 6.668326386716217e-05
- O 0 4.906349931843579e-05
amplified O 0 9.373365173814818e-05
AVP O 0 0.00044121965765953064
- O 0 0.0001058948619174771
NPII O 0 0.00048629759112372994
DNA O 0 7.503618689952418e-05
. O 0 3.022114105988294e-05

In O 0 7.932082553452346e-06
one O 0 7.510798241128214e-07
of O 0 1.3785334829208296e-07
the O 0 2.2459310855538206e-07
families O 0 6.224556727829622e-07
, O 0 4.0063713413474034e-07
affected O 0 1.5708269529568497e-06
individuals O 0 1.9734642364710453e-07
presented O 0 7.872410492382187e-07
a O 0 1.3827972225044505e-06
novel O 0 4.736234131996753e-06
nonsense O 0 1.764874832588248e-05
mutation O 0 5.330341537046479e-06
in O 0 3.9628011450076883e-07
exon O 0 5.732718818762805e-06
3 O 0 2.3472328791740438e-07
of O 0 5.5752106931095113e-08
the O 0 1.6303559391417366e-07
gene O 0 1.0092182947119e-06
, O 0 8.68888108129795e-08
consisting O 0 1.8938374068966368e-07
in O 0 2.3521336345311283e-07
a O 0 2.119574673997704e-06
G O 0 0.0027982033789157867
to O 0 2.0582062916219e-06
T O 0 0.0001784097112249583
transition O 0 2.540269633755088e-06
at O 0 1.2590812730195466e-06
nucleotide O 0 4.0217782952822745e-06
2101 O 0 5.404354305937886e-05
, O 0 3.60977509217264e-07
which O 0 3.089006384016102e-07
produces O 0 5.868782864126842e-07
a O 0 3.4219914368804893e-07
stop O 0 1.4175697060636594e-06
signal O 0 3.1705203582532704e-06
in O 0 9.322338314632361e-07
codon O 0 1.8758080841507763e-05
82 O 0 1.0225693586107809e-05
( O 0 6.223931904969504e-06
Glu O 0 0.0018609750550240278
) O 0 2.8978759019082645e-06
of O 0 2.643364723553532e-06
NPII O 0 0.0013101220829412341
. O 0 4.615903162630275e-05

The O 0 0.0001158643135568127
premature O 0 0.011702651157975197
termination O 0 0.00024595411377958953
eliminates O 0 5.137808693689294e-05
part O 0 2.198947186116129e-06
of O 0 3.209409840110311e-07
the O 0 8.636139341433591e-07
C O 0 3.429120988585055e-05
- O 0 7.98798464529682e-06
terminal O 0 2.8243932774785208e-06
domain O 0 3.7587986412290775e-07
of O 0 9.473951934069191e-08
NPII O 0 2.3294573111343198e-05
, O 0 9.412676860165448e-08
including O 0 5.8965984095493695e-08
a O 0 1.8556775671640935e-07
cysteine O 0 1.5923927776384517e-06
residue O 0 1.7207855762535473e-06
in O 0 1.7373561433942086e-07
position O 0 3.5866398206962913e-07
85 O 0 3.753092414626735e-07
, O 0 7.344245744889122e-08
which O 0 7.334823948212943e-08
could O 0 1.2061188670031697e-07
be O 0 4.065900682803658e-08
involved O 0 1.0093783231468478e-07
in O 0 1.7090904691485775e-07
the O 0 5.010983272768499e-07
correct O 0 9.733284059620928e-06
folding O 0 8.756928764341865e-06
of O 0 9.704409649202717e-07
the O 0 1.068623078026576e-05
prohormone O 0 0.004988159518688917
. O 0 5.900286851101555e-05

In O 0 1.6102561858133413e-05
the O 0 1.982270305234124e-06
second O 0 2.154240974050481e-06
family O 0 2.265192506456515e-06
, O 0 2.181964759984112e-07
a O 0 4.6201125769584905e-07
G279A O 0 6.418082648451673e-06
substitution O 0 1.1349096666890546e-06
at O 0 4.5447470142789825e-07
position O 0 8.685481702741527e-07
- O 0 1.4541941482093534e-06
1 O 0 1.0554856544331415e-07
of O 0 2.9340263552057877e-08
the O 0 1.5748062764942006e-07
signal O 0 2.812802904372802e-06
peptide O 0 3.8101668451417936e-06
was O 0 1.2743882962240605e-06
observed O 0 1.4489877457890543e-06
in O 0 5.508744038706936e-07
all O 0 6.046088287803286e-07
affected O 0 1.0043877409771085e-05
individuals O 0 7.221256964839995e-06
. O 0 2.489934558980167e-05

This O 0 8.038419036893174e-05
missense O 0 0.005038871429860592
mutation O 0 0.00023579901608172804
, O 0 2.60454316958203e-06
which O 0 1.2621397900147713e-06
replaces O 0 6.120786565588787e-05
Ala O 0 0.0015277932398021221
with O 0 1.661470378166996e-06
Thr O 0 0.06374048441648483
, O 0 3.367113663443888e-07
is O 0 1.8847168803404202e-07
frequent O 0 2.104183522533276e-06
among O 0 3.3663220619928325e-06
FNDI B-Disease 1 1.0
patients O 0 0.18738460540771484
and O 0 4.811938651982928e-07
is O 0 1.532825564254381e-07
thought O 0 2.0816921164623636e-07
to O 0 1.9568372522371646e-07
reduce O 0 6.370138407874038e-07
the O 0 2.302048471847229e-07
efficiency O 0 1.0005320518757799e-06
of O 0 1.790902786069637e-07
cleavage O 0 5.327312464942224e-06
by O 0 1.0458659289724892e-06
signal O 0 2.9101418476784602e-05
peptidases O 0 0.0001810807443689555
. O 0 6.4144355746975634e-06
. O 0 2.367584420426283e-05

Genetic O 0 0.0009085121564567089
heterogeneity O 0 0.0005076842498965561
of O 0 1.9162036551279016e-05
Saethre B-Disease 1 0.9423162937164307
- I-Disease 1 0.9996824264526367
Chotzen I-Disease 1 0.9999927282333374
syndrome I-Disease 1 0.9999998807907104
, O 0 1.769128289197397e-06
due O 0 5.8008245105156675e-06
to O 0 2.018953182414407e-06
TWIST O 0 8.866971620591357e-05
and O 0 1.260783574252855e-05
FGFR O 1 0.7590155601501465
mutations O 0 0.0017286529764533043
. O 0 4.615251600625925e-05

Thirty O 0 0.0003253179311286658
- O 0 0.00035542689147405326
two O 0 4.541862381302053e-06
unrelated O 0 0.00022007001098245382
patients O 0 2.4946857593022287e-05
with O 0 3.466131488494284e-07
features O 0 1.1979915370829985e-06
of O 0 8.135905886774708e-07
Saethre B-Disease 1 0.9457484483718872
- I-Disease 1 0.9990606904029846
Chotzen I-Disease 1 0.9999910593032837
syndrome I-Disease 1 0.9999990463256836
, O 0 6.893044997013931e-07
a O 0 2.947799885077984e-06
common O 0 6.315561768133193e-05
autosomal B-Disease 1 0.5733789205551147
dominant I-Disease 0 0.0007220779662020504
condition I-Disease 0 0.0017443399410694838
of O 0 1.382297568852664e-06
craniosynostosis B-Disease 1 0.9937216639518738
and O 0 0.0002714528236538172
limb B-Disease 1 0.9998224377632141
anomalies I-Disease 0 0.4609888195991516
, O 0 5.421621267487353e-07
were O 0 2.4902143991312187e-07
screened O 0 3.7735603655164596e-06
for O 0 4.940776534567703e-07
mutations O 0 1.4437569916481152e-05
in O 0 6.89921989760478e-07
TWIST O 0 2.684787250473164e-05
, O 0 1.1931980452573043e-06
FGFR2 O 0 0.00016117900668177754
, O 0 1.6145655763466493e-06
and O 0 2.6929333216685336e-06
FGFR3 O 0 0.0015563686611130834
. O 0 3.606866084737703e-05

Nine O 0 5.8686608099378645e-05
novel O 0 3.1786785257281736e-05
and O 0 2.195416300310171e-06
three O 0 2.531905920477584e-06
recurrent O 0 0.009155575186014175
TWIST O 0 0.02007737010717392
mutations O 0 0.0004079052887391299
were O 0 1.1214768846912193e-06
found O 0 9.94163315226615e-07
in O 0 1.3834923038302804e-06
12 O 0 5.171521479496732e-06
families O 0 1.4313663996290416e-05
. O 0 3.808065957855433e-05

Seven O 0 4.295047256164253e-05
families O 0 8.690413778822403e-06
were O 0 1.581194396749197e-06
found O 0 6.876138058942161e-07
to O 0 2.759427388809854e-07
have O 0 1.7214439651525026e-07
the O 0 4.205116113098484e-07
FGFR3 O 0 0.0008758410112932324
P250R O 0 0.000224154835450463
mutation O 0 1.1677289876388386e-05
, O 0 1.5090886051893904e-07
and O 0 6.200490787477975e-08
one O 0 5.1618751939486174e-08
individual O 0 7.660923273533626e-08
was O 0 9.784571375348605e-07
found O 0 2.6493333393773355e-07
to O 0 1.5025516120203974e-07
have O 0 1.7363539939196926e-07
an O 0 5.000876512895047e-07
FGFR2 O 0 0.0003530762332957238
VV269 O 0 0.00020912678155582398
- O 0 8.1707737990655e-05
270 O 0 7.614116475451738e-05
deletion O 0 0.0005445442511700094
. O 0 4.8221823817584664e-05

To O 0 1.5283898392226547e-05
date O 0 7.894801456131972e-06
, O 0 8.205998938137782e-07
our O 0 5.60564728857571e-07
detection O 0 3.876813025271986e-06
rate O 0 1.271805899705214e-06
for O 0 2.426844503133907e-07
TWIST O 0 1.4757912140339613e-05
or O 0 2.0721699911518954e-06
FGFR O 0 0.007636729162186384
mutations O 0 1.2703507309197448e-05
is O 0 1.9170661857970117e-07
68 O 0 8.734990046832536e-07
% O 0 1.7413205455341085e-07
in O 0 2.2494614881907182e-07
our O 0 8.424779593951826e-07
Saethre B-Disease 1 0.9117854833602905
- I-Disease 1 0.999983549118042
Chotzen I-Disease 1 0.9999997615814209
syndrome I-Disease 1 1.0
patients O 0 0.001969598699361086
, O 0 2.269176349045665e-07
including O 0 1.406438627782336e-07
our O 0 2.601370852062246e-07
five O 0 1.852950163083733e-06
patients O 0 0.000586872745770961
elsewhere O 0 1.1494848877191544e-05
reported O 0 4.07432671636343e-05
with O 0 3.0797220915701473e-06
TWIST O 0 0.007292736321687698
mutations O 0 0.0008522357093170285
. O 0 3.509791713440791e-05

More O 0 9.157944077742286e-06
than O 0 1.439252059753926e-06
35 O 0 2.032111979133333e-06
different O 0 6.287511951086344e-07
TWIST O 0 0.00020420431974343956
mutations O 0 4.210105907986872e-05
are O 0 1.3349614391700015e-07
now O 0 2.333840143364796e-07
known O 0 3.936577002150443e-07
in O 0 3.30065290654602e-07
the O 0 1.0034705155703705e-06
literature O 0 8.22115453047445e-06
. O 0 1.5554262063233182e-05

The O 0 2.3209466235130094e-05
most O 0 2.62732260125631e-06
common O 0 2.7924497771891765e-06
phenotypic O 0 9.491181117482483e-06
features O 0 2.3972042981768027e-06
, O 0 2.6674396735870687e-07
present O 0 2.5080942123167915e-07
in O 0 1.0440567166369874e-07
more O 0 4.2692356316820224e-08
than O 0 4.051926794090832e-08
a O 0 1.2375727465041564e-07
third O 0 3.0382369686776656e-07
of O 0 1.3178443225569936e-07
our O 0 2.6119034828298027e-06
patients O 0 5.7038039813051e-05
with O 0 1.5083230664458824e-06
TWIST O 0 0.03366116061806679
mutations O 0 6.577093154191971e-05
, O 0 3.7186191548244096e-07
are O 0 1.2789146808245277e-07
coronal B-Disease 0 3.304725032649003e-05
synostosis I-Disease 0 7.589787855977193e-05
, O 0 1.1494238378872979e-06
brachycephaly B-Disease 0 6.625982496188954e-05
, O 0 1.0950478781523998e-06
low B-Disease 0 1.5801626432221383e-05
frontal I-Disease 1 0.7138698101043701
hairline I-Disease 1 0.9999244213104248
, O 0 1.1460107998573221e-05
facial B-Disease 1 0.8261760473251343
asymmetry I-Disease 0 0.005145685747265816
, O 0 8.610845725343097e-06
ptosis B-Disease 1 0.9363676905632019
, O 0 3.1304527965403395e-06
hypertelorism B-Disease 0 0.0012172479182481766
, O 0 1.1475092378532281e-06
broad B-Disease 0 5.049132141721202e-06
great I-Disease 0 2.79109985967807e-06
toes I-Disease 0 5.854708797414787e-05
, O 0 1.176627733912028e-06
and O 0 2.244450342914206e-06
clinodactyly B-Disease 0 0.0009245810797438025
. O 0 3.45826665579807e-05

Significant O 0 9.130599210038781e-05
intra O 0 0.00022460795298684388
- O 0 0.00010662024578778073
and O 0 3.7109566619619727e-06
interfamilial O 0 0.00015637789329048246
phenotypic O 0 3.1793726520845667e-05
variability O 0 4.458237162907608e-05
is O 0 6.420626732506207e-07
present O 0 8.111787792586256e-07
for O 0 5.188908289710525e-07
either O 0 3.650693315648823e-06
TWIST O 0 0.0009448638302274048
mutations O 0 0.0004379006859380752
or O 0 2.0279057935113087e-05
FGFR O 0 0.1255585104227066
mutations O 0 0.0011511297198012471
. O 0 5.3666481107939035e-05

The O 0 3.718848165590316e-05
overlap O 0 4.083958629053086e-05
in O 0 3.5293580822326476e-06
clinical O 0 1.4123048458714038e-05
features O 0 1.8931471004179912e-06
and O 0 1.9430927977737156e-07
the O 0 1.954446275931332e-07
presence O 0 4.989700528312824e-07
, O 0 6.353999992825266e-08
in O 0 4.7501391264859194e-08
the O 0 6.734793345231083e-08
same O 0 1.2682168915034708e-07
genes O 0 2.8355756853670755e-07
, O 0 3.280761973201152e-08
of O 0 3.9629135528684856e-08
mutations O 0 1.2131330322517897e-06
for O 0 3.640418810846313e-08
more O 0 4.000521514058164e-08
than O 0 5.544859504880151e-08
one O 0 2.316084675157981e-07
craniosynostotic B-Disease 0 0.12035307288169861
condition I-Disease 0 0.006647121161222458
- O 0 5.778970262326766e-06
such O 0 1.6704484551155474e-07
as O 0 2.639440026541706e-07
Saethre B-Disease 0 3.8262849557213485e-05
- I-Disease 0 1.0764038052002434e-05
Chotzen I-Disease 0 1.556938332214486e-05
, I-Disease 0 3.193256361555541e-07
Crouzon I-Disease 0 1.6354573745047674e-05
, I-Disease 0 4.4574599655788916e-07
and I-Disease 0 2.422385023237439e-06
Pfeiffer I-Disease 1 0.8779149055480957
syndromes I-Disease 1 0.5433533191680908
- O 0 1.1040964636777062e-05
support O 0 3.6547442050505197e-07
the O 0 1.6387969026254723e-07
hypothesis O 0 1.1850286227854667e-06
that O 0 1.02680409952427e-07
TWIST O 0 2.8205820399307413e-06
and O 0 3.015044853782456e-07
FGFRs O 0 1.3644325917994138e-05
are O 0 7.800705503768768e-08
components O 0 1.677332051031044e-07
of O 0 4.012748888726492e-08
the O 0 9.662283417810613e-08
same O 0 2.6274477704646415e-07
molecular O 0 1.747497094584105e-06
pathway O 0 1.1802399058069568e-06
involved O 0 2.584809237760055e-07
in O 0 1.2393444137615006e-07
the O 0 2.3039878271902126e-07
modulation O 0 7.560423455288401e-06
of O 0 5.911226139687642e-07
craniofacial O 1 0.8991627097129822
and O 0 5.936211891821586e-06
limb O 0 0.11238875240087509
development O 0 3.3874869131977903e-06
in O 0 1.7895589508043486e-06
humans O 0 5.748858256993117e-06
. O 0 2.366550234000897e-06
. O 0 1.1648837244138122e-05

Mutation O 0 0.002538524568080902
analysis O 0 0.0001711579825496301
of O 0 4.336375786806457e-05
UBE3A O 1 0.9983816146850586
in O 1 0.9995860457420349
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.999789297580719
. O 0 0.00022759301646146923

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0021072125528007746
AS B-Disease 0 0.002260490320622921
) O 0 4.291174718673574e-06
is O 0 6.985873710618762e-07
caused O 0 4.110050667804899e-06
by O 0 1.1756474123103544e-06
chromosome O 0 1.6980191503535025e-05
15q11 O 0 4.0041231841314584e-05
- O 0 1.7976386516238563e-05
q13 O 0 2.101782592944801e-05
deletions O 0 1.4661401110060979e-05
of O 0 4.203496075660951e-07
maternal O 0 1.1974002518400084e-05
origin O 0 1.222247988152958e-06
, O 0 5.732963472837582e-07
by O 0 1.8314696035304223e-06
paternal O 0 0.00035758200101554394
uniparental B-Disease 1 0.7626882195472717
disomy I-Disease 0 0.3504311442375183
( O 0 3.0928003980079666e-05
UPD B-Disease 1 0.998974084854126
) O 0 8.680273708705499e-07
15 O 0 3.7748239378743165e-07
, O 0 1.436114871466998e-07
by O 0 6.467394086939748e-07
imprinting O 1 0.7669933438301086
defects O 1 0.9726755619049072
, O 0 2.1772400771169487e-07
and O 0 1.8280269387105363e-07
by O 0 8.498973329551518e-07
mutations O 0 1.6224286810029298e-05
in O 0 1.203220676870842e-06
the O 0 6.927379672561074e-06
UBE3A O 0 0.007913091219961643
gene O 0 0.00019591236195992678
. O 0 3.9919606933835894e-05

UBE3A O 0 0.013967873528599739
encodes O 0 0.0005521601997315884
a O 0 6.943722837604582e-05
ubiquitin O 0 0.00026666009216569364
- O 0 5.676699220202863e-05
protein O 0 8.09078846941702e-06
ligase O 0 1.0713384654081892e-05
and O 0 1.0718111980168032e-06
shows O 0 6.388027486536885e-06
brain O 0 0.003945841453969479
- O 0 5.014147245674394e-05
specific O 0 1.3518420018954203e-05
imprinting O 0 0.0009959812741726637
. O 0 5.762796354247257e-05

Here O 0 5.686310396413319e-05
we O 0 8.497874659951776e-06
describe O 0 3.9862927224021405e-05
UBE3A O 0 0.0006123479688540101
coding O 0 0.0001232861541211605
- O 0 7.742423622403294e-05
region O 0 9.496812708675861e-06
mutations O 0 4.651679046219215e-05
detected O 0 1.1492022167658433e-05
by O 0 1.1044039638363756e-06
SSCP O 0 0.00015300347877200693
analysis O 0 2.187633072026074e-06
in O 0 6.913176662237674e-07
13 O 0 1.2959565083292546e-06
AS B-Disease 0 1.1455333151388913e-05
individuals O 0 8.448683956885361e-07
or O 0 2.797690285660792e-06
families O 0 1.323331889580004e-05
. O 0 2.4375069187954068e-05

Two O 0 2.9474313123500906e-05
identical O 0 4.671977512771264e-05
de O 0 4.6648499846924096e-05
novo O 0 6.644877430517226e-05
5 O 0 5.485108886205126e-06
- O 0 1.792007424228359e-05
bp O 0 2.2186353817232884e-05
duplications O 0 1.6097355910460465e-05
in O 0 1.4220773891793215e-06
exon O 0 2.179008697567042e-05
16 O 0 2.563012003520271e-06
were O 0 1.419195655216754e-06
found O 0 5.3204989853838924e-06
. O 0 1.3633191883855034e-05

Among O 0 1.2526770660770126e-05
the O 0 1.910194669108023e-06
other O 0 5.397708946475177e-07
11 O 0 8.197863508030423e-07
unique O 0 9.205614901475201e-07
mutations O 0 1.6010089893825352e-05
, O 0 2.781192165457469e-07
8 O 0 5.998928145345417e-07
were O 0 1.879226658729749e-07
small O 0 2.824677096668893e-07
deletions O 0 9.036210030899383e-06
or O 0 5.38557458185096e-07
insertions O 0 2.0530056644929573e-05
predicted O 0 1.4902396287652664e-05
to O 0 5.416133035396342e-07
cause O 0 7.253011972352397e-06
frameshifts O 0 8.457536750938743e-05
, O 0 1.607800470537768e-07
1 O 0 3.0271687023741833e-07
was O 0 4.864487550548802e-07
a O 0 4.588169133512565e-07
mutation O 0 2.8983733955101343e-06
to O 0 1.861276501813336e-07
a O 0 3.243146693421295e-07
stop O 0 1.310809125243395e-06
codon O 0 4.566566985886311e-06
, O 0 1.635744411032647e-07
1 O 0 3.160806443247566e-07
was O 0 3.870692921736918e-07
a O 0 9.206896720570512e-07
missense O 0 9.637552284402773e-05
mutation O 0 1.0058543921331875e-05
, O 0 2.2417026457333122e-07
and O 0 1.7872363855531148e-07
1 O 0 5.19772356710746e-07
was O 0 2.112658648911747e-06
predicted O 0 4.212592557450989e-06
to O 0 2.981140596602927e-07
cause O 0 1.009530251394608e-06
insertion O 0 1.3673717376150307e-06
of O 0 1.1255726661829613e-07
an O 0 2.569928767570673e-07
isoleucine O 0 5.4860229283804074e-05
in O 0 3.837264728190348e-07
the O 0 4.5782473989675054e-07
hect O 0 1.5549740055575967e-05
domain O 0 8.289808306471969e-07
of O 0 1.0603444877688162e-07
the O 0 4.917891942568531e-07
UBE3A O 0 6.3661667809356e-05
protein O 0 1.4876347904646536e-06
, O 0 1.7597174917227676e-07
which O 0 1.2056000286975177e-07
functions O 0 4.4369579654812696e-07
in O 0 3.9989276956475805e-07
E2 O 0 2.1843225113116205e-05
binding O 0 3.654141664810595e-06
and O 0 1.1904430721187964e-06
ubiquitin O 0 5.78218896407634e-05
transfer O 0 2.2314387024380267e-05
. O 0 3.649001882877201e-05

Eight O 0 9.70455221249722e-06
of O 0 9.301805903305649e-07
the O 0 9.097056477003207e-07
cases O 0 1.2309651538089383e-06
were O 0 7.247489861583745e-07
familial O 0 0.0003059970331378281
, O 0 6.073863119127054e-07
and O 0 3.2563804097662796e-07
five O 0 6.597014703402238e-07
were O 0 2.6241725663567195e-06
sporadic O 0 0.0001311796804657206
. O 0 3.261789242969826e-05

In O 0 3.749072129721753e-05
two O 0 7.150658348109573e-06
familial O 0 0.0284108929336071
cases O 0 5.013099325879011e-06
and O 0 9.044434818861191e-07
one O 0 3.890358470926003e-07
sporadic O 0 1.6817040886962786e-05
case O 0 2.843191850843141e-06
, O 0 9.676259651314467e-07
mosaicism O 0 0.00010181432298850268
for O 0 1.7821570281739696e-06
UBE3A O 0 0.1404811441898346
mutations O 0 0.00024080995353870094
was O 0 4.32125943916617e-06
detected O 0 3.815290256170556e-06
in O 0 2.2444365299634228e-07
the O 0 1.3878808147183008e-07
mother O 0 6.964009457988141e-07
of O 0 3.751925348183249e-08
three O 0 8.817264784966028e-08
AS B-Disease 0 6.0805621615145355e-05
sons O 0 0.00011951078340644017
, O 0 5.77273979729398e-08
in O 0 8.417890740020084e-08
the O 0 2.706450175082864e-07
maternal O 0 2.957355900434777e-05
grandfather O 0 4.714346687251236e-06
of O 0 5.1828592972924525e-08
two O 0 9.310506499105031e-08
AS B-Disease 0 1.465669470235298e-06
first O 0 3.208133705356886e-07
cousins O 0 2.939207206509309e-06
, O 0 7.855591377392557e-08
and O 0 4.587372970377146e-08
in O 0 7.56553504288604e-08
the O 0 1.9002327178441192e-07
mother O 0 1.897848846965644e-06
of O 0 1.6666581359459087e-07
an O 0 8.935604682847043e-07
AS B-Disease 0 0.0018776924116536975
daughter O 0 0.019715717062354088
. O 0 3.4581149520818144e-05

The O 0 1.3571055205829907e-05
frequencies O 0 2.3861553927417845e-05
with O 0 1.4147416322884965e-06
which O 0 1.0923682793873013e-06
we O 0 5.138202254784119e-07
detected O 0 2.226957440143451e-05
mutations O 0 7.655833542230539e-06
were O 0 2.523569548884552e-07
5 O 0 3.5119794006277516e-07
( O 0 2.2855741121929896e-07
14 O 0 1.7188602896567318e-07
% O 0 7.358028852877396e-08
) O 0 5.4049163367153596e-08
of O 0 2.3144412608644416e-08
35 O 0 2.2686202783006593e-07
in O 0 2.543226287343714e-07
sporadic O 0 7.337996976275463e-06
cases O 0 3.8912489230824576e-07
and O 0 1.2888570211089245e-07
8 O 0 3.4547986160760047e-07
( O 0 1.7661869833318633e-07
80 O 0 2.1126274418747926e-07
% O 0 9.784163523818279e-08
) O 0 7.315097150240035e-08
of O 0 4.858501867488485e-08
10 O 0 3.2907212244026596e-07
in O 0 2.0547936401271727e-06
familial O 0 0.04789600148797035
cases O 0 1.5893258023425005e-05
. O 0 7.108854788384633e-06
. O 0 2.3247346689458936e-05

The O 0 0.00040196473128162324
hemochromatosis B-Disease 1 0.9999995231628418
845 O 1 0.9327957630157471
G O 1 0.9660160541534424
- O 0 0.03339201956987381
- O 0 0.0001759065198712051
> O 0 1.536362833576277e-05
A O 0 1.9050226001127157e-06
and O 0 6.271163215387787e-07
187 O 0 7.956341505632736e-06
C O 0 0.00016419764142483473
- O 0 0.00048017362132668495
- O 0 0.000323897780617699
> O 0 6.749601743649691e-05
G O 0 0.0069518918171525
mutations O 0 3.901894160662778e-05
: O 0 1.084777409232629e-06
prevalence O 0 1.172717475128593e-05
in O 0 1.052953507496568e-06
non O 0 5.308496838551946e-06
- O 0 5.781847357866354e-05
Caucasian O 0 7.658478716621175e-05
populations O 0 3.39490725309588e-05
. O 0 2.109231718350202e-05

Hemochromatosis B-Disease 1 0.9998818635940552
, O 0 0.00018989641102962196
the O 0 0.00315232016146183
inherited B-Disease 1 1.0
disorder I-Disease 1 0.9999995231628418
of I-Disease 0 3.1772340207680827e-06
iron I-Disease 0 0.018624529242515564
metabolism I-Disease 0 0.00016069591220002621
, O 0 5.094818789075362e-07
leads O 0 1.4630300029239152e-06
, O 0 2.5585060825505934e-07
if O 0 4.1232084413422854e-07
untreated O 0 4.4297408749116585e-05
, O 0 1.9425682751261775e-07
to O 0 4.6051033564253885e-07
progressive O 0 0.0023546325974166393
iron B-Disease 0 0.4838654100894928
overload I-Disease 0 0.1682818979024887
and O 0 7.681460374442395e-06
premature B-Disease 0 0.027450911700725555
death I-Disease 0 0.00033733880263753235
. O 0 3.7447702197823673e-05

The O 0 0.0002556408289819956
hemochromatosis B-Disease 1 0.9999916553497314
gene O 0 0.0002938708639703691
, O 0 5.2655295803560875e-06
HFE O 0 0.008018659427762032
, O 0 1.8904534044850152e-06
recently O 0 4.851866378885461e-06
has O 0 3.517744460168615e-07
been O 0 1.7971699151075882e-07
identified O 0 3.737352187727083e-07
, O 0 8.875696977383996e-08
and O 0 9.810025147771739e-08
characterization O 0 8.302649234792625e-07
of O 0 7.059524875785428e-08
this O 0 2.0990793814235076e-07
gene O 0 2.854886133718537e-06
has O 0 2.997555839101551e-07
shown O 0 3.296481736470014e-07
that O 0 5.9010087483102325e-08
it O 0 4.805911757443937e-08
contains O 0 1.0590024857037861e-07
two O 0 1.4217408761396655e-07
mutations O 0 3.135475253657205e-06
that O 0 7.758326603379828e-08
result O 0 2.70576379080012e-07
in O 0 2.3505998569817166e-07
amino O 0 1.1874541314682574e-06
acid O 0 3.1233196295943344e-06
substitutions O 0 3.168975581502309e-06
- O 0 4.3520208237168845e-06
cDNA O 0 1.1380950127204414e-05
nucleotides O 0 9.929192856361624e-06
845 O 0 7.95950909378007e-05
G O 0 0.00029365686350502074
- O 0 7.342611934291199e-05
- O 0 1.6712670912966132e-05
> O 0 4.754049768962432e-06
A O 0 1.062216369973612e-06
( O 0 1.2089614074284327e-06
C282Y O 0 1.0739592653408181e-05
) O 0 5.235688149696216e-07
and O 0 3.826247052529652e-07
187 O 0 5.947329555056058e-06
C O 0 7.837478187866509e-05
- O 0 0.00023956118093337864
- O 0 0.00015862016880419105
> O 0 5.829805013490841e-05
G O 0 0.000124753249110654
( O 0 9.41830876399763e-06
H63D O 0 0.0004529410507529974
) O 0 1.173928194475593e-05
. O 0 2.037437297985889e-05

Although O 0 0.001420675660483539
hemochromatosis B-Disease 1 0.9999983310699463
is O 0 9.998768291552551e-06
common O 0 5.130840690981131e-06
in O 0 2.6384209377283696e-06
Caucasians O 0 1.8802367776515894e-05
, O 0 1.1492703606563737e-06
affecting O 0 8.71803149493644e-06
> O 0 1.913807682285551e-05
= O 0 1.4796936739003286e-05
1 O 0 1.4658861573479953e-06
/ O 0 7.66702760301996e-06
300 O 0 2.697850902677601e-07
individuals O 0 5.354279863922784e-08
of O 0 2.4471589199492882e-08
northern O 0 2.813267201418057e-07
European O 0 2.5900453692884184e-07
origin O 0 2.1766358315744583e-07
, O 0 1.019035025251469e-07
it O 0 4.904505956915273e-08
has O 0 8.869130851962836e-08
not O 0 3.557988037528048e-08
been O 0 9.768238840024424e-08
recognized O 0 2.0806500344860979e-07
in O 0 3.7748455383734836e-07
other O 0 9.197963208862348e-07
populations O 0 1.800198333512526e-05
. O 0 1.9407443687669e-05

The O 0 3.290817767265253e-05
present O 0 1.8105440176441334e-05
study O 0 9.208036317431834e-06
used O 0 3.7036520552646834e-06
PCR O 0 3.553038914105855e-05
and O 0 1.1730134019671823e-06
restriction O 0 7.043075129331555e-06
- O 0 2.3791433704900555e-05
enzyme O 0 5.33495904164738e-06
digestion O 0 4.691656613431405e-06
to O 0 2.605606539418659e-07
analyze O 0 8.769662827035063e-07
the O 0 1.060378878037227e-07
frequency O 0 7.036067017907044e-07
of O 0 1.0677786121959798e-07
the O 0 5.606603963315138e-07
845 O 0 0.00010346820636186749
G O 0 0.004476473666727543
- O 0 0.00021914576063863933
- O 0 1.1529234143381473e-05
> O 0 1.798243033590552e-06
A O 0 4.982543941878248e-07
and O 0 2.930448204097047e-07
187 O 0 6.950440820219228e-06
C O 0 0.00018214051669929177
- O 0 0.0003142494533676654
- O 0 0.00018132022523786873
> O 0 6.640898936893791e-05
G O 0 0.0018098758300766349
mutations O 0 3.781009581871331e-05
in O 0 3.240344312871457e-06
HLA O 0 0.12374340742826462
- O 0 1.3245490663393866e-05
typed O 0 3.4751810744637623e-06
samples O 0 5.363167474570218e-07
from O 0 2.55029902973547e-07
non O 0 5.815575150336372e-07
- O 0 2.750712155830115e-06
Caucasian O 0 2.2651493054581806e-06
populations O 0 5.479454330270528e-07
, O 0 7.21458235375394e-08
comprising O 0 2.0114606513743638e-07
Australian O 0 6.422831688723818e-07
Aboriginal O 0 1.01509078831441e-06
, O 0 1.3123585063112841e-07
Chinese O 0 1.8474102603249776e-07
, O 0 3.148616087855771e-07
and O 0 8.380002327612601e-07
Pacific O 0 1.8549675587564707e-05
Islanders O 0 0.00011064472346333787
. O 0 2.881248656194657e-05

Results O 0 0.0002944454608950764
showed O 0 4.274339153198525e-05
that O 0 2.2045092009648215e-06
the O 0 2.694089289434487e-06
845 O 0 0.0004322863824199885
G O 0 0.12220724672079086
- O 0 0.004012691788375378
- O 0 5.402756869443692e-05
> O 0 7.464258487743791e-06
A O 0 2.1590392407233594e-06
mutation O 0 9.623430742067285e-06
was O 0 6.835464319010498e-07
present O 0 2.0835828706822213e-07
in O 0 1.165750660447884e-07
these O 0 1.4367024903094716e-07
populations O 0 6.648248245255672e-07
( O 0 5.687763291462034e-07
allele O 0 4.3219647523073945e-06
frequency O 0 2.1337309590307996e-06
0 O 0 3.4990480912711064e-07
. O 0 7.5159434231864e-08
32 O 0 1.3859853709163872e-07
% O 0 7.777677524245519e-08
) O 0 6.611450942273223e-08
, O 0 3.484621302618507e-08
and O 0 5.0268305074041564e-08
, O 0 8.322072631017363e-08
furthermore O 0 2.902035873830755e-07
, O 0 5.837212313508644e-08
it O 0 7.508091215413515e-08
was O 0 5.409659706856473e-07
always O 0 1.6686351500538876e-07
seen O 0 3.1876575690148456e-07
in O 0 1.9597732148213254e-07
conjunction O 0 1.945287749549607e-06
with O 0 2.1932398794888286e-06
HLA O 0 0.2961830198764801
haplotypes O 0 3.9817143260734156e-05
common O 0 1.592550688656047e-06
in O 0 5.91173318298388e-07
Caucasians O 0 3.061221377720358e-06
, O 0 2.5307903683824406e-07
suggesting O 0 1.5020646060293075e-06
that O 0 3.312718206416321e-07
845 O 0 6.795999797759578e-05
G O 0 0.014821228571236134
- O 0 0.0024076756089925766
- O 0 6.949208182049915e-05
> O 0 5.33497950527817e-06
A O 0 2.435737087580492e-06
may O 0 2.108815806423081e-06
have O 0 9.562309344346431e-08
been O 0 8.015496177904424e-08
introduced O 0 3.3058191206691845e-07
into O 0 1.7274928154620284e-07
these O 0 1.8757334885322052e-07
populations O 0 1.1556240906429593e-06
by O 0 1.565691036375938e-06
Caucasian O 0 4.733727473649196e-05
admixture O 0 0.00019516398606356233
. O 0 4.1350536776008084e-05

187 O 0 0.001395318191498518
C O 0 0.009277865290641785
- O 0 0.0024858887773007154
- O 0 0.00042177826981060207
> O 0 5.02761613461189e-05
G O 0 0.00013240004773251712
was O 0 1.748874183249427e-06
present O 0 8.60214186104713e-07
at O 0 6.904479619151971e-07
an O 0 5.454616029965109e-07
allele O 0 1.4537321476382203e-05
frequency O 0 6.57213740851148e-06
of O 0 8.360827905562473e-07
2 O 0 8.662595064379275e-06
. O 0 1.7227595890290104e-05

68 O 0 0.00022104513482190669
% O 0 7.524070952058537e-06
in O 0 1.0716711358327302e-06
the O 0 4.4860667003376875e-07
two O 0 3.3575773272787046e-07
populations O 0 1.8908032188846846e-06
analyzed O 0 3.675909738376504e-06
( O 0 8.732907872399664e-07
Australian O 0 1.4527305438605254e-06
Aboriginal O 0 2.3396573851641733e-06
and O 0 5.671091685144347e-07
Chinese O 0 1.240583060280187e-06
) O 0 5.942929874436231e-06
. O 0 1.749142938933801e-05

In O 0 1.661749047343619e-05
the O 0 4.3395921238698065e-06
Australian O 0 8.783198609307874e-06
Aboriginal O 0 7.1568251769349445e-06
samples O 0 2.069146830763202e-06
, O 0 4.0057676642391016e-07
187 O 0 4.645416538551217e-06
C O 0 8.827049896353856e-05
- O 0 0.0003009300562553108
- O 0 0.00011963324504904449
> O 0 2.772490552160889e-05
G O 0 0.0001489561836933717
was O 0 1.180985123028222e-06
found O 0 2.044580895699255e-07
to O 0 1.417496520161876e-07
be O 0 8.424283493013718e-08
associated O 0 5.872970518794318e-07
with O 0 8.046835091590765e-07
HLA O 0 0.4469161629676819
haplotypes O 0 3.064638440264389e-05
common O 0 8.266227382591751e-07
in O 0 6.73952229135466e-07
Caucasians O 0 4.083413841726724e-06
, O 0 3.331111599891301e-07
suggesting O 0 2.1807259145134594e-06
that O 0 1.0587317689214615e-07
it O 0 1.2082462319540355e-07
was O 0 4.890498530585319e-07
introduced O 0 1.6803177231849986e-06
by O 0 7.484170509997057e-07
recent O 0 6.1422579165082425e-06
admixture O 0 0.00013526309339795262
. O 0 3.861843651975505e-05

In O 0 1.8742985048447736e-05
the O 0 2.2668909878120758e-06
Chinese O 0 1.1425211141613545e-06
samples O 0 2.3869863525760593e-06
analyzed O 0 3.998117790615652e-06
, O 0 6.619462737944559e-07
187 O 0 7.597370768053224e-06
C O 0 8.427604916505516e-05
- O 0 0.00034675802453421056
- O 0 0.00013971187581773847
> O 0 3.1140381906880066e-05
G O 0 0.00020901396055705845
was O 0 1.5734567568870261e-06
present O 0 4.152211374730541e-07
in O 0 2.472046674029116e-07
association O 0 4.005087532732432e-07
with O 0 7.350874398071028e-08
a O 0 1.9920079807889124e-07
wide O 0 3.563238522019674e-07
variety O 0 2.3811810478946427e-07
of O 0 4.612826387528912e-07
HLA O 1 0.6159548759460449
haplotypes O 0 6.543436757056043e-05
, O 0 2.637208353917231e-07
showing O 0 9.184411737805931e-07
this O 0 1.1550539369409307e-07
mutation O 0 1.5787323945914977e-06
to O 0 1.0402600736370005e-07
be O 0 6.733881718901102e-08
widespread O 0 4.552776431410166e-07
and O 0 1.489779890562204e-07
likely O 0 8.652627343508357e-07
to O 0 2.480269358784426e-07
predate O 0 1.0949864190479275e-05
the O 0 3.3903523899425636e-07
more O 0 2.797092975015403e-07
genetically O 0 5.526989752979716e-06
restricted O 0 5.317921932146419e-06
845 O 0 0.00034114779555238783
G O 0 0.02256680838763714
- O 0 0.0006899539730511606
- O 0 0.00013753025268670171
> O 0 2.9961329346406274e-05
A O 0 1.324069125985261e-05
mutation O 0 0.00013191511970944703
. O 0 2.9197599360486493e-05

Genotype O 1 0.9644396305084229
- O 1 0.906438410282135
phenotype O 1 0.9272754192352295
correlations O 0 0.0033741167280822992
in O 0 0.0004585329443216324
attenuated B-Disease 1 0.9990468621253967
adenomatous I-Disease 1 0.9999995231628418
polyposis I-Disease 1 0.9999980926513672
coli I-Disease 1 0.9999735355377197
. O 0 0.0007410282851196826

Germ O 1 0.9241938591003418
- O 0 0.034349292516708374
line O 0 7.453952275682241e-05
mutations O 0 4.359005106380209e-05
of O 0 8.756642273510806e-07
the O 0 2.7296546249999665e-06
tumor B-Disease 0 0.0010517124319449067
suppressor O 0 0.0017240042798221111
APC O 0 0.00020315017900429666
are O 0 8.185020874407201e-07
implicated O 0 5.6534045143052936e-05
in O 0 3.3020973205566406e-05
attenuated B-Disease 1 0.9976887702941895
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 0.9999972581863403
( O 0 0.0005273512215353549
AAPC B-Disease 1 0.999992847442627
) O 0 5.094656899018446e-06
, O 0 1.2008109706584946e-06
a O 0 3.3116234590124805e-06
variant O 0 0.0002625906199682504
of O 0 3.054834087379277e-05
familial B-Disease 1 0.9999995231628418
adenomatous I-Disease 1 0.9999994039535522
polyposis I-Disease 1 0.9999998807907104
( O 0 0.002480666618794203
FAP B-Disease 0 0.1701112985610962
) O 0 6.183960795169696e-05
. O 0 3.7212957977317274e-05

AAPC B-Disease 1 0.9999909400939941
is O 0 2.6411436920170672e-05
recognized O 0 5.168908046471188e-06
by O 0 1.0622650279401569e-06
the O 0 9.608249911252642e-07
occurrence O 0 5.4096371968626045e-06
of O 0 5.207841127230495e-07
< O 0 7.38003518563346e-06
100 O 0 1.5394940646729083e-06
colonic B-Disease 0 0.0006185522070154548
adenomas I-Disease 0 0.0005558282136917114
and O 0 7.175183327490231e-07
a O 0 1.8479930758985574e-06
later O 0 3.873804962495342e-05
onset O 1 0.996193528175354
of O 0 0.2208305150270462
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 3.277357609476894e-05
age O 0 4.920171704725362e-06
> O 0 8.645700290799141e-06
40 O 0 1.6939263787207892e-06
years O 0 3.0137218800518895e-06
) O 0 7.115705557225738e-06
. O 0 1.3901997590437531e-05

The O 0 1.8440534404362552e-05
aim O 0 1.778794830897823e-05
of O 0 8.14637189705536e-07
this O 0 5.460726697492646e-07
study O 0 1.4603174349758774e-06
was O 0 2.204168822572683e-06
to O 0 2.498545200069202e-06
assess O 0 0.00011105547309853137
genotype O 0 0.013359558768570423
- O 0 0.04385576397180557
phenotype O 0 0.009791742078959942
correlations O 0 0.00011609954526647925
in O 0 3.709412339958362e-05
AAPC B-Disease 1 0.9999728202819824
families O 0 7.281162106664851e-05
. O 0 5.259321187622845e-05

By O 0 5.600229269475676e-05
protein O 0 5.6562403187854216e-05
- O 0 4.536376582109369e-05
truncation O 0 8.998670091386884e-05
test O 0 1.2362093912088312e-05
( O 0 3.1560223305859836e-06
PTT O 0 3.150711199850775e-05
) O 0 8.983898283076996e-07
assay O 0 4.914380042464472e-06
, O 0 1.1580771541730428e-07
the O 0 1.488530187998549e-07
entire O 0 7.563311896774394e-07
coding O 0 2.3142838472267613e-06
region O 0 3.163888777635293e-07
of O 0 9.363470354628589e-08
the O 0 6.087026349632652e-07
APC B-Disease 0 0.00013976394257042557
gene O 0 6.5239287323493045e-06
was O 0 1.3719472917728126e-06
screened O 0 4.760715000884375e-06
in O 0 5.38957692697295e-07
affected O 0 1.4960144198994385e-06
individuals O 0 2.848001656730048e-07
from O 0 7.125105412342236e-07
11 O 0 1.1639620424830355e-05
AAPC B-Disease 1 0.9999830722808838
kindreds O 0 0.0001423338399035856
, O 0 4.683805627792026e-07
and O 0 3.436708766457741e-07
their O 0 4.6068385017861146e-07
phenotypic O 0 1.042369785864139e-05
differences O 0 8.923017958295532e-06
were O 0 8.46606053528376e-06
examined O 0 0.0006421816069632769
. O 0 5.420085653895512e-05

Five O 0 7.436770829372108e-05
novel O 0 0.00011478387023089454
germ O 0 0.00270467740483582
- O 0 0.00037758355028927326
line O 0 4.476172034628689e-05
APC B-Disease 0 0.0013024451909586787
mutations O 0 3.068182559218258e-05
were O 0 8.873561796463036e-07
identified O 0 2.211871333201998e-06
in O 0 1.2415678156685317e-06
seven O 0 8.370566320081707e-06
kindreds O 0 0.0007297243573702872
. O 0 4.296587940189056e-05

Mutations O 0 0.00940727349370718
were O 0 6.161430974316318e-06
located O 0 2.1234875475784065e-06
in O 0 4.259394472683198e-07
three O 0 1.1695144763734788e-07
different O 0 7.73619177607543e-08
regions O 0 2.2651268238860212e-07
of O 0 8.696856212964121e-08
the O 0 5.042377893005323e-07
APC B-Disease 0 0.00017172456136904657
gene O 0 4.0993249967868906e-06
( O 0 3.9986798583413474e-07
1 O 0 2.0000886991056177e-07
) O 0 8.536651563417763e-08
at O 0 7.302828919364401e-08
the O 0 7.785424571693511e-08
5 O 0 2.3266845516900503e-07
end O 0 3.772747163566237e-07
spanning O 0 7.710631848567573e-07
exons O 0 2.7000874069926795e-06
4 O 0 4.0995027461576683e-07
and O 0 1.3223450423538452e-07
5 O 0 2.966908994039841e-07
, O 0 1.0832953734052353e-07
( O 0 1.8541651058967545e-07
2 O 0 1.723854126112201e-07
) O 0 1.2355678791209357e-07
within O 0 2.130714449322113e-07
exon O 0 5.244671228865627e-06
9 O 0 7.265053341143357e-07
, O 0 1.3897734163492714e-07
and O 0 1.5350826743087964e-07
( O 0 2.4185038682844606e-07
3 O 0 1.7164114751722082e-07
) O 0 6.658947171445107e-08
at O 0 9.030302550172564e-08
the O 0 1.068997264042082e-07
3 O 0 3.537802797382028e-07
distal O 0 9.265929293178488e-06
end O 0 5.711429480470542e-07
of O 0 3.3198148230439983e-07
the O 0 3.2249911328108283e-06
gene O 0 6.791976920794696e-05
. O 0 2.1112200556672178e-05

Variability O 0 0.0012658365303650498
in O 0 9.078414223040454e-06
the O 0 1.9650428839668166e-06
number O 0 1.9482044990581926e-06
of O 0 1.4180053767631762e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
was O 0 0.00011551283387234434
most O 0 4.5036418327981664e-07
apparent O 0 1.2024569514323957e-05
in O 0 4.5774791601616016e-07
individuals O 0 2.496534818874352e-07
with O 0 4.278308551874943e-07
mutations O 0 9.601905730960425e-06
in O 0 2.233086462410938e-07
region O 0 5.871302164450753e-07
1 O 0 3.1275831702259893e-07
, O 0 1.1556819146107955e-07
and O 0 2.8976663202229247e-07
upper O 0 0.0670989602804184
- O 1 0.9928816556930542
gastrointestinal O 1 0.9912517666816711
manifestations O 0 0.0002740517375059426
were O 0 1.0522247748667723e-06
more O 0 5.300659609019931e-07
severe O 0 0.20836801826953888
in O 0 3.1976248919818318e-06
them O 0 2.928999720097636e-06
. O 0 1.8707558410824277e-05

In O 0 3.655922773759812e-05
individuals O 0 4.753238954435801e-06
with O 0 2.681902742551756e-06
mutations O 0 3.887505590682849e-05
in O 0 7.596375439788972e-07
either O 0 6.081496621845872e-07
region O 0 1.3174010291550076e-06
2 O 0 4.86554995404731e-07
or O 0 2.1316878928701044e-07
region O 0 3.3331770055156085e-07
3 O 0 2.1042022524397908e-07
, O 0 4.11509155640033e-08
the O 0 5.242832656904284e-08
average O 0 1.7826640430484986e-07
number O 0 6.014641229512563e-08
of O 0 1.4737945264187147e-07
adenomas B-Disease 0 0.0006948933587409556
tended O 0 1.657961001910735e-05
to O 0 4.116560603506514e-07
be O 0 1.1802832489138382e-07
lower O 0 9.62461058406916e-07
than O 0 5.61431008350155e-08
those O 0 3.9953135910764104e-08
in O 0 7.691288317346334e-08
individuals O 0 8.769080039883193e-08
with O 0 1.923881143284234e-07
mutations O 0 5.262908416625578e-06
in O 0 1.6915420530949632e-07
region O 0 4.157140551797056e-07
1 O 0 3.2440252084597887e-07
, O 0 2.0311226478497701e-07
although O 0 7.936341717140749e-07
age O 0 2.893239297918626e-06
at O 0 1.4452723007707391e-05
diagnosis O 1 0.9336979985237122
was O 0 3.483266482362524e-05
similar O 0 4.2026324081234634e-05
. O 0 3.715430648298934e-05

In O 0 0.00011906353756785393
all O 0 3.165827365592122e-05
AAPC B-Disease 1 0.999889612197876
kindreds O 0 0.0009627672843635082
, O 0 2.8536233003251255e-06
a O 0 2.255337449241779e-06
predominance O 0 2.5701425329316407e-05
of O 0 2.1755038233095547e-06
right O 0 0.0008887571166269481
- O 1 0.9983657002449036
sided O 1 0.9999980926513672
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.999998927116394
and O 0 0.0006312016048468649
rectal B-Disease 1 0.9994943141937256
polyp I-Disease 1 0.9986476302146912
sparing O 0 0.0013105683028697968
was O 0 0.00015549527597613633
observed O 0 0.0001352983235847205
. O 0 5.9410969697637483e-05

No O 0 0.0003802588616963476
desmoid B-Disease 1 0.9991704225540161
tumors I-Disease 1 0.9999991655349731
were O 0 8.775044079811778e-06
found O 0 2.8634399313887116e-06
in O 0 2.178568138333503e-06
these O 0 4.328296199673787e-06
kindreds O 0 0.0006627154070883989
. O 0 5.436526771518402e-05

Our O 0 3.0445968150161207e-05
data O 0 1.1521386113599874e-05
suggest O 0 4.86933322463301e-06
that O 0 5.174907755645108e-07
, O 0 4.313225190344383e-07
in O 0 2.6799493753060233e-06
AAPC B-Disease 1 0.9999951124191284
families O 0 1.1447341421444435e-06
, O 0 1.3169433543680498e-07
the O 0 8.31975555115605e-08
location O 0 2.029271541914568e-07
of O 0 1.0260836091902092e-07
the O 0 1.6359533674403792e-06
APC B-Disease 0 0.1481601744890213
mutation O 0 0.00016825489001348615
may O 0 1.3910552297602408e-05
partially O 0 3.2967800507321954e-05
predict O 0 1.4049887795408722e-05
specific O 0 6.225112883839756e-06
phenotypic O 0 7.526435365434736e-05
expression O 0 5.080550545244478e-05
. O 0 3.729210948222317e-05

This O 0 1.3642204976349603e-05
should O 0 2.5876554445858346e-06
help O 0 9.972741281671915e-07
in O 0 2.7326501594870933e-07
the O 0 2.2229598073408852e-07
design O 0 1.4305243212220375e-06
of O 0 3.343294849855738e-07
tailored O 0 0.041648779064416885
clinical O 1 0.5297675132751465
- O 1 0.7103307247161865
management O 0 0.0001496573386248201
protocols O 0 1.706960392766632e-05
in O 0 5.22522782375745e-07
this O 0 3.8749325881326513e-07
subset O 0 3.1084859983820934e-06
of O 0 2.64489517576294e-06
FAP B-Disease 1 0.9708230495452881
patients O 0 0.019821006804704666
. O 0 1.0294323146808892e-05
. O 0 3.2843970984686166e-05

Wilms B-Disease 1 0.9982079267501831
' I-Disease 0 0.0015492035308852792
tumor I-Disease 0 0.004284247290343046
1 O 0 5.30759598404984e-06
and O 0 1.9595559024310205e-06
Dax O 0 0.09580159187316895
- O 0 1.505906129750656e-05
1 O 0 1.2782724070348195e-06
modulate O 0 1.2090226846339647e-05
the O 0 7.443910021720512e-07
orphan O 0 2.6163756047026254e-05
nuclear O 0 1.4299202121037524e-05
receptor O 0 6.609839329030365e-05
SF O 0 0.03258564695715904
- O 0 1.1787768016802147e-05
1 O 0 5.695177947018237e-07
in O 0 4.217478135615238e-07
sex O 0 2.335288172616856e-06
- O 0 7.187522896856535e-06
specific O 0 3.227465185773326e-06
gene O 0 2.7874933948623948e-05
expression O 0 2.224310446763411e-05
. O 0 2.3181861251941882e-05

Products O 0 8.058948878897354e-05
of O 0 1.0327695235901047e-05
steroidogenic O 0 0.0038665207102894783
factor O 0 2.586279333627317e-05
1 O 0 5.989460532873636e-06
( O 0 6.946338999114232e-06
SF O 0 0.16388221085071564
- O 0 1.663313560129609e-05
1 O 0 9.437977155357657e-07
) O 0 7.871502134548791e-07
and O 0 1.186514623441326e-06
Wilms B-Disease 0 0.4218650460243225
tumor I-Disease 0 0.0028808729257434607
1 O 0 2.312642209290061e-06
( O 0 1.8617590740177548e-06
WT1 O 0 0.0002625210036057979
) O 0 7.596839850521064e-07
genes O 0 7.340155434576445e-07
are O 0 5.4445340680331356e-08
essential O 0 1.6541486047572107e-07
for O 0 2.2859489945403766e-07
mammalian O 0 8.821098163025454e-06
gonadogenesis O 0 8.486507431371137e-05
prior O 0 4.599183284881292e-06
to O 0 2.6478528525331058e-06
sexual O 0 2.414774826320354e-05
differentiation O 0 9.843364387052134e-05
. O 0 4.106520282221027e-05

In O 0 6.0460322856670246e-05
males O 0 8.526173769496381e-05
, O 0 8.27246367407497e-06
SF O 0 0.32150188088417053
- O 0 2.192031024605967e-05
1 O 0 1.1366850003469153e-06
participates O 0 1.8876215790442075e-06
in O 0 3.6413288739822747e-07
sexual O 0 7.172247933340259e-07
development O 0 5.296389531395107e-07
by O 0 3.8099418020465237e-07
regulating O 0 3.150206794089172e-06
expression O 0 9.442433679396345e-07
of O 0 1.629114052548175e-07
the O 0 1.1145889402541798e-06
polypeptide O 0 7.363822805928066e-05
hormone O 0 0.0001266079198103398
Mullerian O 0 0.0004739021824207157
inhibiting O 0 0.0001390488032484427
substance O 0 8.792220614850521e-05
( O 0 2.6013731257990003e-05
MIS O 0 0.0007747939089313149
) O 0 1.751815580064431e-05
. O 0 2.419848897261545e-05

Here O 0 3.2439555070595816e-05
, O 0 3.188921027685865e-06
we O 0 6.560737801919458e-07
show O 0 2.674250936252065e-06
that O 0 1.4823551737208618e-06
WT1 O 0 0.0014028490986675024
- O 0 0.00013624013809021562
KTS O 0 0.0002578549028839916
isoforms O 0 3.079911766690202e-05
associate O 0 6.140460300230188e-06
and O 0 1.1220696478630998e-06
synergize O 0 0.00010689152986742556
with O 0 5.243590749159921e-06
SF O 1 0.9425665140151978
- O 0 4.354260818217881e-05
1 O 0 1.0590382544251042e-06
to O 0 9.204246111949033e-07
promote O 0 9.29922316572629e-06
MIS O 0 0.0005544449668377638
expression O 0 3.957162334700115e-05
. O 0 2.4368351660086773e-05

In O 0 8.210811938624829e-05
contrast O 0 9.956012945622206e-05
, O 0 1.324233289778931e-05
WT1 O 0 0.07569126784801483
missense O 0 0.03096594847738743
mutations O 0 0.00020174685050733387
, O 0 7.87591716289171e-07
associated O 0 1.3085558521197527e-06
with O 0 4.3107866076752543e-07
male B-Disease 0 5.041034910391318e-06
pseudohermaphroditism I-Disease 1 0.9975111484527588
in O 0 2.3407095795846544e-05
Denys B-Disease 1 0.9806910753250122
- I-Disease 1 0.9974023103713989
Drash I-Disease 1 0.999961256980896
syndrome I-Disease 1 0.9999997615814209
, O 0 2.518552264518803e-06
fail O 0 1.3494035556504969e-05
to O 0 2.1818616460222984e-06
synergize O 0 0.00016001061885617673
with O 0 1.3281122846819926e-05
SF O 1 0.9888421297073364
- O 0 0.00017998887051362544
1 O 0 1.1729513062164187e-05
. O 0 2.0472300093388185e-05

Additionally O 0 0.00011230208474444225
, O 0 4.6120617298583966e-06
the O 0 2.1623982320306823e-06
X O 0 0.005119753535836935
- O 0 0.00019530656572896987
linked O 0 1.9143259123666212e-05
, O 0 5.078795766166877e-07
candidate O 0 3.4355362004134804e-06
dosage O 0 0.00015013557276688516
- O 0 6.12591247772798e-05
sensitive O 0 6.589408712898148e-06
sex O 0 4.075966899108607e-06
- O 0 9.934914487530477e-06
reversal O 0 1.1181534318893682e-05
gene O 0 4.451238055480644e-06
, O 0 5.072827207186492e-07
Dax O 0 0.000832446210552007
- O 0 8.463550329906866e-06
1 O 0 7.408633564409683e-07
, O 0 4.282737791072577e-07
antagonizes O 0 1.6726400644984096e-05
synergy O 0 5.865096227353206e-06
between O 0 1.4741939367013401e-06
SF O 0 0.06072581186890602
- O 0 6.87868987370166e-06
1 O 0 4.3771603941422654e-07
and O 0 3.0604516609855636e-07
WT1 O 0 0.0002255453437101096
, O 0 1.9629416669886268e-07
most O 0 8.50815595754284e-08
likely O 0 3.175669291977101e-07
through O 0 1.1962136170495796e-07
a O 0 2.2409373912068986e-07
direct O 0 5.031108685216168e-07
interaction O 0 9.79551373347931e-07
with O 0 1.948332510437467e-06
SF O 1 0.8819366097450256
- O 0 9.418405534233898e-05
1 O 0 1.4957041457819287e-05
. O 0 1.778375735739246e-05

We O 0 5.374934698920697e-05
propose O 0 0.0001358875015284866
that O 0 5.978635272185784e-06
WT1 O 0 0.0007413980783894658
and O 0 4.828606506634969e-06
Dax O 0 0.14435335993766785
- O 0 5.892735498491675e-05
1 O 0 1.588326426826825e-06
functionally O 0 5.720463377656415e-06
oppose O 0 1.5362485328296316e-06
each O 0 8.502590986836367e-08
other O 0 1.0587217502688873e-07
in O 0 4.794939059138414e-07
testis O 0 3.374275911482982e-05
development O 0 2.343938604099094e-06
by O 0 3.3227779567823745e-06
modulating O 0 0.007626242935657501
SF O 1 0.8229690790176392
- O 0 3.501420724205673e-05
1 O 0 2.7547864647203824e-06
- O 0 1.8271715816808864e-05
mediated O 0 6.072797259548679e-05
transactivation O 0 0.00023192753724288195
. O 0 8.367995178559795e-06
. O 0 1.564832382427994e-05

A O 0 0.00023140470148064196
mouse O 0 0.0009385889279656112
model O 0 0.00014139585255179554
for O 0 6.815229426138103e-05
Prader B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9297161102294922
- O 1 0.5542563796043396
centre O 0 0.006315881852060556
mutations O 0 0.0007151911850087345
. O 0 4.5740645873593166e-05

Imprinting O 0 0.005527807399630547
in O 0 4.5495035010389984e-05
the O 0 1.1216502571187448e-05
15q11 O 0 0.0001386991934850812
- O 0 3.638431371655315e-05
q13 O 0 2.2202944819582626e-05
region O 0 1.561633325763978e-06
involves O 0 8.274753895420872e-07
an O 0 4.5168121687311213e-07
imprinting O 0 9.31946124183014e-05
centre O 0 2.6351106498623267e-05
( O 0 1.7021657185978256e-06
IC O 0 3.557538366294466e-05
) O 0 3.7289532883733045e-07
, O 0 9.510180376537392e-08
mapping O 0 5.920998091824003e-07
in O 0 9.563257918898671e-08
part O 0 1.5833855115943152e-07
to O 0 1.280481711773973e-07
the O 0 2.7604832553151937e-07
promoter O 0 3.934575943276286e-06
and O 0 2.8632140924855776e-07
first O 0 1.4032194712854107e-06
exon O 0 3.02423595712753e-05
of O 0 3.5580028452386614e-06
SNRPN O 0 0.0028858832083642483
. O 0 5.427875657915138e-05

Deletion O 0 0.0019177491776645184
of O 0 1.9731793145183474e-05
this O 0 1.2129399692639709e-05
IC O 0 0.0007675936794839799
abolishes O 0 0.0007614280912093818
local O 0 1.3610679161502048e-05
paternally O 0 0.00021226366516202688
derived O 0 1.0863057468668558e-05
gene O 0 8.737158168514725e-06
expression O 0 2.420551254544989e-06
and O 0 1.1735033922377625e-06
results O 0 1.0581747119431384e-05
in O 0 0.00013399757153820246
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0017793083097785711
PWS B-Disease 1 0.9999977350234985
) O 0 6.03438493271824e-05
. O 0 3.093095074291341e-05

We O 0 1.3012760973651893e-05
have O 0 2.799999265334918e-06
created O 0 2.955180207209196e-06
two O 0 9.248838637176959e-07
deletion O 0 0.00025682197883725166
mutations O 0 8.079032704699785e-05
in O 0 2.8853671665274305e-06
mice O 0 0.0004447929095476866
to O 0 1.8570951851870632e-06
understand O 0 1.2549106031656265e-05
PWS B-Disease 1 0.9999972581863403
and O 0 8.128700983434101e-07
the O 0 4.584888699810108e-07
mechanism O 0 2.223295723524643e-06
of O 0 4.888955231763248e-07
this O 0 2.0382624370540725e-06
IC O 0 0.0008877195068635046
. O 0 2.8156851840321906e-05

Mice O 0 0.007486718241125345
harbouring O 0 0.00145793950650841
an O 0 1.4155273674987257e-05
intragenic O 0 0.0012118667364120483
deletion O 0 0.00018188018293585628
in O 0 3.94679727833136e-06
Snrpn O 0 0.00015482446178793907
are O 0 8.820273365017783e-07
phenotypically O 0 9.150219557341188e-05
normal O 0 3.588827212297474e-06
, O 0 3.0796468308835756e-07
suggesting O 0 2.911910087277647e-06
that O 0 3.4840903140320734e-07
mutations O 0 4.625946075975662e-06
of O 0 2.633267399687611e-07
SNRPN O 0 0.0008124099113047123
are O 0 1.5865659008795774e-07
not O 0 2.3088290390660404e-07
sufficient O 0 1.5895310525593231e-06
to O 0 4.390452431835001e-06
induce O 0 0.002840157598257065
PWS B-Disease 1 0.9999967813491821
. O 0 0.00011313820868963376

Mice O 0 0.004306101240217686
with O 0 6.624409252253827e-06
a O 0 3.775482355194981e-06
larger O 0 4.63254218630027e-06
deletion O 0 2.086194399453234e-05
involving O 0 2.1015623588027665e-06
both O 0 8.19994340872654e-07
Snrpn O 0 5.642395626637153e-05
and O 0 8.130995752253511e-07
the O 0 3.5092514281132026e-06
putative O 0 0.02537781372666359
PWS O 1 0.9999998807907104
- O 0 0.01779847778379917
IC O 0 0.0002252850536024198
lack O 0 2.2474018805951346e-06
expression O 0 9.636972890803008e-07
of O 0 2.093238293809918e-07
the O 0 1.3800780607198249e-06
imprinted O 0 0.00014556538371834904
genes O 0 1.1290616384940222e-05
Zfp127 O 0 4.720145807368681e-05
( O 0 3.6490362163021928e-06
mouse O 0 1.0157406904909294e-05
homologue O 0 1.9248413082095794e-05
of O 0 5.669713232236973e-07
ZNF127 O 0 8.768425323069096e-05
) O 0 1.1729507605195977e-06
, O 0 5.376352874009172e-07
Ndn O 0 0.00011114618246210739
and O 0 8.244702485171729e-07
Ipw O 0 9.218655759468675e-05
, O 0 3.2390451565333933e-07
and O 0 2.8233006332811783e-07
manifest O 0 1.290905856876634e-05
several O 0 1.3450304550133296e-06
phenotypes O 0 0.00020942153059877455
common O 0 1.4817906048847362e-05
to O 0 0.00014681548054795712
PWS B-Disease 1 1.0
infants O 1 0.9148722290992737
. O 0 8.693394920555875e-05

These O 0 1.3689185834664386e-05
data O 0 7.16201429895591e-06
demonstrate O 0 2.9787358926114393e-06
that O 0 2.1576137498868775e-07
both O 0 7.926011846848269e-08
the O 0 1.1520945975007635e-07
position O 0 2.485644472471904e-07
of O 0 4.881817616819717e-08
the O 0 2.3167029894466395e-07
IC O 0 2.3603704903507605e-05
and O 0 1.2211755517910206e-07
its O 0 1.7899806437071675e-07
role O 0 2.1076104417261377e-07
in O 0 1.1382868336795582e-07
the O 0 1.1262223154062667e-07
coordinate O 0 6.526851734633965e-07
expression O 0 2.1218164647507365e-07
of O 0 6.814389053033665e-08
genes O 0 3.998470106125751e-07
is O 0 7.319842154629441e-08
conserved O 0 2.1845382036644878e-07
between O 0 1.3272520504870045e-07
mouse O 0 2.4537032459193142e-06
and O 0 9.653810195686674e-08
human O 0 1.345445781453236e-07
, O 0 6.667169571983322e-08
and O 0 6.510327921205317e-08
indicate O 0 3.1247688525581907e-07
that O 0 3.8829888637792465e-08
the O 0 9.59825143809212e-08
mouse O 0 3.972111699113157e-06
is O 0 7.926722389584029e-08
a O 0 2.3337734944561817e-07
suitable O 0 1.0359234465795453e-06
model O 0 3.661711389213451e-06
system O 0 1.519508032288286e-06
in O 0 1.3088624939427973e-07
which O 0 8.820292407563102e-08
to O 0 7.263488299713572e-08
investigate O 0 6.032979058545607e-07
the O 0 1.2633545054541173e-07
molecular O 0 1.4470156202150974e-06
mechanisms O 0 7.5313619163353e-07
of O 0 1.3512463681308873e-07
imprinting O 0 3.76676871383097e-05
in O 0 3.4664947179408045e-07
this O 0 1.2101813240406045e-07
region O 0 3.9017652397888014e-07
of O 0 1.1558208967699102e-07
the O 0 7.584243917335698e-07
genome O 0 1.308643459196901e-05
. O 0 4.155850092502078e-06
. O 0 1.4315794032881968e-05

Mutations O 0 0.0010656720260158181
of O 0 7.15873648005072e-06
the O 0 5.4719630497857e-06
ATM O 0 0.0001448397379135713
gene O 0 3.8892929296707734e-05
detected O 0 2.4275361283798702e-05
in O 0 3.0205180792108877e-06
Japanese O 0 0.0035808891989290714
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
patients O 1 0.7540547251701355
: O 0 9.330734656032291e-07
possible O 0 8.049643724916677e-07
preponderance O 0 3.3218464068340836e-06
of O 0 1.2134785265516257e-07
the O 0 3.6951107063032396e-07
two O 0 9.576945103617618e-07
founder O 0 0.00011373671441106126
mutations O 0 5.1081929996144027e-05
4612del165 O 0 5.715068255085498e-05
and O 0 7.916062713775318e-06
7883del5 O 0 0.0002930175687652081
. O 0 3.013457535416819e-05

The O 0 6.444023892981932e-05
ATM O 0 0.001154012861661613
( O 0 3.468029171926901e-05
A O 0 0.21437032520771027
- O 1 0.9975963234901428
T O 1 0.9997641444206238
, O 0 1.8142142153010354e-06
mutated O 0 1.6193233022931963e-05
) O 0 1.111741994463955e-06
gene O 0 3.516641754686134e-06
on O 0 1.0193689377047122e-06
human O 0 6.168009804241592e-06
chromosome O 0 0.00010797096911119297
11q22 O 0 0.00021088628272991627
. O 0 2.7729427529266104e-05

3 O 0 7.290617941180244e-05
has O 0 8.228786100517027e-06
recently O 0 1.2336868167039938e-05
been O 0 9.913816256812424e-07
identified O 0 5.437217396320193e-07
as O 0 1.2372706237329112e-07
the O 0 1.806683229688133e-07
gene O 0 1.4565425772161689e-06
responsible O 0 4.982976520295779e-07
for O 0 1.755391565438913e-07
the O 0 1.2091112466805498e-06
human O 0 0.00013878362369723618
recessive B-Disease 1 0.9999991655349731
disease I-Disease 1 0.9999997615814209
ataxia B-Disease 1 1.0
- I-Disease 1 0.999997615814209
telangiectasia I-Disease 1 0.9999998807907104
( O 0 8.213341061491519e-05
A B-Disease 1 0.8478542566299438
- I-Disease 1 0.9966816306114197
T I-Disease 1 0.999847412109375
) O 0 2.89050967694493e-05
. O 0 2.3640988729312085e-05

In O 0 2.0744968423969112e-05
order O 0 5.886355211259797e-06
to O 0 1.017789372781408e-06
define O 0 1.5067588492456707e-06
the O 0 3.3395824061699386e-07
types O 0 9.120501545112347e-07
of O 0 6.106160981289577e-07
disease O 0 0.14875257015228271
- O 0 0.0008505421574227512
causing O 0 3.2715743145672604e-05
ATM O 0 0.00018069922225549817
mutations O 0 1.1696014553308487e-05
in O 0 4.3784879721897596e-07
Japanese O 0 6.2446938500215765e-06
A B-Disease 1 0.9998441934585571
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.003903475357219577
as O 0 1.984501096785607e-07
well O 0 8.76869492572041e-08
as O 0 7.016394221182054e-08
to O 0 8.997722744652492e-08
look O 0 3.4151645422753063e-07
for O 0 1.227223123123622e-07
possible O 0 1.0547324791332358e-06
mutational O 0 0.0001936635817401111
hotspots O 0 2.3854183382354677e-05
, O 0 4.3698400986613706e-07
reverse O 0 6.669250524282688e-06
- O 0 3.884614670823794e-06
transcribed O 0 2.653021965670632e-06
RNA O 0 1.2533333801911795e-06
derived O 0 4.810062250726332e-07
from O 0 1.9100420445283817e-07
ten O 0 4.633946275589551e-07
patients O 0 4.631813226296799e-06
belonging O 0 1.5080929642863339e-06
to O 0 2.7985657879980863e-07
eight O 0 4.503401385136385e-07
unrelated O 0 3.861729055643082e-06
Japanese O 0 8.918951607483905e-06
A B-Disease 1 0.9923187494277954
- I-Disease 1 0.9999842643737793
T I-Disease 1 0.9999984502792358
families O 0 3.3780793273763265e-06
was O 0 4.9981385927821975e-06
analyzed O 0 5.484010671352735e-06
for O 0 9.215488034897135e-07
mutations O 0 1.0129371730727144e-05
by O 0 7.762440645819879e-07
the O 0 2.324168463019305e-06
restriction O 0 2.2453268684330396e-05
endonuclease O 0 0.00024616316659376025
fingerprinting O 0 6.322395347524434e-05
method O 0 3.4199798392364755e-05
. O 0 2.4185477741411887e-05

As O 0 2.1277477571857162e-05
has O 0 4.762058779306244e-06
been O 0 1.3982528344058665e-06
reported O 0 6.212652806425467e-06
by O 0 5.883526910110959e-07
others O 0 9.266584584111115e-07
, O 0 5.492177592714143e-07
mutations O 0 6.226662662811577e-06
that O 0 1.8814736790773168e-07
lead O 0 5.575762997978018e-07
to O 0 4.3548342887334e-07
exon O 0 1.1365287718945183e-05
skipping O 0 4.32487104262691e-06
or O 0 1.3701495618079207e-06
premature O 0 2.1684531020582654e-05
protein O 0 1.8694736354518682e-06
truncation O 0 8.940496627474204e-06
were O 0 5.014956059312681e-07
also O 0 5.987668600937468e-07
predominant O 0 4.6466921048704535e-06
in O 0 1.2510214446592727e-06
our O 0 4.171749878878472e-06
mutants O 0 0.0003008789790328592
. O 0 1.8068474673782475e-05

Six O 0 2.8214721169206314e-05
different O 0 4.793987955054035e-06
mutations O 0 3.3084081223933026e-05
were O 0 4.7561860583300586e-07
identified O 0 6.708978617098182e-07
on O 0 2.4525752451154403e-07
12 O 0 1.9468357947971526e-07
of O 0 9.464452688234815e-08
the O 0 8.302696983264468e-07
16 O 0 1.5223410628095735e-05
alleles O 0 0.00031183919054456055
examined O 0 0.0009070992819033563
. O 0 6.152714922791347e-05

Four O 0 2.279749787703622e-05
were O 0 5.364622211345704e-06
deletions O 0 3.8169080653460696e-05
involving O 0 3.8121406760183163e-06
a O 0 2.8843380732723745e-06
loss O 0 1.5115605492610484e-05
of O 0 2.1797309557314293e-07
a O 0 8.976584240372176e-07
single O 0 2.3952025003382005e-06
exon O 0 1.9764223907259293e-05
exon O 0 1.537182106403634e-05
7 O 0 1.5370617347798543e-06
, O 0 3.280903513314115e-07
exon O 0 7.604460279253544e-06
16 O 0 1.030426346915192e-06
, O 0 5.55866733975563e-07
exon O 0 1.7681551980786026e-05
33 O 0 4.341955900599714e-06
or O 0 3.404031303944066e-06
exon O 0 8.707597589818761e-05
35 O 0 3.088390803895891e-05
. O 0 2.4072907763184048e-05

The O 0 3.059101800317876e-05
others O 0 1.4931545592844486e-05
were O 0 1.4012991869094549e-06
minute O 0 3.6982062283641426e-06
deletions O 0 2.139706521120388e-05
, O 0 1.0732195505624986e-06
4649delA O 0 2.3712134861852974e-05
in O 0 1.9980041088274447e-06
exon O 0 2.820151530613657e-05
33 O 0 3.004687869179179e-06
and O 0 1.110193011299998e-06
7883del5 O 0 4.7029276174725965e-05
in O 0 7.092237865435891e-06
exon O 0 0.00016565404075663537
55 O 0 5.040275209466927e-05
. O 0 3.832562288152985e-05

The O 0 6.753780326107517e-05
mutations O 0 0.0004061651707161218
4612del165 O 0 0.00012597351451404393
and O 0 3.020604481207556e-06
7883del5 O 0 5.255815995042212e-05
were O 0 8.807732001514523e-07
found O 0 3.4816093830158934e-07
in O 0 1.2391576831305429e-07
more O 0 6.346115100086536e-08
than O 0 5.311741091418298e-08
two O 0 1.3838391055287502e-07
unrelated O 0 3.044068535018596e-06
families O 0 6.518242798847496e-07
; O 0 4.979859795639641e-07
44 O 0 6.421447551474557e-07
% O 0 2.107077960999959e-07
( O 0 2.1244022718747146e-07
7 O 0 2.0446802295737143e-07
of O 0 4.6815639365149764e-08
16 O 0 1.7903425941767637e-07
) O 0 6.586516576589929e-08
of O 0 2.7149493320166584e-08
the O 0 1.8248618971483666e-07
mutant O 0 1.898313348647207e-05
alleles O 0 4.943754902342334e-06
had O 0 2.6098490479853353e-07
one O 0 4.7989413332061304e-08
of O 0 8.674954443677052e-08
the O 0 6.481731134044821e-07
two O 0 3.945660409954144e-06
mutations O 0 0.00030151676037348807
. O 0 2.5890285542118363e-05

The O 0 6.293792102951556e-05
4612del165 O 0 0.0050870091654360294
mutations O 0 0.00047268293565139174
in O 0 1.538121978228446e-06
three O 0 3.548297797806299e-07
different O 0 1.677748002748558e-07
families O 0 3.038501006358274e-07
were O 0 1.0363191194073806e-07
all O 0 3.0690209484873776e-08
ascribed O 0 1.2329483070061542e-06
to O 0 1.366529147617257e-07
the O 0 3.244718129735702e-07
same O 0 3.854179340123665e-06
T O 1 0.7862269878387451
- O 0 0.00025659584207460284
- O 0 1.3236083759693429e-05
> O 0 2.1005184862588067e-06
A O 0 3.1966808933248103e-07
substitution O 0 5.927370807512489e-07
at O 0 2.5394820113433525e-07
the O 0 4.778983111464186e-07
splice O 0 3.3802625694079325e-05
donor O 0 7.554253443231573e-06
site O 0 8.113312105706427e-06
in O 0 4.622576852852944e-06
intron O 0 0.0003976905136369169
33 O 0 4.130891102249734e-05
. O 0 3.296421346021816e-05

Microsatellite O 0 0.008325425907969475
genotyping O 0 0.0021358767990022898
around O 0 1.6840565876918845e-05
the O 0 4.310035819798941e-06
ATM O 0 0.00014027651923242956
locus O 0 4.7795001592021435e-05
also O 0 1.9960043573519215e-06
indicated O 0 5.591457465925487e-06
that O 0 3.3206319471901224e-07
a O 0 7.304124096663145e-07
common O 0 2.360727876293822e-06
haplotype O 0 0.003702456597238779
was O 0 1.8674742250368581e-06
shared O 0 3.788853746300447e-07
by O 0 2.0023846047934057e-07
the O 0 5.925008395024634e-07
mutant O 0 3.2962896511889994e-05
alleles O 0 1.4752523384231608e-05
in O 0 1.3960888054498355e-06
both O 0 3.1171186947176466e-06
mutations O 0 0.00014736107550561428
. O 0 2.3170767235569656e-05

This O 0 1.8519365767133422e-05
suggests O 0 1.164888271887321e-05
that O 0 5.272918883747479e-07
these O 0 1.8334426954424998e-07
two O 0 5.099568056721182e-07
founder O 0 0.003852196503430605
mutations O 0 0.0002629262744449079
may O 0 1.990643795579672e-06
be O 0 1.6508676026205649e-07
predominant O 0 1.9061075136050931e-06
among O 0 5.282154802443983e-07
Japanese O 0 5.034929017710965e-06
ATM O 0 0.00027025077724829316
mutant O 0 0.00040984596125781536
alleles O 0 0.0003819733683485538
. O 0 4.754488691105507e-05

W474C O 0 0.0019107150146737695
amino O 0 0.0001786359352990985
acid O 0 9.882330050459132e-05
substitution O 0 3.460209700278938e-05
affects O 0 1.55248762894189e-05
early O 0 2.5224487671948737e-06
processing O 0 9.600428256817395e-07
of O 0 1.0122491289621394e-07
the O 0 2.445885627366806e-07
alpha O 0 1.7682123143458739e-06
- O 0 7.300830020540161e-07
subunit O 0 5.296111567076878e-07
of O 0 1.0318223075955757e-07
beta O 0 2.449606881782529e-06
- O 0 4.942934538121335e-06
hexosaminidase O 0 1.217242515849648e-05
A O 0 8.339192163475673e-07
and O 0 2.0651238230584568e-07
is O 0 2.726355887716636e-07
associated O 0 2.7887106170965126e-06
with O 0 4.1954690459533595e-06
subacute O 1 0.9979717135429382
G B-Disease 0 0.02827838622033596
( I-Disease 0 1.2456342119548935e-05
M2 I-Disease 0 0.00033495709067210555
) I-Disease 0 1.0300509529770352e-05
gangliosidosis I-Disease 0 0.00033886602614074945
. O 0 2.877040060411673e-05

Mutations O 0 0.002672246191650629
in O 0 1.7471806131652556e-05
the O 0 1.22566680147429e-05
HEXA O 0 0.010271020233631134
gene O 0 1.9936223907279782e-05
, O 0 4.335370817898365e-07
encoding O 0 1.5373300357168773e-06
the O 0 2.6418624088364595e-07
alpha O 0 1.9310218704049475e-06
- O 0 1.5393017065434833e-06
subunit O 0 1.3199691011323011e-06
of O 0 1.796760216166149e-07
beta O 0 2.774550239337259e-06
- O 0 5.263751972961472e-06
hexosaminidase O 0 1.1742394235625397e-05
A O 0 8.201241712413321e-07
( O 0 4.626280940556171e-07
Hex O 0 2.747372036537854e-06
A O 0 4.4389133790900814e-07
) O 0 1.5207170633857459e-07
, O 0 7.574790572562051e-08
that O 0 1.0450130361050469e-07
abolish O 0 5.998344022373203e-06
Hex O 0 1.0294422281731386e-05
A O 0 1.4498874634227832e-06
enzyme O 0 7.2383695624012034e-06
activity O 0 1.908303784148302e-05
cause O 0 0.07002153247594833
Tay B-Disease 1 0.9999995231628418
- I-Disease 1 0.999984622001648
Sachs I-Disease 1 0.9999992847442627
disease I-Disease 1 0.889668345451355
( O 0 1.0835204193426762e-05
TSD B-Disease 0 0.023261720314621925
) O 0 9.123625090978749e-07
, O 0 2.0878094630916166e-07
the O 0 6.601785003113037e-07
fatal O 0 0.1466650366783142
infantile B-Disease 0 0.061361804604530334
form I-Disease 0 2.8849212867498863e-06
of I-Disease 0 1.09512620838359e-06
G I-Disease 0 0.00021149296662770212
( I-Disease 0 3.4637660064618103e-06
M2 I-Disease 0 6.499965820694342e-05
) I-Disease 0 2.415759354335023e-06
gangliosidosis I-Disease 0 8.559590060031042e-05
, I-Disease 0 2.087796474370407e-06
Type I-Disease 0 1.6893583961063996e-05
1 I-Disease 0 1.0577953617030289e-05
. O 0 2.1478310372913256e-05

Less O 0 0.00040634485776536167
severe O 1 0.9959763884544373
, O 0 0.00010130742884939536
subacute O 1 0.999790608882904
( O 0 0.00023179955314844847
juvenile O 1 0.5770162343978882
- O 1 0.7732572555541992
onset O 1 0.9853805899620056
) O 0 9.343377314507961e-06
and O 0 1.068188066710718e-05
chronic O 1 0.9885678291320801
( O 0 4.484245437197387e-06
adult O 0 1.8236392861581407e-05
- O 0 0.015225725248456001
onset O 0 0.0659288689494133
) O 0 8.349863946932601e-07
variants O 0 2.5245233246096177e-06
are O 0 1.4309908635823376e-07
characterized O 0 1.3621005336972303e-06
by O 0 2.1053946852589434e-07
a O 0 6.218148769221443e-07
broad O 0 4.194933353574015e-06
spectrum O 0 1.5273508324753493e-05
of O 0 2.9360370490394416e-07
clinical O 0 0.00015437132969964296
manifestations O 0 0.00011413827451178804
and O 0 7.485670039386605e-07
are O 0 7.510440269697938e-08
associated O 0 3.393648739802302e-07
with O 0 2.1021004670274124e-07
residual O 0 7.691281098232139e-06
levels O 0 1.0838094794962672e-06
of O 0 4.2738145111798076e-07
Hex O 0 2.3752738343318924e-05
A O 0 5.697215783584397e-06
enzyme O 0 3.1664883863413706e-05
activity O 0 3.121345798717812e-05
. O 0 2.1349940652726218e-05

We O 0 3.8575475628022105e-05
identified O 0 3.864444443024695e-05
a O 0 2.052892159554176e-05
1422 O 1 0.8125773072242737
G O 0 0.3683210015296936
- O 0 0.014262090437114239
- O 0 0.00023595553648192436
> O 0 3.252802707720548e-05
C O 0 1.417264502379112e-05
( O 0 1.1242343589401571e-06
amino O 0 9.728557870403165e-07
acid O 0 2.3752825200062944e-06
W474C O 0 6.865700015623588e-06
) O 0 3.4122342640330316e-07
substitution O 0 3.991330288499739e-07
in O 0 1.0408019335272911e-07
the O 0 7.936994705914913e-08
first O 0 1.2675904770276247e-07
position O 0 2.1204004951869138e-07
of O 0 8.39001543795348e-08
exon O 0 4.535002517513931e-06
13 O 0 5.507415039573971e-07
of O 0 2.54500235996602e-07
HEXA O 0 0.0003475894336588681
of O 0 2.655287403285911e-07
a O 0 1.3583515965365223e-06
non O 0 2.5189583539031446e-06
- O 0 1.1748801625799388e-05
Jewish O 0 4.16599277741625e-06
proband O 0 0.0009345529251731932
who O 0 4.162252025707858e-06
manifested O 0 6.32058727205731e-05
a O 0 1.4738670870428905e-05
subacute O 1 0.8481978178024292
variant O 0 0.00028446860960684717
of O 0 3.2555715279158903e-06
G B-Disease 0 0.001189825008623302
( I-Disease 0 9.95997561403783e-06
M2 I-Disease 0 0.00016840914031490684
) I-Disease 0 9.26828033698257e-06
gangliosidosis I-Disease 0 0.0004678787081502378
. O 0 3.7861434975638986e-05

On O 0 2.2457936211139895e-05
the O 0 5.327973212843062e-06
second O 0 1.0233098691969644e-05
maternally O 0 0.04655611887574196
inherited O 0 0.08811584860086441
allele O 0 7.295318937394768e-05
, O 0 4.7438101091756835e-07
we O 0 1.728062812844655e-07
identified O 0 8.409014640164969e-07
the O 0 7.995841997399111e-07
common O 0 0.00013422085612546653
infantile O 1 0.9999974966049194
disease O 1 0.9972803592681885
- O 0 0.0012524888152256608
causing O 0 1.9011416952707805e-05
4 O 0 3.6054714200872695e-06
- O 0 1.538125070510432e-05
bp O 0 1.9556931874831207e-05
insertion O 0 1.3516138096747454e-05
, O 0 1.4741771110493573e-06
+ O 0 1.3641450095747132e-05
TATC O 0 0.00038157845847308636
1278 O 0 0.000525452836882323
, O 0 1.905491330944642e-06
in O 0 2.6878274184127804e-06
exon O 0 0.00010403390479041263
11 O 0 2.6630817956174724e-05
. O 0 3.616721005528234e-05

Pulse O 0 0.016283715143799782
- O 0 0.0009109323145821691
chase O 0 0.00014070213364902884
analysis O 0 8.637954124424141e-06
using O 0 3.06674996863876e-06
proband O 0 0.00022901179909240454
fibroblasts O 0 0.0002491940394975245
revealed O 0 1.132076340581989e-05
that O 0 1.6991054963000352e-07
the O 0 3.072131278258894e-07
W474C O 0 1.0735394425864797e-05
- O 0 2.185485300287837e-06
containing O 0 8.28226916382846e-07
alpha O 0 2.8072904569853563e-06
- O 0 2.681043497432256e-06
subunit O 0 2.2995170638751006e-06
precursor O 0 3.3263606837863335e-06
was O 0 6.745656833118119e-07
normally O 0 5.278402568364982e-07
synthesized O 0 2.1048376765975263e-06
, O 0 1.0899898228444727e-07
but O 0 5.729531693532408e-08
not O 0 8.327884160053145e-08
phosphorylated O 0 2.4417470285698073e-06
or O 0 2.710430635488592e-07
secreted O 0 1.7848104789663921e-06
, O 0 1.0341727829654701e-07
and O 0 9.942451129063556e-08
the O 0 2.801046434797172e-07
mature O 0 2.6353352495789295e-06
lysosomal O 0 0.00011443011317169294
alpha O 0 7.198601451818831e-06
- O 0 5.536211574508343e-06
subunit O 0 3.7346301269280957e-06
was O 0 2.4409462184848962e-06
not O 0 1.6879387203516671e-06
detected O 0 6.0966223827563226e-05
. O 0 2.2998874555923976e-05

When O 0 3.175963865942322e-05
the O 0 7.380513125099242e-06
W474C O 0 0.0001009414772852324
- O 0 1.3153047802916262e-05
containing O 0 2.962361577374395e-06
alpha O 0 6.363863576552831e-06
- O 0 4.6874979489075486e-06
subunit O 0 4.543001978163375e-06
was O 0 1.756925030349521e-06
transiently O 0 4.183857890893705e-05
co O 0 1.531277121102903e-05
- O 0 2.4526736979169073e-06
expressed O 0 3.1982909831640427e-07
with O 0 8.139097928960837e-08
the O 0 2.1619308654408087e-07
beta O 0 2.798832611006219e-06
- O 0 2.3687516659265384e-06
subunit O 0 1.5341344123953604e-06
to O 0 2.3955695382937847e-07
produce O 0 5.6720870134086e-07
Hex O 0 7.403918516502017e-06
A O 0 1.9335391243657796e-06
( O 0 1.194113337987801e-06
alphabeta O 0 2.4575096176704392e-05
) O 0 5.813157031298033e-07
in O 0 7.736750831099926e-07
COS O 0 0.010803384706377983
- O 0 1.7900840248330496e-05
7 O 0 1.5784071365487762e-06
cells O 0 1.81202346993814e-06
, O 0 9.212274676428933e-08
the O 0 1.160281541956465e-07
mature O 0 7.423868169098569e-07
alpha O 0 1.0572077826509485e-06
- O 0 1.2613022590812761e-06
subunit O 0 8.439511134383793e-07
was O 0 3.423597263463307e-07
present O 0 1.4378812807080976e-07
, O 0 4.434639677697305e-08
but O 0 2.687411715385224e-08
its O 0 6.108227523782261e-08
level O 0 9.330577199762047e-08
was O 0 1.8810285951076366e-07
much O 0 1.0468643552030699e-07
lower O 0 1.0274109172314638e-06
than O 0 5.8662312341084544e-08
that O 0 5.5468269977154705e-08
from O 0 1.0927687554840304e-07
normal O 0 5.683523340849206e-07
alpha O 0 1.944527184605249e-06
- O 0 1.945024223459768e-06
subunit O 0 1.4091199318500003e-06
transfections O 0 4.858224201598205e-06
, O 0 1.1072371108866719e-07
although O 0 1.1613742145755168e-07
higher O 0 1.7481342240444064e-07
than O 0 4.0775809395654505e-08
in O 0 1.2947209881986055e-07
those O 0 2.1707361952394422e-07
cells O 0 3.338946726216818e-06
transfected O 0 2.4597489755251445e-05
with O 0 1.959888891178707e-07
an O 0 2.604304540909652e-07
alpha O 0 3.938870577258058e-06
- O 0 6.269684035942191e-06
subunit O 0 8.977124707598705e-06
associated O 0 8.101096682366915e-06
with O 0 8.70845906320028e-06
infantile O 1 0.9099594950675964
TSD B-Disease 1 0.9469776153564453
. O 0 0.00014279643073678017

Furthermore O 0 8.841641101753339e-05
, O 0 2.3221234641823685e-06
the O 0 7.497529850297724e-07
precursor O 0 3.803000481639174e-06
level O 0 4.1569145992070844e-07
of O 0 8.544356688844346e-08
the O 0 4.946207354805665e-07
W474C O 0 9.938078619597945e-06
alpha O 0 5.216666522755986e-06
- O 0 2.7970872906735167e-06
subunit O 0 2.0316063000791473e-06
was O 0 7.189793791440025e-07
found O 0 3.17995159093698e-07
to O 0 3.4661675840652606e-07
accumulate O 0 5.7848315009323414e-06
in O 0 1.457321872067041e-07
comparison O 0 3.618936830207531e-07
to O 0 1.580125683631195e-07
the O 0 2.95220957013953e-07
normal O 0 2.1115367871971102e-06
alpha O 0 7.5416278377815615e-06
- O 0 8.637278369860724e-06
subunit O 0 1.4499550161417574e-05
precursor O 0 2.2727077521267347e-05
levels O 0 1.5869285562075675e-05
. O 0 1.740289371809922e-05

We O 0 2.2500124032376334e-05
conclude O 0 2.7343152396497317e-05
that O 0 1.537437128718011e-06
the O 0 2.9244026791275246e-06
1422 O 0 0.3826344609260559
G O 0 0.10711751878261566
- O 0 0.005794609431177378
- O 0 0.0006313836784102023
> O 0 4.0216731576947495e-05
C O 0 3.8963014958426356e-05
mutation O 0 5.171950306248618e-06
is O 0 1.4812556514698372e-07
the O 0 2.0678297119047784e-07
cause O 0 9.873263024928747e-07
of O 0 2.210078093867196e-07
Hex B-Disease 0 0.00010096901678480208
A I-Disease 0 0.01222131960093975
enzyme I-Disease 1 0.9998898506164551
deficiency I-Disease 1 0.999956488609314
in O 0 1.8067588598569273e-06
the O 0 4.432265086506959e-06
proband O 0 0.0014441400999203324
. O 0 3.1322026188718155e-05

The O 0 4.182589327683672e-05
resulting O 0 6.300895620370284e-05
W474C O 0 0.0001523904938949272
substitution O 0 2.702516758290585e-05
clearly O 0 8.458168849756476e-06
interferes O 0 1.2530187632364687e-05
with O 0 7.431524977619119e-07
alpha O 0 4.305632046452956e-06
- O 0 1.9320386854815297e-06
subunit O 0 1.3064336599200033e-06
processing O 0 3.9127240825109766e-07
, O 0 8.97407019806451e-08
but O 0 4.745321291466098e-08
because O 0 5.052871543398396e-08
the O 0 6.348415126922191e-08
base O 0 3.440020464040572e-07
substitution O 0 8.894844540918712e-07
falls O 0 6.8659951466543134e-06
at O 0 1.637127127196436e-07
the O 0 9.337681206034176e-08
first O 0 1.3217209016147535e-07
position O 0 3.680073064060707e-07
of O 0 1.1638167762839657e-07
exon O 0 6.094373020459898e-06
13 O 0 7.244836410791322e-07
, O 0 3.281901683749311e-07
aberrant O 0 7.835784344933927e-06
splicing O 0 1.0194603419222403e-05
may O 0 1.2452283044694923e-06
also O 0 2.205404001642819e-07
contribute O 0 5.641870188810572e-07
to O 0 5.634121862385655e-07
Hex B-Disease 0 0.000124361424241215
A I-Disease 0 0.00350522855296731
deficiency I-Disease 1 0.6955438256263733
in O 0 6.930815175110183e-07
this O 0 1.0278187119183713e-06
proband O 0 0.0008999449200928211
. O 0 6.807193130953237e-06
. O 0 1.751822310325224e-05

Two O 0 0.000156712849275209
frequent O 0 0.0015248917043209076
missense O 1 0.530351996421814
mutations O 0 0.28940457105636597
in O 0 0.00459698960185051
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0005448310985229909

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.019437389448285103
an O 1 0.9630129337310791
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.8848968744277954
by O 0 5.1668965170392767e-05
early O 0 0.22980135679244995
childhood O 1 0.9999825954437256
deafness B-Disease 1 1.0
and O 1 0.6890822649002075
goiter B-Disease 1 1.0
. O 0 0.00021955148258712143

A O 0 4.430425542523153e-05
century O 0 9.248518836102448e-06
after O 0 2.026114998443518e-06
its O 0 6.478097702711239e-07
recognition O 0 8.251735152953188e-07
as O 0 8.813798899609537e-07
a O 0 8.3364691818133e-05
syndrome O 1 0.9998992681503296
by O 0 1.8115034663424012e-06
Vaughan O 0 0.00020702462643384933
Pendred O 0 0.00047420719056390226
, O 0 5.76629645365756e-07
the O 0 2.8967679099878296e-06
disease O 0 0.018078720197081566
gene O 0 1.533247996121645e-05
( O 0 2.683447746676393e-06
PDS O 0 0.00028187816496938467
) O 0 1.1494818181745359e-06
was O 0 1.7236549183508032e-06
mapped O 0 1.2198398508189712e-05
to O 0 1.7725193401929573e-06
chromosome O 0 4.508499114308506e-05
7q22 O 0 0.00013972267333883792
- O 0 0.00018346206343267113
q31 O 0 0.0003631418221630156
. O 0 4.5606975618284196e-05

1 O 0 3.924178963643499e-05
and O 0 3.490946028250619e-06
, O 0 1.2752649354297318e-06
recently O 0 4.360520961199654e-06
, O 0 2.3082721156697517e-07
found O 0 2.859851804259961e-07
to O 0 3.3117009934358066e-07
encode O 0 3.5721941458177753e-06
a O 0 4.048083155794302e-06
putative O 0 0.00039376868517138064
sulfate O 0 0.0031952657736837864
transporter O 0 0.0019595762714743614
. O 0 4.3442280002636835e-05

We O 0 2.646953180374112e-05
performed O 0 1.9340137441758998e-05
mutation O 0 1.8133587218471803e-05
analysis O 0 1.3182129805500153e-06
of O 0 1.6789675783002167e-07
the O 0 6.752241574758955e-07
PDS B-Disease 0 0.06428659707307816
gene O 0 2.130120810761582e-05
in O 0 1.772245468600886e-06
patients O 0 1.8366174117545597e-05
from O 0 4.1458093846813426e-07
14 O 0 9.098062037082855e-07
Pendred B-Disease 0 2.7095982659375295e-05
families O 0 4.880160986431292e-07
originating O 0 1.1136497732877615e-06
from O 0 1.931357616058449e-07
seven O 0 2.2296413249023317e-07
countries O 0 1.8773727106236038e-07
and O 0 3.2458945042890264e-07
identified O 0 2.8378581191645935e-06
all O 0 1.816936219256604e-06
mutations O 0 0.0001639761176193133
. O 0 2.2147114577819593e-05

The O 0 4.006590825156309e-05
mutations O 0 0.000100543191365432
include O 0 1.7480871292718803e-06
three O 0 6.528924814119819e-07
single O 0 1.1177355645486386e-06
base O 0 2.4161233795894077e-06
deletions O 0 1.0340724656998646e-05
, O 0 3.4302252061024774e-07
one O 0 3.525321119468572e-07
splice O 0 3.91434550692793e-05
site O 0 8.044156857067719e-06
mutation O 0 1.2770449757226743e-05
and O 0 1.4086349438002799e-06
10 O 0 8.310275006806478e-06
missense O 0 0.0017188491765409708
mutations O 0 0.0007204822613857687
. O 0 4.260247078491375e-05

One O 0 0.00010556396591709927
missense O 0 0.006074391771107912
mutation O 0 0.0007496692705899477
( O 0 1.530612826172728e-05
L236P O 0 7.821515464456752e-05
) O 0 1.6845150412336807e-06
was O 0 1.0587091310299002e-06
found O 0 2.4827303946040047e-07
in O 0 1.2578831842802174e-07
a O 0 5.858470899511303e-07
homozygous O 0 7.422299404424848e-06
state O 0 1.5999384572751296e-07
in O 0 1.1627927420931883e-07
two O 0 1.4113820157035661e-07
consanguineous O 0 4.37563139712438e-05
families O 0 2.2510818098453456e-07
and O 0 8.265125472917134e-08
in O 0 1.2665610427120555e-07
a O 0 5.160512159818609e-07
heterozygous O 0 6.634822511841776e-06
state O 0 2.0099132314044255e-07
in O 0 1.5377098350199958e-07
five O 0 1.4496177414002887e-07
additional O 0 8.354610940841667e-07
non O 0 6.046126600267598e-06
- O 0 0.00020736758597195148
consanguineous O 0 0.0005843167891725898
families O 0 2.07418834179407e-05
. O 0 3.0286175388027914e-05

Another O 0 0.0002861040411517024
missense O 0 0.020758092403411865
mutation O 0 0.0008563966257497668
( O 0 1.417445582774235e-05
T416P O 0 8.419074583798647e-05
) O 0 1.5334380805143155e-06
was O 0 9.28950100842485e-07
found O 0 2.9527222977776546e-07
in O 0 1.5281125342880841e-07
a O 0 4.3460221377245034e-07
homozygous O 0 9.951593710866291e-06
state O 0 2.033314530081043e-07
in O 0 9.486610252906758e-08
one O 0 6.947545472257843e-08
family O 0 5.371043698687572e-07
and O 0 8.237976345526477e-08
in O 0 1.2792123982308112e-07
a O 0 6.616205610043835e-07
heterozygous O 0 7.149444172682706e-06
state O 0 3.4212669675071083e-07
in O 0 3.5377553331272793e-07
four O 0 1.363166120427195e-06
families O 0 6.910276169946883e-06
. O 0 1.905775752675254e-05

Pendred B-Disease 1 0.9990025162696838
patients O 0 0.08422818034887314
in O 0 5.549018624151358e-06
three O 0 1.7397085230186349e-06
non O 0 4.1695107029227074e-06
- O 0 6.808506441302598e-05
consanguineous O 0 0.00011159220593981445
families O 0 1.1830480843855185e-06
were O 0 5.073819124845613e-07
shown O 0 7.153516889957245e-07
to O 0 2.8299294285716314e-07
be O 0 3.4137707416448393e-07
compound O 0 6.996641332079889e-06
heterozygotes O 0 4.446319508133456e-05
for O 0 1.4103110288488097e-06
L236P O 0 7.634241774212569e-05
and O 0 5.812785730086034e-06
T416P O 0 0.0004030427662655711
. O 0 4.567639916785993e-05

In O 0 1.4563478544005193e-05
total O 0 2.329469225514913e-06
, O 0 4.46138102461191e-07
one O 0 1.3441517410228698e-07
or O 0 9.930926836432263e-08
both O 0 4.317953639088046e-08
of O 0 4.679421294895292e-08
these O 0 2.058295223150708e-07
mutations O 0 9.762399713508785e-06
were O 0 1.6486239928781288e-07
found O 0 1.1587079740138506e-07
in O 0 5.677424042005441e-08
nine O 0 7.727637552079614e-08
of O 0 6.004142250048972e-08
the O 0 4.6557536848013115e-07
14 O 0 4.210459792375332e-06
families O 0 6.264645435294369e-06
analyzed O 0 4.9930902605410665e-05
. O 0 3.172842480125837e-05

The O 0 8.949539733293932e-06
identification O 0 4.9044679144572e-06
of O 0 6.812166475356207e-07
two O 0 9.423766300642455e-07
frequent O 0 3.646664117695764e-05
PDS B-Disease 1 0.9232979416847229
mutations O 0 8.60723594087176e-05
will O 0 4.367140604699671e-07
facilitate O 0 8.489463994010293e-07
the O 0 1.328773464592814e-06
molecular O 0 0.00015889311907812953
diagnosis O 1 0.9383285045623779
of O 0 0.00027357658836990595
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00018440597341395915

Insertional O 0 0.015206048265099525
mutation O 0 0.0006484031328000128
by O 0 1.4480370737146586e-05
transposable O 0 0.0001496967306593433
element O 0 1.023804725264199e-05
, O 0 1.7656694808465545e-06
L1 O 0 0.0001777742727426812
, O 0 5.03539979490597e-07
in O 0 4.374869035927986e-07
the O 0 2.435667511235806e-06
DMD B-Disease 1 0.9999988079071045
gene O 0 9.713318286230788e-05
results O 0 9.288010915042832e-06
in O 0 5.716537089028861e-06
X B-Disease 0 0.4656607210636139
- I-Disease 0 0.15935397148132324
linked I-Disease 0 0.040952783077955246
dilated I-Disease 1 0.9099713563919067
cardiomyopathy I-Disease 1 0.9999984502792358
. O 0 0.0001563999685458839

X B-Disease 1 0.9658090472221375
- I-Disease 1 0.6429704427719116
linked I-Disease 0 0.324209600687027
dilated I-Disease 1 0.9967349171638489
cardiomyopathy I-Disease 1 0.9999998807907104
( O 0 7.317936979234219e-05
XLDCM B-Disease 0 0.05530155822634697
) O 0 1.9253086520620855e-06
is O 0 3.3821689271462674e-07
a O 0 1.6070537185441935e-06
clinical O 0 8.811290172161534e-05
phenotype O 0 0.0005230497336015105
of O 0 4.545267131561559e-07
dystrophinopathy B-Disease 0 0.004338928032666445
which O 0 6.752054559910903e-07
is O 0 2.4656682739987446e-07
characterized O 0 4.881957465840969e-06
by O 0 1.304996658291202e-06
preferential O 0 5.823670289828442e-05
myocardial B-Disease 1 0.9960474371910095
involvement I-Disease 0 1.575071655679494e-05
without O 0 7.940460022837215e-07
any O 0 9.430194154447236e-07
overt O 0 2.4778348233667202e-05
clinical O 0 0.0001930923608597368
signs O 0 0.00017252743418794125
of O 0 5.68745490454603e-05
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.0003910865925718099

To O 0 1.5891773728071712e-05
date O 0 6.635442787228385e-06
, O 0 7.836717941245297e-07
several O 0 9.048360425367719e-07
mutations O 0 1.2652692021219991e-05
in O 0 1.297179437642626e-06
the O 0 1.849327964009717e-05
Duchenne B-Disease 1 0.9999980926513672
muscular I-Disease 1 0.9999971389770508
dystrophy I-Disease 1 0.9999967813491821
gene O 0 0.00034093225258402526
, O 0 8.363711458514445e-06
DMD O 1 0.9999997615814209
, O 0 1.336431864729093e-06
have O 0 1.7945768604477053e-07
been O 0 3.280067915056861e-07
identified O 0 1.3232257742856746e-06
in O 0 7.946323421492707e-07
patients O 0 9.47167063714005e-06
with O 0 3.2957458984128607e-07
XLDCM B-Disease 0 0.35681137442588806
, O 0 2.2303963476133504e-07
but O 0 9.54716483647644e-08
a O 0 2.409259138858033e-07
pathogenic O 0 2.14744341064943e-06
correlation O 0 9.395239999321348e-07
of O 0 1.295207567864054e-07
these O 0 5.326737095856515e-07
cardiospecific O 0 0.023056546226143837
mutations O 0 0.00010173832561122254
in O 0 3.781695113502792e-06
DMD O 1 0.999809205532074
with O 0 1.8368745031693834e-06
the O 0 2.9819191240676446e-06
XLDCM B-Disease 0 0.4094328284263611
phenotype O 0 0.06107589974999428
has O 0 1.4356386373037822e-06
remained O 0 2.953813691419782e-06
to O 0 1.0621718047332251e-06
be O 0 2.092907834594371e-06
elucidated O 0 0.0003252714523114264
. O 0 2.4707303964532912e-05

We O 0 2.020855390583165e-05
report O 0 9.438901543035172e-06
here O 0 3.024836985332513e-07
the O 0 2.204764655289182e-07
identification O 0 6.128206564426364e-07
of O 0 1.717631334940961e-07
a O 0 6.101946041781048e-07
unique O 0 1.3134443861417822e-06
de O 0 1.1490914403111674e-05
novo O 0 3.2585961889708415e-05
L1 O 0 0.00010659798863343894
insertion O 0 9.826589121075813e-06
in O 0 1.0275324484609882e-06
the O 0 8.136735800690076e-07
muscle O 0 4.8439789679832757e-05
exon O 0 1.7981374185183086e-05
1 O 0 1.0014293820859166e-06
in O 0 1.5351982938227593e-06
DMD O 1 0.9999873638153076
in O 0 2.7741004942072323e-06
three O 0 2.3279280867427588e-06
XLDCM B-Disease 1 0.9738963842391968
patients O 0 0.00010453300637891516
from O 0 6.108659249548509e-07
two O 0 6.81304356930923e-07
unrelated O 0 1.2541161595436279e-05
Japanese O 0 1.2686064110312145e-05
families O 0 2.2545702449860983e-05
. O 0 2.685032995941583e-05

The O 0 2.007453986152541e-05
insertion O 0 0.00011102519783889875
was O 0 5.131286343385e-06
a O 0 1.9307567526993807e-06
5 O 0 1.437962396266812e-06
- O 0 4.448679192137206e-06
truncated O 0 4.18715899286326e-06
form O 0 5.701688223780366e-07
of O 0 1.89222703284031e-07
human O 0 7.946126743263449e-07
L1 O 0 0.00017917194054462016
inversely O 0 3.247298809583299e-05
integrated O 0 5.046513706474798e-06
in O 0 2.468555351242685e-07
the O 0 2.1147781126273912e-07
5 O 0 6.183047958074894e-07
- O 0 3.7725815218436765e-06
untranslated O 0 7.088620350259589e-06
region O 0 6.8996081381556e-07
in O 0 3.0897723490852513e-07
the O 0 6.434658530451998e-07
muscle O 0 0.00011674042616505176
exon O 0 1.692144724074751e-05
1 O 0 6.730523978148995e-07
, O 0 1.1775937736047126e-07
which O 0 9.941199152763147e-08
affected O 0 1.8137716040200758e-07
the O 0 6.729400325866663e-08
transcription O 0 6.107063086346898e-07
or O 0 7.993770623215823e-08
the O 0 5.7878551729118044e-08
stability O 0 2.682398871911573e-07
of O 0 3.622050570584179e-08
the O 0 2.4596258185738407e-07
muscle O 0 1.9554694517864846e-05
form O 0 2.494835200650414e-07
of O 0 1.3163671042093483e-07
dystrophin O 0 4.6395354729611427e-05
transcripts O 0 3.5890871004085056e-06
but O 0 1.317933424616058e-07
not O 0 4.5732814868415517e-08
that O 0 2.556980938095421e-08
of O 0 4.4123570575038684e-08
the O 0 4.7374172140735027e-07
brain O 0 0.00695783318951726
or O 0 1.282512016587134e-06
Purkinje O 0 0.001871056272648275
cell O 0 2.9837066904292442e-05
form O 0 5.709828769795422e-07
, O 0 1.5256777885497286e-07
probably O 0 2.5788727953113266e-07
due O 0 2.5427559080526407e-07
to O 0 8.971263554258257e-08
its O 0 1.679542691590541e-07
unique O 0 2.10873253081445e-07
site O 0 7.525840715061349e-07
of O 0 5.905720854570973e-07
integration O 0 2.2629947125096805e-05
. O 0 2.257888081658166e-05

We O 0 2.3158307158155367e-05
speculate O 0 3.892951281159185e-05
that O 0 5.251019388197165e-07
this O 0 1.811636707316211e-07
insertion O 0 2.0351353668957017e-06
of O 0 1.3728225667364313e-07
an O 0 4.3903793311983463e-07
L1 O 0 0.0002434938942315057
sequence O 0 2.551656962168636e-06
in O 0 5.016456725570606e-06
DMD O 1 0.9999934434890747
is O 0 5.831091698382806e-07
responsible O 0 5.749125762122276e-07
for O 0 7.842611182695691e-08
some O 0 2.7609193153921296e-08
of O 0 2.2854667491856162e-08
the O 0 8.48708552325661e-08
population O 0 1.5544861753369332e-07
of O 0 9.568987024977105e-08
Japanese O 0 5.928416157985339e-06
patients O 0 5.053288987255655e-05
with O 0 3.0085300295468187e-06
XLDCM B-Disease 0 0.22384458780288696
. O 0 8.407399036514107e-06
. O 0 2.0666855562012643e-05

Severe O 1 0.9962531328201294
early O 0 0.1569235920906067
- O 1 0.9998829364776611
onset O 1 0.9999992847442627
obesity B-Disease 1 0.9999998807907104
, O 0 0.0015308274887502193
adrenal B-Disease 1 0.9999985694885254
insufficiency I-Disease 1 0.9999973773956299
and O 0 1.0163724255107809e-05
red O 0 0.005285021848976612
hair O 1 0.993438184261322
pigmentation O 1 0.9985963702201843
caused O 0 0.0013084212550893426
by O 0 2.1596511942334473e-05
POMC O 1 0.9958314299583435
mutations O 0 0.0002529042831156403
in O 0 6.400839083653409e-06
humans O 0 3.454396937740967e-05
. O 0 3.542794001987204e-05

Sequential O 0 0.0007355619454756379
cleavage O 0 0.00028332555666565895
of O 0 3.294964926681132e-06
the O 0 3.0930732464184985e-06
precursor O 0 1.9880933905369602e-05
protein O 0 6.301441771938698e-06
pre O 0 1.9966666513937525e-05
- O 0 2.292175850016065e-05
pro O 0 1.1303200153633952e-05
- O 0 3.4932225389638916e-05
opiomelanocortin O 0 0.00011572650691960007
( O 0 5.31654768565204e-06
POMC O 0 0.0002173926477553323
) O 0 1.3930299473940977e-06
generates O 0 2.42964961216785e-06
the O 0 1.6005717498046579e-06
melanocortin O 0 0.0002510019694454968
peptides O 0 6.72269961796701e-05
adrenocorticotrophin O 0 0.0002661595062818378
( O 0 8.123291991068982e-06
ACTH O 0 0.00014451402239501476
) O 0 1.9364622403372778e-06
, O 0 9.969718348656897e-07
melanocyte O 0 9.94287256617099e-05
- O 0 5.443903501145542e-05
stimulating O 0 4.107448330614716e-05
hormones O 0 3.296415161457844e-05
( O 0 3.6137300867267186e-06
MSH O 0 0.00022041460033506155
) O 0 7.789633968968701e-07
alpha O 0 1.5901619008218404e-06
, O 0 1.6062892882473534e-07
beta O 0 7.637483463440731e-07
and O 0 1.1469071381497997e-07
gamma O 0 1.9059093574469443e-06
as O 0 9.875395079461669e-08
well O 0 9.704708503477377e-08
as O 0 1.369371886994486e-07
the O 0 4.876457637692511e-07
opioid O 0 6.729761662427336e-05
- O 0 3.1493262213189155e-05
receptor O 0 3.7419642467284575e-05
ligand O 0 4.604565037880093e-05
beta O 0 7.931172876851633e-05
- O 0 0.00032187660690397024
endorphin O 0 0.0027499774005264044
. O 0 6.977449083933607e-05

While O 0 2.2506819732370786e-05
a O 0 5.947114004811738e-06
few O 0 2.34524213738041e-06
cases O 0 1.3076514733256772e-06
of O 0 1.3208720019974862e-06
isolated O 1 0.8500934839248657
ACTH B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9998536109924316
have O 0 1.6354525769202155e-06
been O 0 1.938969944603741e-06
reported O 0 3.624831515480764e-05
( O 0 4.8083147703437135e-06
OMIM O 0 0.002443887759000063
201400 O 0 3.670931255328469e-05
) O 0 8.417768526669533e-07
, O 0 2.682739079773455e-07
an O 0 1.215569682244677e-06
inherited O 1 0.9545062780380249
POMC O 1 0.9999779462814331
defect O 1 0.514529824256897
has O 0 2.271652192575857e-06
not O 0 4.2934931343552307e-07
been O 0 6.498033826574101e-07
described O 0 5.3272515287972055e-06
so O 0 1.2224181773490272e-06
far O 0 5.377058641897747e-06
. O 0 1.5231135876092594e-05

Recent O 0 0.0001624993165023625
studies O 0 3.667072087409906e-05
in O 0 4.785569217347074e-06
animal O 0 1.6687125025782734e-05
models O 0 1.90700484381523e-05
elucidated O 0 3.749143434106372e-05
a O 0 1.1241464790145983e-06
central O 0 1.3629010027216282e-06
role O 0 6.029113706063072e-07
of O 0 3.2145590012078173e-07
alpha O 0 1.1275176802882925e-05
- O 0 0.00011899838864337653
MSH O 0 0.0013864011270925403
in O 0 3.541063335887884e-07
the O 0 2.060263142311669e-07
regulation O 0 8.58672535741789e-07
of O 0 1.2222999146160873e-07
food O 0 5.93525612657686e-07
intake O 0 1.8754305983748054e-06
by O 0 1.8887618580265553e-07
activation O 0 1.543087932986964e-06
of O 0 1.5017508303571958e-07
the O 0 1.1943205890929676e-06
brain O 0 0.001316857524216175
melanocortin O 0 0.0015987325459718704
- O 0 1.757749851094559e-05
4 O 0 2.118146085194894e-06
- O 0 1.7993230358115397e-05
receptor O 0 1.676630745350849e-05
( O 0 2.2321207779896213e-06
MC4 O 0 0.015277094207704067
- O 0 0.0002530234050936997
R O 0 0.00011119853297714144
; O 0 5.914484972890932e-07
refs O 0 5.405212050391128e-06
3 O 0 5.929926487624471e-07
- O 0 1.66565712333977e-06
5 O 0 1.8099856902153988e-07
) O 0 6.756460635415351e-08
and O 0 2.7774353483778214e-08
the O 0 6.634036253672093e-08
linkage O 0 1.3777701042272383e-06
of O 0 1.2719426933927025e-07
human O 0 3.5850985113938805e-06
obesity B-Disease 1 0.917797327041626
to O 0 6.770301865799411e-07
chromosome O 0 5.24949473401648e-06
2 O 0 3.110770308012434e-07
in O 0 1.5508479123127472e-07
close O 0 4.062877962951461e-07
proximity O 0 8.097798058770422e-07
to O 0 2.063678863351015e-07
the O 0 3.7252354445627134e-07
POMC O 0 0.0005748839466832578
locus O 0 4.032001015730202e-06
, O 0 1.0680189888034874e-07
led O 0 3.0793000860285247e-07
to O 0 7.406422497524545e-08
the O 0 9.761645713979306e-08
proposal O 0 5.604572379525052e-07
of O 0 6.076504632801516e-08
an O 0 1.4561575767402246e-07
association O 0 8.315137165482156e-07
of O 0 5.350044034457824e-07
POMC O 0 0.06951802223920822
with O 0 6.736785053362837e-06
human O 0 0.00017828811542131007
obesity B-Disease 1 0.9995294809341431
. O 0 5.158949352335185e-05

The O 0 1.7408588973921724e-05
dual O 0 2.3040938685880974e-05
role O 0 4.634062406694284e-06
of O 0 1.389037038279639e-06
alpha O 0 2.7268884878139943e-05
- O 0 0.00013572355965152383
MSH O 0 0.0029625468887388706
in O 0 1.4939728316676337e-06
regulating O 0 6.917529390193522e-06
food O 0 2.013267703659949e-06
intake O 0 8.129639354592655e-06
and O 0 6.840505193395074e-07
influencing O 0 1.2664981113630347e-05
hair O 0 0.16239580512046814
pigmentation O 1 0.9393758177757263
predicts O 0 0.00042527419282123446
that O 0 3.3597748938518635e-07
the O 0 6.831658652117767e-07
phenotype O 0 0.004986680578440428
associated O 0 1.4770098459848668e-06
with O 0 3.207325960374874e-07
a O 0 6.164552360132802e-06
defect O 0 0.0011300928890705109
in O 0 1.3961207514512353e-06
POMC O 0 0.0007853994029574096
function O 0 1.217249405272014e-06
would O 0 4.998626081942348e-07
include O 0 1.351420678474824e-06
obesity B-Disease 0 0.48920363187789917
, O 0 8.637852602078055e-07
alteration O 0 5.603455792879686e-05
in O 0 1.634730870136991e-05
pigmentation O 1 0.997860848903656
and O 0 0.07865434885025024
ACTH B-Disease 1 0.9999973773956299
deficiency I-Disease 1 0.9992048144340515
. O 0 6.026839400874451e-05

The O 0 1.724321009533014e-05
observation O 0 5.175398109713569e-05
of O 0 1.4254366078603198e-06
these O 0 2.0744814719364513e-06
symptoms O 0 0.02493024617433548
in O 0 4.252352709954721e-07
two O 0 3.7109566619619727e-07
probands O 0 0.00016099958156701177
prompted O 0 9.318905540567357e-06
us O 0 4.4738135329680517e-07
to O 0 2.1372368053107493e-07
search O 0 5.402864644565852e-07
for O 0 3.7629519056281424e-07
mutations O 0 8.943660759541672e-06
within O 0 1.7567440409038682e-06
their O 0 7.301043297047727e-06
POMC O 0 0.4759587347507477
genes O 0 0.00010898958134930581
. O 0 4.691644062404521e-05

Patient O 0 0.03204479068517685
1 O 0 1.8924787582363933e-05
was O 0 8.215903108066414e-06
found O 0 6.640333936047682e-07
to O 0 2.14865892189664e-07
be O 0 1.2942616933742102e-07
a O 0 3.3702812629599066e-07
compound O 0 4.024110694444971e-06
heterozygote O 0 1.0965916771965567e-05
for O 0 3.062355347083212e-07
two O 0 5.081378162685724e-07
mutations O 0 9.396150744578335e-06
in O 0 6.502100404759403e-07
exon O 0 1.402359612256987e-05
3 O 0 1.1459803772595478e-06
( O 0 6.936481895536417e-07
G7013T O 0 7.143896255001891e-06
, O 0 3.2486971690559585e-07
C7133delta O 0 1.932972008944489e-05
) O 0 3.6181157270220865e-07
which O 0 1.4532886893903196e-07
interfere O 0 7.984464787114121e-07
with O 0 1.3991208902552899e-07
appropriate O 0 5.209976734477095e-07
synthesis O 0 2.0598163246177137e-06
of O 0 8.716632464711438e-07
ACTH O 0 0.00020409745047800243
and O 0 3.1433585263584973e-06
alpha O 0 6.0342699725879356e-05
- O 0 0.00046502574696205556
MSH O 0 0.017118453979492188
. O 0 3.80010278604459e-05

Patient O 0 0.016636613756418228
2 O 0 3.460361767793074e-05
was O 0 1.1373224879207555e-05
homozygous O 0 2.789610152831301e-05
for O 0 5.362609840631194e-07
a O 0 1.6983195791908656e-06
mutation O 0 1.1554957382031716e-05
in O 0 1.2006725000901497e-06
exon O 0 2.856557330233045e-05
2 O 0 2.7644082365441136e-06
( O 0 2.2465276288130553e-06
C3804A O 0 2.864736052288208e-05
) O 0 3.3722533316904446e-06
which O 0 5.1388574320299085e-06
abolishes O 0 0.000588536961004138
POMC O 0 0.00777826551347971
translation O 0 0.00015140316099859774
. O 0 5.328716724761762e-05

These O 0 2.2822945538791828e-05
findings O 0 2.4089213184197433e-05
represent O 0 2.131693008777802e-06
the O 0 8.278778977910406e-07
first O 0 7.233024348352046e-07
examples O 0 7.648343967048277e-07
of O 0 3.5749374660554167e-07
a O 0 6.356230733217672e-05
genetic B-Disease 1 0.969719409942627
defect I-Disease 1 0.9658808708190918
within O 0 1.237820015376201e-06
the O 0 2.219689804405789e-06
POMC O 0 0.07372540980577469
gene O 0 7.048907718854025e-06
and O 0 3.004327311373345e-07
define O 0 1.7381794350512791e-06
a O 0 2.09743961931963e-06
new O 0 0.0003565736988093704
monogenic B-Disease 1 0.9999668598175049
endocrine I-Disease 1 0.9999940395355225
disorder I-Disease 1 0.984645664691925
resulting O 0 1.09608554339502e-05
in O 0 2.6552822873782134e-06
early O 0 0.00025087970425374806
- O 1 0.9886789917945862
onset O 1 0.9999948740005493
obesity B-Disease 1 0.9999986886978149
, O 0 0.00016211767797358334
adrenal B-Disease 1 0.999994158744812
insufficiency I-Disease 1 0.9999954700469971
and O 0 6.416002179321367e-06
red O 0 0.0003583334619179368
hair O 1 0.9549898505210876
pigmentation O 1 0.9860703349113464
. O 0 1.3735243555856869e-05
. O 0 2.5104898668359965e-05

A O 0 0.00016481915372423828
European O 0 0.00014828884741291404
multicenter O 0 0.41535067558288574
study O 0 4.99916568514891e-05
of O 0 3.2246229238808155e-05
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 2.5395477223355556e-06
classification O 0 3.08516632685496e-06
of O 0 1.6780968792318163e-07
105 O 0 7.127312528609764e-06
mutations O 0 1.688557858869899e-05
and O 0 1.9782673632562364e-07
a O 0 5.785465191365802e-07
general O 0 1.161879822575429e-06
system O 0 2.6551203973212978e-06
for O 0 6.479135663539637e-07
genotype O 0 0.0003509509551804513
- O 0 4.484089004108682e-05
based O 0 3.541550086083589e-06
prediction O 0 2.412963476672303e-05
of O 0 6.378627404046711e-06
metabolic O 1 0.7068642377853394
phenotype O 0 0.137330561876297
. O 0 6.522578769363463e-05

Phenylketonuria B-Disease 1 0.9998688697814941
( O 0 0.0017457061912864447
PKU B-Disease 1 0.992755115032196
) O 0 2.9718705263803713e-05
and O 0 9.622338438930456e-06
mild B-Disease 1 0.9971439242362976
hyperphenylalaninemia I-Disease 1 0.9999998807907104
( O 0 0.008284574374556541
MHP B-Disease 1 0.9999996423721313
) O 0 7.815067874616943e-06
are O 0 2.0505731299635954e-06
allelic B-Disease 1 0.8503453731536865
disorders I-Disease 1 0.9999947547912598
caused O 0 0.0009929246734827757
by O 0 5.985955340293003e-06
mutations O 0 3.787851892411709e-05
in O 0 8.806715641185292e-07
the O 0 1.669994503572525e-06
gene O 0 2.816098822222557e-05
encoding O 0 4.33226341556292e-05
phenylalanine O 0 0.0007871738052926958
hydroxylase O 0 0.012835036031901836
( O 0 6.035628393874504e-05
PAH O 0 0.003959720954298973
) O 0 2.446449434501119e-05
. O 0 2.509183104848489e-05

Previous O 0 0.00018586973601486534
studies O 0 3.649050631793216e-05
have O 0 1.7935946061697905e-06
suggested O 0 3.1495969778916333e-06
that O 0 3.9325698253378505e-07
the O 0 9.562187415212975e-07
highly O 0 8.62072192830965e-06
variable O 0 0.0006096012075431645
metabolic O 1 0.5164722204208374
phenotypes O 0 0.006249808706343174
of O 0 5.4578762501478195e-05
PAH B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9997232556343079
correlate O 0 0.00017460042727179825
with O 0 6.758051313227043e-05
PAH O 1 0.986431896686554
genotypes O 0 0.0038853036239743233
. O 0 0.00010384945926489308

We O 0 2.449647945468314e-05
identified O 0 1.4880851267662365e-05
both O 0 4.5187180148786865e-06
causative O 0 0.00012373355275485665
mutations O 0 0.00013525858230423182
in O 0 4.966550477547571e-06
686 O 0 0.015091844834387302
patients O 0 0.000267722673015669
from O 0 1.616377289792581e-06
seven O 0 2.786514642139082e-06
European O 0 1.2525838428700808e-05
centers O 0 4.108693974558264e-05
. O 0 3.017765629920177e-05

On O 0 1.0649129762896337e-05
the O 0 1.667839455876674e-06
basis O 0 4.25143213078627e-07
of O 0 1.148679302787059e-07
the O 0 2.96729922411032e-07
phenotypic O 0 3.458078936091624e-06
characteristics O 0 1.0333008049201453e-06
of O 0 2.625839385927975e-07
297 O 0 6.758657400496304e-05
functionally O 0 0.003945016767829657
hemizygous O 1 0.931281328201294
patients O 0 0.00027993167168460786
, O 0 2.0454000093650393e-07
105 O 0 8.786422540651984e-07
of O 0 9.515387233705042e-08
the O 0 5.42542863968265e-07
mutations O 0 1.143601184594445e-05
were O 0 2.1900534363794577e-07
assigned O 0 6.861916403977375e-07
to O 0 9.354830154961746e-08
one O 0 5.430294791608503e-08
of O 0 9.784686483271798e-08
four O 0 6.894214834574086e-07
arbitrary O 0 1.6478064935654402e-05
phenotype O 0 0.02023027278482914
categories O 0 2.5712583010317758e-05
. O 0 2.878236409742385e-05

We O 0 2.1162652046768926e-05
proposed O 0 2.1429204934975132e-05
and O 0 1.844211624302261e-06
tested O 0 4.866283234150615e-06
a O 0 4.920481728731829e-07
simple O 0 7.280283966792922e-07
model O 0 1.154648998635821e-06
for O 0 1.6927396018218133e-07
correlation O 0 1.6585319144724053e-06
between O 0 1.2206043038531789e-06
genotype O 0 8.973373769549653e-05
and O 0 2.6391405754111474e-06
phenotypic O 0 5.54112448298838e-05
outcome O 0 4.683611405198462e-05
. O 0 3.748682502191514e-05

The O 0 9.032102389028296e-05
observed O 0 0.00021537940483540297
phenotype O 0 0.0039938767440617085
matched O 0 2.551404759287834e-05
the O 0 2.5952872420020867e-06
predicted O 0 0.00012223576777614653
phenotype O 0 0.0010579004883766174
in O 0 1.0595980484140455e-06
79 O 0 3.2602818009763723e-06
% O 0 1.42376251233145e-07
of O 0 4.212429161043474e-08
the O 0 1.3131496245932794e-07
cases O 0 2.784652792797715e-07
, O 0 8.018631092454598e-08
and O 0 7.303651017309676e-08
in O 0 8.476747836994036e-08
only O 0 5.6623594701932234e-08
5 O 0 1.357438321747395e-07
of O 0 1.0930106242312831e-07
184 O 0 3.3740056096576154e-05
patients O 0 0.0002048049063887447
was O 0 2.4418400244030636e-06
the O 0 7.912249770924973e-07
observed O 0 7.55173277866561e-06
phenotype O 0 4.749540312332101e-05
more O 0 9.297941971908585e-08
than O 0 4.521768559584416e-08
one O 0 7.480946351279272e-08
category O 0 2.6717424361777375e-07
away O 0 2.5256161961806356e-07
from O 0 3.653343014775601e-07
that O 0 7.074539780660416e-07
expected O 0 9.594903531251475e-06
. O 0 1.4376319995790254e-05

Among O 0 8.661992069392e-06
the O 0 1.64805010172131e-06
seven O 0 1.493875970481895e-06
contributing O 0 3.02716239275469e-06
centers O 0 1.3444764590531122e-06
, O 0 1.1715471970319413e-07
the O 0 1.3801027876070293e-07
proportion O 0 3.6697832683785236e-07
of O 0 2.5469717002124526e-07
patients O 0 3.187597030773759e-05
for O 0 2.579364775101567e-07
whom O 0 1.3324612382348278e-06
the O 0 1.1814831850642804e-06
observed O 0 0.000115200447908137
phenotype O 0 0.22273825109004974
did O 0 1.2913461659991299e-06
not O 0 1.051687590347683e-07
match O 0 2.7463664764582063e-07
the O 0 4.6140624476720404e-07
predicted O 0 5.009578671888448e-05
phenotype O 0 0.00020066674915142357
was O 0 1.0936921626125695e-06
4 O 0 6.189750365592772e-07
% O 0 4.37156160160157e-07
- O 0 3.4755094020511024e-06
23 O 0 1.1789484233304393e-06
% O 0 6.19069453478005e-07
( O 0 1.418166107214347e-06
P O 0 0.0001274298265343532
< O 0 7.1854528869153e-06
. O 0 3.964078700846585e-07
0001 O 0 5.6945529649965465e-05
) O 0 2.756947310444957e-07
, O 0 7.892371201023707e-08
suggesting O 0 5.309442485668114e-07
that O 0 6.962495291418236e-08
differences O 0 2.24944642468472e-07
in O 0 1.1652171139076017e-07
methods O 0 3.472791831882205e-07
used O 0 2.467496074132214e-07
for O 0 3.364449412401882e-07
mutation O 0 1.1411586456233636e-05
detection O 0 2.4265271349577233e-05
or O 0 1.2812290151487105e-05
phenotype O 1 0.8667956590652466
classification O 0 0.01067278627306223
may O 0 5.367370249587111e-06
account O 0 4.0508922438675654e-07
for O 0 1.0282779783210572e-07
a O 0 3.6616728493754636e-07
considerable O 0 2.2314759462460643e-06
proportion O 0 2.2503613763547037e-06
of O 0 1.4642332644143607e-06
genotype O 0 0.03362618759274483
- O 0 0.3433104455471039
phenotype O 0 0.2160497009754181
inconsistencies O 0 0.00025057923630811274
. O 0 5.410738231148571e-05

Our O 0 2.302244320162572e-05
data O 0 1.2795403563359287e-05
indicate O 0 6.225878678378649e-06
that O 0 4.952910330757732e-07
the O 0 2.451579348416999e-06
PAH O 1 0.9574259519577026
- O 0 0.012763982638716698
mutation O 0 3.048565486096777e-05
genotype O 0 1.8999760868609883e-05
is O 0 1.6882238185189635e-07
the O 0 1.704987937500846e-07
main O 0 6.12800818089454e-07
determinant O 0 2.333226802875288e-06
of O 0 4.7513080403405183e-07
metabolic O 0 0.060300350189208984
phenotype O 0 0.04281773790717125
in O 0 2.18836976273451e-06
most O 0 4.645190529117826e-06
patients O 0 0.047771889716386795
with O 0 0.011689577251672745
PAH B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999452829360962
. O 0 6.597219908144325e-05

In O 0 1.13351325126132e-05
the O 0 2.0930835944454884e-06
present O 0 1.5254014442689368e-06
study O 0 7.053097306197742e-07
, O 0 1.5972506162142963e-07
the O 0 2.5954233251468395e-07
classification O 0 2.6120178517885506e-06
of O 0 4.0308836446456553e-07
105 O 0 0.0023475438356399536
PAH O 1 0.9999836683273315
mutations O 0 0.0003161796776112169
may O 0 1.4272185353547684e-06
allow O 0 3.102788355135999e-07
the O 0 2.3131354964789352e-07
prediction O 0 2.2877316041558515e-06
of O 0 1.6141808600877994e-07
the O 0 1.0493547506484902e-06
biochemical O 0 0.0001771672978065908
phenotype O 0 0.009649515151977539
in O 0 1.353458515040984e-06
> O 0 6.12586154602468e-06
10 O 0 4.274683078620001e-07
, O 0 2.1977949415941112e-07
000 O 0 1.001020791591145e-06
genotypes O 0 1.8897337213275023e-05
, O 0 2.4812300125631737e-07
which O 0 4.051722726217122e-07
may O 0 1.1303612836854882e-06
be O 0 5.272948655488108e-08
useful O 0 7.875755159147957e-08
for O 0 5.480489662090804e-08
the O 0 1.7722341283388232e-07
management O 0 3.661564505819115e-06
of O 0 8.040897228056565e-07
hyperphenylalaninemia B-Disease 1 0.9998948574066162
in O 0 0.0001195677905343473
newborns O 0 0.13381125032901764
. O 0 2.6388075639260933e-05

Somatic O 0 0.0018900259165093303
instability O 0 0.00027247864636592567
of O 0 3.0913276987121208e-06
the O 0 6.115331416367553e-06
CTG O 0 0.0013001750921830535
repeat O 0 2.8197695428389125e-05
in O 0 2.713893763939268e-06
mice O 0 3.0540650186594576e-05
transgenic O 0 5.646415047522169e-06
for O 0 7.067371825542068e-07
the O 0 1.5207941032713279e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 1.925234028021805e-05
is O 0 1.0472293752172845e-06
age O 0 9.714002544569666e-07
dependent O 0 9.353953487334365e-07
but O 0 1.6127299318213772e-07
not O 0 1.509796732079849e-07
correlated O 0 1.9020599211216904e-06
to O 0 1.714494004545486e-07
the O 0 3.0626765123997757e-07
relative O 0 3.036987891391618e-06
intertissue O 0 5.209504524827935e-05
transcription O 0 1.2075592167093419e-05
levels O 0 5.255415544525022e-06
and O 0 6.1750374698021915e-06
proliferative O 0 0.02225307561457157
capacities O 0 0.00025587904383428395
. O 0 5.23443341080565e-05

A O 0 0.00025792844826355577
( O 0 4.795058703166433e-05
CTG O 0 0.000998835894279182
) O 0 4.182410066277953e-06
nexpansion O 0 3.5203709558118135e-05
in O 0 5.401545308814093e-07
the O 0 3.807824100476864e-07
3 O 0 1.049052571033826e-06
- O 0 6.152206424303586e-06
untranslated O 0 1.4850811567157507e-05
region O 0 2.7368071187083842e-06
( O 0 9.327905559075589e-07
UTR O 0 8.224697921832558e-06
) O 0 2.466635180553567e-07
of O 0 1.315192577067137e-07
the O 0 1.7459744867664995e-06
DM O 1 0.9999927282333374
protein O 0 1.606243858987e-05
kinase O 0 0.000198576322873123
gene O 0 1.2292358405829873e-05
( O 0 1.7679240045254119e-06
DMPK O 0 5.561065336223692e-05
) O 0 7.927461638246314e-07
is O 0 3.916778723578318e-07
responsible O 0 2.429262849545921e-06
for O 0 6.012329777149716e-06
causing O 1 0.8670690059661865
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.4724746644496918
DM B-Disease 1 0.9999998807907104
) O 0 6.024811591487378e-05
. O 0 4.862574496655725e-05

Major O 0 7.128144352464005e-05
instability O 0 0.0001601159165147692
, O 0 1.173615487459756e-06
with O 0 3.408006534755259e-07
very O 0 2.3328433940150717e-07
large O 0 2.749110024069523e-07
expansions O 0 2.695697958188248e-06
between O 0 2.437981834191305e-07
generations O 0 4.657685508391296e-07
and O 0 1.499195150245214e-07
high O 0 5.918874990129552e-07
levels O 0 4.72162213327465e-07
of O 0 2.0671652123382955e-07
somatic O 0 6.665960245300084e-05
mosaicism O 0 0.0014650247758254409
, O 0 9.616932175049442e-07
is O 0 5.970044298919674e-07
observed O 0 6.650976956734667e-06
in O 0 7.621717941219686e-06
patients O 0 0.0004958005738444626
. O 0 2.2233924028114416e-05

There O 0 1.549812986922916e-05
is O 0 1.6264343685179483e-06
a O 0 1.5194717661870527e-06
good O 0 1.097708832276112e-06
correlation O 0 2.5582944545021746e-06
between O 0 5.996451477585651e-07
repeat O 0 6.7207502070232294e-06
size O 0 1.6883202533790609e-06
( O 0 3.833818880139006e-07
at O 0 2.3526359882453107e-07
least O 0 1.9539635331966565e-07
in O 0 4.7401923097822873e-07
leucocytes O 0 0.00014319336332846433
) O 0 1.0544086990194046e-06
, O 0 8.981773476079979e-07
clinical O 0 7.408923556795344e-05
severity O 0 0.00409172335639596
and O 0 3.32807735503593e-06
age O 0 4.124893621337833e-06
of O 0 4.446333605301334e-06
onset O 1 0.8739193081855774
. O 0 0.00010063642548630014

The O 0 0.00024207467504311353
trinucleotide O 0 0.10139966756105423
repeat O 0 0.000727097736671567
instability O 0 0.000260996661381796
mechanisms O 0 2.3744447389617562e-05
involved O 0 6.66681489747134e-06
in O 0 9.74444810708519e-06
DM B-Disease 1 1.0
and O 0 2.945914047813858e-06
other O 0 1.2243116316312808e-06
human O 0 0.0002279667678521946
genetic B-Disease 1 0.9999467134475708
diseases I-Disease 1 0.9999967813491821
are O 0 2.3911329662951175e-06
unknown O 0 2.0411829609656706e-05
. O 0 2.7385633075027727e-05

We O 0 3.373474828549661e-05
studied O 0 3.726913928403519e-05
somatic O 0 0.00014593116065952927
instability O 0 5.318309922586195e-05
by O 0 1.9041507357542287e-06
measuring O 0 4.441354121809127e-06
the O 0 2.1134385406185174e-06
CTG O 0 0.000435302616097033
repeat O 0 8.17657019069884e-06
length O 0 1.2586802995429025e-06
at O 0 4.064714858031948e-07
several O 0 3.1233506092576135e-07
ages O 0 9.518924457552203e-07
in O 0 2.8198186896588595e-07
various O 0 4.689218258135952e-07
tissues O 0 7.246354016388068e-06
of O 0 3.4148908412134915e-07
transgenic O 0 1.9735141904675402e-05
mice O 0 3.2883588573895395e-05
carrying O 0 1.7146229538411717e-06
a O 0 1.5857580137890182e-06
( O 0 1.666351295170898e-06
CTG O 0 5.771931682829745e-05
) O 0 5.265426921141625e-07
55expansion O 0 3.824846317002084e-06
surrounded O 0 8.177109975804342e-07
by O 0 2.3607834975791775e-07
45 O 0 4.710980192612624e-07
kb O 0 1.138241532316897e-05
of O 0 1.7354965109461773e-07
the O 0 6.312903337857279e-07
human O 0 6.999204288149485e-06
DM B-Disease 1 0.9999992847442627
region O 0 2.952574277514941e-06
, O 0 4.4689440414913406e-07
using O 0 1.0330919621992507e-06
small O 0 2.686827883735532e-06
- O 0 8.11654535937123e-05
pool O 0 5.184620385989547e-05
PCR O 0 0.00028396048583090305
. O 0 3.679071960505098e-05

These O 0 4.715925024356693e-05
mice O 0 0.00132884515915066
have O 0 1.4898126892148866e-06
been O 0 7.718665528955171e-07
shown O 0 9.413122370460769e-07
to O 0 4.1223356106456777e-07
reproduce O 0 2.845448989319266e-06
the O 0 3.2988089060381753e-07
intergenerational O 0 3.4733589018287603e-06
and O 0 2.910178693582566e-07
somatic O 0 9.518375009065494e-06
instability O 0 3.7466950288944645e-06
of O 0 1.381548742074301e-07
the O 0 5.688788746738282e-07
55 O 0 4.244518549967324e-06
CTG O 0 0.0008611060911789536
repeat O 0 1.1023426850442775e-05
suggesting O 0 3.5656014460982988e-06
that O 0 1.8011076008406235e-07
surrounding O 0 6.786779636058782e-07
sequences O 0 6.995640546847426e-07
and O 0 1.701109511031973e-07
the O 0 4.178041876912175e-07
chromatin O 0 8.031263860175386e-06
environment O 0 2.709786713239737e-06
are O 0 1.9988874555565417e-07
involved O 0 7.316421601899492e-07
in O 0 2.19129128709028e-06
instability O 0 0.00010058174666482955
mechanisms O 0 5.966850585537031e-05
. O 0 2.4570363166276366e-05

As O 0 1.8190954506280832e-05
observed O 0 8.231620086007752e-06
in O 0 4.5856847918912536e-07
some O 0 9.680213963747519e-08
of O 0 8.919855076783278e-08
the O 0 6.318860528153891e-07
tissues O 0 0.00027938938001170754
of O 0 3.218054916942492e-05
DM B-Disease 1 1.0
patients O 1 0.8241850137710571
, O 0 4.868696805715444e-07
there O 0 8.240098736678192e-08
is O 0 7.461067497160911e-08
a O 0 2.997021226747165e-07
tendency O 0 1.4234749414754333e-06
for O 0 1.383113499286992e-07
repeat O 0 4.16365355704329e-06
length O 0 1.0011601716541918e-06
and O 0 5.178580977371894e-07
somatic O 0 1.9424885977059603e-05
mosaicism O 0 0.00015666027320548892
to O 0 3.8146680481077055e-07
increase O 0 4.051344149047509e-07
with O 0 1.0488309953871067e-07
the O 0 2.2660040599475906e-07
age O 0 3.898324791862251e-07
of O 0 2.2503262187001383e-07
the O 0 4.469798113859724e-06
mouse O 0 0.0004437341704033315
. O 0 3.433443635003641e-05

Furthermore O 0 0.00021200011542532593
, O 0 6.654275694017997e-06
we O 0 8.026279942896508e-07
observed O 0 1.3036707287028548e-06
no O 0 2.0909398301682813e-07
correlation O 0 1.0616381587169599e-06
between O 0 4.3280795125610894e-07
the O 0 7.859380843910913e-07
somatic O 0 6.983805360505357e-05
mutation O 0 3.0615155992563814e-05
rate O 0 5.527543635253096e-06
and O 0 3.8054458855185658e-06
tissue O 0 0.00026341385091654956
proliferation O 0 0.0001241603313246742
capacity O 0 4.6807090257061645e-05
. O 0 3.22953455906827e-05

The O 0 5.42257766937837e-05
somatic O 0 0.001768896239809692
mutation O 0 0.0005178519641049206
rates O 0 2.4231003408203833e-05
in O 0 1.0238916274829535e-06
different O 0 4.41481120105891e-07
tissues O 0 2.4330851374543272e-05
were O 0 2.981566922244383e-07
also O 0 1.9448482646566845e-07
not O 0 9.68933875356015e-08
correlated O 0 1.3388186062002205e-06
to O 0 8.960558517401296e-08
the O 0 1.3359955630676268e-07
relative O 0 1.201598138322879e-06
inter O 0 9.447870979784057e-06
- O 0 0.002452125074341893
tissue O 0 1.9795763364527375e-05
difference O 0 4.1657924043647654e-07
in O 0 1.90870736105353e-07
transcriptional O 0 1.7821809024098911e-06
levels O 0 3.182694285897014e-07
of O 0 4.380124707381583e-08
the O 0 1.27214889289462e-07
three O 0 3.389304765732959e-07
genes O 0 1.7647839740675408e-06
( O 0 8.765966867940733e-07
DMAHP O 0 3.1063202186487615e-05
, O 0 5.070133397566678e-07
DMPK O 0 2.2269785404205322e-05
and O 0 3.599894853323349e-07
59 O 0 1.1528885579537018e-06
) O 0 3.19216013622281e-07
surrounding O 0 8.718279218555836e-07
the O 0 1.0448370630911086e-06
repeat O 0 3.2499749067937955e-05
. O 0 3.5719183415494626e-06
. O 0 1.4041635949979536e-05

A O 0 0.000320079387165606
novel O 0 0.0004335841513238847
missense O 0 0.15642686188220978
mutation O 0 0.004453374072909355
in O 0 2.601283813419286e-05
patients O 0 9.843317820923403e-05
from O 0 2.2245342279347824e-06
a O 0 9.253186362911947e-06
retinoblastoma B-Disease 1 0.6579965353012085
pedigree O 0 0.0002593129756860435
showing O 0 3.3388099836884066e-05
only O 0 8.062905294536904e-07
mild O 0 0.00010495689639355987
expression O 0 1.5928332004477852e-06
of O 0 4.045780315209413e-07
the O 0 1.632577732380014e-05
tumor B-Disease 1 0.9357340931892395
phenotype O 0 0.24708837270736694
. O 0 6.40413782093674e-05

We O 0 1.9392919057281688e-05
have O 0 1.8479842083252151e-06
used O 0 8.958257353697263e-07
single O 0 1.3122374866725295e-06
strand O 0 1.098593020287808e-05
conformation O 0 1.3259937077236827e-05
polymorphism O 0 1.7775499145500362e-05
analysis O 0 1.3782038195131463e-06
to O 0 3.4934728887492383e-07
study O 0 3.3660222698017606e-07
the O 0 2.243845926841459e-07
27 O 0 8.608773214291432e-07
exons O 0 2.1327950889826752e-06
of O 0 1.1909046548908009e-07
the O 0 1.069771883521753e-06
RB1 O 0 0.002265479415655136
gene O 0 4.240970156388357e-06
in O 0 3.0929592753636825e-07
individuals O 0 1.6854343698469165e-07
from O 0 2.710846729314653e-07
a O 0 1.6718173583285534e-06
family O 0 1.6426398360636085e-05
showing O 0 3.3013733627740294e-05
mild O 0 0.0026054331101477146
expression O 0 2.8151830520073418e-06
of O 0 8.840535201670718e-07
the O 0 9.79987089522183e-06
retinoblastoma B-Disease 1 0.954679548740387
phenotype O 0 0.394914448261261
. O 0 7.522688974859193e-05

In O 0 2.097109245369211e-05
this O 0 2.405143504802254e-06
family O 0 9.446502190257888e-06
affected O 0 3.94002063330845e-06
individuals O 0 8.544451475245296e-07
developed O 0 3.6209996324032545e-05
unilateral B-Disease 1 0.6606943607330322
tumors I-Disease 1 0.9999998807907104
and O 0 1.1288551604593522e-06
, O 0 1.2461889298265305e-07
as O 0 8.748514801482088e-08
a O 0 2.0359223640298296e-07
result O 0 3.844183709134086e-07
of O 0 2.1659428739440045e-07
linkage O 0 1.2883858289569616e-05
analysis O 0 1.933815838128794e-06
, O 0 6.130381393631978e-07
unaffected O 0 6.407252658391371e-05
mutation O 0 1.1612369235081133e-05
carriers O 0 2.904172561102314e-06
were O 0 2.452792671192583e-07
also O 0 1.8956190217522817e-07
identified O 0 8.936677886595135e-07
within O 0 6.850526119706046e-07
the O 0 2.296475258845021e-06
pedigree O 0 0.00015363621059805155
. O 0 2.9524129786295816e-05

A O 0 4.558884393190965e-05
single O 0 1.27536532090744e-05
band O 0 1.0793403816933278e-05
shift O 0 6.415341431420529e-06
using O 0 1.467224592488492e-06
SSCP O 0 0.00025084312073886395
was O 0 2.7837525067297975e-06
identified O 0 1.2469859029806685e-06
in O 0 4.1692820218486304e-07
exon O 0 9.699056136014406e-06
21 O 0 6.671341452602064e-07
which O 0 1.6455170737117442e-07
resulted O 0 1.0034848401119234e-06
in O 0 3.225331113299035e-07
a O 0 2.408703721812344e-06
missense O 0 0.00022884855570737273
mutation O 0 1.0591417776595335e-05
converting O 0 3.2718471629777923e-06
a O 0 8.613162208348513e-06
cys O 1 0.8093720078468323
- O 0 0.0007940040668472648
- O 0 7.677812391193584e-05
> O 0 2.085185951727908e-05
arg O 0 3.605590245570056e-05
at O 0 1.23718984923471e-06
nucleotide O 0 3.223023668397218e-06
position O 0 1.6438777947769267e-06
28 O 0 2.129169615727733e-06
in O 0 1.1126285244245082e-06
the O 0 4.413924671098357e-06
exon O 0 0.00032186307362280786
. O 0 3.761469997698441e-05

The O 0 9.81499397312291e-05
mutation O 0 0.0004167341685388237
destroyed O 0 7.63207208365202e-05
an O 0 6.640051196882268e-06
NdeI O 0 0.0004764268815051764
restriction O 0 7.673888467252254e-05
enzyme O 0 9.488802606938407e-05
site O 0 7.044466474326327e-05
. O 0 4.373699630377814e-05

Analysis O 0 3.704441769514233e-05
of O 0 1.8520686353440396e-06
all O 0 4.2742342998280947e-07
family O 0 1.6041046819736948e-06
members O 0 4.405957270137151e-07
demonstrated O 0 1.8349870742895291e-06
that O 0 2.2142067734876036e-07
the O 0 9.643446219342877e-07
missense O 0 0.0002705880324356258
mutation O 0 0.00010553659376455471
co O 0 0.00024721803492866457
- O 0 6.308248703135177e-05
segregated O 0 1.5344476196332835e-05
with O 0 2.6747559331852244e-06
patients O 0 0.000561048393137753
with O 0 0.0001171082622022368
tumors B-Disease 1 0.9999998807907104
or O 0 4.427803560247412e-06
who O 0 5.455364657791506e-07
, O 0 1.0367461555915725e-07
as O 0 7.198857332468833e-08
a O 0 2.000800378709755e-07
result O 0 2.0943124923178402e-07
of O 0 9.216422114377565e-08
linkage O 0 1.0920412933046464e-05
analysis O 0 9.354675967188086e-07
had O 0 7.652517410861037e-07
been O 0 2.8804629437217955e-07
predicted O 0 1.9025316078113974e-06
to O 0 2.9600894890791096e-07
carry O 0 1.403430928803573e-06
the O 0 4.011611508758506e-06
predisposing O 0 0.0005533173098228872
mutation O 0 0.00028988654958084226
. O 0 4.0946521039586514e-05

These O 0 8.979016456578393e-06
observations O 0 1.1875710697495379e-05
point O 0 1.3235539881861769e-06
to O 0 3.1666721156398125e-07
another O 0 3.1329508942690154e-07
region O 0 4.1591630406401237e-07
of O 0 1.337989772309811e-07
the O 0 6.404836199180863e-07
RB1 O 0 0.001393915037624538
gene O 0 4.169403382547898e-06
where O 0 3.390151732673985e-07
mutations O 0 1.8809473658620846e-06
only O 0 6.14469755078062e-08
modify O 0 1.2696003750534146e-06
the O 0 1.0265730310266008e-07
function O 0 1.3023444012105756e-07
of O 0 3.287558669740065e-08
the O 0 1.775221534217053e-07
gene O 0 9.019215099215216e-07
and O 0 8.76190782150843e-08
raise O 0 3.6225421240487776e-07
important O 0 1.0479171663746456e-07
questions O 0 3.571301476767985e-07
for O 0 2.614395384625823e-07
genetic O 0 6.5131985138577875e-06
counseling O 0 3.124514842056669e-05
in O 0 9.060707952812663e-07
families O 0 8.527372870048566e-07
with O 0 5.580795345849765e-07
these O 0 8.798799058240547e-07
distinctive O 0 0.00012602734204847366
phenotypes O 0 0.00991178397089243
. O 0 6.546315489686094e-06
. O 0 2.5066527086892165e-05

Maternal B-Disease 0 0.018664797767996788
disomy I-Disease 1 0.5726640224456787
and O 0 0.04311603307723999
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 3.3717926271492615e-05
with O 0 2.542101583458134e-06
gamete O 0 8.51942750159651e-05
complementation O 0 0.04151177778840065
in O 0 1.286942506339983e-06
a O 0 1.7022208567141206e-06
case O 0 1.1103624046882032e-06
of O 0 4.618302398284868e-07
familial O 0 0.0014647227944806218
translocation O 0 0.00016940994828473777
( O 0 2.0280676835682243e-06
3 O 0 8.84039991433383e-07
; O 0 5.785338430541742e-07
15 O 0 4.954204655405192e-07
) O 0 4.686772570039466e-07
( O 0 9.583990276951226e-07
p25 O 0 2.6270412490703166e-05
; O 0 1.3081914858048549e-06
q11 O 0 1.3734666936215945e-05
. O 0 8.189268783098669e-07
2 O 0 2.7792905257228995e-06
) O 0 4.834587343793828e-06
. O 0 1.0240215488011017e-05

Maternal B-Disease 0 0.41288861632347107
uniparental I-Disease 1 0.9955765008926392
disomy I-Disease 1 0.9828778505325317
( I-Disease 0 0.0012805028818547726
UPD I-Disease 1 0.9999865293502808
) I-Disease 0 5.708963726647198e-06
for I-Disease 0 8.798891144579102e-07
chromosome I-Disease 0 6.177700015541632e-06
15 I-Disease 0 4.5707045615017705e-07
is O 0 9.886174012763149e-08
responsible O 0 2.392526141647977e-07
for O 0 4.50675230467823e-08
an O 0 6.18997404444599e-08
estimated O 0 2.6658682372726616e-07
30 O 0 2.0897955721466133e-07
% O 0 1.1498707408463815e-07
of O 0 8.90574582967929e-08
cases O 0 1.9066255845245905e-06
of O 0 2.2934307708055712e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.004949890077114105
PWS B-Disease 1 0.9999978542327881
) O 0 6.51602604193613e-05
. O 0 4.268115299055353e-05

We O 0 2.4412731363554485e-05
report O 0 8.888587217370514e-06
on O 0 6.845210123174184e-07
an O 0 3.0220431312955043e-07
unusual O 0 8.167444889295439e-07
case O 0 5.224595156505529e-07
of O 0 2.0795351929336903e-07
maternal B-Disease 0 3.201733125024475e-05
disomy I-Disease 0 0.001239355537109077
15 I-Disease 0 3.1833544653636636e-06
in O 0 8.557934961572755e-06
PWS B-Disease 1 0.9999997615814209
that O 0 6.516278858725855e-07
is O 0 1.460031739952683e-07
most O 0 7.095175647009455e-08
consistent O 0 3.099257241956366e-07
with O 0 1.377384961642747e-07
adjacent O 0 2.9268999242049176e-06
- O 0 8.443895239906851e-06
1 O 0 3.926685963051568e-07
segregation O 0 1.6980410464384477e-06
of O 0 1.1522978127231909e-07
a O 0 1.1567960882530315e-06
paternal O 0 0.0011786113027483225
t O 0 0.0009501934982836246
( O 0 5.364644835026411e-07
3 O 0 3.06728338728135e-07
; O 0 2.0266782030375907e-07
15 O 0 2.503888083538186e-07
) O 0 3.2766382673798944e-07
( O 0 5.090146828479192e-07
p25 O 0 1.3658306670549791e-05
; O 0 5.196108077143435e-07
q11 O 0 4.548056040221127e-06
. O 0 2.0354427476831916e-07
2 O 0 2.532717360281822e-07
) O 0 1.391270672002065e-07
with O 0 1.3432072876184975e-07
simultaneous O 0 3.2021139304561075e-06
maternal O 0 4.677768811234273e-05
meiotic O 0 0.0003754870849661529
nondisjunction O 0 0.00025191446184180677
for O 0 3.1535405469185207e-06
chromosome O 0 8.82259919308126e-05
15 O 0 2.0385394236654975e-05
. O 0 2.613223659864161e-05

The O 0 0.0001701286673778668
patient O 0 0.07003860175609589
( O 0 4.351886673248373e-05
J O 0 0.06665460765361786
. O 0 1.0047393743661814e-06
B O 0 3.106387566731428e-06
. O 0 1.5796662466982525e-07
) O 0 1.150282074036113e-07
, O 0 5.134361558134515e-08
a O 0 1.6957093862401962e-07
17 O 0 5.76634533899778e-07
- O 0 5.482112101162784e-06
year O 0 6.32933620181575e-07
- O 0 7.283893410203746e-06
old O 0 1.5621337752236286e-06
white O 0 1.5813437812539632e-06
male O 0 5.402411034083343e-07
with O 0 8.953140877565602e-07
PWS B-Disease 1 0.9999996423721313
, O 0 1.1898846423719078e-06
was O 0 1.3306097343956935e-06
found O 0 2.0822182023039204e-07
to O 0 1.2145390826390212e-07
have O 0 1.2447719655028777e-07
47 O 0 6.626005983889627e-07
chromosomes O 0 5.450159505926422e-07
with O 0 1.0995114507750259e-07
a O 0 7.16209115125821e-07
supernumerary O 0 9.952708933269605e-05
, O 0 9.590170293449773e-07
paternal O 0 0.00013591808965429664
der O 0 0.0012637211475521326
( O 0 5.320106311046402e-07
15 O 0 1.5236392414408328e-07
) O 0 7.78607827101041e-08
consisting O 0 7.978887595072592e-08
of O 0 3.184412022960714e-08
the O 0 1.0206242251342701e-07
short O 0 1.1391114185244078e-06
arm O 0 7.150351302698255e-05
and O 0 2.0295985336815647e-07
the O 0 3.3721525483088044e-07
proximal O 0 0.0001045958197209984
long O 0 2.8273577754589496e-06
arm O 0 1.6527514162589796e-05
of O 0 2.49730135237769e-07
chromosome O 0 6.265667252591811e-06
15 O 0 6.922650186425017e-07
, O 0 2.4135914600265096e-07
and O 0 1.1294742989775841e-06
distal O 0 0.0031043814960867167
chromosome O 0 0.001294282847084105
arm O 0 0.1463155746459961
3p O 0 0.15542307496070862
. O 0 7.519045902881771e-05

The O 0 8.770214481046423e-05
t O 0 0.0019931895658373833
( O 0 4.716725470643723e-06
3 O 0 1.3608645303975209e-06
; O 0 3.461621815858962e-07
15 O 0 1.8844760063529975e-07
) O 0 1.2851647568368207e-07
was O 0 1.3058327397175162e-07
present O 0 6.778481775882028e-08
in O 0 5.3346976613966035e-08
the O 0 9.198719652658838e-08
balanced O 0 8.494387770952017e-07
state O 0 2.477803491274244e-07
in O 0 2.721044154441188e-07
the O 0 1.7937931033884524e-06
patients O 0 0.000350069283740595
father O 0 1.064596108335536e-05
and O 0 1.1276973737039953e-06
a O 0 1.2191850146336947e-05
sister O 0 0.0025179057847708464
. O 0 3.786417801165953e-05

Fluorescent O 0 0.0036136789713054895
in O 0 3.4561635402496904e-05
situ O 0 0.0001251965732080862
hybridization O 0 3.4178283385699615e-05
analysis O 0 6.350077455863357e-06
demonstrated O 0 4.616602836904349e-06
that O 0 5.366082405089401e-07
the O 0 2.1315954654710367e-06
PWS B-Disease 1 0.9999734163284302
critical O 0 4.973242539563216e-06
region O 0 1.660629095567856e-06
resided O 0 5.512251391337486e-06
on O 0 2.8518283556877577e-07
the O 0 2.1758866353138728e-07
derivative O 0 2.6457375952304574e-06
chromosome O 0 3.951980033889413e-06
3 O 0 4.1988647581092664e-07
and O 0 9.055226257714821e-08
that O 0 4.254311392060117e-08
there O 0 6.389291229424998e-08
was O 0 3.736856513114617e-07
no O 0 1.423500606279049e-07
deletion O 0 1.8410222537568188e-06
of O 0 9.362720732042362e-08
the O 0 1.1344000085955486e-06
PWS B-Disease 1 0.9999715089797974
region O 0 1.8443664657752379e-06
on O 0 3.9297580656239006e-07
the O 0 2.99240042522797e-07
normal O 0 1.3932186675447156e-06
pair O 0 1.0004366686189314e-06
of O 0 5.814887344968156e-07
15s O 0 3.591499989852309e-05
present O 0 4.9153968575410545e-06
in O 0 9.496215170656797e-06
J O 0 0.12354802340269089
. O 0 4.465095480554737e-05

B O 0 0.014059099368751049
. O 0 0.0011454969644546509

Methylation O 0 0.0010127462446689606
analysis O 0 0.0001061442744685337
at O 0 1.4493660273728892e-05
exon O 0 5.635431443806738e-05
alpha O 0 6.377095360221574e-06
of O 0 2.6283126430826087e-07
the O 0 5.221128276389209e-07
small O 0 9.29957138851023e-07
nuclear O 0 1.3010278962610755e-05
ribonucleoprotein O 0 0.0002348949492443353
- O 0 5.490198964253068e-05
associated O 0 5.616597718471894e-06
polypeptide O 0 3.007357008755207e-05
N O 0 3.244156687287614e-05
( O 0 1.7184698890559957e-06
SNRPN O 0 5.712131678592414e-05
) O 0 7.030707820376847e-07
gene O 0 1.74082049397839e-06
showed O 0 8.141603302647127e-07
a O 0 2.3637029755718686e-07
pattern O 0 1.1375916528777452e-06
characteristic O 0 3.7115614759386517e-07
of O 0 5.2411834872145846e-08
only O 0 9.681709656206294e-08
the O 0 4.7468873276557133e-07
maternal O 0 8.199630974559113e-05
chromosome O 0 2.661446706042625e-05
15 O 0 3.9107985685404856e-06
in O 0 6.219403985596728e-06
J O 0 0.028917508199810982
. O 0 3.222867599106394e-05

B O 0 0.011486716568470001
. O 0 0.0008939207182265818

Maternal B-Disease 0 0.042045120149850845
disomy I-Disease 0 0.13869990408420563
was O 0 8.906223956728354e-05
confirmed O 0 1.7309741451754235e-05
by O 0 1.9230608359066537e-06
polymerase O 0 3.1350686185760424e-05
chain O 0 2.6455903935129754e-05
reaction O 0 4.349830305727664e-06
analysis O 0 9.728410077514127e-07
of O 0 2.9409915214273497e-07
microsatellite O 0 3.2100488169817254e-05
repeats O 0 9.020642210089136e-06
at O 0 7.229086804727558e-07
the O 0 6.310471007964225e-07
gamma O 0 1.6700243577361107e-05
- O 0 1.8098931832355447e-05
aminobutyric O 0 4.6630575525341555e-05
acid O 0 1.577270813868381e-05
receptor O 0 2.5172023015329614e-05
beta3 O 0 4.599583553499542e-05
subunit O 0 2.7329440854373388e-05
( O 0 6.741458037140546e-06
GABRB3 O 0 0.0002232138649560511
) O 0 1.563938712934032e-05
locus O 0 0.00013606928405351937
. O 0 2.946202948805876e-05

A O 0 0.0004625142610166222
niece O 0 0.2756284773349762
( O 0 3.4462962503312156e-05
B O 0 2.851239150913898e-05
. O 0 6.932494329703331e-07
B O 0 1.8253003872814588e-06
. O 0 9.027667857708366e-08
) O 0 8.682171426244167e-08
with O 0 5.2989303611639116e-08
45 O 0 1.852046267458718e-07
chromosomes O 0 4.411684244587377e-07
and O 0 5.7154409205395496e-08
the O 0 1.1730688243005716e-07
derivative O 0 8.862110689733527e-07
3 O 0 2.981913951316528e-07
but O 0 8.077469004774684e-08
without O 0 9.925606292426892e-08
the O 0 2.8779641070286743e-07
der O 0 0.000547222385648638
( O 0 5.103626108393655e-07
15 O 0 2.4652288743709505e-07
) O 0 1.5947864540066803e-07
demonstrated O 0 7.195479838628671e-07
a O 0 8.885755846677057e-07
phenotype O 0 0.0007070599240250885
consistent O 0 6.83970256432076e-07
with O 0 1.1569843394454438e-07
that O 0 2.3881469246589404e-07
reported O 0 4.074055141245481e-06
for O 0 3.168877640291612e-07
haploinsufficiency O 0 3.7546822568401694e-05
of O 0 1.715995381346147e-06
distal O 0 0.002086730906739831
3 O 0 5.170804797671735e-05
p O 0 0.0007513389573432505
. O 0 3.847767584375106e-05

Uniparental B-Disease 1 0.9999890327453613
disomy I-Disease 1 0.9999666213989258
associated O 0 0.0007443072972819209
with O 0 1.883321783680003e-05
unbalanced O 0 0.0005681620095856488
segregation O 0 2.746079735516105e-05
of O 0 5.354014547265251e-07
non O 0 2.1236578504613135e-06
- O 0 2.5342069420730695e-05
Robertsonian O 0 9.227617556462064e-05
translocations O 0 7.781179738231003e-05
has O 0 1.0795964726639795e-06
been O 0 5.759201258115354e-07
reported O 0 1.0521613148739561e-05
previously O 0 1.2660540278375265e-06
but O 0 1.439199621700027e-07
has O 0 8.466454914923816e-08
not O 0 2.9535490497778483e-08
, O 0 2.364829754242237e-08
to O 0 4.0975166371026717e-08
our O 0 6.795128371095416e-08
knowledge O 0 2.1259891980207613e-07
, O 0 1.1870324811980026e-07
been O 0 2.2461517801275477e-07
observed O 0 5.236227593741205e-07
in O 0 1.9588686939187028e-07
a O 0 9.421780760021647e-07
case O 0 4.59214925285778e-06
of O 0 1.0503687008167617e-05
PWS B-Disease 1 0.9999963045120239
. O 0 0.0001539829099783674

Furthermore O 0 0.00021509864018298686
, O 0 6.2968829297460616e-06
our O 0 2.1932378331257496e-06
findings O 0 4.8797692215885036e-06
are O 0 1.2676751737217273e-07
best O 0 2.9744674634457624e-07
interpreted O 0 1.5714831533841789e-06
as O 0 6.828583423157397e-07
true O 0 3.6229571378498804e-06
gamete O 0 6.31002985755913e-05
complementation O 0 0.0006417554104700685
resulting O 0 2.7820120521937497e-05
in O 0 1.6442618289147504e-05
maternal B-Disease 0 0.14581100642681122
UPD I-Disease 1 0.9999902248382568
15 I-Disease 0 0.00014076102524995804
and O 0 0.0001443209475837648
PWS B-Disease 1 0.9999836683273315

Schwartz B-Disease 1 0.9958360195159912
- I-Disease 1 0.9997900128364563
Jampel I-Disease 1 0.9999889135360718
syndrome I-Disease 1 0.9999996423721313
type I-Disease 0 6.389820191543549e-05
2 I-Disease 0 5.595895800070139e-06
and O 0 4.3499298953975085e-06
Stuve B-Disease 1 0.9962179064750671
- I-Disease 1 0.999998927116394
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
: O 0 1.2367509043542668e-06
a O 0 1.0101831549036433e-06
case O 0 1.0923109812210896e-06
for O 0 4.027824900276755e-07
" O 0 1.4143598718874273e-06
lumping O 0 2.828236756613478e-05
" O 0 7.384596756310202e-06
. O 0 1.2374596735753585e-05

Recent O 0 9.622988727642223e-05
studies O 0 1.6549121937714517e-05
demonstrated O 0 5.156343831913546e-06
the O 0 4.248789480243431e-07
existence O 0 7.586805281789566e-07
of O 0 1.1604099370288168e-07
a O 0 1.191385763377184e-06
genetically O 0 2.7331009277986595e-06
distinct O 0 1.0861531336558983e-06
, O 0 2.877854399230273e-07
usually O 0 2.576601332293649e-07
lethal O 0 1.1390441159164766e-06
form O 0 2.0881738294065144e-07
of O 0 1.3815369470648875e-07
the O 0 1.4544854138875962e-06
Schwartz B-Disease 1 0.7236574292182922
- I-Disease 1 0.9974448680877686
Jampel I-Disease 1 0.9999748468399048
syndrome I-Disease 1 0.9999997615814209
( O 0 3.0414161301450804e-05
SJS B-Disease 1 0.5076968669891357
) O 0 9.820787454373203e-07
of O 0 7.336754492826003e-07
myotonia B-Disease 1 0.8375527858734131
and O 0 2.5412255126866512e-05
skeletal B-Disease 1 0.9999383687973022
dysplasia I-Disease 1 0.9999858140945435
, O 0 1.4199808902048972e-06
which O 0 1.0535924275245634e-06
we O 0 5.526835025193577e-07
called O 0 2.0002571545774117e-05
SJS B-Disease 1 0.987216055393219
type I-Disease 0 3.667634882731363e-05
2 I-Disease 0 1.242345661012223e-05
. O 0 1.7046322682290338e-05

This O 0 0.0005858932854607701
disorder O 1 0.9980034232139587
is O 0 3.436850192883867e-06
reminiscent O 0 1.7113039575633593e-05
of O 0 3.9596389456164616e-07
another O 0 1.1301241329420009e-06
rare O 0 8.821561095828656e-06
condition O 0 0.00021013438527006656
, O 0 5.437518098005967e-07
the O 0 2.6133136543649016e-06
Stuve B-Disease 1 0.9870674014091492
- I-Disease 1 0.9999862909317017
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
( O 0 2.6000339858001098e-05
SWS B-Disease 1 0.9977864027023315
) O 0 7.523113936258596e-07
, O 0 1.0378937531640986e-07
which O 0 1.3229971784767258e-07
comprises O 0 4.4232609752725693e-07
campomelia B-Disease 0 2.7955060431850143e-05
at O 0 1.6229698758252198e-06
birth O 0 1.3170369129511528e-05
with O 0 4.550815901893657e-06
skeletal B-Disease 1 0.9990851879119873
dysplasia I-Disease 1 0.9999189376831055
, O 0 4.6708082663826644e-06
contractures B-Disease 0 0.09936556965112686
, O 0 8.724117606107029e-07
and O 0 8.339160899595299e-07
early B-Disease 0 1.4996803656686097e-05
death I-Disease 0 0.00014120127889327705
. O 0 2.822002352331765e-05

To O 0 2.4602861230960116e-05
test O 0 1.08565127447946e-05
for O 0 5.715549491469574e-07
possible O 0 1.356091729576292e-06
nosologic O 0 0.0001255802490049973
identity O 0 3.2245732199953636e-06
between O 0 1.995699904000503e-06
these O 0 6.727964318997692e-06
disorders O 1 0.9969634413719177
, O 0 5.900693054172734e-07
we O 0 1.1028215141095643e-07
reviewed O 0 6.796553861931898e-07
the O 0 1.4340250231725804e-07
literature O 0 2.673162100563786e-07
and O 0 1.0500239966404479e-07
obtained O 0 4.133358117996977e-07
a O 0 2.924902844370081e-07
follow O 0 9.160949616671132e-07
- O 0 1.2983936130694929e-06
up O 0 4.0772079046291765e-08
of O 0 1.3438743451388291e-08
the O 0 3.203357579195654e-08
only O 0 2.7166640492737315e-08
two O 0 8.34629929613584e-08
surviving O 0 6.169528933241963e-05
patients O 0 2.737116847129073e-05
, O 0 1.5430541111527418e-07
one O 0 1.3624106998122443e-07
with O 0 1.2361094832158415e-06
SJS B-Disease 1 0.9986214637756348
type I-Disease 0 4.74642592962482e-06
2 I-Disease 0 4.0809584334056126e-07
at O 0 2.2691570222832524e-07
age O 0 1.8297676263046014e-07
10 O 0 1.0620305346265013e-07
years O 0 1.169388426092155e-07
and O 0 6.739175972825251e-08
another O 0 2.1646275172315654e-07
with O 0 1.136032551585231e-06
SWS B-Disease 1 0.9990468621253967
at O 0 3.2886891858652234e-06
age O 0 2.754061370069394e-06
7 O 0 5.535926447919337e-06
years O 0 1.101442194340052e-05
. O 0 2.0386307369335555e-05

Patients O 1 0.9762244820594788
reported O 0 0.0008160154102370143
as O 0 5.557539680012269e-06
having O 0 1.2651605175051372e-05
either O 0 7.638333772774786e-05
neonatal O 1 1.0
SJS B-Disease 1 0.9999998807907104
or O 0 0.00021566338546108454
SWS B-Disease 1 0.9996156692504883
presented O 0 7.426958745782031e-06
a O 0 1.1994228543699137e-06
combination O 0 1.7019774531945586e-06
of O 0 2.6687220611165685e-07
a O 0 5.591036369878566e-06
severe O 1 0.831002414226532
, O 0 2.5270153855672106e-05
prenatal O 1 0.9996261596679688
- O 1 0.9999709129333496
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 0.9999997615814209
( O 0 3.034242763533257e-05
with O 0 3.539825411280617e-05
congenital B-Disease 1 0.9999970197677612
joint I-Disease 0 0.1427047848701477
contractures I-Disease 1 0.999987006187439
, O 0 0.0004883247893303633
respiratory O 1 0.9991734623908997
and O 0 1.8860973796108738e-06
feeding O 0 1.462757518311264e-05
difficulties O 0 4.636396170099033e-06
, O 0 3.9613652802472643e-07
tendency O 0 4.179706593276933e-06
to O 0 2.074871190416161e-06
hyperthermia B-Disease 1 0.9776671528816223
, O 0 3.0642777915090846e-07
and O 0 1.819750821141497e-07
frequent O 0 6.184915946505498e-06
death O 0 0.0005298813921399415
in O 0 3.315162302897079e-06
infancy O 0 0.0026294547133147717
) O 0 2.398543585968582e-07
with O 0 1.1281088774239834e-07
a O 0 8.633734864815779e-07
distinct O 0 5.395267180574592e-06
campomelic B-Disease 0 0.07967173308134079
- I-Disease 0 0.15423549711704254
metaphyseal I-Disease 1 0.8473430275917053
skeletal I-Disease 1 0.9988563060760498
dysplasia I-Disease 1 0.9998742341995239
. O 0 9.580356709193438e-05

The O 0 1.7450127415941097e-05
similarity O 0 1.2792243978765327e-05
of O 0 1.1206730050616898e-06
the O 0 1.7247352843696717e-06
clinical O 0 0.00011644735059235245
and O 0 6.941101219126722e-06
radiographic O 1 0.9681801199913025
findings O 0 0.004093378782272339
is O 0 4.807548634744307e-07
so O 0 1.67742157941575e-07
extensive O 0 2.677318207133794e-06
that O 0 1.5752252693346236e-06
these O 0 1.3412924090516753e-05
disorders O 1 0.9997550845146179
appear O 0 1.0063110494229477e-05
to O 0 3.24140899010672e-07
be O 0 1.7699944976357074e-07
a O 0 5.507756100087136e-07
single O 0 2.9819732390024e-06
entity O 0 2.3732087356620468e-05
. O 0 1.6874295397428796e-05

The O 0 1.6430862160632387e-05
follow O 0 1.8823915524990298e-05
- O 0 1.6325651813531294e-05
up O 0 6.594120804948034e-07
observation O 0 1.245851990461233e-06
of O 0 7.659520662173236e-08
an O 0 1.397367412891981e-07
identical O 0 1.8117108311344055e-06
and O 0 1.661237547523342e-07
unique O 0 3.745144283584523e-07
pattern O 0 2.6667478323361138e-06
of O 0 4.205348886898719e-07
progressive O 1 0.9495164752006531
bone B-Disease 1 0.9993218183517456
dysplasia I-Disease 1 0.9997414946556091
in O 0 1.0574195812296239e-06
the O 0 5.725117944166414e-07
two O 0 1.1010954494850012e-06
patients O 0 6.957681762287393e-05
( O 0 3.680406450712326e-07
one O 0 1.2349977396297618e-07
with O 0 1.0634651061991462e-06
SJS B-Disease 1 0.9990686774253845
type I-Disease 0 5.579982826020569e-06
2 I-Disease 0 3.0985418675300025e-07
, O 0 7.140506852465478e-08
one O 0 8.223549485819603e-08
with O 0 4.655012162402272e-07
SWS B-Disease 1 0.9925405383110046
) O 0 6.879345733068476e-07
surviving O 0 1.5594559954479337e-06
beyond O 0 9.709352752906852e-07
infancy O 0 5.079431502963416e-05
adds O 0 1.2032515996907023e-06
to O 0 8.520075311935216e-08
the O 0 8.268656870313862e-08
evidence O 0 2.85401029032073e-07
in O 0 3.0067405987210805e-07
favor O 0 1.167934442491969e-06
of O 0 9.446144417779578e-07
identity O 0 2.408880027360283e-05
. O 0 2.6449748474988155e-05

The O 0 5.56150553165935e-05
hypothesis O 0 0.00013891707931179553
that O 0 9.267926543543581e-06
SWS B-Disease 1 0.998230516910553
and O 0 3.680546069517732e-05
SJS B-Disease 1 0.9996225833892822
type I-Disease 0 1.249865545105422e-05
2 I-Disease 0 6.86583064180013e-07
are O 0 8.99367265105866e-08
the O 0 3.2961168017209275e-07
same O 0 4.008578252978623e-05
disorder O 1 0.9937514662742615
should O 0 8.257040917669656e-07
be O 0 2.8374068961056764e-07
testable O 0 3.6806245589104947e-06
by O 0 8.208768917938869e-07
molecular O 0 6.348485385387903e-06
methods O 0 4.285252543922979e-06
. O 0 3.1745294108986855e-06
. O 0 1.2534417692222632e-05

A O 0 0.0002327409602003172
mouse O 0 0.0007363453623838723
model O 0 9.886373300105333e-05
of O 0 1.8182247004006058e-05
severe O 1 0.9999998807907104
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.04691667854785919
defects O 1 0.9998185038566589
in O 0 5.442361725727096e-05
hemostasis O 1 0.9979800581932068
and O 0 0.001250982517376542
thrombosis B-Disease 1 0.9999467134475708
. O 0 0.0001452542346669361

von B-Disease 1 0.998580813407898
Willebrand I-Disease 1 0.9978390336036682
factor I-Disease 0 0.0022797088604420424
( I-Disease 0 0.0009207709808833897
vWf I-Disease 1 0.9244812726974487
) I-Disease 0 0.26057377457618713
deficiency I-Disease 1 0.9999961853027344
causes O 1 0.9841012358665466
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.0001379734167130664
humans O 0 0.00011914371134480461
. O 0 4.817921944777481e-05

We O 0 2.2279748009168543e-05
generated O 0 1.7897460566018708e-05
a O 0 4.484673354454571e-06
mouse O 0 3.2503652619197965e-05
model O 0 4.259355591784697e-06
for O 0 3.3314927350147627e-07
this O 0 7.929654088911775e-07
disease O 0 3.972100603277795e-05
by O 0 5.41771441930905e-07
using O 0 2.6234517918055644e-06
gene O 0 2.542539186833892e-05
targeting O 0 4.066246037837118e-05
. O 0 3.1518440664513037e-05

vWf B-Disease 1 0.9867386817932129
- I-Disease 1 0.9997236132621765
deficient I-Disease 1 0.9960334897041321
mice O 0 0.0016547642881050706
appeared O 0 2.0534052964649163e-05
normal O 0 5.176959348318633e-06
at O 0 1.628818608878646e-06
birth O 0 1.562461329740472e-05
; O 0 5.248095362730965e-07
they O 0 1.348049067928514e-07
were O 0 2.8187594125483884e-07
viable O 0 3.235616532037966e-06
and O 0 1.5398244386233273e-06
fertile O 0 4.4678130507236347e-05
. O 0 2.924980071838945e-05

Neither O 0 0.0026098533999174833
vWf O 0 0.011880815029144287
nor O 0 0.001240268349647522
vWf O 0 0.006677689962089062
propolypeptide O 0 0.10253667086362839
( O 0 0.0002286304661538452
von B-Disease 1 0.8802708387374878
Willebrand I-Disease 1 0.9704859852790833
antigen O 0 0.035212308168411255
II O 0 0.018060563132166862
) O 0 3.0903579499863554e-06
were O 0 1.081263690139167e-06
detectable O 0 4.729788543045288e-06
in O 0 6.42694317321002e-07
plasma O 0 1.7104721337091178e-05
, O 0 6.328328367999347e-07
platelets O 0 1.962665919563733e-05
, O 0 3.166249200603488e-07
or O 0 6.015501980982663e-07
endothelial O 0 2.808417775668204e-05
cells O 0 2.3715115275990684e-06
of O 0 2.0739936701374972e-07
the O 0 1.9396504740143428e-06
homozygous O 0 0.00023485574638471007
mutant O 0 0.00036038621328771114
mice O 0 0.0006788988248445094
. O 0 4.051351425005123e-05

The O 0 0.00010768256470328197
mutant O 0 0.057476483285427094
mice O 1 0.9284698367118835
exhibited O 1 0.8944766521453857
defects O 1 0.9982426166534424
in O 0 7.1683966780256014e-06
hemostasis O 0 0.014273524284362793
with O 0 1.296582013310399e-06
a O 0 8.732360583962873e-06
highly O 0 4.291923323762603e-05
prolonged O 1 0.9924557209014893
bleeding O 1 0.979678750038147
time O 0 2.1230362108326517e-06
and O 0 1.03599256817688e-06
spontaneous O 0 2.1142343030078337e-05
bleeding O 0 0.004236122593283653
events O 0 1.0229136933048721e-06
in O 0 4.5861483499720634e-07
approximately O 0 1.0625061577229644e-06
10 O 0 1.0937484375972417e-06
% O 0 1.227641519108147e-06
of O 0 3.2292075502482476e-06
neonates O 0 0.0036946372129023075
. O 0 5.3869727707933635e-05

As O 0 1.3074458365736064e-05
in O 0 2.439140416754526e-06
the O 0 1.4123381788522238e-06
human O 0 8.412708666583057e-06
disease O 0 0.0005128695629537106
, O 0 2.016090832057671e-07
the O 0 3.5549501831155794e-07
factor O 0 1.6973190213320777e-06
VIII O 0 0.003370103891938925
level O 0 5.005294383408909e-07
in O 0 2.58034162925469e-07
these O 0 1.737849970595562e-07
mice O 0 2.2582929886993952e-05
was O 0 6.202276949807128e-07
reduced O 0 6.407713613043597e-07
strongly O 0 6.86923669945827e-07
as O 0 6.357478810059547e-08
a O 0 1.1212421924255978e-07
result O 0 1.4415307703075086e-07
of O 0 4.9672618018803405e-08
the O 0 1.705625578551917e-07
lack O 0 4.589368529650528e-07
of O 0 2.293594150160061e-07
protection O 0 8.563935807615053e-06
provided O 0 4.702030764747178e-06
by O 0 8.940462976170238e-06
vWf O 0 0.0007269736961461604
. O 0 4.6117580495774746e-05

Defective O 1 0.999829888343811
thrombosis B-Disease 1 0.9999591112136841
in O 0 0.00015945588529575616
mutant O 0 0.04429905489087105
mice O 0 0.035318464040756226
was O 0 6.319900421658531e-06
also O 0 5.571446877183917e-07
evident O 0 9.738582775753457e-07
in O 0 1.8769537746265996e-07
an O 0 2.587922267593967e-07
in O 0 1.307403294958931e-06
vivo O 0 8.380801591556519e-05
model O 0 1.4797937183175236e-05
of O 0 8.094439181149937e-06
vascular B-Disease 1 0.9999984502792358
injury I-Disease 1 0.9777530431747437
. O 0 0.0001322781463386491

In O 0 2.3404976673191413e-05
this O 0 3.7027552934887353e-06
model O 0 5.930564384470927e-06
, O 0 5.756488690167316e-07
the O 0 1.032491127261892e-06
exteriorized O 0 0.00018234174058306962
mesentery O 0 0.00048657969455234706
was O 0 7.663474207220133e-06
superfused O 0 7.056683534756303e-05
with O 0 1.924983735079877e-06
ferric O 0 0.008800549432635307
chloride O 0 2.0474722987273708e-05
and O 0 3.3436327839808655e-07
the O 0 3.476211247743777e-07
accumulation O 0 3.951199687435292e-06
of O 0 6.944610504433513e-07
fluorescently O 0 0.008608948439359665
labeled O 0 0.00044472215813584626
platelets O 0 0.000660910562146455
was O 0 8.441229510935955e-06
observed O 0 9.381269592267927e-06
by O 0 8.561339200241491e-06
intravital O 0 0.0014855115441605449
microscopy O 0 0.0015495916595682502
. O 0 5.7656929129734635e-05

We O 0 1.9724344383575954e-05
conclude O 0 2.854692138498649e-05
that O 0 1.2766448662659968e-06
these O 0 9.743469036038732e-07
mice O 0 4.5273009163793176e-05
very O 0 1.140067752203322e-06
closely O 0 1.3806447896058671e-05
mimic O 0 0.13417653739452362
severe O 1 0.9987155199050903
human O 0 0.0697082057595253
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 1.0365645721321926e-05
will O 0 1.0120510296474095e-06
be O 0 1.1695891544150072e-07
very O 0 8.397685036243274e-08
useful O 0 7.279354719003095e-08
for O 0 4.991185065250647e-08
investigating O 0 5.792686579297879e-07
the O 0 1.6121424550874508e-07
role O 0 3.587488492939883e-07
of O 0 2.653713124800561e-07
vWf O 0 1.857543429650832e-05
in O 0 6.016948077558482e-07
normal O 0 6.375295924954116e-06
physiology O 0 5.0771697715390474e-05
and O 0 1.8774564978230046e-06
in O 0 3.487044887151569e-05
disease O 0 0.41308242082595825
models O 0 2.378419776505325e-05
. O 0 3.4427550872351276e-06
. O 0 1.3909849258197937e-05

Oral O 0 0.0032932155299931765
contraceptives O 0 0.008372682146728039
and O 0 6.786360700061778e-06
the O 0 5.278355274640489e-06
risk O 0 5.066582525614649e-05
of O 0 6.961292820051312e-05
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0003604019002523273

Hereditary B-Disease 1 0.9999998807907104
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9999995231628418
Clinical O 1 0.8941957950592041
Study O 0 0.0007087457925081253
Group O 0 0.00033500182325951755
. O 0 8.655161946080625e-05

BACKGROUND O 0 0.0009609317639842629
Women O 0 2.5674800781416707e-05
with O 0 3.3155797609651927e-06
mutations O 0 4.427460953593254e-05
in O 0 5.497051347447268e-07
either O 0 5.465998924591986e-07
the O 0 9.72416160038847e-07
BRCA1 O 0 0.00010974692850140855
or O 0 6.111910693107347e-07
the O 0 1.0406843102828134e-06
BRCA2 O 0 0.0003202997613698244
gene O 0 4.142902525927639e-06
have O 0 2.2464065807525913e-07
a O 0 1.129141537603573e-06
high O 0 7.79732181399595e-06
lifetime O 0 6.622761429753155e-05
risk O 0 0.00041174289071932435
of O 0 0.00690119992941618
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0003269914595875889

Oral O 0 0.006157644093036652
contraceptives O 1 0.906195878982544
protect O 0 0.004171569366008043
against O 1 0.9878778457641602
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 3.746723450603895e-06
general O 0 4.489778802962974e-06
, O 0 2.0946801271293225e-07
but O 0 8.729512757099656e-08
it O 0 6.871766800031764e-08
is O 0 5.80777168579516e-08
not O 0 4.2038649894493574e-08
known O 0 1.4104280410265346e-07
whether O 0 1.4933189618204779e-07
they O 0 7.287523118293393e-08
also O 0 1.881087854371799e-07
protect O 0 7.101281198629295e-07
against O 0 1.474355713071418e-06
hereditary B-Disease 0 0.0027135873679071665
forms I-Disease 0 2.175321424147114e-05
of I-Disease 0 0.013569703325629234
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00017449755978304893

METHODS O 0 0.00015698804054409266
We O 0 8.236346729972865e-06
enrolled O 0 1.583995071996469e-05
207 O 0 3.496552017168142e-05
women O 0 6.990971542109037e-06
with O 0 0.0016036516753956676
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.1475092378532281e-06
161 O 0 2.1363127871154575e-06
of O 0 1.5219112015074643e-07
their O 0 3.6926024904460064e-07
sisters O 0 2.697878699109424e-06
as O 0 1.4790620639359986e-07
controls O 0 3.583136503948481e-06
in O 0 2.481864100900566e-07
a O 0 1.1237187891310896e-06
case O 0 5.51106313650962e-06
- O 0 7.351074600592256e-05
control O 0 3.0330078516271897e-05
study O 0 1.2922731002618093e-05
. O 0 1.4356302926898934e-05

All O 0 1.3278337064548396e-05
the O 0 6.540836693602614e-06
patients O 0 7.672703213756904e-05
carried O 0 6.234172815311467e-06
a O 0 4.84382235299563e-06
pathogenic O 0 6.679425132460892e-05
mutation O 0 2.5039169486262836e-05
in O 0 1.3091823802824365e-06
either O 0 4.196304871584289e-06
BRCA1 O 0 0.00019556893676053733
( O 0 2.2571189219888765e-06
179 O 0 8.918033017835114e-06
women O 0 1.8458443946656189e-06
) O 0 1.3402046761257225e-06
or O 0 2.858215339074377e-06
BRCA2 O 0 0.00045746483374387026
( O 0 4.447699211596046e-06
28 O 0 1.0135382581211161e-05
women O 0 6.421437774406513e-06
) O 0 1.2840496310673188e-05
. O 0 2.5853816623566672e-05

The O 0 2.8455944629968144e-05
control O 0 4.7266858018701896e-05
women O 0 2.083834260702133e-06
were O 0 5.995976835038164e-07
enrolled O 0 1.4398602843357367e-06
regardless O 0 6.408557169379492e-07
of O 0 1.5197630887087143e-07
whether O 0 9.540772225591354e-07
or O 0 5.582866151598864e-07
not O 0 1.591982794479918e-07
they O 0 1.8275596858075005e-07
had O 0 1.5612178003721056e-06
either O 0 5.413280632637907e-06
mutation O 0 0.00012169693945907056
. O 0 2.2548454580828547e-05

Lifetime O 0 0.0005745178204961121
histories O 0 0.00013816590944770724
of O 0 4.290355718694627e-06
oral O 0 9.325239807367325e-05
- O 0 0.019025422632694244
contraceptive O 0 0.010937131941318512
use O 0 1.4865825050947024e-06
were O 0 3.054212243114307e-07
obtained O 0 4.9957094461206e-07
by O 0 4.210855024666671e-07
interview O 0 7.539326816186076e-06
or O 0 2.3360179568499007e-07
by O 0 2.224450668109057e-07
written O 0 3.69059591776022e-07
questionnaire O 0 2.8013187147735152e-06
and O 0 1.593931813204108e-07
were O 0 2.1592812515791593e-07
compared O 0 1.3120222774887225e-06
between O 0 1.7687874560579075e-06
patients O 0 0.00026769968098960817
and O 0 8.657728471916926e-07
control O 0 6.42735612927936e-05
women O 0 5.510593155122478e-07
, O 0 1.04287849467255e-07
after O 0 5.109094445288065e-07
adjustment O 0 8.707784218131565e-07
for O 0 9.856444904698947e-08
year O 0 2.6595628810355265e-07
of O 0 1.8351360608903633e-07
birth O 0 3.2733343687141314e-05
and O 0 2.752651198534295e-06
parity O 0 7.014629227342084e-05
. O 0 2.4947523343143985e-05

RESULTS O 0 0.00033280346542596817
The O 0 2.28392964345403e-05
adjusted O 0 0.00022192193137016147
odds O 0 0.00030158774461597204
ratio O 0 0.00030518011772073805
for O 0 0.4558835029602051
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 1.5274657926056534e-05
with O 0 1.9741588630495244e-07
any O 0 1.4581253537926386e-07
past O 0 3.0064882139413385e-07
use O 0 2.734214490374143e-07
of O 0 2.3609050003869925e-07
oral O 0 6.288362055784091e-05
contraceptives O 0 0.22848741710186005
was O 0 3.548920722096227e-05
0 O 0 3.0259669074439444e-05
. O 0 1.9254708604421467e-05

5 O 0 5.636038622469641e-05
( O 0 6.7818577917933e-06
95 O 0 5.095512278785463e-06
percent O 0 2.1862815628992394e-06
confidence O 0 2.674001052582753e-06
interval O 0 2.1017367544118315e-06
, O 0 2.6327452928853745e-07
0 O 0 6.053726906429802e-07
. O 0 1.0910506631489625e-07
3 O 0 2.630581832363532e-07
to O 0 2.476031966125447e-07
0 O 0 1.055406642080925e-06
. O 0 3.916872231002344e-07
8 O 0 2.3830832560634008e-06
) O 0 2.8607294098037528e-06
. O 0 8.740858902456239e-06

The O 0 3.838077827822417e-05
risk O 0 4.5337255869526416e-05
decreased O 0 9.685209079179913e-06
with O 0 4.455883129139693e-07
increasing O 0 1.1802286508100224e-06
duration O 0 2.593891622382216e-06
of O 0 2.105836500732039e-07
use O 0 9.88126998890948e-07
( O 0 1.0553944775892887e-06
P O 0 1.46590518852463e-05
for O 0 1.5665287378396897e-07
trend O 0 2.0391257748997305e-06
, O 0 2.713112507990445e-07
< O 0 2.3609281925018877e-06
0 O 0 4.89556214233744e-07
. O 0 1.4291265415522503e-07
001 O 0 2.452779199302313e-06
) O 0 1.2947876371072198e-07
; O 0 5.05398034533755e-08
use O 0 4.459270996903797e-08
for O 0 2.4644194240863726e-08
six O 0 8.26436874490355e-08
or O 0 7.196002371756549e-08
more O 0 3.518039193295408e-08
years O 0 3.002465405188559e-07
was O 0 8.644478270980471e-07
associated O 0 2.513899062250857e-07
with O 0 6.388365392240303e-08
a O 0 3.006884128353704e-07
60 O 0 1.0345709142711712e-06
percent O 0 5.3064213716425e-06
reduction O 0 6.68216853227932e-06
in O 0 3.896866928698728e-06
risk O 0 6.0350932471919805e-05
. O 0 2.0458326616790146e-05

Oral O 0 0.0014799468917772174
- O 0 0.011014158837497234
contraceptive O 0 0.0018677081679925323
use O 0 8.288778190035373e-06
protected O 0 0.00010177540389122441
against O 1 0.847589373588562
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999960660934448
both O 0 7.04839749232633e-07
for O 0 2.68893018073868e-07
carriers O 0 1.26788461329852e-06
of O 0 2.0272715062219504e-07
the O 0 3.181218062309199e-06
BRCA1 O 0 0.06515546143054962
mutation O 0 5.1725459343288094e-05
( O 0 2.131652536263573e-06
odds O 0 1.074252122634789e-05
ratio O 0 1.8497739802114666e-06
, O 0 2.460216705912899e-07
0 O 0 3.155277283894975e-07
. O 0 6.996642554213395e-08
5 O 0 1.3576377000390494e-07
; O 0 1.4711572760006675e-07
95 O 0 6.653493755948148e-07
percent O 0 8.677699270265293e-07
confidence O 0 1.6187668734346516e-06
interval O 0 1.0792608691190253e-06
, O 0 1.1723139436981e-07
0 O 0 2.2135121469091246e-07
. O 0 3.523035019270537e-08
3 O 0 8.362137293715932e-08
to O 0 6.132754037935229e-08
0 O 0 1.851933149055185e-07
. O 0 5.8399297842015585e-08
9 O 0 1.7102578908634314e-07
) O 0 6.78929907849124e-08
and O 0 4.290590993605292e-08
for O 0 4.36159197647612e-08
carriers O 0 4.354992029220739e-07
of O 0 9.675691359234406e-08
the O 0 1.8227067357656779e-06
BRCA2 O 0 0.07655118405818939
mutation O 0 3.541051046340726e-05
( O 0 2.1003420442866627e-06
odds O 0 1.0447720342199318e-05
ratio O 0 1.6585858020334854e-06
, O 0 1.850931994340499e-07
0 O 0 3.7115688655831036e-07
. O 0 7.759008013863422e-08
4 O 0 3.461107098701177e-07
; O 0 2.3175958574483957e-07
95 O 0 1.1314267567286151e-06
percent O 0 2.2069154965720372e-06
confidence O 0 2.3484558369091246e-06
interval O 0 1.4854543906039908e-06
, O 0 1.296921965376896e-07
0 O 0 4.3883284206458484e-07
. O 0 8.87610340782885e-08
2 O 0 1.818260670916061e-07
to O 0 2.1555551654728333e-07
1 O 0 5.214947691456473e-07
. O 0 3.9954397834662814e-07
1 O 0 1.857856886999798e-06
) O 0 5.044627414463321e-06
. O 0 1.0667731658031698e-05

CONCLUSIONS O 0 0.0011452246690168977
Oral O 0 0.0007336385315284133
- O 0 0.114174023270607
contraceptive O 0 0.012924517504870892
use O 0 6.378506441251375e-06
may O 0 3.805979531534831e-06
reduce O 0 3.218355004719342e-06
the O 0 1.6263537645500037e-06
risk O 0 5.390693695517257e-05
of O 0 0.0011791617143899202
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 8.178362804756034e-06
women O 0 1.7835325252235634e-06
with O 0 1.7102202036767267e-06
pathogenic O 0 0.00012575292203109711
mutations O 0 3.570742410374805e-05
in O 0 2.0963436782039935e-06
the O 0 9.57361680775648e-06
BRCA1 O 0 0.002349027432501316
or O 0 0.00010620947432471439
BRCA2 O 0 0.009702160954475403
gene O 0 0.001332476851530373

A O 0 9.584999497747049e-05
Japanese O 0 3.9801234379410744e-05
family O 0 3.0131355742923915e-05
with O 0 6.204836608958431e-06
adrenoleukodystrophy B-Disease 1 0.9999916553497314
with O 0 2.5790279778448166e-06
a O 0 2.6683558189688483e-06
codon O 0 1.830500696087256e-05
291 O 0 1.566064020153135e-05
deletion O 0 4.529892248683609e-05
: O 0 6.550010311912047e-07
a O 0 9.516328418612829e-07
clinical O 0 1.8264832760905847e-05
, O 0 8.655978263050201e-07
biochemical O 0 1.9395416529732756e-05
, O 0 5.101640567772847e-07
pathological O 0 1.3861251318303403e-05
, O 0 6.742575919815863e-07
and O 0 3.4638255783647764e-06
genetic O 0 7.921995711512864e-05
report O 0 9.484133624937385e-05
. O 0 2.8877049771836028e-05

We O 0 1.8464870663592592e-05
report O 0 1.101750967791304e-05
a O 0 2.1465853023983072e-06
Japanese O 0 4.026698206871515e-06
family O 0 9.831931492954027e-06
with O 0 1.3847232366970275e-05
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.00434340862557292
ALD B-Disease 1 0.9999994039535522
) O 0 5.613313192043279e-07
with O 0 7.927130951657091e-08
a O 0 1.7047669587100245e-07
three O 0 1.5281416665402503e-07
base O 0 1.2300263279030332e-06
pair O 0 3.345474397065118e-06
deletion O 0 4.61390518466942e-05
( O 0 2.1122659745742567e-06
delGAG O 0 2.34136387007311e-05
291 O 0 1.2517240975284949e-05
) O 0 1.5605896805936936e-06
in O 0 2.0175693862256594e-06
the O 0 1.6996456906781532e-05
ALD B-Disease 1 0.9999983310699463
gene O 0 0.0005712442798539996
. O 0 6.887325434945524e-05

A O 0 5.837994103785604e-05
variety O 0 1.222725859406637e-05
of O 0 2.5460831238888204e-06
phenotypes O 0 0.0004242597206030041
were O 0 1.0518776889512083e-06
observed O 0 2.4773667064437177e-06
within O 0 9.226770885106816e-07
this O 0 1.0235645504508284e-06
family O 0 2.2856138457427733e-05
. O 0 1.6272895663860254e-05

While O 0 2.9580609407275915e-05
the O 0 1.103789054468507e-05
proband O 0 0.027307774871587753
( O 0 1.4928098607924767e-05
patient O 0 4.602163244271651e-05
1 O 0 8.647990625831881e-07
) O 0 3.2780229730633437e-07
was O 0 6.797979494876927e-07
classified O 0 6.178744911267131e-07
as O 0 9.042505411116508e-08
having O 0 2.1688799733965425e-07
a O 0 4.053825364280783e-07
rare O 0 1.8082171209243825e-06
intermediate O 0 1.9031775764233316e-06
type O 0 1.6390969221902196e-06
of O 0 2.6434150868226425e-07
adult O 0 9.099910130316857e-06
cerebral O 0 0.03452524170279503
and O 0 4.39952646047459e-06
cerebello O 1 0.9584706425666809
- O 1 0.7683935165405273
brain O 0 0.007280629128217697
stem O 0 4.895439815300051e-06
forms O 0 4.607603329986887e-07
, O 0 1.7433927723686793e-07
his O 0 1.5436178273375845e-06
younger O 0 2.152627166651655e-05
brother O 0 0.0004960662336088717
( O 0 2.8404060685716104e-06
patient O 0 9.651905202190392e-06
2 O 0 5.003347496312927e-07
) O 0 2.6625497184795677e-07
and O 0 3.5108340057377063e-07
nephew O 0 0.005997827276587486
( O 0 2.8858735277026426e-06
patient O 0 1.503905514255166e-05
3 O 0 6.787822144360689e-07
) O 0 4.926256451653899e-07
had O 0 1.2476948541007005e-06
a O 0 1.416205213899957e-05
childhood O 1 0.9757109880447388
ALD B-Disease 1 1.0
type O 0 0.02222202531993389
. O 0 4.9352187488693744e-05

Another O 0 0.0002209519880125299
nephew O 0 0.233627587556839
( O 0 4.763174365507439e-05
patient O 0 0.0001268900086870417
4 O 0 3.1715064778836677e-06
) O 0 4.88973853407515e-07
of O 0 2.3289042871965648e-07
patient O 0 2.7526972189662047e-05
1 O 0 9.063672905540443e-07
was O 0 1.6896732404347858e-06
classified O 0 1.551629225104989e-06
as O 0 3.504344476823462e-07
having O 0 7.507696864195168e-07
an O 0 1.1074563417423633e-06
adolescent O 0 0.0003141910710837692
form O 0 1.7002244931063615e-05
. O 0 2.4811857656459324e-05

The O 0 2.3667378627578728e-05
tau O 0 7.785647903801873e-05
level O 0 4.278392680134857e-06
in O 0 1.8111061308445642e-06
the O 0 3.606647851484013e-06
cerebrospinal O 1 0.74070143699646
fluid O 0 0.03491024300456047
( O 0 4.412127236719243e-05
CSF O 1 0.9654209017753601
) O 0 9.864425010164268e-07
in O 0 4.0846808246897126e-07
patient O 0 1.4710757568536792e-05
1 O 0 3.140866624562477e-07
was O 0 6.486832830887579e-07
as O 0 7.131536960969243e-08
high O 0 1.539403058359312e-07
as O 0 5.8344742370763925e-08
that O 0 6.998578072625605e-08
of O 0 2.1125366345131624e-07
patients O 0 0.0004424047947395593
with O 0 0.011658662930130959
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9999058246612549
( O 0 1.8963482943945564e-05
AD B-Disease 0 0.00013342854799702764
) O 0 1.067239008989418e-05
. O 0 1.2739405065076426e-05

His O 0 0.0005076375091448426
brain O 1 0.5598655939102173
magnetic O 0 0.0009071506792679429
resonance O 0 0.005131719633936882
image O 0 0.006770421285182238
( O 0 3.3474912925157696e-05
MRI O 1 0.77268385887146
) O 0 3.641617468019831e-06
showed O 0 0.00020288943778723478
abnormalities B-Disease 0 0.1007409617304802
in I-Disease 0 2.727578305439238e-07
the I-Disease 0 2.8840582899647416e-07
bilateral I-Disease 0 2.5230792743968777e-06
cerebellar I-Disease 0 0.016215015202760696
hemispheres I-Disease 0 0.00011328989785397425
and O 0 8.019408596737776e-06
brain O 0 0.0720023661851883
stem O 0 2.3968359528225847e-05
, O 0 3.0364731173904147e-07
but O 0 1.2845865171584592e-07
not O 0 7.118137546058279e-08
in O 0 1.8200250906375004e-07
the O 0 1.5374048416560981e-06
cerebral O 0 0.4839102327823639
white O 0 2.3729598979116417e-05
matter O 0 3.314513037366851e-07
, O 0 8.368264303726392e-08
where O 0 9.872833572899253e-08
marked O 0 4.090598508810217e-07
reductions O 0 8.690619210938166e-07
of O 0 1.2974328456039075e-07
the O 0 1.994029616980697e-06
cerebral O 0 0.24022503197193146
blood O 0 1.1402372365409974e-05
flow O 0 2.5102626750594936e-06
and O 0 1.0003107036027359e-06
oxygen O 0 7.598565571242943e-05
metabolism O 0 2.3404798412229866e-05
were O 0 4.173737124801846e-07
clearly O 0 1.276988200515916e-06
demonstrated O 0 2.5137028387689497e-06
by O 0 1.8670095869310899e-06
positron O 0 0.0006542393821291625
emission O 0 0.0006679035723209381
tomography O 0 0.038648560643196106
( O 0 2.2373389583663084e-05
PET O 0 0.00020213426614645869
) O 0 1.2143496860517189e-05
. O 0 1.4671275494038127e-05

In O 0 0.00020816928008571267
patients O 0 0.00024418323300778866
2 O 0 2.0769696220668266e-06
and O 0 3.318087067327724e-07
3 O 0 4.1121424487755576e-07
, O 0 1.598678665004627e-07
the O 0 8.116268190860865e-07
autopsy O 1 0.6764211058616638
findings O 0 8.310419070767239e-05
showed O 0 2.65845337708015e-05
massive O 0 5.871179382666014e-05
demyelination B-Disease 1 0.9986431002616882
of I-Disease 0 6.085505219743936e-07
the I-Disease 0 4.669792815548135e-06
cerebral I-Disease 1 0.570194661617279
white I-Disease 0 1.2304954907449428e-05
matter I-Disease 0 1.757490224463254e-07
with O 0 6.814480713046578e-08
sparing O 0 6.343561267385667e-07
of O 0 4.6275253851035814e-08
the O 0 4.176241361619759e-07
U O 0 0.006268081720918417
- O 0 0.0020683116745203733
fibers O 0 2.7401623810874298e-05
, O 0 1.8586140981824428e-07
compatible O 0 4.987184070159856e-07
with O 0 1.1440985048238872e-07
the O 0 5.452181994769489e-07
findings O 0 1.5750205420772545e-05
of O 0 5.866382252861513e-06
childhood O 1 0.9284908175468445
ALD B-Disease 1 0.9999996423721313
. O 0 0.0002477997331880033

Oleic O 0 0.009002079255878925
and O 0 0.00011688499944284558
erucic O 0 0.004592381417751312
acids O 0 0.00010866579395951703
( O 0 1.071483529813122e-05
Lorenzos O 0 6.28344714641571e-05
Oil O 0 4.711124347522855e-06
) O 0 7.965428494571825e-07
were O 0 2.59587636719516e-07
administered O 0 2.036315891018603e-06
to O 0 1.1237744956815732e-06
patients O 0 9.278768629883416e-06
1 O 0 2.3445639385499817e-07
and O 0 1.930019095652824e-07
4 O 0 5.632134616462281e-07
, O 0 1.3919952834839933e-07
but O 0 1.5615454174167098e-07
sufficient O 0 9.811500376599724e-07
effectiveness O 0 1.6202502592932433e-05
was O 0 5.097281700727763e-06
not O 0 1.0833621217898326e-06
obtained O 0 9.344714271719567e-06
. O 0 1.5339881429099478e-05

The O 0 2.6903333491645753e-05
findings O 0 4.993171023670584e-05
in O 0 1.7587589127288084e-06
this O 0 4.6885250526429445e-07
family O 0 1.909886805151473e-06
suggest O 0 8.220614517995273e-07
that O 0 1.1623004780858537e-07
delGAG291 O 0 5.419799890660215e-06
is O 0 6.7298500994184e-08
part O 0 7.250947220427406e-08
of O 0 3.874510667856157e-08
the O 0 2.321010867945006e-07
cause O 0 2.0443910671019694e-06
of O 0 3.9732225332045346e-07
Japanese O 0 8.90187657205388e-05
ALD B-Disease 1 0.9999980926513672
with O 0 9.412518920726143e-06
phenotypic O 0 0.00016891153063625097
variations O 0 0.0001186061927000992
. O 0 4.901453939964995e-05

Moreover O 0 0.0001523168321000412
, O 0 2.7723549465008546e-06
although O 0 4.6951248577897786e-07
the O 0 1.4688708915855386e-07
scale O 0 4.655260852359788e-07
of O 0 6.164206922676385e-08
the O 0 1.6091810550733499e-07
study O 0 4.0186893102145405e-07
is O 0 7.381010647122821e-08
limited O 0 6.492260808954597e-07
, O 0 6.003237729146349e-08
there O 0 3.1092099561647046e-08
is O 0 3.481472177213618e-08
a O 0 1.2579516805999447e-07
possibility O 0 5.573551220550144e-07
that O 0 2.826741365424823e-07
PET O 0 0.00010016577289206907
can O 0 8.06052184998407e-07
detect O 0 2.4885599486879073e-05
an O 0 1.2390081565172295e-06
insidious B-Disease 0 0.09888631850481033
lesion I-Disease 1 0.9866583943367004
which O 0 1.3974876083011623e-06
is O 0 5.183452458368265e-07
undetectable O 0 7.828404704923742e-06
by O 0 5.622657113235618e-07
computed O 0 8.912165867513977e-06
tomogram O 0 0.00014758550969418138
( O 0 5.683117706212215e-06
CT O 1 0.9453261494636536
) O 0 6.438089599214436e-07
or O 0 7.183481329775532e-07
MRI O 0 0.004354322794824839
analysis O 0 4.801047452929197e-07
, O 0 7.953847358521671e-08
and O 0 4.741033166055786e-08
that O 0 2.8760426928897687e-08
the O 0 6.199154967134746e-08
higher O 0 2.550016802160826e-07
level O 0 1.9515108817813598e-07
of O 0 1.0023526897384727e-07
tau O 0 2.942497076219297e-06
reflects O 0 6.630607458646409e-07
the O 0 2.0488671736984543e-07
process O 0 5.083563792140922e-07
of O 0 1.0265588343827403e-06
neuronal B-Disease 0 0.00603882921859622
degeneration I-Disease 1 0.9988871216773987
in O 0 0.0006879799766466022
ALD B-Disease 1 0.9999997615814209
. O 0 0.00014330864360090345

Lorenzos O 0 0.0035529278684407473
Oil O 0 5.81021340622101e-05
should O 0 2.5475524125795346e-06
be O 0 3.6608034292839875e-07
given O 0 2.839058197423583e-07
in O 0 2.8092216552977334e-07
the O 0 4.387834451335948e-07
early O 0 3.4821348435798427e-06
stage O 0 1.0870705409615766e-05
. O 0 3.499465947243152e-06
. O 0 1.6217682059505023e-05

Nonsense O 0 0.002978253411129117
mutation O 0 0.0009326528524979949
in O 0 1.3586673958343454e-05
exon O 0 7.032659777905792e-05
4 O 0 2.14528381548007e-06
of O 0 4.1108327764050046e-07
human O 0 1.0981381137753488e-06
complement O 0 4.238633209752152e-06
C9 O 0 0.015435853973031044
gene O 0 1.2879767382401042e-05
is O 0 2.595856471998559e-07
the O 0 3.41025639727377e-07
major O 0 1.218285433424171e-06
cause O 0 3.0610287922172574e-06
of O 0 9.335772688245925e-07
Japanese O 0 3.054519766010344e-05
complement B-Disease 0 0.0009437487460672855
C9 I-Disease 1 0.9999710321426392
deficiency I-Disease 1 0.9997076392173767
. O 0 8.014462218852714e-05

Deficiency B-Disease 1 0.9928169250488281
of I-Disease 0 4.79907930639456e-06
the I-Disease 0 2.4500345716660377e-06
ninth I-Disease 0 5.2662426242022775e-06
component I-Disease 0 1.7907743767864304e-06
of I-Disease 0 2.1980778797114908e-07
human I-Disease 0 5.928953896727762e-07
complement I-Disease 0 2.2726921997673344e-06
( O 0 1.4861147974443156e-06
C9 O 0 0.00019991776207461953
) O 0 2.757675474640564e-07
is O 0 4.772661554852675e-08
the O 0 6.417223374910463e-08
most O 0 1.7193029577811103e-07
common O 0 1.30875068862224e-05
complement B-Disease 1 0.9995692372322083
deficiency I-Disease 1 0.9999992847442627
in O 0 7.136836188692541e-07
Japan O 0 2.1679775272787083e-06
but O 0 2.3443112695531454e-07
is O 0 1.423681084133932e-07
rare O 0 8.458931120003399e-07
in O 0 3.3202394433828886e-07
other O 0 3.899180001099012e-07
countries O 0 2.0357856556074694e-06
. O 0 1.3770287296210881e-05

We O 0 1.6602109099039808e-05
studied O 0 1.2372177479846869e-05
the O 0 1.843037125581759e-06
molecular O 0 1.0947191185550764e-05
basis O 0 1.6588008975304547e-06
of O 0 2.6570151021587662e-06
C9 B-Disease 1 0.9999964237213135
deficiency I-Disease 1 0.9911465048789978
in O 0 6.926004516571993e-07
four O 0 6.309207947197137e-07
Japanese O 0 2.2581551093026064e-05
C9 B-Disease 1 0.9999840259552002
- I-Disease 1 0.9999895095825195
deficient I-Disease 1 0.9997288584709167
patients O 0 0.04375797137618065
who O 0 1.198856898554368e-05
had O 0 0.0007440891349688172
suffered O 1 0.999964714050293
from O 0 0.030327215790748596
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 0.9999996423721313
. O 0 0.00022718064428772777

Direct O 0 0.00010893886792473495
sequencing O 0 7.236935925902799e-05
of O 0 6.43485100226826e-06
amplified O 0 0.00013576200581155717
C9 O 0 0.0004962565726600587
cDNA O 0 6.666914123343304e-05
and O 0 2.812529373841244e-06
DNA O 0 5.95534356762073e-06
revealed O 0 9.759383829077706e-06
a O 0 1.8272528450324899e-06
nonsense O 0 8.521377822034992e-06
substitution O 0 4.4325315684545785e-06
( O 0 2.831081246768008e-06
CGA O 0 0.0002926847373601049
- O 0 0.00014327571261674166
- O 0 4.282131703803316e-05
> O 0 2.3506956495111808e-05
TGA O 0 0.00023122827406041324
) O 0 7.932936796350987e-07
at O 0 3.794661154188361e-07
codon O 0 2.734255986069911e-06
95 O 0 7.325756428144814e-07
in O 0 4.495051655339921e-07
exon O 0 5.461848559207283e-06
4 O 0 5.364583444134041e-07
in O 0 2.3297886286854919e-07
the O 0 4.797266797140765e-07
four O 0 2.867071543732891e-06
C9 B-Disease 1 0.9716860055923462
- I-Disease 1 0.8472107648849487
deficient I-Disease 0 0.019044402986764908
individuals O 0 5.631766271108063e-06
. O 0 1.3860510080121458e-05

An O 0 4.943173917126842e-05
allele O 0 0.0004014090809505433
- O 0 4.9712783948052675e-05
specific O 0 3.0558398975699674e-06
polymerase O 0 2.7188491003471427e-05
chain O 0 3.938380177714862e-05
reaction O 0 5.366054665500997e-06
system O 0 2.850541477528168e-06
designed O 0 4.362034815130755e-06
to O 0 2.825606486567267e-07
detect O 0 3.0984053864813177e-06
exclusively O 0 2.1367742419897695e-07
only O 0 3.2305269570542805e-08
one O 0 1.8482557706533953e-08
of O 0 1.7749293590441084e-08
the O 0 5.82334536147755e-08
normal O 0 4.050532709243271e-07
and O 0 1.9758219593768445e-07
mutant O 0 8.376427103939932e-06
alleles O 0 3.997435214841971e-06
indicated O 0 1.3046233107161243e-06
that O 0 3.740007770147713e-08
all O 0 1.5795675878393922e-08
the O 0 4.9553577241567837e-08
four O 0 5.181030928724795e-07
patients O 0 1.6239690012298524e-05
were O 0 4.2909837816296204e-07
homozygous O 0 6.449202373914886e-06
for O 0 1.2032603535772068e-07
the O 0 3.138785302780889e-07
mutation O 0 3.7668150980607606e-06
in O 0 3.5703681078302907e-07
exon O 0 5.0394733079883736e-06
4 O 0 4.027924660476856e-07
and O 0 7.564308646124118e-08
that O 0 6.28803960012192e-08
the O 0 1.7809479402330908e-07
parents O 0 5.830841587339819e-07
of O 0 1.8422518621719064e-07
patient O 0 2.8866752472822554e-05
2 O 0 2.4568550998083083e-06
were O 0 4.076806362718344e-06
heterozygous O 0 0.00014900433598086238
. O 0 2.950710040749982e-05

The O 0 2.462039265083149e-05
common O 0 1.5652876754757017e-05
mutation O 0 3.064866177737713e-05
at O 0 2.423422301944811e-06
codon O 0 8.915319995139726e-06
95 O 0 2.120990075127338e-06
in O 0 6.684868480988371e-07
exon O 0 1.8108565200236626e-05
4 O 0 1.21979439882125e-06
might O 0 4.4930112608199124e-07
be O 0 9.198281247790874e-08
responsible O 0 4.3834262442032923e-07
for O 0 2.0103215092603932e-07
most O 0 7.190952260316408e-07
Japanese O 0 0.00040900366730056703
C9 B-Disease 1 0.9999992847442627
deficiency I-Disease 1 0.9999445676803589
. O 0 1.2004907148366328e-05
. O 0 2.966547071991954e-05

BRCA1 O 0 0.02662125788629055
required O 0 4.271841680747457e-05
for O 0 5.102397608425235e-06
transcription O 0 5.049319224781357e-05
- O 0 0.00041973867337219417
coupled O 0 0.0005324865342117846
repair O 0 0.002498368266969919
of O 0 3.884614670823794e-06
oxidative O 0 0.009588226675987244
DNA O 0 0.000464500772068277
damage O 0 0.0022633937187492847
. O 0 4.561249807011336e-05

The O 0 0.0003772132040467113
breast B-Disease 1 0.9999525547027588
and I-Disease 1 0.9594576358795166
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 0.7164649367332458
gene O 0 0.00037416836130432785
BRCA1 O 0 0.00040329236071556807
encodes O 0 2.192194187955465e-05
a O 0 7.884508704592008e-06
zinc O 0 7.185855065472424e-05
finger O 0 1.1280317266937345e-05
protein O 0 2.2841084046376636e-06
of O 0 5.197540531298728e-07
unknown O 0 4.1560483623470645e-06
function O 0 1.1481341971375514e-05
. O 0 1.4058009583095554e-05

Association O 0 0.0001011982312775217
of O 0 3.863659458147595e-06
the O 0 6.678249974356731e-06
BRCA1 O 0 0.0001647074386710301
protein O 0 2.4529476831958164e-06
with O 0 2.553774720581714e-07
the O 0 5.643823897116818e-07
DNA O 0 7.132010978239123e-06
repair O 0 0.007090785540640354
protein O 0 5.981139111099765e-06
Rad51 O 0 6.977043085498735e-05
and O 0 2.955702882445621e-07
changes O 0 4.544352236734994e-07
in O 0 1.1088432927408576e-07
the O 0 1.1459144388936693e-07
phosphorylation O 0 9.516400609754783e-07
and O 0 1.1155062651369008e-07
cellular O 0 7.879869485805102e-07
localization O 0 7.811847808625316e-07
of O 0 4.208678561212764e-08
the O 0 1.018378270600806e-07
protein O 0 4.382644647193956e-07
after O 0 5.389957209445129e-07
exposure O 0 3.84629220206989e-06
to O 0 2.5232472466996114e-07
DNA O 0 2.157040853489889e-06
- O 0 2.4740829758229665e-05
damaging O 0 9.445177056477405e-06
agents O 0 1.3875674085284118e-06
are O 0 1.0516955484263235e-07
consistent O 0 2.566580690199771e-07
with O 0 7.422077175078812e-08
a O 0 2.778983514417632e-07
role O 0 5.665907565344241e-07
for O 0 9.039192150339659e-07
BRCA1 O 0 0.00020826698164455593
in O 0 4.782138603331987e-06
DNA O 0 0.00021642967476509511
repair O 1 0.6657848358154297
. O 0 5.594378671958111e-05

Here O 0 2.1128696971572936e-05
, O 0 1.6912306364247343e-06
it O 0 2.9052924332972907e-07
is O 0 1.7891511561174411e-07
shown O 0 4.880774895354989e-07
that O 0 2.60212260627668e-07
mouse O 0 1.4555938832927495e-05
embryonic O 0 4.8502650315640494e-05
stem O 0 0.0001322963071288541
cells O 0 0.0003579733893275261
deficient B-Disease 0 0.0063285864889621735
in I-Disease 0 2.6502175387577154e-06
BRCA1 I-Disease 0 0.0010357496794313192
are O 0 4.162091329362738e-07
defective O 0 9.480625885771587e-05
in O 0 2.875171389860043e-07
the O 0 1.9999971812012518e-07
ability O 0 5.397477593760414e-07
to O 0 1.1526803689321241e-07
carry O 0 2.939937360224576e-07
out O 0 1.9153281982653425e-07
transcription O 0 2.537695536375395e-06
- O 0 2.2187155991559848e-05
coupled O 0 3.853907765005715e-05
repair O 0 6.55729163554497e-05
of O 0 3.0066087219893234e-07
oxidative O 0 0.0002697716699913144
DNA O 0 1.2963451808900572e-05
damage O 0 8.533705840818584e-05
, O 0 3.342331922340236e-07
and O 0 2.545436927903211e-07
are O 0 3.545070796917571e-07
hypersensitive O 0 0.0003715211933013052
to O 0 3.0873179639456794e-06
ionizing O 0 0.0005793891614302993
radiation O 0 0.0014336814638227224
and O 0 3.4538834370323457e-06
hydrogen O 0 0.0001392916456097737
peroxide O 0 0.0014617583947256207
. O 0 3.498656951705925e-05

These O 0 1.6443091226392426e-05
results O 0 1.336387049377663e-05
suggest O 0 5.98457381784101e-06
that O 0 1.0763849331851816e-06
BRCA1 O 0 3.2791584089864045e-05
participates O 0 2.439684749333537e-06
, O 0 1.7756040904259862e-07
directly O 0 3.386293769835902e-07
or O 0 2.840885997557052e-07
indirectly O 0 1.5545396081506624e-06
, O 0 1.7188700951464853e-07
in O 0 3.015271943240805e-07
transcription O 0 3.994447524746647e-06
- O 0 3.54395633621607e-05
coupled O 0 5.611208689515479e-05
repair O 0 0.0003731086617335677
of O 0 7.560780659332522e-07
oxidative O 0 0.0065548778511583805
DNA O 0 0.00012766481086146086
damage O 0 0.0011270086979493499
. O 0 9.640185453463346e-06
. O 0 2.124716411344707e-05

Truncation O 0 0.016429048031568527
mutations O 0 0.005590884480625391
in O 0 1.1118108886876144e-05
the O 0 4.5399265218293294e-06
transactivation O 0 0.00012230164429638535
region O 0 5.6042272262857296e-06
of O 0 1.633606871109805e-06
PAX6 O 0 0.0027543629985302687
result O 0 6.4614414441166446e-06
in O 0 2.2738977349945344e-06
dominant O 0 5.372771920519881e-05
- O 0 0.00036034261574968696
negative O 0 6.316820508800447e-05
mutants O 0 0.000239647546550259
. O 0 3.2357434974983335e-05

PAX6 O 0 0.14669588208198547
is O 0 1.806523505365476e-05
a O 0 4.742028067994397e-06
transcription O 0 1.0494104571989737e-05
factor O 0 1.3685380508832168e-06
with O 0 1.672029696919708e-07
two O 0 2.000430185944424e-07
DNA O 0 2.6187524326815037e-06
- O 0 7.243838808790315e-06
binding O 0 2.695985813261359e-06
domains O 0 3.995506631326862e-06
( O 0 8.612501574134512e-07
paired O 0 2.393094973740517e-06
box O 0 3.067378884225036e-06
and O 0 5.612467930404819e-07
homeobox O 0 2.550144745327998e-05
) O 0 3.5142909382557264e-07
and O 0 1.8955159930555965e-07
a O 0 1.0455398751219036e-06
proline O 0 6.0353748267516494e-05
- O 0 2.6300391255063005e-05
serine O 0 4.077802077517845e-05
- O 0 4.134525443078019e-05
threonine O 0 7.258514233399183e-05
( O 0 5.309631433192408e-06
PST O 0 0.00021728426509071141
) O 0 4.732567958853906e-06
- O 0 1.1895343050127849e-05
rich O 0 8.918058483686764e-06
transactivation O 0 0.0001872554566944018
domain O 0 5.542266080738045e-05
. O 0 3.096928776358254e-05

PAX6 O 0 0.25123584270477295
regulates O 0 0.007153049577027559
eye O 0 0.009993146173655987
development O 0 2.0325271179899573e-05
in O 0 3.4694919577304972e-06
animals O 0 2.220466967628454e-06
ranging O 0 3.1702422802482033e-06
from O 0 1.4476988781098044e-06
jellyfish O 0 1.709829484752845e-05
to O 0 1.209948777614045e-06
Drosophila O 0 1.0144889529328793e-05
to O 0 3.461111191427335e-06
humans O 0 1.708574200165458e-05
. O 0 1.351477112621069e-05

Heterozygous O 0 0.21661321818828583
mutations O 0 0.001783477608114481
in O 0 4.693831670010695e-06
the O 0 1.8410222537568188e-06
human O 0 4.4011380850861315e-06
PAX6 O 0 0.004595584236085415
gene O 0 1.6941337889875285e-05
result O 0 1.13271039481333e-06
in O 0 3.6893709420837695e-07
various O 0 6.281039759414853e-07
phenotypes O 0 3.449900395935401e-05
, O 0 3.971283035753004e-07
including O 0 1.2813482044293778e-06
aniridia B-Disease 1 0.9999902248382568
, O 0 0.00011814812751254067
Peters B-Disease 1 0.999998927116394
anomaly I-Disease 1 0.9999619722366333
, O 0 1.4817793271504343e-05
autosomal B-Disease 0 0.014918074943125248
dominant I-Disease 0 0.0001438752078684047
keratitis I-Disease 1 0.5743563175201416
, O 0 7.2275952334166504e-06
and O 0 1.2721317943942267e-05
familial B-Disease 1 0.9751754999160767
foveal I-Disease 1 0.9998849630355835
dysplasia I-Disease 1 0.9999887943267822
. O 0 0.00027497197152115405

It O 0 1.2183447324787267e-05
is O 0 1.3372056173466262e-06
believed O 0 1.8324443544770475e-06
that O 0 3.0781492910136876e-07
the O 0 6.312349114523386e-07
mutated O 0 2.4260712962131947e-05
allele O 0 1.5583020285703242e-05
of O 0 7.079473789417534e-07
PAX6 O 0 0.00019587688439060003
produces O 0 3.4718489132501418e-06
an O 0 6.418337648028682e-07
inactive O 0 1.0518562703509815e-05
protein O 0 1.7537075791551615e-06
and O 0 5.932811291131657e-07
aniridia B-Disease 1 0.9791544675827026
is O 0 1.4663098681921838e-06
caused O 0 1.9240189431002364e-05
due O 0 7.483288300136337e-06
to O 0 4.864473794441437e-06
genetic O 0 8.019078813958913e-05
haploinsufficiency O 0 0.003545204410329461
. O 0 5.284977305564098e-05

However O 0 3.1388197385240346e-05
, O 0 3.0401433832594194e-06
several O 0 1.5420316685776925e-06
truncation O 0 0.00016713478544261307
mutations O 0 0.00013753995881415904
have O 0 6.153447316137317e-07
been O 0 4.469097518722265e-07
found O 0 3.5391661867834046e-07
to O 0 2.1706927100240136e-07
occur O 0 4.6251957996901183e-07
in O 0 1.9136248852191784e-07
the O 0 5.821478907819255e-07
C O 0 8.109436748782173e-05
- O 0 1.4482249753200449e-05
terminal O 0 3.3943974813155364e-06
half O 0 2.484177628048201e-07
of O 0 1.9439823972788872e-07
PAX6 O 0 0.018670540302991867
in O 0 5.442806923383614e-06
patients O 0 3.599784031393938e-05
with O 0 1.118405180022819e-06
Aniridia B-Disease 1 0.9967733025550842
resulting O 0 7.283767899934901e-06
in O 0 4.4455561010181555e-07
mutant O 0 6.326014499791199e-06
proteins O 0 5.13476322794304e-07
that O 0 9.742525008960001e-08
retain O 0 7.253491958181257e-07
the O 0 2.0321841986969957e-07
DNA O 0 1.7402843468516949e-06
- O 0 4.691280992119573e-06
binding O 0 9.976984074455686e-07
domains O 0 1.0412203437226708e-06
but O 0 1.349994391830478e-07
have O 0 8.842527421393243e-08
lost O 0 4.5053431563246704e-07
most O 0 7.511486188604977e-08
of O 0 1.2370158231078676e-07
the O 0 1.7821877236201544e-06
transactivation O 0 0.0002126522158505395
domain O 0 4.886859096586704e-05
. O 0 2.5409297450096346e-05

It O 0 1.3087283150525764e-05
is O 0 1.082122935258667e-06
not O 0 3.402291213205899e-07
clear O 0 5.558189855037199e-07
whether O 0 5.155823714630969e-07
such O 0 4.167230827079038e-07
mutants O 0 0.0029625569004565477
really O 0 2.8402218958945014e-06
behave O 0 2.4112387109198608e-06
as O 0 4.5337557708080567e-07
loss O 0 8.172796697181184e-06
- O 0 3.7560678265435854e-06
of O 0 2.1719267806474818e-07
- O 0 1.1474685379653238e-05
function O 0 1.518695285085414e-06
mutants O 0 1.1155269930895884e-05
as O 0 6.304347834884538e-07
predicted O 0 9.621779099688865e-06
by O 0 3.924742031813366e-06
haploinsufficiency O 0 0.0008071043412201107
. O 0 3.208531052223407e-05

Contrary O 0 7.81915950938128e-05
to O 0 2.236185991932871e-06
this O 0 5.653714651998598e-07
theory O 0 5.564224920817651e-07
, O 0 1.5311773893245118e-07
our O 0 1.338887187785076e-07
data O 0 5.252767891761323e-07
showed O 0 1.0390123179604416e-06
that O 0 7.70775088199116e-08
these O 0 1.175475432546591e-07
mutants O 0 6.092664534662617e-06
are O 0 7.676866431438611e-08
dominant O 0 3.7811757920280797e-06
- O 0 1.808379965950735e-05
negative O 0 1.9334395346959354e-06
in O 0 4.999326961296902e-07
transient O 0 1.8767312212730758e-05
transfection O 0 0.0016004033386707306
assays O 0 2.3717224394204095e-05
when O 0 8.99924771147198e-07
they O 0 2.045552207619039e-07
are O 0 9.249988863757608e-08
coexpressed O 0 8.088119102467317e-06
with O 0 6.017567670824064e-07
wild O 0 8.485015314363409e-06
- O 0 0.0003921879397239536
type O 0 0.00016879788017831743
PAX6 O 0 0.006757305935025215
. O 0 6.615526945097372e-05

We O 0 2.151488297386095e-05
found O 0 5.8295067901781294e-06
that O 0 6.468244464485906e-07
the O 0 1.0478206604602747e-06
dominant O 0 4.4316846469882876e-05
- O 0 0.0013754165265709162
negative O 0 1.0805783858813811e-05
effects O 0 5.495905497809872e-06
result O 0 5.239394340605941e-07
from O 0 2.549109865412902e-07
the O 0 2.9360649023146834e-07
enhanced O 0 4.846326191909611e-06
DNA O 0 2.1506384655367583e-06
binding O 0 1.7958539046958322e-06
ability O 0 1.2027937827951973e-06
of O 0 4.6019644628358947e-07
these O 0 2.529432322262437e-06
mutants O 0 0.00031476098229177296
. O 0 3.503330663079396e-05

Kinetic O 0 0.0003097789012826979
studies O 0 2.7022537324228324e-05
of O 0 1.5090396345840418e-06
binding O 0 7.117130735423416e-06
and O 0 1.5459544329132768e-06
dissociation O 0 9.758094529388472e-05
revealed O 0 1.5942367099341936e-05
that O 0 2.22287923179465e-07
various O 0 3.245287700792687e-07
truncation O 0 2.5549354177201167e-05
mutants O 0 5.8994093706132844e-05
have O 0 4.112134490696917e-07
3 O 0 6.853074410173576e-07
- O 0 3.071919309149962e-06
5 O 0 5.181643700780114e-07
- O 0 2.8936451599292923e-06
fold O 0 1.8105604340235004e-06
higher O 0 3.651922213521175e-07
affinity O 0 5.939854190728511e-07
to O 0 1.38350529255149e-07
various O 0 2.5642049195084837e-07
DNA O 0 1.4728293535881676e-06
- O 0 3.3387366329407087e-06
binding O 0 6.68849111207237e-07
sites O 0 5.639928417622286e-07
when O 0 1.9089058866939013e-07
compared O 0 3.7487356507881486e-07
with O 0 1.0521731041990279e-07
the O 0 5.856448979102424e-07
wild O 0 7.141907190089114e-06
- O 0 0.0003999021428171545
type O 0 0.00019104710372630507
PAX6 O 0 0.006856392603367567
. O 0 6.258206121856347e-05

These O 0 1.931258157128468e-05
results O 0 9.608024811313953e-06
provide O 0 1.701021687949833e-06
a O 0 1.2203529422549764e-06
new O 0 1.5214611721603433e-06
insight O 0 2.8781282708223443e-06
into O 0 3.0390222605092276e-07
the O 0 2.569587991274602e-07
role O 0 6.058208441572788e-07
of O 0 4.634874528619548e-07
mutant O 0 5.086314195068553e-05
PAX6 O 0 0.0007739205029793084
in O 0 8.117460311041214e-06
causing O 0 0.00029419714701361954
aniridia B-Disease 1 0.9977745413780212
. O 0 1.3905286323279142e-05
. O 0 3.3350035664625466e-05

Reversal O 0 0.004662621300667524
of O 0 0.00013040432531852275
severe O 1 0.999995231628418
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 0.00011787467519752681
excellent O 0 7.689095218665898e-05
neuropsychologic O 1 0.6266692280769348
outcome O 0 1.262725709239021e-05
in O 0 1.4434858712775167e-06
very B-Disease 0 1.0178243883274263e-06
- I-Disease 0 1.8299735529581085e-05
long I-Disease 0 3.2303350963047706e-06
- I-Disease 0 1.710065953375306e-05
chain I-Disease 0 1.4985682355472818e-05
acyl I-Disease 0 4.718543277704157e-05
- I-Disease 0 4.762511161970906e-05
coenzyme I-Disease 0 0.00010874291911022738
A I-Disease 0 0.00019184700795449317
dehydrogenase I-Disease 1 0.9909088015556335
deficiency I-Disease 1 0.9770954847335815
. O 0 5.918420720263384e-05

Very B-Disease 0 0.0001404043287038803
- I-Disease 0 0.0003936442662961781
long I-Disease 0 3.250532608944923e-05
- I-Disease 0 7.01091848895885e-05
chain I-Disease 0 4.117759090149775e-05
acyl I-Disease 0 7.40479226806201e-05
- I-Disease 0 2.558944106567651e-05
coenzyme I-Disease 0 2.033356940955855e-05
A I-Disease 0 7.019966687948909e-06
dehydrogenase I-Disease 0 0.0005903388955630362
( I-Disease 0 1.0403735359432176e-05
VLCAD I-Disease 1 0.8721886873245239
) I-Disease 0 0.00034674745984375477
deficiency I-Disease 1 0.604475200176239
is O 0 4.271793727639306e-07
a O 0 8.474866262986325e-06
disorder O 0 0.3459349572658539
of O 0 4.2556428070383845e-07
fatty O 0 1.5070640984049533e-05
acid O 0 4.4582820919458754e-06
beta O 0 2.1247963104542578e-06
oxidation O 0 1.964167950063711e-06
that O 0 2.1116765935857984e-07
reportedly O 0 2.69801012109383e-06
has O 0 4.5153305450185144e-07
high O 0 1.256972268492973e-06
rates O 0 2.7311546091368655e-06
of O 0 1.2018972483929247e-06
morbidity O 1 0.9577791094779968
and O 0 2.018236045842059e-05
mortality O 0 0.0024632855784147978
. O 0 2.8157979613752104e-05

We O 0 1.2763898666889872e-05
describe O 0 9.820068953558803e-06
the O 0 1.2158201343481778e-06
outcome O 0 1.4240017662814353e-06
of O 0 1.5173461065387528e-07
a O 0 7.140819207052118e-07
5 O 0 1.4190129604685353e-06
- O 0 1.8447728507453576e-05
year O 0 1.1185139783265186e-06
- O 0 1.183839685836574e-05
old O 0 4.31901798947365e-06
girl O 0 2.5608896976336837e-05
with O 0 3.5983219277113676e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 1.329439101027674e-06
was O 0 9.645192449170281e-07
first O 0 1.829565263733457e-07
seen O 0 4.1507152559461247e-07
at O 0 1.791673156503748e-07
5 O 0 2.127315497091331e-07
months O 0 4.5406832782646234e-07
of O 0 1.7669080421001127e-07
age O 0 2.887178197852336e-06
with O 0 1.4710392861161381e-05
severe O 1 0.9999985694885254
hypertrophic B-Disease 1 0.9999998807907104
cardiomyopathy I-Disease 1 1.0
, O 0 0.08521151542663574
hepatomegaly B-Disease 1 1.0
, O 0 0.002588568953797221
encephalopathy B-Disease 1 0.9957848191261292
, O 0 4.5305496314540505e-06
and O 0 1.2369689102342818e-05
hypotonia B-Disease 1 0.9745315909385681
. O 0 7.173530320869759e-05

Biochemical O 0 0.027992375195026398
studies O 0 0.0118733374401927
indicated O 1 0.9999692440032959
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 0.00100449298042804
by O 0 3.527251919877017e-06
a O 0 6.754103196726646e-06
stable O 0 0.00014533099601976573
yet O 0 1.0839710739674047e-05
inactive O 0 0.0001421505876351148
enzyme O 0 9.273372415918857e-05
. O 0 2.4640710762469098e-05

Molecular O 0 0.00103690882679075
genetic O 0 0.00011634746624622494
analysis O 0 9.822240826906636e-06
of O 0 1.2783480087819044e-06
her O 0 1.5564499335596338e-05
VLCAD O 0 0.2647189199924469
gene O 0 6.603690417250618e-05
revealed O 0 2.306604255863931e-05
a O 0 4.460795480554225e-06
T1372C O 0 0.00013545167166739702
( O 0 5.982120001135627e-06
F458L O 0 3.9486207242589444e-05
) O 0 4.052780695928959e-06
missense O 0 8.707399683771655e-05
mutation O 0 1.3516550097847357e-05
and O 0 1.0418938245493337e-06
a O 0 8.85587724042125e-06
1668 O 0 0.1738934963941574
ACAG O 0 0.12547585368156433
1669 O 0 0.00920000672340393
splice O 0 0.002105208346620202
site O 0 0.00026681728195399046
mutation O 0 0.0008453574264422059
. O 0 7.650711631868035e-05

After O 0 0.000238127657212317
initial O 0 0.00017944478895515203
treatment O 0 0.0001624999422347173
with O 0 3.3077662919822615e-06
intravenous O 0 0.00016446216613985598
glucose O 0 0.00014725516666658223
and O 0 1.7547231436765287e-06
carnitine O 0 0.0003439142310526222
, O 0 3.502079266581859e-07
the O 0 4.840959491048125e-07
patient O 0 2.023410524998326e-05
has O 0 5.627388190987404e-07
thrived O 0 3.1137255973590072e-06
on O 0 3.4643167623471527e-07
a O 0 8.356085459126916e-07
low O 0 9.44143994274782e-06
- O 0 4.526523480308242e-05
fat O 0 7.830391041352414e-06
diet O 0 5.129759756528074e-06
supplemented O 0 2.8941142318217317e-06
with O 0 3.0280230589596613e-07
medium O 0 3.208095677109668e-06
- O 0 6.189577106852084e-06
chain O 0 7.533958523708861e-06
triglyceride O 0 1.4061000001674984e-05
oil O 0 2.7018568289349787e-06
and O 0 7.278930524989846e-07
carnitine O 0 5.8475994592299685e-05
and O 0 1.0290132195223123e-06
avoidance O 0 2.3065316781867296e-05
of O 0 2.7682124255079543e-06
fasting O 0 0.0004532450984697789
. O 0 4.229840851621702e-05

Her O 0 0.004202818498015404
ventricular O 1 0.9998507499694824
hypertrophy O 1 0.9997157454490662
resolved O 0 0.00026434138999320567
significantly O 0 3.722967812791467e-05
over O 0 1.5454237427547923e-06
1 O 0 6.309003310889238e-07
year O 0 3.360127038831706e-07
, O 0 1.8320916694847256e-07
and O 0 3.704001869664353e-07
cognitively O 0 0.0022985897958278656
, O 0 2.881963041545532e-07
she O 0 2.4022384081945347e-07
is O 0 5.33820916359673e-08
in O 0 7.188580752881535e-08
the O 0 2.098927325278055e-07
superior O 0 1.913029564093449e-06
range O 0 1.8361320144322235e-06
for O 0 1.3461198022923782e-06
age O 0 1.1734558938769624e-05
. O 0 1.5604911823174916e-05

Clinical O 0 0.0012034320970997214
recognition O 0 7.656010711798444e-05
of O 0 0.00020931771723553538
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 1.509097160123929e-06
important O 0 2.96401594823692e-07
because O 0 2.167430608324139e-07
it O 0 5.116345036526582e-08
is O 0 2.9109326504794808e-08
one O 0 1.9781818849651245e-08
of O 0 1.9593240807580514e-08
the O 0 1.4298845485427591e-07
few O 0 6.069323035262641e-07
directly O 0 1.2378941391943954e-05
treatable O 0 0.4545181095600128
causes O 0 2.4547458451706916e-05
of O 0 2.649275074873003e-06
cardiomyopathy B-Disease 1 0.9999998807907104
in O 0 2.897237936849706e-05
children O 0 9.41504094953416e-06
. O 0 3.86722740586265e-06
. O 0 1.7809623386710882e-05

Cloning O 0 0.00026780713233165443
of O 0 5.790825525764376e-06
a O 0 3.538933697200264e-06
novel O 0 5.835903721163049e-06
member O 0 1.39635653795267e-06
of O 0 2.735823727562092e-07
the O 0 8.822258337204403e-07
low O 0 1.9909319235011935e-05
- O 0 8.275354048237205e-05
density O 0 2.389336805208586e-05
lipoprotein O 0 0.0011091855121776462
receptor O 0 0.0002184254553867504
family O 0 4.1689942008815706e-05
. O 0 2.592766577436123e-05

A O 0 0.00013869786926079541
gene O 0 0.00013455429871100932
encoding O 0 2.733952715061605e-05
a O 0 5.693696039088536e-06
novel O 0 7.232635653053876e-06
transmembrane O 0 2.361748556722887e-05
protein O 0 3.8844518712721765e-06
was O 0 1.4358111002366059e-06
identified O 0 1.141499524237588e-06
by O 0 3.3557975598341727e-07
DNA O 0 1.7139182091341354e-06
sequence O 0 1.0336418654333102e-06
analysis O 0 6.671805863334157e-07
within O 0 5.559992359849275e-07
the O 0 2.5909471332852263e-06
insulin B-Disease 0 0.36302146315574646
- I-Disease 1 0.9867857098579407
dependent I-Disease 1 0.9726142287254333
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 3.618352275225334e-05
IDDM B-Disease 0 0.0123329758644104
) O 0 8.678943231643643e-06
locus O 0 7.38601156626828e-05
IDDM4 O 0 0.00037661526584997773
on O 0 2.4493721866747364e-05
chromosome O 0 0.0002915342920459807
11q13 O 0 0.0006983662024140358
. O 0 6.0323138313833624e-05

Based O 0 3.3762651582947e-05
on O 0 4.556474323180737e-06
its O 0 2.879997964555514e-06
chromosomal O 0 0.0004187493759673089
position O 0 2.5343481411255198e-06
, O 0 2.958661298180232e-07
this O 0 2.002310139914698e-07
gene O 0 1.355719291495916e-06
is O 0 1.1556301870996322e-07
a O 0 3.4607111842888116e-07
candidate O 0 7.930788683552237e-07
for O 0 3.315341530196747e-07
conferring O 0 0.00010086644033435732
susceptibility O 0 0.13994507491588593
to O 0 0.0004643360443878919
diabetes B-Disease 1 0.9999185800552368
. O 0 6.394465162884444e-05

The O 0 4.944522515870631e-05
gene O 0 9.73270507529378e-05
, O 0 3.1963566016202094e-06
termed O 0 4.9251288146479055e-05
low O 0 1.9007589799002744e-05
- O 0 3.4830867662094533e-05
density O 0 7.468252533726627e-06
lipoprotein O 0 0.00014707203081343323
receptor O 0 2.702135498111602e-05
related O 0 4.127412012167042e-06
protein O 0 1.7297162457907689e-06
5 O 0 1.1945644473598804e-06
( O 0 9.906066225084942e-07
LRP5 O 0 4.865534356213175e-05
) O 0 3.6130575153947575e-07
, O 0 1.6031810901040444e-07
encodes O 0 1.1050782404709025e-06
a O 0 4.782078804055345e-07
protein O 0 5.988553652969131e-07
of O 0 1.6922811596487009e-07
1615 O 0 4.024849840789102e-05
amino O 0 1.2728432920994237e-06
acids O 0 5.037869073021284e-07
that O 0 6.61898269527228e-08
contains O 0 1.5689209931224468e-07
conserved O 0 6.574034614459379e-07
modules O 0 1.3637344409289653e-06
which O 0 1.1477638395263057e-07
are O 0 3.190801933783405e-08
characteristic O 0 2.3370074586637202e-07
of O 0 9.594737093721051e-08
the O 0 5.954089488113823e-07
low O 0 1.2918862012156751e-05
- O 0 0.00011726737284334376
density O 0 1.9452118067420088e-05
lipoprotein O 0 0.0008341048378497362
( O 0 9.601228157407604e-06
LDL O 0 0.00017048203153535724
) O 0 6.246033990464639e-06
receptor O 0 5.533626244869083e-05
family O 0 2.3240696464199573e-05
. O 0 1.961090492841322e-05

These O 0 1.1241196261835285e-05
modules O 0 2.9289129088283516e-05
include O 0 1.9875101315847132e-06
a O 0 1.6895669432415161e-06
putative O 0 1.3269058399600908e-05
signal O 0 4.586192972055869e-06
peptide O 0 2.591626753201126e-06
for O 0 1.8639588006408303e-07
protein O 0 3.1006291578705714e-07
export O 0 2.7094691290585615e-07
, O 0 8.770852844008914e-08
four O 0 3.094534974934504e-07
epidermal O 0 3.266910061938688e-05
growth O 0 4.570213150145719e-06
factor O 0 2.4790517727524275e-06
( O 0 1.741796950227581e-06
EGF O 0 4.973620525561273e-05
) O 0 5.524284460989293e-07
repeats O 0 2.782520596156246e-06
with O 0 3.494212705845712e-07
associated O 0 1.943676124938065e-06
spacer O 0 2.1907186237513088e-05
domains O 0 4.7535377234453335e-06
, O 0 6.094089712860296e-07
three O 0 1.0178194997934042e-06
LDL O 0 0.00018014029774349183
- O 0 4.7088880819501355e-05
receptor O 0 1.8518270735512488e-05
( O 0 1.2433843039616477e-06
LDLR O 0 3.715933780767955e-05
) O 0 8.741656642996531e-07
repeats O 0 3.0927076295483857e-06
, O 0 1.3332336834537273e-07
a O 0 2.1980569897550595e-07
single O 0 5.133128411216603e-07
transmembrane O 0 3.089877509410144e-06
spanning O 0 1.4095501228439389e-06
domain O 0 1.4550377045452478e-06
, O 0 2.4603670567557856e-07
and O 0 2.6169323064095806e-07
a O 0 2.529265657358337e-06
cytoplasmic O 0 6.04317247052677e-05
domain O 0 4.9341364501742646e-05
. O 0 2.772371590253897e-05

The O 0 2.40942226810148e-05
encoded O 0 2.2044498109607957e-05
protein O 0 5.105678610561881e-06
has O 0 4.784601514984388e-07
a O 0 3.8560068560400396e-07
unique O 0 3.793496148318809e-07
organization O 0 5.947006798123766e-07
of O 0 3.4410734883749683e-07
EGF O 0 0.00013549183495342731
and O 0 9.751556717674248e-07
LDLR O 0 0.0033401690889149904
repeats O 0 4.1330073145218194e-05
; O 0 8.367145483134664e-07
therefore O 0 3.3171374980156543e-07
, O 0 2.1868518729206698e-07
LRP5 O 0 0.00023248212528415024
likely O 0 1.228976884704025e-06
represents O 0 3.41606352094459e-07
a O 0 3.39767410650893e-07
new O 0 5.082318352833681e-07
category O 0 5.690508260158822e-07
of O 0 1.7100035165640293e-07
the O 0 1.7602826574147912e-06
LDLR O 0 0.018071597442030907
family O 0 8.864434494171292e-05
. O 0 3.397842010599561e-05

Both O 0 3.05741086776834e-05
human O 0 1.4743057363375556e-05
and O 0 2.5955298497137846e-06
mouse O 0 6.28298002993688e-05
LRP5 O 0 0.0025620160158723593
cDNAs O 0 0.00029952096519991755
have O 0 7.193544888650649e-07
been O 0 3.9698971932011773e-07
isolated O 0 1.1374223731763777e-06
and O 0 1.3491127504039468e-07
the O 0 1.914289242677114e-07
encoded O 0 1.2416008985383087e-06
mature O 0 8.575260039833665e-07
proteins O 0 3.439712088493252e-07
are O 0 4.4466666793141485e-08
95 O 0 4.416735919221537e-07
% O 0 2.1180157716571557e-07
identical O 0 1.0635604894559947e-06
, O 0 1.4456485075697856e-07
indicating O 0 1.034099341268302e-06
a O 0 3.396300201075064e-07
high O 0 7.749451924610185e-07
degree O 0 9.655427675170358e-07
of O 0 3.5451890312288015e-07
evolutionary O 0 1.0670792107703164e-05
conservation O 0 1.5259633073583245e-05
. O 0 4.974485364073189e-06
. O 0 2.006883551075589e-05

The O 0 5.575705654337071e-05
APC B-Disease 0 0.0003658001951407641
variants O 0 7.015686423983425e-05
I1307K O 0 6.563772330991924e-05
and O 0 1.4501005125566735e-06
E1317Q O 0 2.8804162866435945e-05
are O 0 6.588401220142259e-07
associated O 0 5.657502333633602e-05
with O 1 0.9354523420333862
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.212804636452347e-05
but O 0 5.641041411763581e-07
not O 0 1.7416046205198654e-07
always O 0 1.582078397177611e-07
with O 0 1.353423328964709e-07
a O 0 1.4201312978912028e-06
family O 0 9.779955689737108e-06
history O 0 1.028690439852653e-05
. O 0 2.06423119379906e-05

Classical O 0 0.011998754926025867
familial B-Disease 1 0.9999994039535522
adenomatous I-Disease 1 0.9999995231628418
polyposis I-Disease 1 0.9999998807907104
( O 0 0.010680478066205978
FAP B-Disease 1 0.592025637626648
) O 0 9.84862617769977e-06
is O 0 7.964509336488845e-07
a O 0 2.3593074729433283e-06
high O 0 3.459269646555185e-05
- O 0 0.4922609031200409
penetrance O 1 0.9777136445045471
autosomal B-Disease 1 0.993517279624939
dominant I-Disease 1 0.7328579425811768
disease I-Disease 1 0.6320626735687256
that O 0 7.678798397137143e-07
predisposes O 0 2.7859759939019568e-05
to O 0 3.4361249845460407e-07
hundreds O 0 3.1299643410420686e-07
or O 0 1.8739275731149974e-07
thousands O 0 4.701541627127881e-07
of O 0 1.2430662536644377e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.6748360991477966
carcinoma I-Disease 1 1.0
and O 0 5.08143921251758e-06
that O 0 4.6800241193523107e-07
results O 0 1.5773508721395046e-06
from O 0 8.763710184211959e-07
truncating O 0 0.00034178831265307963
mutations O 0 2.9527423976105638e-05
in O 0 9.77733293439087e-07
the O 0 3.7783065636176616e-06
APC B-Disease 0 0.000569221971090883
gene O 0 0.00012888331548310816
. O 0 2.748872611846309e-05

A O 0 0.00024171189579647034
variant O 0 0.0006425513420253992
of O 0 2.1014217054471374e-05
FAP B-Disease 0 0.03405513986945152
is O 0 8.024195994948968e-05
attenuated B-Disease 1 0.9750052690505981
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 0.9999799728393555
, O 0 3.971581463702023e-06
which O 0 1.0682517768145772e-06
results O 0 2.156812570319744e-06
from O 0 1.3051385394646786e-06
germ O 0 0.010257814079523087
- O 0 0.00040688482113182545
line O 0 9.589735782356001e-06
mutations O 0 4.049797553307144e-06
in O 0 1.1682759293307754e-07
the O 0 1.208169067012932e-07
5 O 0 2.5031883410520095e-07
and O 0 8.894049585705943e-08
3 O 0 2.493665078873164e-07
regions O 0 3.5269184195385606e-07
of O 0 2.707379564981238e-07
the O 0 4.75797332910588e-06
APC B-Disease 0 0.0007729328935965896
gene O 0 0.00013993839093018323
. O 0 3.268830187153071e-05

Attenuated B-Disease 1 0.9999507665634155
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 1 0.9998866319656372
have O 0 2.4729415599722415e-05
" O 0 1.1014063602488022e-05
multiple O 0 0.0001417554885847494
" O 0 0.24161991477012634
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999991655349731
( O 0 9.787009730644058e-06
typically O 0 1.4031044202056364e-06
fewer O 0 4.757555984724604e-07
than O 0 1.3316883951119962e-07
100 O 0 3.0694135944031586e-07
) O 0 2.4660374720042455e-07
without O 0 2.8751824743267207e-07
the O 0 1.0463508033353719e-06
florid O 0 0.000658233358990401
phenotype O 0 0.00047221482964232564
of O 0 1.631039822314051e-06
classical O 0 3.052102692890912e-05
FAP B-Disease 0 0.005701815243810415
. O 0 5.798490019515157e-05

Another O 0 5.2957584557589144e-05
group O 0 3.3066859032260254e-05
of O 0 2.119109922205098e-06
patients O 0 3.899937291862443e-05
with O 0 1.447607928639627e-06
multiple O 0 4.834209175896831e-05
adenomas B-Disease 1 0.5840104818344116
has O 0 6.2457834246743005e-06
no O 0 1.4776128409721423e-06
mutations O 0 5.300677003106102e-06
in O 0 2.1253627835449151e-07
the O 0 3.4577254837131477e-07
APC B-Disease 0 4.5212866098154336e-05
gene O 0 1.7644205172473448e-06
, O 0 9.375783349696576e-08
and O 0 6.381557682288985e-08
their O 0 4.1560940644558286e-07
phenotype O 0 0.14353680610656738
probably O 0 1.8198218185716541e-06
results O 0 5.064082984063134e-07
from O 0 1.939982183785105e-07
variation O 0 5.994553475829889e-07
at O 0 4.4174353774906194e-07
a O 0 6.44819124318019e-07
locus O 0 7.812146577634849e-06
, O 0 3.341818910485017e-07
or O 0 5.04544630075543e-07
loci O 0 2.9612656362587586e-06
, O 0 2.7847616479448334e-07
elsewhere O 0 1.580461798766919e-06
in O 0 7.362625638052123e-07
the O 0 3.6052995255886344e-06
genome O 0 7.770813681418076e-05
. O 0 2.3970163965714164e-05

Recently O 0 0.0005385702243074775
, O 0 9.476150808040984e-06
however O 0 2.751832425929024e-06
, O 0 6.256563551687577e-07
a O 0 1.5570976756862365e-06
missense O 0 4.8962541768560186e-05
variant O 0 2.2668245946988463e-05
of O 0 8.933423032431165e-07
APC B-Disease 0 0.0001319269504165277
( O 0 1.210180698762997e-06
I1307K O 0 1.4391408512892667e-05
) O 0 6.493077648883627e-07
was O 0 7.017812322374084e-07
described O 0 1.1526774414960528e-06
that O 0 1.658429340523071e-07
confers O 0 2.1298926640156424e-06
an O 0 3.9285137631850375e-07
increased O 0 8.624743713880889e-06
risk O 0 4.1165854781866074e-05
of O 0 0.0008465886348858476
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 2.7427097393228905e-06
including O 0 1.3206439462010167e-06
multiple O 0 3.7395951949292794e-05
adenomas B-Disease 0 0.03680747002363205
, O 0 3.818085588136455e-06
in O 0 9.79348988039419e-06
Ashkenazim O 0 0.0011723287170752883
. O 0 6.250273872865364e-05

We O 0 1.902710209833458e-05
have O 0 3.3886822166095953e-06
studied O 0 2.190597570006503e-06
a O 0 8.222088467846334e-07
set O 0 5.885721066078986e-07
of O 0 2.452399883168255e-07
164 O 0 2.473939093761146e-05
patients O 0 0.00015241504297591746
with O 0 9.925689482770395e-06
multiple O 1 0.9955553412437439
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999997615814209
and I-Disease 0 0.0023732923436909914
/ I-Disease 1 0.9975426197052002
or I-Disease 0 0.0015489468351006508
carcinoma I-Disease 1 1.0
and O 0 2.5474359972577076e-06
analyzed O 0 1.3183537703298498e-05
codons O 0 3.6892262869514525e-05
1263 O 0 0.0014767132233828306
- O 0 0.00023756232985761017
1377 O 0 0.0008080277475528419
( O 0 4.705583705799654e-06
exon O 0 2.555091487010941e-05
15G O 0 3.1692681659478694e-05
) O 0 3.6124095004197443e-07
of O 0 1.050761184728799e-07
the O 0 4.98323345254903e-07
APC B-Disease 0 4.443203579285182e-05
gene O 0 7.43377586331917e-06
for O 0 1.044341956912831e-06
germ O 0 0.0004887722316198051
- O 0 8.438380609732121e-05
line O 0 2.6770325348479673e-05
variants O 0 6.899755680933595e-05
. O 0 2.1810585167258978e-05

Three O 0 8.731910929782316e-05
patients O 0 0.00017737504094839096
with O 0 2.5367589842062443e-06
the O 0 2.460020141370478e-06
I1307K O 0 8.014171180548146e-05
allele O 0 4.942754458170384e-05
were O 0 6.330929522846418e-07
detected O 0 3.3154217362607596e-06
, O 0 2.0012983270589757e-07
each O 0 1.5246233431298606e-07
of O 0 9.041399380294024e-07
Ashkenazi O 0 0.00028397265123203397
descent O 0 0.0002645739004947245
. O 0 7.436167652485892e-05

Four O 0 0.00013897537428420037
patients O 0 0.001716956146992743
had O 0 5.311586392053869e-06
a O 0 3.4397094168525655e-06
germ O 0 0.0016527230618521571
- O 0 6.92095491103828e-05
line O 0 7.82250936026685e-06
E1317Q O 0 4.629026079783216e-05
missense O 0 3.437486520851962e-05
variant O 0 1.222366790898377e-05
of O 0 3.3911413765963516e-07
APC O 0 0.0003835979150608182
that O 0 2.4484876348651596e-07
was O 0 4.3132087057529134e-07
not O 0 4.2427153346125124e-08
present O 0 8.112502314361336e-08
in O 0 1.0816106055244745e-07
controls O 0 9.73248461377807e-06
; O 0 1.0326117205750052e-07
one O 0 2.0080541673905827e-08
of O 0 1.6431107141556822e-08
these O 0 4.40054037653681e-08
individuals O 0 6.230139604213036e-08
had O 0 2.0023637148369744e-07
an O 0 1.1452664949729296e-07
unusually O 0 3.95675442632637e-06
large O 0 2.372049294763201e-07
number O 0 1.094669244139368e-07
of O 0 2.6568227440293413e-07
metaplastic B-Disease 0 0.029421575367450714
polyps I-Disease 0 0.0003653286839835346
of I-Disease 0 9.592996548235533e-07
the I-Disease 0 4.688763056037715e-06
colorectum I-Disease 0 0.0033357685897499323
. O 0 3.351777922944166e-05

There O 0 1.6104926544358023e-05
is O 0 1.4749068668606924e-06
increasing O 0 1.3886594842915656e-06
evidence O 0 6.002665031701326e-07
that O 0 1.8774603915971966e-07
there O 0 1.8339865448524506e-07
exist O 0 6.510315415653167e-07
germ O 0 6.283848051680252e-05
- O 0 5.6928652156784665e-06
line O 0 8.37739719372621e-07
variants O 0 5.567770813286188e-07
of O 0 7.66899361792639e-08
the O 0 2.670733465492958e-07
APC B-Disease 0 3.540496982168406e-05
gene O 0 1.541647975500382e-06
that O 0 1.3197811199461285e-07
predispose O 0 1.7830070646596141e-06
to O 0 1.759918859534082e-07
the O 0 1.579132913320791e-07
development O 0 4.214128921375959e-07
of O 0 5.513988980965223e-07
multiple O 1 0.9300153255462646
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9328194260597229
carcinoma I-Disease 1 1.0
, O 0 1.3511963743439992e-06
but O 0 1.9199679002213088e-07
without O 0 2.0310818626967375e-07
the O 0 3.155758747652726e-07
florid O 0 0.00020948161545675248
phenotype O 0 8.529392653144896e-05
of O 0 1.9766059722314822e-07
classical O 0 1.2739994872390525e-06
FAP B-Disease 0 0.0001778190489858389
, O 0 2.195612154309856e-07
and O 0 9.695439473489387e-08
possibly O 0 3.534582333486469e-07
with O 0 1.2007809857550455e-07
importance O 0 2.166082367693889e-06
for O 1 0.7733416557312012
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 0.00014288455713540316
in O 0 5.256420649857318e-07
the O 0 6.077397074477631e-07
general O 0 2.5106887733272742e-06
population O 0 1.8857143686545896e-06
. O 0 2.568179525042069e-06
. O 0 1.4320245099952444e-05

Genomic O 0 0.0008514146902598441
structure O 0 4.5213942939881235e-05
of O 0 4.9704640332493e-06
the O 0 3.418617052375339e-05
human O 0 0.28612175583839417
congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999998807907104
diarrhea I-Disease 1 1.0
( O 0 0.00124983093701303
CLD B-Disease 1 0.9996634721755981
) O 0 5.201730891712941e-05
gene O 0 0.0001454804587410763
. O 0 4.260917557985522e-05

Congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999998807907104
diarrhea I-Disease 1 1.0
( O 0 0.052301499992609024
CLD B-Disease 1 0.9999821186065674
) O 0 2.6959090973832645e-05
is O 0 2.4439600565528963e-06
caused O 0 1.640972368477378e-05
by O 0 2.2061497020331444e-06
mutations O 0 2.0010777006973512e-05
in O 0 5.570075813920994e-07
a O 0 1.3992158756082063e-06
gene O 0 4.760551746585406e-06
which O 0 8.835402240947587e-07
encodes O 0 1.1851997442136053e-05
an O 0 8.376458936254494e-06
intestinal O 1 0.9339911341667175
anion O 0 0.001812349888496101
transporter O 0 0.00251412158831954
. O 0 6.449618376791477e-05

We O 0 1.9490871636662632e-05
report O 0 7.800355888321064e-06
here O 0 3.6057735997019336e-07
the O 0 2.462747374920582e-07
complete O 0 6.166877142277372e-07
genomic O 0 3.7141146549402038e-06
organization O 0 3.151536134282651e-07
of O 0 8.486292557563502e-08
the O 0 4.145437628721993e-07
human O 0 3.6671840462076943e-06
CLD B-Disease 1 0.7021867632865906
gene O 0 1.2435167263902258e-05
which O 0 6.542936716869008e-07
spans O 0 2.7431728994997684e-06
approximately O 0 1.9706667444552295e-06
39kb O 0 4.4941360101802275e-05
, O 0 8.110249041237694e-07
and O 0 5.266215339361224e-07
comprises O 0 4.574595095618861e-06
21 O 0 1.6898386093089357e-05
exons O 0 0.0001729959767544642
. O 0 4.627203452400863e-05

All O 0 4.820385220227763e-05
exon O 0 0.0009067411301657557
/ O 0 0.0003095592255704105
intron O 0 0.00031265217694453895
boundaries O 0 8.95078574103536e-06
conform O 0 1.902784606500063e-05
to O 0 1.941936488947249e-06
the O 0 5.539126505027525e-06
GT O 0 0.23443475365638733
/ O 1 0.8196972608566284
AG O 1 0.9988927245140076
rule O 0 0.00010461437341291457
. O 0 3.730249227373861e-05

An O 0 1.676566716923844e-05
analysis O 0 8.173295100277755e-06
of O 0 5.956026143394411e-07
the O 0 1.1606528005358996e-06
putative O 0 2.847543692041654e-05
promoter O 0 1.4843306416878477e-05
region O 0 2.866207751139882e-06
sequence O 0 1.7367146938340738e-06
shows O 0 1.773425651663274e-06
a O 0 2.581980879767798e-06
putative O 0 0.000155287969391793
TATA O 0 0.007353152148425579
box O 0 1.024058656184934e-05
and O 0 8.768985253482242e-07
predicts O 0 2.987236985063646e-05
multiple O 0 4.573980277200462e-06
transcription O 0 1.7708294762996957e-05
factor O 0 6.991418558754958e-06
binding O 0 1.1233952136535663e-05
sites O 0 1.3752597624261398e-05
. O 0 2.2682517737848684e-05

The O 0 3.29684917232953e-05
genomic O 0 0.0001128000658354722
structure O 0 2.111840331053827e-05
was O 0 3.007141458510887e-06
determined O 0 8.705990808266506e-07
using O 0 4.181489998700272e-07
DNA O 0 7.096176091181405e-07
from O 0 1.4016504223945958e-07
several O 0 1.5904500116903364e-07
sources O 0 3.5614581861409533e-07
including O 0 1.977771404426676e-07
multiple O 0 8.604258709965507e-07
large O 0 1.0943348343062098e-06
- O 0 4.200016337563284e-05
insert O 0 2.6753357815323398e-05
libaries O 0 3.442919114604592e-05
and O 0 7.203746577033598e-07
genomic O 0 7.386111519736005e-06
DNA O 0 5.355881057766965e-06
from O 0 2.9604975679831114e-06
Finnish O 0 0.14358004927635193
CLD B-Disease 1 0.9999994039535522
patients O 0 0.3338993489742279
and O 0 8.795243047643453e-06
controls O 0 0.0005623329780064523
. O 0 3.5285043850308284e-05

Exon O 0 0.004423837177455425
- O 0 0.0002929750771727413
specific O 0 8.418391189479735e-06
primers O 0 0.00012802051787730306
developed O 0 1.5833787983865477e-05
in O 0 7.290713028851314e-07
this O 0 2.3047064701131603e-07
study O 0 7.566832778138632e-07
will O 0 4.271728357707616e-07
facilitate O 0 2.714121592362062e-06
mutation O 0 1.9007191440323368e-05
screening O 0 9.940998097590636e-06
studies O 0 2.3455327209376264e-06
of O 0 5.046611022407888e-07
patients O 0 3.875231050187722e-05
with O 0 1.3878069466954912e-06
the O 0 6.170917913550511e-05
disease O 1 0.9354491233825684
. O 0 5.320100171957165e-05

Genomic O 0 0.00048628737567923963
sequencing O 0 7.507768896175548e-05
of O 0 5.0669218580878805e-06
a O 0 3.28759997501038e-05
BAC O 1 0.8965663909912109
clone O 0 0.34281718730926514
H O 1 0.9976231455802917
_ O 0 4.493638243729947e-06
RG364P16 O 0 3.171121352352202e-05
revealed O 0 4.999577868147753e-06
the O 0 2.560637142323685e-07
presence O 0 2.936969565325853e-07
of O 0 5.90702207148297e-08
another O 0 3.266476653607242e-07
, O 0 2.103271441455945e-07
highly O 0 3.8430366089414747e-07
homologous O 0 2.0843629044975387e-06
gene O 0 1.1613614105954184e-06
3 O 0 1.517550032303916e-07
of O 0 4.455938196201714e-08
the O 0 4.878150434706185e-07
CLD B-Disease 1 0.9755424857139587
gene O 0 5.45684042663197e-06
, O 0 1.2292940709812683e-07
with O 0 7.689440906233358e-08
a O 0 3.287057381839986e-07
similar O 0 1.206487354465935e-06
genomic O 0 6.546302756760269e-06
structure O 0 1.7046512539309333e-06
, O 0 2.8041307587045594e-07
recently O 0 4.393664767121663e-06
identified O 0 1.2306680901019718e-06
as O 0 6.072971245885128e-07
the O 0 3.187876791344024e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 0.00020166185277048498
( O 0 6.173683232191252e-06
PDS B-Disease 0 0.00038974781637080014
) O 0 3.5224886687501566e-06
. O 0 2.4974829102575313e-06
. O 0 8.304000402858946e-06

The O 0 6.930255040060729e-05
APCI1307K O 0 0.20274263620376587
allele O 0 0.04669463634490967
and O 0 0.0009352352353744209
cancer B-Disease 1 0.9971733093261719
risk O 0 1.4701472537126392e-05
in O 0 7.802578352311684e-07
a O 0 1.6402290157202515e-06
community O 0 2.8554663913382683e-06
- O 0 2.7608630261966027e-05
based O 0 1.3741483826379408e-06
study O 0 1.1647155133687193e-06
of O 0 1.2936117173012462e-06
Ashkenazi O 0 0.000308513903291896
Jews O 0 3.967338125221431e-05
. O 0 4.5422119001159444e-05

Mutations O 0 0.13368558883666992
in O 0 7.345848280237988e-05
APC O 0 0.004899817984551191
are O 0 3.4312040497752605e-06
classically O 0 0.0005861407262273133
associated O 0 2.9247652491903864e-05
with O 0 4.11399123549927e-05
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
( O 0 0.0004070120630785823
FAP B-Disease 0 0.01339147612452507
) O 0 2.2023741621524096e-06
, O 0 5.565329388446116e-07
a O 0 3.298624505987391e-06
highly O 0 0.00017080224642995745
penetrant O 1 0.9999992847442627
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999966621398926
disorder I-Disease 1 1.0
characterized O 0 0.08896701037883759
by O 0 1.3266526366351172e-05
multiple O 0 0.006888710893690586
intestinal O 1 0.9999982118606567
polyps B-Disease 1 0.7733632922172546
and O 0 1.528975531073229e-06
, O 0 4.108175630790356e-07
without O 0 4.854032908951922e-07
surgical O 0 0.00027129013324156404
intervention O 0 5.573845101025654e-06
, O 0 2.539300396620092e-07
the O 0 3.8159890891620307e-07
development O 0 5.883044195797993e-06
of O 0 0.001349731581285596
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.00020903848053421825
CRC B-Disease 0 0.05327978357672691
) O 0 1.6027184756239876e-05
. O 0 2.1743924662587233e-05

APC B-Disease 0 0.06639961898326874
is O 0 2.151455555576831e-05
a O 0 5.907223021495156e-05
tumour O 1 0.9999990463256836
- O 0 0.0023625821340829134
suppressor O 0 0.0005257026059553027
gene O 0 1.249825072591193e-05
, O 0 7.014801326477027e-07
and O 0 9.694233540358255e-07
somatic O 0 0.00012679131759796292
loss O 0 0.0004641548730432987
occurs O 0 3.749172174138948e-05
in O 0 7.117262430256233e-05
tumours B-Disease 1 0.9999876022338867
. O 0 0.00010781365563161671

The O 0 0.0001355505082756281
germline O 1 0.8713142275810242
T O 1 0.912551999092102
- O 0 9.019656863529235e-05
to O 0 1.9056584505960927e-06
- O 0 7.010533863649471e-06
A O 0 1.2334764960542088e-06
transversion O 0 2.583131572464481e-05
responsible O 0 1.315056351813837e-06
for O 0 2.652144530657097e-07
the O 0 6.308907245511364e-07
APC O 0 2.7135287382407114e-05
I1307K O 0 1.8879147319239564e-05
allele O 0 1.2845738638134208e-05
converts O 0 2.4016753741307184e-06
the O 0 3.855977297462232e-07
wild O 0 1.4063356275073602e-06
- O 0 5.4979504966468085e-06
type O 0 8.139413694152609e-07
sequence O 0 4.199100942514633e-07
to O 0 2.2172896763095196e-07
a O 0 1.7867247379399487e-06
homopolymer O 1 0.6657845973968506
tract O 1 0.6360123753547668
( O 0 3.845940227620304e-06
A8 O 0 0.006376397795975208
) O 0 6.088524173719634e-07
that O 0 1.8919401156836102e-07
is O 0 3.2074669320536486e-07
genetically O 0 6.584396032849327e-06
unstable O 0 0.00022647475998383015
and O 0 2.6188422452833038e-06
prone O 0 3.9404312701663e-05
to O 0 6.65058360027615e-06
somatic O 0 0.0012745719868689775
mutation O 0 0.0004362543113529682
. O 0 4.130993693252094e-05

The O 0 5.5563959904247895e-05
I1307K O 0 0.0005550292553380132
allele O 0 0.0003248948778491467
was O 0 1.1409855687816162e-05
found O 0 4.252034159435425e-06
in O 0 4.16047805629205e-06
6 O 0 3.843066588160582e-05
. O 0 4.3148593249497935e-05

1 O 0 4.0236445784103125e-05
% O 0 5.628276085190009e-06
of O 0 1.1003459121639025e-06
unselected O 0 0.00017339791520498693
Ashkenazi O 0 0.00018315094348508865
Jews O 0 4.120482572034234e-06
and O 0 1.0647560202414752e-06
higher O 0 1.9964691091445275e-06
proportions O 0 3.2136624668055447e-06
of O 0 4.368502573015576e-07
Ashkenazim O 0 4.6098368329694495e-05
with O 0 1.5465353726540343e-06
family O 0 7.446903055097209e-06
or O 0 7.529056915700494e-07
personal O 0 2.54894030149444e-06
histories O 0 6.820638191129547e-06
of O 0 1.7196372255057213e-06
CRC B-Disease 0 0.1714601069688797
( O 0 1.177527337858919e-05
ref O 0 0.00019075350428465754
. O 0 1.349450258203433e-06
2 O 0 3.4331026199652115e-06
) O 0 6.205380941537442e-06
. O 0 1.1154439562233165e-05

To O 0 2.7125402993988246e-05
evaluate O 0 2.0467889044084586e-05
the O 0 8.438175882474752e-07
role O 0 1.2153378747825627e-06
of O 0 3.250758027206757e-07
I1307K O 0 0.00010383876360720024
in O 0 2.060810584225692e-05
cancer B-Disease 0 0.19822436571121216
, O 0 5.422282924882893e-07
we O 0 4.379652978059312e-07
genotyped O 0 2.692774432944134e-05
5 O 0 1.3188215461923392e-06
, O 0 1.0442045095260255e-06
081 O 0 0.00015166251978371292
Ashkenazi O 0 5.760856583947316e-05
volunteers O 0 3.5536927498469595e-06
in O 0 1.1378584758858779e-06
a O 0 5.083581982034957e-06
community O 0 1.539125878480263e-05
survey O 0 0.00011175341933267191
. O 0 4.2357747588539496e-05

Risk O 0 0.0005246471264399588
of O 0 1.624813194212038e-05
developing O 0 0.02413429133594036
colorectal B-Disease 1 1.0
, I-Disease 0 0.00020146198221482337
breast I-Disease 1 0.8633148670196533
and I-Disease 0 3.978139829996508e-06
other I-Disease 0 3.19402533932589e-06
cancers I-Disease 0 0.09190141409635544
were O 0 5.259434487925319e-07
compared O 0 1.0702310646593105e-06
between O 0 7.397908916573215e-07
genotyped O 0 0.00019491476996336132
I1307K O 0 5.7245757488999516e-05
carriers O 0 5.0662652029132005e-06
and O 0 3.7475987824109325e-07
non O 0 1.074598117156711e-06
- O 0 1.0633581950969528e-05
carriers O 0 1.343028429801052e-06
and O 0 8.904505932605389e-08
their O 0 1.2479335964599159e-07
first O 0 8.953004453360336e-07
- O 0 1.8660481146071106e-05
degree O 0 1.0265950550092384e-05
relatives O 0 3.7719157262472436e-05
. O 0 3.863828897010535e-05

Sperm O 0 0.0011606308398768306
DNA O 0 0.0002639852755237371
analysis O 0 4.996034112991765e-05
in O 0 1.2317071195866447e-05
a O 0 5.481394691742025e-05
Friedreich B-Disease 1 0.9992840886116028
ataxia I-Disease 1 0.9999456405639648
premutation O 0 0.3517884910106659
carrier O 0 0.0012303255498409271
suggests O 0 6.181318440212635e-06
both O 0 8.932664741223562e-07
meiotic O 0 3.971672776970081e-05
and O 0 9.345499734081386e-07
mitotic O 0 7.684858428547159e-05
expansion O 0 7.854713658161927e-06
in O 0 1.3290435845192405e-06
the O 0 2.9059374355711043e-06
FRDA B-Disease 0 0.0013316096737980843
gene O 0 0.00013269328337628394
. O 0 3.5049550206167623e-05

Friedreich B-Disease 1 0.9999943971633911
ataxia I-Disease 1 0.999998927116394
is O 0 0.000187581405043602
usually O 0 3.1186053092824295e-05
caused O 0 3.1578911148244515e-05
by O 0 7.651692612853367e-07
an O 0 3.234877397062519e-07
expansion O 0 1.8615211274664034e-06
of O 0 3.024738930434978e-07
a O 0 3.116108246103977e-06
GAA O 0 0.00021433627989608794
trinucleotide O 0 0.0011060158722102642
repeat O 0 1.482961124565918e-05
in O 0 1.2345261666268925e-06
intron O 0 3.460688458289951e-05
1 O 0 9.718727369545377e-07
of O 0 2.799812364173704e-07
the O 0 3.302379582237336e-06
FRDA B-Disease 0 0.003242252394556999
gene O 0 0.00019080260244663805
. O 0 3.450518852332607e-05

Occasionally O 0 0.00012603335198946297
, O 0 4.154693215241423e-06
a O 0 2.482120180502534e-06
fully O 0 4.121889560337877e-06
expanded O 0 5.574116585194133e-06
allele O 0 1.2328777302172966e-05
has O 0 3.7774853467453795e-07
been O 0 2.1924839188613987e-07
found O 0 3.1722760240882053e-07
to O 0 2.0579301462930744e-07
arise O 0 1.055510324476927e-06
from O 0 1.9899802339296002e-07
a O 0 5.03531396134349e-07
premutation O 0 1.4497833944915328e-05
of O 0 2.0569451919527637e-07
100 O 0 5.280648451844172e-07
or O 0 1.1498677849886008e-06
less O 0 5.049508217780385e-06
triplet O 0 0.0013546149712055922
repeats O 0 0.000286299706203863
. O 0 3.074116102652624e-05

We O 0 1.596843321749475e-05
have O 0 2.3513850919698598e-06
examined O 0 8.513059583492577e-06
the O 0 1.006175807560794e-06
sperm O 0 5.020735898142448e-06
DNA O 0 2.4226437744800933e-06
of O 0 6.21237575160194e-07
a O 0 9.71609006228391e-06
premutation O 0 0.04333542659878731
carrier O 0 0.01072250958532095
. O 0 4.432124478626065e-05

This O 0 3.8404763472499326e-05
mans O 0 0.0003252782626077533
leucocyte O 0 0.0035924725234508514
DNA O 0 3.857853153022006e-05
showed O 0 1.013072414934868e-05
one O 0 6.449827196775004e-07
normal O 0 2.551910029069404e-06
allele O 0 8.916518709156662e-06
and O 0 2.3705341334334662e-07
one O 0 2.702988410874241e-07
allele O 0 3.4945435345434817e-06
of O 0 3.3035186675078876e-07
approximately O 0 1.5406823195007746e-06
100 O 0 4.765720859722933e-06
repeats O 0 9.494667028775439e-05
. O 0 2.6202707886113785e-05

His O 0 4.844043724006042e-05
sperm O 0 6.306834984570742e-05
showed O 0 8.643854016554542e-06
an O 0 7.539964599345694e-07
expanded O 0 5.0246540013176855e-06
allele O 0 1.3807290997647215e-05
in O 0 6.639593266299926e-07
a O 0 8.774439379521937e-07
tight O 0 7.115406788216205e-06
range O 0 1.2564281632876373e-06
centering O 0 2.919963435488171e-06
on O 0 4.7593351837349473e-07
a O 0 6.945809332137287e-07
size O 0 1.4402379520106479e-06
of O 0 5.25513769389363e-07
approximately O 0 5.923838216403965e-06
320 O 0 7.671342609683052e-05
trinucleotide O 0 0.0035689822398126125
repeats O 0 0.0005361284129321575
. O 0 6.0916478105355054e-05

His O 0 0.0002842454705387354
affected O 0 0.00038802839117124677
son O 0 0.003944295458495617
has O 0 4.953456937073497e-06
repeat O 0 2.554340971983038e-05
sizes O 0 7.797113539709244e-06
of O 0 1.671546328907425e-06
1040 O 0 0.00012348780001048
and O 0 5.662333023792598e-06
540 O 0 0.00014484525308944285
. O 0 4.241328133502975e-05

These O 0 1.8879110939451493e-05
data O 0 7.047025519568706e-06
suggest O 0 2.7863497962243855e-06
that O 0 2.400553000825312e-07
expansion O 0 1.8850598735298263e-06
occurs O 0 4.4913622332387604e-07
in O 0 8.920179084270785e-08
two O 0 4.9928228662565743e-08
stages O 0 3.109643103016424e-07
, O 0 5.5408207799700904e-08
the O 0 4.985134083312914e-08
first O 0 1.373811358007515e-07
during O 0 7.509437409680686e-07
meiosis O 0 2.79699929706112e-06
followed O 0 7.59920226300892e-07
by O 0 3.7671998143196106e-07
a O 0 8.501227739543538e-07
second O 0 4.8759084165794775e-06
mitotic O 0 0.0004642703279387206
expansion O 0 8.560063724871725e-05
. O 0 3.859784919768572e-05

We O 0 8.561420145269949e-06
also O 0 1.7082967360693146e-06
show O 0 9.883154916678905e-07
that O 0 1.3213264082878595e-07
in O 0 1.2573711671848287e-07
all O 0 8.194723477572552e-08
informative O 0 1.2949619758728659e-06
carrier O 0 0.0002638252335600555
father O 0 1.0164809282287024e-05
to O 0 4.94060657274531e-07
affected O 0 2.460268888171413e-06
child O 0 4.1449379750702064e-06
transmissions O 0 3.161461791023612e-05
, O 0 9.669271605616814e-08
with O 0 7.055809447820138e-08
the O 0 1.2370323076993373e-07
notable O 0 1.8215496311313473e-07
exception O 0 1.550735646560497e-07
of O 0 4.382330942576118e-08
the O 0 2.7909669597647735e-07
premutation O 0 0.00020228291396051645
carrier O 0 2.1884758098167367e-05
, O 0 1.1358003604300393e-07
the O 0 9.558534941334074e-08
expansion O 0 1.4205891147867078e-06
size O 0 2.597466163933859e-06
decreases O 0 8.9309014583705e-06
. O 0 2.8977599413337884e-06
. O 0 1.5678300769650377e-05

The O 0 5.008499283576384e-05
R496H O 0 0.00035258260322734714
mutation O 0 8.95069315447472e-05
of O 0 2.4131459213094786e-06
arylsulfatase O 0 0.00041347448132000864
A O 0 1.9908067770302296e-05
does O 0 9.779303582035936e-06
not O 0 6.959156507946318e-06
cause O 0 0.0015844287117943168
metachromatic B-Disease 1 0.9999772310256958
leukodystrophy I-Disease 1 0.9999973773956299
. O 0 0.0003351238265167922

Deficiency B-Disease 1 0.9995653033256531
of I-Disease 0 5.785565372207202e-05
arylsulfatase I-Disease 0 0.003898016642779112
A I-Disease 0 0.00015211626305244863
( O 0 5.061212505097501e-05
ARSA O 0 0.017513945698738098
) O 0 1.81980685738381e-05
enzyme O 0 4.93988991365768e-05
activity O 0 4.786392310052179e-05
causes O 0 0.000642986036837101
metachromatic B-Disease 1 0.9998387098312378
leukodystrophy I-Disease 1 0.9999986886978149
( O 0 0.0006508450605906546
MLD B-Disease 1 0.9999393224716187
) O 0 6.219385250005871e-05
. O 0 4.7502104280283675e-05

A O 0 5.600789882009849e-05
number O 0 6.213446340552764e-06
of O 0 4.877303581451997e-06
ARSA O 1 0.7110235691070557
gene O 0 0.0003213032614439726
mutations O 0 0.00012349874305073172
responsible O 0 8.295633961097337e-06
for O 0 3.4948834581882693e-06
MLD B-Disease 1 0.9999850988388062
have O 0 9.029438842844684e-06
been O 0 6.3203101490216795e-06
identified O 0 4.570371675072238e-05
. O 0 3.141562774544582e-05

Recently O 0 0.0001999364176299423
, O 0 5.560481895372504e-06
the O 0 1.9797234926954843e-06
R496H O 0 5.493781281984411e-05
mutation O 0 1.3643597412738018e-05
of O 0 8.422225050708221e-07
ARSA O 1 0.5664336085319519
was O 0 9.74978320300579e-06
proposed O 0 2.4955829758255277e-06
to O 0 4.173442675892147e-07
be O 0 1.734535146624694e-07
a O 0 5.014205157749529e-07
cause O 0 4.38062807006645e-06
of O 0 9.758850865182467e-07
MLD B-Disease 1 0.9998623132705688
( O 0 6.25827442490845e-06
Draghia O 0 0.00010032234422396868
et O 0 5.7115001254715025e-05
al O 0 1.6928644981817342e-05
. O 0 5.272697762848111e-07
, O 0 6.349135333039158e-07
1997 O 0 7.592525435029529e-06
) O 0 7.74861837271601e-06
. O 0 1.2526626051112544e-05

We O 0 2.4072814994724467e-05
have O 0 4.226338660373585e-06
investigated O 0 1.3282819963933434e-05
the O 0 1.689263967818988e-06
R496H O 0 0.00011228987568756565
mutation O 0 1.774555494193919e-05
and O 0 4.588922308812471e-07
found O 0 6.11564246355556e-07
this O 0 3.0506259918183787e-07
mutation O 0 2.734287136263447e-06
at O 0 3.204262952749559e-07
a O 0 3.751289057163376e-07
relatively O 0 6.969962100811244e-07
high O 0 5.911846301387413e-07
frequency O 0 1.5539452533630538e-06
in O 0 1.523880541753897e-07
an O 0 1.597026795252532e-07
African O 0 3.4635240808711387e-07
American O 0 5.625907419926079e-07
population O 0 9.655316262069391e-07
( O 0 1.336810441898706e-06
f O 0 8.586966032453347e-06
= O 0 5.309742846293375e-06
0 O 0 9.916813041854766e-07
. O 0 3.091387554832181e-07
09 O 0 4.285587692720583e-06
, O 0 5.527546704797714e-07
n O 0 8.215699381253216e-06
= O 0 1.1454404557298403e-05
61 O 0 5.997622793074697e-06
subjects O 0 7.942058800836094e-06
) O 0 1.2106563190172892e-05
. O 0 1.922716728586238e-05

The O 0 8.939833787735552e-05
ARSA O 0 0.009519845247268677
enzyme O 0 6.412345101125538e-05
activity O 0 8.756511306273751e-06
in O 0 5.824034019497049e-07
subjects O 0 8.179152928278199e-07
with O 0 1.5037457501421159e-07
and O 0 1.1079468720254226e-07
without O 0 7.9396748731142e-08
the O 0 2.2541581756740925e-07
R496H O 0 5.979775596642867e-05
mutation O 0 1.69453469425207e-05
was O 0 2.1662042399839265e-06
determined O 0 1.129945189859427e-06
and O 0 2.2776690400405641e-07
found O 0 5.043330020271242e-07
to O 0 3.754087742890988e-07
be O 0 7.855798571654304e-07
normal O 0 1.4190063666319475e-05
. O 0 1.382503796776291e-05

It O 0 1.415837868989911e-05
is O 0 1.7007572523652925e-06
therefore O 0 1.4106594790064264e-06
concluded O 0 2.0299057723605074e-06
that O 0 2.787120934044651e-07
the O 0 5.153685833647614e-07
R496H O 0 3.523796476656571e-05
mutation O 0 1.1011732567567378e-05
of O 0 6.917370569681225e-07
ARSA O 0 0.31515827775001526
does O 0 2.1540190573432483e-06
not O 0 4.0527854139327246e-07
negatively O 0 1.4663042975371354e-06
influence O 0 5.093269237477216e-07
the O 0 2.052800454066528e-07
activity O 0 7.438459874720138e-07
of O 0 3.683721274683194e-07
ARSA O 0 0.04511852562427521
and O 0 4.1737925471352355e-07
is O 0 2.3710315133484983e-07
not O 0 3.095919396400859e-07
a O 0 1.829350253501616e-06
cause O 0 4.228049874654971e-05
of O 0 2.4489869247190654e-05
MLD B-Disease 1 0.9999805688858032

Down O 0 0.0004392312257550657
- O 0 0.00015990505926311016
regulation O 0 2.695256262086332e-05
of O 0 3.7361689919634955e-06
transmembrane O 0 0.0001071337828761898
carbonic O 0 0.0007110711303539574
anhydrases O 0 0.011480777524411678
in O 0 0.0007557554636150599
renal B-Disease 1 0.9999998807907104
cell I-Disease 1 0.9999973773956299
carcinoma I-Disease 1 1.0
cell O 0 0.017139267176389694
lines O 0 1.1464764611446299e-05
by O 0 1.7150366602436407e-06
wild O 0 5.599365522357402e-06
- O 0 0.00026394904125481844
type O 0 0.0002198263246100396
von B-Disease 0 0.44586625695228577
Hippel I-Disease 1 0.8268407583236694
- I-Disease 0 0.02770238183438778
Lindau I-Disease 0 0.06496831029653549
transgenes O 0 0.0037204145919531584
. O 0 0.0001446249953005463

To O 0 6.356734229484573e-05
discover O 0 0.00014018118963576853
genes O 0 3.083188130403869e-05
involved O 0 7.218523478513816e-06
in O 0 5.952867923042504e-06
von B-Disease 0 0.3380056321620941
Hippel I-Disease 1 0.9765843749046326
- I-Disease 0 0.3701782822608948
Lindau I-Disease 0 0.18076099455356598
( O 0 1.0673519682313781e-05
VHL B-Disease 0 0.0002996160474140197
) O 0 2.4774565190455178e-06
- O 0 1.5973337212926708e-05
mediated O 0 3.977634696639143e-05
carcinogenesis O 0 0.0005003959522582591
, O 0 8.878759558683669e-07
we O 0 8.215770890274143e-07
used O 0 6.8643108534161e-05
renal B-Disease 1 0.9999992847442627
cell I-Disease 1 0.9999500513076782
carcinoma I-Disease 1 1.0
cell O 0 0.026369770988821983
lines O 0 4.15508657169994e-05
stably O 0 0.00016049161786213517
transfected O 0 0.00017081266560126096
with O 0 1.8515513602324063e-06
wild O 0 1.231411260960158e-05
- O 0 0.00041956306085921824
type O 0 0.0001560106175020337
VHL O 0 0.020750343799591064
- O 0 0.0004361300088930875
expressing O 0 0.00018832908244803548
transgenes O 0 0.0016122075030580163
. O 0 0.00010648358875187114

Large O 0 6.87669453327544e-05
- O 0 5.1271192205604166e-05
scale O 0 9.098183909372892e-06
RNA O 0 7.17731700206059e-06
differential O 0 6.747787210770184e-06
display O 0 5.1024653657805175e-06
technology O 0 4.9324717110721394e-06
applied O 0 8.26037990009354e-07
to O 0 2.1620463996896433e-07
these O 0 1.431508138693971e-07
cell O 0 1.0115239092556294e-05
lines O 0 1.840346271819726e-06
identified O 0 4.215370950078068e-07
several O 0 3.2083173095998063e-07
differentially O 0 1.2333927770669106e-05
expressed O 0 1.7742037243806408e-06
genes O 0 1.2858616855737637e-06
, O 0 1.3713282953631278e-07
including O 0 1.9861256816966488e-07
an O 0 7.170476692408556e-07
alpha O 0 2.5729310436872765e-05
carbonic O 0 0.0002189126971643418
anhydrase O 0 0.0003979220346082002
gene O 0 3.412252772250213e-05
, O 0 4.118042397749377e-06
termed O 0 0.00015228067059069872
CA12 O 0 0.00447018351405859
. O 0 0.00010086296970257536

The O 0 4.587134390021674e-05
deduced O 0 9.370398038299754e-05
protein O 0 1.2086584320059046e-05
sequence O 0 3.5108446354570333e-06
was O 0 1.8019269418800832e-06
classified O 0 1.6758064020905294e-06
as O 0 2.0356350205474882e-07
a O 0 3.0679271389999485e-07
one O 0 2.6647904860510607e-07
- O 0 9.951812899089418e-06
pass O 0 2.143760184480925e-06
transmembrane O 0 2.0858680727542378e-05
CA O 0 2.3305626655201195e-06
possessing O 0 8.689044648235722e-07
an O 0 2.5216235144398524e-07
apparently O 0 4.143550540902652e-06
intact O 0 6.998149274295429e-06
catalytic O 0 9.45349529501982e-06
domain O 0 2.602246695460053e-06
in O 0 1.0978261570926406e-06
the O 0 1.5036841887194896e-06
extracellular O 0 5.1921950216637924e-05
CA O 0 7.566901331301779e-05
module O 0 0.0003987211093772203
. O 0 5.112286817166023e-05

Reintroduced O 0 0.0035406420938670635
wild O 0 0.000349782727425918
- O 0 0.0012143863132223487
type O 0 0.00011908216401934624
VHL B-Disease 0 0.0015830427873879671
strongly O 0 3.7606740079354495e-05
inhibited O 0 2.702181700442452e-05
the O 0 7.561653205812036e-07
overexpression O 0 6.955208846193273e-06
of O 0 1.890668528403694e-07
the O 0 6.214354471012484e-07
CA12 O 0 0.0001674723462201655
gene O 0 6.20517994320835e-06
in O 0 7.317357244573941e-07
the O 0 3.76266461898922e-06
parental O 1 0.959779679775238
renal B-Disease 1 0.9999998807907104
cell I-Disease 1 0.9999979734420776
carcinoma I-Disease 1 1.0
cell O 0 0.32193875312805176
lines O 0 0.00028778763953596354
. O 0 6.0434667830122635e-05

Similar O 0 0.0003425036557018757
results O 0 6.744724669260904e-05
were O 0 3.8986026993370615e-06
obtained O 0 5.984585186524782e-06
with O 0 2.9718182759097544e-06
CA9 O 1 0.5220567584037781
, O 0 1.7415244428775623e-06
encoding O 0 8.944727596826851e-06
another O 0 2.42004125539097e-06
transmembrane O 0 3.5945729905506596e-05
CA O 0 3.456130571066751e-06
with O 0 2.4847037138897576e-07
an O 0 4.860430067310517e-07
intact O 0 1.2455107025743928e-05
catalytic O 0 3.3569631341379136e-05
domain O 0 2.2352000087266788e-05
. O 0 1.7533548088977113e-05

Although O 0 4.372311013867147e-05
both O 0 3.607920689319144e-06
domains O 0 7.298899163288297e-06
of O 0 3.895444820045668e-07
the O 0 1.269786821467278e-06
VHL B-Disease 0 0.0004926648689433932
protein O 0 3.9642177398491185e-06
contribute O 0 1.0014580311690224e-06
to O 0 3.626261104727746e-07
regulation O 0 1.727242192828271e-06
of O 0 2.8505502314146725e-07
CA12 O 0 0.00011117161193396896
expression O 0 1.0855742402782198e-06
, O 0 1.8443365945586265e-07
the O 0 3.569360558230983e-07
elongin O 0 2.332482472411357e-05
binding O 0 3.2083923997561214e-06
domain O 0 3.6066614939045394e-06
alone O 0 1.6823764781292994e-06
could O 0 1.4934541923139477e-06
effectively O 0 1.0353553079767153e-05
regulate O 0 0.0001169543611467816
CA9 O 0 0.009402529336512089
expression O 0 6.147254316601902e-05
. O 0 4.2331903387093917e-05

We O 0 0.00014143226144369692
mapped O 0 0.0008384070824831724
CA12 O 0 0.0038792418781667948
and O 0 2.732281973294448e-05
CA9 O 0 0.12965938448905945
loci O 0 7.895420276327059e-05
to O 0 5.483665063366061e-06
chromosome O 0 3.6315021134214476e-05
bands O 0 1.712750417937059e-05
15q22 O 0 0.00012035961117362604
and O 0 9.59451062954031e-06
17q21 O 0 0.0004319960135035217
. O 0 5.467951268656179e-05

2 O 0 9.835830860538408e-05
respectively O 0 2.857140134437941e-05
, O 0 2.8154302071925486e-06
regions O 0 5.09813708049478e-06
prone O 0 1.8777551304083318e-05
to O 0 1.3157236935512628e-06
amplification O 0 2.5304832888650708e-05
in O 0 9.59258500188298e-07
some O 0 1.5811311868674238e-06
human O 0 3.5885350371245295e-05
cancers B-Disease 0 0.14023159444332123
. O 0 4.5786731789121404e-05

Additional O 0 2.9213029847596772e-05
experiments O 0 2.7826012228615582e-05
are O 0 4.3615176537059597e-07
needed O 0 6.635921749875706e-07
to O 0 2.4219960437221744e-07
define O 0 7.116114488781022e-07
the O 0 3.4407025850669015e-07
role O 0 6.16075226389512e-07
of O 0 6.914336836416624e-07
CA O 0 0.0005407570861279964
IX O 1 0.5466720461845398
and O 0 6.820592716394458e-06
CA O 0 7.620653923368081e-05
XII O 0 0.0024956236593425274
enzymes O 0 1.6743479136493988e-06
in O 0 1.8761467401873233e-07
the O 0 1.5343772474807338e-07
regulation O 0 1.2545159506771597e-06
of O 0 2.0293411751026724e-07
pH O 0 6.938328624528367e-06
in O 0 2.781987689104426e-07
the O 0 4.286995647362346e-07
extracellular O 0 4.674195224652067e-06
microenvironment O 0 2.506336932128761e-05
and O 0 2.494511761597096e-07
its O 0 4.6940058950895036e-07
potential O 0 1.0927037692454178e-06
impact O 0 2.58635782302008e-06
on O 0 1.8092201571562327e-05
cancer B-Disease 1 0.7236740589141846
cell O 0 0.0006454730173572898
growth O 0 5.271191184874624e-05
. O 0 2.824454895744566e-05

A O 0 0.00013628433225676417
gene O 0 0.00014729180838912725
encoding O 0 4.6074062993284315e-05
a O 0 8.403600077144802e-06
transmembrane O 0 3.22099331242498e-05
protein O 0 5.031818545830902e-06
is O 0 9.207897733176651e-07
mutated O 0 2.2276964955381118e-05
in O 0 4.928841008222662e-06
patients O 0 0.03898425027728081
with O 1 0.7668074369430542
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.718938410282135
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999996423721313
( O 1 0.9866995811462402
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 6.390576163539663e-05
. O 0 4.1084356780629605e-05

Wolfram B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
( O 0 0.007104314398020506
WFS B-Disease 1 0.9994725584983826
; O 0 0.00024141292669810355
OMIM O 1 0.6276865005493164
222300 O 0 0.000834710372146219
) O 0 5.627524842566345e-06
is O 0 1.528605139355932e-06
an O 0 2.4709235731279477e-05
autosomal B-Disease 1 0.9999979734420776
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 0.9999988079071045
defined O 0 1.7579979612492025e-05
by O 0 2.448723989800783e-06
young O 0 3.663367124318029e-06
- O 0 0.00016893312567844987
onset O 0 0.006387691013514996
non O 0 3.5461271181702614e-05
- O 0 0.1833491027355194
immune O 0 0.3038969337940216
insulin B-Disease 1 0.717715322971344
- I-Disease 1 0.9951100945472717
dependent I-Disease 1 0.9410757422447205
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.0003003659949172288
progressive O 1 0.9954943656921387
optic B-Disease 1 0.9999946355819702
atrophy I-Disease 1 0.9970653653144836
. O 0 0.00011327390529913828

Linkage O 0 0.0010134218027815223
to O 0 1.7782265786081553e-05
markers O 0 2.6011151931015775e-05
on O 0 6.354451215884183e-06
chromosome O 0 0.00020307813247200102
4p O 1 0.6589756608009338
was O 0 1.0360022315580864e-05
confirmed O 0 7.186727998487186e-06
in O 0 1.1797177421613014e-06
five O 0 1.941962182172574e-06
families O 0 1.114910173782846e-05
. O 0 2.1584715796052478e-05

On O 0 1.2015604625048582e-05
the O 0 2.625323986649164e-06
basis O 0 1.1806091606558766e-06
of O 0 7.745403536318918e-07
meiotic O 0 0.007961871102452278
recombinants O 1 0.750689685344696
and O 0 9.149111428996548e-05
disease O 0 0.47572481632232666
- O 0 0.0009610800771042705
associated O 0 1.1465715942904353e-05
haplotypes O 0 3.9114536775741726e-05
, O 0 4.6124128516567e-07
the O 0 1.2937399560541962e-06
WFS B-Disease 1 0.673292338848114
gene O 0 1.694350430625491e-05
was O 0 1.7323708334515686e-06
localized O 0 6.345132078422466e-06
to O 0 5.489287673299259e-07
a O 0 3.1702845717518358e-06
BAC O 0 0.030651340261101723
/ O 0 0.00013975250476505607
P1 O 0 0.00010486896644579247
contig O 0 3.341090268804692e-05
of O 0 4.2721356408037536e-07
less O 0 9.425644975635805e-07
than O 0 9.038433290697867e-07
250 O 0 1.5844514564378187e-05
kb O 0 0.004624947905540466
. O 0 4.0402592276223004e-05

Mutations O 0 0.010396406054496765
in O 0 1.5910334695945494e-05
a O 0 7.878360520408023e-06
novel O 0 1.6279058399959467e-05
gene O 0 2.1987267246004194e-05
( O 0 2.421391855023103e-06
WFS1 O 0 3.6243094655219465e-05
) O 0 6.241212417990027e-07
encoding O 0 1.6879773738764925e-06
a O 0 5.381646701607679e-07
putative O 0 7.384456239378778e-06
transmembrane O 0 8.21497815195471e-06
protein O 0 1.446258238502196e-06
were O 0 2.174951134747971e-07
found O 0 1.3699857959181827e-07
in O 0 1.0207566703002158e-07
all O 0 5.473929221011531e-08
affected O 0 6.385989763657562e-07
individuals O 0 8.614869528855706e-08
in O 0 2.1227192803507933e-07
six O 0 1.4535175978380721e-06
WFS B-Disease 1 0.9635563492774963
families O 0 1.6627034256089246e-06
, O 0 1.9894355318683665e-07
and O 0 1.7687931119780842e-07
these O 0 2.8013133146487235e-07
mutations O 0 6.671559276583139e-06
were O 0 2.9713800131503376e-07
associated O 0 1.3241952956377645e-06
with O 0 1.202847784043115e-06
the O 0 0.00012351418263278902
disease O 1 0.9954937696456909
phenotype O 1 0.5175980925559998
. O 0 5.272990892990492e-05

WFS1 O 0 0.36415690183639526
appears O 0 0.00018156017176806927
to O 0 5.394541858549928e-06
function O 0 3.2577395359112415e-06
in O 0 8.64233470565523e-07
survival O 0 5.608900210063439e-06
of O 0 4.914001010547508e-07
islet O 0 3.0719267670065165e-05
beta O 0 2.082931860059034e-05
- O 0 7.799038576195017e-05
cells O 0 8.58902967593167e-06
and O 0 1.0377725629950874e-06
neurons O 0 4.60765695606824e-05
. O 0 4.054616510984488e-06
. O 0 1.3948451851319987e-05

Stable O 0 0.0003137671737931669
interaction O 0 1.648388206376694e-05
between O 0 1.6714666344341822e-06
the O 0 5.751659273300902e-07
products O 0 6.753265324732638e-07
of O 0 1.6070400477019575e-07
the O 0 9.901957582769683e-07
BRCA1 O 0 0.00016708316979929805
and O 0 6.1624245972780045e-06
BRCA2 O 0 0.00896830391138792
tumor B-Disease 0 0.001878239563666284
suppressor O 0 0.0003329167375341058
genes O 0 1.1909270142496098e-05
in O 0 2.894611043302575e-06
mitotic O 0 0.00026157681713812053
and O 0 1.0380920684838202e-05
meiotic O 0 0.006109523121267557
cells O 0 0.0005731408600695431
. O 0 4.757382339448668e-05

BRCA1 O 1 0.8261696696281433
and O 0 0.00013718394620809704
BRCA2 O 0 0.010359054431319237
account O 0 8.577357220929116e-06
for O 0 5.694569722436427e-07
most O 0 2.4661645170453994e-07
cases O 0 4.0207785900747695e-07
of O 0 2.3685117866989458e-07
familial O 0 0.0019537173211574554
, O 0 2.3318032162933378e-06
early O 0 8.059564424911514e-05
onset O 1 0.9992233514785767
breast B-Disease 1 0.9658055901527405
and I-Disease 0 0.0001970932789845392
/ I-Disease 1 0.9999769926071167
or I-Disease 1 0.994742751121521
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999985694885254
and O 0 1.2497002899181098e-06
encode O 0 7.477160579583142e-06
products O 0 2.417137238808209e-06
that O 0 2.0921366683523956e-07
each O 0 3.558834009709244e-07
interact O 0 1.7932387663677218e-06
with O 0 2.420749751763651e-06
hRAD51 O 0 0.0003592773573473096
. O 0 3.7096247979206964e-05

Results O 0 0.00018118265143129975
presented O 0 2.633229087223299e-05
here O 0 2.5783933779166546e-06
show O 0 2.9370919492066605e-06
that O 0 9.089017680707911e-07
BRCA1 O 0 8.277517918031663e-05
and O 0 1.7926370219356613e-06
BRCA2 O 0 0.0003878146526403725
coexist O 0 7.813920092303306e-06
in O 0 5.098007136439264e-07
a O 0 1.0794996114782407e-06
biochemical O 0 1.346174849459203e-05
complex O 0 2.1225584987405455e-06
and O 0 3.9121903228078736e-07
colocalize O 0 5.2351922931848094e-05
in O 0 1.1112924767076038e-06
subnuclear O 0 6.003618909744546e-05
foci O 0 4.283189991838299e-05
in O 0 9.097169026972551e-07
somatic O 0 2.5380575607414357e-05
cells O 0 5.1480055844876915e-06
and O 0 9.646520737760511e-08
on O 0 1.1145853306970821e-07
the O 0 1.3213806937528716e-07
axial O 0 2.3059033082972746e-06
elements O 0 4.968806592842157e-07
of O 0 4.441259306986467e-07
developing O 0 1.4568880942533724e-05
synaptonemal O 0 0.0008950248011387885
complexes O 0 0.00020259773009456694
. O 0 3.215113247279078e-05

Like O 0 0.00029146228916943073
BRCA1 O 0 0.0033330111764371395
and O 0 3.0402967240661383e-05
RAD51 O 0 0.010180122219026089
, O 0 1.5804309441591613e-05
BRCA2 O 0 0.0005061558913439512
relocates O 0 0.00022803721367381513
to O 0 7.420168913085945e-06
PCNA O 0 0.0004520107468124479
+ O 0 1.4219080185284838e-05
replication O 0 7.709875717409886e-06
sites O 0 1.3908741038903827e-06
following O 0 1.832416387514968e-06
exposure O 0 5.085531029180856e-06
of O 0 4.732829381737247e-07
S O 0 0.0001584642886882648
phase O 0 1.1144339623569977e-05
cells O 0 1.978677937586326e-05
to O 0 3.1482124995818594e-06
hydroxyurea O 0 0.0013537283521145582
or O 0 2.740507261478342e-05
UV O 0 0.13547445833683014
irradiation O 0 0.0007271684007719159
. O 0 4.4349108065944165e-05

Thus O 0 0.00010164736886508763
, O 0 1.4630002624471672e-05
BRCA1 O 0 0.00015488913049921393
and O 0 2.6945003810396884e-06
BRCA2 O 0 0.00011512422497617081
participate O 0 1.0322016805730527e-06
, O 0 2.0273371603707346e-07
together O 0 2.001907262183522e-07
, O 0 1.0682369833148186e-07
in O 0 1.5836165800919844e-07
a O 0 4.7275062797780265e-07
pathway O 0 2.881341515603708e-06
( O 0 8.872123089531669e-07
s O 0 1.9693181457114406e-05
) O 0 1.4250014146455214e-07
associated O 0 1.930784776504879e-07
with O 0 3.3596332826846265e-08
the O 0 6.475923441939813e-08
activation O 0 7.048961947475618e-07
of O 0 1.0236831116117173e-07
double O 0 1.1062118119298248e-06
- O 0 1.3922083780926187e-05
strand O 0 8.694111784279812e-06
break O 0 8.11445715953596e-06
repair O 0 0.019102662801742554
and O 0 3.0289468213595683e-06
/ O 0 0.00011903016275027767
or O 0 2.560093207648606e-06
homologous O 0 3.962180926464498e-05
recombination O 0 0.00010060822387458757
. O 0 2.765959652606398e-05

Dysfunction O 0 0.4140265882015228
of O 0 9.188966032525059e-06
this O 0 2.6267364319210174e-06
pathway O 0 2.1146455765119754e-05
may O 0 4.240800080879126e-06
be O 0 1.5260415864304377e-07
a O 0 2.927112916495389e-07
general O 0 5.686700319529336e-07
phenomenon O 0 1.206337856274331e-06
in O 0 1.2827979389840038e-07
the O 0 1.810037417726562e-07
majority O 0 3.392726171114191e-07
of O 0 8.221635994232201e-08
cases O 0 2.3502613544224005e-07
of O 0 3.2990922704811965e-07
hereditary B-Disease 1 0.9986128807067871
breast I-Disease 1 0.9975970387458801
and I-Disease 0 0.00336174457333982
/ I-Disease 1 0.9999988079071045
or I-Disease 1 0.9999077320098877
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 1.9835239072563127e-05
. O 0 3.607289181672968e-05

A O 0 0.00021045659377705306
novel O 0 0.00017234265396837145
Arg362Ser O 0 0.0015978188021108508
mutation O 0 7.817563891876489e-05
in O 0 2.200585640821373e-06
the O 0 1.8203668332716916e-06
sterol O 0 9.2315960500855e-05
27 O 0 1.9724871890502982e-05
- O 0 5.114554369356483e-05
hydroxylase O 0 0.0003035195404663682
gene O 0 1.7640235455473885e-05
( O 0 2.261462668684544e-06
CYP27 O 0 7.742187881376594e-05
) O 0 6.515769541692862e-07
: O 0 2.0225114383265463e-07
its O 0 2.4215643179559265e-07
effects O 0 1.5780912008267478e-06
on O 0 3.3807049248935073e-07
pre O 0 4.746489139506593e-06
- O 0 2.846724328264827e-06
mRNA O 0 2.428709194646217e-06
splicing O 0 8.446133506367914e-06
and O 0 9.327193879471452e-07
enzyme O 0 1.384706047247164e-05
activity O 0 1.8926177290268242e-05
. O 0 1.589454768691212e-05

A O 0 0.00012745073763653636
novel O 0 5.8140591136179864e-05
C O 0 5.743325164075941e-05
to O 0 9.43888665005943e-07
A O 0 1.7494680832896847e-06
mutation O 0 6.665975888608955e-06
in O 0 3.3154361744891503e-07
the O 0 6.208301215337997e-07
sterol O 0 4.390842514112592e-05
27 O 0 6.2494241319654975e-06
- O 0 1.8843709767679684e-05
hydroxylase O 0 8.411658927798271e-05
gene O 0 8.751485438551754e-06
( O 0 1.8427558643452358e-06
CYP27 O 0 4.46561498392839e-05
) O 0 5.888595637770777e-07
was O 0 6.692932288387965e-07
identified O 0 8.276545599983365e-07
by O 0 3.702236028857442e-07
sequencing O 0 3.599881665650173e-06
amplified O 0 2.4558086806791835e-05
CYP27 O 0 0.00024464275338687
gene O 0 9.885314284474589e-06
products O 0 1.9174333374394337e-06
from O 0 4.7129842073445616e-07
a O 0 1.874733243312221e-06
patient O 0 9.779426909517497e-05
with O 0 1.4296459994511679e-05
cerebrotendinous B-Disease 1 0.9999761581420898
xanthomatosis I-Disease 1 0.9999839067459106
( O 0 0.0001838653552113101
CTX B-Disease 1 0.5899611711502075
) O 0 2.9667931812582538e-05
. O 0 2.6181700377492234e-05

The O 0 7.218608516268432e-05
mutation O 0 0.0003528623783495277
changed O 0 2.6452749807504006e-05
the O 0 4.250140591466334e-06
adrenodoxin O 0 0.00013441014743875712
cofactor O 0 3.932038089260459e-05
binding O 0 9.773671081347857e-06
residue O 0 1.995699858525768e-05
362Arg O 0 3.0726972909178585e-05
to O 0 2.4084372398647247e-06
362Ser O 0 4.7821220505284145e-05
( O 0 5.271921054372797e-06
CGT O 0 8.0773992522154e-05
362Arg O 0 3.491766983643174e-05
to O 0 2.104520490320283e-06
AGT O 0 0.0007182768313214183
362Ser O 0 4.0449664084007964e-05
) O 0 6.162750310068077e-07
, O 0 1.0972697594979763e-07
and O 0 1.027599623171227e-07
was O 0 6.11321638643858e-07
responsible O 0 2.8070710413885536e-06
for O 0 6.912121989444131e-06
deficiency O 0 0.1849387139081955
in O 0 2.7525308610165666e-07
the O 0 3.9772712057128956e-07
sterol O 0 2.8144395400886424e-05
27 O 0 4.1050370782613754e-06
- O 0 7.147944415919483e-06
hydroxylase O 0 2.269718788738828e-05
activity O 0 1.000154270514031e-06
, O 0 8.197740442028589e-08
as O 0 9.308748616376761e-08
confirmed O 0 3.8114100675556983e-07
by O 0 1.7136080998625403e-07
expression O 0 3.73031923572853e-07
of O 0 1.229324624318906e-07
mutant O 0 7.3582277764217e-06
cDNA O 0 1.2221918950672261e-05
into O 0 5.177240836928831e-06
COS O 0 0.0028315933886915445
- O 0 6.0933791246498004e-05
1 O 0 1.3866300832887646e-05
cells O 0 7.303456368390471e-05
. O 0 2.3996948584681377e-05

Quantitative O 0 0.00033901818096637726
analysis O 0 4.120705125387758e-05
showed O 0 1.534301190986298e-05
that O 0 4.987630859432102e-07
the O 0 3.687169112254196e-07
expression O 0 8.428380056102469e-07
of O 0 3.3548249689374643e-07
CYP27 O 0 5.468796007335186e-05
gene O 0 6.872965514048701e-06
mRNA O 0 3.6553265090333298e-06
in O 0 8.180791724043956e-07
the O 0 1.5519696034971275e-06
patient O 0 3.747270966414362e-05
represented O 0 9.698759640741628e-06
52 O 0 4.379764504847117e-05
. O 0 4.243553485139273e-05

5 O 0 5.629045335808769e-05
% O 0 4.781554707733449e-06
of O 0 1.0409721653559245e-06
the O 0 2.7205535388930002e-06
normal O 0 1.6139489162014797e-05
level O 0 1.6223280908889137e-05
. O 0 2.9367640308919363e-05

As O 0 1.5978348528733477e-05
the O 0 4.944797183270566e-06
mutation O 0 3.1634313927497715e-05
occurred O 0 5.130679710418917e-06
at O 0 6.820071121182991e-07
the O 0 3.885582486873318e-07
penultimate O 0 5.848021828569472e-06
nucleotide O 0 1.8215755517303478e-06
of O 0 2.47211033865824e-07
exon O 0 1.4519697288051248e-05
6 O 0 1.874046802186058e-06
( O 0 1.1027747177649871e-06
- O 0 1.8814533859767835e-06
2 O 0 2.03256220743242e-07
position O 0 3.038628335616522e-07
of O 0 1.649772229939117e-07
exon O 0 7.978741450642701e-06
6 O 0 1.9113008420390543e-06
- O 0 1.143584813689813e-05
intron O 0 2.287122879351955e-05
6 O 0 1.5590873090332025e-06
splice O 0 1.075713134923717e-05
site O 0 1.057486088029691e-06
) O 0 9.918982613044136e-08
of O 0 2.3577049645950865e-08
the O 0 1.108923655124272e-07
gene O 0 1.3559287026509992e-06
, O 0 1.2722144049348572e-07
we O 0 7.451311745398925e-08
hypothesized O 0 1.7231272977369372e-06
that O 0 1.172999546383835e-07
the O 0 7.535356871812837e-07
mutation O 0 4.003138019470498e-05
may O 0 5.037627943238476e-06
partially O 0 7.909482519607991e-06
affect O 0 9.751669267643592e-07
the O 0 2.5055675223484286e-07
normal O 0 1.1719008625732386e-06
splicing O 0 4.0303093555849046e-06
efficiency O 0 2.3408490505971713e-06
in O 0 5.341478868103877e-07
exon O 0 1.0498359188204631e-05
6 O 0 8.650118843434029e-07
and O 0 2.5405600467820477e-07
cause O 0 1.7708669020066736e-06
alternative O 0 1.00137981462467e-06
splicing O 0 5.159589818504173e-06
elsewhere O 0 1.454212338103389e-06
, O 0 1.0605305789113117e-07
which O 0 1.4061369313367322e-07
resulted O 0 1.0540305765971425e-06
in O 0 6.629165909544099e-07
decreased O 0 1.0101916814164724e-05
transcript O 0 2.6979332687915303e-05
in O 0 1.5826609569558059e-06
the O 0 6.240972197701922e-06
patient O 0 0.0009333320194855332
. O 0 3.248190478188917e-05

Transfection O 0 0.0035103538539260626
of O 0 1.5212626749416813e-05
constructed O 0 7.180759712355211e-05
minigenes O 0 0.0006031888769939542
, O 0 6.986473408687743e-07
with O 0 2.9679333124477125e-07
or O 0 3.427668104905024e-07
without O 0 1.388842036931237e-07
the O 0 2.6910132078228344e-07
mutation O 0 2.9024947707512183e-06
, O 0 1.5104953376976482e-07
into O 0 6.107762260398886e-07
COS O 0 0.007230456452816725
- O 0 1.3145147022441961e-05
1 O 0 5.996188292556326e-07
cells O 0 1.867659648269182e-06
confirmed O 0 4.936838990943215e-07
that O 0 6.82221781289627e-08
the O 0 1.9612183166373143e-07
mutant O 0 1.0176527212024666e-05
minigene O 0 5.1421615353319794e-05
was O 0 9.05855699784297e-07
responsible O 0 4.55053680070705e-07
for O 0 1.0378956716294852e-07
a O 0 2.861387997654674e-07
mRNA O 0 1.1625603519860306e-06
species O 0 3.5754044347413583e-07
alternatively O 0 2.762990106930374e-06
spliced O 0 9.571261216478888e-06
at O 0 5.556717042054515e-07
an O 0 5.093551180834766e-07
activated O 0 5.182568565942347e-05
cryptic O 0 1.2918603715661447e-05
5 O 0 1.7679408301773947e-06
splice O 0 2.0788500478374772e-05
site O 0 2.152745764760766e-06
88 O 0 3.1438742098544026e-06
bp O 0 7.082227966748178e-06
upstream O 0 1.2202388006699039e-06
from O 0 2.4173485257961147e-07
the O 0 1.872271582215035e-07
3 O 0 4.4251260078453925e-07
end O 0 7.057531092868885e-07
of O 0 7.463827387255151e-07
exon O 0 0.00010008957906393334
6 O 0 2.2392066966858692e-05
. O 0 2.2836487914901227e-05

Our O 0 2.5008886950672604e-05
data O 0 8.07525520940544e-06
suggest O 0 2.181291620217962e-06
that O 0 2.178257574314557e-07
the O 0 2.7799589474852837e-07
C O 0 4.630563580576563e-06
to O 0 1.4714591145548184e-07
A O 0 8.675266940372239e-07
mutation O 0 3.7493614399863873e-06
at O 0 1.994540070882067e-07
the O 0 2.0136121747782454e-07
penultimate O 0 3.2740726965130307e-06
nucleotide O 0 9.463176411372842e-07
of O 0 1.2244933600413788e-07
exon O 0 3.4800598314177478e-06
6 O 0 3.19960292927135e-07
of O 0 7.301645155166625e-08
the O 0 3.443693401550263e-07
CYP27 O 0 0.0011333682341501117
gene O 0 3.0156106731737964e-06
not O 0 1.3951796518085757e-07
only O 0 1.692587829893455e-07
causes O 0 1.2286509445402771e-05
the O 0 1.337174944637809e-05
deficiency B-Disease 0 0.11529417335987091
in I-Disease 0 4.5323290009946504e-07
the I-Disease 0 7.436076430167304e-07
sterol I-Disease 0 4.501333023654297e-05
27 I-Disease 0 4.453900601220084e-06
- I-Disease 0 8.916552360460628e-06
hydroxylase I-Disease 0 2.680885518202558e-05
activity I-Disease 0 1.6838821466080844e-06
, O 0 1.3410760857368587e-07
but O 0 9.04683545854823e-08
also O 0 1.7819807851537917e-07
partially O 0 2.062993416984682e-06
leads O 0 4.0050571215033415e-07
to O 0 1.9779524507157475e-07
alternative O 0 6.556135190294299e-07
pre O 0 3.9674023355473764e-06
- O 0 1.764107651069935e-06
mRNA O 0 1.2950780501341796e-06
splicing O 0 3.471153377176961e-06
of O 0 3.190957897913904e-07
the O 0 2.0899519768136088e-06
gene O 0 5.1987695769639686e-05
. O 0 2.0940835383953527e-05

To O 0 1.7569218471180648e-05
our O 0 2.886699121518177e-06
knowledge O 0 1.3499844726538868e-06
, O 0 2.4661787279001146e-07
this O 0 1.0078085921350066e-07
is O 0 6.036223965111276e-08
the O 0 1.5730439884009684e-07
first O 0 4.4187666503603396e-07
report O 0 3.0513347155647352e-06
regarding O 0 8.918892717701965e-07
effects O 0 3.1577505978930276e-06
on O 0 6.054067398508778e-07
pre O 0 5.087034423922887e-06
- O 0 1.145184000961308e-06
mRNA O 0 5.197679229240748e-07
splicing O 0 9.368326345793321e-07
of O 0 6.091218551773636e-08
a O 0 4.13482496242068e-07
mutation O 0 2.795095497276634e-06
at O 0 2.8909533966725576e-07
the O 0 3.1090351626517077e-07
- O 0 2.3876739305705996e-06
2 O 0 2.0635823716474988e-07
position O 0 3.4916644153781817e-07
of O 0 1.2958240347415995e-07
a O 0 1.4701603276989772e-06
5 O 0 5.011034318158636e-06
splice O 0 0.00015526443894486874
site O 0 3.3794254704844207e-05
. O 0 2.2753663870389573e-05

ATM O 0 0.23944668471813202
germline O 1 0.9926609992980957
mutations O 0 0.0629720464348793
in O 0 6.894547550473362e-05
classical O 0 0.0025584332179278135
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.350506991147995
in O 0 2.3629104362044018e-06
the O 0 2.5699141588120256e-06
Dutch O 0 6.35318792774342e-05
population O 0 1.5984216588549316e-05
. O 0 2.7207684979657643e-05

Germline O 1 0.9935042262077332
mutations O 0 0.02648051455616951
in O 0 1.585830068506766e-05
the O 0 5.222610070632072e-06
ATM O 0 0.00011076992814196274
gene O 0 1.0447551176184788e-05
are O 0 3.18161369250447e-07
responsible O 0 1.9938318018830614e-06
for O 0 2.5326955892523983e-06
the O 1 0.6373792290687561
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 0.9999998807907104
( O 0 0.00018845232261810452
A B-Disease 1 0.7736271023750305
- I-Disease 1 0.9960765242576599
T I-Disease 1 0.9997828602790833
) O 0 2.615549965412356e-05
. O 0 2.3874485123087652e-05

In O 0 2.6765603251988068e-05
our O 0 5.234707259660354e-06
study O 0 2.6633676952769747e-06
, O 0 3.2731495025473123e-07
we O 0 1.254241652759447e-07
have O 0 9.18607838684693e-08
determined O 0 5.056376153333986e-07
the O 0 3.539335011737421e-07
ATM O 0 8.17918626125902e-05
mutation O 0 1.3332427442946937e-05
spectrum O 0 6.6771358433470596e-06
in O 0 5.761816055382951e-07
19 O 0 1.3959451052869554e-06
classical O 0 2.5198858111252775e-06
A B-Disease 1 0.9997574687004089
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.0013121026568114758
, O 0 1.3813800592288317e-07
including O 0 1.0096287184069297e-07
some O 0 8.747847601853209e-08
immigrant O 0 1.3834686569680343e-06
populations O 0 7.676235327380709e-07
, O 0 1.129127014110054e-07
as O 0 5.3368957253496774e-08
well O 0 6.150090570145039e-08
as O 0 7.923487288508113e-08
12 O 0 2.1198748356709984e-07
of O 0 1.6740607122756046e-07
Dutch O 0 4.754290330311051e-06
ethnic O 0 2.52747668127995e-06
origin O 0 9.57423799263779e-06
. O 0 1.8538905351306312e-05

Both O 0 2.2923724827705882e-05
the O 0 8.658746082801372e-06
protein O 0 2.047647831204813e-05
truncation O 0 8.315793093061075e-05
test O 0 1.6162792235263623e-05
( O 0 4.052231815876439e-06
PTT O 0 2.7851017875946127e-05
) O 0 4.0670298062650545e-07
and O 0 1.0468563971244293e-07
the O 0 2.870924618036952e-07
restriction O 0 3.8792131817899644e-06
endonuclease O 0 6.907215720275417e-05
fingerprinting O 0 3.171671778545715e-05
( O 0 3.0726578188478015e-06
REF O 0 9.294841584051028e-05
) O 0 2.4265438014481333e-07
method O 0 2.0025547087243467e-07
were O 0 8.542922813603582e-08
used O 0 1.0227658719941246e-07
and O 0 6.70922872814117e-08
compared O 0 2.630225708344369e-07
for O 0 6.537104724202436e-08
their O 0 1.589766185361441e-07
detection O 0 2.9138325317035196e-06
efficiency O 0 2.1163550627534278e-06
, O 0 1.5512162576669652e-07
identifying O 0 5.137878815730801e-07
76 O 0 1.0786568509502104e-06
% O 0 1.472789961098897e-07
and O 0 7.603320995031027e-08
60 O 0 2.1825100304795342e-07
% O 0 1.0604698985616778e-07
of O 0 8.461837808226846e-08
the O 0 9.935661182680633e-07
mutations O 0 3.649976497399621e-05
, O 0 1.253903633369191e-06
respectively O 0 1.5907589840935543e-05
. O 0 2.3142147256294265e-05

Most O 0 0.0001224391016876325
patients O 0 0.024071866646409035
were O 0 2.6743425678432686e-06
found O 0 2.2088779587647878e-06
to O 0 1.7237683778148494e-06
be O 0 1.7569718693266623e-06
compound O 0 5.653630796587095e-05
heterozygote O 0 0.0010325924959033728
. O 0 4.062199150212109e-05

Seventeen O 0 0.0005308208637870848
mutations O 0 0.000580145395360887
were O 0 2.1425112208817154e-06
distinct O 0 1.2399372053550906e-06
, O 0 2.1506599523490877e-07
of O 0 8.569686826831457e-08
which O 0 1.9768529568864324e-07
10 O 0 2.778678549475444e-07
were O 0 2.662727638380602e-07
not O 0 5.057036673861148e-07
reported O 0 4.346925561549142e-05
previously O 0 2.169524486816954e-05
. O 0 1.8006996469921432e-05

Mutations O 0 0.004125527571886778
are O 0 8.2141004895675e-06
small O 0 5.676390628650552e-06
deletions O 0 7.423874194500968e-05
or O 0 3.3470223570475355e-06
point O 0 7.220058250823058e-06
mutations O 0 8.269138197647408e-05
frequently O 0 2.31372923735762e-05
affecting O 0 3.0307495762826875e-05
splice O 0 0.0004118767683394253
sites O 0 6.502060568891466e-05
. O 0 3.828975241049193e-05

Moreover O 0 0.00027504799072630703
, O 0 1.8260374417877756e-05
a O 0 1.957256972673349e-05
16 O 0 4.254079976817593e-05
. O 0 5.3399489843286574e-05

7 O 0 0.0002790624275803566
- O 0 0.00031200781813822687
kb O 0 0.0006164393271319568
genomic O 0 6.136612500995398e-05
deletion O 0 1.9912889911211096e-05
of O 0 2.683852358131844e-07
the O 0 3.3377071417817206e-07
3 O 0 4.3516541836652323e-07
end O 0 3.5438608847471187e-07
of O 0 5.431455463167367e-08
the O 0 1.8632478315794287e-07
gene O 0 1.9195867935195565e-06
, O 0 1.2975787910818326e-07
most O 0 9.632070430143358e-08
likely O 0 3.1005106393422466e-07
a O 0 2.179839100335812e-07
result O 0 2.0392023714066454e-07
of O 0 8.115287641885516e-08
recombination O 0 1.132202783082903e-06
between O 0 1.2346116307071497e-07
two O 0 9.764998054606622e-08
LINE O 0 9.445892032999836e-07
elements O 0 5.492136097018374e-07
, O 0 5.05500224790012e-07
was O 0 3.646427330750157e-06
identified O 0 1.697689003776759e-05
. O 0 1.5852372598601505e-05

The O 0 1.776953286025673e-05
most O 0 3.1217950891004875e-06
frequently O 0 5.438728749140864e-06
found O 0 2.441076503600925e-06
mutation O 0 9.359232535643969e-06
, O 0 2.91767065618842e-07
identified O 0 5.130734734848375e-07
in O 0 1.7688874720533931e-07
three O 0 1.8132752188648738e-07
unrelated O 0 2.081379534502048e-06
Turkish O 0 5.855371455254499e-06
A B-Disease 1 0.9818700551986694
- I-Disease 1 0.9997674822807312
T I-Disease 1 0.99996018409729
individuals O 0 3.5938779774369323e-07
, O 0 1.382737622179775e-07
was O 0 4.541873863672663e-07
previously O 0 5.623917331831763e-07
described O 0 7.545546623077826e-07
to O 0 9.228946851180808e-08
be O 0 6.349759473778249e-08
a O 0 3.5144182675139746e-07
Turkish O 0 5.689614226866979e-06
A B-Disease 1 0.6755354404449463
- I-Disease 1 0.9993808269500732
T I-Disease 1 0.9999865293502808
founder O 0 0.002312666969373822
mutation O 0 0.0003645406977739185
. O 0 3.909454608219676e-05

The O 0 1.332762258243747e-05
presence O 0 7.854444447730202e-06
of O 0 7.691851919844339e-07
a O 0 2.2201174942892976e-06
founder O 0 0.00010429583926452324
mutation O 0 1.0462416867085267e-05
among O 0 2.652483317433507e-07
relatively O 0 3.6455298868531827e-07
small O 0 1.460313114876044e-07
ethnic O 0 1.629196333396976e-07
population O 0 1.5006426679065044e-07
groups O 0 1.1378440234466325e-07
in O 0 1.0428048824451253e-07
Western O 0 6.065504294383572e-07
Europe O 0 2.3051818516250933e-06
could O 0 5.410557832874474e-07
indicate O 0 7.52055996144918e-07
a O 0 5.771925088993157e-07
high O 0 1.5812170204299036e-06
carrier O 0 1.2735069503833074e-05
frequency O 0 4.783579697686946e-06
in O 0 6.392900218088471e-07
such O 0 1.0896463891185704e-06
communities O 0 1.1022764738299884e-05
. O 0 2.6390391212771647e-05

In O 0 7.873359572840855e-05
patients O 0 3.786244633374736e-05
of O 0 5.275302896734502e-07
Dutch O 0 3.720808308571577e-06
ethnic O 0 3.852948395888234e-07
origin O 0 5.366937330109067e-07
, O 0 1.7918149808338057e-07
however O 0 2.1430803087696404e-07
, O 0 1.0422978391488869e-07
no O 0 1.0673551287254668e-07
significant O 0 4.224941676511662e-07
founder O 0 2.403414146101568e-05
effect O 0 3.1630547709937673e-06
could O 0 1.245564476448635e-06
be O 0 9.785261454453575e-07
identified O 0 1.1067762898164801e-05
. O 0 1.1217807696084492e-05

The O 0 4.6303066483233124e-05
observed O 0 7.263443694682792e-05
genetic O 0 2.6882200472755358e-05
heterogeneity O 0 1.9765993783948943e-05
including O 0 8.685242391948123e-07
the O 0 6.458745929194265e-07
relative O 0 2.41951283896924e-06
high O 0 1.107444631998078e-06
percentage O 0 5.51201765119913e-07
of O 0 2.8919572514496394e-07
splice O 0 0.00027796393260359764
- O 0 0.011081771925091743
site O 0 2.8186728741275147e-05
mutations O 0 2.9535875000874512e-05
had O 0 1.0374301382398698e-06
no O 0 2.952662896404945e-07
reflection O 0 2.030502173511195e-06
on O 0 1.4480897334578913e-06
the O 0 7.994218321982771e-06
phenotype O 0 0.009177714586257935
. O 0 3.6713547160616145e-05

All O 0 5.366013647289947e-05
patients O 0 0.0008619118598289788
manifested O 0 0.00018457869009580463
classical O 0 2.17452925426187e-05
A B-Disease 1 0.9575102925300598
- I-Disease 1 0.9975948929786682
T I-Disease 1 0.9980952143669128
and O 0 1.9780138700298266e-06
increased O 0 9.08387028175639e-06
cellular O 0 4.352633186499588e-05
radioresistant O 0 0.0003576873568817973
DNA O 0 5.48450589121785e-05
synthesis O 0 0.00011350724525982514
. O 0 4.608909512171522e-05

Determination O 0 8.338853513123468e-05
of O 0 2.0651666545745684e-06
the O 0 1.93846153706545e-06
genomic O 0 1.4516581359202974e-05
structure O 0 1.3927509598943288e-06
of O 0 2.1706719621761295e-07
the O 0 7.068362606332812e-07
COL4A4 O 0 0.00045787511044181883
gene O 0 6.227737685549073e-06
and O 0 3.043991227968945e-07
of O 0 7.204048984021938e-07
novel O 0 0.00013514423335436732
mutations O 0 0.18509715795516968
causing O 1 0.8117882013320923
autosomal B-Disease 1 0.9999967813491821
recessive I-Disease 1 0.9999998807907104
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0005017325165681541

Autosomal B-Disease 1 0.9999996423721313
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 5.873497502761893e-05
a O 0 8.941657870309427e-05
progressive O 1 0.7368342876434326
hematuric B-Disease 1 0.9994022846221924
glomerulonephritis I-Disease 1 0.9999994039535522
characterized O 0 0.020491911098361015
by O 0 1.2471507034206297e-05
glomerular B-Disease 1 0.7848343253135681
basement I-Disease 1 0.9512038826942444
membrane I-Disease 1 0.5684656500816345
abnormalities I-Disease 1 0.9942770600318909
and O 0 1.5824948604858946e-06
associated O 0 3.2167224617296597e-06
with O 0 7.925336831249297e-07
mutations O 0 1.847156454459764e-05
in O 0 1.9901737857708213e-07
either O 0 2.2211521866211115e-07
the O 0 2.567153387644794e-07
COL4A3 O 0 0.00010960343206534162
or O 0 3.16986870529945e-07
the O 0 3.758902664685593e-07
COL4A4 O 0 0.00015929997607599944
gene O 0 2.709662567212945e-06
, O 0 1.3166132362130156e-07
which O 0 1.2084721845440072e-07
encode O 0 1.1505270549605484e-06
the O 0 4.359022796052159e-07
alpha3 O 0 3.8102956750663e-05
and O 0 2.00223121282761e-06
alpha4 O 0 0.006990837398916483
type O 0 0.004145416896790266
IV O 1 0.9886903762817383
collagen O 0 0.0014042850816622376
chains O 0 8.685837383382022e-05
, O 0 3.165788939440972e-06
respectively O 0 1.720973159535788e-05
. O 0 2.0555682567646727e-05

To O 0 2.0042019968968816e-05
date O 0 1.2000030437775422e-05
, O 0 1.7284664863836952e-06
mutation O 0 9.381717063661199e-06
screening O 0 2.1139828731975285e-06
in O 0 1.5605688474806811e-07
the O 0 1.2138245608639409e-07
two O 0 1.1824327827980596e-07
genes O 0 4.891697926723282e-07
has O 0 2.0361319741368789e-07
been O 0 2.1285595153130998e-07
hampered O 0 7.114986146916635e-06
by O 0 1.6582821160682215e-07
the O 0 1.6098380228868336e-07
lack O 0 5.970101142338535e-07
of O 0 4.748906974327838e-07
genomic O 0 3.8234727981034666e-05
structure O 0 1.7090991605073214e-05
information O 0 1.0087053851748351e-05
. O 0 2.1507785277208313e-05

We O 0 3.393738734303042e-05
report O 0 1.4485313840850722e-05
here O 0 5.150791935193411e-07
the O 0 2.597077468635689e-07
complete O 0 5.595739480668271e-07
characterization O 0 1.3723633855988737e-06
of O 0 7.188347694864206e-08
the O 0 1.5467006164726627e-07
48 O 0 4.5030574824522773e-07
exons O 0 1.526364712844952e-06
of O 0 7.051450978678986e-08
the O 0 3.76180736338938e-07
COL4A4 O 0 0.0007830472895875573
gene O 0 5.476891601574607e-06
, O 0 1.634086999047213e-07
a O 0 2.252486268616849e-07
comprehensive O 0 1.1262958423685632e-06
gene O 0 2.3020490971248364e-06
screen O 0 7.836703161956393e-07
, O 0 8.896764569499283e-08
and O 0 5.133862401862643e-08
the O 0 7.358926978895397e-08
subsequent O 0 5.414083261712221e-07
detection O 0 1.2365810562187107e-06
of O 0 1.3185305647311907e-07
10 O 0 5.539288281397603e-07
novel O 0 4.364223514130572e-06
mutations O 0 2.1898182239965536e-05
in O 0 2.4840287551342044e-06
eight O 0 0.00029759391327388585
patients O 1 0.9997599720954895
diagnosed O 1 0.9999992847442627
with O 1 0.6327762007713318
autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00037796382093802094

Furthermore O 0 0.00014869292499497533
, O 0 5.6551070883870125e-06
we O 0 9.530969578008808e-07
identified O 0 2.243970811832696e-06
a O 0 1.3454101690513198e-06
glycine O 0 2.373824463575147e-05
to O 0 7.463905831173179e-07
alanine O 0 1.0057986401079688e-05
substitution O 0 1.8833707144949585e-06
in O 0 3.8787226230851957e-07
the O 0 4.671457816129987e-07
collagenous O 0 8.251407416537404e-05
domain O 0 1.7644929357629735e-06
that O 0 1.892281176196775e-07
is O 0 1.7156047249500261e-07
apparently O 0 9.395544111612253e-07
silent O 0 2.634006250445964e-06
in O 0 2.553779552272317e-07
the O 0 5.428595954981574e-07
heterozygous O 0 2.173936263716314e-05
carriers O 0 5.447023795568384e-06
, O 0 8.26813504772872e-07
in O 0 1.543974121887004e-06
11 O 0 1.58931525220396e-05
. O 0 2.7834767024614848e-05

5 O 0 3.728734372998588e-05
% O 0 1.9819319732050644e-06
of O 0 1.971069991668628e-07
all O 0 1.3560124045852717e-07
control O 0 3.018450343006407e-06
individuals O 0 2.4016773636503785e-07
, O 0 9.538318579416227e-08
and O 0 8.717599797591902e-08
in O 0 1.396574731415967e-07
one O 0 1.4123136793386948e-07
control O 0 3.248264874855522e-06
individual O 0 3.235072085772117e-07
homozygous O 0 6.895392289152369e-06
for O 0 3.0795027328167635e-07
this O 0 8.714596333447844e-07
glycine O 0 8.088097092695534e-05
substitution O 0 4.470464409678243e-05
. O 0 3.163588189636357e-05

There O 0 1.5123362572921906e-05
has O 0 2.6835091375687625e-06
been O 0 5.373354383664264e-07
no O 0 1.6004572955807816e-07
previous O 0 3.780155566346366e-07
finding O 0 1.6405498115545925e-07
of O 0 7.442590543860206e-08
a O 0 3.257498804032366e-07
glycine O 0 7.264260602823924e-06
substitution O 0 1.0594868626867537e-06
that O 0 1.3172952151307982e-07
is O 0 9.164097747316191e-08
not O 0 7.762383091858283e-08
associated O 0 3.524393150655669e-07
with O 0 1.8214748820355453e-07
any O 0 5.381610890253796e-07
obvious O 0 9.11735332920216e-06
phenotype O 0 0.004016328137367964
in O 0 6.262166152737336e-06
homozygous O 0 0.00030696127214469016
individuals O 0 1.1025918865925632e-05
. O 0 2.7607997253653593e-05

Founder O 0 0.006379930768162012
BRCA1 O 0 0.08260506391525269
and O 0 6.017421401338652e-05
BRCA2 O 0 0.02196010760962963
mutations O 0 0.0001407064264640212
in O 0 3.327084186821594e-06
French O 0 4.303160676499829e-05
Canadian O 0 0.010938724502921104
breast B-Disease 1 0.9999960660934448
and I-Disease 1 0.9996764659881592
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 0.0001285668695345521
. O 0 8.219405572162941e-05

We O 0 2.2769552742829546e-05
have O 0 3.6053925214218907e-06
identified O 0 3.3490241548861377e-06
four O 0 6.649801775893138e-07
mutations O 0 3.5751490941038355e-06
in O 0 8.847571564274403e-08
each O 0 4.835334621589027e-08
of O 0 1.2094014323338342e-07
the O 0 1.631149098102469e-05
breast B-Disease 1 0.9999682903289795
cancer I-Disease 1 0.9953666925430298
- O 0 0.005747768096625805
susceptibility O 0 8.636084385216236e-05
genes O 0 2.938601937785279e-06
, O 0 6.391680926753907e-07
BRCA1 O 0 3.6098015698371455e-05
and O 0 8.217103300012241e-07
BRCA2 O 0 5.806069748359732e-05
, O 0 3.4518706115704845e-07
in O 0 4.6791714680693985e-07
French O 0 1.5063628779898863e-05
Canadian O 0 0.009919330477714539
breast B-Disease 1 0.9999656677246094
cancer I-Disease 1 0.9999096393585205
and O 1 0.7579492330551147
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.7956646843231283e-05
from O 0 1.0600391760817729e-05
Quebec O 0 0.00038521489477716386
. O 0 6.411904178094119e-05

To O 0 2.75981510640122e-05
identify O 0 3.949061283492483e-05
founder O 0 0.00029283130425028503
effects O 0 0.0001276231778319925
, O 0 8.30441535981663e-07
we O 0 3.7242409689497435e-07
examined O 0 6.517541805806104e-06
independently O 0 3.889508207066683e-06
ascertained O 0 1.5451199942617677e-05
French O 0 1.1581645594560541e-05
Canadian O 0 0.002110093366354704
cancer B-Disease 0 0.4161929488182068
families O 0 5.629191832667857e-07
for O 0 1.0316569643009643e-07
the O 0 2.005318151532265e-07
distribution O 0 4.807003506357432e-07
of O 0 1.1766979923777399e-07
these O 0 6.350958301482024e-07
eight O 0 6.489360202976968e-06
mutations O 0 0.00020370783749967813
. O 0 2.0275943825254217e-05

Mutations O 0 0.012287682853639126
were O 0 1.1578288649616297e-05
found O 0 3.330220579300658e-06
in O 0 1.4356605788634624e-06
41 O 0 5.341383712220704e-06
of O 0 1.1052237596231862e-06
97 O 0 3.329151149955578e-05
families O 0 2.1011392163927667e-05
. O 0 4.0528932004235685e-05

Six O 0 2.4082826712401584e-05
of O 0 2.688371068870765e-06
eight O 0 5.696607331628911e-06
mutations O 0 6.52280286885798e-05
were O 0 1.5499698520216043e-06
observed O 0 2.8403301257640123e-06
at O 0 1.2394784789648838e-06
least O 0 2.5253659714508103e-06
twice O 0 2.9466300475178286e-05
. O 0 3.0395400244742632e-05

The O 0 0.00015294541663024575
BRCA1 O 0 0.016107922419905663
C4446T O 0 0.003683132352307439
mutation O 0 0.0004173654888290912
was O 0 5.094958396512084e-06
the O 0 6.995347803240293e-07
most O 0 4.645432909455849e-07
common O 0 1.7668115788183059e-06
mutation O 0 1.016687474475475e-05
found O 0 6.5721474129532e-07
, O 0 2.0804436928756331e-07
followed O 0 9.408096843799285e-07
by O 0 9.891292620523018e-07
the O 0 7.0247215262497775e-06
BRCA2 O 0 0.007220119703561068
8765delAG O 0 0.0011579417623579502
mutation O 0 0.000553019461221993
. O 0 5.546882312046364e-05

Together O 0 2.522621252865065e-05
, O 0 2.9184714094299125e-06
these O 0 7.89953787716513e-07
mutations O 0 6.912319804541767e-06
were O 0 2.910073249040579e-07
found O 0 2.3590278885876614e-07
in O 0 1.4378991863850388e-07
28 O 0 3.0610414114562445e-07
of O 0 7.033115423382696e-08
41 O 0 1.0526282494538464e-06
families O 0 4.123082817386603e-07
identified O 0 1.0769166465252056e-06
to O 0 2.9667955914192135e-07
have O 0 4.657072452118882e-07
a O 0 7.652351996512152e-06
mutation O 0 0.00024375917564611882
. O 0 3.2393061701441184e-05

The O 0 3.3021038689184934e-05
odds O 0 5.347408296074718e-05
of O 0 8.050918722801725e-07
detection O 0 4.058543709106743e-06
of O 0 1.816891312955704e-07
any O 0 1.3601724901946e-07
of O 0 1.281687644905105e-07
the O 0 5.058566330262693e-07
four O 0 4.286544026399497e-06
BRCA1 O 0 0.10328029096126556
mutations O 0 0.00019312735821586102
was O 0 1.3043848412053194e-05
18 O 0 1.080772199202329e-05
. O 0 2.0236382624716498e-05

7x O 0 0.2703866958618164
greater O 0 5.6427343224640936e-05
if O 0 3.6724966321344255e-06
one O 0 5.866129981768609e-07
or O 0 3.0797878025623504e-07
more O 0 1.3135291965227225e-07
cases O 0 1.5556148582618334e-06
of O 0 0.001985185779631138
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 2.938927082141163e-06
also O 0 5.553633286581316e-07
present O 0 4.7449503881580313e-07
in O 0 4.0869252870834316e-07
the O 0 1.799608639885264e-06
family O 0 2.3637019694433548e-05
. O 0 2.3411159418174066e-05

The O 0 2.0370409401948564e-05
odds O 0 5.4521959100384265e-05
of O 0 1.29883585486823e-06
detection O 0 4.878694653598359e-06
of O 0 1.2651280201225745e-07
any O 0 1.2016262473935058e-07
of O 0 1.2059071252679132e-07
the O 0 5.090030299470527e-07
four O 0 7.379640464932891e-06
BRCA2 O 0 0.21476778388023376
mutations O 0 0.00013964259414933622
was O 0 1.0342036148358602e-05
5 O 0 2.2237525627133437e-05
. O 0 2.2916117814020254e-05

3x O 0 0.007135981693863869
greater O 0 6.969182868488133e-05
if O 0 3.997481144324411e-06
there O 0 5.103781290927145e-07
were O 0 1.6641089928270958e-07
at O 0 1.4140671567020036e-07
least O 0 1.3503498053069052e-07
five O 0 1.5139188747070875e-07
cases O 0 5.384521841733658e-07
of O 0 3.491332336125197e-06
breast B-Disease 1 0.9999896287918091
cancer I-Disease 1 0.9499349594116211
in O 0 2.225370280939387e-06
the O 0 5.265580057312036e-06
family O 0 8.999038982437924e-05
. O 0 2.9989540053065866e-05

Interestingly O 0 0.0003074706473853439
, O 0 2.9053028356429422e-06
the O 0 7.873995286900026e-07
presence O 0 1.0817968814080814e-06
of O 0 3.5980687584924453e-07
a O 0 0.0009100521565414965
breast B-Disease 1 0.9999963045120239
cancer I-Disease 1 0.9913161993026733
case O 0 7.171774541347986e-06
< O 0 9.440692338102963e-06
36 O 0 8.228536785281904e-07
years O 0 2.1756396506589226e-07
of O 0 9.61531156917772e-08
age O 0 5.982205948384944e-07
was O 0 1.2293097597648739e-06
strongly O 0 1.7756323131834506e-06
predictive O 0 1.5578208376609837e-06
of O 0 6.33957029094745e-08
the O 0 9.447065707490765e-08
presence O 0 1.4495567768335604e-07
of O 0 4.4020346479101136e-08
any O 0 4.7716238071870976e-08
of O 0 6.570167698782825e-08
the O 0 5.017070634494303e-07
eight O 0 4.892555352853378e-06
mutations O 0 0.00013699286500923336
screened O 0 0.00017795049643609673
. O 0 3.4003020118689165e-05

Carriers O 0 0.00017513164493720978
of O 0 1.5438475884366198e-06
the O 0 1.245032422048098e-06
same O 0 1.0179602440985036e-06
mutation O 0 5.003346359444549e-06
, O 0 1.7168223109820246e-07
from O 0 1.2307251040510891e-07
different O 0 6.897556659168913e-08
families O 0 1.7886581815673708e-07
, O 0 1.1916090869590334e-07
shared O 0 4.427861597378069e-07
similar O 0 1.553133301968046e-06
haplotypes O 0 2.7875785235664807e-05
, O 0 2.337586835210459e-07
indicating O 0 7.505785788453068e-07
that O 0 6.50382503408764e-08
the O 0 1.570708576537072e-07
mutant O 0 6.8652416302938946e-06
alleles O 0 2.4531980216124794e-06
were O 0 1.8770397502976266e-07
likely O 0 3.1174465675576357e-07
to O 0 9.925700794610748e-08
be O 0 5.209748010770454e-08
identical O 0 3.917521951279923e-07
by O 0 1.308906121266773e-07
descent O 0 1.1490993756524404e-06
for O 0 1.947168044580394e-07
a O 0 2.1795283373649e-06
mutation O 0 9.8557202363736e-06
in O 0 5.850297384313308e-07
the O 0 1.5424258208440733e-06
founder O 0 5.025171412853524e-05
population O 0 7.294173883565236e-06
. O 0 1.5502801034017466e-05

The O 0 1.7649323126534e-05
identification O 0 1.1587069820961915e-05
of O 0 1.7801764897740213e-06
common O 0 8.160880497598555e-06
BRCA1 O 0 0.0009127475786954165
and O 0 1.538010656076949e-05
BRCA2 O 0 0.12701597809791565
mutations O 0 4.8306195822078735e-05
will O 0 5.330506951395364e-07
facilitate O 0 2.0600305106199812e-06
carrier O 0 1.7709138774080202e-05
detection O 0 5.013195277570048e-06
in O 0 1.1009568652298185e-06
French O 0 1.824677747208625e-05
Canadian O 0 0.008985789492726326
breast B-Disease 1 0.9999909400939941
cancer I-Disease 1 0.9999645948410034
and O 1 0.8576964735984802
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 0.0001250138011528179
. O 0 7.534435280831531e-05

Are O 0 6.0814203607151285e-05
Dp71 O 0 0.0009663182427175343
and O 0 2.522318209230434e-05
Dp140 O 0 0.0021199521142989397
brain O 0 0.18579956889152527
dystrophin O 0 0.003548441920429468
isoforms O 0 0.00018668212578631938
related O 0 4.599184467224404e-05
to O 0 2.3073302145348862e-05
cognitive B-Disease 0 0.03738252818584442
impairment I-Disease 1 0.9855939745903015
in O 0 0.008907965384423733
Duchenne B-Disease 1 0.9999998807907104
muscular I-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999997615814209
? O 0 0.0028332918882369995

Molecular O 0 0.0008744475780986249
study O 0 6.380991544574499e-05
and O 0 6.6015359152515884e-06
neuropsychological O 0 0.004984825849533081
analysis O 0 3.804201469392865e-06
were O 0 7.659753009647829e-07
performed O 0 1.2337821999608423e-06
concurrently O 0 2.576527776909643e-06
on O 0 3.5732334708882263e-06
49 O 0 3.9256876334547997e-05
patients O 0 0.0001888663973659277
with O 0 6.75766495987773e-05
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.003545062616467476
DMD B-Disease 1 0.9999998807907104
) O 0 2.471896323186229e-06
in O 0 2.846339555162558e-07
order O 0 2.935728957709216e-07
to O 0 1.6324872831319226e-07
find O 0 2.7148880121785623e-07
a O 0 2.5560746053088224e-07
molecular O 0 1.755278844939312e-06
explanation O 0 9.667276117397705e-07
for O 0 2.6569594524517015e-07
the O 0 2.521914893804933e-06
cognitive B-Disease 0 0.0037163463421165943
impairment I-Disease 0 0.03285118192434311
observed O 0 1.7181739167426713e-05
in O 0 7.157534582802327e-06
most O 0 6.518643203889951e-05
DMD B-Disease 1 1.0
patients O 1 0.9906256198883057
. O 0 8.927701856009662e-05

Complete O 0 6.798761751269922e-05
analysis O 0 1.242869439010974e-05
of O 0 8.863243010637234e-07
the O 0 1.2395481689964072e-06
dystrophin O 0 0.003914886619895697
gene O 0 2.6485287889954634e-05
was O 0 2.330820507268072e-06
performed O 0 9.187021987600019e-07
to O 0 1.993089284724192e-07
define O 0 4.278275866909098e-07
the O 0 1.7545310981859075e-07
localization O 0 1.4390298019861802e-06
of O 0 1.713902264555145e-07
deletions O 0 4.124952738493448e-06
and O 0 3.0011543117325346e-07
duplications O 0 4.4671774048765656e-06
in O 0 4.517510205914732e-07
relation O 0 1.2334105576883303e-06
to O 0 6.632745339629764e-07
the O 0 1.9070020016442868e-06
different O 0 1.0272081453877036e-05
DMD B-Disease 1 0.9999953508377075
promoters O 0 0.0007295512477867305
. O 0 5.651625542668626e-05

Qualitative O 0 0.00029481007368303835
analysis O 0 2.0268325897632167e-05
of O 0 1.2102764230803587e-06
the O 0 1.4071566738493857e-06
Dp71 O 0 0.0001236956741195172
transcript O 0 3.137713065370917e-05
and O 0 5.957201665296452e-07
testing O 0 1.0845457154573523e-06
for O 0 8.692942543575555e-08
the O 0 1.1472079819441205e-07
specific O 0 2.143470680948667e-07
first O 0 3.0635590064775897e-07
exon O 0 3.1051260975800687e-06
of O 0 1.634250708093532e-07
Dp140 O 0 7.480127351300325e-06
were O 0 3.1806126798983314e-07
also O 0 4.104404354166036e-07
carried O 0 3.195094905095175e-06
out O 0 3.9862588891992345e-06
. O 0 1.727125527395401e-05

Neuropsychological O 0 0.23217377066612244
analysis O 0 0.0002027490409091115
assessed O 0 7.777277642162517e-05
verbal O 0 3.521721009747125e-05
and O 0 6.250419119169237e-06
visuospatial O 0 0.000548795098438859
intelligence O 0 4.084877946297638e-05
, O 0 1.321052195635275e-06
verbal O 0 9.442700502404477e-06
memory O 0 7.299774006241933e-05
, O 0 9.138838095168467e-07
and O 0 1.055956317941309e-06
reading O 0 9.103833690460306e-06
skills O 0 2.6995907319360413e-05
. O 0 2.8074187866877764e-05

Comparison O 0 5.974002488073893e-05
of O 0 4.913503744319314e-06
molecular O 0 2.851184763130732e-05
and O 0 2.802397830237169e-06
psychometric O 0 0.00039597568684257567
findings O 0 7.265362364705652e-05
demonstrated O 0 5.98987799094175e-06
that O 0 2.635750036006357e-07
deletions O 0 5.038473773311125e-06
and O 0 2.7684026804308814e-07
duplications O 0 3.707949645104236e-06
that O 0 1.6065773422724305e-07
were O 0 2.3185397424185794e-07
localized O 0 3.1219024094752967e-06
in O 0 2.3276720639842097e-07
the O 0 3.380147290954483e-07
distal O 0 2.2523265215568244e-05
part O 0 4.6039573931011546e-07
of O 0 1.2704273899544205e-07
the O 0 4.341498254234466e-07
gene O 0 3.276802544860402e-06
seemed O 0 9.855577900452772e-07
to O 0 2.0223917829298443e-07
be O 0 2.0783734555607225e-07
preferentially O 0 5.121830326970667e-06
associated O 0 2.572098765085684e-06
with O 0 4.110611826035893e-06
cognitive B-Disease 0 0.014776824042201042
impairment I-Disease 0 0.2713606655597687
. O 0 5.153894380782731e-05

Two O 0 4.240106500219554e-05
altered O 0 0.0002479053509887308
Dp71 O 0 0.00028283841675147414
transcripts O 0 2.7862708520842716e-05
and O 0 9.855257303570397e-07
two O 0 4.477971060623531e-07
deleted O 0 5.6550911722297315e-06
Dp140 O 0 1.2141100341978017e-05
DNA O 0 3.1668489555158885e-06
sequences O 0 1.6725413161111646e-06
were O 0 3.1604903938386997e-07
found O 0 3.4755350952764275e-07
in O 0 4.247987135386211e-07
four O 0 3.154939122396172e-06
patients O 0 0.0008228413644246757
with O 0 0.0002568724739830941
severe O 1 0.9999998807907104
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 0.9999942779541016
. O 0 0.00024764641420915723

These O 0 4.401058686198667e-05
findings O 0 5.635555135086179e-05
suggest O 0 4.3928266677539796e-06
that O 0 2.4338791604350263e-07
some O 0 1.0556829010965885e-07
sequences O 0 3.8694156501151156e-07
located O 0 2.8965723686269484e-07
in O 0 9.936061928783602e-08
the O 0 1.3594203096545243e-07
distal O 0 6.767243121430511e-06
part O 0 2.0120285171287833e-07
of O 0 5.244872980370019e-08
the O 0 1.9363315573173168e-07
gene O 0 9.085932219932147e-07
and O 0 1.1561085955236194e-07
, O 0 6.366870763940824e-08
in O 0 8.718330946066999e-08
particular O 0 1.484297342813079e-07
, O 0 1.3232444473487703e-07
some O 0 2.1209285705481307e-07
DMD B-Disease 1 0.999680757522583
isoforms O 0 1.2135450560890604e-05
expressed O 0 9.272073953070503e-07
in O 0 2.5493383759567223e-07
the O 0 1.7809422843129141e-06
brain O 1 0.9211812615394592
may O 0 8.82921176525997e-06
be O 0 1.8354477049342677e-07
related O 0 3.9801474827072525e-07
to O 0 2.704855432966724e-07
the O 0 1.356130496787955e-06
cognitive B-Disease 0 0.006246318109333515
impairment I-Disease 1 0.5058364868164062
associated O 0 4.33724453614559e-05
with O 0 3.568931788322516e-05
DMD B-Disease 1 0.9999998807907104
. O 0 2.8466856747400016e-05
. O 0 4.3088235543109477e-05

I1307K O 0 0.010210764594376087
APC O 0 0.02267218381166458
and O 0 4.5097807742422447e-05
hMLH1 O 0 0.004117821343243122
mutations O 0 0.00026521895779296756
in O 0 1.6833666904858546e-06
a O 0 1.4389941043191357e-06
non O 0 2.554720140324207e-06
- O 0 6.288702934398316e-06
Jewish O 0 1.6749868336773943e-06
family O 0 2.4373196083615767e-06
with O 0 2.0643080915760947e-06
hereditary B-Disease 1 0.907341480255127
non I-Disease 0 0.1183210164308548
- I-Disease 1 0.9999994039535522
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0003564309445209801

We O 0 2.1158075469429605e-05
describe O 0 1.769762639014516e-05
a O 0 5.911044809181476e-06
French O 0 2.068329558824189e-05
Canadian O 0 8.0321122368332e-05
hereditary B-Disease 1 0.9664259552955627
non I-Disease 0 0.2207067459821701
- I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.02561156079173088
HNPCC B-Disease 1 0.9999244213104248
) O 0 8.227271791838575e-06
kindred O 0 0.00020904526172671467
which O 0 1.002977796815685e-06
carries O 0 2.756342155407765e-06
a O 0 3.443365812927368e-06
novel O 0 1.9156628695782274e-05
truncating O 0 0.0005172098753973842
mutation O 0 0.0001429707044735551
in O 0 1.758524012984708e-05
hMLH1 O 0 0.0009212966542690992
. O 0 7.355702837230638e-05

Interestingly O 0 0.0003604210796765983
, O 0 6.5211170294787735e-06
the O 0 2.3481268272007583e-06
I1307K O 0 0.0001343035401077941
APC O 0 0.00030065016471780837
polymorphism O 0 3.0927854822948575e-05
, O 0 4.777488697982335e-07
associated O 0 4.376333606614935e-07
with O 0 7.412146629803829e-08
an O 0 2.3214626310164022e-07
increased O 0 7.617147730343277e-06
risk O 0 2.321035208296962e-05
of O 0 0.001202985062263906
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 2.0992806639696937e-06
is O 0 1.4757452504454704e-07
also O 0 1.8369534870998905e-07
present O 0 2.4618222482786223e-07
in O 0 3.718860455137474e-07
this O 0 1.0234065257463953e-06
family O 0 1.3022804523643572e-05
. O 0 1.2356661500234623e-05

The O 0 4.13644993386697e-05
I1307K O 0 0.0005587829509750009
polymorphism O 0 0.00038166448939591646
has O 0 4.224887561576907e-06
previously O 0 1.7432193999411538e-06
only O 0 1.4811978132911463e-07
been O 0 2.1575458220013388e-07
identified O 0 4.6058809743954043e-07
in O 0 1.2843268848428124e-07
individuals O 0 1.0945419148811197e-07
of O 0 2.3498422763168492e-07
self O 0 8.126489410642534e-05
- O 0 0.03228169307112694
reported O 0 0.0002554417587816715
Ashkenazi O 0 0.00015746448480058461
Jewish O 0 2.8485539587563835e-05
origins O 0 0.0001064510943251662
. O 0 3.897148781106807e-05

In O 0 2.0905377823510207e-05
addition O 0 3.0775609047850594e-06
, O 0 4.048837354275747e-07
in O 0 2.999237267431454e-07
this O 0 2.296319081551701e-07
family O 0 2.411625018794439e-06
, O 0 1.5599394487253448e-07
there O 0 8.590192379642758e-08
appears O 0 8.102819606392586e-07
to O 0 1.0974225261861648e-07
be O 0 7.095270149193311e-08
no O 0 7.713649097240705e-08
relationship O 0 1.8874382590183814e-07
between O 0 1.0469361910736552e-07
the O 0 1.4981617368903244e-07
I1307K O 0 4.276601430319715e-06
polymorphism O 0 2.06653976420057e-06
and O 0 9.323407823558227e-08
the O 0 1.3784047325771098e-07
presence O 0 5.166505161469104e-07
or O 0 3.597156137402635e-07
absence O 0 1.8895307221100666e-06
of O 0 1.3717209412789089e-06
cancer B-Disease 1 0.591031014919281
. O 0 6.129754183348268e-06
. O 0 2.3022113964543678e-05

Identification O 0 6.84085171087645e-05
of O 0 4.905899459117791e-06
a O 0 6.621629836445209e-06
novel O 0 1.1582772458496038e-05
mutation O 0 1.0618513442750555e-05
of O 0 5.367735980144062e-07
the O 0 9.313718578596308e-07
CPO O 0 8.096786768874153e-05
gene O 0 5.294846232573036e-06
in O 0 4.4389133790900814e-07
a O 0 1.1812712727987673e-06
Japanese O 0 1.0688137081160676e-05
hereditary B-Disease 0 0.28609198331832886
coproporphyria I-Disease 0 0.05752507969737053
family O 0 0.00017003898392431438
. O 0 3.8270656659733504e-05

Hereditary B-Disease 1 0.9987131357192993
coproporphyria I-Disease 1 0.9915347695350647
( O 0 0.0006826124736107886
HCP B-Disease 1 0.9657094478607178
) O 0 7.85769589128904e-06
is O 0 9.833458989305655e-07
an O 0 3.243460696467082e-06
autosomal B-Disease 1 0.8510197401046753
dominant I-Disease 1 0.7761314511299133
disease I-Disease 1 0.9207608103752136
characterized O 0 0.00014578316768165678
by O 0 5.273509941616794e-06
a O 0 0.0012988835806027055
deficiency B-Disease 0 0.34151124954223633
of I-Disease 0 8.627002330285904e-07
coproporphyrinogen I-Disease 0 0.010163361206650734
oxidase I-Disease 0 0.0001816905860323459
( O 0 3.156949560434441e-06
CPO O 0 3.645085962489247e-05
) O 0 4.1389355942555994e-07
caused O 0 8.587215916122659e-07
by O 0 1.6085964205103664e-07
a O 0 7.492597546843172e-07
mutation O 0 5.989952114759944e-06
in O 0 6.812491051277902e-07
the O 0 2.6748375603347085e-06
CPO O 0 0.0002573956153355539
gene O 0 7.760016160318628e-05
. O 0 2.296319325978402e-05

Only O 0 1.4639452274423093e-05
11 O 0 1.1071416338381823e-05
mutations O 0 1.5125238860491663e-05
of O 0 3.1424963253812166e-07
the O 0 7.414903393510031e-07
gene O 0 5.514686108654132e-06
have O 0 5.568344931816682e-07
been O 0 1.5783620028742007e-06
reported O 0 7.711867510806769e-05
in O 0 4.150247696088627e-05
HCP B-Disease 1 0.999843955039978
patients O 0 0.09553640335798264
. O 0 6.987337110331282e-05

We O 0 2.856987703125924e-05
report O 0 2.992877307406161e-05
another O 0 4.690896275860723e-06
mutation O 0 1.9392049580346793e-05
in O 0 1.2500304364948533e-06
a O 0 2.5563090275682043e-06
Japanese O 0 1.63956774485996e-05
family O 0 6.333124474622309e-05
. O 0 3.5461471270537004e-05

Polymerase O 0 0.002892197808250785
chain O 0 0.0028957342728972435
reaction O 0 0.00025434864801354706
- O 0 9.005793981486931e-05
single O 0 8.359349521924742e-06
strand O 0 4.132687899982557e-05
conformational O 0 5.6308494094992056e-05
polymorphism O 0 3.0947117920732126e-05
and O 0 8.709935173101258e-07
direct O 0 1.4466749007624458e-06
sequence O 0 1.6266251350316452e-06
analyses O 0 2.5458282379986485e-06
demonstrated O 0 2.21737946048961e-06
a O 0 2.059409780486021e-06
C O 0 4.0009283111430705e-05
to O 0 8.349147151420766e-07
T O 0 3.0007648092578165e-05
substitution O 0 1.3748667697655037e-06
in O 0 3.3400124266336206e-07
exon O 0 3.74532305613684e-06
1 O 0 1.9801586859102827e-07
of O 0 6.328334478666875e-08
the O 0 3.0151079499773914e-07
CPO O 0 1.9594979676185176e-05
gene O 0 2.1955042939225677e-06
at O 0 2.8275636054786446e-07
nucleotide O 0 9.228873523170478e-07
position O 0 4.317747936966043e-07
85 O 0 5.849081503583875e-07
, O 0 1.0702927966121933e-07
which O 0 9.473175310859006e-08
lies O 0 2.5557895355632354e-07
in O 0 1.4197478037658584e-07
the O 0 2.9384909794316627e-07
putative O 0 8.438855729764327e-06
presequence O 0 1.2628798685909715e-05
for O 0 4.5939970050312695e-07
targeting O 0 5.669411621056497e-06
to O 0 2.8517513328552013e-06
mitochondria O 0 0.00016318858251906931
. O 0 3.365984230185859e-05

This O 0 5.369443169911392e-05
mutation O 0 0.00012686895206570625
changes O 0 8.976551725936588e-06
the O 0 1.1593562021516846e-06
codon O 0 1.2078690815542359e-05
for O 0 4.934231014885881e-07
glutamine O 0 1.4507932064589113e-05
to O 0 9.682398740551434e-07
a O 0 2.7031016998080304e-06
termination O 0 2.576535553089343e-05
codon O 0 2.2249851099331863e-05
at O 0 1.8171164128943929e-06
amino O 0 7.27466704120161e-06
acid O 0 1.2943080946570262e-05
position O 0 1.1320094017719384e-05
29 O 0 2.7812639018520713e-05
. O 0 2.158031020371709e-05

MaeI O 0 0.0063184406608343124
restriction O 0 0.0002570299548096955
analysis O 0 2.3199243514682166e-05
showed O 0 6.904756446601823e-06
two O 0 5.571138785853691e-07
other O 0 3.144469076232781e-07
carriers O 0 2.5468141302553704e-06
in O 0 6.584236871276516e-07
the O 0 2.0140071228524903e-06
family O 0 3.026757804036606e-05
. O 0 2.047132329607848e-05

The O 0 0.00010221695993095636
C O 0 0.3742307126522064
- O 1 0.6849470138549805
T O 0 0.2426055520772934
mutation O 0 2.2230404283618554e-05
is O 0 3.213952197711478e-07
located O 0 5.844397605869744e-07
within O 0 2.9582551519524714e-07
a O 0 6.426630534406286e-07
recently O 0 6.409763955161907e-06
proposed O 0 4.57769829154131e-06
putative O 0 1.717733175610192e-05
alternative O 0 2.954884166683769e-06
translation O 0 5.958422661933582e-06
initiation O 0 8.200027878046967e-06
codon O 0 2.7830177714349702e-05
( O 0 6.042494987923419e-06
TIC O 0 0.0002296835882589221
- O 0 5.859639259142568e-06
1 O 0 3.464594442448288e-07
) O 0 1.5034100897537428e-07
, O 0 7.215697195306348e-08
supporting O 0 3.670696742119617e-07
that O 0 3.2185161558118125e-07
TIC O 0 0.0005658306763507426
- O 0 1.0458885299158283e-05
1 O 0 3.264315466822154e-07
is O 0 1.0696152230593725e-07
the O 0 2.2621628659180715e-07
real O 0 1.2512208513726364e-06
TIC O 0 5.659288581227884e-05
rather O 0 6.559311600540241e-07
than O 0 6.484971208919887e-07
TIC O 0 0.0002801901428028941
- O 0 1.8510801965021528e-05
2 O 0 2.215153926954372e-06
. O 0 2.4275977921206504e-06
. O 0 9.987998964788858e-06

Human B-Disease 0 0.00044851264101453125
complement I-Disease 0 0.0008216363494284451
factor I-Disease 0 0.05368375778198242
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999966621398926
associated O 0 0.013708606362342834
with O 1 0.7645702362060547
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0011828114511445165

This O 0 2.198554648202844e-05
study O 0 1.2476599295041524e-05
reports O 0 5.981674803479109e-06
on O 0 9.294640790358244e-07
six O 0 1.071555630005605e-06
cases O 0 1.4645154351455858e-06
of O 0 3.7985676044627326e-06
deficiency B-Disease 1 0.8580237030982971
in I-Disease 0 3.57383953542012e-07
the I-Disease 0 3.9660901052229747e-07
human I-Disease 0 1.0377052603871562e-06
complement I-Disease 0 3.4482984574424336e-06
regulatory I-Disease 0 1.887662619992625e-05
protein I-Disease 0 8.51013737701578e-06
Factor I-Disease 0 1.0164635568798985e-05
H I-Disease 1 0.8402443528175354
( O 0 6.337796094157966e-06
FH O 0 0.006384738255292177
) O 0 3.503849939079373e-07
in O 0 1.4157983230234095e-07
the O 0 1.2689912409769022e-07
context O 0 2.9945843493806024e-07
of O 0 3.6878938658446714e-07
an O 0 0.0007511968724429607
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.00033807833096943796

Five O 0 2.3212211090140045e-05
of O 0 2.2137537598609924e-06
the O 0 1.633750230212172e-06
cases O 0 1.939103185577551e-06
were O 0 7.031116524558456e-07
observed O 0 3.4340587262704503e-06
in O 0 1.246019451173197e-06
children O 0 3.29664658238471e-06
presenting O 0 9.161482012132183e-05
with O 1 0.8708028197288513
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.008758891373872757
HUS B-Disease 1 0.9999852180480957
) O 0 5.648802107316442e-05
. O 0 4.769055885844864e-05

Two O 0 1.2007930308755022e-05
of O 0 1.6425786952822818e-06
the O 0 1.4415792293220875e-06
children O 0 3.9556261981488205e-06
exhibited O 0 0.00017457894864492118
a O 0 0.005159261170774698
homozygous O 1 0.9999771118164062
deficiency O 1 0.9992884397506714
characterized O 0 1.6109441276057623e-05
by O 0 2.6155748855671845e-07
the O 0 2.1182299292377138e-07
absence O 0 4.814550038645393e-07
of O 0 4.584031643162234e-08
the O 0 1.5043495693589648e-07
150 O 0 8.489503784403496e-07
- O 0 1.7064281564671546e-05
kD O 0 1.7569520423421636e-05
form O 0 3.038535396626685e-07
of O 0 1.2868795806753042e-07
Factor O 0 1.0978952786899754e-06
H O 0 0.0043665762059390545
and O 0 7.157428427717605e-08
the O 0 1.0395658733841628e-07
presence O 0 2.861245889107522e-07
, O 0 9.078156892883271e-08
upon O 0 2.411518380540656e-07
immunoblotting O 0 1.1236073078180198e-05
, O 0 6.187801915302771e-08
of O 0 3.01830098692335e-08
the O 0 1.6981643113922473e-07
42 O 0 3.563160817066091e-06
- O 0 0.0001477602490922436
kD O 0 0.0009658432682044804
Factor O 0 6.7182186285208445e-06
H O 0 0.14469148218631744
- O 0 7.899124284449499e-06
like O 0 4.470478245366394e-07
protein O 0 9.015964224090567e-07
1 O 0 6.152415039650805e-07
( O 0 1.372547899336496e-06
FHL O 0 0.00024659253540448844
- O 0 4.834153969568433e-06
1 O 0 3.179205521064432e-07
) O 0 1.976566466055374e-07
and O 0 1.5194717661870527e-07
other O 0 5.48989987692039e-07
FH O 0 0.4478411376476288
- O 0 7.129245932446793e-05
related O 0 4.746679223899264e-06
protein O 0 3.142033847325365e-06
( O 0 1.846240479608241e-06
FHR O 0 5.9140096709597856e-05
) O 0 3.3715780318743782e-06
bands O 0 1.357004566671094e-05
. O 0 1.651768252486363e-05

Southern O 0 0.0003172095166519284
blot O 0 0.005409675650298595
and O 0 1.1149441888846923e-05
PCR O 0 8.599261491326615e-05
analysis O 0 2.751152806013124e-06
of O 0 3.105180326201662e-07
DNA O 0 1.2633945516427048e-06
of O 0 1.8857848260722676e-07
one O 0 6.171749191707931e-07
patient O 0 0.00024444059818051755
with O 0 6.976397708058357e-05
homozygous O 1 0.9999769926071167
deficiency O 1 0.9964256882667542
ruled O 0 3.4540710203145863e-06
out O 0 1.1748232253694368e-07
the O 0 6.468935964676348e-08
presence O 0 1.0888137325082425e-07
of O 0 3.207527399240462e-08
a O 0 1.5810300624252704e-07
large O 0 1.8645845045739406e-07
deletion O 0 3.0522458018822363e-06
of O 0 1.1977820690844965e-07
the O 0 1.1813817764050327e-06
FH O 1 0.5782874822616577
gene O 0 3.352596877448377e-06
as O 0 1.586293478794687e-07
the O 0 3.9052980582710006e-07
underlying O 0 3.570017724996433e-05
defect O 0 0.00010658415703801438
for O 0 1.7032472214850713e-06
the O 0 6.740506796631962e-05
deficiency O 1 0.9616147875785828
. O 0 4.110582813154906e-05

The O 0 9.925774975272361e-06
other O 0 1.1674467259581434e-06
four O 0 7.778120334478444e-07
children O 0 8.58180442264711e-07
presented O 0 2.3715454062767094e-06
with O 0 1.5080531738931313e-05
heterozygous O 1 0.9995436072349548
deficiency O 1 0.9950024485588074
and O 0 1.5869592289163847e-06
exhibited O 0 2.3500613679061644e-05
a O 0 1.981461309696897e-06
normal O 0 5.593703008344164e-06
immunoblotting O 0 0.0001341469178441912
pattern O 0 2.2469837404059945e-06
of O 0 1.6752858300606022e-07
proteins O 0 6.356108315230813e-07
of O 0 2.898727586853056e-07
the O 0 3.2587090572633315e-06
FH O 1 0.8063444495201111
family O 0 6.83201797073707e-05
. O 0 4.05866012442857e-05

Factor B-Disease 1 0.9799679517745972
H I-Disease 1 1.0
deficiency I-Disease 1 0.9998295307159424
is O 0 2.0371353457449004e-06
the O 0 1.5605688759023906e-06
only O 0 4.106211235921364e-06
complement B-Disease 1 0.9988570213317871
deficiency I-Disease 1 0.9999998807907104
associated O 0 5.9470599808264524e-05
with O 0 3.612211730796844e-05
HUS B-Disease 1 0.9999715089797974
. O 0 0.00011910816829185933

These O 0 1.4327499229693785e-05
observations O 0 2.9330663892324083e-05
suggest O 0 6.647343070653733e-06
a O 0 1.4881570677971467e-06
role O 0 2.403022790531395e-06
for O 0 2.1234229734545806e-06
FH O 1 0.7562122344970703
and O 0 6.880697128508473e-06
/ O 0 0.0036756161134690046
or O 0 4.712449481303338e-06
FH O 0 0.18822351098060608
receptors O 0 2.2499050828628242e-05
in O 0 8.567853342356102e-07
the O 0 1.5627252878402942e-06
pathogenesis O 0 0.0002547155600041151
of O 0 1.2142755622335244e-05
idiopathic O 1 0.9999979734420776
HUS B-Disease 1 0.9999990463256836
. O 0 2.7937448976445012e-05
. O 0 4.885657472186722e-05

Further O 0 3.9505983295384794e-05
evidence O 0 6.039102117938455e-06
for O 0 6.16942998021841e-07
a O 0 9.894529284792952e-07
major O 0 2.0048585156473564e-06
ancient O 0 1.0896072126342915e-05
mutation O 0 0.010870191268622875
underlying O 1 0.5904859304428101
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 2.1950641894363798e-05
linkage O 0 0.0018837765092030168
disequilibrium O 0 0.07295620441436768
studies O 0 6.725988441758091e-06
in O 0 1.2073356856490136e-06
the O 0 1.2359668062345008e-06
Japanese O 0 1.0473418114997912e-05
population O 0 1.522404909337638e-05
. O 0 2.224868512712419e-05

The O 0 0.00725708669051528
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.987071692943573
DM B-Disease 1 1.0
) O 0 5.218598380452022e-05
mutation O 0 5.999784843879752e-05
is O 0 5.884834308744757e-07
an O 0 9.582929578755284e-07
unstable O 0 0.00020339572802186012
( O 0 2.9791788165312028e-06
CTG O 0 0.00010155600466532633
) O 0 5.687329576176126e-07
n O 0 2.1697562715417007e-06
repeat O 0 1.66597646966693e-06
, O 0 7.920737488120722e-08
present O 0 1.4445473084379046e-07
at O 0 1.1945456890316564e-07
a O 0 1.7598115675809822e-07
copy O 0 4.85766804558807e-07
number O 0 3.82763332140712e-08
of O 0 5.526213442408334e-08
5 O 0 4.3431467133814294e-07
- O 0 4.0354325392399915e-06
37 O 0 7.771350851726311e-07
repeats O 0 2.379948909947416e-06
on O 0 4.068054124672926e-07
normal O 0 1.4826916867605178e-06
chromosomes O 0 2.018050281549222e-06
but O 0 2.423939235995931e-07
amplified O 0 3.637996769612073e-06
to O 0 2.82124176465004e-07
50 O 0 6.64154356400104e-07
- O 0 3.81812924388214e-06
3000 O 0 6.501760708488291e-06
copies O 0 2.927653667939012e-06
on O 0 1.9292130673420615e-05
DM B-Disease 1 0.9999977350234985
chromosomes O 0 0.00020546323503367603
. O 0 3.5825782106257975e-05

Previous O 0 0.0002710631233640015
findings O 0 0.00013749550271313637
in O 0 8.678620361024514e-06
Caucasian O 0 3.69555018551182e-05
populations O 0 6.329019925033208e-06
of O 0 8.789288585830946e-07
a O 0 4.698714110418223e-05
DM B-Disease 1 1.0
founder O 0 0.014229788444936275
chromosome O 0 2.625603519845754e-05
raise O 0 2.1317621303751366e-06
a O 0 6.612257266169763e-07
question O 0 3.8840116189930995e-07
about O 0 1.4432873740588548e-07
the O 0 2.9360145958889916e-07
molecular O 0 2.0905617930111475e-06
events O 0 5.380687184697308e-07
involved O 0 4.6193505909286614e-07
in O 0 3.865978044359508e-07
the O 0 1.7488274579591234e-06
expansion O 0 6.362312706187367e-05
mutation O 0 0.00019374556723050773
. O 0 2.9538832677644677e-05

To O 0 3.5722547181649134e-05
investigate O 0 5.0403807108523324e-05
whether O 0 4.219130005367333e-06
a O 0 2.2855247152619995e-06
founder O 0 2.1577347069978714e-05
chromosome O 0 8.200216143450234e-06
for O 0 4.847200330004853e-07
the O 0 6.816502263973234e-06
DM B-Disease 1 1.0
mutation O 0 5.160651926416904e-05
exists O 0 4.5570510565084987e-07
in O 0 1.0227775959492647e-07
the O 0 6.822660481020648e-08
Japanese O 0 3.837498923076055e-07
population O 0 2.578120472662704e-07
, O 0 1.3285031741361308e-07
we O 0 1.2555246087231353e-07
genotyped O 0 2.2490125047625042e-05
families O 0 8.084772957772657e-07
using O 0 9.523337212158367e-07
polymorphic O 0 2.609189505164977e-05
markers O 0 3.5889161154045723e-06
near O 0 2.5667593490652507e-06
the O 0 1.0790818123496138e-06
( O 0 2.7972021143796155e-06
CTG O 0 0.00015407809405587614
) O 0 1.982251433219062e-06
n O 0 4.343608452472836e-06
repeat O 0 5.437971594801638e-06
region O 0 3.0730093385500368e-06
and O 0 1.7937931033884524e-06
constructed O 0 5.1172621169826016e-05
haplotypes O 0 0.0007806742796674371
. O 0 4.896613609162159e-05

Six O 0 3.250470763305202e-05
different O 0 5.269236680760514e-06
haplotypes O 0 8.39180574985221e-05
were O 0 1.9526089545252034e-06
found O 0 2.4501910047547426e-06
and O 0 7.373942480626283e-06
DM B-Disease 1 1.0
alleles O 0 0.00013900359044782817
were O 0 2.2084145712142345e-06
always O 0 4.202737272862578e-06
haplotype O 0 0.0004609382012858987
A O 0 3.770067633013241e-05
. O 0 4.0201506635639817e-05

To O 0 2.2084730517235585e-05
find O 0 4.544726380117936e-06
an O 0 4.059853040416783e-07
origin O 0 4.6688390398230695e-07
of O 0 1.2955658235114242e-07
the O 0 5.632994088955456e-07
( O 0 1.5043610801512841e-06
CTG O 0 9.189735283143818e-05
) O 0 4.920556762044725e-07
n O 0 1.9995634374936344e-06
repeat O 0 2.154165031242883e-06
mutation O 0 1.994394779103459e-06
and O 0 7.947553370968308e-08
to O 0 1.0040595554983156e-07
investigate O 0 7.992273935997218e-07
the O 0 1.0760670932086214e-07
mechanism O 0 2.8150063258181035e-07
of O 0 4.369011108451559e-08
the O 0 1.4935838521523692e-07
expansion O 0 2.1819741959916428e-06
mutation O 0 2.3699788016529055e-06
in O 0 1.4181753726916213e-07
the O 0 1.4353152266721736e-07
Japanese O 0 6.091154887144512e-07
population O 0 2.007003701010035e-07
we O 0 7.357593290180375e-08
have O 0 9.606237227899328e-08
studied O 0 5.080830760562094e-07
90 O 0 6.303782811301062e-07
Japanese O 0 1.4635654224548489e-05
DM B-Disease 1 0.9999995231628418
families O 0 1.3690563491763896e-06
comprising O 0 9.634712796469103e-07
190 O 0 2.8267754714761395e-06
affected O 0 2.4553044113417855e-06
and O 0 7.562489940937667e-07
130 O 0 8.012001671886537e-06
unaffected O 0 9.674207831267267e-05
members O 0 9.593760296411347e-06
. O 0 2.1524894691538066e-05

The O 0 3.788469621213153e-05
results O 0 3.5983732232125476e-05
suggest O 0 4.553316557576181e-06
that O 0 3.0063134204283415e-07
a O 0 3.576768108359829e-07
few O 0 3.3350147532473784e-07
common O 0 6.822712634857453e-07
ancestral O 0 3.415677565499209e-05
mutations O 0 9.743574082676787e-06
in O 0 2.611064076063485e-07
both O 0 2.0094473995868611e-07
Caucasian O 0 1.9763281216000905e-06
and O 0 1.9415774943354336e-07
Japanese O 0 6.34460150195082e-07
populations O 0 6.917318273735873e-07
have O 0 8.387471694959459e-08
originated O 0 3.662119922864804e-07
by O 0 9.263389699754043e-08
expansion O 0 5.690291686732962e-07
of O 0 6.973753130523619e-08
an O 0 2.589766268101812e-07
ancestral O 0 1.181604056910146e-05
n O 0 1.12136567622656e-05
= O 0 5.447460353025235e-06
5 O 0 7.084573212523537e-07
repeat O 0 3.327299737065914e-06
to O 0 6.661239240202121e-07
n O 0 8.285775038530119e-06
= O 0 6.919574843777809e-06
19 O 0 3.074082087550778e-06
- O 0 6.842293714726111e-06
37 O 0 4.1756502469070256e-06
copies O 0 7.227925834740745e-06
. O 0 1.5868012269493192e-05

These O 0 1.9597389837144874e-05
data O 0 9.149528523266781e-06
support O 0 3.885422302118968e-06
multistep O 0 3.711698445840739e-05
models O 0 3.357729156050482e-06
of O 0 4.900494445791992e-07
triplet O 0 0.00012709999282378703
repeat O 0 7.923206794657744e-06
expansion O 0 2.5036449642357184e-06
that O 0 2.332411810357371e-07
have O 0 1.3449120217501331e-07
been O 0 1.8540802670941048e-07
proposed O 0 6.993146257627814e-07
for O 0 4.651018343793112e-07
both O 0 5.192107892071363e-06
DM B-Disease 1 0.9999998807907104
and O 0 3.5561679396778345e-05
Friedreichs B-Disease 1 0.8364505767822266
ataxia I-Disease 1 0.9994294047355652
. O 0 1.6524281818419695e-05
. O 0 2.585253241704777e-05

The O 0 2.107791806338355e-05
molecular O 0 4.195580550003797e-05
basis O 0 5.369935479393462e-06
of O 0 1.3698419024876785e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
in O 0 7.598665661134874e-07
the O 0 3.596624367219192e-07
western O 0 2.1957596345600905e-06
Cape O 0 1.877751674328465e-05
, O 0 8.144841672219627e-07
South O 0 2.969642537209438e-06
Africa O 0 1.0029080840467941e-05
. O 0 1.1207584975636564e-05

Deficiency B-Disease 1 0.977449357509613
of I-Disease 0 2.8652564196818275e-06
the I-Disease 0 1.9886551854142454e-06
sixth I-Disease 0 3.8037733247620054e-06
component I-Disease 0 1.4278011803980917e-06
of I-Disease 0 1.0768186342602348e-07
human I-Disease 0 3.3593775583540264e-07
complement I-Disease 0 1.0053987580249668e-06
( O 0 1.0828930498973932e-06
C6 O 0 0.00015188292309176177
) O 0 4.2857163862208836e-07
has O 0 1.6669395108692697e-07
been O 0 1.7008402153351199e-07
reported O 0 1.4788619182581897e-06
in O 0 6.686450149118173e-08
a O 0 8.740308743426795e-08
number O 0 3.4057251241392805e-08
of O 0 3.4733407261455795e-08
families O 0 1.1542291389332604e-07
from O 0 9.571378001282937e-08
the O 0 1.9829536768156686e-07
western O 0 1.412090227859153e-06
Cape O 0 2.9819826522725634e-05
, O 0 9.283019153372152e-07
South O 0 4.1596090341045056e-06
Africa O 0 1.6313357264152728e-05
. O 0 2.014056190091651e-05

Meningococcal B-Disease 1 0.9999977350234985
disease I-Disease 1 0.9999603033065796
is O 0 2.33299197134329e-05
endemic O 0 0.00010268668847857043
in O 0 1.397221012666705e-06
the O 0 8.841277008286852e-07
Cape O 0 1.8457900296198204e-05
and O 0 2.6496388727537123e-07
almost O 0 1.7708487121126382e-07
all O 0 6.684754083607913e-08
pedigrees O 0 2.2954900487093255e-06
of O 0 4.666079291837377e-07
total O 0 4.377993900561705e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 7.532995368819684e-06
C6Q0 O 0 0.008070934563875198
) O 0 8.45289093831525e-07
have O 0 2.538663750328851e-07
been O 0 3.1661889465794957e-07
ascertained O 0 4.1958091969718225e-06
because O 0 4.820702201868698e-07
of O 0 1.9155197605869034e-06
recurrent O 1 0.9995428323745728
disease O 1 0.9917888045310974
. O 0 5.712289203074761e-05

We O 0 1.428764244337799e-05
have O 0 1.8904570424638223e-06
sequenced O 0 8.418921424890868e-06
the O 0 5.95917924783862e-07
expressed O 0 1.1130478014820255e-06
exons O 0 2.7736482479667757e-06
of O 0 1.3104249774187338e-07
the O 0 6.276225121837342e-07
C6 O 0 0.00023059244267642498
gene O 0 3.633098231148324e-06
from O 0 2.14318660596291e-07
selected O 0 3.048683083761716e-07
cases O 0 1.9100093595625367e-07
and O 0 1.284522852529335e-07
have O 0 1.0360424340660757e-07
found O 0 1.5001303665940213e-07
three O 0 2.3716104635695956e-07
molecular O 0 0.00047072183224372566
defects O 0 0.17391979694366455
leading O 0 9.333066373073962e-07
to O 0 4.6896252570149954e-07
total O 0 2.824124067046796e-06
deficiency O 1 0.6623695492744446
879delG O 0 5.66963353776373e-05
, O 0 2.5031144446074904e-07
which O 0 1.1795721377438895e-07
is O 0 6.310965261491219e-08
the O 0 1.9390185457268672e-07
common O 0 2.57826786764781e-06
defect O 0 3.825785097433254e-05
in O 0 2.3356972178589785e-07
the O 0 2.886463050799648e-07
Cape O 0 9.054584552359302e-06
and O 0 3.4941393778353813e-07
hitherto O 0 4.7256448851840105e-06
unreported O 0 1.7050365386239719e-06
, O 0 9.962572988797547e-08
and O 0 7.892084852301195e-08
1195delC O 0 2.6402783532830654e-06
and O 0 1.7033920585163287e-07
1936delG O 0 8.633985089545604e-06
, O 0 9.566797132265492e-08
which O 0 5.773918232421238e-08
have O 0 4.477134041280806e-08
been O 0 9.57676533630547e-08
previously O 0 5.412255177361658e-07
reported O 0 3.2954867492662743e-06
in O 0 5.595450716100459e-07
African O 0 2.7415774184191832e-06
- O 0 6.515280256280676e-05
Americans O 0 9.169164513878059e-06
. O 0 2.1056181140011176e-05

We O 0 1.5765594071126543e-05
also O 0 2.646282609930495e-06
show O 0 1.7293665450779372e-06
that O 0 2.080164023254838e-07
the O 0 3.8049125805628137e-07
879delG O 0 2.691934787435457e-05
and O 0 2.9798779905831907e-06
1195delC O 1 0.8184297680854797
defects O 1 0.9836317300796509
are O 0 3.1709180348116206e-07
associated O 0 1.1698897424139432e-06
with O 0 4.293120525744598e-07
characteristic O 0 5.084582880954258e-05
C6 O 1 0.8872402310371399
/ O 0 0.03741036355495453
C7 O 0 0.001013164990581572
region O 0 7.970314982230775e-06
DNA O 0 8.691434231877793e-06
marker O 0 1.4379033927980345e-05
haplotypes O 0 2.313618824700825e-05
, O 0 3.961999937018845e-07
although O 0 6.527399136757595e-07
small O 0 6.684148274871404e-07
variations O 0 5.116460670251399e-06
were O 0 2.455323055983172e-06
observed O 0 3.2686522899894044e-05
. O 0 2.36210416915128e-05

The O 0 6.096413198974915e-05
1936delG O 0 0.17623353004455566
defect O 0 0.38542065024375916
was O 0 1.3665510778082535e-05
observed O 0 3.3550597891007783e-06
only O 0 1.9110551363610284e-07
once O 0 3.8930380696911016e-07
in O 0 1.622869376660674e-07
the O 0 3.019171117557562e-07
Cape O 0 1.746271300362423e-05
, O 0 1.8370691634572722e-07
but O 0 1.1758578466469771e-07
its O 0 7.64030971822649e-07
associated O 0 8.927358976507094e-06
haplotype O 0 0.003070023376494646
could O 0 3.551172085280996e-06
be O 0 1.783946004252357e-06
deduced O 0 5.523129948414862e-05
. O 0 2.1185613150009885e-05

The O 0 1.578776937094517e-05
data O 0 7.556905529781943e-06
from O 0 1.0684331073207431e-06
the O 0 7.895644102973165e-07
haplotypes O 0 6.1012982769170776e-05
indicate O 0 3.1791616947884904e-06
that O 0 1.5716361190243333e-07
these O 0 8.895796810293177e-08
three O 0 2.44835689500178e-07
molecular O 0 0.0003592603898141533
defects O 0 0.3874845802783966
account O 0 5.779999696642335e-07
for O 0 2.0332097960817919e-07
the O 0 3.876214123010868e-06
defects O 0 0.47445914149284363
in O 0 1.0507110914659279e-07
all O 0 3.917984514600903e-08
the O 0 1.6042638151247957e-07
38 O 0 1.495526589678775e-06
unrelated O 0 9.833526746660937e-06
C6Q0 O 0 0.018346233293414116
individuals O 0 4.3924902115577424e-07
we O 0 1.371928703974845e-07
have O 0 1.7433660559618147e-07
studied O 0 1.1271372386545409e-06
from O 0 7.798323053975764e-07
the O 0 3.588888830563519e-06
Cape O 0 0.00037732845521532
. O 0 3.126088631688617e-05

We O 0 1.417972998751793e-05
have O 0 1.8383589122095145e-06
also O 0 9.9186775059934e-07
observed O 0 1.6547338645978016e-06
the O 0 7.23917310097022e-07
879delG O 0 0.000336744386004284
defect O 0 8.048366726143286e-05
in O 0 5.885726750420872e-07
two O 0 8.746209800847282e-07
Dutch O 0 0.005483124405145645
C6 B-Disease 1 0.9999997615814209
- I-Disease 1 0.9981744289398193
deficient I-Disease 1 0.9980119466781616
kindreds O 0 4.076449113199487e-05
, O 0 2.8841461130468815e-07
but O 0 1.1329237992185881e-07
the O 0 2.7003912350664905e-07
879delG O 0 9.18705336516723e-05
defect O 0 3.7083864299347624e-05
in O 0 1.5349144177889684e-07
the O 0 3.175929634835484e-07
Cape O 0 7.017867756076157e-05
probably O 0 2.3080835944710998e-06
did O 0 2.825304648013116e-07
not O 0 7.12829972826512e-08
come O 0 1.735491537147027e-07
from O 0 2.083499452965043e-07
The O 0 5.409473828876799e-07
Netherlands O 0 1.0509878848097287e-05
. O 0 2.9473640097421594e-06
. O 0 1.3765614312433172e-05

Complement B-Disease 1 0.9931582808494568
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.232835347764194e-05
seven O 0 2.7249936920270557e-06
further O 0 4.9195100473298226e-06
molecular O 0 0.0012966913636773825
defects O 1 0.8622044920921326
and O 0 8.430751563537342e-07
their O 0 2.161672227884992e-06
associated O 0 5.549199340748601e-05
marker O 0 0.00018745874695014209
haplotypes O 0 0.001107585383579135
. O 0 5.9789141232613474e-05

Seven O 0 3.445077163632959e-05
further O 0 1.4116330021352042e-05
molecular O 0 3.382981594768353e-05
bases O 0 2.2106434698798694e-05
of O 0 6.295376078924164e-05
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 6.313111498457147e-06
described O 0 8.426720160059631e-05
. O 0 5.79773768549785e-05

All O 0 7.38866856409004e-06
these O 0 2.215717813669471e-06
new O 0 8.167996384145226e-06
molecular O 0 0.0007966338307596743
defects O 0 0.2332216054201126
involve O 0 1.7114699630838004e-06
single O 0 1.818980194912001e-06
- O 0 6.728310836479068e-06
nucleotide O 0 1.602921088306175e-06
events O 0 4.270506508419203e-07
, O 0 1.684414030478365e-07
deletions O 0 2.163464614568511e-06
and O 0 1.6225770593791822e-07
substitutions O 0 8.164330438376055e-07
, O 0 9.699619596403863e-08
some O 0 5.080219267483699e-08
of O 0 9.695920510921496e-08
which O 0 4.5836122808395885e-07
alter O 0 1.760023951646872e-05
splice O 0 1.8824939616024494e-05
sites O 0 1.0676600368242362e-06
, O 0 2.7722757067749626e-07
and O 0 4.4467563498074014e-07
others O 0 3.5514428873284487e-06
codons O 0 7.594798080390319e-05
. O 0 2.15916516026482e-05

They O 0 1.3126532394380774e-05
are O 0 8.010129590729775e-07
distributed O 0 1.517073997092666e-06
along O 0 5.594789058704919e-07
the O 0 7.33194895019551e-07
C7 O 0 0.00044333504047244787
gene O 0 5.37462847205461e-06
, O 0 1.7601840340830677e-07
but O 0 8.768327575126023e-08
predominantly O 0 3.1377737741422607e-07
towards O 0 5.417326747192419e-07
the O 0 7.176811891440593e-07
3 O 0 4.946716671838658e-06
end O 0 1.6242973288171925e-05
. O 0 2.1281228328007273e-05

All O 0 1.0621419278322719e-05
were O 0 4.142696980125038e-06
found O 0 3.14483986585401e-06
in O 0 3.2420691695733694e-06
compound O 0 4.331276431912556e-05
heterozygous O 0 0.0002157191192964092
individuals O 0 1.8678927517612465e-05
. O 0 4.2415951611474156e-05

The O 0 0.0002843129332177341
C6 O 1 0.9140663146972656
/ O 0 0.3866446316242218
C7 O 0 0.15616852045059204
marker O 0 0.00023873875034041703
haplotypes O 0 0.0005250155809335411
associated O 0 1.5202982467599213e-05
with O 0 2.0938382476742845e-06
most O 0 1.1873117728100624e-05
C7 B-Disease 1 0.9999923706054688
defects I-Disease 1 0.9998621940612793
are O 0 1.4265762047216413e-06
tabulated O 0 4.766937126987614e-05
. O 0 6.254217623791192e-06
. O 0 2.1586647562799044e-05

A O 0 0.00011169951176270843
genome O 0 0.00013310767826624215
- O 0 2.6702022296376526e-05
wide O 0 3.0331959806062514e-06
search O 0 2.377779992457363e-06
for O 0 9.820394097914686e-07
chromosomal O 0 0.00028541096253320575
loci O 0 4.0239861846202984e-05
linked O 0 0.0020302091725170612
to O 0 3.2881547667784616e-05
mental O 1 0.9818137884140015
health O 0 0.038736410439014435
wellness O 0 0.046695273369550705
in O 0 2.7102312287752284e-06
relatives O 0 6.526754077640362e-06
at O 0 2.6170098408329068e-06
high O 0 5.357954796636477e-05
risk O 0 0.00011420566443121061
for O 0 0.00044205973972566426
bipolar B-Disease 1 1.0
affective I-Disease 1 0.9999983310699463
disorder I-Disease 1 0.9997289776802063
among O 0 7.13350857495243e-07
the O 0 1.2469479315768695e-06
Old O 0 1.6134041288751177e-05
Order O 0 8.071606316661928e-06
Amish O 0 0.0003419490240048617
. O 0 4.2932213546009734e-05

Bipolar B-Disease 1 1.0
affective I-Disease 1 0.9999997615814209
disorder I-Disease 1 0.9999998807907104
( O 0 0.03438154235482216
BPAD B-Disease 1 0.9999998807907104
; O 1 0.8817201852798462
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 0.9993616938591003
) O 0 2.465525540173985e-06
is O 0 4.811103622159862e-07
characterized O 0 5.649269496643683e-06
by O 0 4.1850523757602787e-07
episodes O 0 3.0582216368202353e-06
of O 0 6.36745426163543e-07
mania B-Disease 0 0.3995630443096161
and O 0 3.1497622785536805e-06
/ O 0 0.0013213325291872025
or O 0 2.701503944990691e-06
hypomania B-Disease 0 0.004945662338286638
interspersed O 0 9.111686267715413e-06
with O 0 1.0898418167926138e-06
periods O 0 1.3043637409282383e-05
of O 0 6.140588993730489e-06
depression B-Disease 1 0.7366352081298828
. O 0 6.34589814580977e-05

Compelling O 0 0.00014722091145813465
evidence O 0 1.8898923372034915e-05
supports O 0 1.182551022793632e-05
a O 0 3.5014088552998146e-06
significant O 0 2.9647128485521534e-06
genetic O 0 4.687971795647172e-06
component O 0 2.273563495691633e-06
in O 0 6.285893050517188e-07
the O 0 1.9617043562902836e-06
susceptibility O 0 0.00011481835099402815
to O 0 8.32833302411018e-06
develop O 0 0.00036353044561110437
BPAD B-Disease 1 0.9999055862426758
. O 0 0.00012759727542288601

To O 0 1.7076750737032853e-05
date O 0 5.516048076970037e-06
, O 0 6.552090781042352e-07
however O 0 3.6579521633939294e-07
, O 0 1.8667552126316878e-07
linkage O 0 3.457967068243306e-06
studies O 0 4.682966334712546e-07
have O 0 9.802300837691291e-08
attempted O 0 1.2278499070816906e-06
only O 0 1.1054645199237711e-07
to O 0 2.825509284321015e-07
identify O 0 3.418902906560106e-06
chromosomal O 0 0.00014492579794023186
loci O 0 8.707213055458851e-06
that O 0 4.1227011138289527e-07
cause O 0 4.596087819663808e-06
or O 0 3.7891788906563306e-07
increase O 0 7.729162803116196e-07
the O 0 1.039767653310264e-06
risk O 0 7.874484253989067e-06
of O 0 2.1324167391867377e-06
developing O 0 0.0001586369617143646
BPAD B-Disease 1 0.9999687671661377
. O 0 0.00011274329153820872

To O 0 2.474422763043549e-05
determine O 0 9.342513294541277e-06
whether O 0 2.6775223886943422e-06
there O 0 3.8258605172813986e-07
could O 0 5.735872719014878e-07
be O 0 2.6690275944929454e-07
protective O 0 3.988779280916788e-05
alleles O 0 6.7159635364077985e-06
that O 0 1.7158909315639903e-07
prevent O 0 1.2174097037132015e-06
or O 0 2.5294440320067224e-07
reduce O 0 9.583267228663317e-07
the O 0 2.6399862917969585e-07
risk O 0 6.080134085095779e-07
of O 0 1.0719680432202949e-07
developing O 0 6.07087940807105e-06
BPAD B-Disease 1 0.9999933242797852
, O 0 8.162337508110795e-07
similar O 0 9.363502613268793e-07
to O 0 2.8815838959417306e-07
what O 0 1.9838957143747393e-07
is O 0 1.4363340028467064e-07
observed O 0 1.09603934106417e-06
in O 0 8.785718819126487e-07
other O 0 8.666900612297468e-06
genetic B-Disease 1 0.9999892711639404
disorders I-Disease 1 1.0
, O 0 4.5456540647137444e-06
we O 0 7.329082905016548e-07
used O 0 7.876633753767237e-05
mental O 1 0.981351375579834
health O 0 0.08672744780778885
wellness O 0 0.19794881343841553
( O 0 2.6463987978786463e-06
absence O 0 2.486194944140152e-06
of O 0 4.198928706955485e-07
any O 0 0.00010401654435554519
psychiatric B-Disease 1 1.0
disorder I-Disease 1 0.999969482421875
) O 0 9.23072263958602e-07
as O 0 2.279676891703275e-07
the O 0 4.541449527550867e-07
phenotype O 0 0.00019477971363812685
in O 0 3.4903825962828705e-07
our O 0 4.801844397661625e-07
genome O 0 3.098739398410544e-06
- O 0 7.443352842528839e-06
wide O 0 2.326214826098294e-06
linkage O 0 1.3086709259368945e-05
scan O 0 2.8764692615368403e-05
of O 0 1.4992237140631914e-07
several O 0 2.803989218591596e-07
large O 0 7.97185009560053e-07
multigeneration O 0 8.801634248811752e-05
Old O 0 3.826301963272272e-06
Order O 0 1.4639764458479476e-06
Amish O 0 3.8319267332553864e-05
pedigrees O 0 4.983148392057046e-05
exhibiting O 0 1.2651509678107686e-05
an O 0 1.3159419722796883e-06
extremely O 0 1.539037657494191e-05
high O 0 3.476552592474036e-05
incidence O 0 0.00029637047555297613
of O 0 7.380703664239263e-06
BPAD B-Disease 1 0.9999597072601318
. O 0 0.00011854762124130502

We O 0 2.471130937919952e-05
have O 0 2.5447941425227327e-06
found O 0 9.977459285437362e-07
strong O 0 8.632277399556187e-07
evidence O 0 4.279022789432929e-07
for O 0 1.635476110095624e-07
a O 0 1.1375503845556523e-06
locus O 0 1.8066131815430708e-05
on O 0 5.195476205699379e-06
chromosome O 0 0.0001484853564761579
4p O 0 0.005568292923271656
at O 0 4.274595085007604e-06
D4S2949 O 0 3.495241980999708e-05
( O 0 2.246304802611121e-06
maximum O 0 4.343281489127548e-06
GENEHUNTER O 0 0.0004255807725712657
- O 0 2.0718280211440288e-05
PLUS O 0 6.104220119595993e-06
nonparametric O 0 4.5326061808736995e-05
linkage O 0 1.6445097571704537e-05
score O 0 1.8754199118120596e-06
= O 0 4.523659299593419e-06
4 O 0 8.398098998441128e-07
. O 0 3.3075755823119835e-07
05 O 0 1.0199776625086088e-05
, O 0 8.155474233717541e-07
P O 0 6.0596310504479334e-05
= O 0 3.0733494895685e-06
5 O 0 3.568441684365098e-07
. O 0 1.255070856132079e-07
22 O 0 8.130809305839648e-07
x O 0 8.450330824416596e-06
10 O 0 5.331808665687277e-07
( O 0 6.62383229155239e-07
- O 0 3.558515118129435e-06
4 O 0 6.807165959799022e-07
) O 0 3.95184144963423e-07
; O 0 5.667858999913733e-07
SIBPAL O 0 3.1192746973829344e-05
Pempirical O 0 2.144515201507602e-05
value O 0 6.614919243475015e-07
< O 0 3.2737227684265235e-06
3 O 0 8.640653845759516e-07
x O 0 7.003350219747517e-06
10 O 0 4.122555594676669e-07
( O 0 6.312493496807292e-07
- O 0 2.6503237222641474e-06
5 O 0 4.0095591202771175e-07
) O 0 1.9632244629974593e-07
) O 0 1.5276302178790502e-07
and O 0 8.010712093664552e-08
suggestive O 0 1.7000859315885464e-06
evidence O 0 2.5265509862038016e-07
for O 0 1.0718454035441027e-07
a O 0 6.042952236384735e-07
locus O 0 1.5436855392181315e-05
on O 0 7.174374331953004e-06
chromosome O 0 0.0004163402772974223
4q O 1 0.9836269617080688
at O 0 5.617379883915419e-06
D4S397 O 0 7.626746082678437e-05
( O 0 3.830485638900427e-06
maximum O 0 5.669379333994584e-06
GENEHUNTER O 0 0.0006702741375193
- O 0 2.7668593247653916e-05
PLUS O 0 5.790190698462538e-06
nonparametric O 0 3.234299583709799e-05
linkage O 0 1.417445582774235e-05
score O 0 1.3372554121815483e-06
= O 0 3.6929443467670353e-06
3 O 0 5.756609198215301e-07
. O 0 1.940786944487627e-07
29 O 0 1.074825604518992e-06
, O 0 4.518944933806779e-07
P O 0 6.64100080030039e-05
= O 0 4.624587745638564e-06
2 O 0 4.727817781713384e-07
. O 0 1.7838681287685176e-07
57 O 0 1.3323633538675494e-06
x O 0 7.281198577402392e-06
10 O 0 4.861616957896331e-07
( O 0 8.387278285226785e-07
- O 0 2.9755785817542346e-06
3 O 0 6.555697495969071e-07
) O 0 3.542279500834411e-07
; O 0 6.732019528499222e-07
SIBPAL O 0 2.603624488983769e-05
Pempirical O 0 1.841484299802687e-05
value O 0 8.372142019652529e-07
< O 0 3.5439320527075324e-06
1 O 0 6.163278953863482e-07
x O 0 4.502728188526817e-06
10 O 0 3.563415305052331e-07
( O 0 4.2016526435872947e-07
- O 0 2.0759953258675523e-06
3 O 0 2.686684865693678e-07
) O 0 1.491758894189843e-07
) O 0 1.0236011860342842e-07
that O 0 5.6693405525720664e-08
are O 0 9.757903995932793e-08
linked O 0 2.0170606148894876e-05
to O 0 1.3350329936656635e-05
mental O 1 0.9240351319313049
health O 0 0.2242019772529602
wellness O 0 0.2344120889902115
. O 0 8.92157549969852e-05

These O 0 4.277079278836027e-05
findings O 0 4.593569610733539e-05
are O 0 6.677974511148932e-07
consistent O 0 1.0923943136731395e-06
with O 0 2.452916874062794e-07
the O 0 4.860939952777699e-07
hypothesis O 0 1.8707559092945303e-06
that O 0 1.1880608496994682e-07
certain O 0 2.151160458652157e-07
alleles O 0 2.8460135581553914e-06
could O 0 3.627914679782407e-07
prevent O 0 1.4004655213284423e-06
or O 0 5.242862926024827e-07
modify O 0 1.1803877896454651e-05
the O 0 9.058142040885286e-07
clinical O 0 3.752763586817309e-05
manifestations O 0 1.585400605108589e-05
of O 0 9.195595112032606e-07
BPAD B-Disease 1 0.9999498128890991
and O 0 1.6235333077929681e-06
perhaps O 0 1.6320217355314526e-06
other O 0 1.6226820207521087e-06
related O 0 0.008009371347725391
affective B-Disease 1 0.9999823570251465
disorders I-Disease 1 0.9999967813491821
. O 0 0.00012928702926728874

Segregation O 0 0.028751971200108528
distortion O 0 0.17614662647247314
in O 0 0.03597325086593628
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
. O 0 0.001611853833310306

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9977332353591919
DM B-Disease 1 1.0
) O 0 2.538977423682809e-05
is O 0 1.3471075135385036e-06
an O 0 2.7800963380286703e-06
autosomal B-Disease 1 0.7231801152229309
dominant I-Disease 0 0.26873764395713806
disease I-Disease 0 0.2285321205854416
which O 0 4.916494731332932e-07
, O 0 1.1785151343701727e-07
in O 0 1.0653821647110817e-07
the O 0 2.060726842501026e-07
typical O 0 2.8382073651300743e-06
pedigree O 0 8.51214281283319e-06
, O 0 2.71605074431136e-07
shows O 0 5.135361220709456e-07
a O 0 5.911891207688313e-07
three O 0 8.79364847605757e-07
generation O 0 7.8849152487237e-06
anticipation O 0 3.98865740862675e-05
cascade O 0 0.0003215622273273766
. O 0 3.749926690943539e-05

This O 0 4.8555360990576446e-05
results O 0 0.00011335300223436207
in O 0 0.00020585465244948864
infertility B-Disease 1 0.999984622001648
and O 1 0.9685917496681213
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00020565219165291637
CDM B-Disease 0 0.0008202322060242295
) O 0 5.755187544309592e-07
with O 0 1.7372600780163339e-07
the O 0 3.1959800139702566e-07
disappearance O 0 7.427595846820623e-06
of O 0 2.1229652702459134e-06
DM B-Disease 1 0.9999998807907104
in O 0 4.01410670747282e-06
that O 0 3.607734925026307e-06
pedigree O 0 0.00012216457980684936
. O 0 2.9159646146581508e-05

The O 0 1.824564787966665e-05
concept O 0 1.1475682185846381e-05
of O 0 1.8949679088109406e-06
segregation O 0 8.377829362871125e-05
distortion O 0 3.9482478314312175e-05
, O 0 3.776318351356167e-07
where O 0 1.369792528294056e-07
there O 0 1.0215532597612764e-07
is O 0 9.870498729469546e-08
preferential O 0 1.1272823030594736e-06
transmission O 0 4.015431386505952e-06
of O 0 4.793205832243075e-08
the O 0 1.1976267444424593e-07
larger O 0 5.345310682969284e-07
allele O 0 5.3295384532248136e-06
at O 0 5.70018755752244e-07
the O 0 1.6419537587353261e-06
DM B-Disease 1 0.9999996423721313
locus O 0 3.941878458135761e-05
, O 0 4.198856800030626e-07
has O 0 1.7115337413997622e-07
been O 0 9.040142856520106e-08
put O 0 1.6004038627670525e-07
forward O 0 2.508869556550053e-07
to O 0 2.240879837245302e-07
explain O 0 1.345048303846852e-06
partially O 0 2.8042907160852337e-06
the O 0 4.04342728188567e-07
maintenance O 0 1.1106462807219941e-05
of O 0 1.4285039924288867e-06
DM B-Disease 1 0.9999996423721313
in O 0 1.59556987000542e-06
the O 0 2.1221312636043876e-06
population O 0 8.321870154759381e-06
. O 0 1.4490979083348066e-05

In O 0 3.7923229683656245e-05
a O 0 1.4494240531348623e-05
survey O 0 2.0021159798488952e-05
of O 0 2.0207583020237507e-06
DM B-Disease 1 0.9999994039535522
in O 0 1.9737174170586513e-06
Northern O 0 3.616239837356261e-06
Ireland O 0 4.533731043920852e-06
, O 0 6.671672281299834e-07
59 O 0 4.334644927439513e-06
pedigrees O 0 4.385038118925877e-05
were O 0 5.474656973092351e-06
ascertained O 0 0.00012788399180863053
. O 0 2.9741504476987757e-05

Sibships O 0 0.001141930464655161
where O 0 4.085696218680823e-06
the O 0 9.03166096577479e-07
status O 0 6.250945148167375e-07
of O 0 6.399438490234388e-08
all O 0 3.1351262919088185e-08
the O 0 6.327646673298659e-08
members O 0 1.4532109560150275e-07
had O 0 6.377408681146335e-07
been O 0 2.445423774588562e-07
identified O 0 8.169205898411747e-07
were O 0 2.8726117307087407e-07
examined O 0 4.775284196512075e-06
to O 0 1.511747740323699e-07
determine O 0 2.781645491722884e-07
the O 0 2.0042206472226098e-07
transmission O 0 6.038549145159777e-06
of O 0 1.2263842563697835e-07
the O 0 1.5088697864484857e-06
DM B-Disease 1 0.9999979734420776
expansion O 0 1.3672668501385488e-05
from O 0 1.2308324812693172e-06
affected O 0 3.1842048429098213e-06
parents O 0 1.585032350703841e-06
to O 0 5.450606863632856e-07
their O 0 1.6760445760155562e-06
offspring O 0 4.067347617819905e-05
. O 0 1.9444345525698736e-05

Where O 0 1.762138526828494e-05
the O 0 7.698847184656188e-06
transmitting O 0 0.0001345596683677286
parent O 0 7.390139944618568e-05
was O 0 4.996766165277222e-06
male O 0 3.845357241516467e-06
, O 0 2.786230425044778e-06
58 O 0 3.162043867632747e-05
. O 0 3.1408439099323004e-05

3 O 0 2.0861027223872952e-05
% O 0 1.7040855482264305e-06
of O 0 1.9208910373436083e-07
the O 0 3.6270498071644397e-07
offspring O 0 4.179252300673397e-06
were O 0 3.078930319588835e-07
affected O 0 5.696986704606388e-07
, O 0 8.349451263711671e-08
and O 0 7.785929767578637e-08
in O 0 9.784536558754553e-08
the O 0 1.448025983563639e-07
case O 0 2.2155057877171203e-07
of O 0 1.0265965499911545e-07
a O 0 8.875448997969215e-07
female O 0 3.5913949432142545e-06
transmitting O 0 0.00015394503134302795
parent O 0 6.194519664859399e-05
, O 0 1.7120771644840715e-06
68 O 0 2.7796413633041084e-05
. O 0 1.822555896069389e-05

7 O 0 0.0002864220296032727
% O 0 2.986439358210191e-05
were O 0 1.06441348179942e-05
affected O 0 5.888528176001273e-05
. O 0 3.42954954248853e-05

Studies O 0 9.899071301333606e-05
on O 0 1.6588055586908013e-05
meiotic O 0 0.0009085502824746072
drive O 0 0.0001105005867430009
in O 0 1.95374341274146e-05
DM B-Disease 1 0.9999998807907104
have O 0 8.792650305622374e-07
shown O 0 7.898181593191111e-07
increased O 0 1.2256807622179622e-06
transmission O 0 7.227160494949203e-06
of O 0 9.083734653358988e-08
the O 0 2.4267589537885215e-07
larger O 0 1.244761620000645e-06
allele O 0 7.525441560574109e-06
at O 0 9.560098988004029e-07
the O 0 3.430033075346728e-06
DM B-Disease 1 0.9999953508377075
locus O 0 4.314933539717458e-05
in O 0 3.1084266538528027e-06
non O 0 2.001424945774488e-05
- O 0 0.07760949432849884
DM O 1 0.9999977350234985
heterozygotes O 0 0.0010323519818484783
for O 0 9.573087481840048e-06
CTGn O 0 0.0008269302197732031
. O 0 4.608399831340648e-05

This O 0 2.1137282601557672e-05
study O 0 9.51323818298988e-06
provides O 0 2.9506322789529804e-06
further O 0 1.2719928008664283e-06
evidence O 0 8.472106856061146e-07
that O 0 3.0288319408100506e-07
the O 0 1.9594158402469475e-06
DM B-Disease 1 0.9999986886978149
expansion O 0 4.023138899356127e-05
tends O 0 2.0275112547096796e-05
to O 0 2.238930164821795e-06
be O 0 2.2586348222830566e-06
transmitted O 0 0.00016748800408095121
preferentially O 0 0.00014969788026064634
. O 0 2.6844083549804054e-05

Diagnosis O 1 0.9984404444694519
of O 0 0.0006923730834387243
hemochromatosis B-Disease 1 0.9999988079071045
. O 0 0.00108216458465904

If O 0 0.0008596288971602917
untreated O 1 0.9924302697181702
, O 0 0.0007601607358083129
hemochromatosis B-Disease 1 1.0
can O 0 0.0005976378452032804
cause O 0 0.15625527501106262
serious O 0 0.11392142623662949
illness O 1 0.9657518863677979
and O 0 5.252369192021433e-06
early B-Disease 0 0.00031597388442605734
death I-Disease 0 0.0030734874308109283
, O 0 4.2048756654367025e-07
but O 0 2.582261799943808e-07
the O 0 1.883995764728752e-06
disease O 0 0.003526753280311823
is O 0 3.2668566518623265e-07
still O 0 1.231811893376289e-06
substantially O 0 5.220072125666775e-05
under O 0 0.0002784588432405144
- O 1 0.9990003705024719
diagnosed O 1 0.9994103908538818
. O 0 3.8486374251078814e-05

The O 0 2.200039307354018e-05
cornerstone O 0 6.008705895510502e-05
of O 0 2.043981567112496e-06
screening O 0 1.602330303285271e-05
and O 0 1.026021550387668e-06
case O 0 1.9012655911865295e-06
detection O 0 9.149040124611929e-06
is O 0 2.5852853013930144e-07
the O 0 4.4896535200678045e-07
measurement O 0 3.194820465068915e-06
of O 0 7.365300689343712e-07
serum O 0 3.509664747980423e-05
transferrin O 0 3.854304668493569e-05
saturation O 0 1.2543757293315139e-05
and O 0 8.634048072053702e-07
the O 0 2.2761735181120457e-06
serum O 0 9.730933379614726e-05
ferritin O 0 0.00022568536223843694
level O 0 1.623083335289266e-05
. O 0 2.4296114133903757e-05

Once O 0 8.627639181213453e-05
the O 0 1.1677468137349933e-05
diagnosis O 0 0.02963913045823574
is O 0 1.0602368547552032e-06
suspected O 0 1.2831071217078716e-05
, O 0 1.2420177881722338e-06
physicians O 0 1.1249990166106727e-05
must O 0 1.4094720199864241e-06
use O 0 2.67173982138047e-06
serum O 0 5.731272176490165e-05
ferritin O 0 7.876454037614167e-05
levels O 0 2.9973323307785904e-06
and O 0 1.0390083389211213e-06
hepatic O 0 0.00041865199455060065
iron O 0 4.4730997615261e-05
stores O 0 9.67029518506024e-06
on O 0 1.460298790334491e-05
liver O 1 0.8225998282432556
biopsy O 1 0.8644342422485352
specimens O 0 1.1309604815323837e-05
to O 0 3.304808615212096e-06
assess O 0 0.0007662657299079001
patients O 0 1.8670592908165418e-05
for O 0 1.0701743491381421e-07
the O 0 2.046137410616211e-07
presence O 0 1.010208166007942e-06
of O 0 9.361878028357751e-07
iron B-Disease 0 0.011080986820161343
overload I-Disease 0 0.02383018098771572
. O 0 3.0509152566082776e-05

Liver O 1 0.9999665021896362
biopsy O 1 0.9993576407432556
is O 0 8.625063856015913e-06
also O 0 1.0653309345798334e-06
used O 0 2.820926852109551e-07
to O 0 1.4728895791904506e-07
establish O 0 4.081915960796323e-07
the O 0 1.342444022611744e-07
presence O 0 2.924261650605331e-07
or O 0 1.3311473878729885e-07
absence O 0 5.081305403109582e-07
of O 0 2.234833544889625e-07
cirrhosis B-Disease 0 0.08828648924827576
, O 0 5.951069397269748e-07
which O 0 1.0299676205249853e-06
can O 0 1.3743397175858263e-06
affect O 0 1.8845614249585196e-05
prognosis O 0 0.33183011412620544
and O 0 8.401228114962578e-06
management O 0 0.0003159820334985852
. O 0 3.0189976314431988e-05

A O 0 0.00017371829017065465
DNA O 0 0.0001739088911563158
- O 0 0.0002399994555162266
based O 0 3.268338559792028e-06
test O 0 1.8987396970260306e-06
for O 0 1.9488606994855218e-07
the O 0 5.130074214321212e-07
HFE O 0 0.0030505878385156393
gene O 0 3.212556521248189e-06
is O 0 1.5140705045268987e-07
commercially O 0 4.73544787382707e-07
available O 0 1.469436909928845e-07
, O 0 3.916893831501511e-08
but O 0 3.732852604798609e-08
its O 0 1.0241733860993918e-07
place O 0 1.6180446493763156e-07
in O 0 2.4120544139805133e-07
the O 0 1.6659414541209117e-06
diagnosis O 0 0.0988292396068573
of O 0 4.5530555325967725e-06
hemochromatosis B-Disease 1 1.0
is O 0 5.470971700560767e-06
still O 0 3.801590310104075e-06
being O 0 6.702208338538185e-06
evaluated O 0 8.813744352664798e-05
. O 0 2.6868876375374384e-05

Currently O 0 2.1340860257623717e-05
, O 0 1.10755979676469e-06
the O 0 4.389927426018403e-07
most O 0 1.3381480812313384e-07
useful O 0 1.70543032140813e-07
role O 0 1.7583083433692082e-07
for O 0 7.490569942092407e-08
this O 0 9.379020582400699e-08
test O 0 8.038927035158849e-07
is O 0 5.686711901375929e-08
in O 0 6.921053596897764e-08
the O 0 1.5395762886782904e-07
detection O 0 2.9525688205467304e-06
of O 0 5.12512542627519e-07
hemochromatosis B-Disease 1 0.9999970197677612
in O 0 5.580146194006375e-07
the O 0 2.5145368454104755e-07
family O 0 8.182445299098617e-07
members O 0 1.3223677797213895e-07
of O 0 1.4257082625590556e-07
patients O 0 7.188688414316857e-06
with O 0 2.0636491626646603e-07
a O 0 3.6513895338430302e-06
proven O 0 8.140911631926429e-06
case O 0 6.510259709102684e-07
of O 0 4.3848265818269283e-07
the O 0 2.5085610104724765e-05
disease O 0 0.29662856459617615
. O 0 4.396796430228278e-05

It O 0 2.3828810299164616e-05
is O 0 4.76164132123813e-06
crucial O 0 1.7490992831881158e-05
to O 0 6.518089503515512e-05
diagnose O 1 0.9999954700469971
hemochromatosis B-Disease 1 1.0
before O 0 0.21773524582386017
hepatic B-Disease 1 0.9999978542327881
cirrhosis I-Disease 1 0.9999903440475464
develops O 0 0.17506010830402374
because O 0 3.397880573174916e-05
phlebotomy O 1 0.9949427247047424
therapy O 1 0.9823048114776611
can O 0 2.1550857127294876e-05
avert O 1 0.9828012585639954
serious O 1 0.9996405839920044
chronic O 1 1.0
disease O 1 0.9999366998672485
and O 0 1.022875676426338e-05
can O 0 6.912669050507247e-07
even O 0 3.8157233461788564e-07
lead O 0 9.358610668641631e-07
to O 0 6.570236337211099e-07
normal O 0 4.6093264245428145e-06
life O 0 6.069270057196263e-06
expectancy O 0 1.9177978174411692e-05
. O 0 3.1201520869217347e-06
. O 0 1.2301868991926312e-05

Prevalence O 0 0.0008754830923862755
of O 0 6.459968517447123e-06
the O 0 6.773984296160052e-06
I1307K O 0 0.00033072291989810765
APC B-Disease 0 0.0008456619107164443
gene O 0 2.072369352390524e-05
variant O 0 2.070397931674961e-05
in O 0 5.486298846335558e-07
Israeli O 0 2.300743290106766e-06
Jews O 0 5.536398930416908e-07
of O 0 1.1273333910821748e-07
differing O 0 9.51816161887109e-07
ethnic O 0 3.546159916822944e-07
origin O 0 9.913569556374568e-07
and O 0 3.935521363018779e-06
risk O 0 0.0005265157669782639
for O 0 0.26391926407814026
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00029079560772515833

BACKGROUND O 0 0.0005550641799345613
& O 0 0.0003443889145273715
AIMS O 0 3.6301411455497146e-05
Israeli O 0 1.1720176189555787e-05
Jews O 0 2.3520333343185484e-06
of O 0 3.5293140854264493e-07
European O 0 3.4856134334404487e-06
birth O 0 0.0002888905582949519
, O 0 5.641036295855884e-07
i O 0 3.157492756145075e-07
. O 0 1.2447873132259701e-07
e O 0 8.432527920376742e-07
. O 0 9.133265166383353e-08
, O 0 1.3744391935688327e-07
Ashkenazim O 0 4.127648026042152e-06
, O 0 1.957212418801646e-07
have O 0 1.7332553170490428e-07
the O 0 2.223499222964165e-06
highest O 1 0.8444245457649231
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.003922212868928909
of O 0 5.113037673254439e-07
any O 0 8.962897481978871e-07
Israeli O 0 9.510553354630247e-06
ethnic O 0 4.470079602469923e-06
group O 0 2.0025285266456194e-05
. O 0 2.7847670935443603e-05

The O 0 7.296683179447427e-05
I1307K O 0 0.0011091295164078474
APC B-Disease 0 0.0034903998021036386
gene O 0 0.00022632752370554954
variant O 0 0.0003758312377613038
was O 0 1.4991283933341037e-05
found O 0 4.763594461110188e-06
in O 0 5.740842880186392e-06
6 O 0 3.398548506083898e-05
. O 0 2.7926022085011937e-05

1 O 0 2.9415481549222022e-05
% O 0 2.72397255685064e-06
of O 0 4.343556554431416e-07
American O 0 9.452145945942902e-07
Jews O 0 1.1503437917781412e-06
, O 0 2.9787369726363977e-07
28 O 0 8.062559118116042e-07
% O 0 1.6250594114808337e-07
of O 0 1.5912738149381767e-07
their O 0 0.001004713005386293
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 0.00013010077236685902
, O 0 7.076456540744402e-07
but O 0 1.8270195312197757e-07
not O 0 1.2247257075159723e-07
in O 0 4.798200166078459e-07
non O 0 3.6130097669229144e-06
- O 0 3.371220009285025e-05
Jews O 0 9.29448833630886e-06
. O 0 1.9689256077981554e-05

We O 0 2.0594767192960717e-05
assessed O 0 3.5070614103460684e-05
the O 0 4.540801455732435e-06
I1307K O 0 0.00022936277673579752
prevalence O 0 8.573575905757025e-05
in O 0 1.1804818313976284e-06
Israeli O 0 3.7826257539563812e-06
Jews O 0 9.157264457826386e-07
of O 0 1.5421376531321584e-07
differing O 0 1.1440803291407065e-06
ethnic O 0 3.914560409157275e-07
origin O 0 9.796242466109106e-07
and O 0 3.003175152116455e-06
risk O 0 0.0004892778233624995
for O 0 0.4070354700088501
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.000432613305747509

METHODS O 0 0.00026056726346723735
DNA O 0 6.664435204584152e-05
samples O 0 1.1277714293100871e-05
from O 0 1.96142559616419e-06
500 O 0 2.054488049907377e-06
unrelated O 0 2.9856582841603085e-06
Jews O 0 5.092909418635827e-07
of O 0 1.461171166283748e-07
European O 0 6.336849764920771e-07
or O 0 3.8467803165076475e-07
non O 0 6.414935000975674e-07
- O 0 1.5246886277964222e-06
European O 0 2.591920917893731e-07
origin O 0 1.333070827058691e-07
, O 0 5.4859700782117216e-08
with O 0 5.610969822100742e-08
or O 0 1.1532389265767051e-07
without O 0 7.514152144949549e-08
a O 0 2.2853060954730609e-07
personal O 0 1.9168171547789825e-06
and O 0 1.7756933630153071e-06
/ O 0 0.0038545397110283375
or O 0 5.547879027290037e-07
family O 0 7.711734610893473e-07
history O 0 2.732616337652871e-07
of O 0 2.4584906554991903e-07
neoplasia B-Disease 0 0.19045576453208923
, O 0 5.635868660647247e-07
were O 0 3.4659757375266054e-07
examined O 0 2.515371761546703e-06
for O 0 9.128405054070754e-08
the O 0 2.8949486363671895e-07
I1307K O 0 2.5364364773849957e-05
variant O 0 1.1878270015586168e-05
by O 0 3.7625324011969496e-07
the O 0 5.645374017149152e-07
allele O 0 1.1982522664766293e-05
- O 0 4.313362296670675e-06
specific O 0 1.6760029666329501e-06
oligonucleotide O 0 0.0001023742079269141
( O 0 9.286115528084338e-06
ASO O 0 0.003872564062476158
) O 0 9.561919796396978e-06
method O 0 2.0380766727612354e-05
. O 0 1.9244556824560277e-05

RESULTS O 0 0.0003296532668173313
In O 0 1.0806042155309115e-05
persons O 0 4.934758180752397e-06
at O 0 2.972107267851243e-06
average O 0 1.4191931768436916e-05
risk O 0 0.0001298865827266127
for O 0 0.06333302706480026
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 8.832311323203612e-06
I1307K O 0 0.002297324826940894
was O 0 1.556086317577865e-05
found O 0 2.4967637273221044e-06
in O 0 4.035505753563484e-06
5 O 0 1.8572016415419057e-05
. O 0 2.7010350095224567e-05

0 O 0 5.187849819776602e-05
% O 0 2.8101992484153016e-06
of O 0 5.555307325266767e-07
120 O 0 2.3892364424682455e-06
European O 0 3.310151896585012e-06
and O 0 2.4015564576984616e-06
1 O 0 1.1432675819378346e-05
. O 0 2.0091698388569057e-05

6 O 0 6.64270410197787e-05
% O 0 5.964915544609539e-06
of O 0 9.572835324433981e-07
188 O 0 8.413751857005991e-06
non O 0 2.8629895041376585e-06
- O 0 9.900060831569135e-06
European O 0 2.428667585263611e-06
Jews O 0 3.5664108963828767e-06
( O 0 4.031508979096543e-06
P O 0 9.48153028730303e-05
= O 0 1.0022558853961527e-05
0 O 0 2.5482597720838385e-06
. O 0 1.1547283520485507e-06
08 O 0 2.6723932023742236e-05
) O 0 8.603368769399822e-06
. O 0 1.491926104790764e-05

It O 0 4.4615673687076196e-05
occurred O 0 9.265126573154703e-05
in O 0 1.0587802535155788e-05
15 O 0 3.19288155878894e-05
. O 0 4.628280294127762e-05

4 O 0 5.3684805607190356e-05
% O 0 3.349515736772446e-06
of O 0 9.404185448147473e-07
52 O 0 6.770070285710972e-06
Ashkenazi O 0 0.0001783493353286758
Israelis O 0 6.796725938329473e-05
with O 0 0.00016869907267391682
familial O 1 0.9999974966049194
cancer B-Disease 1 0.999964714050293
( O 0 2.568658055679407e-05
P O 0 0.0012710047885775566
= O 0 1.2160254300397355e-05
0 O 0 1.4437819118029438e-06
. O 0 4.383183807021851e-07
02 O 0 1.1314524272165727e-05
) O 0 2.3137731375300064e-07
and O 0 1.404671934324142e-07
was O 0 4.4570774093699583e-07
not O 0 1.132527316372034e-07
detected O 0 1.0234873570880154e-06
in O 0 2.0949038059825398e-07
51 O 0 8.932468631428492e-07
non O 0 4.5820388550055213e-07
- O 0 1.3147854360795463e-06
European O 0 5.203442583479045e-07
Jews O 0 1.5492988723053713e-06
at O 0 5.963891908322694e-06
increased O 0 0.009087944403290749
cancer B-Disease 1 0.9991441965103149
risk O 0 0.00027983429026789963
. O 0 5.471278927871026e-05

Colorectal B-Disease 1 0.9999871253967285
neoplasia I-Disease 1 0.9994064569473267
occurred O 0 0.0020413158927112818
personally O 0 0.00013639769167639315
or O 0 1.8010198346019024e-06
in O 0 4.037339351725677e-07
the O 0 1.9497288406000735e-07
families O 0 1.5817012410934694e-07
of O 0 4.900419980913284e-08
13 O 0 2.0307815873366053e-07
of O 0 8.59396109831323e-08
20 O 0 5.4879683375475e-07
Ashkenazi O 0 2.3080301616573706e-05
I1307K O 0 3.4601736842887476e-05
carriers O 0 3.961179118050495e-06
, O 0 1.0972550512633461e-07
8 O 0 1.2304153074182977e-07
of O 0 4.910225115395406e-08
whom O 0 5.349411367205903e-07
also O 0 2.378387193857634e-07
had O 0 4.2215663142997073e-07
a O 0 4.3315563402757107e-07
personal O 0 2.8672463940893067e-06
or O 0 1.0600244877423393e-06
family O 0 1.9641547623905353e-06
history O 0 1.8524750657888944e-06
of O 0 2.8883127924927976e-06
noncolonic O 1 0.6189056038856506
neoplasia B-Disease 1 0.9877911806106567
. O 0 0.00010230034968117252

CONCLUSIONS O 0 0.0005314309382811189
The O 0 4.664071457227692e-05
I1307K O 0 0.0021151183173060417
APC O 0 0.18482622504234314
variant O 0 0.006529297214001417
may O 0 5.427024916571099e-06
represent O 0 9.281177426601062e-07
a O 0 2.0372092421894195e-06
susceptibility O 0 0.00011912077752640471
gene O 0 1.56266542035155e-05
for O 0 5.679552941728616e-06
colorectal B-Disease 1 0.9999980926513672
, I-Disease 0 7.497444016735244e-07
or I-Disease 0 2.649692021350347e-07
other I-Disease 0 1.291582378826206e-07
, I-Disease 0 8.342334467670298e-07
cancers I-Disease 0 8.958164107752964e-05
in O 0 6.398950631592015e-07
Ashkenazi O 0 5.466845686896704e-05
Jews O 0 1.0340737617298146e-06
, O 0 2.032166719345696e-07
and O 0 3.0112687454675324e-07
partially O 0 1.1955596164625604e-05
explains O 0 1.4446537761614309e-06
the O 0 4.034737344227324e-07
higher O 0 8.976619938039221e-06
incidence O 0 0.02928314171731472
of O 0 0.0012041464215144515
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.0574815860309172e-05
European O 0 2.5560371796018444e-05
Israelis O 0 0.00011090986663475633
. O 0 5.040342148276977e-05

Systematic O 0 0.00039627624209970236
analysis O 0 6.285760900937021e-05
of O 0 1.2260524272278417e-05
coproporphyrinogen O 0 0.4765830338001251
oxidase O 0 0.4315486252307892
gene O 0 0.08555157482624054
defects O 1 0.9465988874435425
in O 0 9.328473424830008e-06
hereditary B-Disease 1 0.829262912273407
coproporphyria I-Disease 0 0.39028915762901306
and O 0 4.2137977288803086e-05
mutation O 0 0.0005511550698429346
update O 0 0.0006296313367784023
. O 0 5.991625221213326e-05

Hereditary B-Disease 1 0.995377779006958
coproporphyria I-Disease 1 0.8909106254577637
( O 0 0.0002862584951799363
HC B-Disease 0 0.4061478078365326
) O 0 1.0469304470461793e-05
is O 0 1.7328202375210822e-06
an O 0 5.681362381437793e-06
acute O 1 0.9976806640625
hepatic B-Disease 1 0.9999940395355225
porphyria I-Disease 1 0.9999992847442627
with O 0 0.0012531790416687727
autosomal O 1 0.9974362254142761
dominant O 0 0.020043211057782173
inheritance O 0 0.007229590322822332
caused O 0 0.0003367739263921976
by O 0 7.745633411104791e-06
deficient B-Disease 0 0.0002485540462657809
activity I-Disease 0 3.6684780297946418e-06
of I-Disease 0 1.6286104482787778e-06
coproporphyrinogen I-Disease 0 0.009451043792068958
III I-Disease 0 0.11366288363933563
oxidase I-Disease 0 0.00023182782751973718
( O 0 1.633755164220929e-05
CPO O 0 0.00012921099551022053
) O 0 8.297105523524806e-06
. O 0 1.8705915863392875e-05

Clinical O 0 0.017000410705804825
manifestations O 0 0.0006735335336998105
of O 0 5.505022727447795e-06
the O 0 0.00020094630599487573
disease O 1 0.9565566778182983
are O 0 1.2136306395404972e-06
characterized O 0 0.00014029913290869445
by O 0 9.629894520912785e-06
acute O 0 0.31658682227134705
attacks O 0 0.0038464772514998913
of O 0 0.00010175685747526586
neurological B-Disease 1 1.0
dysfunction I-Disease 1 0.9999217987060547
often O 0 2.4275987016153522e-05
precipitated O 0 0.0007276287069544196
by O 0 1.3173031447877293e-06
drugs O 0 4.960993010172388e-06
, O 0 7.28438919850305e-07
fasting O 0 2.159863470296841e-05
, O 0 2.044765324171749e-06
cyclical O 0 0.0020202461164444685
hormonal O 0 0.0010060607455670834
changes O 0 8.320140295836609e-06
, O 0 2.355175638513174e-06
or O 0 7.643579738214612e-05
infectious B-Disease 1 0.9977329969406128
diseases I-Disease 1 0.9948150515556335
. O 0 8.846195851219818e-05

Skin O 1 0.9999997615814209
photosensitivity O 1 0.9999926090240479
may O 0 0.011838189326226711
also O 0 1.0409868991700932e-05
be O 0 3.171633352394565e-06
present O 0 1.4311439372249879e-05
. O 0 2.9508648367482238e-05

The O 0 1.5212206562864594e-05
seven O 0 7.968247700773645e-06
exons O 0 3.149686745018698e-05
, O 0 1.260325916518923e-06
the O 0 1.5928073935356224e-06
exon O 0 7.305316103156656e-05
/ O 0 6.107213266659528e-05
intron O 0 3.683882096083835e-05
boundaries O 0 7.570571369797108e-07
and O 0 1.6416126413787424e-07
part O 0 1.9376541615656606e-07
of O 0 1.0405894812492988e-07
3 O 0 4.346954654010915e-07
noncoding O 0 3.0389696803467814e-06
sequence O 0 4.2234671582264127e-07
of O 0 9.77383010081212e-08
the O 0 3.66277276953042e-07
CPO O 0 4.9152429710375145e-05
gene O 0 3.3877645364555065e-06
were O 0 2.789682014281425e-07
systematically O 0 2.263814621983329e-06
analyzed O 0 1.1952823797400924e-06
by O 0 2.379179022682365e-07
an O 0 3.174467053668195e-07
exon O 0 1.5835812519071624e-05
- O 0 6.732033853040775e-06
by O 0 1.1092172371718334e-06
- O 0 2.30301284318557e-05
exon O 0 7.283342711161822e-05
denaturing O 0 0.00038887234404683113
gradient O 0 0.00024987568031065166
gel O 0 0.0006120917969383299
electrophoresis O 0 0.00010013406426878646
( O 0 4.568535132420948e-06
DGGE O 0 8.284394425572827e-05
) O 0 9.465939001529478e-07
strategy O 0 1.277626552109723e-06
followed O 0 4.860086733060598e-07
by O 0 1.5100962968972453e-07
direct O 0 3.964940447076515e-07
sequencing O 0 8.809831797407242e-07
in O 0 2.2687979139845993e-07
seven O 0 9.967055802917457e-07
unrelated O 0 2.5798846763791516e-05
heterozygous O 0 0.002400799887254834
HC B-Disease 1 0.998381495475769
patients O 0 0.0032426295801997185
from O 0 1.2413510148689966e-06
France O 0 1.2612598766281735e-05
, O 0 6.028539019098389e-07
Holland O 0 1.708431045699399e-05
, O 0 3.6365329947329883e-07
and O 0 3.973396758283343e-07
Czech O 0 1.0545762052061036e-05
Republic O 0 1.7731952539179474e-05
. O 0 2.336256147827953e-05

Seven O 0 0.00010161655518459156
novel O 0 0.0001076422049663961
mutations O 0 8.791952859610319e-05
and O 0 1.1435513442847878e-06
two O 0 1.1851541330543114e-06
new O 0 8.753805559535976e-06
polymorphisms O 0 9.105810022447258e-05
were O 0 6.0595880313485395e-06
detected O 0 0.00015953164256643504
. O 0 2.436881732137408e-05

Among O 0 3.94767957914155e-05
these O 0 4.8406773203168996e-06
mutations O 0 3.221030056010932e-05
two O 0 6.760894279977947e-07
are O 0 4.226029659548658e-07
missense O 0 3.206777910236269e-05
( O 0 1.3166450116841588e-06
G197W O 0 9.592259630153421e-06
, O 0 3.368886893895251e-07
W427R O 0 6.7344481067266315e-06
) O 0 2.2542032240835397e-07
, O 0 5.3774609654055894e-08
two O 0 5.3207354966389175e-08
are O 0 5.597672014800992e-08
nonsense O 0 1.4543495581165189e-06
( O 0 4.744787531762995e-07
Q306X O 0 5.681893526343629e-06
, O 0 2.823828424425301e-07
Q385X O 0 3.645516244432656e-06
) O 0 1.8108144672623894e-07
, O 0 3.235016166058813e-08
two O 0 3.30105507373446e-08
are O 0 6.029596022472106e-08
small O 0 3.4148385452681396e-07
deletions O 0 1.5003985026851296e-05
( O 0 1.8468570033292053e-06
662de14bp O 0 1.8539649317972362e-05
; O 0 1.2241692957104533e-06
1168del3bp O 0 1.5065208572195843e-05
removing O 0 2.054417336694314e-06
a O 0 5.955889719189145e-07
glycine O 0 1.0346702765673399e-05
at O 0 5.781973300145182e-07
position O 0 8.300867762045527e-07
390 O 0 2.286610424562241e-06
) O 0 2.8349697345220193e-07
, O 0 7.149064629174973e-08
and O 0 3.826341554713508e-08
one O 0 4.3696442020291215e-08
is O 0 9.425360047998765e-08
a O 0 5.516008627637348e-07
splicing O 0 1.549340049677994e-05
mutation O 0 1.4049218407308217e-05
( O 0 1.8753950143945985e-06
IVS1 O 0 0.0001227978355018422
- O 0 3.8352314732037485e-05
15c O 0 0.0001350762031506747
- O 0 0.00020778560428880155
- O 0 6.1034399550408125e-05
> O 0 1.3525963368010707e-05
g O 0 1.8106666175299324e-05
) O 0 5.839450523126288e-07
which O 0 2.466267972067726e-07
creates O 0 8.129429716063896e-07
a O 0 5.922680657022283e-07
new O 0 3.287275148977642e-06
acceptor O 0 5.596769187832251e-05
splice O 0 0.00031906270305626094
site O 0 6.338887760648504e-05
. O 0 3.887546336045489e-05

The O 0 3.547303640516475e-05
pathological O 0 8.754439477343112e-05
significance O 0 5.259697445580969e-06
of O 0 4.369477721866133e-07
the O 0 6.716826987940294e-07
point O 0 1.1507652288855752e-06
mutations O 0 9.94116908259457e-06
G197W O 0 8.682105544721708e-06
, O 0 4.1758070778996625e-07
W427R O 0 6.379528258548817e-06
, O 0 9.484981688956395e-08
and O 0 5.842970907110612e-08
the O 0 1.61860029379568e-07
in O 0 5.57265821043984e-07
- O 0 1.3890467926103156e-05
frame O 0 1.6471090930281207e-05
deletion O 0 2.2605898266192526e-05
390delGly O 0 2.61254081124207e-05
were O 0 3.3969547530432465e-07
assessed O 0 6.139268293736677e-07
by O 0 1.389699235687658e-07
their O 0 1.4083217081406474e-07
respective O 0 5.633671094074089e-07
expression O 0 6.744228358002147e-07
in O 0 2.751625345354114e-07
a O 0 5.95583856011217e-07
prokaryotic O 0 3.3882104162330506e-06
system O 0 2.683173988771159e-06
using O 0 2.102919552271487e-06
site O 0 9.921251148625743e-06
- O 0 3.950560494558886e-05
directed O 0 2.4312061214004643e-05
mutagenesis O 0 0.0003146127855870873
. O 0 5.01466856803745e-05

These O 0 4.948480273014866e-05
mutations O 0 0.0003458219289314002
resulted O 0 1.7584503439138643e-05
in O 0 1.1095409035988268e-06
the O 0 5.749893716711085e-07
absence O 0 2.8994820695515955e-06
or O 0 4.339205190717621e-07
a O 0 9.959093176803435e-07
dramatic O 0 8.597421583544929e-06
decrease O 0 9.260080332751386e-06
of O 0 2.069097490675631e-06
CPO O 0 0.0003077260626014322
activity O 0 7.295500108739361e-05
. O 0 3.865148391923867e-05

The O 0 2.5180330339935608e-05
two O 0 1.111758865590673e-05
polymorphisms O 0 0.00010157857468584552
were O 0 3.16851946990937e-06
localized O 0 2.3548056560684927e-05
in O 0 1.3972503438708372e-06
noncoding O 0 1.3418566595646553e-05
part O 0 4.935021706842235e-07
of O 0 9.372082132586002e-08
the O 0 3.0431522191065596e-07
gene O 0 1.9784513369813794e-06
1 O 0 4.1552777929609874e-07
) O 0 2.664922646999912e-07
a O 0 1.1284397487543174e-06
C O 0 9.510343807050958e-05
/ O 0 0.0002056306111626327
G O 0 3.255583578720689e-05
polymorphism O 0 4.726749011751963e-06
in O 0 2.666163254616549e-07
the O 0 4.5251982783156564e-07
promotor O 0 4.15473805333022e-05
region O 0 7.441780098815798e-07
, O 0 2.2190920390130486e-07
142 O 0 1.6237067939073313e-06
bp O 0 5.873032932868227e-06
upstream O 0 1.315738700213842e-06
from O 0 2.1722003396007494e-07
the O 0 1.9552832952740573e-07
transcriptional O 0 3.3547971725056414e-06
initiation O 0 1.736436502142169e-06
site O 0 2.7236064852331765e-06
( O 0 1.3472256341628963e-06
- O 0 1.1751625606848393e-05
142C O 0 6.244369433261454e-05
/ O 0 0.0002006495196837932
G O 0 2.946472704934422e-05
) O 0 2.0486328367042006e-07
, O 0 5.890865395485889e-08
and O 0 6.512463812669012e-08
2 O 0 2.226139912409053e-07
) O 0 1.273916439004097e-07
a O 0 2.850030966783379e-07
6 O 0 1.0933188150374917e-06
bp O 0 1.637180321267806e-05
deletion O 0 1.1113371328974608e-05
polymorphism O 0 5.823078481625998e-06
in O 0 2.2792856668729655e-07
the O 0 2.1983755971177743e-07
3 O 0 4.6014733356969373e-07
noncoding O 0 3.127388481516391e-06
part O 0 2.8819906106036797e-07
of O 0 1.2913396574276703e-07
the O 0 4.3630569734887104e-07
CPO O 0 2.2545702449860983e-05
gene O 0 3.605602387324325e-06
, O 0 2.2821349432433635e-07
574 O 0 4.007168172392994e-06
bp O 0 4.4618504944082815e-06
downstream O 0 7.941384296827891e-07
of O 0 5.360912069818369e-08
the O 0 1.2657038439556345e-07
last O 0 3.774881349727366e-07
base O 0 3.749694030830142e-07
of O 0 1.0403593364571861e-07
the O 0 9.76060960056202e-07
normal O 0 1.4876070054015145e-05
termination O 0 7.71571503719315e-05
codon O 0 5.846913336426951e-05
( O 0 7.366351837845286e-06
+ O 0 3.0542516469722614e-05
574 O 0 7.73659412516281e-05
delATTCTT O 0 0.0001860967167885974
) O 0 2.058981772279367e-05
. O 0 2.7137020879308693e-05

Five O 0 7.028415711829439e-05
intragenic O 0 0.0016252093482762575
dimorphisms O 0 0.001071620499715209
are O 0 1.189537442769506e-06
now O 0 6.269477239584376e-07
well O 0 3.2726813969929935e-07
characterized O 0 4.640439328795765e-06
and O 0 1.5196587810351048e-07
the O 0 2.4763718897702347e-07
high O 0 6.366761908793706e-07
degree O 0 8.644008175906492e-07
of O 0 3.3430268331358093e-07
allelic O 0 8.140023419400677e-05
heterogeneity O 0 7.767382339807227e-05
in O 0 4.251457994541852e-06
HC B-Disease 0 0.1570758819580078
is O 0 4.5051882580082747e-07
demonstrated O 0 7.574153642053716e-07
with O 0 9.88395001400022e-08
seven O 0 2.6052686052935314e-07
new O 0 5.491413048730465e-07
different O 0 1.2292085216358828e-07
mutations O 0 1.5087632618815405e-06
making O 0 9.271926870724201e-08
a O 0 1.528688358121144e-07
total O 0 1.3889030014979653e-07
of O 0 1.86468582796806e-07
nineteen O 0 9.506727110419888e-06
CPO O 1 0.633657693862915
gene B-Disease 0 0.1482492834329605
defects I-Disease 1 0.9987460374832153
reported O 0 0.00014915359497535974
so O 0 9.634694606575067e-07
far O 0 1.7824086171458475e-06
. O 0 2.2619758510700194e-06
. O 0 9.680574294179678e-06

Coincidence O 0 0.00025338554405607283
of O 0 7.3451033131277654e-06
two O 0 3.4215449886687566e-06
novel O 0 1.1968715625698678e-05
arylsulfatase O 0 0.00011649578664219007
A O 0 8.986401553556789e-06
alleles O 0 3.93794834963046e-05
and O 0 2.4643643428134965e-06
mutation O 0 4.97051005368121e-05
459 O 0 0.000102440026239492
+ O 0 8.41401779325679e-05
1G O 0 0.0009638577466830611
> O 0 1.5251863260345999e-05
A O 0 1.544636916150921e-06
within O 0 7.827844683561125e-07
a O 0 1.6576955204072874e-06
family O 0 7.3777623583737295e-06
with O 0 7.748662028461695e-06
metachromatic B-Disease 1 0.9999973773956299
leukodystrophy I-Disease 1 0.9999988079071045
: O 0 4.780223207490053e-06
molecular O 0 6.7395103542367e-06
basis O 0 1.7913621377374511e-06
of O 0 1.9500741927913623e-06
phenotypic O 0 0.00014459065278060734
heterogeneity O 0 0.0008797076297923923
. O 0 9.484061592957005e-05

In O 0 1.8184311556979083e-05
a O 0 6.8720150920853484e-06
family O 0 4.540740974334767e-06
with O 0 4.053017619298771e-07
three O 0 5.637277240566618e-07
siblings O 0 1.4547832506650593e-05
, O 0 2.6023258214991074e-07
one O 0 2.8103846716476255e-07
developed O 0 4.143309524806682e-06
classical O 0 7.767685019643977e-06
late O 0 0.009216547943651676
infantile O 1 0.9999508857727051
metachromatic B-Disease 1 0.9999994039535522
leukodystrophy I-Disease 1 0.9999998807907104
( O 0 0.00030414958018809557
MLD B-Disease 1 0.9999827146530151
) O 0 3.3710123261698755e-06
, O 0 5.28265843513509e-07
fatal O 0 8.415494812652469e-05
at O 0 8.801400781521806e-07
age O 0 5.903023634346027e-07
5 O 0 4.7598521746294864e-07
years O 0 3.3003001931319886e-07
, O 0 1.5347650617059116e-07
with O 0 1.1657311915769242e-06
deficient O 0 0.03666896000504494
arylsulfatase O 0 0.0002861635584849864
A O 0 6.144643066363642e-06
( O 0 2.843758693416021e-06
ARSA O 0 0.0002527323958929628
) O 0 6.737543003509927e-07
activity O 0 9.260541560252022e-07
and O 0 3.171078333252808e-07
increased O 0 6.5139315665874165e-06
galactosylsulfatide O 0 0.0031318729743361473
( O 0 3.1011051760287955e-05
GS O 1 0.9832130074501038
) O 0 1.7161743016913533e-05
excretion O 0 9.518580191070214e-05
. O 0 2.7098927603219636e-05

The O 0 7.971455488586798e-06
two O 0 1.5990428892109776e-06
other O 0 7.752697115392948e-07
siblings O 0 1.327077825408196e-05
, O 0 8.798899671091931e-07
apparently O 0 7.999068657227326e-06
healthy O 0 4.481129053601762e-06
at O 0 5.854795972481952e-07
12 O 0 6.017900773258589e-07
( O 0 4.147019581068889e-07
1 O 0 3.100676337908226e-07
/ O 0 6.0840243349957746e-06
2 O 0 1.9089968361640786e-07
) O 0 8.289470088129747e-08
and O 0 4.8231299842882436e-08
15 O 0 9.290054236998913e-08
years O 0 9.73132543435895e-08
, O 0 5.866555952138697e-08
respectively O 0 1.6005198233415285e-07
, O 0 3.632095868510987e-08
and O 0 3.7902335492390193e-08
their O 0 1.171129468957588e-07
father O 0 7.85010888648685e-06
, O 0 2.913047012498282e-07
apparently O 0 4.487608293857193e-06
healthy O 0 9.134882361649943e-07
as O 0 9.937767231349426e-08
well O 0 1.361662498311489e-07
, O 0 1.9599823986027332e-07
presented O 0 2.399109234829666e-06
ARSA O 0 0.24384649097919464
and O 0 3.962902155763004e-06
GS O 1 0.8437347412109375
values O 0 8.862144795784843e-07
within O 0 3.9601715684511873e-07
the O 0 4.103195010429772e-07
range O 0 3.411744046388776e-06
of O 0 9.968585800379515e-06
MLD B-Disease 1 0.9999998807907104
patients O 1 0.854004979133606
. O 0 9.629091800889e-05

Mutation O 0 0.0053117466159164906
screening O 0 0.00026021176017820835
and O 0 4.195053406874649e-06
sequence O 0 4.270381850801641e-06
analysis O 0 2.256516381748952e-06
disclosed O 0 5.404449439083692e-06
the O 0 3.795576901666209e-07
involvement O 0 1.2932218851346988e-06
of O 0 2.1260377991438872e-07
three O 0 3.9011774788377807e-07
different O 0 1.3261276308185188e-06
ARSA O 1 0.9863716959953308
mutations O 0 4.587877992889844e-05
being O 0 6.25800794296083e-07
the O 0 3.1296119118451315e-07
molecular O 0 2.36902951655793e-06
basis O 0 7.492111535611912e-07
of O 0 1.7360357560392004e-06
intrafamilial O 0 0.0007273825467564166
phenotypic O 0 0.0002782221417874098
heterogeneity O 0 0.001013264525681734
. O 0 9.359342220705003e-05

The O 0 8.583097223890945e-05
late O 0 0.12567414343357086
infantile O 1 0.9999954700469971
patient O 1 0.9990224838256836
inherited O 1 0.8183477520942688
from O 0 3.534013103489997e-06
his O 0 1.2086007700418122e-05
mother O 0 3.076116263400763e-05
the O 0 9.308301400778873e-07
frequent O 0 1.0350235243095085e-05
0 O 0 5.344420969777275e-06
- O 0 7.604843267472461e-05
type O 0 2.159575160476379e-05
mutation O 0 1.4463891602645162e-05
459 O 0 2.024908462772146e-05
+ O 0 1.1043786798836663e-05
1G O 0 0.00014345493400469422
> O 0 5.2841223805444315e-06
A O 0 5.215067062636081e-07
, O 0 1.3058564718448906e-07
and O 0 8.208160551248511e-08
from O 0 1.463660623812757e-07
his O 0 1.2520860082076979e-06
father O 0 7.616428320034174e-06
a O 0 8.036726626414747e-07
novel O 0 1.3441250530377147e-06
, O 0 1.4297071970759134e-07
single O 0 5.989992928334686e-07
basepair O 0 2.1728417777922004e-05
microdeletion O 0 1.060565045918338e-05
of O 0 2.2803118326919503e-07
guanine O 0 2.5604911115806317e-06
at O 0 5.450934281725495e-07
nucleotide O 0 2.6536065433901967e-06
7 O 0 1.510728566245234e-06
in O 0 1.0240097481073462e-06
exon O 0 3.941153045161627e-05
1 O 0 3.7664162846340332e-06
( O 0 6.67563290335238e-06
7delG O 0 0.00010274937812937424
) O 0 1.090410842152778e-05
. O 0 1.3723562915401999e-05

The O 0 3.94119051634334e-05
two O 0 2.0837744159507565e-05
clinically O 0 0.004840907175093889
unaffected O 0 0.0006211342988535762
siblings O 0 3.80615601898171e-05
carried O 0 3.8791686165495776e-06
the O 0 2.0253344246157212e-06
maternal O 0 0.00010195511276833713
mutation O 0 4.517549677984789e-05
459 O 0 4.271633588359691e-05
+ O 0 3.2036266929935664e-05
1G O 0 0.00040194077882915735
> O 0 8.135516509355512e-06
A O 0 1.0503620160307037e-06
and O 0 1.6546363212910364e-07
, O 0 6.784107853263777e-08
on O 0 1.0847944054148684e-07
their O 0 2.548271424984705e-07
paternal O 0 2.2996329789748415e-05
allele O 0 1.3192467122280505e-05
, O 0 2.1395923965883412e-07
a O 0 4.0088096397994377e-07
novel O 0 1.293985519623675e-06
cytosine O 0 4.260269633959979e-06
to O 0 6.110273602644156e-07
thymidine O 0 2.919684993685223e-05
transition O 0 3.756179012270877e-06
at O 0 1.172874704025162e-06
nucleotide O 0 6.9754082687722985e-06
2435 O 0 7.4947856774088e-05
in O 0 1.6701759477655287e-06
exon O 0 1.8671909856493585e-05
8 O 0 1.7245296248802333e-06
, O 0 2.4961107669696503e-07
resulting O 0 1.1156546406709822e-06
in O 0 2.1424936846869969e-07
substitution O 0 1.521466970189067e-06
of O 0 5.256591180113901e-07
alanine O 0 4.544898547464982e-05
464 O 0 3.2073374313768e-05
by O 0 5.554503786697751e-06
valine O 0 0.0009545484208501875
( O 0 1.2486550986068323e-05
A464V O 0 0.00012427511683199555
) O 0 1.399289885739563e-05
. O 0 1.7793428924051113e-05

The O 0 0.00015582999913021922
fathers O 0 0.0003373685758560896
genotype O 0 0.0008404651889577508
thus O 0 2.8782747904188e-05
was O 0 5.098868132336065e-05
7delG O 0 0.0017804930685088038
/ O 0 0.0028423971962183714
A464V O 0 0.0017397478222846985
. O 0 0.00013751976075582206

Mutation O 0 0.00840926356613636
A464V O 0 0.003624205244705081
was O 0 5.451592733152211e-05
not O 0 1.541633309898316e-06
found O 0 1.3118595916239428e-06
in O 0 1.037984247886925e-06
18 O 0 9.6484727691859e-06
unrelated O 0 0.047035302966833115
MLD B-Disease 1 1.0
patients O 0 0.16200624406337738
and O 0 3.0126932415441843e-06
50 O 0 8.454660019197036e-06
controls O 0 0.0003430384094826877
. O 0 3.031024243682623e-05

A464V O 0 0.003124058246612549
, O 0 2.2479405743069947e-05
although O 0 9.006923392007593e-06
clearly O 0 7.93497292761458e-06
modifying O 0 4.7449226258322597e-05
ARSA O 0 0.10054659843444824
and O 0 9.23327388591133e-06
GS O 1 0.9991099238395691
levels O 0 5.672364750353154e-06
, O 0 7.245935194077902e-07
apparently O 0 3.677389258882613e-06
bears O 0 4.148615971644176e-06
little O 0 1.0158190661968547e-06
significance O 0 1.7701510159895406e-06
for O 0 8.947499168243667e-07
clinical O 0 3.970172838307917e-05
manifestation O 0 4.489235652727075e-05
of O 0 3.0539781619154382e-06
MLD B-Disease 1 0.9999585151672363
, O 0 2.231618509540567e-06
mimicking O 0 2.17060496652266e-05
the O 0 4.07970810556435e-06
frequent O 0 0.00011481223191367462
ARSA O 1 0.625174343585968
pseudodeficiency O 0 0.01619148999452591
allele O 0 0.0012517679715529084
. O 0 8.672114927321672e-05

Our O 0 4.002614878118038e-05
results O 0 2.717387178563513e-05
demonstrate O 0 8.68261940922821e-06
that O 0 6.034003376953478e-07
in O 0 6.212595167198742e-07
certain O 0 1.330449890701857e-06
genetic O 0 3.8098380173323676e-05
conditions O 0 0.010446269065141678
MLD B-Disease 1 0.9999992847442627
- O 0 0.010673522017896175
like O 0 3.0099477044132072e-06
ARSA O 0 0.2623271346092224
and O 0 7.686164281039964e-06
GS O 1 0.9971893429756165
values O 0 1.5176325405263924e-06
need O 0 4.69486082010917e-07
not O 0 1.1498718066604852e-07
be O 0 1.2361101653368678e-07
paralleled O 0 4.60835963167483e-06
by O 0 4.010624707007082e-06
clinical O 0 0.39287737011909485
disease O 0 0.10261508822441101
, O 0 2.210638854194258e-07
a O 0 5.263584057502158e-07
finding O 0 6.989998837525491e-07
with O 0 2.3222030449687736e-06
serious O 0 0.0009570686961524189
diagnostic O 1 0.5611980557441711
and O 0 3.742877743206918e-05
prognostic O 0 0.02618391625583172
implications O 0 0.0003431447548791766
. O 0 5.536772732739337e-05

Moreover O 0 0.0002997714909724891
, O 0 2.4984401534311473e-05
further O 0 2.991975452459883e-05
ARSA O 0 0.44424718618392944
alleles O 0 0.0001746204070514068
functionally O 0 3.479153019725345e-05
similar O 0 2.7005198717233725e-06
to O 0 1.0925411970674759e-06
A464V O 0 5.4955107771093026e-05
might O 0 1.7099005162890535e-06
exist O 0 3.3663241083559114e-07
which O 0 1.2268229454548418e-07
, O 0 4.246244955652401e-08
together O 0 8.690256692034382e-08
with O 0 1.8821519631728734e-07
0 O 0 3.272524054409587e-06
- O 0 0.0012642942601814866
type O 0 0.00012527871876955032
mutations O 0 4.3336389353498816e-05
, O 0 8.757143632465159e-07
may O 0 8.078090104390867e-06
cause O 0 1.921041439345572e-05
pathological O 0 9.468681673752144e-05
ARSA O 1 0.9266800284385681
and O 0 2.0653615138144232e-05
GS O 1 0.9998700618743896
levels O 0 3.941110207961174e-06
, O 0 2.4066110881904024e-07
but O 0 1.604237951369214e-07
not O 0 2.612690650494187e-07
clinical O 0 1.1323008948238567e-05
outbreak O 0 1.3198055057728197e-05
of O 0 3.6110731116423267e-07
the O 0 1.6295412933686748e-05
disease O 0 0.15519508719444275
. O 0 3.777081701628049e-06
. O 0 2.0261522877262905e-05

Human O 0 0.022211674600839615
MLH1 O 1 0.9999964237213135
deficiency O 1 0.9999927282333374
predisposes O 0 0.09372297674417496
to O 0 0.00021474988898262382
hematological B-Disease 1 0.9997245669364929
malignancy I-Disease 1 0.9997139573097229
and O 0 0.0009618413168936968
neurofibromatosis B-Disease 1 0.9999958276748657
type I-Disease 0 0.002043785760179162
1 I-Disease 0 4.7564884880557656e-05
. O 0 4.6889388613635674e-05

Heterozygous O 0 0.04799913614988327
germ O 1 0.7377547025680542
- O 0 0.029822664335370064
line O 0 8.796514157438651e-05
mutations O 0 5.120009882375598e-05
in O 0 1.35040295390354e-06
the O 0 1.9569320102164056e-06
DNA O 0 4.659457044908777e-05
mismatch O 0 0.0007019519107416272
repair O 0 0.023519327864050865
genes O 0 1.513340430392418e-05
lead O 0 8.30959379527485e-06
to O 0 1.9620352759375237e-05
hereditary B-Disease 1 0.9999798536300659
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0004826451768167317

The O 0 0.0003036054549738765
disease O 1 0.8360998034477234
susceptibility O 0 0.0002442151017021388
of O 0 1.05555159279902e-06
individuals O 0 1.4432312127610203e-06
who O 0 2.2104413801571354e-06
constitutionally O 0 1.780812999641057e-05
lack O 0 2.2799383714300347e-06
both O 0 8.524251029484731e-07
wild O 0 6.497874437627615e-06
- O 0 0.0024994974955916405
type O 0 3.669303987408057e-05
alleles O 0 2.7528179998626e-05
is O 0 1.6657539845255087e-06
unknown O 0 1.0132531315321103e-05
. O 0 1.8058553905575536e-05

We O 0 1.0706133252824657e-05
have O 0 1.727092353576154e-06
identified O 0 1.4833861996521591e-06
three O 0 5.545630870074092e-07
offspring O 0 3.3516664643684635e-06
in O 0 1.0532729675105656e-06
a O 0 4.9343718274030834e-05
hereditary B-Disease 1 0.999998927116394
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.03569602966308594
who O 0 2.103273982356768e-05
developed O 0 0.003505861386656761
hematological B-Disease 1 0.9986602067947388
malignancy I-Disease 1 0.8813777565956116
at O 0 2.2503570562548703e-06
a O 0 8.929897035159229e-07
very O 0 3.863906385959126e-07
early O 0 2.078963234453113e-06
age O 0 4.949482104166236e-07
, O 0 6.3838946573469e-08
and O 0 5.5103310359072566e-08
at O 0 1.2824945372358343e-07
least O 0 6.670425989341311e-08
two O 0 3.86639733562788e-08
of O 0 6.297160837220872e-08
them O 0 1.4419968863421673e-07
displayed O 0 2.5401966468052706e-06
signs O 0 6.1772643675794825e-06
of O 0 1.8323115682505886e-06
neurofibromatosis B-Disease 1 0.9997913241386414
type I-Disease 0 8.687178342370316e-05
1 I-Disease 0 6.019340617058333e-06
( O 0 2.054000287898816e-05
NF1 B-Disease 0 0.001325676217675209
) O 0 1.8676753825275227e-05
. O 0 2.469161518092733e-05

DNA O 0 0.0003751924086827785
sequence O 0 5.8104240451939404e-05
analysis O 0 1.9780742150032893e-05
and O 0 2.8136855689808726e-06
allele O 0 5.2820498240180314e-05
- O 0 1.0855828804778866e-05
specific O 0 1.1109153774668812e-06
amplification O 0 1.3122126802045386e-05
in O 0 4.628081171631493e-07
two O 0 6.128977929620305e-07
siblings O 0 1.416175473423209e-05
revealed O 0 1.0450708941789344e-05
a O 0 6.842796665296191e-06
homozygous O 0 0.0008926265290938318
MLH1 O 0 0.4147484302520752
mutation O 0 0.0001356927677989006
( O 0 7.974275831656996e-06
C676T O 0 0.0001575966743985191
- O 0 0.00037356314714998007
- O 0 0.00016276045062113553
> O 0 0.00010968583228532225
Arg226Stop O 0 0.00026566634187474847
) O 0 2.476157715136651e-05
. O 0 2.7327381758368574e-05

Thus O 0 8.931355841923505e-05
, O 0 9.705385309644043e-06
a O 0 1.1591778275032993e-05
homozygous O 0 0.00032195731182582676
germ O 0 0.0021589489188045263
- O 0 0.0002688550448510796
line O 0 5.135888568474911e-05
MLH1 O 0 0.1874534785747528
mutation O 0 8.310466364491731e-05
and O 0 7.371959782176418e-06
consequent O 1 0.9726080298423767
mismatch O 1 0.9999918937683105
repair O 1 1.0
deficiency O 1 0.9999957084655762
results O 0 1.1524736692081206e-05
in O 0 1.7834357777246623e-06
a O 0 2.671730544534512e-05
mutator O 1 0.9995198249816895
phenotype O 1 0.9684023261070251
characterized O 0 0.001959160203114152
by O 0 5.541442078538239e-05
leukemia B-Disease 1 0.9999703168869019
and O 0 0.00019524885283317417
/ O 1 0.9998956918716431
or O 0 0.46172162890434265
lymphoma B-Disease 1 1.0
associated O 0 0.0007662452990189195
with O 0 3.751411350094713e-05
neurofibromatosis B-Disease 1 0.9999972581863403
type I-Disease 0 0.00013671514170709997
1 I-Disease 0 5.282706297293771e-06
. O 0 4.193201220914489e-06
. O 0 1.822349258873146e-05

Missense O 1 0.9509344100952148
mutations O 0 0.06311099976301193
in O 0 6.034513717168011e-06
the O 0 8.046482093959639e-07
most O 0 3.1338680628323345e-07
ancient O 0 5.880306730432494e-07
residues O 0 1.2841226180171361e-06
of O 0 1.795025355022517e-07
the O 0 9.299446901422925e-07
PAX6 O 0 0.0004007149545941502
paired O 0 1.157140013674507e-05
domain O 0 4.003383310191566e-06
underlie O 0 2.3565287847304717e-05
a O 0 1.864959472186456e-06
spectrum O 0 1.7802982256398536e-05
of O 0 2.866185695893364e-06
human O 0 0.02176721580326557
congenital B-Disease 1 1.0
eye I-Disease 1 0.9999972581863403
malformations I-Disease 1 0.9999983310699463
. O 0 0.00018819734395947307

Mutations O 0 0.0015813825884833932
of O 0 1.2437895748007577e-05
the O 0 1.09694728962495e-05
human O 0 2.5557981643942185e-05
PAX6 O 0 0.38362300395965576
gene O 0 0.003108399687334895
underlie O 1 0.9452409744262695
aniridia B-Disease 1 1.0
( O 0 0.20133312046527863
congenital B-Disease 1 0.9999581575393677
absence I-Disease 0 3.57579006049491e-06
of I-Disease 0 1.728202931872147e-07
the I-Disease 0 6.539100354530092e-07
iris I-Disease 0 0.014503763988614082
) O 0 4.2940050093420723e-07
, O 0 1.1773916952506625e-07
a O 0 5.52007122678333e-07
rare O 0 7.6266405812930316e-06
dominant O 0 0.0004005786031484604
malformation B-Disease 1 0.6893484592437744
of I-Disease 0 1.0225215874015703e-06
the I-Disease 0 6.878164640511386e-06
eye I-Disease 0 0.004221916198730469
. O 0 4.348169022705406e-05

The O 0 3.876894697896205e-05
spectrum O 0 9.025388135341927e-05
of O 0 6.679377293039579e-06
PAX6 O 1 0.9476679563522339
mutations O 0 0.05315488204360008
in O 0 7.158483640523627e-05
aniridia B-Disease 1 1.0
patients O 0 0.3512827157974243
is O 0 7.696056627537473e-07
highly O 0 1.2935994391227723e-06
biased O 0 2.0599441086233128e-06
, O 0 8.697420383896315e-08
with O 0 1.0675770312218447e-07
92 O 0 1.4346188663694193e-06
% O 0 9.734982597819908e-08
of O 0 4.749776394419314e-08
all O 0 1.7039526767348434e-07
reported O 0 0.0018000226700678468
mutations O 0 1.7856747945188545e-05
leading O 0 1.230625912285177e-06
to O 0 1.0509411367820576e-06
premature O 0 3.620219285949133e-05
truncation O 0 6.228301572264172e-06
of O 0 1.9780542004355084e-07
the O 0 4.2094654872926185e-07
protein O 0 1.7852020164355054e-06
( O 0 7.058985147523344e-07
nonsense O 0 1.3618667935588746e-06
, O 0 1.5462374847174942e-07
splicing O 0 2.9472573714883765e-06
, O 0 2.3158371220688423e-07
insertions O 0 3.6701544559036847e-06
and O 0 3.477782968275278e-07
deletions O 0 4.28704333899077e-06
) O 0 2.1471083755386644e-07
and O 0 7.459019002453715e-08
just O 0 7.462961093551712e-08
2 O 0 1.6464495899981557e-07
% O 0 7.737032348131834e-08
leading O 0 1.3221432482168893e-07
to O 0 9.94565638734457e-08
substitution O 0 2.4432301870547235e-07
of O 0 4.8249425788071676e-08
one O 0 1.5663674446386722e-07
amino O 0 1.0573691042736755e-06
acid O 0 2.8322074285824783e-06
by O 0 8.264540269919962e-07
another O 0 3.083448291363311e-06
( O 0 1.1287408597127069e-05
missense O 0 0.000249223958235234
) O 0 1.311872256337665e-05
. O 0 1.8716067643254064e-05

The O 0 2.0417086489032954e-05
extraordinary O 0 1.700232496659737e-05
conservation O 0 5.0603930503712036e-06
of O 0 4.0847237414709525e-07
the O 0 6.381235380104044e-07
PAX6 O 0 0.00016704144945833832
protein O 0 1.4801544239162467e-06
at O 0 2.439753927774291e-07
the O 0 2.3316445663112972e-07
amino O 0 1.1783369018303347e-06
acid O 0 1.579926788508601e-06
level O 0 5.590239879893488e-07
amongst O 0 1.1754210618164507e-06
vertebrates O 0 9.529001545161009e-06
predicts O 0 4.20785800088197e-05
that O 0 6.367016567310202e-07
pathological O 0 0.00012896960834041238
missense O 0 0.0898594781756401
mutations O 0 0.0002622698375489563
should O 0 8.300923468596011e-07
in O 0 2.8317327860349906e-07
fact O 0 3.8716450490028365e-07
be O 0 1.584751174732446e-07
common O 0 3.622099598032946e-07
even O 0 2.6196440217063355e-07
though O 0 3.227127933769225e-07
they O 0 9.013043467120951e-08
are O 0 6.674294894537525e-08
hardly O 0 7.475774737031315e-07
ever O 0 1.0529013252380537e-06
seen O 0 3.2218435990216676e-06
in O 0 1.2432441508281045e-05
aniridia B-Disease 1 0.9999986886978149
patients O 0 0.42100033164024353
. O 0 4.4710443035000935e-05

This O 0 2.571410186646972e-05
indicates O 0 2.3954191419761628e-05
that O 0 8.235853670157667e-07
there O 0 2.5939041847777844e-07
is O 0 1.3452572034111654e-07
a O 0 4.880514552496606e-07
heavy O 0 4.7228742914739996e-05
ascertainment O 0 0.005425270181149244
bias O 0 1.3968846360512543e-05
in O 0 2.869799402560602e-07
the O 0 1.5022936850073165e-07
selection O 0 3.672864465897874e-07
of O 0 2.8661756346082257e-07
patients O 0 3.98801093979273e-05
for O 0 1.0399083976153634e-06
PAX6 O 1 0.7782530784606934
mutation O 0 3.697982901940122e-05
analysis O 0 8.938442874750763e-07
and O 0 2.207775651186239e-07
that O 0 1.691768005684935e-07
the O 0 7.545646667495021e-07
missing O 0 1.2369276191748213e-05
PAX6 O 1 0.6347769498825073
missense O 0 0.3917049169540405
mutations O 0 0.003031934378668666
frequently O 0 0.00010738006676547229
may O 0 0.00010393445700174198
underlie O 0 0.0008590188226662576
phenotypes O 0 0.0006324038258753717
distinct O 0 1.4220680895959958e-05
from O 0 1.2506500752351712e-05
textbook O 0 0.0010077913757413626
aniridia B-Disease 1 0.9997238516807556
. O 0 0.00014169697533361614

Here O 0 4.496262772590853e-05
we O 0 3.4540084925538395e-06
present O 0 2.2575882212549914e-06
four O 0 2.04178786589182e-06
novel O 0 1.610845902177971e-05
PAX6 O 0 0.09079109132289886
missense O 0 0.0843103751540184
mutations O 0 0.0001800089521566406
, O 0 6.919614179423661e-07
two O 0 3.8497088894473563e-07
in O 0 6.527536129397049e-07
association O 0 2.9507195904443506e-06
with O 0 1.7637880773690995e-06
atypical O 0 0.010458456352353096
phenotypes O 0 0.01921352744102478
ectopia B-Disease 0 0.006983644794672728
pupillae I-Disease 0 0.009425202384591103
( O 0 5.12717724632239e-06
displaced B-Disease 0 4.629795057553565e-06
pupils I-Disease 0 6.0453771766333375e-06
) O 0 3.132173105768743e-06
and O 0 2.4658504116814584e-05
congenital B-Disease 1 0.9999984502792358
nystagmus I-Disease 1 0.6827135682106018
( O 0 2.604734618216753e-06
searching B-Disease 0 2.299008428963134e-06
gaze I-Disease 0 8.007151336641982e-06
) O 0 2.149095337244944e-07
, O 0 5.1726082972436416e-08
and O 0 3.524244718278169e-08
two O 0 6.01969105673561e-08
in O 0 1.7543739261327573e-07
association O 0 7.686931553507748e-07
with O 0 2.667877367912297e-07
more O 0 9.273223326999869e-07
recognizable O 0 0.00014747113164048642
aniridia B-Disease 1 0.9999527931213379
phenotypes O 0 0.05051952227950096
. O 0 5.8976540458388627e-05

Strikingly O 0 0.0015626648673787713
, O 0 3.785837407122017e-06
all O 0 4.0095207509693864e-07
four O 0 7.16685292445618e-07
mutations O 0 5.785697339888429e-06
are O 0 1.3340005011741596e-07
located O 0 3.7165699495744775e-07
within O 0 2.5705389816721436e-07
the O 0 6.264911007747287e-07
PAX6 O 0 0.00028058848693035543
paired O 0 5.287660769681679e-06
domain O 0 1.2117108099118923e-06
and O 0 2.566837622453022e-07
affect O 0 9.846352213571663e-07
amino O 0 9.059317562787328e-07
acids O 0 6.11735742950259e-07
which O 0 1.235397206755806e-07
are O 0 3.856226982179578e-08
highly O 0 1.496319868010687e-07
conserved O 0 5.402060310188972e-07
in O 0 1.949462813399805e-07
all O 0 1.3184978797653457e-07
known O 0 1.1050140074075898e-06
paired O 0 6.0584784478123765e-06
domain O 0 1.102859005186474e-05
proteins O 0 2.4879500415408984e-05
. O 0 1.9069066183874384e-05

Our O 0 2.528838194848504e-05
results O 0 1.2588287972903345e-05
support O 0 2.9499822176148882e-06
the O 0 1.4849105127723305e-06
hypothesis O 0 5.537975084735081e-06
that O 0 1.9626384073490044e-07
the O 0 1.36345178702868e-07
under O 0 3.2295972118845384e-07
- O 0 1.3324878409548546e-06
representation O 0 4.0959972125165223e-07
of O 0 3.3881283911796345e-07
missense O 0 0.0005163470632396638
mutations O 0 3.218969504814595e-05
is O 0 3.5658086972034653e-07
caused O 0 4.93765310238814e-06
by O 0 9.655630037741503e-07
ascertainment O 0 0.0006796300294809043
bias O 0 4.626082591130398e-05
and O 0 6.239623644432868e-07
suggest O 0 7.513398259106907e-07
that O 0 8.752954272495117e-08
a O 0 4.145173022607196e-07
substantial O 0 1.803353939067165e-06
burden O 0 8.118760888464749e-06
of O 0 9.442217674404674e-07
PAX6 B-Disease 1 0.9963156580924988
- I-Disease 1 0.9905487895011902
related I-Disease 0 0.02659735642373562
disease I-Disease 0 0.18302498757839203
remains O 0 3.5284363093524007e-06
to O 0 8.224190537475806e-07
be O 0 9.150463711193879e-07
uncovered O 0 3.3958724088734016e-05
. O 0 5.621785021503456e-06
. O 0 1.9802448150585406e-05

The O 0 4.170059764874168e-05
chromosomal O 0 0.00033195738797076046
order O 0 4.597047791321529e-06
of O 0 6.920432156221068e-07
genes O 0 3.4614611195138423e-06
controlling O 0 4.474104571272619e-06
the O 0 9.182449502986856e-07
major O 0 3.008145540661644e-06
histocompatibility O 0 0.0002536801912356168
complex O 0 3.0107112252153456e-06
, O 0 5.705060743821377e-07
properdin O 0 5.7269837270723656e-05
factor O 0 2.746701511568972e-06
B O 0 4.922208518109983e-06
, O 0 3.249561473239737e-07
and O 0 1.8190999071521219e-06
deficiency B-Disease 0 0.00022602928220294416
of I-Disease 0 6.430897769860167e-08
the I-Disease 0 2.147511821704029e-07
second I-Disease 0 8.749079825065564e-07
component I-Disease 0 2.158335291824187e-06
of I-Disease 0 8.974110983217543e-07
complement I-Disease 0 2.456216316204518e-05
. O 0 1.4337914763018489e-05

The O 0 1.6058056644396856e-05
relationship O 0 1.2839736882597208e-05
of O 0 8.170779892680002e-07
the O 0 1.3364866617848747e-06
genes O 0 4.880407232121797e-06
coding O 0 9.75406146608293e-06
for O 0 7.964197834553488e-07
HLA O 0 0.0031598075293004513
to O 0 3.9778331029083347e-07
those O 0 2.573661674887262e-07
coding O 0 2.888946482926258e-06
for O 0 2.5208467491211195e-07
properdin O 0 7.531754818046466e-05
Factor O 0 2.99805287795607e-06
B O 0 5.202680313232122e-06
allotypes O 0 2.9181286663515493e-05
and O 0 4.574773413423827e-07
for O 0 1.2061722145517706e-06
deficiency B-Disease 0 0.0003224023967050016
of I-Disease 0 6.6316957259005e-08
the I-Disease 0 1.4632823308602383e-07
second I-Disease 0 3.2993875720421784e-07
component I-Disease 0 4.7394556190738513e-07
of I-Disease 0 9.522958066554565e-08
complement I-Disease 0 1.6105486793094315e-06
( O 0 2.1051348539913306e-06
C2 O 0 0.0017574680969119072
) O 0 4.201989440844045e-07
was O 0 4.339486565640982e-07
studied O 0 4.329623664034443e-07
in O 0 1.5246524753820268e-07
families O 0 2.9920352062617894e-07
of O 0 3.7308032574401295e-07
patients O 0 0.00039784767432138324
with O 0 0.00015705601254012436
connective O 1 0.9999995231628418
tissue O 1 0.9999996423721313
disorders O 1 0.9999985694885254
. O 0 9.568780660629272e-05

Patients O 0 0.2552643120288849
were O 0 1.0162677426706068e-05
selected O 0 5.166788923816057e-06
because O 0 1.0025340770880575e-06
they O 0 2.485476215952076e-07
were O 0 4.3957675188721623e-07
heterozygous O 0 2.5901521439664066e-05
or O 0 6.081854735384695e-06
homozygous O 0 0.005699316039681435
for O 0 0.0029791793785989285
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
. O 0 0.00011443797848187387

12 O 0 6.18275735178031e-05
families O 0 1.4111873497313354e-05
with O 0 2.338653303013416e-06
15 O 0 6.463992576755118e-06
matings O 0 0.00013130821753293276
informative O 0 9.817370300879702e-05
for O 0 0.04772021248936653
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 1.2074509868398309e-05
found O 0 2.1031417418271303e-05
. O 0 2.8436819775379263e-05

Of O 0 3.2963522244244814e-05
57 O 0 8.751752466196194e-05
informative O 0 3.6411041946848854e-05
meioses O 0 0.0001637336245039478
, O 0 6.060982400413195e-07
two O 0 2.4931253506110806e-07
crossovers O 0 4.073456238984363e-06
were O 0 2.9618908570228086e-07
noted O 0 6.676789894299873e-07
between O 0 1.3414270370049053e-06
the O 0 0.0019524438539519906
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999980926513672
gene O 0 6.922532520547975e-06
and O 0 5.286674991111795e-07
the O 0 1.8805492345563835e-06
HLA O 0 0.4488910734653473
- O 0 0.00014359207125380635
B O 0 5.028488885727711e-06
gene O 0 2.2620104118686868e-06
, O 0 1.1070005001556638e-07
with O 0 1.3330925696664053e-07
a O 0 6.462831265707791e-07
recombinant O 0 6.894912075949833e-06
fraction O 0 2.5215924779331544e-06
of O 0 1.5545647329417989e-06
0 O 0 2.286021481268108e-05
. O 0 2.253256934636738e-05

035 O 1 0.5278573632240295
. O 0 0.005262728780508041

A O 0 0.00033554231049492955
lod O 0 0.021234387531876564
score O 0 6.541609764099121e-06
of O 0 9.651063237470225e-07
13 O 0 1.6731092955524218e-06
was O 0 1.2993685913897934e-06
calculated O 0 2.1983119040669408e-06
for O 0 7.010808644736244e-07
linkage O 0 0.0002450087631586939
between O 0 0.004466893617063761
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 3.385466698091477e-05
HLA O 1 0.9934892654418945
- O 0 0.00032680571894161403
B O 0 3.20722983815358e-06
at O 0 1.8594083428524755e-07
a O 0 1.579504953497235e-07
maximum O 0 3.247721451771213e-07
likelihood O 0 7.412230615955195e-07
value O 0 9.60409352046554e-08
of O 0 6.250588313605476e-08
the O 0 3.200100309186382e-07
recombinant O 0 5.057006546849152e-06
fraction O 0 2.7323010272084503e-06
of O 0 1.1227504046473769e-06
0 O 0 2.3142432837630622e-05
. O 0 1.9075032469118014e-05

04 O 0 0.048528041690588
. O 0 0.001671002246439457

18 O 0 0.00011853881733259186
families O 0 1.5245347640302498e-05
with O 0 3.0990820505394368e-06
21 O 0 6.884609319968149e-06
informative O 0 7.79290530772414e-06
matings O 0 2.565463182691019e-05
for O 0 5.90970387293055e-07
both O 0 9.013840553961927e-07
properdin O 0 0.0001739885046845302
Factor O 0 6.741091510775732e-06
B O 0 7.325831120397197e-06
allotype O 0 4.501096918829717e-05
and O 0 3.5772907267528353e-06
HLA O 0 0.3351335823535919
- O 0 0.00017718959134072065
B O 0 1.2455736396077555e-05
were O 0 1.3852641131961718e-06
found O 0 5.215263627178501e-06
. O 0 2.01952425413765e-05

Of O 0 2.183860124205239e-05
72 O 0 6.99767260812223e-05
informative O 0 2.5496827220194973e-05
meioses O 0 0.00019443179189693183
, O 0 7.925254408291948e-07
three O 0 3.494286033856042e-07
recombinants O 0 7.298478885786608e-05
were O 0 3.363778944276419e-07
found O 0 2.4146896748789004e-07
, O 0 1.1616688766480365e-07
giving O 0 4.050471034133807e-07
a O 0 7.314970957850164e-07
recombinant O 0 6.1398627622111235e-06
fraction O 0 2.6710342808655696e-06
of O 0 1.4848920955046196e-06
0 O 0 1.9137438357574865e-05
. O 0 2.3277540094568394e-05

042 O 0 0.058173418045043945
. O 0 0.0018477829871699214

A O 0 0.00023421307560056448
lod O 0 0.0016521643847227097
score O 0 2.941068942163838e-06
of O 0 3.8351427633642743e-07
16 O 0 1.13362352749391e-06
between O 0 2.031555823123199e-06
HLA O 1 0.6673261523246765
- O 0 0.00010522618686081842
B O 0 3.997633484686958e-06
and O 0 4.095251142643974e-07
Factor O 0 2.1039345483586658e-06
B O 0 5.220563707553083e-06
allotypes O 0 4.880251071881503e-05
was O 0 1.3363005564315245e-06
calculated O 0 7.106687576197146e-07
at O 0 1.9412645713146048e-07
a O 0 2.0478866247231053e-07
maximum O 0 4.774223043568782e-07
likelihood O 0 8.305405003738997e-07
value O 0 9.791817490167887e-08
of O 0 5.805091518595873e-08
the O 0 3.349914265982079e-07
recombinant O 0 6.0018915064574685e-06
fraction O 0 2.164804072890547e-06
of O 0 9.879744311547256e-07
0 O 0 2.274646067235153e-05
. O 0 1.9145085389027372e-05

04 O 0 0.055017221719026566
. O 0 0.003279171884059906

A O 0 6.213576853042468e-05
crossover O 0 4.217805326334201e-05
was O 0 9.467588824918494e-06
shown O 0 2.9850489227101207e-06
to O 0 5.711968924515531e-07
have O 0 2.2510516828333493e-07
occurred O 0 7.71922543663095e-07
between O 0 2.3614408917183027e-07
genes O 0 1.0977759075103677e-06
for O 0 2.858101311176142e-07
Factor O 0 1.3593585208582226e-06
B O 0 3.034295559700695e-06
and O 0 1.1346920700816554e-06
HLA O 1 0.5316371917724609
- O 0 0.0030393979977816343
D O 0 0.0006060699233785272
, O 0 1.6531835456135013e-07
in O 0 2.2177381708843313e-07
which O 0 9.400670819559309e-07
HLA O 0 0.05267039313912392
- O 0 8.71774391271174e-05
D O 0 0.00020165146270301193
segregared O 0 2.680336001503747e-05
with O 0 1.4822987850493519e-06
HLA O 0 0.053339097648859024
- O 0 1.338152196694864e-05
A O 0 2.647146175149828e-06
and O 0 2.448369059493416e-06
B O 0 4.525720942183398e-05
. O 0 2.078441684716381e-05

These O 0 1.7264963389607146e-05
studies O 0 1.3534168829210103e-05
suggest O 0 3.426162038522307e-06
that O 0 2.5183695129271655e-07
the O 0 3.1473283002014796e-07
genes O 0 1.4586304359909263e-06
for O 0 4.1577672504899965e-07
Factor O 0 3.2593086416454753e-06
B O 0 5.485101792146452e-05
and O 0 0.0021248317789286375
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999958276748657
are O 0 1.9969344577930315e-07
located O 0 4.4860323100692767e-07
outside O 0 1.962241640285356e-07
those O 0 9.777261311683105e-08
for O 0 2.40010649577016e-07
HLA O 0 0.04257882758975029
, O 0 6.268138008636015e-08
that O 0 3.328259268187139e-08
the O 0 5.537123115573195e-08
order O 0 1.1291970025695264e-07
of O 0 8.196552414574398e-08
genese O 0 0.00013056097668595612
is O 0 8.824143833408016e-07
HLA O 0 0.018060453236103058
- O 0 6.50306310490123e-06
A O 0 8.713000738680421e-07
, O 0 3.3993299553003453e-07
- O 0 1.137461276812246e-05
B O 0 2.016053713305155e-06
, O 0 2.589304699540662e-07
- O 0 2.4369397578993812e-05
D O 0 8.754823647905141e-05
, O 0 3.0283177920864546e-07
Factor O 0 1.6905468100958387e-06
B O 0 6.359992767102085e-06
allotype O 0 0.008956432342529297
, O 0 0.009448939003050327
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.999998927116394
, O 0 3.7135018260414654e-07
that O 0 1.2358908918486122e-07
the O 0 3.7905380168012925e-07
genes O 0 4.6155028030625544e-06
coding O 0 4.9796995881479234e-05
for O 0 0.0001242350845132023
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999995231628418
and O 0 1.7777656466932967e-06
Factor O 0 3.5563643905334175e-06
B O 0 5.20226376465871e-06
allotypes O 0 1.576009344717022e-05
are O 0 1.320331222132154e-07
approximately O 0 2.3420632544457476e-07
3 O 0 4.021587756142253e-07
- O 0 2.617104428281891e-06
- O 0 1.4542135886586038e-06
5 O 0 2.1004973405069904e-07
centimorgans O 0 3.888061200996162e-06
from O 0 1.9031327269658505e-07
the O 0 4.840455858357018e-07
HLA O 0 0.0034815312828868628
- O 0 6.7025980570178945e-06
A O 0 1.7258623756788438e-06
and O 0 1.641377593841753e-06
HLA O 0 0.3380471169948578
- O 0 5.1912153139710426e-05
B O 0 3.2413520330010215e-06
loci O 0 1.3465166830428643e-06
, O 0 9.461347616479543e-08
and O 0 7.145274594222428e-08
that O 0 4.357559291179314e-08
the O 0 1.6467510022266652e-07
apparent O 0 2.0559618860716e-06
lack O 0 4.107870097413979e-07
of O 0 1.0097404157249912e-07
recombinants O 0 2.346625660720747e-05
between O 0 4.2813778122763324e-07
the O 0 6.215196322045813e-07
Factor O 0 2.427838580842945e-06
B O 0 7.235222710733069e-06
gene O 0 1.4241201824916061e-05
and O 0 0.0001583037810632959
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999990463256836
gene O 0 1.0378604201832786e-05
suggests O 0 1.1665608781186165e-06
that O 0 9.468207906593307e-08
these O 0 5.886687048928252e-08
two O 0 1.250910059980015e-07
genes O 0 9.181907216770924e-07
lie O 0 5.585651479123044e-07
in O 0 1.619580842771029e-07
close O 0 6.051706691323488e-07
proximity O 0 1.4421593732549809e-06
to O 0 5.551197546083131e-07
one O 0 7.702238917772775e-07
another O 0 4.621060725185089e-06
. O 0 1.2389783478283789e-05

Distribution O 0 7.952848682180047e-05
of O 0 6.55676785754622e-06
emerin O 0 0.0004020975320599973
and O 0 5.821373633807525e-06
lamins O 0 0.004199495539069176
in O 0 3.373359959368827e-06
the O 0 2.5088552320085e-06
heart O 0 0.00014953466597944498
and O 0 1.0511245136513025e-06
implications O 0 7.97636039351346e-06
for O 0 2.1373889467213303e-06
Emery B-Disease 1 0.8677786588668823
- I-Disease 1 0.986191987991333
Dreifuss I-Disease 1 0.9999330043792725
muscular I-Disease 1 0.9999943971633911
dystrophy I-Disease 1 0.9999934434890747
. O 0 0.00017753355496097356

Emerin O 0 0.002345808083191514
is O 0 8.799464012554381e-06
a O 0 3.65636537935643e-06
nuclear O 0 8.28506290417863e-06
membrane O 0 6.6231900746061e-06
protein O 0 1.2673648370764568e-06
which O 0 2.119373476716646e-07
is O 0 1.3738755910708278e-07
missing O 0 1.0590483725536615e-06
or O 0 1.7232129039257416e-06
defective O 0 0.00014875788474455476
in O 0 6.282474714680575e-06
Emery B-Disease 0 0.46659067273139954
- I-Disease 1 0.9125383496284485
Dreifuss I-Disease 1 0.999929666519165
muscular I-Disease 1 0.9999974966049194
dystrophy I-Disease 1 0.9999980926513672
( O 0 0.0002475855580996722
EDMD B-Disease 1 0.9996944665908813
) O 0 4.283945600036532e-05
. O 0 3.928207661374472e-05

It O 0 1.0708073205023538e-05
is O 0 8.18344460640219e-07
one O 0 2.0148684143350692e-07
member O 0 2.9954043156976695e-07
of O 0 7.194930873311023e-08
a O 0 5.198586450205767e-07
family O 0 1.3607036635221448e-06
of O 0 5.248936645330105e-07
lamina O 0 0.19632115960121155
- O 0 0.0003785321314353496
associated O 0 1.942553126355051e-06
proteins O 0 6.860973940092663e-07
which O 0 2.755065224846476e-07
includes O 0 6.656546247540973e-07
LAP1 O 0 7.761667075101286e-05
, O 0 1.156723214990052e-06
LAP2 O 0 0.00013051180576439947
and O 0 4.9255518206337e-06
lamin O 0 0.01351914368569851
B O 0 0.00023967999732121825
receptor O 0 0.000270196411293
( O 0 2.6954232453135774e-05
LBR O 0 0.0012263597454875708
) O 0 2.3769960534991696e-05
. O 0 3.248165739933029e-05

A O 0 0.00010978837235597894
panel O 0 7.480726344510913e-05
of O 0 3.918750280718086e-06
16 O 0 1.0070848475152161e-05
monoclonal O 0 0.0001001525015453808
antibodies O 0 3.060199014726095e-05
( O 0 3.0885723845130997e-06
mAbs O 0 5.647746365866624e-05
) O 0 6.254225013435644e-07
has O 0 1.681465704450602e-07
been O 0 1.4247662249999848e-07
mapped O 0 1.260777935385704e-06
to O 0 9.702913672526847e-08
six O 0 1.326935716861044e-07
specific O 0 1.542480276839342e-07
sites O 0 3.9610250723853824e-07
throughout O 0 4.767293546592555e-07
the O 0 4.537600943876896e-07
emerin O 0 2.5118739358731546e-05
molecule O 0 3.287134177298867e-06
using O 0 1.2719781352643622e-06
phage O 0 1.3303647392604034e-05
- O 0 2.689273742362275e-06
displayed O 0 9.056855674316466e-07
peptide O 0 1.8848422769224271e-06
libraries O 0 8.618778224445123e-07
and O 0 1.459628009570224e-07
has O 0 1.735491537147027e-07
been O 0 1.4105530965480284e-07
used O 0 2.0408988632425462e-07
to O 0 4.4168035628899815e-07
localize O 0 2.8348089472274296e-05
emerin O 0 8.332177822012454e-05
in O 0 7.409728937091131e-07
human O 0 1.3150713584764162e-06
and O 0 1.805656324904703e-06
rabbit O 0 0.0008836775086820126
heart O 0 0.0086751664057374
. O 0 3.822291182586923e-05

Several O 0 9.573654097039253e-05
mAbs O 0 0.0013795995619148016
against O 0 2.055603363260161e-05
different O 0 5.12969108967809e-06
emerin O 0 0.010045433416962624
epitopes O 0 0.013144643977284431
did O 0 4.184508725302294e-06
not O 0 3.275466724517173e-07
recognize O 0 8.169704415195156e-07
intercalated O 0 1.3811345525027718e-05
discs O 0 1.171706935565453e-05
in O 0 2.521508122299565e-07
the O 0 3.454360353316588e-07
heart O 0 7.288505003089085e-05
, O 0 1.2835847940095846e-07
though O 0 1.0671942618500907e-07
they O 0 5.5446264468628215e-08
recognized O 0 2.4444631208098144e-07
cardiomyocyte O 0 1.429108942829771e-05
nuclei O 0 6.708986802550498e-06
strongly O 0 2.129657104887883e-06
, O 0 1.0630864011318408e-07
both O 0 6.178520095545537e-08
at O 0 1.2963914741703775e-07
the O 0 1.7368940063988703e-07
rim O 0 2.5413744424440665e-06
and O 0 2.9291709324752446e-07
in O 0 8.510304496667231e-07
intranuclear O 0 0.00010922471847152337
spots O 0 1.2534728739410639e-05
or O 0 4.29688225267455e-06
channels O 0 2.627322101034224e-05
. O 0 1.6498601326020434e-05

A O 0 0.0002882750704884529
polyclonal O 0 0.0030540903098881245
rabbit O 0 0.0011396679328754544
antiserum O 0 0.001073524123057723
against O 0 2.2210188035387546e-05
emerin O 0 0.002854397054761648
did O 0 3.3836379316198872e-06
recognize O 0 1.6819850543470238e-06
both O 0 3.420640553031262e-07
nuclear O 0 2.6782731765706558e-06
membrane O 0 2.4969683636300033e-06
and O 0 3.5742453974307864e-07
intercalated O 0 1.6524598322575912e-05
discs O 0 9.777018931345083e-06
but O 0 1.986152113886419e-07
, O 0 1.0200851363606489e-07
after O 0 4.831444471165014e-07
affinity O 0 1.8435151787343784e-06
purification O 0 1.851542492659064e-06
against O 0 5.65236632610322e-07
a O 0 6.870108109069406e-07
pure O 0 9.569549774823827e-07
- O 0 1.1657217328320257e-05
emerin O 0 2.1347965230233967e-05
band O 0 2.054758397207479e-06
on O 0 3.5965695133199915e-07
a O 0 3.444609717462299e-07
western O 0 1.2973143839190016e-06
blot O 0 0.00016245871665887535
, O 0 3.836543953639193e-07
it O 0 2.0348080909116106e-07
stained O 0 1.5008679838501848e-05
only O 0 1.74298207866741e-07
the O 0 8.114008664961148e-07
nuclear O 0 2.0935962311341427e-05
membrane O 0 6.362300337059423e-05
. O 0 2.250314901175443e-05

These O 0 2.7691057766787708e-05
results O 0 1.9871269614668563e-05
would O 0 2.004355565077276e-06
not O 0 3.1136406164478103e-07
be O 0 1.3836016421464592e-07
expected O 0 5.190684646549926e-07
if O 0 2.3207387300772098e-07
immunostaining O 0 1.6537256669835187e-05
at O 0 6.436094395212422e-07
intercalated O 0 2.2318770788842812e-05
discs O 0 3.127668605884537e-05
were O 0 2.2007816369296052e-07
due O 0 2.657329218891391e-07
to O 0 5.45620899572441e-08
a O 0 1.0339183376117944e-07
product O 0 9.6930911297477e-08
of O 0 3.622354682875084e-08
the O 0 1.430807969882153e-07
emerin O 0 8.749047992751002e-05
gene O 0 2.2489712137030438e-06
and O 0 1.2979909058685735e-07
, O 0 9.370634046490522e-08
therefore O 0 9.587895277718417e-08
, O 0 4.1155313823537654e-08
cast O 0 1.0401172545471127e-07
some O 0 3.721897101627292e-08
doubt O 0 1.830811271474886e-07
upon O 0 1.097644357628269e-07
the O 0 5.520055879060237e-07
hypothesis O 0 2.9350980184972286e-05
that O 0 1.1110128070868086e-05
cardiac B-Disease 1 0.9999995231628418
defects I-Disease 1 0.9998501539230347
in O 0 1.2306973985687364e-05
EDMD B-Disease 1 0.9999983310699463
are O 0 8.069812906796869e-07
caused O 0 7.1894287430041e-06
by O 0 5.413675125964801e-07
absence O 0 1.5365179706350318e-06
of O 0 7.538080808444647e-07
emerin O 0 0.0008272809791378677
from O 0 5.4038414418755565e-06
intercalated O 0 0.00043871792149730027
discs O 0 0.0003067529760301113
. O 0 3.493602343951352e-05

Although O 0 0.000131576947751455
emerin O 0 0.004217852838337421
was O 0 1.7615724573261105e-05
abundant O 0 4.041571628476959e-06
in O 0 4.830651505471906e-07
the O 0 2.686710161015071e-07
membranes O 0 3.2912150800257223e-06
of O 0 2.351850980630843e-07
cardiomyocyte O 0 7.933380402391776e-05
nuclei O 0 1.3599598787550349e-05
, O 0 2.861376628970902e-07
it O 0 1.3977378898744064e-07
was O 0 4.412104885886947e-07
absent O 0 9.879582876237691e-07
from O 0 1.7226477666554274e-07
many O 0 9.79377929866132e-08
non O 0 1.2010091268166434e-06
- O 0 7.061705400701612e-05
myocyte O 0 0.005946571938693523
cells O 0 1.910840546770487e-05
in O 0 1.0383724884377443e-06
the O 0 4.09482072427636e-06
heart O 0 0.0015016497345641255
. O 0 3.7482786865439266e-05

This O 0 1.5921155863907188e-05
distribution O 0 8.538948350178543e-06
of O 0 9.720990874484414e-07
emerin O 0 0.0005376708577387035
was O 0 2.1610994735965505e-06
similar O 0 6.069438995837118e-07
to O 0 1.7975862931507436e-07
that O 0 4.7317282536596394e-08
of O 0 8.66210783101451e-08
lamin O 0 6.409593333955854e-05
A O 0 1.1697826494128094e-06
, O 0 1.391061061895016e-07
a O 0 4.1602658029660233e-07
candidate O 0 1.4010238373884931e-06
gene O 0 2.327000174773275e-06
for O 0 2.1487470291958743e-07
an O 0 1.2415843002600013e-06
autosomal O 0 0.0020602401345968246
form O 0 5.328704901330639e-06
of O 0 7.454561455233488e-06
EDMD B-Disease 1 0.9999294281005859
. O 0 0.00010679311526473612

In O 0 6.833222869317979e-05
contrast O 0 7.700057904003188e-05
, O 0 1.0601887879602145e-05
lamin O 0 0.4206812381744385
B1 O 1 0.8418816328048706
was O 0 6.931476946192561e-06
absent O 0 4.575865204969887e-06
from O 0 9.059317562787328e-07
cardiomyocyte O 0 4.2703060898929834e-05
nuclei O 0 7.662947609787807e-06
, O 0 2.928040032657009e-07
showing O 0 1.8156542864744551e-06
that O 0 7.364037060142437e-07
lamin O 0 0.23513182997703552
B1 O 0 0.4691503942012787
is O 0 2.1589887921891204e-07
not O 0 7.865996565215028e-08
essential O 0 1.188370077898071e-07
for O 0 7.971449633714656e-08
localization O 0 1.7903407751873601e-06
of O 0 1.9146487773014087e-07
emerin O 0 3.6898029065923765e-05
to O 0 6.214651762093126e-07
the O 0 2.2698309294355568e-06
nuclear O 0 9.529198723612353e-05
lamina O 0 0.00435509392991662
. O 0 4.38882052549161e-05

Lamin O 1 0.999222993850708
B1 O 1 0.9968453049659729
is O 0 1.695048740657512e-05
also O 0 4.109541350771906e-06
almost O 0 1.6222766134887934e-06
completely O 0 8.010259989532642e-06
absent O 0 1.612693267816212e-05
from O 0 4.18761010223534e-06
skeletal O 0 0.06309454888105392
muscle O 0 0.040104515850543976
nuclei O 0 0.00037187396083027124
. O 0 3.544460196280852e-05

In O 0 9.10962262423709e-05
EDMD B-Disease 1 0.9964483976364136
, O 0 2.287690222146921e-06
the O 0 6.739348918927135e-07
additional O 0 9.280097401642706e-07
absence O 0 2.6812633677764097e-06
of O 0 1.0962223768729018e-06
lamin O 1 0.8703064322471619
B1 O 1 0.9795058965682983
from O 0 3.927025773009518e-06
heart O 0 0.0003498672740533948
and O 0 3.393954102648422e-06
skeletal O 0 0.15722936391830444
muscle O 0 0.003379048779606819
nuclei O 0 2.5116678443737328e-05
which O 0 7.860189725761302e-07
already O 0 1.1395873116271105e-06
lack O 0 2.0729094103444368e-06
emerin O 0 0.02296546846628189
may O 0 3.6930712212779326e-06
offer O 0 4.4369579654812696e-07
an O 0 1.16695090923713e-07
alternative O 0 6.322814556369849e-07
explanation O 0 5.506831826096459e-07
of O 0 8.859696265517414e-08
why O 0 4.6070056214375654e-07
these O 0 2.5787818458411493e-07
tissues O 0 2.1725805709138513e-05
are O 0 1.645303768782469e-07
particularly O 0 1.913294227051665e-06
affected O 0 8.235632776631974e-06
. O 0 3.0521787266479805e-06
. O 0 1.6701231288607232e-05

Genetic O 0 0.000609728682320565
mapping O 0 0.00017130198830273002
of O 0 5.615569079964189e-06
the O 0 9.241854058927856e-06
copper B-Disease 0 0.0001114354599849321
toxicosis I-Disease 0 0.0026265298947691917
locus O 0 6.163602665765211e-05
in O 0 3.2815617032611044e-06
Bedlington O 0 0.00020073220366612077
terriers O 0 9.483808389632031e-05
to O 0 2.364057536397013e-06
dog O 0 3.861338700517081e-05
chromosome O 0 5.991700163576752e-06
10 O 0 3.8678368241562566e-07
, O 0 1.26446110471079e-07
in O 0 1.446018131900928e-07
a O 0 6.441430286940886e-07
region O 0 3.1750651032780297e-06
syntenic O 0 0.00013367545034270734
to O 0 1.2729319678328466e-06
human O 0 3.1962649700290058e-06
chromosome O 0 2.7807680453406647e-05
region O 0 1.4026993994775694e-05
2p13 O 0 0.00038610631600022316
- O 0 0.0003895084373652935
p16 O 0 0.0009022880112752318
. O 0 6.802587449783459e-05

Abnormal O 1 0.980697751045227
hepatic B-Disease 1 0.9981967806816101
copper I-Disease 0 0.007910322397947311
accumulation I-Disease 0 9.367949678562582e-05
is O 0 1.6304256860166788e-06
recognized O 0 8.204245318665926e-07
as O 0 7.573560765194998e-07
an O 0 0.0002130696811946109
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 6.281354217207991e-06
man O 0 1.175326087832218e-05
, O 0 6.554284368576191e-07
mouse O 0 2.1248499251669273e-05
, O 0 1.028914084599819e-06
rat O 0 7.67604069551453e-05
and O 0 3.36662355948647e-06
dog O 0 0.00023264290939550847
. O 0 2.3419042918249033e-05

The O 0 2.888228300435003e-05
major O 0 2.1731111701228656e-05
cause O 0 2.5430001187487505e-05
of O 0 2.977247504531988e-06
hepatic B-Disease 1 0.9204216599464417
copper I-Disease 0 0.009227531030774117
accumulation I-Disease 0 6.956142169656232e-05
in O 0 1.5229854852805147e-06
man O 0 4.069107944815187e-06
is O 0 5.292294531500374e-07
a O 0 2.889690449592308e-06
dysfunctional O 0 0.00046782701974734664
ATP7B O 0 0.010413678362965584
gene O 0 4.160518801654689e-05
, O 0 2.7472358397062635e-06
causing O 0 0.00032132567139342427
Wilson B-Disease 0 0.19189681112766266
disease I-Disease 1 0.9146400094032288
( O 0 6.0278744058450684e-05
WD B-Disease 1 0.7000943422317505
) O 0 2.4283652237500064e-05
. O 0 2.5901792469085194e-05

Mutations O 0 0.006910830736160278
in O 0 1.597996561031323e-05
the O 0 4.385191914479947e-06
ATP7B O 0 0.0014662015018984675
genes O 0 8.1978387242998e-06
have O 0 5.049846549809445e-07
also O 0 4.2105256170543726e-07
been O 0 4.1191759692082996e-07
demonstrated O 0 1.9687902295117965e-06
in O 0 1.2440330010576872e-06
mouse O 0 4.777285357704386e-05
and O 0 7.2729953899397515e-06
rat O 0 0.0013393964618444443
. O 0 3.1858951842878014e-05

The O 0 4.462907600100152e-05
ATP7B O 0 0.0027594349812716246
gene O 0 6.176759052323177e-05
has O 0 1.93941559700761e-06
been O 0 6.022551133355591e-07
excluded O 0 1.326032815995859e-06
in O 0 1.6379922840314975e-07
the O 0 1.7040078148511384e-07
much O 0 6.667906404800306e-07
rarer O 0 2.208041405538097e-05
human O 0 9.604891602066346e-06
copper B-Disease 1 0.6122164726257324
overload I-Disease 1 0.9959343671798706
disease O 0 0.005816246848553419
non B-Disease 0 4.432011792232515e-06
- I-Disease 0 4.4799471652368084e-05
Indian I-Disease 0 7.62696799938567e-06
childhood I-Disease 0 0.0038548947777599096
cirrhosis I-Disease 0 0.2723390460014343
, O 0 3.0626815714640543e-06
indicating O 0 5.9007037634728476e-05
genetic O 0 7.850740075809881e-05
heterogeneity O 0 0.0005260634934529662
. O 0 5.868823063792661e-05

By O 0 5.240606333245523e-05
investigating O 0 7.885922968853265e-05
the O 0 1.2928352589369752e-05
common O 0 0.0003403110313229263
autosomal O 1 0.9990847110748291
recessive O 1 0.999794065952301
copper B-Disease 0 0.49479788541793823
toxicosis I-Disease 1 0.9921717643737793
( O 0 3.41059967468027e-05
CT B-Disease 1 0.8252354860305786
) O 0 1.6232050938924658e-06
in O 0 8.859279887474258e-07
Bedlington O 0 0.0001053674568538554
terriers O 0 0.00014904300041962415
, O 0 6.668695391454094e-07
we O 0 1.5976239353676647e-07
have O 0 1.582375688258253e-07
identified O 0 5.099782356410287e-07
a O 0 3.8499035781569546e-07
new O 0 1.1254369383095764e-06
locus O 0 1.13998721644748e-05
involved O 0 2.58996146840218e-06
in O 0 3.368450052221306e-05
progressive O 1 0.9999948740005493
liver B-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
. O 0 0.00013920904893893749

We O 0 3.6561425076797605e-05
examined O 0 0.0001286372571485117
whether O 0 8.946066373027861e-06
the O 0 7.531752544309711e-06
WD B-Disease 0 0.16479450464248657
gene O 0 3.140095577691682e-05
ATP7B O 0 0.00038663888699375093
was O 0 3.273332595199463e-06
also O 0 8.080471616267459e-07
causative O 0 6.182904598972527e-06
for O 0 8.803482955954678e-07
CT B-Disease 1 0.7405019402503967
by O 0 1.2223003977851477e-06
investigating O 0 5.414013685367536e-06
the O 0 1.8870528037950862e-06
chromosomal O 0 0.00043035802082158625
co O 0 3.839483906631358e-05
- O 0 6.1578066379297525e-06
localization O 0 4.724594873550814e-06
of O 0 4.4453102532315825e-07
ATP7B O 0 8.633253310108557e-05
and O 0 5.937169476055715e-07
C04107 O 0 1.0763791578938253e-05
, O 0 3.6295344330028456e-07
using O 0 1.1845687595268828e-06
fluorescence O 0 1.5704938050475903e-05
in O 0 1.6301053165079793e-06
situ O 0 2.6819467166205868e-05
hybridization O 0 1.5083810467331205e-05
( O 0 3.1238528208632488e-06
FISH O 0 7.035998805804411e-06
) O 0 7.354923582170159e-06
. O 0 1.4805588762101252e-05

C04107 O 0 0.0014457260258495808
is O 0 1.3499031410901807e-05
an O 0 5.4069137149781454e-06
anonymous O 0 3.4989003324881196e-05
microsatellite O 0 0.0005110669299028814
marker O 0 0.0001034681117744185
closely O 0 2.3158043404691853e-05
linked O 0 0.00015205984527710825
to O 0 2.395492083451245e-05
CT B-Disease 1 0.9986873269081116
. O 0 7.141846435843036e-05

However O 0 0.00010487127292435616
, O 0 1.6461133782286197e-05
BAC O 0 0.0005586891784332693
clones O 0 6.703584222123027e-05
containing O 0 1.0248480066366028e-05
ATP7B O 0 0.0001473808806622401
and O 0 2.5765743885131087e-06
C04107 O 0 4.8066784074762836e-05
mapped O 0 1.4615415238949936e-05
to O 0 5.038993435846351e-07
the O 0 1.176304635919223e-06
canine O 0 4.331557283876464e-05
chromosome O 0 1.4399439351109322e-05
regions O 0 2.9247346446936717e-06
CFA22q11 O 0 2.813959144987166e-05
and O 0 1.0867789796975558e-06
CFA10q26 O 0 3.773239950533025e-05
, O 0 3.134690018669062e-07
respectively O 0 6.871923119433632e-07
, O 0 1.8471477858383878e-07
demonstrating O 0 1.2018157349302783e-06
that O 0 1.4235916978577734e-06
WD B-Disease 1 0.8990172743797302
cannot O 0 3.6733410979650216e-06
be O 0 6.328871791083657e-07
homologous O 0 1.477813748351764e-05
to O 0 1.304223042097874e-05
CT B-Disease 1 0.9923506379127502
. O 0 5.1853425247827545e-05

The O 0 4.367443762021139e-05
copper O 0 0.00011604651808738708
transport O 0 4.761948366649449e-05
genes O 0 1.352784784103278e-05
CTR1 O 0 9.199546184390783e-05
and O 0 1.2060847893735627e-06
CTR2 O 0 0.0003372238716110587
were O 0 7.149513976401067e-07
also O 0 3.2125791449288954e-07
excluded O 0 9.317930107499706e-07
as O 0 1.81139824917409e-07
candidate O 0 8.690818162904179e-07
genes O 0 1.4315151020127814e-06
for O 0 7.119996894289216e-07
CT B-Disease 1 0.9989544153213501
since O 0 2.6597226678859442e-06
they O 0 2.0151375679233752e-07
both O 0 2.589023040400207e-07
mapped O 0 8.813161912257783e-06
to O 0 1.7180176428155391e-06
canine O 0 0.00014267598453443497
chromosome O 0 0.00010679138358682394
region O 0 3.891997766913846e-05
CFA11q22 O 0 0.0014197787968441844
. O 0 5.4699587053619325e-05

2 O 0 0.0003868746862281114
- O 0 0.00046441348968073726
22 O 0 0.00014203500177245587
. O 0 6.044025576557033e-05

5 O 0 0.0024912722874432802
. O 0 0.0007306986371986568

A O 0 9.718674118630588e-05
transcribed O 0 0.00012755456555169076
sequence O 0 1.3001038496440742e-05
identified O 0 4.8016700020525604e-06
from O 0 5.343170528249175e-07
the O 0 3.554299041752529e-07
C04107 O 0 1.7286185538978316e-05
- O 0 9.214458259521052e-06
containing O 0 1.3277727930471883e-06
BAC O 0 0.0004965002299286425
was O 0 1.091108515538508e-06
found O 0 1.466372481218059e-07
to O 0 8.98067966659255e-08
be O 0 7.380320710126398e-08
homologous O 0 6.124332685431e-07
to O 0 1.2457101661311754e-07
a O 0 3.3750094985407486e-07
gene O 0 1.9098995380772976e-06
expressed O 0 8.286654633593571e-07
from O 0 3.469686475909839e-07
human O 0 7.074567065501469e-07
chromosome O 0 7.113344508979935e-06
2p13 O 0 2.2357286070473492e-05
- O 0 1.5941910533001646e-05
p16 O 0 1.2440220416465309e-05
, O 0 1.9641063886410848e-07
a O 0 3.3432309010095196e-07
region O 0 7.944898925416055e-07
devoid O 0 1.2413617014317424e-06
of O 0 2.3794672188159893e-07
any O 0 6.801766971875622e-07
positional O 0 4.519661524682306e-05
candidate O 0 2.1764251869171858e-05
genes O 0 5.4241496400209144e-05
. O 0 2.591365046100691e-05

Molecular O 0 0.00020350146223790944
analysis O 0 1.131797853304306e-05
of O 0 1.261591023649089e-06
the O 0 2.366288526900462e-06
APC B-Disease 0 0.00023503944976255298
gene O 0 9.440458597964607e-06
in O 0 1.0858373116207076e-06
205 O 0 7.237113095470704e-06
families O 0 1.5936871022859123e-06
: O 0 6.352066748149809e-07
extended O 0 8.708308996574488e-06
genotype O 0 0.004359988961368799
- O 0 0.0031902517657727003
phenotype O 0 0.0005543665029108524
correlations O 0 1.1259091479587369e-05
in O 0 1.2668850786212715e-06
FAP B-Disease 0 0.0001574221532791853
and O 0 4.3127107574036927e-07
evidence O 0 2.449309874918981e-07
for O 0 7.43404982017637e-08
the O 0 1.1801189003790569e-07
role O 0 4.5004816229266e-07
of O 0 2.4972513301690924e-07
APC B-Disease 0 2.9858927518944256e-05
amino O 0 3.27061479765689e-06
acid O 0 1.512425751570845e-05
changes O 0 3.143906724289991e-05
in O 0 0.2809506058692932
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9884118437767029
. O 0 0.00018280374933965504

BACKGROUND O 0 0.000769499340094626
/ O 0 0.00033260046620853245
AIMS O 0 2.2291076675173827e-05
The O 0 1.5012539051895146e-06
development O 0 4.8154920477827545e-06
of O 0 0.00045795197365805507
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.3763012652343605e-06
a O 0 2.323833541595377e-06
variable O 0 5.2485434025584254e-06
range O 0 1.032136651701876e-06
of O 0 5.980871833344281e-07
extracolonic O 0 0.002303847810253501
manifestations O 0 0.0012231528526172042
in O 0 0.0002053743228316307
familial B-Disease 1 0.9999997615814209
adenomatous I-Disease 1 0.9999996423721313
polyposis I-Disease 1 0.9999998807907104
( O 0 0.00012922343739774078
FAP B-Disease 0 0.0014827924314886332
) O 0 8.604176855442347e-07
is O 0 1.1570924840498265e-07
the O 0 1.1950652378800442e-07
result O 0 1.669698406203679e-07
of O 0 5.849974371585631e-08
the O 0 4.851593757848605e-07
dominant O 0 2.072814095299691e-05
inheritance O 0 6.50980364298448e-05
of O 0 2.199734990426805e-05
adenomatous B-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999991655349731
coli I-Disease 1 0.9999579191207886
( O 0 9.348246385343373e-05
APC B-Disease 0 0.0017441788222640753
) O 0 2.995589966303669e-05
gene O 0 0.00014573481166735291
mutations O 0 0.0003305252466816455
. O 0 2.9762324629700743e-05

In O 0 2.3512582629336976e-05
this O 0 1.3885482985642739e-06
study O 0 1.969092636500136e-06
, O 0 3.3994825798799866e-07
direct O 0 1.3862328387403977e-06
mutation O 0 4.117206117371097e-06
analysis O 0 4.2879401007667184e-07
of O 0 1.0058440125249035e-07
the O 0 7.263453198902425e-07
APC B-Disease 0 0.0006018815329298377
gene O 0 6.3352458710141946e-06
was O 0 9.13202484298381e-07
performed O 0 7.386628908534476e-07
to O 0 3.983994645295752e-07
determine O 0 2.6222610358672682e-06
genotype O 0 0.00040076885488815606
- O 0 0.0011961248237639666
phenotype O 0 0.0003463602624833584
correlations O 0 3.938653208024334e-06
for O 0 2.205361937512862e-07
nine O 0 6.302009296632605e-07
extracolonic O 0 7.893462316133082e-05
manifestations O 0 1.323021569987759e-05
and O 0 3.3333043347738567e-07
to O 0 3.5961477351520443e-07
investigate O 0 3.129181322947261e-06
the O 0 6.783719186387316e-07
incidence O 0 2.2573196474695578e-05
of O 0 7.671245043638919e-07
APC B-Disease 0 0.0038428325206041336
mutations O 0 6.0245358326938e-05
in O 0 3.858018317259848e-06
non O 0 0.00022735289530828595
- O 1 0.9999454021453857
FAP O 1 0.9999994039535522
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0002653873525559902

METHODS O 0 0.00012604754010681063
The O 0 1.7951440895558335e-05
APC B-Disease 0 0.0011416509514674544
gene O 0 5.2848616178380325e-05
was O 0 5.909365427214652e-06
analysed O 0 1.2712511306745e-05
in O 0 1.0886617474170635e-06
190 O 0 6.804175427532755e-06
unrelated O 0 2.3055883502820507e-05
FAP B-Disease 0 0.00017163142911158502
and O 0 1.4293460708358907e-06
15 O 0 3.754514182219282e-06
non O 0 8.891542529454455e-05
- O 1 0.9999773502349854
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.10186155140399933
using O 0 1.606988371349871e-05
denaturing O 0 0.03669876977801323
gradient O 0 0.0007623930578120053
gel O 0 0.0008760171476751566
electrophoresis O 0 3.2381289202021435e-05
, O 0 5.652204890793655e-07
the O 0 5.259840918370173e-07
protein O 0 2.1443652258312795e-06
truncation O 0 1.620072544028517e-05
test O 0 4.000120043201605e-06
, O 0 4.0460736272507347e-07
and O 0 6.245808776839112e-07
direct O 0 5.664974196406547e-06
sequencing O 0 4.1679610149003565e-05
. O 0 2.625959132274147e-05

RESULTS O 0 0.00027433093055151403
Chain O 0 0.00014447489229496568
terminating O 0 6.733793270541355e-05
signals O 0 3.244840627303347e-05
were O 0 7.295540171980974e-07
only O 0 1.7780816108370345e-07
identified O 0 8.759799925428524e-07
in O 0 7.96719064055651e-07
patients O 0 1.559190968691837e-05
belonging O 0 2.783465561151388e-06
to O 0 4.6738017545067123e-07
the O 0 1.3455231737680151e-06
FAP B-Disease 0 0.0006149464752525091
group O 0 8.3481963883969e-06
( O 0 2.9420591545203933e-06
105 O 0 3.373314029886387e-05
patients O 0 0.00020046939607709646
) O 0 8.388698006456252e-06
. O 0 2.166807826142758e-05

Amino O 0 0.00019987524137832224
acid O 0 0.000148453502333723
changes O 0 1.4947601812309586e-05
were O 0 1.503385874457308e-06
identified O 0 2.6031204924947815e-06
in O 0 5.426701363830944e-07
four O 0 1.420767944182444e-06
patients O 0 3.585353260859847e-05
, O 0 8.127975092975248e-08
three O 0 7.572608495820532e-08
of O 0 6.169335620143102e-08
whom O 0 6.439981348194124e-07
belonged O 0 1.5413803566843853e-06
to O 0 2.0590059079950151e-07
the O 0 3.3757757478269923e-07
non O 0 1.4850394336463069e-06
- O 0 4.0494818676961586e-05
FAP O 0 0.0001248525077244267
group O 0 3.365043812664226e-05
of O 0 0.008035007864236832
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9970554113388062
. O 0 0.0001669742341618985

Genotype O 1 0.9389829635620117
- O 1 0.9521943926811218
phenotype O 1 0.8290739059448242
correlations O 0 0.00028451060643419623
identified O 0 2.267518539156299e-05
significant O 0 2.403446615062421e-06
differences O 0 1.7421607481082901e-06
in O 0 3.163900998970348e-07
the O 0 3.115598019576282e-07
nature O 0 5.389422312873648e-07
of O 0 1.0559487151340363e-07
certain O 0 7.337174565691384e-07
extracolonic O 0 0.0006462916499003768
manifestations O 0 0.00016562448581680655
in O 0 1.3318754099600483e-05
FAP B-Disease 1 0.5452627539634705
patients O 0 0.00018832369823940098
belonging O 0 1.0249818842567038e-05
to O 0 1.6751529301473056e-06
three O 0 3.4162433166784467e-06
mutation O 0 0.00019325224275235087
subgroups O 0 0.00010538032074691728
. O 0 4.4061689550289884e-05

CONCLUSIONS O 0 0.0013266714522615075
Extended O 0 0.0007415026775561273
genotype O 1 0.7567693591117859
- O 1 0.5254270434379578
phenotype O 0 0.08007194101810455
correlations O 0 4.065982284373604e-05
made O 0 1.332210786131327e-06
in O 0 5.584021778304304e-07
this O 0 3.1731354965813807e-07
study O 0 2.4846567612257786e-06
may O 0 2.8529891551443143e-06
have O 0 6.695345433627153e-08
the O 0 8.781064053664522e-08
potential O 0 1.6304397831845563e-07
to O 0 7.228756260246882e-08
determine O 0 1.5073783288244158e-07
the O 0 1.233832307434568e-07
most O 0 1.0530504113148709e-07
appropriate O 0 4.5683469807045185e-07
surveillance O 0 2.5832523533608764e-05
and O 0 3.0709115890203975e-06
prophylactic O 1 0.613193929195404
treatment O 1 0.733911395072937
regimens O 0 0.011213346384465694
for O 0 1.536462377771386e-06
those O 0 1.6502488051628461e-06
patients O 0 6.509145896416157e-05
with O 0 2.5945448669517646e-06
mutations O 0 0.00019927677931264043
associated O 0 3.556683168426389e-06
with O 0 1.0283813480782555e-06
life O 0 3.3256983442697674e-05
threatening O 0 0.07111681997776031
conditions O 0 0.009288509376347065
. O 0 4.0204922697739676e-05

This O 0 2.420605960651301e-05
study O 0 9.914109796227422e-06
also O 0 1.3200245803091093e-06
provided O 0 9.135858363151783e-07
evidence O 0 3.515886533023149e-07
for O 0 1.3107948859669705e-07
the O 0 3.226749640816706e-07
pathological O 0 1.4935432773199864e-05
nature O 0 6.949944122425222e-07
of O 0 1.001546223733385e-07
amino O 0 8.927852945816994e-07
acid O 0 1.7694707139526145e-06
changes O 0 8.561956406083482e-07
in O 0 6.695996717098751e-07
APC O 0 7.370075763901696e-05
associated O 0 9.856657925411128e-07
with O 0 1.8256749001466233e-07
both O 0 6.657073186033813e-07
FAP B-Disease 0 8.071040065260604e-05
and O 0 3.138248530376586e-06
non O 0 0.0002002697583520785
- O 1 0.999995231628418
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9966885447502136
. O 0 2.2418735170504078e-05
. O 0 4.687892214860767e-05

Inherited B-Disease 1 0.9999995231628418
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
and O 1 0.9843313097953796
cancer B-Disease 1 0.9999878406524658
risk O 0 3.0954910471336916e-05
of O 0 1.1188191137989634e-06
the O 0 7.748655661998782e-06
APC O 0 0.002604361390694976
I1307K O 0 0.0015190662816166878
polymorphism O 0 0.0013016260927543044
. O 0 7.32268308638595e-05

Germ O 0 0.3381529152393341
- O 0 0.0015821341658011079
line O 0 3.3119307772722095e-05
and O 0 3.6509786696115043e-06
somatic O 0 6.986137304920703e-05
truncating O 0 0.00033818569499999285
mutations O 0 3.241160084144212e-05
of O 0 4.801262321052491e-07
the O 0 1.178665115730837e-06
APC B-Disease 0 0.00017630010552238673
gene O 0 5.8067244026460685e-06
are O 0 1.6086930543224298e-07
thought O 0 7.203843210845662e-07
to O 0 1.4287928706835373e-06
initiate O 0 0.014738664962351322
colorectal B-Disease 1 0.9999998807907104
tumor I-Disease 1 0.7956253290176392
formation O 0 0.00032832156284712255
in O 0 0.0007938732160255313
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.0002358453202759847
sporadic O 1 0.9909824728965759
colorectal O 1 1.0
carcinogenesis O 1 0.9617711305618286
, O 0 3.6040710256202146e-05
respectively O 0 7.262917642947286e-05
. O 0 5.9235815569991246e-05

Recently O 0 0.00028135674074292183
, O 0 5.324803169060033e-06
an O 0 3.012095476151444e-06
isoleucine O 0 0.004030809737741947
- O 0 0.0003732753684744239
- O 0 6.721456156810746e-05
> O 0 2.2725645976606756e-05
lysine O 0 4.134004848310724e-05
polymorphism O 0 2.899471110140439e-05
at O 0 3.0724172574991826e-06
codon O 0 3.3991123927989975e-05
1307 O 0 0.00012893615348730236
( O 0 3.0994162898423383e-06
I1307K O 0 8.68429196998477e-06
) O 0 2.39381336086808e-07
of O 0 5.659303425886719e-08
the O 0 2.3379548963475827e-07
APC B-Disease 0 3.153214493067935e-05
gene O 0 1.7929995692611556e-06
has O 0 1.9188530586689012e-07
been O 0 1.0470021294395337e-07
identified O 0 2.1103237202169112e-07
in O 0 8.871025869439109e-08
6 O 0 3.929165757199371e-07
% O 0 1.52233056383011e-07
- O 0 1.5409233355967444e-06
7 O 0 3.894969040629803e-07
% O 0 1.0377512182913051e-07
of O 0 7.58070157758084e-08
the O 0 6.395753757715283e-07
Ashkenazi O 0 3.642229421529919e-05
Jewish O 0 9.579471225151792e-06
population O 0 9.90579337667441e-06
. O 0 1.9647559383884072e-05

To O 0 4.483135853661224e-05
assess O 0 9.873194358078763e-05
the O 0 2.8585095606104005e-06
risk O 0 5.81440463065519e-06
of O 0 3.6701402450489695e-07
this O 0 6.641835170739796e-07
common O 0 5.866058018000331e-06
APC B-Disease 0 0.0005359112983569503
allelic O 0 0.0005928831524215639
variant O 0 0.07546430081129074
in O 0 0.0009169114637188613
colorectal O 1 1.0
carcinogenesis O 1 0.9455716609954834
, O 0 3.3058047392842127e-06
we O 0 1.9140682638862927e-07
have O 0 1.7649426808930002e-07
analyzed O 0 8.467906695841521e-07
a O 0 2.912966579060594e-07
large O 0 5.118209287502395e-07
cohort O 0 7.584919330838602e-06
of O 0 5.852763820257678e-07
unselected O 0 0.0001449573173886165
Ashkenazi O 0 0.00010244482109555975
Jewish O 0 7.245620963658439e-06
subjects O 0 7.444942639267538e-06
with O 0 5.293695721775293e-06
adenomatous B-Disease 1 0.9809589982032776
polyps I-Disease 0 0.46037840843200684
and O 0 3.915276010957314e-06
. O 0 7.931885193102062e-06
or O 1 0.8875864744186401
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.2925449937029043e-06
for O 0 7.460824917870923e-07
the O 0 5.480998879647814e-06
APC O 0 0.0008033599588088691
I1307K O 0 0.0007880282355472445
polymorphism O 0 0.0006698376382701099
. O 0 5.3442381613422185e-05

The O 0 7.377642032224685e-05
APC O 0 0.0010076647158712149
I1307K O 0 0.000371222966350615
allele O 0 0.00018163201457355171
was O 0 3.567543672033935e-06
identified O 0 1.205785679303517e-06
in O 0 3.7590677948173834e-07
48 O 0 9.49550496898155e-07
( O 0 4.735420873203111e-07
10 O 0 2.415438018488203e-07
. O 0 1.58603185695938e-07
1 O 0 4.2555819845802034e-07
% O 0 3.1005225764602073e-07
) O 0 3.4942993920594745e-07
of O 0 7.742079901618126e-07
476 O 0 0.0007524398388341069
patients O 0 0.004814514424651861
. O 0 5.980579953757115e-05

Compared O 0 6.305296119535342e-05
with O 0 1.8890153796746745e-06
the O 0 1.0492426554264966e-06
frequency O 0 3.031258756891475e-06
in O 0 2.024454630600303e-07
two O 0 8.589717026552535e-08
separate O 0 3.255535716562008e-07
population O 0 2.2266982568908134e-07
control O 0 6.592649697267916e-07
groups O 0 1.331528380887903e-07
, O 0 6.712991762469755e-08
the O 0 2.3656086511891772e-07
APC O 0 2.1072031813673675e-05
I1307K O 0 2.362712621106766e-05
allele O 0 1.251805224455893e-05
is O 0 1.9176438570411847e-07
associated O 0 3.16067399808162e-07
with O 0 7.5076478367464e-08
an O 0 1.1724122828127292e-07
estimated O 0 5.167076437828655e-07
relative O 0 2.75331558441394e-06
risk O 0 2.0078355191799346e-06
of O 0 7.463841598109866e-07
1 O 0 8.61653097672388e-06
. O 0 1.7138730981969275e-05

5 O 0 0.0007736012921668589
- O 0 0.0008795470930635929
1 O 0 0.00012758035154547542
. O 0 9.281095117330551e-05

7 O 0 0.0008187079802155495
for O 0 0.00035235140239819884
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9999579191207886
( O 0 7.777737482683733e-05
both O 0 1.5440535207744688e-05
P O 0 0.029786046594381332
= O 0 0.00011254489072598517
. O 0 4.534742856776575e-06
01 O 0 0.00019059768237639219
) O 0 1.4634523722634185e-05
. O 0 2.0106210286030546e-05

Furthermore O 0 0.0001813368289731443
, O 0 8.395149052375928e-06
compared O 0 6.634126293647569e-06
with O 0 1.5156944073169143e-06
noncarriers O 0 0.0004034002486150712
, O 0 2.4478461000398966e-06
APC O 0 0.00010663894499884918
I1307K O 0 6.068878064979799e-05
carriers O 0 1.0300706890120637e-05
had O 0 1.0423410685689305e-06
increased O 0 7.921657356746437e-07
numbers O 0 3.3951150157918164e-07
of O 0 4.521371863575041e-07
adenomas B-Disease 0 0.08252886682748795
and O 0 0.03602254018187523
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9997459053993225
per O 0 2.652689363458194e-05
patient O 0 0.03632311522960663
( O 0 1.0920433851424605e-05
P O 0 0.0012621659552678466
= O 0 4.201710908091627e-06
. O 0 2.6032617483906506e-07
03 O 0 2.4481589662173064e-06
) O 0 1.2328185050591856e-07
, O 0 3.958667704750951e-08
as O 0 3.439370033220257e-08
well O 0 5.042300443847125e-08
as O 0 7.728316120392265e-08
a O 0 5.212103815210867e-07
younger O 0 7.612841272930382e-06
age O 0 5.615954705717741e-06
at O 0 3.0589937523473054e-05
diagnosis O 1 0.8535475134849548
. O 0 5.4642558097839355e-05

We O 0 1.8761729734251276e-05
conclude O 0 2.2401593014365062e-05
that O 0 1.0018860621130443e-06
the O 0 1.463398461964971e-06
APC O 0 8.342989895027131e-05
I1307K O 0 5.293779031489976e-05
variant O 0 3.2544692658120766e-05
leads O 0 3.718598236446269e-06
to O 0 1.025355459205457e-06
increased O 0 6.659101018158253e-06
adenoma B-Disease 1 0.9938696622848511
formation O 0 5.441073426482035e-06
and O 0 3.140662840905861e-07
directly O 0 4.0722031258155766e-07
contributes O 0 9.507328968538786e-07
to O 0 1.788284578196908e-07
3 O 0 2.3134575144467817e-07
% O 0 1.4809350545874622e-07
- O 0 1.0047086789199966e-06
4 O 0 2.405688803719386e-07
% O 0 8.805298534753092e-08
of O 0 9.88459021300514e-08
all O 0 6.239331469259923e-07
Ashkenazi O 0 0.17095905542373657
Jewish O 1 0.9994392991065979
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00029793998692184687

The O 0 2.2737265680916607e-05
estimated O 0 2.006076101679355e-05
relative O 0 2.5252038540202193e-05
risk O 0 1.4093851859797724e-05
for O 0 1.9856306607834995e-06
carriers O 0 0.00015470420476049185
may O 0 1.6758154743001796e-05
justify O 0 1.0332877536711749e-05
specific O 0 1.674117925176688e-06
clinical O 0 2.4239556296379305e-05
screening O 0 4.852653091802495e-06
for O 0 1.9409277740578545e-07
the O 0 2.753925230081222e-07
360 O 0 1.3127744296070887e-06
, O 0 1.3483577276929282e-07
000 O 0 3.605457266075973e-07
Americans O 0 2.2607048322242917e-07
expected O 0 4.99830662192835e-07
to O 0 2.3772942370214878e-07
harbor O 0 6.938262231415138e-06
this O 0 1.8640653820511943e-07
allele O 0 7.035716862446861e-06
, O 0 1.1405730759861399e-07
and O 0 1.6647740608277672e-07
genetic O 0 9.343967235508899e-07
testing O 0 7.586877472931519e-07
in O 0 1.0021500429502339e-07
the O 0 9.206917184201302e-08
setting O 0 2.572110986420739e-07
of O 0 6.583125866654882e-08
long O 0 1.7342981664114632e-06
- O 0 3.4202148526674137e-05
term O 0 2.4848582143022213e-06
- O 0 8.617977073299699e-06
outcome O 0 1.2302809864195297e-06
studies O 0 1.2343118669377873e-06
may O 0 2.317092821613187e-06
impact O 0 5.215880719333654e-06
significantly O 0 0.0014217711286619306
on O 1 0.9981478452682495
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 0.09136579185724258
in O 0 2.8369947813189356e-06
this O 0 1.9834767499560257e-06
population O 0 6.9997045102354605e-06
. O 0 1.6142568711075e-05

Localization O 0 0.00034560178755782545
of O 0 1.1049929526052438e-05
human O 0 1.367558888887288e-05
BRCA1 O 0 0.0003042617754545063
and O 0 1.0264178627039655e-06
its O 0 1.8934883883048315e-06
loss O 0 2.317697726539336e-05
in O 0 4.1433273167967855e-07
high O 0 2.322462250958779e-06
- O 0 1.2714791409962345e-05
grade O 0 1.8106727566191694e-06
, O 0 5.985498887639551e-07
non B-Disease 0 1.626464472792577e-05
- I-Disease 1 0.9900237917900085
inherited I-Disease 1 0.9999815225601196
breast I-Disease 1 0.9999940395355225
carcinomas I-Disease 1 0.9999966621398926
. O 0 0.00018485150940250605

Although O 0 3.20232538797427e-05
the O 0 5.150716333446326e-06
link O 0 1.9565868569770828e-05
between O 0 3.2744908367021708e-06
the O 0 1.0126957022293936e-05
BRCA1 O 0 0.400752454996109
tumour B-Disease 1 0.9999935626983643
- O 0 0.00034313692594878376
suppressor O 0 0.0002957655815407634
gene O 0 2.3014628823148087e-05
and O 0 4.620267645805143e-06
hereditary B-Disease 1 0.999624490737915
breast I-Disease 1 0.9999961853027344
and I-Disease 1 0.9991353154182434
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
is O 0 9.940988547896268e-07
established O 0 7.884048613959749e-07
, O 0 8.102126258791031e-08
the O 0 8.800228101790708e-08
role O 0 3.2980256037262734e-07
, O 0 7.450629624372596e-08
if O 0 4.731610658836871e-08
any O 0 3.496178635487013e-08
, O 0 5.097516009300307e-08
of O 0 9.663315836405673e-08
BRCA1 O 0 2.2663100025965832e-05
in O 0 7.923077873783768e-07
non B-Disease 0 1.3379518350120634e-05
- I-Disease 1 0.7053182125091553
familial I-Disease 1 0.9874087572097778
cancers I-Disease 1 0.8772141933441162
is O 0 5.040933956479421e-06
unclear O 0 4.243108196533285e-05
. O 0 2.725154445215594e-05

BRCA1 O 1 0.9995354413986206
mutations O 0 0.03949805721640587
are O 0 3.966346866945969e-06
rare O 0 7.406602435366949e-06
in O 0 3.7321626678021858e-06
sporadic B-Disease 0 0.12841923534870148
cancers I-Disease 1 0.8894405961036682
, O 0 1.225935648108134e-06
but O 0 5.08164930579369e-07
loss O 0 7.315861239476362e-06
of O 0 4.660244883325504e-07
BRCA1 O 0 0.00042286445386707783
resulting O 0 7.789079063513782e-06
from O 0 1.2334011216807994e-06
reduced O 0 8.35828177514486e-06
expression O 0 3.134904318358167e-06
or O 0 8.843571208672074e-07
incorrect O 0 3.475678568065632e-06
subcellular O 0 9.080111340153962e-06
localization O 0 6.9160255407041404e-06
is O 0 3.525119325331616e-07
postulated O 0 5.9981666709063575e-06
to O 0 1.877283182238898e-07
be O 0 5.563801863672779e-08
important O 0 6.5592487885624e-08
in O 0 2.949851136690995e-07
non B-Disease 0 7.709647434239741e-06
- I-Disease 0 0.17011620104312897
familial I-Disease 1 0.9957334399223328
breast I-Disease 1 0.9999922513961792
and I-Disease 1 0.9978502988815308
ovarian I-Disease 1 1.0
cancers I-Disease 1 0.9999996423721313
. O 0 0.00017891722382046282

Epigenetic O 0 0.020711373537778854
loss O 0 0.021533412858843803
, O 0 4.315325440984452e-06
however O 0 1.5132117141547496e-06
, O 0 2.810432988553657e-07
has O 0 2.205347158223958e-07
not O 0 9.325950856009513e-08
received O 0 3.073502909956005e-07
general O 0 4.446361572263413e-07
acceptance O 0 1.9982308003818616e-06
due O 0 2.560608209023485e-06
to O 0 2.6764118388200586e-07
controversy O 0 1.307934553551604e-06
regarding O 0 6.360608040267834e-07
the O 0 3.091982989644748e-07
subcellular O 0 4.121842266613385e-06
localization O 0 2.7138910354551626e-06
of O 0 2.1552918383349606e-07
BRCA1 O 0 2.2278665710473433e-05
proteins O 0 5.453014182421612e-07
, O 0 9.379449750213098e-08
reports O 0 2.48060047169929e-07
of O 0 6.203364932844124e-08
which O 0 1.9249236515861412e-07
have O 0 9.329438199756623e-08
ranged O 0 6.265568117669318e-07
from O 0 1.5301424127756036e-07
exclusively O 0 3.187590777997684e-07
nuclear O 0 1.809887180570513e-06
, O 0 8.506939508379219e-08
to O 0 1.3269293219764222e-07
conditionally O 0 1.24977732411935e-05
nuclear O 0 1.5213480537568103e-06
, O 0 8.701054099446992e-08
to O 0 1.5730574887129478e-07
the O 0 7.334515998991264e-07
ER O 0 0.006755162496119738
/ O 0 0.0001856324088294059
golgi O 0 0.0001541677484055981
, O 0 2.9425345360323263e-07
to O 0 3.9283042951865355e-07
cytoplasmic O 0 9.020815014082473e-06
invaginations O 0 1.9055431039305404e-05
into O 0 1.2006530596408993e-06
the O 0 2.181949184887344e-06
nucleus O 0 4.160907701589167e-05
. O 0 2.830891935445834e-05

In O 0 1.9335453544044867e-05
an O 0 2.136891680493136e-06
attempt O 0 5.703413080482278e-06
to O 0 9.257681199414947e-07
resolve O 0 3.920769358956022e-06
this O 0 2.3169991436589044e-07
issue O 0 8.214564672925917e-07
, O 0 2.0625357421977242e-07
we O 0 1.6096507238216873e-07
have O 0 3.5183686009077064e-07
comprehensively O 0 3.434033351368271e-05
characterized O 0 2.3153274014475755e-05
19 O 0 1.1458458175184205e-05
anti O 0 0.013611458241939545
- O 0 0.2987639605998993
BRCA1 O 0 0.0056438264437019825
antibodies O 0 0.0001970265875570476
. O 0 4.7851004637777805e-05

These O 0 6.637378828600049e-05
reagents O 0 0.00030711377621628344
detect O 0 0.00011946636368520558
a O 0 5.884469373995671e-06
220 O 0 1.9527074982761405e-05
- O 0 9.095543646253645e-05
kD O 0 0.00012045674520777538
protein O 0 4.528994395514019e-06
localized O 0 6.060755822545616e-06
in O 0 3.867511964017467e-07
discrete O 0 1.596967308614694e-06
nuclear O 0 4.629106115316972e-06
foci O 0 2.1716941773775034e-05
in O 0 3.7398513086372986e-07
all O 0 1.416755992522667e-07
epithelial O 0 4.900757267023437e-05
cell O 0 2.6879793949774466e-05
lines O 0 1.5056384654599242e-06
, O 0 1.1001176858371764e-07
including O 0 8.388015970695051e-08
those O 0 1.6138638159191032e-07
derived O 0 3.274572009104304e-06
from O 0 2.398079595877789e-05
breast B-Disease 1 0.9606508612632751
malignancies I-Disease 0 0.2944202125072479
. O 0 6.8988352722954e-05

Immunohistochemical O 0 0.017114441841840744
staining O 0 0.0023222763556987047
of O 0 1.3317585398908705e-05
human O 0 6.542139453813434e-05
breast O 0 0.2831541895866394
specimens O 0 2.4367584046558477e-05
also O 0 7.312554771488067e-06
revealed O 0 0.0001858590985648334
BRCA1 O 0 0.0003464413166511804
nuclear O 0 3.618390474002808e-05
foci O 0 0.00036185726639814675
in O 0 2.9362066925386898e-05
benign O 1 0.9994626641273499
breast O 1 0.9823371171951294
, O 0 3.642590672825463e-05
invasive B-Disease 1 0.898469090461731
lobular I-Disease 1 0.9999961853027344
cancers I-Disease 1 0.8985069394111633
and O 0 8.890841854736209e-06
low B-Disease 0 0.0002597217389848083
- I-Disease 0 0.02019776776432991
grade I-Disease 0 0.0006069262744858861
ductal I-Disease 1 0.999308705329895
carcinomas I-Disease 1 0.9999878406524658
. O 0 0.0002684720675460994

Conversely O 0 0.001016296911984682
, O 0 2.7622983907349408e-05
BRCA1 O 0 0.0004437321040313691
expression O 0 9.2650634542224e-06
was O 0 5.343381417333148e-06
reduced O 0 4.18541458202526e-06
or O 0 8.745359423301124e-07
undetectable O 0 9.067165592568927e-06
in O 0 2.118058120004207e-07
the O 0 1.349953180351804e-07
majority O 0 2.3778203228630446e-07
of O 0 8.188317934809675e-08
high O 0 2.368636614846764e-06
- O 0 4.5253585994942114e-05
grade O 0 4.361115770734614e-06
, O 0 2.332739541088813e-06
ductal B-Disease 1 0.9882974028587341
carcinomas I-Disease 1 0.9999921321868896
, O 0 9.690241995485849e-07
suggesting O 0 2.7338621748640435e-06
that O 0 2.077971004155188e-07
absence O 0 8.280871384158672e-07
of O 0 3.200860305696551e-07
BRCA1 O 0 0.007224516477435827
may O 0 2.1004100290156202e-06
contribute O 0 2.688627489533246e-07
to O 0 8.982135568658123e-08
the O 0 1.9394217076751374e-07
pathogenesis O 0 5.191088348510675e-06
of O 0 5.8116832235555194e-08
a O 0 3.2962364571176295e-07
significant O 0 2.9562696113316633e-07
percentage O 0 8.509971962666896e-07
of O 0 4.811961389350472e-07
sporadic B-Disease 1 0.7421353459358215
breast I-Disease 1 0.9999918937683105
cancers I-Disease 1 0.94777911901474
. O 0 1.037103447742993e-05
. O 0 2.5009458113345318e-05

